Title of Invention	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA
Abstract	Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

Title of Invention

TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA

Abstract

Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

Full Text	FORM 2 THE PATENTS ACT, 1970 (39 of 1970) & THE PATENTS RULES, 2003 COMPLETE SPECIFICATION (Sec section 10, rule 13) "TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF" ASTRAZENECA AB, SE -151 85 Sodertalje, Sweden. The following specification particularly describes the invention and the manner in which it is to be performed. WO 2008/112003 PCT/US2007/075117 TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF BACKGROUND OF THE INVENTION Cross Reference to Related Applications \|001j This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application Serial No. 60/835,647, filed August 3, 2006, the entirety of which is hereby incorporated by reference. Field of the Invention [002] The invention relates to targeted binding agents against the largci antigen PDGFR-alpha and uses of such agents. In some embodiments, the invention relates lo fully human monoclonal antibodies directed to PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such targeted binding agents or antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha. Description of the Related Art [003} Platelet derived growth factor (PDGF) is a protein that regulates cell growth and division. There are five different isoforms of PDGF (A, B. C. D, and an AB helerodimer) that exist as dimers and activate the cellular response through two different receptors (PDGFR-alpha and PDGFR-beta). Specifically, PDGF dimers bind lo two receptors simultaneously to induce receptor dimerization, autophosphorylation and intracellular signaling. \|004] Platelet derived growth factor receptor-alpha (PDGFR-alpha, also known as CDJ40a.) is a type HI receptor tyrosine kinase characterized by an extracellular domain having Five lgG-like domains, a transmembrane domain and a catalytic intracellular domain. PDGFR-alpha can form homodimers or heterodimers with the structurally similar PDGFR-beta. PDGF-AA activates only alpha-alpha receptor dimers, PDGF-AB and PDGF-CC WO 2008/112003 PCT/US2007/075117 activate alpha-alpha and/or alpha-beta receptor diniers and PDGF-BB activates ail three combinations of receptor dimers. J005] PDGFR-alpha has been linked to tumorigenesis and has been implicated in a number of cancers including breast, lung, ovarian, prostate, colon and endometrial cancers. as well as hepatocellular carcinoma, glioblastoma, melanoma, and gastrointestinal stromal tumor (GIST)). J006] Several companies have developed therapeutic agents that target PDGFR-alpha. Gleevec® (Novartis®) and SUTENT/SU1124S (sunitinib malate, Pfizer®) are small molecule drugs that target PDGFR-alpha as well as other receptor tyrosine kinases. In addition, monoclonal antibodies that target PDGFR-alpha have been reported. International publication number WO 1992/013867 describes that mouse or rabbit monoclonal and/or polyclonal antibodies may be prepared to PDGF receptor constructs. international publication number WO 1995/000659 relates to a monoclonal antibody, specific for PDGFR-alpha, characterized in that it binds PDGFR-alpha and does not bind PDGFR-beta. The application discloses two antibodies; characterized as having half maximal binding affinity oi~ 50pM and 75pM as measured by solid phase enzyme linked immunosorbent assay. International publication number WO2006/138729 discloses a fully human monoclonal antibody, tenned 3G3 (ImClone Systems, Inc.), that targets PDGFR-alpha. This antibody has" a reported affinity for soluble PDGFR-alpha of 40 pM as measured in a bivalent affinity assay; in which soluble PDGFR-alpha was immobilized on a sensor chip and antibody was injected at various concentrations. As discussed herein, in a bivalent assay, experimental artefacts may affect the measured affinity. [0071 An antibody with an affinity higher than 40 pM, may be desirable as such an antibody may produce a greater extent and/or duration of PDGFR-alpha inhibition when administered to humans at standard doses. An antibody with an affinity higher than 40pM may be administered at a lower effective dose than an antibody with a lower affninity, or may be administered at longer dosing intervals in comparison with a standard dosing interval for an antibody with a lower affinity. 3 WO 2008/112003 PCTYUS2007/075117 SUMMARY OF THE INVENTION [008] Embodiments of the invention relate to targeted binding agents that specifically bind to PDGFR-alpha and inhibit the growth of cells that express PDGFR-alpha. Mechanisms by which this can be achieved can include, and are not limited to, blocking ligand binding and/or inhibiting cell signaling implicated in tumor cell growth as weil as inhibition of the stromal fibroblast component leading to reduced angiogenesis. The targeted binding agents are useful for reducing tumour growth and angiogenesis. [009] In one embodiment of the invention, the targeted binding agent is a fully human antibody that binds to PDGFR-alpha and inhibits binding of PDGF-AA, PDGF-AB. PDGF-BB, and/or PDGF-CC ligands to PDGFR-alpha. Yet another embodiment of the invention is a fully human monoclonal antibody that binds to PDGFR-alpha and inhibits receptor autophosphorylation. Another embodiment of the invention is a fully human monoclonal antibody that binds to PDGFR-alpha and inhibits downstream cell signaling implicated in cell growth. (0010J In some embodiments, the targeted binding agent binds to PDGFR-alpha and does not cross-react with PDGFR-beta receptor, that is, the agent is mono-specific. In some embodiments, the targeted binding agent binds to PDGFR-alpha and docs not cross react with other Class III receptor tyrosine kinase family members, such as. for example, FLT3. c-kit, and/or CSF-1R. J0011] Another embodiment of the invention is a targeted binding agent that competes for binding with any of the targeted binding agents or antibodies described herein. \|0012] In one embodiment, the targeted binding agent binds PDGFR-alpha with a KD of less than about 500 picomolar (pM). In another embodiment, the targeted binding agent binds with a KD less than about 400, 300, 200 or 100 pM. In one embodiment, the targeted binding agent binds with a KD of less than about 75, 60, 50: 40, 30, 20, 10 or 5 pM. Affinity and/or avidity measurements can be measured by FMAT, FACS, KinExA® and/or BIACORE®, as described herein. \|00131 In another embodiment, the targeted binding agent binds PDGFR-alpha with a KD less than about 400, 300, 200, or 100, 75, 60, 50, 40, 30. 20, 10, or 5 pM as measured in a monovalent affinity assay. Monovalent affinity may be measured in a BIACORE® assay in which soluble receptor is flowed over immobilized antibody. In comparison with a WO 2008/112003 PCT/US2007/0751I7 bivalent affinity assay, the KD as reported by a monovalent affinity assay is much less likely to be affected by experimental artefacts and is thus able to report a KD much closer lo the true monovalent affinity of the antibody. In a bivalent affinity assay, the density of immobilized receptor influences the extent to which single antibody molecules bind twice and/or rebind immobilized receptor as they are flowed over. As such, in a bivalent affinity assay, the density of receptor can directly affect the reported KD. Thus, a monovalent affinity assay provides a much more biologically-relevant measurement of affinity. \|00141 In another embodiment, the targeted binding agent inhibits ligand-induced transphosphorylation within the receptor dimer with an IC50 less than about 400, 300. 200, or 100, 75, 60, 50, 40, 30, 20, 10, or 5 pM when performed at close to saturating ligand levels. \|0015\| In another embodiment, the targeted binding agent inhibits ligand-induced receptor autophosphorylation with an IC50 less than about 400, 300, 200, 100, 75, 60, 50. 40. 30, 20, 10 or 5 pM when performed at close to saturating ligand levels. \|0016] In one embodiment of the invention, the targeted binding agent is an antibody. In one embodiment of the invention, the targeted binding agent is a monoclonal antibody. In one embodiment of the invention, the targeted binding agent is a fully human monoclonal antibody. In another embodiment of the invention, the targeted binding agent is a fully human monoclonal antibody of the IgGl, IgG2, IgG3 or IgG4 isotype. In another embodiment of the invention, the targeted binding agent is a fully human monoclonal antibody of the IgG2 isotype. This isotype has reduced potential to elicit effector function in comparison with other isotypes, which may lead lo reduced toxicity. 10017\| A further embodiment is an antibody that binds to PDGFR-alpha and comprises a heavy chain amino acid sequence having one, two or three of the complementarity determining regions (CDR) sequences shown in Table 12 and a light chain amino acid sequence having one, two or three of the CDR sequences shown in Table 13. In certain embodiments the antibody is a fully human monoclonal antibody. In some embodiments, the invention provides an antibody thai binds Ihe same epitope as any of the antibodies disclosed herein. [0018} In one embodiment, the heavy chain of antibody 2.175.3, 2.451.1, 2.449.1.3, 2.998.2 or 2.84.3 is paired with a heterologous light chain. Lighl-chain promiscuity is well WO 2008/112003 PCT/US2007/075117 established in the art. Thus, the heavy chain of any of antibodies 2.175.3, 2.451.1, 2.449.1.3, 2.998.2 or 2.84.3 or another antibody as disclosed herein may be paired with the light chain of any of antibodies 2.175.3. 2.451.1, 2.449.1.3, 2.998.2, 2.84.37 or other antibody as disclosed herein. [0019] In one embodiment an antigen binding site may comprise a heavy chain CDRl, CDR2 and CDR3 and a light chain CDRl, CDR2 and CDR3 of any of antibodies 2.175.3, 2.451.1, 2.449.1.3, 2.998.2, 2.84.3 with as many as twenty, sixteen, ten, nine or fewer, e.g. one, two, three, four or five, amino acid additions, substitutions, deletions, and/or insertions within the disclosed CDRs. Such modifications may potentially be made at any residue within the CDRs. (0020] In another embodiment the targeted binding agent or antibody may comprise a sequence comprising any one. two. three, four, five or six of the CDRl. CDR2 or CDR3 sequences as shown in Table 12 or Table 13. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence as shown in Table 12. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence as shown in Table 13. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence as shown in Table 12 and a CDRl, CDR2 and CDR3 sequence as shown in Table !3. It is noted that those of ordinary skill in the art can readily accomplish CDR detenninations. See for example, Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bcthesda MD (1991), vols. 1-3. }0021] In another embodiment the targeted binding agent or antibody may comprise a sequence comprising any one, two, three, four, five or six of the CDRl, CDR2 and CDR3 sequences of any one of the fully human monoclonal antibodies 2.175.3, 2.449.1.3 or 2.998.2, as shown in Table ! 2 or in Table 13. In one embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3, 2.449.1.3 or 2.998.2, as shown in Table 12. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.2, 2.449.1.3 or 2.998.2, as shown in Table 13. In another embodiment the targeted WO 2008/112003 PCT/US2007/075II7 binding agent or antibody may comprise a sequence comprising a CDR1, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3, 2.449.1.3 or 2.998.2 as shown in Table 12, and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3, 2.449.1.3 or 2.998.2 as shown in Table 13. [0022] In another embodiment the targeted binding agent or antibody comprises a sequence comprising a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3 as shown in Table 12 and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3 as shown in Table 13. In another embodiment the targeted binding agent or antibody comprises a sequence comprising a CDRI. CDR2 and CDR3 sequence of fully human monoclonal antibody 2.449-1.3 as shown in Table 12 and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.449.1.3 as shown in Table 13. In another embodiment the targeted binding agent or antibody comprises a sequence comprising a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.998.2 as shown in Table 12 and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.998.2 as shown in Table 13. [0023J A further embodiment of the invention is a targeted binding agent which competes for binding to PDGFR-alpha with the targeted binding agent or antibodies of the invention. In another embodiment of the invention there is an antibody which competes for binding to PDGFR-alpha with the targeted binding agent or antibodies of the invention. In another embodiment the targeted binding agent or antibody competes for binding lo PDGFR-alpha with any one of fully human monoclonal antibodies 2-175.3, 2.449.1.3 or 2.998.2. In one embodiment of the invention there is provided an antibody which competes with any one of fully human monoclonal antibodies 2.175.3, 2.449.1.3 of 2.998.2 for binding to PDGFR-alpha. \|0024\| A further embodiment of the invention is a targeted binding agent or antibody • that binds to the same epitope on PDGFR-alpha as the targeted binding agent or antibodies of the invention. In another embodiment of the invention there is an antibody that binds to the same epitope on PDGFR-alpha as the targeted binding agent or antibodies of the invention. In one embodiment of the invention there is provided a targeted binding agent that binds to the same epitope on PDGFR-alpha as any one of fully human monoclonal antibodies 2.175.3. 2.449.1.3 or 2.998.2. In one embodiment of the invention there is provided an antibody that WO 2008/112003 PCT/US2007/075117 binds to the same epitope on PDGFR-alpha as any one of fully human monoclonal antibodies 2.175.3, 2.449.1.3 or 2.998.2. J0025J A further embodiment of the invention is a targeted binding agent or antibody comprising the contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 of any one of the monoclonal antibodies as shown in Table ] 2 or Table 13. [0026\| One embodiment provides a targeted binding agent, or antigen-binding portion thereof, wherein the agent, or binding portion, comprises a heavy chain polypeptide having the sequence of SEQ ID NO.:2. In one embodiment, the agent, or binding portion thereof, further comprises a light chain polypeptide having the sequence of SEQ ID NO.:4. Another embodiment is a targeted binding agent, or antigen-binding portion (hereof, wherein the agent, or binding portion, comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 10. In one embodiment, the agent, or binding portion thereof, further comprises a light chain polypeptide having the sequence of SEQ ID NO.: 12. Still another embodiment is a targeted binding agent, or antigen-binding portion thereof, wherein the agent, or binding portion, comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 14. In one embodiment, the agent, or binding portion thereof, further comprises a light chain polypeptide having the sequence of SEQ ID NO.: 16. \|0027) In one embodiment, the targeted binding agent comprises one or more of fully human monoclonal antibodies 2.175.3, 2.449.1.3 or 2.998.2. \|0028\| In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 2, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 6. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 10, wherein the sequence comprises any one of the unique combinations of germline and non-germiine residues indicated by each row of Table 8. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 14, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 10. In one embodiment, the targeted binding agent of the invention comprises a WO 2008/112003 PCT/US2007/075117 polypeptide comprising the sequence of SEQ ID NO.: 4, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 7. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 12, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 9. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 16. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 11. [0029] In one embodiment, the antibody of the invention comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 2. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 6. In one embodiment, the antibody of the invention comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 10. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 8. In one embodiment, the antibody of the invention comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 14. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by eacli row of Table 10. In one embodiment, the antibody of the invention comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 4, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 7. In one embodiment, the antibody of the invention comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 12, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 9. In one embodiment, the antibody of the invention comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 16, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 11. (0030) In one embodiment, the targeted binding agent or antibody of the invention comprises a heavy chain sequence according to SEQ ID NO: 2, 6 or 10, wherein the residue at position 30 is selected from: S or R; WO 2008/112003 PCT/US2007/075U7 the residue at position 31 is selected from: S, N or D; the residue at position 33 is selected from: G or Y; the residue at position 35 is selected from: S, H or N; the residue at position 50 is selected from: Y, V or F; the residue at position 53 is selected from: Y, S or R; the residue at position 54 is selected from: S or D; the residue at position 57 is selected from: T, L, N or I; the residue at position 58 is selected from: K or I; the residue at position 61 is selected from: V or A: the residue at position 99 is selected from: G, D or E or the residue is deleted; the residue at position 100 is selected from: G or the residue is deleted; the residue at position 101 is selected from: S, H, P or R; the residue at position 102 is selected from: Y or I; the residue at position 103 is selected from: S, V or A; the residue at position 104 is selected from: G or A; the residue at position 105 is selected from: S or R; the residue at position 106 is selected from: P or G; the residue at position 107 is selected from: F or M; and the residue at position 109 is selected from: Y or V. This group of'Tieavy chain sequences is named "'Group A". (0031 ] In one embodiment, the targeted binding agent or antibody of the invention comprises a heavy chain sequence according to SEQ ID NO: 14 or 18, wherein the residue at position 27 is selected from: G or D; the residue at position 28 is selected from: S or F; the residue at position 32 is selected from: S or F; the residue at position 33 is selected from: S, N, T or 1; the residue at position 52 is selected from: S or T; the residue at position 56 is selected from: S or T; the residue at position 58 is selected from: S or T; the residue at position 63 is selected from: S or P; the residue at position 100 is selected from: H or the residue is deleted; WO 2008/112003 PCT/US2007/075117 the residue at position 101 is selected from: H or the residue is deleted; and the residue at position 103 is selected from: V or the residue is deleted. This group of heavy chain sequences is named "Group B". (003J2J In one embodiment, the targeted binding agent or antibody of the invention comprises aflight chain sequence according to SEQ ID NO: 4, 8 or 12, wherein the residue at position 25 is selected from: A or P; the residue at position 27 is selected from: Q, R or H; the residue at position 28 is selected from: G, V, S, I, D or R; the residue at position 29 is selected from: I or F; 1 the residue at position 30 is selected from: S, N. A, R or T; the residue at position 31 is selected from: S, H. K, T or R; the residue at position 32 is selected from: S. T, Y, D. N or F: the residue at position 33 is selected from: L or 1; the residue at position 50 is selected from: A. G, L, Y, S or V; the residue at position 51 is selected from: A, G or S; the residue at position 53 is selected from: T, Q, N, H, R or S; the residue at position 54 is selected from: L, R or S; the residue at position 55 is selected from: Q, P. F, A or V: the residue at position 56 is selected from: S, N, T or G; the residue at position 91 is selected from: S orT; the residue at position 92 is^lected from: Y or F; the residue at position 94 is selected from: N, T, S or the residue is deleted; the residue at position 95 is selected from: F, W, P, 1, A. L or the residue is deleted; the residue at position 96 is selected from: P or the residue is deleted; and [0033] the residue at position 97 is selected from: W, L, R, I or the residue is deleted. This group of light chain sequences is named "Group C'[0034] In one embodiment, the targeted binding agent or antibody of the invention comprises a light c hain sequence according to SEQ ID NO: 16 or 20, wherein the residue at position 28 is selected from: S, I, G, D, R or V; the residue at position 29 is selected from: F, 1 or V; WO 2008/112003 PCT/US2007/075U7 the residue at position 30 is selected from: S, A, T. G, R or N; the residue at position 31 is selected from: S, R. K, N orT; the residue at position 32 is selected from: Y, F. W, N, D or S: the residue at position 33 is selected from: L or I; the residue at position 34 is selected from: N, A or H; the residue at position 50 is selected from: A, Y, G, L or V; the residue at position 51 is selected from: A, G or S; the residue at position 52 is selected from: A, Y, G, L or V; the residue at position 54 is selected from: L, R or S; the residue at position 55 is selected from: Q, F, V. A or P; the residue at position 56 is selected from: S. N, T or G: the residue at position 92 is selected from: S or T; and the residue at position 93 is selected from: S, N or 1. This group of light chain sequences is named "Group D". (0035] In one embodiment the targeted binding agent or antibody of the invention comprises any one of the Group A heavy chain sequences and any one of the Group C or Group D light chain sequences. \|0036] In one embodiment the targeted binding agent or antibody of the invention comprises any one of the Group B heavy chain sequences and any one of the Group C or Group D light chain sequences. \|0037] In one embodiment, the targeted binding agent comprises an antibody which comprises variants or derivative of the CDRs disclosed herein or the light or heavy chain sequences disclosed herein or the monoclonal antibodies disclosed herein. Variants include antibodies comprising light or heavy chain sequences which have at least about 60, 70, 80, 85, 90, 95, 98 or about 99% amino acid sequence identity with any of the CDRI, CDR2 or CDR3s as shown in Table 12 or Table 13, or with the light or heavy chain sequences disclosed herein, or with the monoclonal antibodies disclosed herein. In one embodiment variants comprise changes in the the CDR sequences or light or heavy chain sequences disclosed herein that are naturally occuning or are introduced by in vitro engineering of native sequences using recombinant DNA techniques or mutagenesis techniques. Naturally occurring variants include those which are generated in vivo in the corresponding gennline WO 2008/112003 PCT/US2007/075117 nucleotide sequences during the generation of an antibody to a foreign antigen. In one embodiment the derivative may be a heteroantibody, that is an antibody in which two or more antibodies are linked together. Derivatives include antibodies which have been chemically modified. Examples include covalent attachment of one or more polymers, such as water-soluble polymers, N-linked, or O-linked carbohydrates, sugars, phosphates, and/or other such molecules. The derivatives are modified in a manner that is different from naturally occurring or starting antibody, either in the type or location of the molecules attached. Derivatives further include deletion of one or more chemical groups which are naturally present on the antibody. [0038) Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH3-I! genu line sequence. Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH4-39 germ line sequence. Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a Dl-26, D6-6 or D7-27 germ line sequence. Some embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a VK light chain. Still other embodiments of the invention include a monoclonal antibody that comprises a VK light chain paired with a heavy chain encoded by, or derived from, a VH3-11 or VH4-39 heavy chain gene. In some embodiments, the VK light chain polypeptide is encoded by, or derived from, a JK1 light chain gene. In other embodiments, the VK light chain polypeptide is encoded by, or derived from, a JK5 light chain gene. [0039\| Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH3-11 germ line sequence, and a Vk light chain polypeptide derived from a 012 light chain gene. Additional embodiments of the invention include human, monoclonal antibodies that, bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH3-11 genii line sequence, and a Vk light chain polypeptide derived from the 012 germline sequence light chain wherein the second amino acid in CDR1 of the light chain encodes proline. This combination of VH3-11 heavy chain gene usage in combination with 012 light chain gene usage along with proline encoded for at the second amino acid position of CDR1 of the light WO 2008/112003 PCT/US2007/075117 chain is exemplified in antibodies derived from two antibodies from independent lineages with diverse CDR3 heavy chain and light chain sequences, namely 2.449.1.3 and 2.175.3 {see Tables 12 and 13). 100401 Monoclonal antibodies 2.175.3 and 2.449.1.3 are both high affinity antibodies to PDGFRa, and block PDGF-driven cellular responses with high potency in vitro. Although these two antibodies share VH (VH3-11) and Vk (012) usage, they diverge in D, JH and Jk usage. Thus, they are derived from different B-cell lineages. They do, however, share unusual sequence patterns in Vk. Residue 25 is a proline in both antibodies, mutated from the germline alanine. Proline is not used by any of the Vk germline genes, and occurs at this location in only 0.2% of human sequences in the Kabat database. Proline at position 25 would insert a rigid peptide bond and a sharp angle in the peptide backbone, and would therefore produce unique structural characteristics wiihin this Vk region of the lisjhi chain of both of these antibodies. Similarly, a mutant arginine is used by both 2.175.3 and 2.449.1.3 in position 27e (Kabat numbering) of CDR1 of Vk. Arginine is not used in this canonical location in any Vk germline genes, and occurs in only 0.4% of human sequences in the Kabat database. In one embodiment of the invention there is provided a human monoclonal antibody that binds PDGFR-alpha and comprises a proline at residue 25. In one embodiment of the invention there is provided a human monoclonal antibody that binds PDGFR-alpha and comprises an arginine at position 27e of CDR1. [0041] In other embodiments the invention provides compositions, including a targeted binding agent of the invention or binding fragment thereof, and a pharmaceutically acceptable carrier. In other embodiments the invention provides compositions, including an antibody of the invention or binding fragment thereof, and a pharmaceutical^ acceptable carrier. \|0042\| Still further embodiments of the invention include methods of effectively treating an animal suffering from a neoplastic disease, including selecting an animal in need of treatment for a neoplastic disease, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds to PDGFR-alpha. In certain embodiments, the animal is human. In certain embodiments, the targeted binding agent is a fully human monoclonal antibody. In certain embodiments, the targeted binding agent is an WO 2008/112003 PCT/US2007/075117 antibody of the invention and may be selected from the group consisting of 2.175.3, 2.449.1.3, or 2.998.2. J0043J Treatable neoplastic diseases, include, for example, cancers including, melanoma, small cell lung cancer, non-small cell lung cancer, glioma, hepatocellular (liver) carcinoma, thyroid tumor, gastric (stomach) cancer, prostate cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, esophageal carcinoma, head and neck cancers, mesothelioma, sarcomas, biliary (cholangiocarcinoma), small bowel adenocarcinoma, pediatric malignancies, epidermoid carcinoma, and gastrointestinal stromal tumor (GIST). (0044] In one embodiment the present invention is suitable for use in antagonizing PDGFR-alpha, in patients with a tumour which is dependent alone, or in part, on a PDGFR-alpha. \|004S\| Additional embodiments of the invention include methods of inhibiting tumor cell growth in an animal. These methods include selecting an animal in need of treatment for tumor cell growth, and administering to the animal a therapeutically effective dose of a targeted binding agent, wherein said agent specifically binds to PDGFR-alpha. In another embodiment the method includes selecting an animal in need of treatment for tumor cell growth, and administering to the animal a therapeutically effective dose of a fully human monoclonal antibody, wherein said antibody specifically binds to PDGFR-alpha. [00461 Further embodiments of the invention include the use of a targeted binding agent in the preparation of medicament for the treatment of diseases involving PDGFR-alpha expression in an animal, wherein the agent specifically binds to PDGFR-alpha. In another embodiment the invention includes the use of an antibody in the preparation of medicament for the treatment of diseases involving PDGFR-alpha expression in an animal, wherein the monoclonal antibody specifically binds to PDGFR-alpha. [0047\| In other embodiments, the targeted binding agents or antibodies described herein can be used for the preparation of a medicament for the treatment of neoplastic diseases in an animal, wherein the antibody specifically binds to PDGFR-alpha. {0048] Embodiments of the invention described herein relate to monoclonal antibodies that bind PDGFR-alpha and affect PDGFR-alpha function. Other embodiments relate to fully human anti-PDGFR-alpha antibodies and anti-PDGFR-alpha antibody WO 2008/112003 PCT/US2007/075117 preparations with desirable properties from a therapeutic perspective, including high binding affinity for PDGFR-alpha, high selectivity for inhibition of PDGFR-alpha signaling, low toxicity, the ability to block PDGF-AA ligands from binding to PDGFR-alpha, the ability lo block PDGF-AB ligands from binding to PDGFR-alpha, the ability to block PDGF-BB ligands from binding to PDGFR-alpha, the ability to block PDGF-CC ligands from binding to PDGFR-alpha. and/or the ability to inhibit tumor cell growth in vitro and in vivo. Some embodiments relate to fully human anti-PDGFR-alpha antibodies that do not substantially cross react with PDGFR-beta. Still other embodiments relate to fully human anti-PDGFR-alpha antibodies and anti-PDGFR-alpha antibody preparations that do not result in a significant Human Anti-Chimeric Antibody (HACA) response, thereby allowing for repeated administration. [0049) In one embodiment, the invention includes antibodies that bind to PDGFR- alpha with very high affinities (Kd). For example a human, rabbit, mouse, chimeric or humanized antibody that is capable of binding PDGFR-alpha with a Kd less than, but not limited to, 10-5, 10-6, 10-7, 10-8, 10-9, 10-10 or 10-11M, or any range or value therein. Affinity and/or avidity measurements can be measured by KinExA® and/or BIACORE®, as described herein. [0050) Accordingly, one embodiment described herein includes isolated antibodies, or fragments of those antibodies, that bind to PDGFR-alpha. As known in the art, the antibodies can advantageously be, for example, polyclonal, oligoclonal, monoclonal, chimeric, humanized, and/or fully human antibodies. Embodiments of the invention described herein also provide cells for producing these antibodies. [0051] It will be appreciated that embodiments of the invention arc not limited to any particular form of an antibody or method of generation or production. For example, the anti-PDGFR-alpha antibody can be a full-length antibody (e.g., having an intact human Fc region) or an antibody binding fragment (e.g., a Fab, Fab' or F(abr)2, FV or dAb). In addition, the antibody can be manufactured from a hybridoma that secretes the antibody, or from a recombinantly engineered cell that has been transformed or transfected with a gene or genes encoding the antibody. In addition, the antibodies can be single-domain antibodies such as camelid or human single VH or VL domains that bind lo PDGFR-alpha, such as a dAb fragment, WO 2008/112003 PCT/US2007/075117 10052] Other embodiments of the invention include isolated nucleic acid molecules encoding any of the targeted binding agents or antibodies described herein, vectors having isolated nucleic acid molecules encoding anti-PDGFR-alpha antibodies or a host cell transformed with any of such nucleic acid molecules. In addition, one embodiment of the invention is a method of producing an anti-PDGFR-alpha antibody by culturing host cells under conditions wherein a nucleic acid molecule is expressed to produce the antibody followed by recovering the antibody. [0053] A further embodiment herein includes a method of producing high affinity antibodies to PDGFR-alpha by immunizing a mammal with cells expressing human PDGFR-alpha, isolated cell membranes containing human PDGFR-alpha, purified human PDGFR-alpha, or a fragment thereof, and/or one or more orthologous sequences or fragments thereof. \|0U54\| Other embodiments are based upon the generation and identification of isolated antibodies that bind specifically to PDGFR-alpha. PDGFR-alpha is expressed on a number of tumor types. Antibodies that neutralize PDGFR-alpha can prevent PDGFR-alpha induced tumor growth and other desired effects. J0055J Another embodiment of the invention includes a method of diagnosing diseases or conditions in which an antibody prepared as described herein is utilized to detect the level of PDGFR-alpha in a patient or patient sample. In further embodiments, methods for the identification of risk factors, diagnosis of disease, and staging of disease is presented which involves the identification of the expression and/or overexpression of PDGFR-alpha using anti-PDGFR-alpha antibodies. In some embodiments, the methods comprise administering to a patient a fully human antibody conjugate that selectively binds to a PDGFR-alpha protein on a cell. The antibody conjugate comprises an antibody that selectively binds to PDGFR-alpha and a label. The methods further comprise observing the presence of the label in the patient. A relatively high amount of the label will indicate a relatively high risk of the disease and a relatively low amount of the label will indicate a relatively low risk of the disease. In one embodiment, the label is a green fluorescent protein. [0056] The invention further provides methods for assaying the level of PDGFR-alpha in a patient sample, comprising contacting an anti-PDGFR-alpha antibody with a biological sample from a patient, and detecting the level of binding between said antibody WO 2008/112003 PCT/US2007/075117 and PDGFR-alpha in said sample. In more specific embodiments, the biological sample is blood or serum. \|0057] Another embodiment of the invention includes a method for diagnosing a condition associated with the expression of PDGFR-alpha in a cell by contacting serum or a cell with an anti-PDGFR-alpha antibody, and thereafter detecting the presence of PDGFR-alpha. {0058] In another embodiment, the invention includes an assay kit for detecting PDGFR-alpha in mammalian tissues, cells, or body fluids to screen for diseases involving cells that express PDGFR-alpha. The kit includes an antibody that binds to PDGFR-alpha and a means for indicating the reaction of the antibody with PDGFR-alpha, if present. Preferably the antibody is a monoclonal antibody. In one embodiment, the antibody that binds PDGFR-alpha is labeled. In another embodiment the antibody is an unlabeled primary antibody and the kit further includes a means for detecting the primary antibody, in one embodiment, the means includes a labeled second antibody that is an antiimmunoglobulin. Preferably the antibody is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radiopaque material. J0059] Yet another embodiment includes methods for treating diseases or conditions associated with the expression of PDGFR-alpha in a patient, by administering to the patient an effective amount of an anti-PDGFR-alpha antibody. The anti-PDGFR-alpha antibody can be adminislercd alone, or can be administered in combination with additional antibodies or chemotherapeutic drug or radiation therapy. For example, a monoclonal, oligoclonal or polyclonal mixture of PDGFR-alpha antibodies that inhibit tumor growth can be administered in combination with a drug shown to inhibit tumor cell proliferation directly. The method can be performed in vivo and the patient is preferably a human patient. \|0060] In some embodiments, the anli-PDGFR-alpha antibodies can be modified lo enhance their capability of fixing complement and participating in complement-dependent cytotoxicity (CDC). In other embodiments, the anli-PDGFR-alpha antibodies can be modified to enhance their capability of activating effector cells and participating in antibody-dependent cytotoxicity (ADCC). In yet other embodiments, the anti-PDGFR-alpha antibodies can be modified both to enhance their capability of activating effector cells and WO 2008/112003 PCT/US2007/075117 participating in antibody-dependent cytotoxicity (ADCC) and to enhance their capability of fixing complement and participating in complement-depend£nt cytotoxicity (CDC). [0061] In another embodiment, the invention provides an article of manufacture including a container. The container includes a composition containing an anti-PDGFR-alpha antibody, and a package insert or label indicating that the composition can be used to treat diseases characterized by the expression or overexpression of PDGFR-alpha. [0062] In other embodiments, the invention provides a kit for treating diseases involving the expression of PDGFR-alpha, comprising anti-PDGFR-alpha monoclonal antibodies and instructions to administer the monoclonal antibodies to a subject in need of treatment [0063] In another aspect, a method of selectively killing a cancerous cell in a patient is provided. The method comprises administering a fully human antibody conjugate to a patient. The fully human antibody conjugate comprises 3" antibody that can bind to the extracellular domain of PDGFR-alpha and an agent. The agent is either a toxin, a radioisotope, or another substance that will kill a cancer cell. The antibody conjugate thereby selectively kills the cancer cell. The agent can be saporin. 10064] In one aspect, a conjugated fully human antibody that binds to PDGFR-alpha is provided. Attached to the antibody is an agent, and the binding of the antibody to a cell results in the delivery of the agent to the cell. In one embodiment, the above conjugated fully human antibody binds to an extracellular domain of PDGF^-alpha. In another embodiment, the antibody and conjugated toxin are internalized by a cell that expresses PDGFR-alpha. In another embodiment, the agent is a cytotoxic agent. In another embodiment, the agent is, for example saporin, or auristatin. pseudomonas exotoxin, gelonin, ricin, calicheamicin or maytansine-based lmmunoconjugates, and the like. In still another embodiment, the agent is a radioisotope. [0065] In some embodiments of the invention, tfie glycosylation patterns of the antibodies provided herein are modified to enhance ADCC and CDC effector function. See Shields RL et al., (2002) JBC. 277:26733; Shinkawa T e al., (2003) JBC. 278:3466 and Okazaki A et al., (2004) J. Mol. Biol., 336: 1239. WO 2008/112003 PCT/US2007/075117 BRIEF DESCRIPTION OF THE DRAWINGS (0066) Figure 1 is a graph showing the dose responses for 5 selected monoclonal antibodies for % inhibition of PDGF-AA-induced proliferation of MG-63 tumor cells against antibody in ng/ml. Cell stimulation was conducted using 100 ng/ml (3.45nM) PDGF-AA. [0067] Figures 2a-2b show the results of in vivo antitumor evaluation of 2.175.3 and 2.449.1.3 in the Calu-6 non-small cell lung carcinoma xenograft model. Figure 2a shows the average tumor size (mm3) vs. time (days) and Figure 2b shows the average body weight (g) vs. time (days). The square points represent the vehicle treatment group; the circular points represent the 2.175.3 10 mg/kg treatment group; the triangular points represent the 2.449.1.3 lOmg/kg treatment group. [0068J Figure 3 shows the results of in vivo evaluation of the antibodies in the UI IS glioma xenograft model in SCID mice. Tumor size (mm3) versus lime (days) of treatment with antibodies is graphed. The square points show the vehicle treatment group; the circular points show the 2.175.3 10 mg/kg treatment group; the triangular points show the 2.449.1.3 10 mg/kg treatment group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT \|0069] Embodiments of the invention described herein relate to targeted binding agents that bind lo PDGFR-alpha. In some embodiments, the targeted binding agents are antibodies that bind to PDGFR-alpha and inhibit tumor cell growth. Other embodiments of the invention include fully human anti-PDGFR-alpha antibodies, and antibody preparations that are therapeutically useful. Such anti-PDGFR-alpha antibody preparations preferably have desirable therapeutic properties, including strong binding affinity for PDGFR-alpha, high selectivity for inhibition of PDGFR-alpha signaling, low toxicity, the ability to block PDGF-AA ligands from binding to PDGFR-alpha, the ability to block PDGF-AB ligands from binding to PDGFR-alpha or PDGFR-alpha/beta heterodimers, the ability to block PDGF-BB ligands from binding to PDGFR-alpha or PDGFR-alpha/beta heterodimers, the ability to bock PDGF-CC ligands from binding to PDGFR-alpha or PDGFR-alpha/beta heterodimers, and/or the ability to inhibit tumor cell growth in vitro and in vivo. Some WO 2008/112003 PCT/US2007/075117 embodiments relate to fully human anti-PDGFR-atpha antibodies that do not cross-react with PDGFR-beta. \|0070j Embodiments of the invention also include targeted binding agents which are isolated binding fragments of anti-PDGFR-alpha antibodies. Preferably, the binding fragments are derived from fully human anti-PDGFR-alpha antibodies. Exemplary fragments include Fv, Fab' dAb or other wel-known antibody fragments, as described in more detail below. Embodiments of the invention also include cells that express fully human antibodies against PDGFR-alpha. Examples of cells include hybridomas, or recombinantly created ceils, such as Chinese hamster ovary (CHO) cells that produce antibodies against PDGFR-alpha. 10071] In addition, embodiments of the invention include methods of using these antibodies for treating diseases. Anti-PDGFR-alpha antibodies arc useful for inhibiting tumor growth. The mechanism of action can include, but is not limited to, blocking ligand binding and/or inhibiting cell signaling implicated in cell growth. Diseases that are treatable through this mechanism include, but are not limited to, neoplastic diseases, such as, cancers including, lung cancer, ovarian cancer, prostate cancer, colon cancer, glioblastoma, melanoma and gastrointestinal stromal tumor (GIST). J0072] Other embodiments of the invention include diagnostic assays for specifically determining the presence and/or quantity of PDGFR-alpha in a patient or biological sample. The assay kit can include anti-PDGFR-alpha antibodies along with the necessary labels for detecting such antibodies. These diagnostic assays are useful lo screen for PDGFR-alpha-related diseases including, but not limited to, neoplastic diseases, such as cancers including, breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, glioblastoma, melanoma and gastrointestinal stromal tumor (GIST). \|0073] Another embodiment is an antibody comprising a heavy chain polypeptide comprising the sequence of SEQ ID NO.:2. In one embodiment, the antibody further comprises a light chain polypeptide comprising the sequence of SEQ ID NO.:4. Another embodiment includes an antibody comprising a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 10. In one embodiment, the antibody further comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 12. Still another embodiment is an antibody comprising a heavy chain polypeptide comprising the sequence of SEQ ID WO 2008/112003 PCT/US2007/075117 NO.: 14. In one embodiment, the antibody further comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 16. (0074] Yet another embodiment is a hybridoma that produces the light chain and/or the heavy chain of antibody as described hereinabove. The hybridoma may produce a light chain and/or a heavy chain of a fully human monoclonal antibody. In one embodiment, the hybridoma produces the light chain and/or the heavy chain of the fully human monoclonal antibody 2.175.3, 2.449.1.3, and 2.998.2. Alternatively the hybridoma may produce an antibody that binds to the same epitope or epitopes as fully human monoclonal antibody 2.175.3, 2.449.1.3, and 2.998.2. Alternatively the hybridoma may produce an antibody that competes for binding to PDGFR-alpha with fully human monoclonal antibody 2.175.3, 2.449.1.3, and 2.998.2. [0075[ Still another embodiment is a nucleic acid molecule encoding the light chain or the heavy chain of the antibody as described hereinabove. In this embodiment, the nucleic acid molecule may encode the light chain or the heavy chain of a fully human monoclonal antibody. In one embodiment, the nucleic acid molecule encodes the light chain or the heavy chain of one of the fully human monoclonal antibodies 2.175.3, 2.449.1.3, or 2.998.2. 1007.6] An additional embodiment is a vector comprising a nucleic acid molecule or molecules as described hereinabove, wherein the vector encodes a light chain and/or a heavy chain of an antibody as defined hereinabove. [0077] One embodiment of the invention includes a host cell comprising a vector as described hereinabove. Alternatively the host cell may comprise more than one vector. \|0078\| In addition, one embodiment of the invention is a method of producing an antibody by culturing host cells under conditions wherein a nucleic acid molecule is expressed to produce the antibody, followed by recovery of the antibody. (0079] In one embodiment the invention includes a method of making a targeted binding agent by transfecting at least one host cell with at least one nucleic acid molecule encoding the targeted binding agent as described hereinabove, expressing the nucleic acid molecule in the host cell and isolating the targeted binding agent. Another embodiment of the invention is a method of making an antibody by transfecting at least one host cell with at least one nucleic acid molecule encoding the antibody as described hereinabove, expressing the nucleic acid molecule in the host cell and isolating the antibody. WO 2008/112003 PCTYUS2007/075117 [0080J Another aspect of the invention is a method of inhibiting the growth of cells that express PDGFR-alpha by administering a targeted binding agent as described hereinabove. The method may include selecting an animal in need of treatment for disease-related to PDGFR-alpha expression, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds to PDGFR-alpha. [0081] Still another aspect is a method of treating a neoplastic disease in a mammal by administering a therapeutically effective amount of a targeted binding agent that specifically binds PDGFR-alpha. The method may include selecting an animal in need of treatment for a neoplastic disease, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds PDGFR-alpha. The agent can be administered alone, or can be administered in combination with a second anti-neoplastic agent selected from an antibody, a chemotherapeutic drug, or a radioactive drug. [0082J One other aspect is a method of treating cancer in a mammal by administering a therapeutically effective amount of a targeted binding agent that specifically binds PDGFR-alpha. The method may include selecting an animal in need of treatment for cancer, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds PDGFR-alpha. The agent can be administered alone, or can be administered in combination with a second anli-neoplastic agent selected from an antibody, a chemotherapeutic drug, or a radioactive drug. [0083] According to another aspect of Ihe invention a targeted binding agent can be used that specifically binds PDGFR-alpha for the manufacture of a medicament for the treatment of a neoplastic disease. [0084] One embodiment the invention is particularly suitable for use in inhibiting tumor growth in patients with a tumor that is dependent alone, or in part, on PDGFR-alpha expression. [0085] Another embodiment of the invention includes an assay kit for detecting PDGFR-alpha in mammalian tissues, cells, or body fluids to screen for neoplastic and/or fibrotic and/or immune system diseases. The kit includes a targeted binding agent thai binds to PDGFR-alpha and a means for indicating the reaction of the targeted binding agent with PDGFR-alpha, if present. The targeted binding agent may be a monoclonal antibody. In one embodiment, the antibody that binds PDGFR-alpha is labeled. In another embodiment the WO 2008/112003 PCT/US2007/075117 antibody is an unlabeled primary antibody and the kit further includes a means for detecting the primary antibody. In one embodiment, the means includes a labeled second antibody that is an anti-immunoglobulin. Preferably the antibody is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radio-opaque material. [0086] Further embodiments, features, and the like regarding anti-PDGFR-alpha antibodies are provided in additional detail below. Definitions J0087J Unless otherwise defined, scientific and technical terms used herein shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless othenvise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the art. I0088J Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofeclion). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook ct al. Molecular Cloning: A Laboratory Manual (3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001)), which is incorporated herein by reference. The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. WO 2008/112003 PCT/US2007/075I17 [0089] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings: \|0090] A compound refers to any small molecular weight compound with a molecular weight of less than about 2000 Daitons. (0091] The term "'PDGFR-alpha" refers to the platelet derived growth factor tyrosine kinase receptor-alpha encoded by the PDGFR-alpha gene. PDGFR-alpha is also known as CD140aandPDGFR-a. [0092] The term "neutralizing" when referring to a targeted binding agent such as an antibody relates to the ability of said agent to eliminate, or significantly reduce, the activity of a target antigen. Accordingly, a "neutralizing" anti-PDGFR-alpha antibody of the invention is capable of eliminating or significantly reducing the activity of PDGFR-alpha. A neutralizing PDGFR-alpha antibody may, for example, act by blocking the binding of ligand to its receptor PDGFR-alpha. [0093] The term "isolated polynucleotide" as used herein shall mean a polynucleotide that has been isolated from its naturally occurring environment. Such polynucleotides may be genomic, cDNA, or synthetic. Isolated polynucleotides preferably are not associated with all or a portion of the polynucleotides they associate with in nature. The isolated polynucleotides may be operably linked to another polynucleotide that it is not linked to in nature. In addition, isolated polynucleotides preferably do not occur in nature as part of a larger sequence. [0094J The term "isolated protein"' referred to herein means a protein that has been isolated from its naturally occurring environment. Such proteins may be derived from genomic DNA, cDNA, recombinant DNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g. free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature. [0095] The term "'polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus. Preferred polypeptides in accordance with the invention comprise the human heavy chain immunoglobulin molecules and the human WO 2008/112003 PCT/US2007/075117 kappa light chain immunoglobulin molecules, as well as antibody molecules formed by combinations comprising the heavy chain immunoglobulin molecules with light chain immunoglobulin molecules, such as the kappa or lambda light chain immunoglobulin molecules, and vice versa, as well as fragments and analogs thereof. Preferred polypeptides in accordance with the invention may also comprise solely the human heavy chain immunoglobulin molecules or fragments thereof. [0096] The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. - For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring. \|0097\| The term "operably linked" as used herein refers to positions of components so described that are in a relationship permitting them to function in their intended manner. For example, a control sequence "operably linked" to a coding sequence is connected in such a way that expression of the coding sequence is achieved under conditions compatible vith the control sequences. \|0098] The term "control sequence" as used herein refers to polynucleotide sequences that are necessary either to effect or to affect the expression and processing of coding sequences to which they are connected. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences may include promoters, enhancers, introns, transcription termination sequences, polyadenylation signal sequences, and 5' and '3 untranslated regions. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. 10099] The term "polynucleotide" as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, or RNA-DNA hetero-duplexes. The term includes single and double stranded forms of DNA. WO 2008/112003 PCT/US2007/075117 [00100] The term "oligonucleotide" referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring linkages. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g. for probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant. Oligonucleotides can be either sense or antisense oligonucleotides. [00101] The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleo tides and ribonucleotides. The term "'modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "oligonucleotide linkages" referred to herein includes oligonucleotides linkages such as phosphorothioatc, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate: phosphoroanilothioate, phosphoraniiadate, phosphoroamidate, and the like. See e.g., LaPlanche et al. Nucl. Acids Res. 14:9081 (1986); Stec et al. J. Am. Chem. Soc. 106:6077 (1984); Stein et ai. Nucl. Acids Res. 16:3209 (1988); Zon et al. Anti-Cancer Drug Design 6:539 (1991); Zon et at. Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al. U.S. Patent No. 5,151,510; Uhlmann and Peyman Chemical Reviews 90:543 (1990), the disclosures of which are hereby incorporated by reference. An oligonucleotide can include a label for detection, if desired. [00102] The term "selectively hybridize" referred to herein means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments thereof selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, or antibody fragments and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%. WO 2008/112003 PCT/US2007/075117 100103} The term i:CDR region" or "'CDR" is intended lo indicate the hypervariable regions of the heavy and light chains of the immunoglobulin as defined by Kabat et al. 1991 (Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest, 5lh Edition. US Department of Health and Human Services, Public Service, NIK Washington), and later editions. An antibody typically contains 3 heavy chain CDRs and 3 light chain CDRs. The term CDR or CDRs is used here in order to indicate, according to the case, one of these regions or several, or even the whole, of these regions which contain the majority of the amino acid residues responsible for the binding by affinity of the antibody for the antigen or the epitope which it recognizes. [00104] The third CDR of the heavy chain (HCDR3) has a greater size variability (greater diversity essentially due to the mechanisms of arrangement of the genes which give rise to it). It may be as short as 2 amino acids although the longest size known is 26- CDR length may also vary according to the length that can be accommodated by the particular underlying framework. Functionally, HCDR3 plays a role in part in the determination of the specificity of the antibody (Segal et al., PNAS, 71:4298-4302, 1974, Am it et al., Science. 233:747-753, 1986, Chothia et al., J. Mol. Biol., 196:901-917, 1987, Chothia ct al., Nature. 342:877- 883, 1989, Caton et al., J. Immunol, 144:1965-1968, 1990. Sharon et al., PNAS, 87:4814-4817, 1990, Sharon et al., J. Immunol., 144:4863-4869, 1990, Kabat ct al., J. Immunol., 147:1709-1719, 1991). [00105] The term a ;set of CDRs" referred to herein comprises CDR1, CDR2 and CDR3. Thus, a set of HCDRs refers to HCDRI, HCDR2 and HCDR3, and a set of LCDRs refers to LCDR1, LCDR2 and LCDR3. Unless otherwise stated, a "set of CDRs" includes HCDRs and LCDRs. {00106) Two amino acid sequences are 'homologous" if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least about 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN WO 2008/112003 PCT/US2007/075117 with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M.O., in Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or pails thereof are more preferably homoJogous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. It should be appreciated that there can be differing regions of homology within two orthologous sequences. For example, the functional sites of mouse and human orthologues may have a higher degree of homology than non-functional regions. (00107] The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. \|00108j In contradistinction, the term '"complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA". [00109] The term 'sequence identity" or "'identity' with reference to a sequence means that two polynucleotide or amino acid sequences are identical (i.e.. on a nucleotide-by-nucleotide or rcsidue-by-residuc basis) over the comparison window. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more preferably at least 99 percent sequence identity, as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of WO 2008/112003 PCT/US2007/075117 sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence. \|001101 As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology - A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. Stereoisomers (e.g., P-amino acids) of the twenty conventional amino acids, unnatural amino acids such as a-, a-di substituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional arAino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, y-carboxyglutamate, c-N,N,N-trimethyilysine, e-N-aceiyllysine. O-phosphoserine. N-acetylserine. N-formylm£thionine. 3-melhylhisiidine. 5-hydroxylysine, a-N-methylarginine, and other similar aminc> acids and imino acids (e.g.. 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention. \|00111\| Similarly, unless specified otherwise, the left-hand end of single-stranded polynucleotide sequences is the 5' end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as 'upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as ^downstream sequences1'. [00112] As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of WO 2008/112003 PCT/US2007/075117 amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxy 1 side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine. [00113\| As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present invention, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%. 90%; 95%, and most preferably 99% sequence identity to the antibodies or immunoglobulin molecules described herein. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that have related side chains. Genetically encoded amino acids are generally divided into families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are an aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding function or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Assays are described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. WO 2008/112003 PCIYUS2007/075117 Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequencee databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et al. Science 253:164 (1991). Thus, the foregoing examples demonstrate lhal those of skill in the art can recognize sequence motifs a.nd structural conformations that may be used to define structural and functional domains in accordance with the antibodies described herein. \|001141 Preferred amino acid substitutions a.re those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation. (3) alter binding affinity for forming protein complexes. (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs, Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular Contacts. A consen'ative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend tQ break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide seminary and tertiary structures are described in Proteins, Structures and Molecular Principles fCreinhlon. Ed,, W. H. Freeman and Company, New York (1984)); Introduction to Proteih Structure (C. Branden and J. Tooze, eds.. Garland Publishing, New York, N.Y. (1991)); and Thornton el at. Nature 354:105 (1991), which are each incorporated herein by reference. [001151 Variants of the VH and VL domains and CDRs of the present invention, -including those for which mino acid sequences are set out herein, and which can be employed in targeting agents and antibodies for PDGFR-alpjha can be obtained by means of methods of sequence alteration or mutation and screening for antigen targeting with desired characteristics. Examples of desired characteristics include but are not limited to: increased binding affinity for antigen relative to known antibodies which are specific for the antigen; WO 2008/112003 PCT/US2007/075117 increased neutralization of an antigen activity relative to known antibodies which are specific for the antigen if the activity is known; specified competitive ability with a known antibody or ligand to the antigen at a specific molar ratio; ability to immunoprecipitalc ligand-receptor complex; ability to bind to a specified epitope; linear epitope, e.g. peptide sequence identified using peptide-binding scan, e.g. using peptides screened in linear and/or constrained conformation; conformational epitope, formed by non-continuous residues; ability to modulate a new biological activity of PDGFR-alpha, or downstream molecule; ability to bind and/or neutralize and/or for any other desired property. (00116] The techniques required to make substitutions within amino acid sequences of CDRs. antibody VH or VL domains and antigen binding sites are available in the art. Variants of antibody molecules disclosed herein may be produced and used in the present invention. Following the lead of computational chemistry in applying multivariate data analysis techniques to the . structure/prop erty-activity relationships (Wold, et al. Multivariate data analysis in chemistry. Chemometrics -Mathematics and Statistics in Chemistry (Ed.: B. Kowalski), D. Reidel Publishing Company, Dordrecht, Holland, 1984) quantitative activity-property relationships of antibodies can be derived using well-known mathematical techniques, such as statistical regression, pattern recognition and classification (Norman et ai. Applied Regression Analysis. Wiley-Intcrscience; 3rd edition (April 1998); Kandel, Abraham & Backer, Eric. Computer-Assisted Reasoning in Cluster Analysis. Prentice Hall PTR, (May II, 1995); Krzanowski, Wojtek. Principles of Multivariate Analysis: A User's Perspective (Oxford Statistical Science Series, No 22 (Paper)). Oxford University Press; (December 2000); Witten, Ian H. & Frank, Eibe. Data Mining: Practical Machine Learning Tools and Techniques with Java Implementations. Morgan Kaufmann; (October 11, 1999);Denison David G. T. (Editor), Christopher C. Holmes, Bani K. Mallick, Adrian F. M. Smith. Bayesian Methods for Nonlinear Classification and Regression (Wiley Series in Probability and Statistics). John Wiley & Sons; (July 2002); Ghose, Amp K. & . Viswanadhan, Vellarkad N. Combinatorial Library Design and Evaluation Principles, Software, Tools, and Applications in Drug Discovery). The properties of antibodies can be derived from empirical and theoretical models (for example, analysis of likely contact residues or calculated physicochemical property) of antibody sequence, functional and three-dimensional structures and these properties can be considered singly and in combination. WO 2008/112003 PCT/US2007/075117 [00117) An antibody antigen-binding site composed of a VH domain and a VL domain is typically formed by six loops of polypeptide: three from the light chain variable domain (VL) and three from the heavy chain variable domain (VH). Analysis of antibodies of known atomic structure has elucidated relationships between the sequence and three-dimensional structure of antibody combining sites. These relationships imply that, except for the third region (loop) in VH domains, binding site loops have one of a small number of main-chain conformations: canonical structures. The canonical structure formed in a particular loop has been shown to be determined by its size and the presence of certain residues at key sites in both the loop and in framework regions. [001181 This study of sequence-structure relationship can be used for prediction of those residues in an antibody of known sequence, but of an unknown three-dimensional structure, which are important in maintaining the three-dimensional structure of its CDR loops and hence maintain binding specificity. These predictions can be backed up by comparison of the predictions to the output from lead optimization experiments. In a structural approach, a model can be created of the antibody molecule using any freely available or commercial package, such as WAM. A protein visualisation and analysis software package, such as Insight II (Accelrys, Inc.) or Deep View may then be used to evaluate possible substitutions at each position in the CDR. This information may then be used to make substitutions likely to have a minimal or beneficial effect on activity or confer other desirable properties. (00119\| The term "polypeptide fragment" as used herein refers to a polypeptide that has an ammo-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full-length cDNA sequence. Fragments typically are at least 5. 6, 8 or 10 amino acids long, preferably at least 14 amino acids long, more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long. The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has at least one of the following properties: (1) specific binding to a PDGFR-aipha, under suitable binding conditions, (2) ability to inhibit binding of PDGF-AA, (3) ability to inhibit binding of PDGF-AB, (4) ability to inhibit WO 2008/112003 PCT/US2007/075117 binding of PDGF-BB, and/or (5) ability to inhibit binding of PDGF-CC. Typically, polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide. \|00120] Peptide analogs are commonly used in the pharmaceutical industry as non-peplide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed 'peptide mimetics" or "peplidomimetics". Fauchere, J. Adv. Drug Res. 15:29 (1986); Veber and Freidinger TINS p.392 (1985); and Evans et al. J. Med. Chem. 30:1229 (1987), which are incorporated herein by reference. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH2NH--, --CH2S-, -CH2-CH2-, ~ CH=CH~(cis and trans), --COCH2-, --CH(OH)CH2~, and -CH2SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch Ann. Rev. Biochem. 61:387 (J992), incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide. [00121] As used herein, the term "antibody" refers to a polypeptide or group of polypeptides that are comprised of at least one binding domain that is formed from the folding of polypeptide chains having three-dimensional binding spaces with internal surface shapes and charge distributions complementary to the features of an antigenic determinant of an antigen. An antibody typically has a tetrameric form, Comprising two identical pairs of polypeptide chains, each pair having one '"light" and one "heavy" chain. The variable regions of each light/heavy chain pair form an antibody binding site. WO 2008/112003 PCT/US2007/075117 [00122) As used herein, a "targeted binding agent" is an agent, e.g. an antibody, or binding fragment thereof, that binds to a target site. In one embodiment, the targeted binding agent is specific for only one target site. In other embodiments, the targeted binding agent is specific for more than one target site. In one embodiment, the targeted binding agent may be a monoclonal antibody and the target site may be an epitope. As described below, a targeted binding agent may comprise at least one antigen binding domain (e.g. a CDR) of an antibody, wherein said domain is fused or contained within a heterologous protein scaffold, e.g. a non-antibody protein scaffold. \|00123] "Binding fragments" of an antibody are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab'. F(ab,)2, Fv, dAb and single-chain antibodies. An antibody other than a "bispecific" or "bi functional" antibody is understood to have each of its binding sites identical. An antibody substantially inhibits adhesion of a receptor to a counter-receptor when an excess of antibody reduces the quantity of receptor bound to counter-receptor by at least about 20%, 40%, 60% or 80%, and more usually greater 'han about 85% (as measured in an in vitro competitive binding assay). (00124] An antibody may be oligocional, a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a multi-specific antibody, a bi¬specific antibody, a catalytic antibody, a chimeric antibody, a humanized antibody, a fully human antibody, an anti-idiotypic antibody and antibodies that can be labeled in soluble or bound form as well as fragments, variants or derivatives (hereof, either alone or in combination with other amino acid sequences provided by known techniques. An antibody may be from any species. The term antibody also includes binding fragments of the antibodies of the invention; exemplary fragments include Fv, Fab, Fab7, single stranded antibody (svFC), dimeric variable region (Diabody) and disulphide stabilized variable region (dsFv). 100125] It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments arc (Ward, E.S. et al., (1989) Nature 341, 544-546) the Fab fragment consisting of VL, VH, CL and CHI domains; (McCafferty et al (1990) Nature, 348, 552-554) the Fd fragment consisting of the VH and CHI domains; (Holt et al (2003) Trends in Biotechnology 21, 484-490) the Fv fragment WO 2008/112003 PCT/US2007/075117 consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989), McCafferty et al (1990) Nature, 348, 552-554, Holt et al (2003) Trends in Biotechnology 21, 484-490], which consists of a VH or a VL domain; (vj iso/afeo1 CDR regions; (yi'j F(ab')2 fragments, a bfvatent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird et al, (1988) Science, 242, 423-426, , Huston et al, (1988) PNAS USA, 85, 5879-5883); (viii) bispecific single chain Fv dingers (PCT/US92/09965) and (ix) "diabodies", multivalent or multi specific fragments constructed by gene fusion (WO94/13804; Holliger, P. (1993) et al, Proc. Natl. Acad. Sci. USA 90 6444-6448,). Fv, scFv or diabody molecules may be stabilized by the incorporation of disulphide bridges linking the VH and VL domains (Reiler, Y. et al. Nature Biotech. 14, 1239-1245, 1996). Minibodies comprising a scFv joined to a CH3 domain may also be made (Hu, S. ei al, (1996) Cancer Res., 56, 3055-3061). Other examples of binding fragments are Fab', which differs from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CHI domain, including one or more cysteines from the antibody hinge region, and Fab'-SH, which is a Fab' fragment in which the cysteine residue(s) of the constant domains bear a free thiol group. (001261 The term 'epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and may, but not always, have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is (00127] The tenn "agent" is used herein to denote a'chemical compound, a mixture of chemical compounds, a biological macromolecuie, or an extract made from biological materials. (00128] "Active" or 'activity1' in regard to a PDQFR-alpha polypeptide refers to a portion of a PDGFR-alpha polypeptide that has a biological or an immunological activity of a native PDGFR-alpha polypeptide. "Biological" when used herein refers to a biological WO 2008/112003 PCTYUS2007/075117 function that results from the activity of the native PDGFR-alpha polypeptide. A preferred PDGFR-alpha biological activity includes, for example, autophosphorylation. \|00129] 'Mammal" when used herein refers to any animal that is considered a mammal. Preferably, the mammal is human. \|00130] Digestion of antibodies with the enzyme, papain, results in two identical antigen-bin ding fragments, known also as "Fab" fragments, and a "Fc1" fragment, having no antigen-binding activity but having the ability to crystallize. Digestion of antibodies with the enzyme, pepsin, results in the a F(ab')2 fragment in which the two anus of the antibody molecule remain linked and comprise two-antigen binding sites. The F(ab')2 fragment has the ability to crosslink antigen. J001311 "Fv" when used herein refers to the minimum fragment of an antibody that retains both antigen-recognition and antigen-binding sites. [00132[ "Fab" when used herein refers to a fragment of an antibody that comprises the constant domain of the light chain and the CH1 domain of the heavy chain. [00133] A i(dAb" is a single domain antibody and comprises either the variable domain of an antibody heavy chain (VH domain) or the variable domain of an antibody light chain (VL domain). Each dAb contains three of the six naturally occurring CDRs (Ward et al.s Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544-546 (1989); Holt, et al., Domain antibodies: protein for therapy, Trends Biotechnol. 21, 484-^9 (2003)). With molecular weights ranging from 11 to 15 kDa, they are four times smaller than a fragment antigen binding (Fab)2 and half the size of a single chain Fv (scFv) molecule. [00134] The term "mAb" refers to monoclonal antibody. \|00135\| "Liposome" when used herein refers to a small vesicle that may be useful for delivery of drugs that may include the PDGFR-alpha polypeptide of the invention or antibodies to such a PDGFR-alpha polypeptide to a mammal. \|00136J 'Label" or "labeled" as used herein refers to the addition of a detectable moiety to a polypeptide, for example, a radiolabel, fluorescent label, enzymatic label chemiluminescent labeled or a biotinyl group. Radioisotopes or radionuclides may include 3H, 14C, 15N, 35S, 90Y, 99Tc, lllln, 125L 1311, fluorescent labels may include rhodamine. WO 2008/112003 PCT/US2007/075U7 lanthanide phosphors or FITC and enzymatic labels may include horseradish peroxidase, P-galactosidase, luciferase, alkaline phosphatase. [00137] Additional labels include, by way of illustration and not limitation: enzymes, such as glucose-6-phosphate dehydrogenase ("G6PDH"), alpha-D-galactosidase, glucose oxydase, glucose amylase, carbonic anhydrase. acetylcholinesterase, lysozyme, maiate dehydrogenase and peroxidase; dyes; additional fluorescent labels or fluorescein include, such as fluorescein and its derivatives, fluorochrome, GFP (GFP for "Green Fluorescent Protein"), dansyl, umbel liferone, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine; fluorophores such as lanthanide cryptates and chelates e.g. Europium etc (Perkin Elmer and Cis Biointernational); chemoluminescent labels or chemiluminescerSj such as isoluminol, luminol and the dioxetanes; sensitizers: coenzymes; enzyme substrates; particles, such as latex or carbon particles; metal sol; crystallite; liposomes; cells, etc., which may be further labelled with a dye, catalyst or other detectable group; molecules such as biotin, digoxygenin or 5-bromodeoxyuridine; toxin moieties, such as for example a toxin moiety selected from a group of Pseudomonas exotoxin (PE or a cytotoxic fragment or mutant thereof), Diptheria toxin or a cytotoxic fragment or mutant thereof, a botulinum toxin A, B, C, D, E or F, ricin or a cytotoxic fragment thereof e.g. ricin A, abrin or a cytotoxic fragment thereof, saporin or a cytotoxic fragment thereof, pokeweed antiviral toxin or a cytotoxic fragment thereof and bryodin I or a cytotoxic fragment thereof. \|001381 The term "pharmaceutical agent or drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (Parker, S., Ed., McGraw-Hill, San Francisco (1985)), (incorporated herein by reference). [00139] As used herein, "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of ail macromolecular species present in the WO 2008/112003 PCT/US2007/O-?sm composition, more preferably more than about 85%, 90%. 95%, and 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species. \|00140] "Antibody-dependent cell-mediated cytotoxicity" and "ADCC refer to a cell-mediated reaction in which non-specific cytotoxic cells that express Ig Fc receptors (FcRs) (e.g. Natural Killer (NK) cells, monocytes, neutrophils, and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. The primary cells for mediating ADCC, NK cells, express FcyRIII only, whereas monocytes express FcyRI, FcyRII and FCYRIII. FcRs expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in U.S. Patent No. 5,500,362, or 5,821,337 can be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest can be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes el al. PNAS (USA) 95:652- 656(1988). ■ ' [00141J 'Complement dependent cytotoxicity" and "CPC" refer to the mechanism by which antibodies carry put their cell-killing function. It is initiated by the binding of Clq, a constituent of the first component of complement, to (he Fc domain of Igs. IgG or IgM, which are in complex with antigen (Hughs-Jones, N.C., and B. Gardner. 1979. Mol. Immunol. 16:697). Clq is a large, structurally complex glycoprotein of-410 kDa present in human serum at a concentration of 70 ug/ml (Cooper, N.R. 1985. Adv. Immunol. 37:151). Together with two serine proteases, Clr and Cls, Clq forms the complex CI, the first component of complement. At least two of the N-terminal globular heads of Clq must be bound to the Fc of Igs for CI activation, hence for initiation of the complement cascade (Cooper. N.R. 1985. Adv. Immunol, 37:151). [00142] 'Whole blood assays" use unfractionated blood as a source of natural effectors. Blood contains complement in the plasma, together with FcR-expressing celjular effectors, such as polymorphonuclear cells (PMNs) and mononuclear cells (MNCs). Thus, WO 2008/112003 PCT/US2007/075117 whole blood assays allow simultaneous evaluation of the synergy of both ADCC and CDC effector mechanisms in vitro. (00143] The term "patient" includes human and veterinary subjects. \|00144] The term "and/or': as used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example "A and/or B" is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein. Antibody Structure \|00145J The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light' (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The ammo-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-teiminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as lgM, lgD. IgA. and igE, respectively. Within light and heavy chains, the variable and constant regions are joined by a \J" region of about 12 or more amino acids, with the heavy chain also including a "D:' region of about 10 more amino acids. See generally, Fundamental Immunology Ch. 7 (Paul. W., ed„ 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair form the antibody binding site. 100146] Thus, an intact antibody has two binding sites. Except in bifunclional or bispecific antibodies, the two binding sites are the same. [00147] The chains ail exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR 1, CDR1, FR2, CDR2. FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of WO 2008/112003 PCT/US2007/075U7 Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. Mo!. Biol. 196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989). (00148J A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmatm Clin. Exp. Immunol. 79: 315-321 (1990), Kostelny et al. J. Immunol. 148:1547-1553 (1992). Bispecific antibodies do not exist in the form of fragments having a single binding site (e.g., Fab, Fab', and Fv). [00149\| Typically, a VH domain is paired with a VL domain to provide an antibody antigen-binding site, although a VH or VL domain alone may be used to bind antigen. The VH domain (see Table 12) may be paired with the VL domain (see Table 13). so that an antibody antigen-binding site is formed comprising both the VH and VL domains. Human Antibodies and Humanization of Antibodies [00150] Human antibodies avoid some of the problems associated with antibodies that possess murine or rat variable and/or constant regions. The presence of such murine or rat derived proteins can lead to the rapid clearance of the antibodies or can lead to the generation of an immune response against the antibody by a patient. In order to avoid the utilization of murine or rat derived antibodies, fully human antibodies can be generated through the introduction of functional human antibody loci into a rodent, other mamma! or animal so that the rodent, other mammal or animal produces fully human antibodies. [001511 One method for generating fully human antibodies is through the use of XenoMousc® strains of mice that have been engineered lo contain up to but less than 1000 kb-sized germ line configured fragments of the human hea.vy chain locus and kappa light chain locus. See Mendez et al. Nature Genetics 15:146-156 (1997) and Green and Jakobovils J. Exp. Med. 188:483-495 (1998). The XenoMouse® strains are available from Amgen, Inc. (Fremont, California, U.S.A). [001521 Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in U.S. WO 2008/112003 PCT/US2007/075117 Patent Application Serial No. 08/759,620, filed December 3, 1996 and International Patent Application Nos. WO 98/24893, published June 11. 1998 and WO 00/76310, published December 21, 2000, the disclosures of which are hereby incorporated by reference. See also Mendez et ai. Nature Genetics 15:146-156 (1997), the disclosure of which is hereby incorporated by reference. 100153\| The production of the XenoMouse® strains of mice is further discussed and delineated in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30, 1992, 08/031,801, filed March 15, 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995, 08/430, 938, filed April 27, 1995, 08/464,584. filed June 5, 1995, 08/464,582. filed June 5. 1995, 08/463.191. filed June 5, 1995, 08/462.S37, filed June 5, 1995, 08/486.853, filed June 5, 1995. 08/486,857, filed June 5, 1995, 08/486,859. filed June 5, 1995. 08/462,513, filed June 5, 1995, 08/724,752, filed October 2, 1996. 08/759,620, filed December 3, 1996, U.S. Publication 2003/0093820, filed November 30, 2001 and U.S. Patent Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598 and Japanese Patent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2. See also European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No.. WO 96/34096, published October 31, 1996, WO 98/24893, published June 11, 1998, WO 00/76310, published December 21, 2000. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirely. J00154J In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces {individual genes) from the Ig locus. Thus, one or more VH genes, one or more DH genes, one or more JH genes, a mu constant region, and usually a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani et al. and U.S. Patent Nos. 5,545,806, 5,625,825, 5.625,126, 5,633.425. 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,877,397, 5,874,299, and 6,255,458 each to Lonberg and Kay, U.S. Patent No. 5,591,669 and 6,023.010 to Krimpenfort and Bems, U.S. WO 2008/112003 PCT/US2007/075117 Patent Nos. 5,612,205, 5,721,367, and 5,789,215 to Bems et al., and U.S. Patent No. 5,643,763 to Choi and Dunn, and GenPhann Internationa] U.S. Patent Application Serial Nos. 07/574,748, filed August 29, 1990. 07/575,962, filed August 31,1990. 07/810,279. filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,068, filed June 23. 1992. 07/990,860, filed December 16, 1992, 08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 3 994, the disclosures of which are hereby incorporated by reference. See also European Patent No. 0 546 073 BK International Patent Application Nos. WO 92/03918, WO 92/22645. WO 92/22647. WO 92/22670, WO 93/J2227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884 and U.S. Patent No. 5.981.175, the disclosures of which are hereby incorporated by reference in their entirety. See further Taylor et al., 1992, Chen et al., 1993, Tuaillon et al., 1993, Choi et al.. 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuaillon et al., (1995), Fishwild et al., (1996), the disclosures of which are hereby incorporated by reference in their entiiety, (001551 Kirin has also demonstrated the generation of human antibodies from mice in which, through microcell fusion, large pieces of chromosomes, or entire chromosomes, have been introduced. See European Patent Application Nos. 773 2S8 and 843 961. the disclosures of which are hereby incorporated by reference. Additionally. ICMTM- mice, which are the result of cross-breeding of Kirin's Tc mice with Medarex's minilocus (Humab) mice have been generated. These mice possess the human IgH iranschromosome of the Kirin mice and the kappa chain transgene of the Genpharm mice (Ishida et al.. Cloning Stem Cells. (2002)4:91-102). (00156] Human antibodies can also be derived by in vitro methods. Suitable examples include but are not limited to phage display (CAT, Morphosys, Dyax, Biosite/Medarex, Xoma, Symphogen, Alexion (formerly Proliferon), Affimed) ribosome display (CAT), yeast display, and the like. (00157] In another embodiment, the antibodies of the invention the compete with the disclosed antibodies. Competition between antibodies may be assayed easily in vitro, for example using ELISA and/or by tagging a specific reporter molecule to one binding member which can be detected in the presence of one or more other untagged antibodies, to enable WO 2008/112003 PCT/US2007/075117 identification of antibodies which bind the same epitope or an overlapping epitope. Such methods are readily known to one of ordinary skill in the art, and are described in more detail herein. Thus, a further aspect of the present invention provides an antigen binding site comprising a human antibody antigen-binding site that competes with an antibody molecule, for example especially an antibody molecule comprising a VH and/or VL domain. CDR e.g. HCDR3 or set of CDRs of the parent antibody or any of antibodies disclosed herein that bind to PDGFR-alpha. In one embodiment, the an antibody of the invention competes with 2.175.3, 2.449.1.3 and /or 2.998.2. Preparation of Antibodies [001581 I" general, antibodies produced by the fused hybridomas were human lgG2 or IgG4 heavy chains with fully human kappa or lambda light chains. Antibodies can also be of other human isotypes, including IgGl heavy chains. The antibodies possessed high affinities, typically possessing a Kd of from about 10-6 through about 10-12 M or below, when measured against cells in FACS-based affinity measurement techniques. The affinity can also be measured by solid phase and solution phase techniques. In one embodiment, the antibodies described herein bind CD PDGFR-alpha 20 with a Kd of less than about 500, 400, 300, 200 or 100 picomolar (pM) and inhibit tumor growth. In some embodiments, the antibodies bind PDGFR-alpha with a Kd of less than about 75, 60, 50. 40. 30,25,20, 10,or5pM. [001591 As will be appreciated, anti-PDGFR-alpha antibodies can be expressed in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies can be used to transform a suitable mammalian host cell. Transfonnation can he by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfeclion procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents arc hereby incorporated herein by reference). The transfonnation procedure used depends upon the host to be transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include dcxtran-mediated transfeclion, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, WO 2008/112003 PCT/US2007/075117 encapsulation of the polynucleotide(s) In liposomes, and direct microinjection of the DNA into nuclei. [00160] Mammalian ceil lines available as hosts for expression are weil known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK.) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), human epithelial kidney 293 cells, and a number of other ceil lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels and produce antibodies with constitutive PDGFR-alpha binding properties. \|00161\| Anti-PDGFR-alpha antibodies are useful in the detection of PDGFR-alpha in patient samples and accordingly are useful as diagnostics for disease states as described herein. In addition, based on their ability to inhibit tumor growth, anti-PDGFR-alpha antibodies have therapeutic effects in treating symptoms and conditions resulting from PDGFR-alpha expression. In specific embodiments, the antibodies and methods herein relate lo the treatment of symptoms resulting from PDGFR-alpha induced tumor growth. Further embodiments involve using the antibodies and methods described herein to treat neoplastic diseases, such as cancers including, lung cancer, ovarian cancer, prostate cancer, colon cancer, glioblastoma, melanoma and gastrointestinal stromal tumor (GIST). Antibody Sequences [001621 Embodiments of the invention include the specific anli-PDGFR-alpha antibodies listed below in Table 1. This table reports the identification number of each anti-PDGFR-alpha antibody, along with the SEQ ID number of variable regions of the corresponding heavy chain and light chain genes. [00163] Each antibody has been given an identification number that includes either two or three numbers separated by one or two decimal points. In some cases, only two identification numbers separated by one decimal point are listed. However, in some cases, several clones of one antibody were prepared. Although the clones have the identical nucleic acid and amino acid sequences as the parent sequence, they may also be listed separately, with the clone number indicated by the number to the right of a second decimal point. Thus, WO 2008/112003 PCT/US2007/075117 for example, the nucleic acid and amino acid sequences of antibody 2.84 are identical to the sequences of antibody 2.84.1, 2.84.2, and 2.84.3. TABLE J mAblD No.: Sequence SEQID NO: 2.175.3 Nucleotide sequence encoding the variable region of the heavy chain 1 Amino acid sequence encoding the variable region of the heavy chain 2 Nucleotide sequence encoding the variable region of the light chain Amino acid sequence encoding the variable region of the light chain 4 2.451.1.1 Nucleotide sequence encoding the variable region of the heavy chain 5 Amino acid sequence encoding the variable region of the heavy chain 6 Nucleotide sequence encoding the variable region of the light chain 012/JK5 7 Amino acid sequence encoding the variable region of the light chain 012/JK5 8 Nucleotide sequence encoding the variable region of the light chain A20/JK5 21 Amino acid sequence encoding the variable region of the light chain A20/JK5 22 2.449.1.3 Nucleotide sequence encoding the variable region of the heavy chain 9 Amino acid sequence encoding the variable region of (he heavy chain 10 Nucleotide sequence encoding the variable region of the light chain 11 Amino acid sequence encoding the variable region of the light chain 12 2.998.2 Nucleotide sequence encoding the variable region of the heavy chain 13 Amino acid sequence encoding the variable region of the heavy chain 14 Nucleotide sequence encoding the variable region of the light chain 15 Amino acid sequence encoding the variable region of the light chain 16 WO 2008/112003 PCT/(iS2007/075II7 2.84.3 Nucleotide sequence encoding the variable region of the heavy chain 1 17 Amino acid sequence encoding the variable region of the heavy chain 18 Nucleotide sequence encoding the variable region of the light chain 19 Amino acid sequence encoding the variable region of the light chain 20 2.1576.1. 2 Nucleotide sequence encoding the variable region of the heavy chain 23 Amino acid sequence encoding the variable region of the heavy chain 24 Nucleotide sequence encoding the variable region of the light chain 25 Amino acid sequence encoding the variable region of the light chain 26 3.625.1 Nucleotide sequence encoding the variable region of the heavy chain 27 Amino acid sequence encoding the variable region of the heavy chain 28 Nucleotide sequence encoding the variable region of the light chain 29 Amino acid sequence encoding the variable region of the light chain 30 2.414.2 Nucleotide sequence encoding the variable region of the heavy chain 31 Amino acid sequence encoding the variable region of the heavy chain 32 Nucleotide sequence encoding the variable region of the light chain T -1 Amino acid sequence encoding the variable region of the light chain 34 2.542.2 Nucleotide sequence encoding the variable region of the heavy chain 35 Amino acid sequence encoding the variable region of the heavy chain 36 Nucleotide sequence encoding the variable region of the light chain 37 Amino acid sequence encoding the variable region of the light chain 3S 2.737.1.4 Nucleotide sequence encoding the variable region of the heavy chain 39 Amino acid sequence encoding the variable region of the heavy chain 40 Nucleotide sequence encoding the variable region of the light chain 41 Amino acid sequence encoding the variable region of the light chain 42 2.1623.2 Nucleotide sequence encoding the variable region of the heavy chain 43 Amino acid sequence encoding the variable region of the heavy chain 44 Nucleotide sequence encoding the variable region of the light chain 45 Amino acid sequence encoding the variable region of the light chain 46 2.1853.3 Nucleotide sequence encoding the variable region of the heavy chain 47 Amino acid sequence encoding the variable region of the heavy chain 4S Nucleotide sequence encoding the variable region of the light chain 49 Amino acid sequence encoding the variable region of the light chain 50 2.1954.2 Nucleotide sequence encoding the variable region of the heavy chain 51 Amino acid sequence encoding the variable region of the heavy chain 52 Nucleotide sequence encoding the variable region of the light chain 53 Amino acid sequence encoding the variable region of the light chain 54 3.23.2 Nucleotide sequence encoding the variable region of the heavy chain 55 Amino acid sequence encoding the variable region of the heavy chain 56 Nucleotide sequence encoding the variable region of the light chain 57 Amino acid sequence encoding the variable region of the light chain 58 3.87.1.1 Nucleotide sequence encoding the variable region of the heavy chain 59 Amino acid sequence encoding the variable region of the heavy chain 60 Nucleotide sequence encoding the variable region of the light chain 61 Amino acid sequence encoding the variable region of the light chain 62 WO 2008/112003 PCT/US2007/075117 3.341.1 Nucleotide sequence encoding the variable region of the heavy chain 63 Amino acid sequence encoding the variable region of the heavy chain 64 Nucleotide sequence encoding the variable region of the light chain 65 Amino acid sequence encoding the variable region of the light chain 66 3.472.1.1 Nucleotide sequence encoding the variable region of the heavy chain 67 Amino acid sequence encoding the variable region of the heavy chain 68 Nucleotide sequence encoding the variable region of the light chain 69 Amino acid sequence encoding the variable region of the light chain 70 3.805.13 Nucleotide sequence encoding the variable region of the heavy chain 71 Amino acid sequence encoding the variable region of the heavy chain 72 Nucleotide sequence encoding the variable region of the light chain 73 Amino acid sequence encoding the variable region of the light chain 74 3.818.4 Nucleotide sequence encoding the variable region of the heavy chain 75 Amino acid sequence encoding the variable region of the heavy chain 76 Nucleotide sequence encoding the variable region of the light chain 77 Amino acid sequence encoding the variable region of the light chain 78 4.16.2 Nucleotide sequence encoding the variable region of the heavy chain 79 Amino acid sequence encoding the variable region of the heavy chain 80 Nucleotide sequence encoding the variable region of the light chain 81 Amino acid sequence encoding the variable region of the light chain 82 5.1.1.1 Nucleotide sequence encoding the variable region of the heavy chain 83 Amino acid sequence encoding the variable region of the heavy chain S4 Nucleotide sequence encoding the variable region of the light chain 85 Amino acid sequence encoding the variable region of the light chain 86 5.9.3 Nucleotide sequence encoding the variable region of the heavy chain 87 Amino acid sequence encoding the variable region of the heavy chain 88 Nucleotide sequence encoding the variable region of the light chain S9 Amino acid sequence encoding the variable region of the light chain 90 2.796.2 Nucleotide sequence encoding the variable region of the heavy chain 91 Amino acid sequence encoding the variable region of the heavy chain 92 Nucleotide sequence encoding the variable region of the light chain 93 Amino acid sequence encoding the variable region of the light chain 94 3.772.2 Nucleotide sequence encoding the variable region of the heavy chain 95 Amino acid sequence encoding the variable region of the heavy chain 96 Nucleotide sequence encoding the variable region of the light chain 97 Amino acid sequence encoding the variable region of the light chain 98 5.16.1 Nucleotide sequence encoding the variable region of the heavy chain 99 Amino acid sequence encoding the variable region of the heavy chain 100 Nucleotide sequence encoding the variable region of the light chain 101 Amino acid sequence encoding the variable region of the light chain 102 2.2002.3 Nucleotide sequence encoding the variable region of the heavy chain 103 Amino acid sequence encoding the variable region of the heavy chain 104 Nucleotide sequence encoding the variable region of the light chain 105 Amino acid sequence encoding the variable region of the light chain 106 WO 2008/112003 PCIYUS2O07/075117 2.2071.1. 3 Nucleotide sequence encoding the variable region of the heavy chain 107 Amino acid sequence encoding the variable region of the heavy chain 10S Nucleotide sequence encoding the variable region of the light chain 109 Amino acid sequence encoding the variable region of the light chain no 3.23.3 Nucleotide sequence encoding the variable region of the heavy chain in Amino acid sequence encoding the variable region of the heavy chain 112 Nucleotide sequence encoding the variable region of the light chain 113 Amino acid sequence encoding the variable region of the light chain 114 3.457.3.1 Nucleotide sequence encoding the variable region of the heavy chain 115 Amino acid sequence encoding the variable region of the heavy chain U6 Nucleotide sequence encoding the variable region of the light chain 117 Amino acid sequence encoding the variable region of the light chain 118 2.84.1 Nucleotide sequence encoding the variable region of the heavy chain i(9 Amino acid sequence encoding the variable region of the heavy chain 120 Nucleotide sequence encoding the variable region of the light chain 121 Amino acid sequence encoding the variable region of the light chain 122 2.35 i.3 Nucleotide sequence encoding the variable region of the heavv chain 123 Amino acid sequence encoding the variable region of the heavy chain 124 , Nucleotide sequence encoding the variable region of the light chain 125 Amino acid sequence encoding the variable region of the light chain 126 \| \|00164\| Antibodies, as described herein in the Examples, were prepared through the utilization of the XenoMouse® technology, as described below. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in the patents: applications, and references disclosed in the background section herein. In particular, however, a preferred embodiment of transgenic production of mice and antibodies therefrom is disclosed in U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996 and International Patent Application Nos. WO 98/24893, published June 11, 1998 and WO 00/76310, published December 21, 2000, the disclosures of which are hereby incorporated by reference See also Mendez et a!. Nature Genetics 15:3 46-156 (1997), the disclosure of which is hereby incorporated by reference. \|00I65J Through the use of such technology, fully human monoclonal antibodies to a variety of antigens have been produced. Essentially^ XenoMouse® lines of mice are immunized with an antigen of interest (e.g. PDGFR-alpha), lymphatic cells (such as B-cells) are recovered from the hyper-immunized mice, and the recovered lymphocytes are fused with a myeloid-type cell line to prepare immortal hybridoma cell lines. These hybridoma WO 2008/112003 PCT/US2007/075117 cell lines are screened and selected to identify hybridoma eel! lines that produced antibodies specific to the antigen of interest. Provided herein are methods for the production of multiple hybridoma cell lines that produce antibodies specific to PDGFR-alpha. Further, provided herein are characterization of the antibodies produced by such cell lines, including nucleotide and amino acid sequence analyses of the heavy and light chains of such antibodies. [00166] Alternatively, instead of being fused to myeloma cells to generate hybridomas, B cells can be directly assayed. For example, CD19+ B cells can be isolated from hyperimmune XenoMouse© mice and allowed to proliferate and differentiate into antibody-secreting plasma cells. Antibodies from the cell supematants are then screened by ELISA for reactivity against the PDGFR-alpha immunogen. The supematants might also be screened for immunoreactivity against fragments of PDGFR-alpha to further map the different antibodies for binding to domains of functional interest on PDGFR-alpha. The antibodies may also be screened other related human receptors and against the rat, the mouse, and non-human primate, such as Cynomolgus monkey, orthologues of PDGFR-alpha, the last to determine species cross-reactivity. B cells from wells containing antibodies of interest may be immortalized by various methods including fusion to make hybridomas either from individual or from pooled wells, or by infection with EBV or transfection by known immortalizing genes and then plating in suitable medium. Alternatively, single plasma cells secreting antibodies with the desired specificities are then isolated using a PDGFR-alpha-specific hemolytic plaque assay (see for example Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-48 (1996)). Cells targeted for lysis are preferably sheep red blood cells (SRBCs) coated with the PDGFR-alpha antigen. [00167J 'n {he presence of a B-cell culture containing plasma cells secreting the immunoglobulin of interest and complement, the formation of a plaque indicates specific PDGFR-alpha-mediated lysis of the sheep red blood cells surrounding the plasma cell of interest. The single antigen-specific plasma cell in the center of the plaque can be isolated and the genetic information that encodes the specificity of the antibody is isolated from the single plasma cell. Using reverse-transcription followed by PCR (RT-PCR), the DNA encoding the heavy and light chain variable regions of the antibody can be cloned. Such cloned DNA can then be further inserted into a suitable expression vector, preferably a vector cassette such as a pcDNA, more preferably such a pcDNA vector containing the constant WO2008/U20U3 PCT/US2007/075117 domains of immunoglobulin heavy and light chain. The generated vector can then be transfected into host cells, e.g., HEK293 cells, CHO cells, and cultured in conventional nutrient media modified as appropriate for inducing transcription, selecting transformants. or amplifying the genes encoding the desired sequences. (00168) Anti-PDGFR-alpha antibodies can have therapeutic effects in treating symptoms and conditions related to PDGFR-alpha expression. For example, the antibodies can inhibit growth of cells expressing PDGFR-alpha, thereby inhibiting tumor growth, or the antibodies can be associated with an agent and deliver a lethal toxin to a targeted cell. Anti-PDGFR-alpha antibodies can have therapeutic effects in treating fibrotic diseases, such as cardiac, lung, liver, kidney or skin fibrosis. Anti-PDGFR-alpha antibodies can also have therapeutic effects in the treatment of allograft vasculopathy or restenosis. In addition, the anti-PDGFR-alpha antibodies are useful as diagnostics for the disease states, especially neoplastic, fibrotic and immune system diseases. \|001691 If desired, the isotype of an anti-PDGFR-alpha antibody can be switched, for example to take advantage of a biological property of a different isotype. For example, in some circumstances it can be desirable in connection with the generation of antibodies as therapeutic antibodies against PDGFR-alpha that the antibodies be capable of fixing complement and participating in complement-dependent cytotoxicity (CDC). There are a number of isotypes of antibodies that are capable of the same, including, without limitation, the following: murine lgM, murine IgG2a, murine lgG2b, murine lgG3, human IgM, human JgA, human IgGl, and human lgG3. In other embodiments it can be desirable in connection with the generation of antibodies as therapeutic antibodies against PDGFR-alpha that the antibodies be capable of binding Fc receptors on effector cells and participating in antibody-dependent cytotoxicity (ADCC). There are a number of isotypes of antibodies that are capable of the same, including, without limitation, the following: murine lgG2a, murine IgG2b, murine IgG3, human IgGl, and human lgG3. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, ratlier, the antibody as generated can possess any isotype and the antibody can be isotype switched thereafter using conventional techniques that are well known in the art. Such techniques include the use of direct recombinant techniques (see e.g., U.S. Patent No. 4,816,397), cell-cell fusion techniques (see e.g., U.S. Patent Nos. 5,916,771 and 6,207,418), among others. WO 2008/112003 PCT/US20UTWI7SH [00170} By way of example, the anti-PDGFR-alpha antibodies discussed herein are fully human antibodies. If an antibody possessed desired binding to PDGFR-alpha, it could be readily isolype switched to generate a human lgM, human JgGl, or human IgG3 isotype, while still possessing the same variable region (which defines the antibody's specificity and some of its affinity). Such molecule would then be capable of fixing complement and participating in CDC and/or be capable of binding to Fc receptors on effector cells and participating in ADCC. [00171] In the cell-cell fusion technique, a myeloma, CHO cell or other cell line is prepared that possesses a heavy chain with any desired isotype and another myeloma, CHO cell or other cell line is prepared that possesses the light chain. Such cells can, thereafter, be fused and a cell line expressing an intact antibody can be isolated. [00172] Accordingly, as antibody candidates are generated thai meet desired ■'structural1' attributes as discussed above, they can generally be provided with at least certain of the desired "functional" attributes through isotype switching. Therapeutic Administration and Formulations [00173j Embodiments of the invention include sterile pharmaceutical formulations of anti-PDGFR-alpha antibodies that are useful as treatments for diseases. Such formulations would inhibit cell growth, thereby effectively treating pathological conditions where, for example, PDGFR-alpha expression is abnormally elevated or PDGFR-alpha expressing cells mediate disease states. Anti-PDGFR-alpha antibodies preferably possess adequate affinity to specifically bind PDGFR-alpha, and preferably have an adequate duration of action to allow for infrequent dosing in humans. A prolonged duration of action will allow for less frequent and more convenient dosing schedules by alternate parenteral routes such as subcutaneous or intramuscular injection. [00174J Sterile formulations can be created, for example, by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution of the antibody. The antibody ordinarily will be stored in lyophilized form or in solution. Therapeutic antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having an adapter that allows retrieval of the formulation, such as a stopper pierceable by & hypodermic injection needle. WO 2008/H2003 PCT/US2Q07/075U7 J00175] The route of antibody administration is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, intrathecal, inhalation or intralesional routes, or by sustained release systems as noted below. The antibody is preferably administered continuously by infusion or by bolus injection. \|00176] An effective amount of antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it is preferred that the therapist titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. Typically, the clinician will administer antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays or by the assays described herein. [001771 Antibodies, as described herein, can be prepared in a mixture with a pharmaceutically acceptable carrier. This therapeutic composition can be administered intravenously or through the nose or lung, preferably as a liquid or powder aerosol (lyophilized). The composition can also be administered parenterally or subcutaneously as desired. When administered systemically, the therapeutic composition should be sterile, pyrogen-free and in a parenterally acceptable solution having due regard for pH, isotonieity, and stability. These conditions are known to those skilled in the art. Briefly, dosage formulations of the compounds described herein are prepared for storage or administration by mixing the compound having the desired degree of purity with physiologically acceptable carriers, excipienls, or stabilizers. Such materials are non-toxic to the recipients at the dosages and concentrations employed, and include buffers such as TR1S HC1, phosphate, citrate, acetate and other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidinone; amino acids such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA: sugar alcohols such as mannitol or sorbitol; counterions such as sodium and/or nonionic surfactants such as TWEEN. PLURONiCS orpolyethyleneglycol. WO 2008/112003 PCT/US2007/073H7 (00178) Sterile compositions for injection can be formulated according to conventional pharmaceutical practice as described in Remington: The Science and Practice of Pharmacy (20th ed, Lippincott Williams & Wilkens Publishers (2003)). For example, dissolution or suspension of the active compound in a vehicle such as water or naturally occurring vegetable oil like sesame, peanut, or cottonseed oil or a synthetic fatty vehicle like ethyl oleate or the like can be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice. [00179] Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-mctbacrylate) as described by Langer et al., J. Biomed Mater. Res.. (1981) 15:167-277 and Langer. Chem. Tech., (1982) 12:98-105, or poly(vinylalcohol)), polylaclides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers, (1983) 22:547-556), non-degradable ethylene-vinyl acetate (Langer et al., supra), degradable lactic acid-glycolic acid copolymers such as the LUPRON Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988). 100180) While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins lor shorter time periods. When encapsulated proteins remain in the body for a long time, they can denature or aggregate as a result of exposure to moisture at 37°C? resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for protein stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be inlermolecular S-S bond formation through disulfide interchange, stabilization can be achieved by modifying sulfhydryl residues., lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions. J00181] Sustained-released compositions also include preparations of crystals of the antibody suspended in suitable formulations capable of maintaining crystals in suspension. These preparations when injected subcutaneously or intraperitonealy can WO 2008/112003 PCT/US2007/075117 produce a sustained release effect. Other compositions also include liposomaliy entrapped antibodies. Liposomes containing such antibodies are prepared by methods known per se: U.S. Pat. No. DE 3,218,121; Epstein et a], Proc. Natl. Acad. Sci. USA. (1985) S2:36S8-3692; Hwang et al., Proc. Natl. Acad. Sci. USA, (1980) 77:4030-4034; EP 52,322: EP 36,676; EP 88,046; EP 143,949; 142,641; Japanese patent application 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. \|00182J The dosage of the antibody formulation for a given patient will be determined by the attending physician taking into consideration various factors known to modify the action of drugs including severity and type of disease, body weight, sex, diet, time and route of administration, other medications and other relevant clinical factors. Therapeutically effective dosages can be determined by either in vitro or in vivo methods. f001831 An effective amount of the antibodies, described herein, to be employed therapeutically will depend, for example, upon the therapeutic objectives, the rouie of administration, and the condition of the patient. Accordingly, it is preferred for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about O.OOlmg/kg to up to lOOmg/kg or more, depending on the factors mentioned above. Typically, the clinician will administer the therapeutic antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays or as described herein. (00184\| It will be appreciated that administration of therapeutic entities in accordance with the compositions and methods herein will be administered with suitable cairiers, excipicnis, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures can be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the WO 2008/112003 PCT/US2007/075117 route of administration. See also Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance.1* Regul. Toxicol. Pharmacol. 32(2):2I0-S (2000), Wang W. :'Lyophilization and development of solid protein pharmaceuticals." Int. J. Pharm. 203(1-2):I-60 (2000), Channan WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts:' J Pharm Sci .89(8):967-78 (2000), Powell el a!. "Compendium of excipients for parenteral formulations" PDA J Pharm Sci Technol, 52:233-311 (1998) and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists. Design and Generation of Other Therapeutics [001851 In accordance with the present invention and based on the activity of the antibodies that are produced and characterized herein with respect to PDGFR-alpha. the design of other therapeutic modalities is facilitated and disclosed to one of skill in the an. Such modalities include, without limitation, advanced antibody therapeutics, such as bispecific antibodies, immunotoxins, radiolabeled therapeutics, and single antibody V domains, antibody-like binding agent based on other than V region scaffolds, generation of peptide therapeutics, gene therapies, particularly intrabodies. antisense therapeutics, and small molecules. (00186) An antigen binding site may be provided by means of arrangement of CDR.S on non-antibody protein scaffolds, such as fibronectin or cytochrome B etc. (Haan & Maggos (2004) BioCentury, 12(5): A1-A6; Koideel al. (1998) Journal of Molecular Biology, 284: 1141-1151; Nygren et al. (1997) Current Opinion in Structural Biology, 7: 463-469) or by randomising Or mutating amino acid residues of a Joop vyjthm a protein scaffoJd to confer binding specificity for a desired target. Scaffolds for engineering novel binding sites in proteins have been reviewed in detail by Nygren et al. (Nygren et al. (1997) Current Opinion in Structural Biology, 7: 463-469). Protein scaffolds for antibody mimics are disclosed in WO/0034784, which is herein incorporated by reference in its entirety, in which the inventors describe proteins (antibody mimics) that include a fibronectin type III domain having at least one randomised loop. A suitable scaffold into which to graft one or more CDRs, e.g. a set of HCDRs, may be provided by any domain member of the immunoglobulin gene superfamily. The scaffold may be a human or non-human protein. An advantage of a WO 2008/112003 PCT/US2007/075117 non-antibody protein scaffold is that it may provide an antigen-binding site in a scaffold molecule that is smaller and/or easier to manufacture than at least some antibody molecules. Small size of a binding member may confer useful physiological properties, such as an ability to enter cells, penetrate deep into tissues or reach targets within other structures, or to bind within protein cavities of the target antigen. Use of antigen binding sites in non-antibody protein scaffolds is reviewed in Wess, 2004 (Wess. L. In: BioCentury, The Bernstein Report on BioBusiness, 12(42), A1-A7, 2004). Typical are proteins having a stable backbone and one or more variable loops, in which the amino acid sequence of the loop or loops is specifically or randomly mutated to create an antigen-binding site that binds the target antigen. Such proteins include the IgG-binding domains of protein A from S. aureus, transferrin, albumin, tetranectin, fibronectin (e.g. 10th fibronectin type III domain), lipocalins as well as gamma-crystalline and other Affilin™ scaffolds (Sal Proteins). Examples of other approaches include synthetic "Microbodies" based on cyclotides - small proteins having intra-molecular disulphide bonds. Microproteins (Versabodies™, Amunix) ?nd ankyrin repeat proteins (DARPins, Molecular Partners). \|00187] In addition to antibody sequences and/or an antigen-binding site, a targeted binding agent according to the present invention may comprise other amino acids, e.g. forming a peptide or polypeptide, such as a folded domain, or to impart to the molecule another functional characteristic in addition to ability to bind antigen. Targeted binding agent s of the invention may carry a detectable label, or may be conjugated to a toxin or a targeting moiety or enzyme (e.g. via a peptidyl bond or linker). For example, a targeted binding agent may comprise a catalytic site (e.g. in an enzyme domain) as well as an antigen binding site, wherein the antigen binding site binds to the antigen and thus targets the catalytic site to the antigen. The catalytic site may inhibit biological function of the antigen, e.g. by cleavage. 1.00188) 'n connection with the generation of advanced antibody therapeutics, where complement fixation is a desirable attribute, it can be possible to sidestep the dependence on complement for cell killing through the use of bispecifics. immunotoxins, or radiolabels, for example. (00189] For example, bispeciftc antibodies can be generated that comprise (i) two antibodies, one with a specificity to PDGFR-alpha and another to a second molecule, that are WO 2008/112003 PCT/US2007/075117 conjugated together, (ii) a single antibody that has one chain specific to PDGFR-alpha and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to both PDGFR-alpha and the other molecule. Such bispecific antibodies can be generated using techniques that are well known; for example, in connection with (i) and (ii) see e.g., Fanger el al. Immunol Methods 4:72-81 (1994) and Wright and Hams, supra, and in connection with (iii) see e.g., Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992). In each case, the second specificity can be made as desired. For example, the second specificity can be made to the heavy chain activation receptors, including, without limitation, CD 16 or CD64 (see e.g., Deo et al. 18:127 (1997)) or CD89 (see e.g., Valerius et al. Blood 90:4485-4492(1997)). (00190] Antibodies can also be modified to act as immunotoxins utilizing techniques that are well known in the an. See e.g., Vitetta Immunol Today 14:252 (1993). See also U.S. Patent No. 5,194,594. In connection with the preparation of radiolabeled antibodies, such modified antibodies can also be readily prepared utilizing techniques that are well known in the art. See e.g., Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafher and Longo, eds., Lippincott Raven (1996)). See also U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules would be likely to kill cells expressing the desired multimeric enzyme.._subunit oligomenzation domain. In some embodiments, a pharmaceutical composition comprising an effective amount of the antibody in association with a pharrnaceutically acceptable carrier or diluent is provided. \|00191j m some embodiments, an anti-PDGFR-alpha antibody is linked to an agent (e.g., radioisotope, pharmaceutical composition, or a toxin). Preferably, such antibodies can be used for the treatment of diseases, such diseases can relate cells expressing PDGFR-alpha or cells overexpressing PDGFR-alpha. For example, it is contemplated that the drug possesses the pharmaceutical property selected from the group of antimitotic, alkylating, antimetabolite, antiangiogenic, apoptotic, alkaloid, COX-2. and antibiotic agents and combinations thereof. The drug can be selected from the group of nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogs, anthracyc lines, taxanes, COX-2 inhibitors, pyrimidine analogs, purine analogs, antimetabolites, antibiotics, enzymes, epipodophyllotoxins, platinum coordination WO 2008/112003 PCT/US2007/075117 complexes, vinca alkaloids, substituted ureas, methyl hydrazine derivatives, adrenocortical suppressants, antagonists, endostatin, taxols. camptothecins, oxaliplalin, doxorubicins and their analogs, and a combination thereof. [00192] Examples of toxins further include gelonin, Pseudomonas exotoxin (PE). PE40, PE38, diphtheria toxin, ricin, ricin, abrin, alpha toxin, saporin, ribonuclease (RNase): DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, Pseudomonas endotoxin, as well as derivatives, combinations and modifications thereof. [00193] Examples of radioisotopes include gamma-emitters, positron-emiIters, and x-ray emitters that can be used for localization and/or therapy, and beta-emitters and alpha-emitters that can be used for therapy. The radioisotopes described previously as useful for diagnostics, prognostics and staging are also useful for therapeutics. Non-limiting examples of anti-cancer or anti-leukemia agents include anthracyclines such as doxorubicin (adriamycin), daunorubicin (daunomycin), idarubicin, detorubicin, carminomycin, cpirubicin, esorubicin, and morpholino and substituted derivatives, combinations and modifications thereof. Exemplary pharmaceutical agents include cis-platinum, taxol, calicheamicin, vincristine, cytarabine (Ara-C), cyclophosphamide, prednisone, daunorubicin, idarubicin. fludarabine, chlorambucil, interferon alpha, hydroxyurea, temozolomide, thalidomide, and bleomycin, and derivatives, combinations and modifications thereof. Preferably, the anti¬cancer or anti-leukemia is doxorubicin, morpholinodoxorubicin, or morpholinodaunorubicin. [00194] The antibodies of the invention also encompass antibodies that have half-lives (e.g., serum half-lives) in a mammal, preferably a human, of greater than that oi" an unmodified antibody. In one embodiment, said antibody half life is greater than about 15 days, greater than about 20 days, greater than about 25 days, greater than about 30 days, greater than about 35 days, greater than about 40 days, greater than about 45 days, greater than about 2 months, greater than about 3 months, greater than about 4 months, or greater than about 5 months. The increased half-lives of the antibodies of the present invention or fragments thereof in a mammal, preferably a human, result in a higher serum titer of said antibodies or antibody fragments in the mammal, and thus, reduce the frequency of the administration of said antibodies or antibody fragments and/or reduces the concentration of said antibodies or antibody fragments to be administered. Antibodies or fragments thereof having increased in vivo half-lives can be generated by techniques known to those of skill in WO 2008/112003 PCT/US2007/075117 the art. For example, antibodies or fragments thereof with increased in vivo half-lives can be generated by modifying (e.g., substituting, deleting or addisjg) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor (see. e.g.. International Publication Nos. WO 97/34631 and WO 02/060919, which are incorporated herein by reference in their entireties). Antibodies or fragments thereof with increased in vivo half-lives can be generated by attaching to said antibodies or antibody fragments polymer molecules such as high molecular weight poiyethyleneglycol (PEG). PEG can be attached to said antibodies or antibody fragments with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of said antibodies or antibody fragments or via epsilon-amino groups present on lysine residues. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used. The degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography. \|00195\| As will be appreciated by one of skill in the art, in the above embodiments, while affinity values can be important, other factors can be as important or more so, depending upon the particular function of the antibody. For example, for an immunotoxin (toxin associated with an antibody), the act of binding of the antibody lo the target can be useful; however, in some embodiments, it is the internalization of the toxin imo the cell that is the desired end result. As such, antibodies with a high percent internalization can be desirable in these situations. Thus, in one embodiment, antibodies with a high efficiency in internalization are contemplated. A high efficiency of internalization can be measured as a percent internalized antibody, and can be from a low value to 100%. For example, in varying embodiments, 0.1-5, 5-10, 10-20, 20-30, 30-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-99, and 99-100% can be a high efficiency. As will be appreciated by one of skill in the art, the desirable efficiency can be different in different embodiments, depending upon, for example, the associated agent, the amount of antibody that can be administered to an area, the side effects of the antibody-agent complex, the type (e.g., cancer type) and severity of the problem to be treated. WO 2008/112003 PCT/US2007/075I17 [00196\| In other embodiments, the antibodies disposed herein provide an assay kit for the detection of PDGFR-alpha expression in mammalian tissues or cells in order to screen for a disease or disorder associated with changes in expression °f PDGFR-alpha. The kit comprises an antibody that binds PDGFR-alpha and means for indicating the reaction of the antibody with the antigen, if present. [00197] in some embodiments, an article of manufacture is provided comprising a container, comprising a composition containing an antrPDGFR-alpha antibody, and a package insert or label indicating that the composition can be used to treat disease mediated by PDGFR-alpha expression. Preferably a mammal and, more preferably, a human, receives the anti-PDGFR-alpha antibody. Combinations (00198\| The anti-neoplastic treatment defined herein may be applied as a sole therapy or may involve, in addition to the compounds of the invention, conventional surgery, bone marrow and peripheral stem cell transplantations or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti tumor agents: (i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-plalin, oxaliplatin. carboplatin, cyclophosphamide, nitrogen mustard, melpMan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimi dines like 5-fluorouracil and tegafur, raltilrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumor antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin. epirtfbicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and tabids like taxol and taxotere and polokinase inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and leniposide, amsacrine, topotecan and camptothecin); (ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene). anliandrogens (for example bicalutamide, flulamide, nilutamide and cyproteronc acetate), LHRH antagonists or LHRH WO 2008/112003 PCT/US2007/075117 agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole. vorazole and exemestane) and inhibitors of 5ct-reductase such as finasteride; (iii) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6-chloro-2,3-niethylenedioxyanilino)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazolme (A2D0530; International Patent Application WO 01/94341) and iV-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-l-yl]-2-methylpyrimidin-4-ylamino}lhiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem.. 2004, 47, 6658-6661), and metalloproteinase inhibitors like rnarimastat, inhibitors of urokinase plasminogen activator receptor function or, inhibitors of cathepsins, inhibitors of serine proteases for example matriptase, hepsin, urokinase, inhibitors of heparanase); (iv) cytotoxic agents such as fludarabine, 2-chlorodeoxyadenosine, chlorambucil or doxorubicin and combination thereoff such as Fludarabine + cyclophosphamide, CVP: cyclophosphamide + vincristine + prednisone, ACVBP: doxorubicin + cyclophosphamide + vindesine + bleomycin + prednisone, CHOP: cyclophosphamide + doxorubicin + vincristine + prednisone, CNOP: cyclophosphamide + mitoxanlrone + vincristine. + prednisone, m-BACOD: methotrexate + bleomycin + doxorubicin + cyclophosphamide + vincristine + dexamethasone + leucovorin., MACOP-B: methotrexate + doxorubicin + cyclophosphamide + vincristine + prednisone fixed dose + bleomycin + leucovorin, or ProMACE CylaBOM: prednisone + doxorubicin + cyclophosphamide + etoposide + cytarabine + bleomycin + vincristine + methotrexate + leucovorin. (v) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbBl antibody cetuximab [Erbitux, C225] and any grovvlh factor or growth factor receptor antibodies disclosed by Stem et al. Critical reviews in oncology/haematology, 2005, Vol. 54, ppl 1-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as A'-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839). A'-(3-ethyny!phenyl)-6,7-bis(2-methoxycthoxy)quinazolin-4-amine (erlotinib, OS1-774) and 6-aciylamido-A/-(3-chloro-4-fluoroplienyl)-7-(3- WO 2008/i 12003 PCT/US2007/07511? morpholinopropoxy)-quinazolin-4-amine (CI 1033)T erbB2 tyrosine kinase inhibitors such as lapatinib, inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-derived growth factor family such as imatinib. inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as famesyl transferase inhibitors, for example sorafcnib (BAY 43-9006)), inhibitors of cell signalling through MEK. and/or AKT kinases, inhibitors of the hepatocyte growth factor family, c-kit inhibitors, abl kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors, aurora kinase inhibitors (for example AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 and AX39459), cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors, and inhibitors of survival signaling proteins such as BcI-2, Bcl-XL for example ABT-737; (vi) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(l-methylpiperidin^_yiniethoxy)quina2oline (Z06474; Example 2 within WO 01/32651), 4-(4-fluoro-2-methylindoI-5-yloxy)-6-methoxy-7-(3-pyrrolidin-l-ylpropoxy)quinazoline (A2D2171; Exarnple 240 within WO 00/47212). vatalanib (PTK787; WO 98/35985) and SU11248 (sunitimb; WO 01/60814), compounds such as those disclosed in International Patent Applications W097/22596, WO 97/30035, WO 97/32856. WO 98/13354, WO00/47212 and WO01/32651 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin avB3 function and angioslatin)] or colony stimulating factor I (CSF1) orCSFl receptor.; (vii) vascular damaging agents such as Combretast^tin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; (viii) antisense therapies, for example those which are directed to the targets listed above, such as G-3139 (Genasense), an anti bcl2 antisense; (ix) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA^ GDEPT (gene directed enzyme pro drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi drug resistance gene therapy; and WO 2008/112003 PCT/US2007/075117 (x) immunotherapy approaches, including for example treatment with Alemtuzumab (campath-lH™), a monoclonal antibody directed at CD52, or treatment with antibodies directed at CD22. ex vivo and in vivo approaches lo increase the immunogenicity of patient tumour cells, transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte macrophage colony stimulating factor, approaches to decrease T cell anergy such as treatment with monoclonal antibodies inhibiting CTLA-4 function, approaches using transfected immune cells such as cytokine trans feet ed dendritic cells, approaches using cytokine transfected tumour cell lines and approaches using anti idiotypic antibodies. (xi) inhibitors of protein degradation such as proteasome inhibitor such as Velcade (bortezomid). (xii) biotherapeutic therapeutic approaches for example those which use peptides or proteins (such as antibodies or soluble external receptor domain constructions) which either sequester receptor ligands, block ligand binding to receptor or decrease receptor signalling (e.g. due to enhanced receptor degradation or lowered expression levels). (00199] Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or phamiaceulically acceptable salts, thereof, within the dosage range described hereinbefore and the other pharmaceutically active agent within its approved dosage range. (00200] In one embodiment of the invention the anti-neoplastic treatments of the invention are combined with agents which inhibit the effects of vascular endothelial growth factor (VEGF), (for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin®), anti-vascular endothelial growth factor receptor antibodies such anti-KDR antibodies and anti-fltl antibodies, compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/3285, WO 98/13354, WOOO/47212 and WOOl/32651) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin avb3 function and angiostalin); In another embodiment of the invention the anti-angiogenic treatments of the invention are combined agents which inhibit the tyrosine kinase activity of the vascular endothelial growth factor receptor, KDR (for example AZD2171 or AZD6474). Additional details on AZD2171 may be found in Wedge et al (2005) Cancer Research. 65(10):43S9-400. Additional details on WO 2008/112003 PCT/US2007/075117 A2D6474 maybe found in Ryan & Wedge (2005) British Journal of Cancer. 92 Suppl l:S6-13. Both publications are herein incorporated by reference in their entireties. In another embodiment of the invention, the fully human antibodies 1.1.2, 1.5.3, 2.1.2 are combined a\one or in combination with Avastin™, AZD2i 1 \ or AZD6474. [002011 Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or pharmaceutical ly acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically active agent within its approved dosage range. EXAMPLES [00202\| The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as limiting upon the teachings herein. EXAMPLE i IMMUNIZATION AND TITERfNG immunogen [00203) Recombinant soluble PDGFR-alpha extracellular domain was obtained from R&D Systems (Minneapolis, MN. Catalog #: 322-PR/CF) and used as an immunogen. In addition, recombinant human PDGFR-alpha expressed in BHK (baby hamster kidney) cells was used as an antigen for immunization. The BHK cells were obtained from the American Type Tissue Collection, catalog no. CCL-10. Immunization (00204) Monoclonal antibodies against PDGFR-alpha were developed by sequentially immunizing XenoMouse® mice (XenoMouse strains: XMG2 (lgG2 kappa) and XM3C-1 (IgG4 kappa) Amgen, Inc. Fremont. CA) with the extracellular domain of PDGFR- alpha (R&D Systems, Catalog #: 322-PR/CF). XenoMouse animals were immunized via footpad route for all injections by conventional means. The total volume of each injection was 50 pi per mouse containing 10 micrograms of PDGFR-alpha extracellular domain, 25 pi WO 2008/112003 PCT/US2007/075117 per footpad. Adjuvants included Titermax GoldTM (Sigma, cat. T2684), aluminum phosphate gel adjuvant, HCL Biosecior (cat 1452-250) and ImmuneEasy mouse adjuvant (qCpG, Qiagen cat. No 303105). The first injection was administered with Titermax GoldTM (Day 0). Boosts were administered as 5 ul of aluminum phosphate gel adjuvant (5ul) and qCpG (15 ul) along with 10 ug of PDGFRalpha extracellular domain on days 3,6,10,13,20,24,27,31 and 34. EXAMPLE 2 RECOVERY OF LYMPHOCYTES, B-CELL ISOLATIONS, FUSIONS AND GENERATION OF HYBRIDOMAS [00205} Immunized mice were sacrificed by cervical dislocation and the draining lymph nodes were harvested and pooled from each cohoit. The lymphoid cells were dissociated by grinding in DMEM to release the cells from the tissues, and the colls were suspended in DMEM. The ceils were counted, and 0.9 ml DMEM per 100 million lymphocytes was added to the ceil pellet to resuspend the cells gently but completely. Using 100 u:l of CD90+ magnetic beads per 100 million cells, the cells were labeled by incubating the cells with the magnetic beads at 4°C for 15 minutes. The magnetically-labeled cell suspension containing up to 108 positive cells (or up to 2x109 total cells) was loaded onto an LS+ column and the column washed with DMEM. The total effluent was collected as the CD90-negative fraction (most of these cells were expected to be B cells). [00206] A fusion was performed by mixing washed enriched B cells from above and nonsecretory myeloma P3X63Ag8.653 cells purchased from ATCC (cat. no. CRL 1580) (Kearney et al, J. Immunol. 123, 1979, 1548-1550) at a ratio of 1:1. The cell mixture was gently pelleted by centrifugation at 800 x g. After complete removal of the supernatant, the cells were treated with 2-4 mL of Pronase solution (CalBiochem, cat. # 53702; 0.5 mg/mL in PBS) for no more than 2 minutes. Then 3-5 ml of FBS was added to stop the enzyme activity and the suspension was adjusted to 40 mL total volume using electro cell fusion solution, ECFS (0.3 M Sucrose, Sigma, Cat# S7903, 0.1 mM Magnesium Acetate, Sigma, Cat# M2545, 0.1 mM Calcium Acetate, Sigma, Cat# C4705). The supernatant was removed after centrifugation and the cells were resuspended in 40 mL ECFS. This wash step was repeated and the cells again were resuspended in ECFS to a concentration of 2x106 cells/mL. WO 2008/112003 PCT/US2007/075117 \|00207] Electro-cell fusion was performed using a fusion generator, model ECM2001, Genetronic, Inc., San Diego, CA. The fusion chamber size used was 2.0 mL, using the following instrument settings: Alignment condition: voltage: 50 V, time: 50 seconds; membrane breaking at: voltage: 3000 V, time: 30 uscconds; post-fusion holding time: 3 seconds. (00208] After ECF, the cell suspensions were carefully removed from the fusion chamber under sterile conditions and transferred into a sterile tube containing the same volume of Hybridoma Culture Medium (DMEM (JRH Biosciences), 15% FBS (Hycione): supplemented with L-glutamine, pen/strep, OP1 (oxaloacetate, pyruvate, bovine insulin) (all from Sigma) and IL-6 (Boehringer Mannheim). The cells were incubated for 15-30 minutes at 37°C, and then centrifuged at 400 x g (1000 rpm) for five minutes. The cells were gently resuspended in a small volume of Hybridoma Selection Medium (Hybridoma Culture Medium supplemented with 0.5x HA (Sigma, cat. # A9666)), and the volume was adjusted appropriately wilh more Hybridoma Selection Medium, based on a final plating of 5x106 B cells total per 96-well plate and 200 JIL per well. The cells were mixed gently and pipetted into 96-well plates and allowed to grow. On day 7 or 10, one-half the medium was removed, and the cells were re-fed with Hybridoma Selection Medium. ELISA screening \|00209] For ELISA analysis, recombinant human PDGFR-alpha (R&D systems, cat#322-PR7CF ), at a concentration of 4ug/ml, was used as a capture reagent. ELISA plates were coated with recombinant human PDGFR-alpha in a volume of 50 (il/well in antigen coating buffer (0.1 M Carbonate Buffer, pH 9.6 NaHC03 (MW 84) 8.4 g/L) and incubated overnight at 4°C. The following day, the ELISA plate was washed 3 times with washing buffer (0.05% Tween 20 in lx PBS) and subsequently blocked wilh 200 (.il/well of blocking buffer (1% BSA, 0.1% Tween 20, 0.01% Thimerosal in lx PBS) for 1 hour at room temperature. Upon completion of the blocking step, 50 ul/welt of hybridoma supernatant was incubated at room temperature for 2 hours. After incubation, the ELISA plate was washed 3 times in washing buffer. Following the wash step, 50 pJ/well of detection antibody was added to the wells and incubated at room temperature for 1 hour. The ELISA plale was subsequently washed 3 times with washing buffer and TMB substrate was added (50 WO 2008/112003 PCT/US2007/075117 uJAvell). Following the addition of the stop solution (50 ul/well). the ELISA plate was read at GSOnm with an ELISA plate reader. The supematants deemed positive by ELISA were subsequently evaluated by FMAT and FACS. EXAMPLE 3 SELECTION OF CANDIDATE ANTIBODIES BY FMAT AND FACS [002101 After 14 days of culture, hybridoma supematants were screened for PDGFR-alpha-specific monoclonal antibodies by Fluorometric Microvolume Assay Technology (FMAT) by screening against either the human osteosarcoma MG-63 cell line or recombinant HEK293 cells that were transfected with human PDGFR-alpha and counter-screening against parental HEK293 cells. [002111 The culture supematants from the positive hybridoma cells growth wells based on the primary screen were removed and the PDGFR-alpha positive hybridoma cells were suspended with fresh hybridoma culture medium and were transferred to 24-well plates. After two days in culture, these supematants were ready for a secondary confirmation screen. In the secondary confirmation screen, the positives in the first screening were screened by FACS with two sets or three sets of detection antibodies used separately: 1.25ug/ml GAH-Gamma Cy5 (JIR# 109-176-098) for human gamma chain detection: 1.25ug/ml GAH-Kappa PE (S.B.#2063-09) for human kappa light chain detection and ].25ug/ml GAH-lambda PE (S.B.#2073-09) for human lambda light chain detection in order to confirm that the anli-PDGFR-alpha antibodies were fully human. EXAMPLE 4 PDGFR TYROSINE PHOSPHORYLATION ASSAY [00212] 791 antibody lines were interrogated using a PDGFR tyrosine phosphorylation (pTyr) assay to determine whether the antibody lines inhibited the phosphorylation of PDGFR-alpha in tumor cells. [00213] Briefly, human osteosarcoma MG-63 cells were seeded at 10,000 cells per well in a 96-well FMAT assay plate in 100 \i\ Starvation Media (1% charcoal/dextran treated FBS) and incubated at 37°C for approximately 20 hours. Starvation Media was removed and 37.5 u.1 of media was added to all wells receiving sample and 12.5 ul was added to wells WO 2008/112003 PCT/US2O07/075117 receiving control (mouse mAb anti-PDGFRa (BD PharMingen catalog # 556001) or mouse IgG2a (serotech, 2X final concentration)) and incubated for 30 minutes at 37°C. 50ul of PDGF-AA (R&D) in 1% assay media at 2X final concentration (50ng/m!) was added to all plates and media added to column 12 of the control plate. Plates were incubated for 10 minutes at 37°C. Media was removed and 100 ul of 3.7% formaldehyde in PBS/3%BSA was added and incubated for 20 minutes at room temperature. Plates were washed two times with PBS and 100 ul permeabilization buffer (0.1% Triton-X in 3%BSA/PBS) was added to each well, incubated at room temperature for 10 minutes, and discarded. 100 ml of 0.6% hydrogen peroxide in PBS/3% BSA was added to inactivate any endogenous peroxidase activity and incubated at room temperature for 20 minutes. Plates were washed three times with PBS/0.1% Tween-20 and blocked with 100 u! 10% FBS in PBS/0.1% Tween-20. Plates were incubated for 1 hour ai room temperature, blocking buffer removed, and 50 ul anti-phospho PDGFa antibody (sc-12910-R) (1 ug/ml) was added to each well in 10% FBS/PBS-T. Plates were incubated for 2 hours at room temperature, then washed three times with PBST, soaking for 5 minutes between each wash. 50 ul of Goat anti-Rabbit IgGFc-HRP secondary antibody diluted in Blocking Buffer was added and incubated at room temperature for 1 hour. Plates were washed three times for 5 minutes with PBST and tapped dry. 50 u.1 of ECL reagent (LumiGLO Reserve, KPL catalog # 54-71-01) was added and RLUs read immediately. Plates were washed two times with PBST and tapped dry. Plates where then frozen at -80°C for 30-60 minutes. Plates were brought to room temperature and 100 ul of CyQuant added to each well. Plates were read at 485 run excitation and 530 nm emission on a fluorescence reader. [00214] 103 lines were selected based on a greater than or equal to 90% neutralization in the pTyr assay, i.e. the selected antibody lines inhibited tyrosine phosphorylation of PDGF receptor-alpha by greater than or equal to 90%. (Data not shown.) EXAMPLE 5 AFFINITY AND CONCENTRATION ANALYSIS OF HYBR1DOMA SUPERNATANTS HIGH ANTIGEN (HA) / LIMITED ANTIGEN (LA) ANALYSIS [00215] 103 antibody lines were interrogated using a high antigen (HA) / limited antigen (LA) analysis as described below. HA is an antibody concentration dependent WO 2008/112003 PCT/US2007/075117 reaction, and is thus a measure of antibody concentration. LA is largely an antibody affinity dependent reaction and thus, can be a measure of antibody affinity. High Antigen Quantitation Assay [00216] Briefly, EL1SA plates were coated with a greater amount of human PDGFR-alpha antigen (R&D Systems, Inc., Minneapolis, MN Cat. No. 322-PR-050/CF) in comparison with the Limited Antigen Quantitation Assay described below. Antibody-containing hybridoma supematants were titrated over a dilution range of 1:51 to 1:1656. A control of a known mouse anti-human PDGFR-alpha-specific antibody (PharMingen Catalog No. 556001) was used to define the linear range of the assay. Data within the linear range were then used to derive the relative concentration of the PDGFR-specific antibody in each titrated sample. Limited Antigen Quantitation Assay 100217] Microliter plates were coated with a lower amount of human PDGFR-alpha antigen in comparison with the High Antigen Quantitation Assay described above. Fifty microliters (50 uX) of human PDGFR-alpha at 64, 32, 16, 8, 4, and 2 ng/ml (covering a range of 8.5 nM to 0.26 nM) in 1% skim milk / IX PBS pH 7.4 / 0.5% azidc was added to each well. The plate was incubated for 30 minutes. (00218J Plates were washed four limes with water, and 50uL of hybridoma supernatant containing test antibodies diluted 1:25 in 1% skim milk / IX PBS pH 7.4 / 0.5% azide were added to the wells. Plates were wrapped tightly with plastic wrap or paraffin film, and incubated overnight with shaking at room temperature. [002191 O" me following day, ali plates were washed five times and 50 uL goat anti-Human IgG Fc HRP polyclonal antibody at a concentration of 0.5 ug/ml in 1% milk, IX PBS pH 7.4 was added to each well. The plates were incubated for \ hour at room temperature. [00220\| Plates were washed at least five times with tap water. Fifty microliters (50) uL of HPR substrate TMB was added to each well, and the plate were incubated for 30 minutes. The HRP-TMB reaction was stopped by adding 50 uL of 1M phosphoric acid to each well. Optical density (absorbance) at 450 ran was measured for each well of the plate. WO 2008/112003 PCT/US2007/075117 (00221] Thirty-four (34) antibody lines were selected based on relative binding affinity. Selection was based on titration of antigen at 16 ng/ml and 2 ng/ml. Selected cut¬offs were LA greater than 0.3 OD units and 3.3 ug/ml. Lines thai exhibited weak reactivity at antigen concentration of 2 ng/ml of antigen were de-selected. (00222] Nine (9) additional lines were added to increase the candidate pool based on inhibition of PDGFR-alpha phosphorylation in MG-63 cells, such that a total of 43 antibody lines that exhibited potent inhibition of tyrosine phosphorylation and high relative affinity based on HA/LA analysis were carried forward. The aforementioned nine additional lines exhibited complete inhibition of PDGFR-alpha phosphorylation (i.e 100%). None of the lines cross-reacted with PDGFR-beta or homologs (FLT3, c-kit, CSF-1R). TABLE 2 SUMMARY OF 43 ANTIBODY LINES SELECTED BASED ON ABILITY TO POTENTLY INHIBIT PDGFR-ALPHA PHOSPHORYLATION IN MG-63 CELLS WO 2008/112003 PCT/US2007/0751I7 2.1696 >100% 2.45] >I00% 3.457 >100% 2.175 99% 2.259 99% 2.998 99% 2.449 99% 2.414 98% 2.84 98% 3.268 98% 2.351 97% 2.S50 95% 3.472 95% 2.886 94% 2.415 94% 3.23 94% 2.10 93% 2.737 93% 2.796 93% 2.565 92% 2.32 92% 2.624 92% 2.862 92% 3.805 92% 2.542 91% 3.289 91% 3.772 91% 2.889 90% WO 2008/112003 PCT/US2007/075117 EXAMPLE 6 IN VITRO SCREENIMG AND DATA ANALYSIS OF CLONED MONOCLONAL ANTIBODIES [00223\| Thirty (30) antibody lines were cloned and interrogated further as follows. pTvr Assay \|00224\| PDGFR Tyrosine Phosphorylation (pTyr assay) was performed using MG-63 cells as described above in Example 4. Results are shown in Table 3. Proliferation Assay [002251 Inhibition of MG-63 cell growth by the purified monoclonal antibodies against PDGFR-alpha was evaluated using a PDGF-AA Proliferation Assay Screen. [00226\| Briefly, MG-63 cells were seeded at 5,000 cells per well in 100 ul full growth media in the inner wells of black clear bottom plates and incubated at 37°C, 5% C02 for 3-4 hours. Cells were washed with PBS IX with media and replaced with growth starvation culture media (MEM, 1% NEAA, 0.1% NaBicarb, 1% L glut) and stai-ved overnight. Media was removed from plates and 50 ui of 2X mAb or media added lo appropriate wells. 50 ul of PDGF-AA titration, 200 ng/ml PDGF-AA or media alone was added and plates incubated for 3 days. Plates were read out with Alamar Blue at 530 excitation and 580 nm emission (100 ul per well/100 ul). \|00227\| Data for the lop 15 monoclonal antibodies, i.e. exhibiting the lowest 1C50 values, for a cell stimulation using 100 ng/ml (3.45 nM) PDGF-AA are summarized below in Table 3. Monoclonal antibodies selected for further analysis are shown in bold. The dose response curves for 5 of the selected antibodies are shown in Figure 1. The preparation of 2.451.1.1 may contain two different antibodies, with the same heavy chain but different light chains, since there were two different light chain sequences detected during sequencing of the DNA for this monoclonal antibody. TABLE 3 PROLIFERATION ASSAY: MG-63 CELLS mAb ICso (ng/ml) 2.175.3 56.1 (0.37 nM) WO 2008/112003 PCT/US2007/075117 2.414.2 349.1 (2.3 nM) 2.451.1.1 283.1 (1.9 nM) 2.542.2 651.6 (4.35 nM) 2.737.1.4 558.5 (3.72 nM) 2.1623.2 981.7 (6.5 nM) 2.1853.3 2679.2 (18 nM) 3.341.2 471.0 (3.1 nM) 2.796.2 756.8 (5nM) 5.16.1 422.7 (2.8 nM) 2.2071.1.3 492.0 (3.3 nM) 2.449.1.3 236.6 (1.57 nM) 2.84.3 480.8 (3-2 nM) 2.998.2 315.5(2.1 nM) 2.351.3 648.6 (4.3 nM) BD556001 2857.6 (19 nM) Hu lgG2 >10ug/mL Hu lgG4 >10 ug/mL FACS Kd Affinity Determination (00228J The affinity of purified monoclonal antibodies (mAbs 2.175.3, 2.449.1.3, 2.451.1.1, 2.998.2. 2.84.3) against PDGFR-alpha was determined by FACS analysis. [00229\| Briefly, MG-63 cells expressing PDGFR-alpha were resuspended in FACS buffer (2% FBS, 0.05% NaN3) at a concentration of approximately 3 to 5 million cells/mL. Cells were kept on ice. Purified antibodies and CD 140a control were serially diluted in filtered IxPBS (2x) across 11 wells in 96-well plates. The twelfth well in each row contained buffer only. Ix PBS and cells were added to each mAb well such that the final volume was 30 uL/well and each well contained approximately 100,000 cells. The final molecular concentration ranges for the mAbs were as follows: WO 2008/112003 PCT/US2007/075117 mAb Concentration 2.451.1.1 = 19.1-0.019nM 2.175.3 = 10.8-0.021 nM 2.449.1.3 = 10.7-0.021 nM 2.449.1.3 = 9.2-0.009 nM 2.84.3 = 4.4-0.009 nM 2.449.1.3 = 9.2 - 0.009 nM 2.998.2 = 4.6-0.009 nM CD 140a = 20.2 - 0.020 nM [00230] Plates were placed on a plate shaker for 5 hours at 4°C. then spun and washed 3x with PBS. 200 u.L of 100 or 131 nM Cy5 goat a-human polyclonal antibody (Jackson Laboratories, #109-175-008) was added to each well, and 200 uL of 100 nM Cy5 goat cc-mouse polyclonal antibody was added to the cells complexed with CD140a antibody. Plates were then placed on a shaker for 40 minutes at 4°C, then spun and washed 3x with PBS. J00231J The Geometric Mean Fluorescence (GMF) of 15,000 to 20,000 cell 4ievents'r for each mAb concentration was determined using a FACSCalibur instrument. For each mAb, the GMF data was normalized for both replicate titrations relative to an identical mAb concentration point in each titration. Corresponding normalized titration points were averaged to give one normalized GMF point for each mAb concentration. Only one titration data set for mAb 2.351.3 was of acceptable quality for analysis. A nonlinear plot of GMF as a function of molecular mAb concentration was fit using Scientist software using the equation: 2 (00232] In the above equation, F = Geometric mean fluorescence, LT = total molecular mAb concentration, P' = proportionality constant that relates arbitrary lluorescence units to bound mAb, and KD = equilibrium dissociation constant. For each WO 2008/112003 PCT/US2007/075117 mAb an estimate for KD was obtained as Pr and KD were allowed to float freely in the nonlinear analysis. Table 4 below lists the resulting KDs for each mAb along with the 95% confidence interval of the fit. MAbs are listed in order of decreasing affinity. TABLE 4 Sample K0(pM) 95% CI (pM) 2.175.3 328 ±202 2.451.1.1 389 ±196 2.449.1.3 (control) 52 ±51 2.449.1.3 53 ±49 2.998.2 57 ±68 (upper CI only) CD140a 146 ±99 2.84.3 j 227 ±121 Mouse cross-reactivity \|00233\| To set up animal xenograft studies, mouse cross-reactivity was determined using FACS analysis performed with N1H3T3 cells, a murine fibroblast line which expresses endogenous PDGFRa. N1H3T3 cells were incubaled at 0.5 X 106 cells/ml with 10 ug/ml of test antibodies on ice for lh, rinsed and then resuspended in PBS with 5 ug/ml of goat-anti-human IgG antibodies labeled with Cy5. Cells were rinsed and analyzed by FACS for the presence of Cy5. Only 3 of the tested monoclonal antibodies exhibited mouse cross-reactivity. Results are summarized in Table 5. Percent Internalization [00234] The percentage of antibody being internalized in cells was determined using a standard internalization protocol. Percent internalization results a( 10 ug/ml are summarized in Table 5. Results J002351 Results of in vitro screening and data analysis of the 30 cloned monoclonal antibodies are summarized in Table 5. mAbs are listed in order of increasing WO 2008/112003 PCT/US2007/0751I7 IC50 values. mAbs in italics were selected as the top ten mAbs and antibodies, in boldface were selected as the three lead candidates. "()"denotes ranking in Table 5. [00236] As can be seen from Table 5, mAb 2.175.3 exhibited exceptional inhibition of PDGF-AA proliferation of MG-63 cells as well as exceptional inhbition of phosphorylation of PDGFR-alpha on MG-63 cells. MAbs 2.449.1.3 and 2.998.2 also inhibited phosphorylation of PDGFR-alpha on MG-63 cells and inhibited PDGF-AA proliferation of MG-63 cells. In addition, mAbs 2.449.1.3 and 2.998.2 also had a high binding affinity for PDGFR-alpha. WO 2008/112003 PCT/US2007/075117 TABLE 5 PDGFR-ALPHA MONOCLONAL ANTIBODY SUMMARY Antibody pTyr Assay: % Inhibition @ 2 ng/ml Proliferation Assay: IC50 ng/ml (1-6-06) Proliferation Assay: IC50 ng/ml (1-23-06) /o Internalization @ lOpg/ml Mouse-Cross Reactivity Affinity 2.175.3 100 67.3(1) (0.45nM) 56.1(1) (0.37nM) 19% Yes 328pM 2.449.1.3 99 178.6(2) (1.2nM) 236.6 (2) (1.57nM) 20% - 52pM 2.451.J.1 100 399.0 (6) (2.67nM) 283.1 (3) (1.9nM) 21% - 389pM 2.998.2 99 307.6(4) (2.05nM) 315.5(4) (2.1nM) 25% - 57pM 2.84.3 98 192.3(3) (1.3nM) 4S0.9 (8) (3.2nM) 26% - 227pM 2.414.2 99 657.7 (9) (4.4nM) 349.1 (5) (2.3nM) 28% - 5.16.1 99 385.5 (5) (2.57nM) 422.7 (6) (2.8 InM) ' 31% - 3.341.2 100 403.6 (7) (2.7nM) 471.0(7) (3. InM) 22% - 2.2071.!.3 99 1,276.4(10) (S.5nM) 492.0 (9) (3.3nM) 21% - 2.737.1.4 99 550.8 (8) (3.7nM) 558.5(10) (3.73nM) 22% - 2.796.2 99 497.7 756.8 19% - 2.542.2 99 1037.5 651.6 26% - 2.351.3 97 1,078.9 648.6 21% - 2.1623.2 97 755.1 981.7 46% Yes 2.1853.3 98 1,122.0 2679.2 30% Yes 3.818.4 92 4,602.6 - 3.457.3.1 85 - - 3.23.3 84 61.9 - 5.1.1.1 77 > 10 ng/mL - 4.16.2 74 > 10 Mg/niL - 3.87.1.1 69 6,237.3 - 2.1576.1.2 65 > 10 ng/mL - 3.472.1.1 61 - - 3.805.1.3 58 1,016.2 - 3.772.2 56 167.9 5.9.3 31 2.2 1 ! WO 2008/112003 PCT/US2007/075117 3.23.2 26 150.3 - 2.1954.2 -3 - - 3.625.1.7 -3 3819.44 - 2.2002.3 -9 - - WO 2008/112003 PCT/US2007/075U7 EXAMPLE 7 STRUCTURAL ANALYSIS OF ANTI-PDGFR-ALPHA ANTIBODIES (00237] The heavy and light chain variable domains of the antibodies were sequenced to detennine their DNA sequences. The complete sequence information for the anti-PDGFR-alpha antibodies is provided in the sequence listing with nucleotide and amino acid sequences for each gamma and kappa chain combination. The variable heavy sequences were analyzed to detennine the VH family, the D-region sequence and the J-region sequence. The sequences were then translated to determine the primary amino acid sequence and compared to the germline VH, D and J-region sequences to assess somatic hypermutations. "-" indicates identity with the germline sequence. ll#:; indicates an additional amino acid in the antibody sequences that is not found in the germline. (00238[ Tabic 12 is a table comparing the antibody heavy chain regions to their cognate germline heavy chain region. Table 13 is a table comparing the antibody kappa light chain regions to their cognate germline light chain region. [00239] The variable (V) regions of immunoglobulin chains are encoded by multiple germline DNA segments, which are joined into functional variable regions (VHDJH or VKJK) during B-cell ontogeny. (00240) It should also be appreciated that where a particular antibody differs from its respective germline sequence at the amino acid level, the antibody sequence can be mutated back to the germline sequence. Such corrective mutations can occur at one, two, three or more positions, or a combination of any of the mutated positions, using standard molecular biological techniques. By way of non-limiting example. Table 12 shows thai the heavy chain sequence of mAb 2.175.3 (SEQ ID NO.: 2) differs from the corresponding germline sequence inter alia through a Q to H mutation (mutation 1) in the FR1 region, a S to H mutation (mutation 2) in die CDRl region, and a S to R mutation (mutation 3) in the CDR2 region. Thus, the amino acid or nucleotide sequence encoding the heavy chain of mAb 2.175.3 can be modified to change mutation 1 to yield the germline sequence at the site of mutation 1. Further, the amino acid or nucleotide sequence encoding the heavy chain of mAb 2.175.3 can be modified to change mutation 2 or mutation 3 to yield the genu line sequence at the site of mutation 2 or mutation 3. Indeed the amino acid or nucleotide sequence encoding the heavy chain of mAb 2.175.3 can encompass any combination of two WO 2008/112003 POVUS2007/075117 or more mutations lo yield the germline sequence at those particular sites. Tables 6-11 below illustrate the position of such variations from the germline for mAb 2.175.3, 2.449.1.3 and 2.998.2. Each row represents a unique combination of germline and non-gennline residues at the positions indicated. In the event of a discrepancy between the sequence listing and tables 6-1 J, the information provided in the table takes precedence. Table 6. Exemplary Mutations of mAb 2.175.3 Heavy Chain (SEQ ID NO: 2) to Germline at the Indicated Residue Number. 3 35 53 57 61 80 99 100 101 106 0 S s T A Y DELETED DELETED DELETED DELETED 0 s ! s T A Y DELETED DELETED DELETED P 0 s s T A \| Y DELETED DELETED P JDELETED 0 s s T A Y DELETED DELETED P P 0 s s T A Y DELETED G DELETED DELETED 0 s s T A Y DELETED G DELETED P 0 s s T A Y DELETED G P DELETED 0 s s T A Y DELETED G P P 0 s s T A Y G DELETED DELETED DELETED 0 s s T A Y G DELETED DELETED P 0 s s T A Y G DELETED P DELETED 0 s s T A Y G DELETED P P 0 s s T A Y G G DELETED DELETED Q s s T A Y G G DELETED P 0 s s T A Y G G P DELETED 0 s s T A Y G G P P 0 s s T ■A \| N DELETED DELETED DELETED DELETED 0 s s T A ! N DELETED DELETED DELETED P 0 s s T A ! N DELETED DELETED P DELETED 0 s s T A N DELETED DELETED P P 0 s s T A N DELETED G DELETED DELETED 0 s s T A N DELETED G DELETED P 0 s s T A N DELETED G P DELETED 0 s s T A N DELETED G P P 0 s s T A N G DELETED DELETED DELETED 0 s s T A N G DELETED DELETED P 0 s s T A N G DELETED P DELETED Q s s T A N G DELETED P P 0 s s T A N G G DELETED DELETED Q s s T A N G ! G DELETED P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 i 106 0 S s T A N G G P (DELETED 0 S s T . A N G G p ! P 0 S s T V Y DELETED DELETED DELETEDIDELETED 0 s s T V Y DELETED DELETED DELETED P 0 s s T V Y DELETED DELETED P DELETED 0 s s T V Y DELETED DELETED P P 0 s s T V Y DELETED G DELETED DELETED 0 s s T V Y DELETED G DELETED P 0 s s T V Y DELETED G P DELETED 0 s s T V Y DELETED G P P 0 s s T V Y G DELETED DELETED DELETED 0 s s T V Y G DELETED DELETED P 0 s s T V Y G DELETED P DELETED 0 s s T V Y G DELETED P P 0 s s T i V Y G G DELETED DELETED 0 s S _\| T V Y G G DELETED P 0 s s T V Y G G P DELETED Q s s T V Y G G P P 0 s s T V N DELETED DELETED DELETED DELETED 0 s s T V N DELETED DELETED DELETED P Q s s T V N DELETED DELETED P DELETED 0 s ■s T V N DELETED DELETED P P 0 s s T V 1 N DELETED G DELETED DELETED 0 s s T v ! N DELETED G DELETED P 0 s ' S T V N DELETED G P DELETED 0 s s T V N DELETED G P P 0 s s T V N G DELETED DELETED DELETED Q s s T V N G DELETED DELETED P 0 s s T V N G DELETED P DELETED 0 s s T V N G DELETED P P 0 s s T V N G G DELETED DELETED 0 s s T V N G G DELETED P 0 s s T V N G G P DELETED 0 s s T V N G G P P 0 s s L A Y DELETED DELETED DELETED DELETED 0 s s L A Y DELETED DELETED DELETED P Q s s L A Y DELETED DELETED P DELETED Q s s L A Y DELETED DELETED P P Q s ■ s L A Y DELETED G DELETED DELETED Q s s L A Y DELETED G DELETED P Q s s L A Y DELETED G P IDELETED Q s s L A Y DELETED G P \| P WO 2008/1120(13 PCI7US2007/075117 3 35 53 57 61 80 99 100 101 i 106 0 S s L A Y G DELETED DELETED DELETED 0 S s L A Y G DELETED DELETED P 0 S s L A Y G DELETED P DELETED 0 S s L A Y G DELETED P P Q S s L A Y G G DELETED DELETED 0 S s L A Y G G DELETED P 0 s s L A Y G G P DELETED Q s s L A Y G G P P 0 s s L A N DELETED DELETED DELETED DELETED 0 s s L A N DELETED DELETED DELETED P 0 s s L A N DELETED DELETED P DELETED 0 s s L A N DELETED DELETED P P 0 s s L A N DELETED G DELETED DELETED 0 s s L A N DELETED G DELETED P 0 s s L A N DELETED G I P DELETED] 0 s s L A N DELETED G \| P P ! 0 s s L A N G DELETED DELETED DELETED! 0 s s L A N G DELETED DELETED P 0 s s L A N G DELETED P DELETED 0 s s L A N G DELETED P P 0 s s L A N G G DELETED DELETED 0 s s L A N G G DELETED P Q s s L A N G G P DELETED 0 s s L A N G G P ; P Q s s L V Y DELETED DELETED DELETEDiDELETED 0 s s L V Y DELETED DELETED DELETED P 0 s s L V Y DELETED DELETED P DELETED 0 s s L V Y DELETED DELETED P P 0 s s L V Y DELETED G DELETED DELETED Q s s L V Y DELETED G DELETED P 0 s s L V Y DELETED G P DELETED 0 s s . L V Y DELETED G P P 0 s- s L V Y G DELETED DELETED DELETED Q s s L V Y G DELETED DELETED P 0 s s L V Y G DELETED P DELETED 0 s s L V Y G DELETED P P 0 s s L V Y G G DELETED DELETED 0 s s L V Y G G DELETED P Q s s L V Y G G P DELETED 0 s s L V Y G G P P 0 s s L V N DELETED DELETED DELETED DELETED Q s s L V N DELETED DELETED DELETED P PCT/OS2rt07/O75li7 3 35 53 57 61 80 99 100 101 106 0 s s L V N DELETED DELETED P DELETED 0 s s L V N DELETED DELETED P P 0 s s L V N DELETED G DELETED DELETED 0 s s L V N DELETED G DELETED P 0 s s L V N DELETED G P DELETED 0 s S L V N DELETED G P P 0 s S L V N G DELETED DELETED DELETED 0 s S L V N G DELETED DELETED P 0 s S L V N G DELETED P DELETED 0 s S L V N G DELETED P P Q - ■ s . S L V N G G DELETEDDELETED 0 s S L V N G G DELETED; P Q s s L V N G G P DELETED 0 s s L V ! N G G P P 0 s R T A J Y DELETED\|DELETED DELETED DELETED 0 s R T A i Y DELETED DELETED DELETED P 0 s R T A \| Y DELETED DELETED P DELETED 0 s R T A t Y DELETED DELETED P P 0 s R T A ! Y DELETED G DELETED DELETED 0 s R T A Y DELETED G DELETED P 0 s R T A Y DELETED G P DELETED 0 s R T A Y DELETED G P P 0 s R T A Y G DELETED DELETED DELETED 0 s R T A Y G DELETED DELETED P 0 s R T A Y G DELETED P DELETED 0 s R T A Y G DELETED P P 0 s R T A Y G G DELETED DELETED 0 s R T A Y G G DELETED P 0 s R T A Y G G P DELETED 0 s R T A Y G G P P 0 s R T A N ' DELETED DELETED DELETED DELETED 0 s R T A N DELETED DELETED DELETED P 0 s R T A N DELETED DELETED P iDELETED 0 s R T A N DELETED DELETED P P 0 s R T A N DELETED G DELETED DELETED 0 s R T A N DELETED G DELETED P 0 s R T A N DELETED G P DELETED 0 s R T A N DELETED G P P 0 s R T A N G DELETED DELETED DELETED 0 s R T A N G DELETED DELETED P 0 s R T A N G DELETED P DELETED 0 s R T A N G DELETED P P WO 2008/112003 PCTAJS2007/075117 3 35 53 57 61 80 99 100 101 106 0 S R T A N G G DELETED DELETED 0 S R T A N G G DELETED P 0 s R T A N G G P DELETED Q s R T A N G G P P 0 s R T V Y DELETED DELETED DELETED DELETED 0 s R T V Y DELETED DELETED DELETED P 0 s R T V Y DELETED DELETED P DELETED 0 s R T V Y DELETED DELETED P P 0 s R T V Y DELETED G DELETED DELETED 0 s R T V Y DELETED G DELETED P 0 s R T V Y DELETED G P DELETED 0 S 1 R T V Y DELETED G P P 0 S \| R T V Y G DELETED DELETED DELETED 0 S _j R T V Y G DELETED DELETED P 0 s R T V Y G DELETED P DELETED 0 s R T V Y G DELETED P P 0 s R T V Y G G DELETED DELETED Q s R T V Y G G DELETED P 0 s R T V Y G G P DELETED 0 s R T V Y G G P P 0 s R T V N DELETED DELETED DELETED DELETED Q s R T V N DELETED DELETED DELETED P 0 s R T V \| N DELETED DELETED P DELETED 0 s R T V 1 N DELETED DELETED P P 0 s R T V ! N DELETED G DELETED DELETED 0 s R T V N DELETED G DELETED P 0 s R T V N DELETED G P DELETED 0 s R T V N DELETED G P P 0 S ! R T V 'N G DELETED DELETED DELETED 0 s ! R T V N G DELETED DELETED P ! 0 S ! R T V N G DELETED P DELETED 0 s R T V N G DELETED P P 0 s R T V N G G DELETED DELETED 0 s R T V N G G DELETED P Q s R T V N G G P DELETED 0 s R T V N G G P P 0 s R L A Y DELETED DELETED DELETED DELETED 0 s R L A Y DELETED DELETED DELETED P 0 s R L A Y DELETED DELETED P DELETED Q s R L A Y DELETED DELETED P P 0 s R L A 1 Y DELETED G DELETED DELETED Q s R L A \| Y DELETED G DELETED P WO 2008/112003 PCT/US2007/075117 3 35 S3 57 61 80 99 100 101 \| 106 0 S R L A Y DELETED G P JDELETED 0 S R L A Y DELETED G P P 0 S R L A Y G DELETED DELETED DELETED 0 S R L A Y G DELETED DELETED P 0 S R L A Y G DELETED P DELETED 0 S R L A Y G DELETED P P 0 S R L A Y G G DELETED DELETED 0 S R L A Y G G DELETED P 0 S R L A Y G G P DELETED Q S R L A Y G G P P 0 S R L A N DELETED DELETED DELETED DELETED 0 S R L A I N DELETED DELETED DELETED P 0 S R L A ! N DELETED DELETED P DELETED 0 S R "R" L A N DELETED DELETED P P 0 S L A 1 N DELETED G DELETED DELETEDj 0 S R . L A N DELETED G DELETED P 0 S R L A N DELETED G P DELETED 0 S R L A N DELETED G P P 0 s R L A N G DELETED DELETED DELETED 0 s R L A N G DELETED DELETED P 0 S j R L A N G DELETED P DELETED 0 S R L A N G DELETED p ! p 0 s R L A N G G DELETEDIDELETED 0 s R L A N G G DELETED: P 0 s R L A N G G P jDELETED 0 s R L A N G G P P 0 s R L V Y DELETED DELETED DELETED DELETED 9 s R L V Y DELETED DELETED DELETED P 0 s R L V Y DELETED DELETED P jDELETED Q s R L V Y DELETED DELETED P P 0 s R L V Y DELETED G DELETED DELETED 0 s R L V Y DELETED G DELETED P 0 s R L V Y DELETED G P DELETED 0 s R L V Y DELETED G P P 0 s R L V Y G DELETED DELETED DELETED 0 s R L V Y G DELETED DELETED P Q s R L V Y G DELETED P DELETED 0 s R L V Y G DELETED P P 0 s R L V Y G G DELETED DELETED Q s R L V Y G G DELETED P 0 s R L V Y G G P DELETED Q s R L V Y G G P j P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 106 0 s R L V N DELETED DELETED DELETED DELETED 0 s R L V N DELETED DELETED DELETED P 0 s R L V N DELETED DELETED P DELETED 0 s R L V N DELETED DELETED P P 0 s R L V N DELETED G DELETED DELETED 0 s R L V N DELETED G DELETED P 0 s R L V N DELETED G P DELETED 0 s R L V N DELETED G P P 0 s R L V N G DELETED DELETED DELETED 0 s R L V N G DELETED DELETED , P 0 s R L V N G DELETED P DELETED 0 s R L V N G DELETED P P 0 s R L V N G G DELETED DELETED 0 s R R L L V N G G DELETED! ' p 0 s V N G G p IDELETED 0 s R L V \| N G G p P 0 H S T A Y DELETED DELETED DELETED DELETED 0 H S T A Y DELETED DELETED DELETED P 0 H s T A Y DELETED DELETED p DELETED Q H s T A 1 Y DELETED DELETED p P 0 H s T A ! Y DELETED G DELETED DELETED 0 H s T A Y DELETED G DELETED P 0 H s T A Y DELETED G P DELETED 0 H s T A Y DELETED G P P 0 H s T A Y G DELETED DELETED DELETED 0 H s T A Y G DELETED DELETED P 0 H s T A Y G DELETED P DELETED 0 H s T A Y G DELETED P P ! 0 H s T A Y G G DELETED DELETED: 0 H s T A Y G G DELETED P . 0 H s T A Y G G P DELETED 0 H s T A Y G G P P 0 H s T A N DELETED DELETED DELETED DELETED 0 H S - T A N DELETED DELETED DELETED P 0 H s T A N DELETED DELETED P DELETED 0 H s T A N DELETED DELETED P P 0 H s T A N DELETED G DELETED\|DELETED 0 H s T A N DELETED G DELETED! P 0 H s T A N DELETED G P IDELETED 0 H s T A N DELETED G P ip 0 H s T A N G DELETED DELETED\|DELETED Q H s T A N G DELETED DELETED P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 106 Q H S T A N G DELETED P DELETED 0 H S T A N G DELETED P P 0 H S T A N G G DELETED DELETED 0 H s T A N G G DELETED P 0 H s 1 T_ A N G G P DELETED 0 H s T A N G G P P Q H s T V Y DELETED DELETED, DELETED DELETED, 0 H s T V Y DELETED DELETED DELETED P 0 H s T V Y DELETED DELETED P DELETED 0 H s T V Y DELETED DELETED P P 0 H s T V Y DELETED G DELETED DELETED 0 H s T V Y DELETED G DELETED P 0 H s T V Y DELETED G P DELETED 0 H s T V Y DELETED G P P 0 H s T V Y G DELETED DELETED DELETED 0 H s T V Y G DELETED DELETED P 0 H s T V Y G DELETED P DELETED 0 H s T V Y G DELETED P P Q H s T V Y G G DELETED DELETED 0 H s T V Y G G DELETED P 0 H s T V Y G G P DELETED Q H s T V Y G G P P Q H s T V N DELETED DELETED DELETED DELETED 0 H s T V N DELETED DELETED DELETED P 0 H s T V N DELETED DELETED P DELETED 0 H s T V N DELETED DELETED P P 0 H s T V N DELETED G DELETED\|DELETED Q H s T V N DELETED G DELETED! P 0 H s T V N DELETED G P DELETED Q H s T V N DELETED G P P ■Q H s T V N G DELETED DELETED DELETED 0 H s T V N G DELETED DELETED P 0 H s T V N G DELETED P DELETED Q H s T V N G DELETED P P 0 H s T V N G G DELETED DELETED 0 H s T V N G G DELETED P 0 H s T V N G G P DELETED Q H s T V N G G P P Q H s L A Y DELETED DELETED DELETED DELETED Q H s L A Y DELETED DELETED DELETED ■ P 0 H s _L_J A Y DELETED DELETED P DELETED Q H ! S L A Y DELETED DELETED P P WP P/J J ?oO? F£?/i\|$W»W»wt i 1 WO 2008/112003 PCT/US2007/07S117 3 35 53 57 61 80 99 100 101 106 0 H S L V Y G G P DELETED 0 H s L V Y G G P P 0 H s L V N DELETED DELETED DELETED DELETED 0 H s L V N DELETED DELETED DELETED P 0 H s L V N DELETED DELETED P DELETED 0 H s L V N DELETED DELETED P P 0 H s L V N DELETED G DELETED DELETED 0 H s L V N DELETED G DELETED P 0 H s L V N DELETED G P DELETED 0 H s L V N DELETED G P . P 0 H s L V N G DELETED DELETED DELETED 0 H s L V N G DELETED DELETED P 0 H s L V N G DELETED P DELETED 0 H s L V \| N G DELETED P P 0 H s L V N G G DELETED DELETED:. 0 H s L V : N G G DELETED p I 0 H s L V j N G G P DELETED 0 H s L V j N G G P P 0 H R T A Y DELETED DELETED DELETED DELETED 0 H R T A Y DELETED DELETED DELETED P 0 H R T A Y DELETED DELETED P DELETED Q H R T A Y DELETED DELETED P P 0 H R T A Y DELETED G DELETED DELETED 0 H R T A Y DELETED G DELETED P 0 H R T A Y DELETED G P DELETED 0 H R T A Y DELETED G P P 0 H R T A Y G DELETED DELETED DELETED 0 H R T A Y G DELETED DELETED P 0 H R T A Y G DELETED P DELETED 0 H R T A Y G DELETED P P 0 H R T A Y G G DELETED DELETED 0 H R T A Y G G DELETED P Q H R T A Y G G P DELETED 0 ' H R T A Y G G P P 0 H R T A N DELETED DELETED DELETED DELETED 0 H R T A N DELETED DELETED DELETED P 0 H R T A N DELETED DELETED P DELETED Q H R T A N DELETED DELETED P P 0 H R T A N DELETED G DELETED DELETED Q H R T A N DELETED G DELETED P 0 H R T A N DELETED G P DELETED Q H R T A N DELETED G P P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 106 Q H R T A N G DELETED DELETED DELETED Q H R T A N G DELETED DELETED P Q H R T A N G DELETED P DELETED Q H R T A N G DELETED P P Q H R T A N G G DELETED DELETED Q H R T A N G G DELETED P Q H R T A N G G P DELETED Q H R T A \| N G G P P Q H R T V \| Y DELETED DELETED DELETED DELETED Q H R T V Y DELETED DELETED DELETED P Q H R T V Y DELETED DELETED P DELETED 0 H R T V Y DELETED DELETED P P 0 H R T V Y DELETED G DELETED DELETED Q H R T V Y DELETED G DELETED P ! 0 H R T V Y DELETED G P DELETED- Q H R T V Y DELETED G p i P Q H R T V Y G DELETED DELETEDiDELETED Q H R T V Y G DELETED DELETED! P Q H R T V Y G DELETED P DELETED Q H R T V Y G DELETED P P Q H R T V Y G G DELETED DELETED Q H R T V Y G G DELETED P Q H R T V Y G G P DELETED Q H R T V Y G G P P Q H R T v ..- N DELETED DELETED DELETED DELETED Q H R T 'V N DELETED DELETED DELETED P Q H R T V N DELETED DELETED P DELETED Q H R T V N DELETED DELETED P P Q H R T V 1 N DELETED G DELETED DELETED Q H R T V t N DELETED G DELETED P 0 H R T V N DELETED G P DELETED Q H R T V N DELETED G P P Q H R T V N G DELETED DELETED DELETED Q H R T V N G DELETED DELETED P Q H R T V N G DELETED P DELETED Q H R T V N G DELETED P P Q H R T V N G G DELETED DELETED Q H R T V N G G DELETED P Q H R T V N G G P DELETED Q H R T V N G G P P Q H R L A Y DELETED DELETED DELETEDiDELETED Q 1 H R L A Y DELETED DELETED DELETED! P PCT/US2007/075U7 3 35 53 57 61 80 99 100 101 106 0 H R L A \| Y DELETED DELETED P DELETED Q H R L A Y DELETED DELETED P P 0 H R L A Y DELETED G DELETED DELETED 0 H R L A Y DELETED G DELETED P 0 H R L A Y DELETED G P DELETED Q H R L A Y DELETED G P P 0 H R L A Y G DELETED DELETED DELETED 0 H R L A Y G DELETED DELETED P Q H R L A Y G DELETED P DELETED Q H R L A Y G DELETED P P 0 H R L A Y G G DELETED DELETED Q H R L A Y G G DELETED P 0 H R L A Y G G P DELETED 0 H R L A Y G G P P 0 H R L A N DELETED DELETED DELETED DELETED Q H R L A N DELETED DELETED DELETED: p 0 H R L A N DELETED DELETED P DELETED 0 H R L A N DELETED DELETED P P 0 H R L A N DELETED G DELETED DELETED 0 H R L A N DELETED G DELETED P 0 H R L A N DELETED G P DELETED 0 H R L A N DELETED G P P 0 H R L A N G DELETED DELETED DELETED 0 H R L A N G DELETED DELETED P 0 H R L A N G DELETED P DELETED 0 H R L A N G DELETED P P 0 H R L A N G G DELETED DELETED Q H R L A N G G DELETED P 0 H R L A N G G P DELETED Q H R L A N G G P P 0 H R L V Y DELETED DELETED DELETED DELETED 0 H R L V Y DELETED DELETED DELETED P 0 H R L V Y DELETED DELETED P DELETED Q H R L V Y DELETED DELETED P P 0 H R L V Y DELETED G DELETED DELETED 0 H \| R L V Y DELETED G DELETED P Q H R L V Y DELETED G P DELETED 0 H R L V Y DELETED G P P 0 H R L V Y G DELETED DELETED DELETED 0 H R L V Y G DELETED DELETED P 0 H R L V Y G DELETED P DELETED Q H R L V Y G DELETED P P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 \| 106 0 H R L V Y G G DELETEDJDELETED 0 H R L V Y G G DELETED P 0 H R L V Y G G P DELETED 0 H R L V Y G G P P 0 H R L V N DELETED DELETED DELETED DELETED 0 H R L V N DELETED\|DELETED DELETED P 0 H R L V N DELETED DELETED P DELETED 0 H R L V N DELETED DELETED P P 0 H R L V N DELETED G DELETED DELETED 0 H R L V N DELETED G DELETED P 0 H R L V N DELETED G P DELETED 0 H ' R L V N DELETED G P P Q H R L V N G DELETED DELETED DELETED 0 H R L L V N G DELETED DELETED P 0 H i R V N G DELETED P DELETED' 0 H j R L V N ! G DELETED P P ; 0 H ! R L V N G G DELETED DELETED 0 H ! R L V N G G DELETED P 0 H R L V N G G P DELETED 0 H R L V N G G P P H S S T A Y DELETED DELETED DELETED DELETED H S S T A Y DELETED DELETED DELETED P H s S T A Y DELETED DELETED P DELETED H s S T A Y DELETED DELETED P P H s s T A Y DELETED G DELETED DELETED H s s T A - Y DELETED G DELETED P H s s T A \| Y DELETED G P DELETED H s s T A \ Y DELETED G j P P H s s T A j Y G DELETEDjDELETED DELETED H s s T A j Y G DELETED DELETED P H s s T A Y G DELETED P DELETED H s s T A Y G DELETED P, P H s s T A Y G G DELETED DELETED H s s T A Y G G DELETED P H s s T A Y G G P DELETED H s s T A Y G G P P H s s T A N DELETED DELETED DELETED DELETED H s s T A N DELETED DELETED DELETED P H s s T A N DELETED DELETED P DELETED H s s T A N DELETED DELETED P P H s s T A N DELETED G DELETED DELETED H s s T A N DELETED G DELETED P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 106 H S s T A i N DELETED G P DELETED H S s T A N DELETED G P P H s s T A N G DELETED DELETED DELETED H s s T A N G DELETED DELETED P H s s T A N G DELETED P DELETED H s s T A N G DELETED P P H s s T A N G G DELETED DELETED H s s T A N G G DELETED P H s s T A N G G P DELETED H s s T A N G G P P H s s T V Y DELETED DELETED DELETED DELETED H s s T V Y DELETED DELETED DELETED P H s s T V Y DELETED DELETED P DELETED H s s T V Y DELETED DELETED P P H s s T V Y DELETED G DELETEDJDELETED H s s T ; v Y DELETED G DELETEDj P H s s T V Y DELETED G P (DELETED H s s T V Y DELETED G P ' P H s s T V Y G DELETED DELETED DELETED H s s T V Y G DELETED DELETED P H s s T V Y G DELETED P DELETED H s s T V Y G DELETED P P H s s T V Y G G DELETED DELETED H s s T V Y G G DELETED P H s s T V Y G G P DELETED H s s T V Y G G P P ! H s s T V N DELETED DELETED DELETED DELETED H s s T V N DELETED DELETED DELETED P H s s T V N DELETED DELETED P DELETED H s s T V N DELETED DELETED P P H s s T V N DELETED G DELETED DELETED H s s • T V N DELETED G DELETED P H s s T V N DELETED G P DELETED H s s T V N DELETED G P P H s s T V N G DELETED DELETED DELETED H s s T V N G DELETED DELETED P H s s T V N G DELETED P DELETED H s s T V' N G DELETED P P H s s T V N G G DELETEDJDELETED H s s T V N G G DELETED! P H s s T V N G G P DELETED H s s T V N G G P P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 106 H S s L A Y DELETED DELETED DELETED DELETED H S s L A Y DELETED DELETED DELETED P H s s L A Y DELETED DELETED P DELETED H s s L A Y DELETED DELETED P P H s s L A Y DELETED G DELETED DELETED H s s L A Y DELETED G DELETED P H s s L A Y DELETED G P DELETED H s s L A Y DELETED G P P H s s L A Y G DELETED DELETED DELETED H s s L A Y G DELETED DELETED P H s s L A Y G DELETED P DELETED H s s L A Y G DELETED P P H s s L A Y G G DELETED DELETED H s s L A Y G G DELETED P H s s L A Y G G P DELETED H s s L A ! Y G G P P H s s L A N DELETED DELETED DELETED DELETED H s s L A N DELETED DELETED DELETED P H s s L A N DELETED DELETED P DELETED H s s L A N DELETED DELETED P P H s s L A N DELETED G DELETED DELETED H s s L A N DELETED G DELETED P H s s L L_ A N DELETED G P DELETED H s s L A N DELETED G \| P P H s s L A N G DELETED DELETED DELETED H s s L A N G DELETED DELETED P H s s L A N G DELETED P DELETED H s s L A N G DELETED P P H s s L A N G G DELETED DELETED H s s L A N G G DELETED P H s s L A N G G P DELETED H s s L A N G G P P H s s L V Y DELETED DELETED DELETED DELETED H s s L V Y DELETED DELETED DELETED P H s s L V Y DELETED DELETED P DELETED H s s L V Y DELETED DELETED P P H s s L V Y DELETED G DELETED DELETED H s s L V Y DELETED G DELETED P H s s L V Y DELETED G P DELETED H s s L V Y DELETED G P P H s s L V Y G DELETED DELETED DELETED H s s L V Y G DELETED DELETED P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 106 H S s L V Y G DELETED P DELETED H S s L V Y G DELETED P P H s s L V j Y G G DELETED DELETED H s s L V Y G G DELETED P H s s L V 1 Y G G P DELETED H s s L V Y G G P P H s j s L V N DELETED DELETED DELETED DELETED H s s L V N DELETED DELETED DELETED P H s s L V N DELETED DELETED P DELETED H s s L V N DELETED DELETED P P H s s L V N DELETED G DELETED DELETED H s s L V N DELETED G DELETED P H s s L V N DELETED G P DELETED H s s L V N DELETED G P i P H ! S s L V N G DELETED DELETE DlDELETED H I S j S L V N G DELETED DELETED; P H\|S S L V N G DELETED P iDELETED H s s L V N G DELETED p ! p H s s L V N G G DELETED DELETED H s s ' L V N G G DELETED P H s s L V N G G P DELETED H s s L V N G G P P H s R T A Y DELETED DELETED DELETED DELETED H s R T A Y DELETED DELETED DELETED! P H s R T A Y DELETED DELETED P DELETED H s R T A Y DELETED DELETED P P H s R T A Y DELETED G DELETED DELETED H s R T A Y DELETED G DELETED P H s R T A Y DELETED G P DELETED H s R T A Y DELETED G P P H s R T A Y G DELETED DELETED DELETED H s R T A Y G DELETED DELETED ■P H s R T A ■ Y - -G -- DELETED P DELETED H s R T A Y G DELETED P P H s R T A Y G G DELETED DELETED H s R T A Y G G DELETED P H s R T A Y G G P DELETED H s R T A Y G G P P H s R T A N DELETED DELETED DELETED DELETED H s R T A N DELETED DELETED DELETED P H s R T A N DELETED DELETED P DELETED H s R T A N DELETED DELETED P P WO2008/H2003 PCT/US2007/0751I7 3 35 53 57 61 80 99 100 101 106 H S R T A N DELETED G DELETED DELETED H S R T A N DELETED G DELETED P H s R T A N DELETED G P DELETED H s R T A N DELETED G P P H S 1 R T A N G DELETED DELETED DELETED H s R T A N G DELETED DELETED P H s R T A N G DELETED P DELETED H s R T A N G DELETED P P H s R T A N G G DELETED DELETED H s R . T A N G G DELETED P H s R T A N G G P DELETED H s R T A N G G P P H s R T V Y DELETED DELETED DELETED DELETED H s R T V Y DELETED DELETED DELETED P ! H s R T V Y DELETED DELETED P DELETED! H S ! R T V j Y DELETED DELETED P P H s R T V Y jDELETED G DELETED DELETED H s R T V Y DELETED G DELETED p H s R T V Y DELETED G P DELETED H s R T V Y DELETED G P P H s R T V Y G DELETED DELETED DELETED H s R T V Y G DELETED DELETED P H s R T V Y G DELETED P DELETED H s R T V Y G DELETED P P H s R T V Y G G DELETED DELETED H s R T V Y G G DELETED P H s R T V Y G G P DELETED H s R T V Y G G P P H s R T V N DELETED DELETED DELETED DELETED H s R T V N DELETED DELETED DELETED P H s R T V N DELETED DELETED P DELETED H s R T V N DELETED DELETED P P H s R T V N DELETED G DELETED DELETED H s R T V N DELETED G DELETED! P H • s R T V N DELETED G P !DELETED H s R T V N DELETED G P I P H s R T V N G DELETED DELETED\|DELETED H s R T V N G DELETED DELETED P H s R T V N G DELETED P DELETED H s R T V N G DELETED P P H s R T V i N G G DELETED DELETED H s R T V N G G DELETED P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 I 99 \| 100 101 \| 106 H S R T V N G G P JDELETED H S R T V N G G P P H s R L A Y DELETED DELETED DELETEDlDELETED H s R L A Y DELETED DELETED DELETED P H s R L A Y DELETED DELETED P DELETED H s R L A Y DELETED DELETED P P H s R L A Y DELETED G DELETED DELETED H s R L A Y DELETED G DELETED P H s R L A Y DELETED G P DELETED H s R L A Y DELETED G P P H s R L A Y G DELETED DELETED DELETED H s R L A Y G DELETED DELETED P H s R L A Y G DELETED P DELETED H s R L A Y G DELETED P P ! H s R L A Y G G DELETED DELETED H s R L A ! Y G G DELETED! P H s R L A Y G G P DELETED H s R L A Y G G P P H s R L A N DELETED DELETED DELETED DELETED H s R ' L A N DELETED DELETED DELETED P H s R L A N DELETED DELETED P DELETED H s R L A N DELETED DELETED P i P H s R L A N DELETED G DELETEDlDELETED H s R L A N DELETED G DELETED! p H s R L A N DELETED G P DELETED H s R L A N DELETED G P P H s R L A N G DELETED DELETED DELETED H s R L A N G DELETED DELETED P H s R L A N G DELETED P DELETED H s R L A N G DELETED P P H s R L A N G G DELETED DELETED H s R L A N G G DELETED P H s R L A N G G P DELETED H s R L A N G G P. P H s R L V Y DELETED DELETED DELETED DELETED H s R L V Y DELETED DELETED DELETED P H s R L V Y DELETED DELETED P DELETED H s R L V Y DELETED DELETED P P H s R L V Y DELETED G DELETED DELETED H s R L V Y DELETED G DELETED P H s R L V Y DELETED G P DELETED H s R L V Y DELETED G P P WO 2008/112003 PCT/US2007/075117 wo Hmnmm PCt/US20df/0?Sl1f 3 35 53 57 61 80 99 100 101 106 H H S T A N DELETED DELETED P DELETED H H S T A N DELETED DELETED P P H H S T A N DELETED G DELETED DELETED H H S T A N DELETED G DELETED P H H S T A N DELETED G P DELETED H H S T A N DELETED G P P H H S T A N G DELETED DELETED DELETED H H S T A N G DELETED DELETED P H H S T A N G DELETED P DELETED H H s T A N G DELETED P P H H s T A N G G DELETED DELETED H H s T A N G G DELETED P H H s T A N G G P DELETED H H s T A N G G P 1 P H H s T V Y DELETED DELETED DELETEDDELETED H H s . T V Y DELETED DELETED DELETED: P H H s T V Y DELETED DELETED P (DELETED H H s T V Y DELETED DELETED P P H H s T V Y DELETED G DELETED DELETED H H s T V Y DELETED G DELETED P H H s T V Y DELETED G P DELETED H H s T V Y DELETED G P P H H s T V Y G DELETED DELETED DELETED H H s T V Y G DELETED DELETED P H H s T V Y G DELETED P DELETED H H s T V Y G DELETED P P H H s T V Y G G DELETED DELETED H H s T V Y G G DELETED P H H s T V Y G G P DELETED H H s T V Y G G P P ■ H H s T V N DELETED DELETED DELETED DELETED H- H s T V N DELETED DELETED DELETED P H H s T V N DELETED DELETED P DELETED H H s T V N DELETED DELETED P P H H s T V N DELETED G DELETED DELETED H H s T V N DELETED G DELETED P H H s T V N DELETED G P DELETED H H s T V N DELETED G P P H H s T V N G DELETED DELETED DELETED H H s T V N G DELETED DELETED P H H s T V N G DELETED P DELETED H H s T V N G DELETED P P WO 2008/112003 PCT/US2007/075117 3 35 53 57 I 61 80 99 100 101 106 H H S T V N G G DELETED DELETED H H S T V N G G DELETED P H H s T V N G G P DELETED H H s T V N G G P P H H s L A _, Y DELETED DELETED DELETED DELETED H H s L A Y DELETED DELETED DELETED P H H s L A Y DELETED DELETED P DELETED H H s L A Y DELETED DELETED P P H H s L A Y DELETED G DELETED DELETED H H s L A Y DELETED G DELETED P H H s L A Y DELETED G P DELETED H H s L A Y DELETED G P P H H s L A Y G DELETED DELETED DELETED H H s L A Y G DELETED DELETED P H H ! S L A Y ! G DELETED p DELETED H H S L A Y G DELETED p ! p H H \| S L A Y G G DELETEDlDELETED H H s L A Y G G DELETED! P H H s L A Y G G P DELETED H H s L A Y G G P ! P H H s L A N DELETED DELETED DELETEDlDELETED H H s L A N DELETED DELETED DELETED! p H H s L A N DELETED DELETED P DELETED H H s L A N DELETED DELETED P P H H s L A N DELETED G DELETED DELETED H H s L A N DELETED G DELETED P H H s L A N DELETED G P DELETED H H s L A N DELETED G P P H H s L A N G DELETED DELETED DELETED H H s L A N G DELETED DELETED P H H s L A N G DELETED P DELETED H H s L A N G DELETED P P H H s L A N G G DELETED DELETED H H s L A N G G DELETED P H H s L A N G G P DELETED H H s L A N G G P P H H s L V Y DELETED DELETED DELETED DELETED H H s L V Y DELETED DELETED DELETED P H H s L V Y DELETED DELETED P DELETED H H s L V Y DELETED DELETED P p H H s L V Y DELETED G DELETED DELETED H H s L V Y DELETED G (DELETED P WO 2008/112003 PCT/US2007/07S117 3 35 53 57 61 80 99 100 101 106 H H S L V Y DELETED G P DELETED H H S L V Y DELETED G P P H H S L V Y G DELETED DELETED DELETED H H S L V Y G DELETED DELETED P H H S L V Y G DELETED V DELETED H H s L V Y G DELETED P P H H s L V Y G G DELETED DELETED H H s L V Y G G DELETED P H H s L V Y G G P DELETED H H s L V Y G G P P H H s L V N DELETED DELETED DELETED DELETED H H s L V N DELETED DELETED DELETED P H H s L V N DELETED DELETED P DELETED H H s L V N DELETED DELETED P P H H ; S L V N DELETED G DELETED DELETED H H i S L V N DELETED G DELETED P H H s L V N DELETED G P DELETED H H s L V N DELETED G P P H H s L V N J G DELETED DELETED DELETED H H s L V N G DELETED DELETED P H H s L V N G DELETED P DELETED H H s L V N G DELETED P P H H s L V N G G DELETED DELETED H H s L V N G G DELETED P H H s L V N G G P DELETED H H s L V \| N G G P P H H R T A Y DELETED DELETED DELETED DELETED H H R T A Y DELETED DELETED DELETED P H H R T A Y DELETED DELETED P DELETED H H R T A Y DELETED DELETED P P H H R T A Y DELETED G DELETED DELETED H H R T A Y DELETED G DELETED P H H R T A Y DELETED G P DELETED H H R T A Y DELETED G P P H H R T A Y G DELETED DELETED DELETED H H R T A Y G DELETED DELETED P H H R T A Y G DELETED P DELETED H H R T A Y G DELETED P ! P H H R T A Y G G DELETEDlDELETED H H R T A Y G G DELETED P H H R T A Y G G P DELETED H H R T A ! Y G G P P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 ! 106 H H R T A N DELETED DELETED DELETED^ DELETED H H R T A N DELETED DELETED DELETED P H H R T A N DELETED DELETED P DELETED H H R T A N DELETED DELETED P P H H R T A N DELETED G DELETED DELETED H H R T A N DELETED G DELETED P H H R T A N DELETED G P DELETED H H R T A N DELETED G P P H H R T A N G DELETED DELETED DELETED H H R T A N G DELETED DELETED P H H R T A N G DELETED P DELETED H H R T A N G DELETED P P H H R T A N G G DELETED DELETED H H R T A N G G DELETED P H H R T A N G G P DELETED, H H i R T A N G G P P H H R T V Y DELETED DELETED DELETED DELETED H H R T V Y DELETED DELETED DELETED P H H R T V Y DELETED DELETED P DELETED H H R T V Y DELETED DELETED P P H H R T V Y DELETED G DELETED DELETED H H R T V Y DELETED G DELETED P H H R T V Y DELETED G P DELETED H H R T V Y DELETED G P P H H R T V Y G DELETED DELETED DELETED H H R T V Y G DELETED DELETED P H H R T V Y G DELETED P DELETED H H R T V Y G DELETED P P H H R T V Y G G DELETED DELETED H H R T V Y G G DELETED P H H R T V Y G G P DELETED H H R T V Y G G P P H H R T V N DELETED DELETED DELETED DELETED H H R T V N DELETED DELETED DELETED P H H R T V N DELETED DELETED P DELETED H H R T V N DELETED DELETED P P H H R T V N DELETED G DELETED DELETED H H R T V N DELETED G DELETED P H H R T V N DELETED G P DELETED H H R T V N DELETED G P - P H H R T V N G DELETED DELETED DELETED H H j R T V N G DELETED DELETED P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 80 99 100 101 106 H H R T V N G DELETED P DELETED H H R T V N G DELETED P P •H H R T V N G G DELETED DELETED H H R T V N G G DELETED P H H R T V N G G P (DELETED H H R T V N G G P P H H R L A Y DELETED DELETED DELETED DELETED H H R L A Y DELETED DELETED DELETED P H H R L A Y DELETED DELETED P DELETED H H R L A Y DELETED DELETED P P H H R L A Y DELETED G DELETED DELETED H H R L A Y DELETED G DELETED P H H R L A Y DELETED G P DELETED H H H "H " R R L A Y DELETED G P P L A Y G DELETED DELETED DELETED H H R L A Y G DELETED DELETED P H H R L A Y G DELETED P IDELETED H H R L A Y G DELETED P P H H R L A Y G G DELETED DELETED H H R L A Y G G DELETED P H H R L A Y G G P DELETED H H R L A Y G G P P H H R L A N DELETED DELETED DELETED DELETED H H R L A N DELETED DELETED DELETED P H H R L A N DELETED DELETED P DELETED H H R L . A N DELETED DELETED P P H H R L A N ■ DELETED G DELETED DELETED H H R L A N DELETED G DELETED P H H R L A N DELETED G P DELETED H H R L A N DELETED G P P H H R L A N G DELETED DELETED DELETED H H R L A N G DELETED DELETED P H H R L A N G DELETED P DELETED H H R L A N G DELETED P P H H \| R L A N G G DELETED DELETED H H ! R L A N G G DELETED P H H R L A N G G P DELETED H H R L A N G G P P H H R L V Y DELETED DELETED DELETED DELETED H H R L V Y DELETED DELETED DELETED P H H R L V Y DELETED DELETED P DELETED H H R L V Y DELETED DELETED P P WO 2008/112003 PCT/US2007/075117 3 35 53 57 61 so 99 100 101 106 H H R L V Y DELETED G DELETED DELETED H H R L V Y DELETED G DELETED P H H R L V Y DELETED G P DELETED H H R L V Y DELETED G P P H H R L V Y G DELETED DELETED DELETED H H R L V Y G DELETED DELETED P H H R L V Y G DELETED P DELETED H H R L V Y G DELETED P P H H R L V Y G G DELETED DELETED H H R L V Y G G DELETED P H H R L V Y G G P DELETED H H R L V Y G G P P H H R L V N DELETED DELETED DELETED DELETED H H R L v N DELETED DELETED DELETED P H H R L V \| N DELETED DELETED P DELETED H H R L V N DELETED DELETED P j P H H R L V N DELETED G DELETEDJDELETED H H R L V -N DELETED G DELETED P H H R I V N DELETED G P DELETED H H R L V N DELETED G P P H H R L V N G DELETED DELETED DELETED H H R L V N G DELETED DELETED P H H R L V N G DELETED P DELETED H H R L V ! N G DELETED P P H H R L V i N G G DELETED DELETED H H R L V N G G DELETED P H H R L V N G G P DELETED H H R L V N G G \| P P Table 7. Exemplary Mutations of mAb 2.175.3 Light Chain (SEQ ID NO: 4) to Germline at the Indicated Residue Number. 25 28 31 46 55 77 A S s L o S A S s L 0 T A s s L p S A s s L P T A s s F 0 g A s s F 0 T A s s F P S A s s F p T WO 2008/112003 PCT/US2007/075117 25 28 31 46 55 77 A S R L Q S A S R L Q T A S R L p S A s R L P_[ T A s R F Q S A s R F Q T A s R F p , S A s R F P_j T A R S L Q S A R S L Q T A R s L p S A R s L P T A R s F Q S A R s F Q 1 T A R s F 1 P I S A R s F P T A R R L Q\ s A R R L Q T A R R L p S A R R L p T A R R F Q S A R R F Q T A R R F p S I A R R F P T P- S S L Q S P s s L Q T P s s L p S P s s L p T P s s F Q S P s s F Q T P s s F P S P s s F P T P s R L ■Q S P s R L 0 T P s R L p S P s R L p T P s R F Q S P s R F _Q_ T P s R F p S P s R F p T P R S L _Q_ S ! P R S L 0 T •j3qiun,M 3npiS3-y paiEDtptq sqj je 3ui\|UU3r) o» (01 :ONOI D3S)U!RMDXA^H i'\'6WZ qv™.P suoiiemw £re\|durax3 "3 o\qs± X d 3 H a d s d 3 a a d X 0 3 a tt d s 0 3 y a d X d 1 a tf d s d 1 a H d X 0 1 a y d s 0 1 a a d 1 d 3 s a d s d 3 s a d X 0 3 s a d s 0 3 s a d X d 1 s a d s a 1 S" a d LL ss 9P I£ 8Z sz Z.USZ.O/Z,OOZSfl/XJd . COOZU/800Z OAV WO 2008/1120(13 PCT/US2007/075117 35 57 99 100 101 N T E G S N T E G R N I DELETED DELETED S N I DELETED DELETED R N I DELETED G S N I DELETED G R N I E DELETED S N I E DELETED R N I E G S N 1 E G R Table 9. Exemplary Mutations of mAb 2.449.! .3 Light Chain (SEQ ID NO: 12) to Gemiline at the Indicated Residue Number. 20 25 29 31 33 49 55 56 i 91 94 95 96 I 107 T A S L Y Q S ! S DELETED DELETED DELETED I T A S L Y Q s s DELETED DELETED DELETED M T A s L Y Q s s DELETED DELETED P I T A s L Y Q s s DELETED DELETED P M T A s L Y Q s s DELETED P DELETED I T A s L Y Q s s DELETED P DELETED M T A s L Y Q s s DELETED P P I T A s L Y Q s s DELETED P P M T A s L Y Q s s N DELETED DELETED I T T A A s s L L Y Y 0 Q s s s s ISI DELETED DELETED DELETED P M I T A s L Y Q s s N DELETED P M T A s L Y. Q s s N P DELETED I T A s L Y Q s s N P DELETED M T A s L Y Q s s N P P I T A s L Y Q s s N P P M T A s L Y Q s T DELETED DELETED DELETED I T A s L Y Q s T DELETED DELETED DELETED M T A s L Y Q s T DELETED DELETED P I T A s L Y Q s T DELETED DELETED P M T A s L Y Q s T DELETED P DELETED I T A s L Y Q s T DELETED P DELETED M T A s L Y Q s T DELETED P P I T A s L Y Q s T DELETED P . P M T A s L Y Q s T N DELETED DELETED I T A s L Y Q s T N DELETED DELETED M T A s L Y Q s T N DELETED P I T A s L Y Q s T N DELETED P M T A s L Y Q s T j N P DELETED I T A s L Y Q s T I N P DELETED M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A S L Y Q S T N P P T A S L Y Q^ s T N P P M T A S L Y Q G S DELETED DELETED DELETED T A S L Y Q G S DELETED DELETED DELETED M T A S L Y Q G s DELETED DELETED P T A S L Y Q G s DELETED DELETED P M T A S L Y Q G s DELETED P DELETED T A S L Y Q G s DELETED P DELETED M T A S L Y Q G s DELETED P P T A S L Y Q G s DELETED P P M T A S L Y Q G s N DELETED DELETED T A S L Y Q G s N DELETED DELETED M T A S L Y Q G s N DELETED P T A S L Y Q G s N DELETED P M T A S L Y Q G s N P DELETED T A s L Y j Q G s N P DELETED M T A s L Y \| Q G s N P \| P T A s L Y ! Q j G s N P P N4 T A s L Y Q l G r DELETED DELETED DELETED T A s L Y Q G T DELETED DELETED DELETED M T A s L Y Q G T DELETED DELETED P T A s L Y Q G T DELETED DELETED P M T A s L Y Q G T DELETED P DELETED T A s L Y Q G T DELETED P DELETED M T A s L Y Q G T DELETED P P T A s L Y Q G T DELETED P P M T A s L Y Q G T N DELETED DELETED T A s L Y Q G T N- DELETED DELETED M T A s L Y Q G T N DELETED P T A s L Y Q G T N DELETED P M T A s L Y 0 G T N P DELETED T A s L Y Q G T N P DELETED M T A s L Y Q G T N P P ■ T A s L Y Q G T N P P M T A s L Y V S S DELETED DELETED DELETED T A s L Y V S S DELETED DELETED DELETED M T A s L Y V S s DB.ETED DELETED P T A s L Y V S s DEI ETED DELETED P M T A s L Y V S s DELETED P DELETED T A s L Y V S s DELETED P DELETED M T A s L Y i V S s DELETED P P T A s L Y V S s DELETED P P M T A s L Y V S s N DELETED DELETED T A s L Y V S s N DELETED DELETED M T A s L Y V s s N DELETED P T A s L Y V s s N DELETED P M T A s L Y V s s N P DELETED WO 2008/112003 PCT/CJS2007/0751I7 20 25 29 31 33 49 55 \| 56 91 94 \| 95 96 107 T A S L Y V s S N P DELETED M T A S L Y V \| S S N P P T A S L Y V s S N P P M T A S L Y V s ! T DELETED DELETED DELETED T A S L Y V s i T DELETED DELETED DELETED M T A S L Y V S ! T DELETED DELETED P T A S L Y V s T DELETED DELETED P M T A S L Y V s T DELETED P DELETED T A S L Y V s T DELETED P DELETED M T A s L Y V s T DELETED P P T A s L Y V s T DELETED P P M T A s L Y V s T N DELETED DELETED T A s L Y V s T N DELETED DELETED M T A s L Y V s T N DELETED P T A s L Y V s T N DELETED P M T A s L Y V s T N P DELETED I ! i T A s L \| Y V S I T N P DELETED M ! T A s L Y j V s ! T N P ! P T A s L Y V s T N P P M T A s L Y V G S DELETED DELETED DELETED T A s L Y V G S DELETED DELETED DELETED M T A s L Y V G s DELETED DELETED P T A s L Y V G s DELETED DELETED P M T A s L Y V G i S DELETED P DELETED T A s L Y V G s DELETED P DELETED M T A s L Y V G s DELETED P P T A s L Y V G s DELETED P P M T A s L Y V G s N DELETED DELETED T A s L Y V G s N DELETED DELETED M T A s L Y V G s N DELETED P T A s L Y V G s N DELETED P M T A s L Y V G s N P DELETED T A s L Y V G s N P DELETED M T A s L Y V G s N P P T A s L Y V G s N P P M T A s L Y V G T DELETED DELETED DELETED T A s L Y V G T DELETED DELETED DELETED M T A s L Y V G T DELETED DELETED P T A s L Y V G T DELETED DELETED P . M T A s L Y V G T DELETED P DELETED T A s L Y V G T DELETED P DELETED M T A s L Y V G T DELETED P P T A s L Y V G T DELETED P P M T A s L Y V G T N DELETED DELETED T A s L Y V G T N DELETED DELETED M T A s L Y V G T N IDELETED P T A S \| L Y V G T N DELETED P M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A S L Y ■V G T . N P DELETED I T A S L Y V G T N P DELETED M T A S L Y V G T N P P I T A S L Y V G T N P P M T A s L H Q S S DELETED DELETED DELETED i T A s L H Q s S DELETED DELETED DELETED M T A s L H Q s s DELETED DELETED P ! T A s L H Q s s DELETED DELETED P M T A s L H Q s s DELETED P DELETED I T A s L H Q s s DELETED P DELETED M T A s L H Q s s DELETED P P I T A s L H Q s s DELETED P P M T A s L H Q s s N DELETED DELETED I T A s L H Q s s N DELETED DELETED M T A s L H Q s s N DELETED P I T A s L H Q s s N DELETED P M T A s L i H Q s s N P DELETED I T A s L H Q s s N P DELETED M T A s L H Q s s N P P i T A s L H Q s I s N P P M T A s L H Q s T DELETED DELETED DELETED I T A s L H Q s T DELETED DELETED DELETED M T A s L H Q s T DELETED DELETED P I T A s L H Q s T DELETED DELETED P M T A s L H Q s T DELETED P DELETED I T A s L H Q s T DELETED P DELETED! M T A s L H Q s T DELETED P P f T A s L H Q s T DELETED P P M T A s L H Q s T N DELETED DELETED I T A s L H Q s T N DELETED DELETED M T A s L H Q s T N DELETED P I T A s L H Q s T N DELETED P M T A s L H Q s T N P DELETED I T A s L H . Q s T N P DELETED M T A s L H Q s T N P P I T A s L H Q s T N P P M T A s L H Q G S DELETED DELETED DELETED I T A s L H Q G S DELETED DELETED DELETED M T A s L H Q G s DELETED DELETED P I T A s L H Q G s DELETED DELETED P M T A s L H Q G s DELETED P DELETED [ T A s L H Q G s DELETED P DELETED M T A s L H Q G s DELETED P P I T A s L H Q G s DELETED P P M T A s L H Q G s N DELETED DELETED i T A s L H Q G s N DELETED DELETED M T A s L H Q G s N DELETED P I WO 2008/112003 PCT/US2O07/O7SH7 20 25 29 31 33 49 \| 55 56 91 94 95 96 107 T A S L H Q G s N DELETED P M T A S L H Q G s N P DELETED T A s L H Q G s N P DELETED M T A s L H Q G s N P P \| I T A s L H Q G s N P P M T A s L H Q G T DELETED DELETED DELETED T A s L H Q G T DELETED DELETED DELETED M T A s L H Q G T DELETED DELETED P T A s L H Q G T DELETED DELETED P M T A s L H Q G T DELETED P DELETED T A s L H Q G T DELETED P DELETED M T A ■ s L H Q G T DELETED P P T A s L H Q G T DELETED P P M T A s L H Q G T N DELETED DELETED T A s L H Q G T N DELETED DELETED M T ~~' A s L H Q G T N DELETED P T ! A i 1 s L H Q i G T N DELETED P M T A s L ! H Q G T N P JDELETED T A s L H Q G T N P JDELETED M T A s L H Q G T N P \| P T A s L H Q G T N P P M T A s L H v- S S DELETED DELETED DELETED T A s L H V S S DELETED DELETED DELETED M T A s L H V S s DELETED DELETED P T A s L H V S s DELETED DELETED P M T A s L H V S s DELETED P DELETED T A s L H V S s DELETED P DELETED M T A s L H V S s DELETED P P T A s L H V S s DELETED P P M T A s L H V S s N DELETED DELETED T A s L H V S s N DELETED DELETED M T A s L H V s i s N DELETED P T A s L H V s s N DELETED P M T A s L H V s s N P DELETED T A s L H V s s N P DELETED M T A s L H . V s s N P P T A s L H V s s N P P M T A s L H V s T DELETED DELETED DELETED T A s L H V s T DELETED DELETED DELETED M T A s L H V s T DELETED DELETED P T A s L H V s T DELETED DELETED P M T A s L H V s T DELETED P DELETED T A s L H V s T DELETED P DELETED M T A s L H V s T DELETED P P T A s L H V s T DELETED P P M T A s L H V s T N DELETED DELETED T A s L H V s T N DELETED DELETED M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A S L H V S T N DELETED P T A S L H V s T N DELETED P M T A S L H V s T N P DELETED T A S L H V s T N P DELETED M T A S L H V s T N P P T A S L H V s T N P P M T A S L H V G S DELETED DELETED DELETED T A S L H V G S DELETED DELETED DELETED M T A s L H V G s DELETED DELETED P T A s L H V G s DELETED DELETED P M T A s L H V G s DELETED P DELETED T A s L H V G s DELETED P DELETED M T A s L H V G s DELETED P P T A s L H V G s DELETED P P M T A s L H V G s N DELETED DELETED T A s L H V G s N DELETED DELETED M T A ! 1 s L H V G s N DELETEDJ P T A s L H V G s N DELETED P M T A s L H V G 3 N P DELETED . i ' i T A s L H V G s N P DELETED M I T A s L H V G s N P P T A s L H V G s N P P M T A s L H V G T DELETED DELETED DELETED T A s L H V G T DELETED DELETED DELETED M T A s L H V G T DELETED DELETED P T A s L H V G T DELETED DELETED P M T A s L H V G T DELETED P DELETED T A s L H V G T DELETED P DELETED M T A s L H V G T DELETED P P T A s L H V G T DELETED P P M T A s L H V G T N DELETED DELETED T A s L H V G T N DELETED DELETED M T A s L H V G T N DELETED P T A s L H V G T N DELETED P M T A s L H V G T N P DELETED T A s L H V G T N P DELETED M T A s L H V G T N P P T A s L H V G T N P P M T A s Y Q S S DELETED DELETED DELETED T A s Y Q S S DELETED DELETED DELETED M T A s Y Q S s DELETED DELETED P T A s Y Q S s DELETED DELETED P M T A s Y Q S s DELETED P DELETED T A s Y Q S s DELETED P DELETED M T A s Y Q S s DELETED P P T A s Y Q S s DELETED P P M T A s Y Q s s N DELETED DELETED ! I WO 2008/112003 PCT/US2O0?/U?SU7 20 25 29 31 33 49 55 56 91 94 95 96 107 T A , S Y Q S S N DELETED DELETED M T A S Y Q S S N DELETED P T A s Y Q S S N DELETED P M T A s Y Q s ! s N P DELETED T A s Y Q S i S N P DELETED M T A s Y Q s S N P P r A s Y Q s S N P P M T A s Y Q s T DELETED DELETED DELETED T A s Y Q s T DELETED DELETED DELETED M T A s Y Q s T DELETED DELETED P T A s Y Q s T DELETED DELETED P M T A s Y Q s T DELETED P DELETED T A "S Y Q s T DELETED P - DELETED M T A s Y Q s T DELETED P P T A s Y Q s T DELETED P P M j T A s Y Q s T N DELETED DELETED T A s Y Q s T N DELETED DELETED M T A s Y Q i S T N DELETED P T A ^s I Y Q s T N DELETED P M T A s Y Q s T N P DELETED T A s Y Q s T N P DELETED M T A s Y Q s T N P P T A s Y Q s T N P P M T A s Y Q G S DELETED DELETED DELETED T A s Y Q G s DELETED DELETED DELETED M T A s Y Q G s DELETED DELETED P T A 5 Y Q G s DELETED DELETED P M T A s Y Q G s DELETED P DELETED T A s Y Q G s DELETED P DELETED M T A s Y Q G s DELETED P P ' T A s Y Q G s DELETED P P M T A s Y Q G s N DELETED DELETED T A s Y Q G s N DELETED DELETED M T A s Y Q G s N DELETED P T A s Y Q -G s N DELETED P M T A s Y Q G s N P DELETED T A s Y Q G s N P DELETED M T A s Y Q G s N- P P T A s Y Q G s ' N P P M T A s Y Q G T DELETED DELETED DELETED T A s Y Q G T DELETED DELETED DELETED M T A s Y Q G T DELETED DELETED P T A s Y Q G T DELETED DELETED P M T A s Y Q G T DELETED P DELETED T A s Y Q G T DELETED P DELETED M T A s Y Q G T DELETED P P T A s Y Q G T DELETED P P M WO 2008/112003 PCT/US2(Ht7/075m 20 25 j 29 31 33 49 55 56 j 91 94 95 j 96 107 T A S Y Q G I T N DELETED DELETED I T A S Y Q G ! T N DELETED DELETED M T A S Y Q G ! T N DELETED P I T A S Y Q G I T N DELETED P M T A S Y Q G j T N P DELETED I T A S Y Q G ! T N P DELETED M T A S Y Q G ! T N P P I T A S Y Q G ! T N P P M T A S Y V S S DELETED DELETED DELETED I T A S Y V S S DELETED DELETED DELETED M T - A S Y V S S DELETED DELETED ' P I T A s Y V S S DELETED DELETED P M T A s Y V S S DELETED P DELETED I T A s Y V S S DELETED P DELETED M T A s Y V S S DELETED P P I T A s Y V S s DELETED P P M T A s Y V S j S N DELETED DELETED I T A s Y V s s N DELETED DELETED M T A s Y V s s N DELETED P I T A s Y V s s N DELETED P M T A s Y V s s N P DELETED I T A s Y V s s N P DELETED M T A s Y v" s s N P P I T A s Y V s s N P P M T A s Y v ■ s T DELETED DELETED DELETED I T A s Y V s T DELETED DELETED DELETED M T A s Y V s T DELETED DELETED P ! I T A s Y V s T DELETED DELETED P \| M T A s Y V s T DELETED P DELETED! I T A s Y V s T DELETED P DELETED! M T A s Y V s T DELETED P ■ P I I T A s Y V s T DELETED P P M T A s Y V s T N DELETED DELETED I T A s Y V s T N DELETED DELETED M T A s Y V s T N DELETED p I T A s Y V s T N DELETED p M T A s Y V s T N P DELETED I T A s Y V s T N P DELETED M T A s Y V s T - N P P I T A s Y V s T N P P M T A s Y V G S DELETED DELETED DELETED I T A s Y V G S DELETED DELETED DELETED M T A s Y V G \| S DELETED DELETED P I T A s Y V G S DELETED DELETED P M T A s Y V G S DELETED P DELETED I T A s Y V G S DELETED P DELETED M T A s Y V G S DELETED P P ! WO 2008/112003 PCT/US2007/075H7 20 25 29 31 33 I 49 55 56 91 94 95 96 107 T A S Y V G s DELETED P P M T A S Y V G s N DELETED DELETED T A s Y V G s N DELETED DELETED M T A s i i Y V G s N DELETED P T A S I Y V G s N DELETED P M T A s Y V G s N P DELETED T A s Y V G s N P DELETED M T A s Y V G s N P P T A s , Y V G s N P P M T A s Y V G T DELETED DELETED DELETED T A s Y V G T DELETED DELETED DELETED M T A s Y V G T DELETED DELETED P T A s Y V G T DELETED DELETED P M T A s Y V G T DELETED P DELETED T A s Y V G T DELETED P DELETED M T A s Y V G T DELETED P P T A s Y V G T DELETED P P M T A s Y V G T N DELETED DELETED T A s Y V G T N DELETED DELETED M T A s Y V G T N DELETED P T A s Y V G T N DELETED P M T A s Y L V G T N P DELETED T A s Y V G T N P DELETED M T A s Y V G T N P P T A s Y V G T N P P M T A s H Q S S DELETED DELETED DELETED T A s H Q S S DELETED DELETED DELETED M T A s H Q s S DELETED DELETED P T A s H Q s s DELETED DELETED P M T A s H Q s s DELETED P DELETED I i T A s H Q s s DELETED P DELETED M T A s H Q s s DELETED P P T A s H Q s s DELETED P P M T A s H Q s s N DELETED DELETED T A s H Q s s N DELETED DELETED M T A s H 0 s L S N DELETED P T A s H Q s s N DELETED P M T A s H Q s s N P DELETED T A s H Q s s N P DELETED M T A s H Q s s N P P T A s H Q s s N P P M T A s H Q s T DELETED DELETED DELETED T A s H Q s T DELETED DELETED DELETED M T A s H Q s T DELETED DELETED P T A s H Q s T DELETED DELETED P M T A s H Q s T DELETED P DELETED T A s H Q s T DELETED! P DELETED M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A S H Q S T DELETED P P I T A S H Q S T DELETED P P M T A S H Q s T N DELETED DELETED I T A S H Q s T N DELETED DELETED M T A S H Q s T N DELETED P I T A S H Q s T N DELETED P M T A S H Q s T N P DELETED i T A S H Q s T N P DELETED M T A S H Q s T N P P I T A S H Q s T N P P M T A S H Q G S DELETED DELETED DELETED I T A S H Q G s DELETED DELETED DELETED M T A S H Q G s DELETED DELETED P I T A s H Q G s DELETED DELETED P M T A s H Q G s DELETED P DELETED I i T A s H Q G s DELETED P DELETED M ; T A s ' H Q G s DELETED P P ' ! T A s I j H Q G s DELETED P P M T A s H Q G s N DELETED DELETED I T A s H Q G s N DELETED DELETED M T A s H Q G s N DELETED P I T A s H Q" G s N DELETED P M T A s H Q G s N P DELETED I T A s H Q G s N P DELETED M T A s H Q G s N P P I T A s H Q G s N P P M T A s H Q G j T DELETED DELETED DELETED I T A s H Q G \| T DELETED DELETED DELETED M T A s H Q G T DELETED DELETED P I T A s H Q G T DELETED DELETED P M T A s H Q G T DELETED P DELETED I T A s H Q G T DELETED P DELETED M T A s H Q G T DELETED P P I T A s H Q G T DELETED P P M T A s H Q G T N DELETED DELETED I T A s H Q G T N DELETED DELETED M T A s H Q G T N DELETED P I T A s H Q G T N DELETED P M T A s H Q G T N P DELETED I T A s H Q G T N P DELETED M T A s H Q G T N P P I T A s H Q G T N P P M T ' A s H V S S DELETED DELETED DELETED I T A s H V S s DELETED DELETED DELETED M T A s H V S s DELETED DELETED P I T A s H V S s DELETED DELETED p i M T A s H V S s DELETED P DELETED! I WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 ) 95 96 DELETED 107 T A S H V s S DELETED P M T A S H V s S DELETED P P T A S H V s S DELETED P P M T A S H V s S N DELETED DELETED T A S H V s S N DELETED DELETED M T A s H V s s N DELETED P T A s H V s s N DELETED P M T A s H V s s N P DELETED T A s H V s s N P DELETED M T A s H V s s N P P T A s H V s s N P P M T A s H V s T DELETED DELETED DELETED T A s H V s T DELETED DELETED DELETED M T A s H V s T DELETED DELETED P T A s H V s T DELETED DELETED P M T A s H V s T DELETED P DELETED I i T A s H V s T DELETED P DELETED M T A s H V s T DELETED P P T A s H V s T DELETED P P M T A s H V s T N DELETED DELETED T A s H V s T N DELETED DELETED M • T A s H V s T N DELETED P T A s H V s T N DELETED P M T A s H V s T N P DELETED T A s H V s T N P DELETED M T A s H V s T N P P T A s H V s T N P P M T A s H V G S DELETED DELETED DELETED T A s H V G S DELETED DELETED DELETED M T A s H V G s DELETED DELETED P T A s H V G s DELETED DELETED P M T A s H V G s DELETED P DELETED T A s H V G s DELETED P DELETED M T A s H V G s DELETED P P T A s H V G s DELETED P P M T A s H V G s N DELETED DELETED T A s H V G s N DELETED DELETED M T A s H V G s N DELETED P T A s H V G s N DELETED P M T A s H V G s N P DELETED T A s H V G s N P DELETED M T A s H V G s N P P T A s H V G s N P P M T A s H J V G T DELETED DELETED DELETED T A s H V G T DELETED DELETED DELETED M T A s H V G T DELETED DELETED P T A s H V G T DELETED DELETED! P M WO 2008/112003 VCT/V&lWtfflSll'T 20 25 29 31 33 49 55 56 91 94 95 96 107 i T A S H V G T DELETED P DELETED T A s H V G T DELETED P DELETED M T A s H V G T DELETED P P T A s H V G T DELETED P P M T A s H V G T N DELETED DELETED T A s H V G T N DELETED DELETED M T A s H V G T N DELETED P T A s H V G T N DELETED P M T A s H V G T N P DELETED T A s H V G T N P DELETED M T A s H V G T N P P T A s H V G T N P P M T A R L Y Q S S DELETED DELETED DELETED T A R L Y Q S s DELETED DELETED DELETED M T A R L Y Q S s DELETED DELETED P T A R L Y Q S s DELETED DELETED P M T A R L Y Q s s DELETED P DELETED T A R L Y Q s s DELETED P DELETED M T A R L Y Q s s DELETED P P T A R L Y Q s s DELETED P P M T A R L Y Q s s N DELETED DELETED T A R L Y Q s s N DELETED DELETED M T A R L Y Q s s N DELETED P T A R L Y Q s s N DELETED P M I T A R L Y Q s s N P DELETED . i T A R L Y Q s s N P DELETED M T A R L Y Q s s N P P T A R L Y Q s s N P P M T A R L Y Q s T DELETED DELETED DELETED T A R L Y Q s T DELETED DELETED DELETED M T A R L Y Q s T DELETED DELETED P T A R L Y Q s T DELETED DELETED P M T A R L Y Q s T DELETED P DELETED T A R L Y Q s T DELETED P DELETED M T A R L Y Q s T DELETED P P T A R L Y Q s T DELETED P P M T A R L Y Q s T N DELETED DELETED T A R L Y Q s T N DELETED DELETED M T A R L Y Q s T N DELETED P T A R L Y Q s T N DELETED P M T A R L Y Q s T N P DELETED T A R L Y Q s T N P DELETED M T A R L Y Q s T N P P T A R L Y Q s T N P P M T A R L Y Q G S DELETED DELETED DELETED I ■T A R L Y Q G S DELETED DELETED DELETED M T A R L Y Q G s DELETED DELETED P WO 2008/1121)03 wrTrtJSiooMrtsm 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R L Y Q G S DELETED DELETED P M T A R L Y Q G S DELETED P DELETED T A R L Y Q G S DELETED P DELETED M T A R L Y Q G s DELETED P P T A R L Y Q G s DELETED P P M T A R L Y Q G s N DELETED DELETED T A R L Y Q G s N DELETED DELETED M T A R L Y Q G s N DELETED P T A R L Y Q G s N DELETED P M T A R L Y Q G s N P DELETED T A R L Y Q G s N P . DELETED M T A R L Y Q G s N P P T A R L Y Q G s N P P M T A R L Y Q G T DELETED DELETED DELETED I I T A R L Y Q G T DELETED DELETED DELETED M T A R L Y 0 G T DELETED DELETED P T A R L Y Q G T DELETED DELETED P M T A R L Y Q G T DELETED P DELETED T A R L Y Q G T DELETED P DELETED M T A R L Y Q G T DELETED P P T A R L Y Q G T DELETED P P M T A R L Y Q G T N DELETED DELETED T A R L Y Q G T N DELETED DELETED M T A R L Y Q G T N DELETED P T A R L Y Q G T N DELETED P M T A R L Y Q G T N P DELETED T A R L Y Q G T N P DELETED M T A R L Y Q G T N P P T A R L Y Q G T N P P M T A R L Y V S S DELETED DELETED DELETED T A R L Y V S S DELETED DELETED DELETED M T A R L Y V S s DELETED DELETED P T A R L Y V S s DELETED DELETED P M T A R L Y V S s DELETED P DELETED T A R L Y V S . s DELETED P DELETED M T . A R L Y V S s DELETED P P T A R L ' Y V S s DELETED P P M T A R L Y V S s N DELETED DELETED T A R L Y V S s • N DELETED DELETED M T A R L Y V S s N DELETED P T A R L Y V S s N DELETED P M T A R L Y V S s N P DELETED I T A R L Y V S s N P DELETED M T A R L Y V S s N P P T A R L Y V S s N P P M T A R L Y V S T DELETED DELETED DELETED T A R L Y V s T DELETED DELETED DELETED M WO 2008/112003 FCT/US2007/07S117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R L Y V s T DELETED DELETED P i T A R L Y V s T DELETED DELETED P M V Ps ] R L Y V S \ T DELETED P DELETED T A R L Y V S I T DELETED P DELETED M T A R L Y V S i T DELETED P P I T A R L Y V S I T DELETED P P M T A R L Y V S i T N DELETED DELETED I T A R L Y V S T N DELETED DELETED M T A R L Y V S T N DELETED P I T A R L Y V s T N DELETED P M T A R L Y V s T N P DELETED I T A R L Y V s T N P DELETED Wl T A R L Y V s T N P P I T A R L Y V s T N P P M T A R L Y V G S DELETED DELETED DELETED I T A R L Y V G s DELETED DELETED DELETED M T ! A R L Y V G s DELETED DELETED P I 1 T \| A R L Y V G s DELETED DELETED P M T i A R L Y V G s DELETED P DELETED I T i A R L Y V G s DELETED P DELETED M T A R L Y V G s DELETED P P I T A R L Y V G s DELETED P P M T A R L Y V G s N DELETED DELETED I T A R L Y V G s N DELETED DELETED M T A R L Y V G s N DELETED P I T A R L Y V G s N DELETED P M T A R L Y V G s N P DELETED I T A R L Y V G s N P DELETED M T A R I L Y V G s N P P I T A R \ L Y V G s M P P Wi T A R L Y V G T DELETED DELETED DELETED I T A R L Y V G T DELETED DELETED DELETED M i T A R L Y V G T DELETED DELETED P I T A R L Y V G T DELETED DELETED P ' M T A R L Y V G T DELETED P DELETED i T A R L Y V G T DELETED P DELETED M T A R L Y V G T DELETED P P I T A R L Y V G T DELETED P P M T A R L Y V G T N DELETED DELETED I T A R L Y V G T N. DELETED DELETED M T A R L Y V G T N DELETED P I T A R L Y V G T N DELETED P M T A R L Y V G T N P DELETED i T A R L Y V G T N P DELETED M T A R L Y V G T N P P ■ I T A R L Y V G T N P P _M_J T A R L H Q S \| S DELETED DELETED DELETED I WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 ! 91 94 95 96 107 T A R L H Q S . S DELETED DELETED DELETED M T A R L H Q S i S DELETED DELETED P T A R L H Q s S DELETED DELETED P M T A R L H Q s S DELETED P DELETED T A R L H Q s s DELETED P DELETED M T A R L H Q s s DELETED P P T A R L -H Q s s DELETED P P M T A R L H Q s s N DELETED DELETED T A R L H Q s s N DELETED DELETED M T A R L H Q s s N DELETED P T A R L H Q s s N DELETED P M T A R L H Q s s N P DELETED T A R L H Q s s N P DELETED M T A R L H Q s s N P P T A R L H Q s s N P P M T A R L H Q s T DELETED DELETED DELETED T A R L H Q S : T DELETED DELETED DELETED M ! T A R L H 0 S T DELETED DELETED P T A R L H Q S T DELETED DELETED P M T A R L H Q S T DELETED P DELETED T A R L H Q S T DELETED P DELETED M T A R L H Q S j T DELETED P P T A R L H Q s T DELETED P P M T A R L H Q s T N DELETED DELETED T A R L H Q s T N DELETED DELETED M T A R L H Q s ! T N DELETED P \| j T A R L H Q s T N DELETED P M T A R ■ L H Q s T N P DELETED T A R L H Q s T N P DELETED M T A R L H Q s T N P P T A R L H Q s T N P P T A R L H Q G S DELETED DELETED DELETED T A R L H Q G j S DELETED DELETED DELETED M T A R L H Q G ! S DELETED DELETED P T A R L H Q G I S DELETED DELETED P T A R L H Q G S DELETED P DELETED T A R L H Q G s DELETED P DELETED M T A R L H Q G s DELETED P P T A R L H Q G s DELETED P P M T A R L H Q G s N DELETED DELETEDJ I T A R L H Q G s N DELETED DELETED M T A R L H Q G s N DELETED P ■ T A R L H Q G s N DELETED P M T A R L H Q G s N P DELETED T A R L H Q G s N P DELETED M T A R L H Q G s N P P 1 T A R L H Q G s N P P M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R L H Q G T DELETED DELETED DELETED ! T A R L H Q G T DELETED DELETED DELETED M T A R L H Q G T DELETED DELETED P T A R L H Q G T DELETED DELETED P M T A R L H Q G T DELETED P DELETED T A R L H Q G T DELETED P DELETED M T A R L H Q G T DELETED P P T A R L H Q G T DELETED P P M T A R L H Q G T N DELETED DELETED T A R L H Q G T N DELETED DELETED M T A R L H Q G T N DELETED P T A R L H Q G T N DELETED P M T A R L H Q G T N P DELETED T A R L H Q G T N P DELETED M T A R L H Q G ! T N P P T A R L H Q G ! T N P P M \| T A R L H V S : S DELETED DELETED DELETED , i ■ \| T A R L _j H V s ! s DELETED DELETED DELETED fv', T A R L H V s S DELETEO DELETED P T A R L H V s s DELETED DELETED P M T A R L H V s s DELETED P DELETED T A R L H V s s DELETED P DELETED M T A R L H V s s DELETED P P T A R L H V s s DELETED P P M T A R L H V s s N DELETED DELETED T A R L H V s s N DELETED DELETED M T A R L H V s s N DELETED P T A R L H V s s N DELETED P M T A R L. H V s s N P DELETED T A R L H V s s N P DELETED M T A R L H V s s N P P T A R L H V s s N P P M T A R L H V s T DELETED DELETED DELETED T A R L H V s T DELETED DELETED DELETED M T A R L H V s T DELETED DELETED P T A R L H V s T DELETED DELETED P M T A R L . H V s T DELETED P DELETED T A R L H V s T DELETED P DELETED M T A R L H V s T DELETED P P T A R L H V s T DELETED P P M T A R L H V s T N DELETED DELETED T A R L H V s T N DELETED DELETED M T A R L H V s T N DELETED P T A R L H V s T N DELETED P M T A R L H V s T N P DELETED T A R L H V s T N P DELETED M T A R L H ! V s T N P P WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R L H V S T N P P M T A R L H V G s DELETED DELETED DELETED T A R L H V G s DELETED DELETED DELETED M T A R L H V G s DELETED DELETED P T A R L H V G s DELETED DELETED P M T A R L H V G s DELETED P DELETED T A R L H V G s DELETED P DELETED M T A R L H V G_i s DELETED P P T A R L H V G s DELETED P P M T A R L H V G s N DELETED DELETED T A R L H V G s N DELETED DELETED M T A R L H V G s N DELETED P T A R L H V G s N DELETED P M T A R L H V G s N P DELETED T A R L H V f G j S N P DELETED M T A R L H V G S N P P T A R L H V G s S N P P M : T A R L H V G T DELETED DELETED DELETED T A R L H V G T DELETED DELETED DELETED M T A R L H V G T DELETED DELETED P T A R L H V G T DELETED DELETED P M T A R L H V G T DELETED P DELETED T A R L H V G T DELETED P DELETED M T A R L H V G T DELETED P P T A R L H V G T DELETED P P M T A R L H V G T N DELETED DELETED T A R L H V G T N DELETED DELETED M T A R L H V G T N DELETED P T A R L H V G T N DELETED P M T A R L H V G T N P DELETED r A R I H V G T N P DELETED M T A R L H V G \| T N P P T A R L H V G ! T N P P M T A R Y Q S S DELETED DELETED DELETED T A R Y Q S S DELETED DELETED DELETED M T A R Y Q s s DELETED DELETED P T A R Y Q s s DELETED DELETED P M T A R Y Q s s DELETED P ■ DELETED T A R Y Q s s DELETED P DELETED M T A R Y Q s s DELETED P P T A R Y Q s s DELETED P P M T A R Y Q s s N DELETED DELETED T A R Y Q s s N DELETED DELETED M T A ■ R Y Q s s N DELETED P T A R Y Q s s N DELETED P \| M T A R Y Q s s N P DELETED) I T I A R Y Q s s N P DELETED\| M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 \| 95 96 107 T A R Y Q S S N P P T A R Y 0 S S N P P M T A R Y Q s T DELETED DELETED DELETED T A R Y Q s T T DELETED DELETED DELETED M T A R Y Q s DELETED DELETED P T A R Y Q s T DELETED DELETED P M T A R Y Q s T DELETED P DELETED T A R Y Q s T DELETED P DELETED M T A R Y Q s T DELETED P P T A R Y Q s T DELETED P P M T A R Y Q s T N DELETED DELETED T A R Y Q s T N DELETED DELETED M T A R Y Q s T N DELETED P T A R Y Q s T N DELETED P M T A R Y Q S I T N P DELETED T A R Y Q S : T N i p DELETED M T A R Y Q S ' T \| N j P P I \| T A R Y Q S i T N \| P P M T A R Y Q G ! S DELETED DELETED DELETED T A R Y Q G S DELETED DELETED DELETED M T A R Y Q G s DELETED DELETED P T A R Y Q G s DELETED DELETED P M T A R Y Q G s DELETED P DELETED T A R Y Q G s DELETED P DELETED M T A R Y Q G s DELETED P P T A R Y Q G s DELETED P P M T A R Y Q G s N DELETED DELETED T A R Y Q G s N DELETED DELETED M T A R Y Q G s N DELETED P T A R Y Q G s N DELETED P M T A R Y Q G s N P DELETED T A R Y Q G s N P DELETED M T A R Y Q G s N P P T A R Y Q G s N P P- M T A R Y Q G T DELETED DELETED DELETED T A R Y Q G T DELETED DELETED DELETED M T A R Y Q G T DELETED DELETED P T A R Y Q G T DELETED DELETED P M T A R Y Q G T DELETED P DELETED T A R Y Q G T DELETED P DELETED M T A R Y Q G T DELETED P P T A R Y Q G T DELETED P P M T A R Y Q G T N DELETED DELETED T A R Y Q G T N DELETED DELETED M T A R Y Q G T N DELETED P T A R Y Q G T N DELETED P M T A R Y Q G T N P DELETED WO 2008/112003 PCT/U32007/07M17 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R Y Q G T N P DELETED M T A R Y Q G T N P P t T A I R Y Q G T N P P M T A R Y V S S DELETED DELETED DELETED I T A R Y V s s DELETED DELETED DELETED M T A R Y V s s DELETED DELETED P I T A R Y V s s DELETED DELETED P M T A R Y V s s DELETED P DELETED I T A R Y V s s DELETED P DELETED M T A R Y V s s DELETED P P I T A R Y V s s DELETED P P M T A R Y V s s N DELETED DELETED I T A R Y V s s N DELETED DELETED M T A R Y V S ! S N DELETED P ! T A R Y V S I S N DELETED P M T A R Y ! V S S N P DELETED I T A R I ! Y I V ( S . S N P DELETED M T A R I \| Y ! V ! S ■ S ; N P P I T A R I Y V ( S i S i N P P M. 1 T A R Y V s T DELETED DELETED DELETED 1 T A R Y V s T DELETED DELETED DELETED M T A R Y V s T DELETED DELETED P 1 T A R Y V s T DELETED DELETED P M T A R Y V s T DELETED P DELETED 1 T A R Y V s T DELETED P DELETED M T A R Y V s T DELETED P P 1 T A R Y V s T DELETED P P M T A R Y V s T N DELETED DELETED 1 T A R Y V s T N DELETED DELETED M T A R Y V s T N DELETED P 1 T A R Y V s T N DELETED P M T A R Y V s : T N P DELETED 1 T A R Y V S T A R Y V S : T , N P P 1 T A R Y V s T N P P M T A R Y V G S DELETED DELETED DELETED 1 T A R Y V G S DELETED DELETED DELETED . M T A R Y V G s DELETED DELETED P 1 T A R Y V G s DELETED DELETED P M T A R Y V G s DELETED P DELETED 1 T A R Y V G s DELETED P DELETED M T A R Y V G s DELETED P P 1 T A R Y V G s DELETED P P M T A R Y V G s N DELETED DELETED 1 T A R Y V G s N DELETED DELETED M T A R Y V G s N DELETED P 1 T A R Y V G s N DELETED P M WO 2008/112003 PCT/US20O7/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R Y V G s N P DELETED T A R Y V G s N P DELETED M T A R Y V G s N P P T A R Y V G s N P j P M T A R Y V G T DELETED DELETEDlDELETED I f T A R Y V G T DELETED DELETED DELETED M : T A R Y V G T DELETED DELETED P i i T A R Y V G T DELETED DELETED P M I T A R Y V G ! T DELETED P DELETED 1 I T A R Y V G T DELETED P DELETED IV. T A R Y V G T DELETED P P T A R Y V G T DELETED P P M T A R Y V G T N DELETED DELETED T A R Y V G T N DELETED DELETED M T A R Y V G T N DELETED P T A R Y V G T N DELETED P M T A R Y V G i T N P DELETED T A R Y V G T N P DELETED M T A R Y V G T N P P T A R Y V G T N P P M T A R H Q S S DELETED DELETED DELETED T A R H Q S S DELETED DELETED DELETED M T A R H Q s s DELETED DELETED P T A R H Q s s DELETED DELETED P M T A R H Q s s DELETED P DELETED T A R H Q s s DELETED P DELETED M T A R H Q s s DELETED P P T A R H Q s s DELETED P P M T A R H Q s s N DELETED DELETED T A R H Q s s N DELETED DELETED M T A R H Q s s N DELETED P T A R H Q s s N DELETED P M T A R H Q s s N P DELETED T A R H Q s s N P DELETED M T A R H Q s s N P P T A R H Q s s N P P M T A R H Q s T DELETED DELETED DELETED T A R H Q s T DELETED DELETED DELETED! M T A R H Q s T DELETED DELETED P T A R H Q s T DELETED DELETED P M T A R H Q s T DELETED P DELETED T A \| R H Q s T DELETED P DELETED M T A R H Q s T DELETED P P T A R H Q s T DELETED P P M T A R H Q s T N DELETED DELETED \| T A R H Q s T N DELETED DELETED M T A R H Q s T N DELETED P WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R H Q s T • N DELETED P M T A R H Q s T N P DELETED T A R H Q s T N P DELETED M T A R H Q s T N P P T A R H Q s T N P P M T A R H Q G S DELETED DELETED DELETED T A R H Q G S DELETED DELETED DELETED M T A R H Q G s DELETED DELETED P T A R ■ H Q G s DELETED DELETED P M T A R H Q G s DELETED P DELETED T A R H Q G s DELETED P DELETED M T A R H Q G s DELETED P P T A R H Q G s DELETED P P M T A R H Q G s N DELETED DELETED T A R H Q G s N DELETED DELETED M T A R H Q G s N DELETED P T A R H Q G s N DELETED P M T A R H Q G s N P DELETED T A R H Q G s N P DELETED M T A R H Q G s N P P T A R K Q G s N P P M T A R H Q G T DELETED DELETED DELETED T A R H Q G T DELETED DELETED DELETED M T A R H Q G T DELETED DELETED P T A R H Q G T I DELETED1 DELETED P M T A R H Q G T DELETED P DELETED T A R H Q G T DELETED P DELETED M T A R H Q G T DELETED P P T A R H Q G T DELETED P P M T A R H Q G T N DELETED DELETED T A R H Q G T N DELETED DELETED M T A R H Q G T N DELETED P T A R H Q G T N DELETED P M T A R H Q G T N P DELETED T A R H Q G T N P DELETED M T A R H Q G T N P P T A R H Q G T N P P M T A R H V S S DELETED DELETED DELETED T A R H V S S DELETED DELETED DELETED M T A R H V S s DELETED DELETED P T A R H V S s DELETED DELETED P M T . A R H V s s DELETED P DELETED T A R H V s s DELETED P DELETED M T A R H V s s DELETED P P T A R H V s s DELETED P P M T A R H V s s N DELETED DELETED T A ! 1 R H V s s N DELETED DELETED M WO 2008/112003 PCTYUS2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A R H V s S N DELETED P M T A R H V s s N DELETED P T A R H V s s N P DELETED T A R H V s s N P DELETED M T A R H V s s N P P i I T A R H V s s N P P M T A R H V s T DELETED DELETED DELETED T A R H V s T DELETED DELETED DELETED M T A R H V s T DELETED DELETED P T A R H V s T DELETED DELETED P M T A R H V s T DELETED P DELETED T A R H V s T DELETED P DELETED M T A R H V s T DELETED P P T A R H V s T DELETED P P M T A R H V S ! T N DELETED DELETED T A R H V S ! T N DELETED DELETED M T A R H V S ! T N DELETED P i I T A R H V S ': T N DELETED P M T A R H V S i T N P DELETED T A R H V S T N P DELETED M T A R H V s T N P P T A R H V s T N P P M T A R H V G S DELETED DELETED DELETED T A R H V G s DELETED DELETED DELETED M T A R H V G s DELETED DELETED P T A R H V G s DELETED DELETED P M T A R H V G s DELETED P DELETED T A R H V G s DELETED P DELETED M T A R H V G s DELETED P P T A R H V G s DELETED P P M T A R H V G s N DELETED DELETED T A R H V G s N DELETED DELETED M T A R H V G s N DELETED P T A R H V G s N DELETED P M T A R H V G s N P DELETED T A R H V G s N P DELETED M T A __n R H V G s N P P T A R H V G s N P P M T A R H V G T DELETED DELETED DELETED f T A R H V G T DELETED DELETED DELETED M T A R H V G T DELETED DELETED P T A R H V G T DELETED DELETED P M T A R H V G T DELETED P DELETED T A R H V G T DELETED P DELETED M T A R H V G T DELETED P P T A R H V G T DELETED P P M T A R H V G T N DELETED DELETED n d d 3313130 S 9 0 A 1 S d V 1 i d d 3313130 s 9 0 A 1 s d V 1 \M 0313130 d 3313130 s 9 0 A 1 s d V 1 i 0313130 d 3313130 s 9 0 A 1 s d V 1 lAj d 0313130 3313130 s 9 D A 1 s d V 1 i d Q313130 3313130 s 9 0 A 1 s d V 1 irti 0313130 0313130 0313130 s ^ o A 1 s d V 1 i 0313130 0313130 0313130 s 9 0 A 1 s d V 1 w d d N 1 S D A 1 s d V 1 i d d N 1 s D A 1 s 3 V 1 w 0313130 d N 1 s 0 A 1 s d V 1 [ 0313130 d N 1 s 0 A 1 s d V 1 irti d 0313130 N 1 s 0 A 1 s 3 V 1 1 d 0313130 N 1 s 0 A 1 s d V 1 n 0313130 0313130 N 1 s 0 A 1 s 3 V 1 i 0313130 0313130 N 1 s 0 A 1 s d V 1 1AI d d 0313130 1 s D A 1 s 3 V 1 1 d d 0313130 1 s 0 A 1 s 3 V 1 IAI 0313130 d 0313130 1 s 0 A 1 s d V 1 1 0313130 d 0313130 1 s D A 1 s d V 1 IN d 0313130 0313130 1 s D A 1 s d V 1 1 d 0313130 0313130 1 s 0 A 1 s d V 1 (A] 0313130 0313130 0313130 1 s 0 A 1 s d V 1 I 0313130 0313130 0313130 1 s 0 A 1 s d V 1 IAI d d N s s 0 A 1 s d V 1 i d d N s s 0 A T s d V 1 w 0313130 d N s s D A 1 s d V 1 i 0313130 d N s s 0 A 1 s d V 1 1 w d 0313130 N s s 0 A 1 s d V 1 i i d 0313130 N s ; s 0 A 1 s d I V x [A\| 0313130 0313130 N s s 0 A i 1 s d V 1 1 0313130 0313130 N S i S D A 1 s 3 V 1 W d d 0313130 S ! S 0 A 1 s d V 1 1 d d 0313130 S \| S D A 1 s d V 1 W 0313130 d 0313130 s s D A 1 s d V 1 1 0313130 d 0313130 s s 0 A 1 s d V 1 W d 0313130 0313130 s s D A 1 s d V 1 1 d 0313130 0313130 s s 0 A 1 s d V 1 n 0313130 0313130 0313130 s s 0 A 1 s d V 1 i 0313130 0313130 0313130 s s 0 A 1 s d V 1 w d d N 1 9 A H y V 1 i d d N 1 9 A H y V 1 w 031313G d N 1 9 A H y V 1 t 0313130 d N 1 9 A H y V 1 w d 0313130 N 1 9 A H y V 1 1 d 0313130 N 1 9 A H y V 1 w 0313130 0313130 N 1 9 A H y V 1 m 96 96 P6 V6 95 SS 6* C£ te GZ sz oz tusuvioossntfoj toommooi O/A WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F S L Y Q G s N DELETED DELETED T A F S L Y Q G s N DELETED DELETED M T A F S L Y Q G s N DELETED P T A F S L Y Q G s N DELETED P M T A F s L Y Q G s N P DELETED T A F s L Y Q G j S N P DELETED M T A F s L Y \| Q G s N P P T A F s L Y Q G s N P P M T A F s L Y Q G T DELETED DELETED DELETED T A F s L Y Q G T DELETED DELETED DELETED M T A F s L Y Q G T DELETED DELETED P T A F s L Y Q G T DELETED DELETED P M T A F s L Y Q G T DELETED P DELETED T A F s L Y Q G T DELETED P DELETED M T A F s L Y Q G T DELETED P P T A F s L I Y Q G T [DELETED P P M T A F i 3 L ! Y Q G T N DELETEDiDELETED T A F \| S L i Y Q G T N DELETED DELETED M T A F i S L Y Q G T N DELETED P T A F s L Y Q G T N DELETED P M T A F s L Y Q G T N P DELETED T A F s L Y Q G T N P DELETED M T A F s L Y Q G T N P P ! I T A F s L Y Q G T N P P i M T A F s L Y V S S DELETED DELETED DELETED T A F s ■ L Y V S s DELETED DELETED DELETED M T A F s L Y V s s DELETED DELETED P T A F s L Y V s s DELETED DELETED P M T A F s L Y V s s DELETED P DELETED T A F s L Y V s s DELETED P DELETED M T A F s L Y V s s DELETED P P T A F s L Y V s s DELETED P P M ! T A F s L Y V s s N DELETED DELETED T A F s L Y V s s N DELETED DELETED M T A F s L Y V s s N DELETED P T A F s L Y V s s N DELETED P M T ■ A ■ F s L Y V s s N P DELETED T A F s L Y V s s N P DELETED M T A F s L Y V s s N P P T A F s L Y V s s N P P M T A F s L Y V s T DELETED DELETED DELETED T A F s L Y V s T DELETED DELETED DELETED M T A F s L Y V s T DELETED DELETED P T A F s L Y V s T DELETED DELETED P M T A F s L Y V s T DELETED P DELETED T A F s L Y V s T DELETED P DELETED M T A F s L Y V s T DELETED P P WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 \| 56 j 91 94 95 96 107 M T A F S L Y V s T DELETED P P T A F S L Y V s T N DELETED DELETED M T A F S L Y V s T N DELETED DELETED T A F S L Y V s T N DELETED P T A F S L Y V s T N DELETED P M T A F S L Y V s T N P DELETED T A F S L Y V s T N P DELETED M T A F S L Y V s T N P P T A F s L Y V s T N P P M T A F s L Y V G S DELETED DELETED DELETED T A F s L Y V G S DELETED DELETED DELETED M T A F s L Y V G s DELETED DELETED P T A F s L Y V G s DELETED DELETED P M T A F s L Y V G s DELETED P DELETED T A F s L Y V G s DELETED P DELETED M T A F s L Y V G i S DELETED P P T A F s L Y V G : S DELETED P P M ! T A F s L Y V G j S N DELETED DELETED i i T A F s L Y V s N DELETED DELETED M T A F s L Y V G S i N DELETED P T A F s L Y V G S N DELETED P M T A F s L Y V G s N P DELETED T A F s L Y V G s N P DELETED M T A F s L Y V G s N P P T A F s L Y V G s N P P M T A F s L Y V G T DELETED DELETED DELETED T A F s L Y V G T DELETED DELETED DELETED M T A F s L Y V G T DELETED DELETED P T A F s L Y V G T DELETED DELETED P M T A F s L Y V G T DELETED P DELETED T A F s L Y V G T DELETED P DELETED M T A F s L Y V G T DELETED P P- T A F s L Y V G j T DELETED P P M T A F s L Y V G I T N DELETED DELETED T A F s L Y V G T N . DELETED DELETED M T A F s L Y V G T N DELETED P T A F s L Y V G T N DELETED P M T A F s L Y V G T N P DELETED T A F s L Y V G T N P DELETED M T A F s L Y V G T N P P T A F s L Y V G T N P P M T A F s L H Q S S DELETED DELETED DELETED T A F s L H Q S s DELETED DELETED DELETED M T A F s L H Q S s DELETED DELETED P T A F s L H Q S s DELETED DELETED P ■ M T A F s L H Q S s DELETED P DELETED T A F s L H Q s s DELETED P DELETED M WO 2008/112003 PCT/US2007/075U7 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F S L H Q S S DELETED P P I I T A F S L H 0 S S DELETED P P M i T A F S L H Q S S N DELETED DELETED I T A F S L H Q S S N DELETED DELETED M T A F S L H Q S S N DELETED P T A F S L H Q S S N DELETED P M T A F S L H Q S s N P DELETED T A F S L H Q S s N P DELETED M T A F S L H Q S s N P P T A F S L H Q S s N P P M T A F S L H Q S T DELETED DELETED DELETED T A F S L H Q S T DELETED DELETED DELETED M T A F S L H Q s T DELETED DELETED P T A F S L H Q s T DELETED DELETED P M T A F S L H 0 s T DELETED P DELETED T A F S L H Q s ■ T DELETED P DELETED M T A F a L H Q s T DELETED P P T A F s L H Q s T DELETED P P M X A ,F s I H O s T ' N DELETED DELETED} } T A F s L H 0 s T N DELETED DELETED M T A F s L H Q s T N DELETED P T A F s L H Q s T N DELETED P M T A F s L H Q s T N P DELETED T A F s L H Q s T N P DELETED M T A F s L H Q s T N P P T A F s L H Q s : T N P P M T A F s L H Q G S DELETED DELETED DELETED T A F s L H Q G ■ S DELETED DELETED DELETED M T A F s L H Q G ! S DELETED DELETED P T A F s L H Q G \| S DELETED DELETED P M T A F s L H Q G S DELETED P DELETED T A F s L H Q G S DELETED P DELETED M T A F s L H Q G s DELETED P P T A F s L H Q G s DELETED P P M T A F s L H Q G s N DELETED DELETED T A F s L H Q G s N DELETED DELETED M T A F s L H Q G s N DELETED P T A F s L H Q G s N DELETED P M . T A F s L H Q G s N P DELETED T A F s L H Q G s N P DELETED M T A F s L H Q G s N" P P T A F s L H Q G s N P P M T A F s L H Q G T DELETED DELETED DELETED T A F s L H Q G T DELETED DELETED DELETED M T A F s L H Q G T DELETED DELETED P T A F s L H Q G T DELETED DELETED! P M 1 T A F s L H Q G T DELETED P IDELETED WO 2008/112003 PCT/US2007/075U7 20 25 29 31 33 49 55 56 [ 91 94 95 96 107 T A F S L H Q G T DELETED P DELETED M T A F S L H Q G T DELETED P P T A F S L H Q G T DELETED P P M T A F S L H Q G T N DELETED DELETED T A F s L H Q G T N DELETED DELETED M T A F s L H Q G T N DELETED P T A ,_ F s L H Q G T N DELETED P M T A F s L H Q G T N P DELETED T A F s L H Q G T N P DELETED M T A F s L H Q G T N P P T A F s L H Q G T N P P M T A .F s L H V S S DELETED DELETED DELETED T A F s L H V S S DELETED DELETED DELETED M T A F s L H V S s DELETED DELETED P T A F s L H V s s DELETED DELETED P M T A F s L H V S S DELETED P DELETED T A F s L H V S ' S DELETED P DELETED M ! T A F s L H v s s DELETED P P T A F s L H V s s DELETED P P M T A F s L H V s s N DELETED DELETED T A F s L H V s s N DELETED DELETED M T A F s L H V s s N DELETED P T A F s L H V s s N DELETED P M T A F s L H V s s N P DELETED T A F s L H V s s N P DELETED M T A F s L H V s s N P P , T A F s L H V s s N P P M T A F s L H V s T DELETED DELETED DELETED T A F s L H V s T DELETED DELETED DELETED M T A F s L H V s T DELETED DELETED P T A F s L H V s T DELETED DELETED P M T A F s L H V s ! T DELETED P DELETED T A F s L H V s ! T DELETED P DELETED M T A F s L H V s T DELETED P P T A F s L H V s T DELETED P P M T A F s L H V s T N DELETED DELETED . T- A F s L H V s T N DELETED DELETED M T A F s L H V s T N DELETED P T A F s L H V s T N DELETED P M T A F s L H V s T N P DELETED T I A F s L H V s T N P DELETED M T A F s L H V s T N P P T A F s L H V s T N P P M T A F s L H V G S DELETED DELETED DELETED T A F s L H V G S DELETED DELETED DELETED M T A \| F s L H V G I S DELETED DELETED P T A F s L H V G \| S DELETED DELETED P M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F S L H V G s DELETED P DELETED T A F S L H V G s DELETED P DELETED M T A F s L H V G s DELETED P P T A F s L H V G s DELETED P P M T A F s L H V G s N DELETED DELETED T A F s L H V G s N DELETED DELETED M T A F s L H V G s N DELETED P T A F s L H V G s N DELETED P M T A F s L H V G s N P DELETED T A F s L H V G s N P DELETED M T A F s L H V G s N P P T A F . s L H V G s N P P M T A F s L H V G T DELETED DELETED DELETED T A F s L H V G T DELETED DELETED DELETED M T A F s L H V G T DELETED DELETED P T A F s L H V G T DELETED DELETED P M ! T A F s L H V G T DELETED P DELETED I i I I T A F s L H V G T DELETED P DELETED M T A F s L H V G T DELETED P P T A F s L H V G T DELETED P P M T A F s L H V G T N DELETED DELETED T A F s L H V G T N DELETED DELETED M T A F s L H V G T N DELETED P T A F s L H V G T N DELETED P M T A F s L H V G T N P DELETED T A F s L H V G T N P DELETED M T A F s L H V G T N P P I I T A F s L H V G T N P P J M T A F s Y Q S S DELETED DELETED DELETED T A F s Y Q S S DELETED DELETED DELETED M T A F s Y Q S s DELETED DELETED P T A F s Y Q S s DELETED DELETED P M T A F s Y Q S s DELETED P DELETED T A F s Y Q S s DELETED P DELETED M T A F s Y Q S s DELETED P P T A F s Y Q S s DELETED P P M T A F s Y Q s s N DELETED DELETED T A F s Y Q s s N. DELETED DELETED M T A F s Y Q s s ■ N DELETED P T A F s Y Q s s N DELETED P M T A F s Y Q s s N P DELETED T A F s Y Q s s N P DELETED M T A F s Y Q s s N P P T A F s I I Y Q s s N P P M T A F s Y Q s T DELETED DELETED DELETED T A F s Y Q s T DELETED DELETED DELETED M T A F S Y Q s T DELETED DELETED P WO 2008/112003 PCT/US2007/0751I7 20 25 29 31 33 49 55 56 i 91 94 95 96 107 T A F S I Y Q s ! T DELETED DELETED P M T A F S Y Q s T DELETED P DELETED T A F s Y Q s T DELETED P DELETED M T A F s I Y Q s T DELETED P P T A F s Y 0 S ! T DELETED P P M T A F s Y Q S I T N DELETED DELETED T A F s Y Q S ! T N DELETED DELETED M T A F s Y Q s ! T N DELETED P T A F s Y Q s T N DELETED P M T A F s Y Q s T N P DELETED T A F s Y Q s T N P DELETED M T A F s Y Q s T N P P T A F s Y Q s i T N P P M T A F s Y Q G \| S DELETED DELETED DELETED T A F s Y Q G i S DELETED DELETED DELETED M T A F s Y Q G : S DELETED DELETED P T A F s Y Q G '- S DELETED DELETED P M ' T A F s Y Q G \| S DELETED P DELETED T A F s Y Q G ! S DELETED P DELETED M T A F s Y Q G ! S DELETED P P T A F s Y Q G S DELETED P P M T A F s Y Q G S N DELETED DELETED T A F s Y Q G s N DELETED DELETED M T A F s Y Q G s N DELETED P T A F s Y Q G s N DELETED P M T A F s Y Q G i S N P DELETED i I i T A F s Y Q G i S N P DELETED M T ... A F s Y Q G s N P P ■ T A F s Y Q G s N P P M T A F s Y Q G T DELETED DELETED DELETED T A F s Y Q G T DELETED DELETED DELETED M T A F s Y Q G T DELETED DELETED P T A F s Y Q G T DELETED DELETED P M T A F s Y Q G T DELETED P DELETED T A F s Y Q G T DELETED P DELETED M T A F s Y Q * G T DELETED P P T A F s Y Q G T DELETED P P M T A F s Y Q G T N DELETED DELETED T A F s Y Q G T - N DELETED DELETED M T A F s Y Q G T N DELETED P T A F s Y Q G T N DELETED P M T A F s Y Q G T N P DELETED T A F s Y Q G T N P DELETED M T A F s Y Q G T N P P . T A F s Y Q G T N P P ■ M T A F s Y V S S DELETED DELETED DELETED T A F s I ! Y V S S DELETED DELETED DELETED M WO 2008/112003 PCT/US2007/0751I7 20 25 29 31 33 49 55 56 91 94 95 96 107 . T A F S Y V s S DELETED DELETED P T A F S Y V s S DELETED DELETED P M T A F S Y V s S DELETED P DELETED T A F s Y V s s DELETED P DELETED M T A F s Y V s s DELETED P P T A F s Y V s s DELETED P P M T A F s Y V s s N DELETED DELETED T A F s Y V s s N DELETED DELETED M T A F s Y V s s N DELETED P T A F s Y V s s N DELETED P M T A F s Y V s s N P DELETED T A F s Y V s s N P DELETED M T A F s Y V s s N P P T A F s Y V s s N P P M T A F s Y V s T DELETED DELETED DELETED T A F s Y V S ! T DELETED DELETED DELETED M j T A F s Y V S ! T DELETED DELETED P I I T A F s Y V s : T DELETED DELETED P M ! T A F s Y V S i T DELETED P DELETED [ i T A F s Y V S ! T DELETED P DELETED M T A F s Y V s T DELETED P P T A F s Y V s T DELETED P P M T A F s Y V s T N DELETED DELETED T A F s Y V s T N DELETED DELETED M T A F s Y V s T N DELETED P T A F s Y V s T N DELETEDI P M T A F s Y V s T N p (DELETED T A F s Y V s T N p DELETED M T A F s Y V s T N p P T A F s Y V s T N p P M T A F s Y V G S DELETED DELETED DELETED I T A F s Y V G S DELETED DELETED DELETED M T A F s Y V G s DELETED DELETED P T A F s Y V G s DELETED DELETED P M T A F s Y V G s DELETED P DELETED T A F s Y V G s DELETED P DELETED M T A F s Y V G s DELETED P P T A F s Y V G s DELETED P P M T A F s Y V G s N DELETED DELETED T A F s Y V G s N DELETED DELETED M T A F s Y V G s N DELETED P T A F s Y V G s N DELETED P M T A F s Y V G s N P DELETED T A F s Y V G s N P DELETED M T A F s Y V G s N P P T A F s Y V G s N P P M T A F s Y V G i T DELETED DELETED DELETED WO 2008/112003 PCT/US2007/075117 20 25 29 31 \| 33 49 55 56 91 94 95 96 107 T A F S I Y V G T DELETED DELETED DELETED M T A F S Y V G T DELETED DELETED P T A F S Y V G T DELETED DELETED P M T A F S Y V G T DELETED P DELETED A F S Y V G T DELETED P DELETED M T A F S Y V G T DELETED P P T A F S Y V G T DELETED P P M T A F S Y V G T N DELETED DELETED T A F s Y V G T N DELETED DELETED M T A F s Y V G T N DELETED P T A F s Y V G T N DELETED P M T A F s Y V G T N P DELETED T A F s Y V G T N P DELETED M T A F s Y V G T N P P T A F s Y V G i T N P P M T A F s H Q s s DELETED DELETED DELETED T A F s H Q S : S DELETED DELETED DELETED M '■ T A F s H Q S S DELETED DELETED P T A F s H Q s s DELETED DELETED P M T A F s H Q s s DELETED P DELETED T A F s H Q s s DELETED P DELETED M T * F s H Q s s DELETED P P T A F s H Q s s DELETED P P M T A F s H Q s s N DELETED DELETED T A F s H Q s s N DELETED DELETED M T A F s H Q s s N DELETED P T A F . s H Q s s N DELETED P M T A F s H 0 s s N P DELETED T A F s H Q s s N P DELETED M T A F s H Q s s N P P T A F s H Q s s N P P M T A F s H Q s T DELETED DELETED DELETED T A F s H Q s T DELETED DELETED DELETED M T A F s H Q s T DELETED DELETED P T A F s H Q s T DELETED DELETED P M " T A m F s H Q s T DELETED P DELETED T A F s H Q s T DELETED P DELETED M T A F s H Q s T DELETED P P T A F s H 0 s T DELETED P P M T A F s H Q s T N DELETED DELETED T A F s H Q s T N DELETED DELETED M T A F s H Q s T N DELETED P T A F s H Q s T N DELETED P M T A F s H Q s T N P DELETED T A F s H Q s T N P DELETED M T A F s H Q s T N P P ] T i A \| F \| S H Q s T N p ! p M WO 200H/112003 PCY/USSoaMlWi H 20 25 29 31 33 49 55 ! 56 91 94 95 96 107 T A F S H Q G s DELETED DELETED DELETED T A F S H Q G s DELETED DELETED DELETED M T A F s H Q G s DELETED DELETED P T A F s H Q G s DELETED DELETED P M \| T A F s H Q G s DELETED P DELETED I ! T A F s H Q G s DELETED P DELETED M T A F s H Q G s DELETED P P T A F s H Q G s DELETED P P M T A F s H Q G s N DELETED DELETED T A F s H Q G s N DELETED DELETED M T A F s H 0 G s N DELETED P T A F s H Q G s N . DELETED P M T A F s H Q G s N P DELETED T A F s H Q G s N P DELETED M T A F s H Q G s N P P T A F s H Q G s N P \| P M T A F s i \| H Q G T DELETED DELETED DELETED T A F s H •Q G T DELETED DELETED DELETED M T A F s H Q G T DELETED DELETED P T A F s H 0 G T DELETED DELETED P M T A F s H Q G T DELETED P DELETED T A F s H .Q G T DELETED P DELETED M T A F s H Q G T DELETED P P T A F s H Q G T DELETED P P M T A F s H Q G T N DELETED DELETED T A F s H Q G T N DELETED DELETED M T A F s H Q G T N DELETED P T A F s H Q G T N DELETED P M T A F s H Q G T N P . DELETED T A F s H Q G T ] N P DELETED M T A F s H Q G T N P P T A F s H Q G T N P P M T A F s H V S S DELETED DELETED DELETED! 1 T A F s H V s S DELETED DELETED DELETED M T A F s H V s s DELETED DELETED P T A F s H V s s DELETED DELETED P M T A F s H V s s DELETED P . DELETED T A F s H V s s DELETED P ■ DELETED M T A F s H V s s DELETED P P T A F s H V s s DELETED P P M T A F s H V s s N DELETED DELETED T A F s H V s s N DELETED DELETED M T A F s H V s s N DELETED P T A F s H V s s N DELETED P M T A F s H V s s N P DELETED T A F s H v s s N P DELETED M T A F s H ! V s ! s N P P WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F S H V s S N P P M T A F S H V s T DELETED DELETED DELETED T A F s H V s T DELETED DELETED DELETED M T A F s H V s T DELETED DELETED P T A F s H V s T DELETED DELETED P M T A F s H V s T DELETED P DELETED T A F s H V s T DELETED P DELETED M T A F s H V s T DELETED P P T A F s H V s T DELETED P P M T A F s H V s T N DELETED DELETED T A F s H V s T N DELETED DELETED M T A F s H V s T N DELETED P T A F s H V s T N DELETED P M T A F s H V s T N P DELETED T A F s H V s T N P DELETED M T A F s H V s T N P P T A F s H V s T N P P \| M T A F s H V \| G ! S DELETED DELETED DELETED T A F s H V \| G S DELETED DELETED DELETED M T A F s H V G S DELETED DELETED P T A F s H V G s DELETED DELETED P M T A F s H V G s DELETED P DELETED T A F s H V G s DELETED P DELETED M T A F s H V G S S DELETED P P T A F s H V G \| S DELETED P P M T A F s H V G I S N DELETED DELETED T A F s H V G ! S N DELETED DELETED M T A F s H V G s N DELETED P T A F s H V G s N DELETED P M T A F s H V G s N . P DELETED T A F s H V G s IS] P DELETED M T A F s H V G s N P P T A F s H V G , s N P P M T A F s H V G T DELETED DELETED DELETED T A F s H V G T DELETED DELETED DELETED M T A F s H V G T DELETED DELETED P T A F s H V G T DELETED DELETED P M T A F s H V G T DELETED P DELETED T A F s H V G T DELETED P DELETED M T A F s H V G T DELETED P P T A F s H V G T DELETED P P M T A F s H V G T N DELETED DELETED T A F s H V G T N DELETED DELETED M T A F s H V G T N DELETED P T A F s H V G T N DELETED P M T A F s I H V G T N P DELETED T A F s I ! H V G T N P DELETED M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 \| 107 T A F S I H V G T N P P i i T A F s I H V G T N P P ! M T A F R L Y Q S S DELETED DELETED DELETED T A F R L Y Q S S DELETED DELETED DELETED M T A F R L Y Q s S DELETED DELETED P T A F R L Y Q s S DELETED DELETED P M T A F R L Y Q s S DELETED P DELETED T A F R L Y Q s S DELETED P DELETED M T . A F R L Y Q s S DELETED P P T A F R L Y Q s S DELETED P P M T A F R L Y Q s S N DELETED DELETED T A F R L Y Q s S N DELETED DELETED M T A F R L Y Q s S N DELETED P T A F R L Y Q s s N DELETED P M T A F R L Y Q s s N P DELETED T A F R L Y Q s s N P DELETED M T A F R L Y Q s s N P 9 i I T A F R L Y Q s s ! N P P M T A F R L Y Q s T DELETED DELETED DELETED T A F R L Y Q s T DELETED DELETED DELETED M T A F R L Y Q s T DELETED DELETED P T A F R L Y Q s T DELETED DELETED P M T A F R L Y Q s T DELETED P [DELETED T A F R L Y Q s T DELETED P iDELETED M T A F R L Y Q s T DELETED P P T A F R L Y Q s T DELETED P P M T A F R L Y Q s T N DELETED DELETED T A F R L Y Q s T N DELETED DELETED M . T A F R L Y Q s T N DELETED P T A F R L Y Q s T N DELETED P M T A F R L Y Q s T N P DELETED T A F R L Y Q s T N P DELETED M T A F R L Y Q s T N P P T A F R L Y Q s T N P P M T A F R L Y Q G S DELETED DELETED DELETED T A F R L Y Q G S DELETED DELETED DELETED M T A F R L Y Q G S DELETED DELETED P T A F R L Y Q G S DELETED DELETED P M T A F R L Y Q G S DELETED P DELETED T A F R L Y Q G S DELETED P DELETED M T A F R L Y Q G S DELETED P P T A F R L Y Q G S DELETED P P M T A F R L Y Q G S N DELETED DELETED T A F R L Y Q G ! S N DELETED DELETED M T .A F R L Y Q G S N DELETED P T A F R L Y Q G s N DELETED P M T A F R L Y Q G s N P DELETED i WO 2008/112003 PCT/US2007/075I17 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F R L Y Q G S N P DELETED M T A F R L Y Q G s N P P T A F R L Y Q G ! S N P P M T A F R L Y Q G T DELETED DELETED DELETED T A F R L Y Q G T DELETED DELETED DELETED M T A F R L Y Q G T DELETED DELETED P T A F R L Y Q G T DELETED DELETED P M T A F R L Y Q G T DELETED P DELETED T A F R L Y Q G T DELETED P DELETED M T A F R L Y Q G T DELETED P P T A F R L Y Q G T DELETED P P M T A F R L Y Q G T ' N DELETED DELETED T A F R L Y Q G T N DELETED DELETED M T A F R L Y Q G T N DELETED P T A F R L Y Q G T N DELETED P M T A F R L Y Q G ! T N \| P DELETED T A F R L Y 0 G ! T N P DELETED M T A F R L Y Q G ! T N P P T A F R L Y Q G j T N P P M T A F R L Y V S \| S DELETED DELETED DELETED T A F R L Y V s S DELETED DELETED DELETED M T A F R L Y V s S DELETED DELETED P T A F R L Y V s s DELETED DELETED P M T A F R L Y V s s DELETED P DELETED T A F R L Y V s s DELETED P DELETED M T A F R L Y V s s DELETED P P T A F R L Y V s s DELETED P P M T A F R L Y V s s N DELETED DELETED T A F R L Y V s s. N DELETED DELETED M T A F R L Y V s s N DELETED P T A F R L Y V s s N DELETED P M T A F R L Y V s s N P DELETED T A F R L Y V s s N P DELETED M T A F R L Y V s s N P P T A F R L Y V s s N P P M T A F R L Y V s T DELETED DELETED DELETED T A F R . L Y V s T DELETED DELETED DELETED M T A F R L Y V s T DELETED DELETED P T A F R L Y V s T DELETED DELETED P M T A F R L Y V S i T DELETED P DELETED T A F R L Y V S ; T DELETED P DELETED M T A F R L Y V s T DELETED P P T A F R L Y V s T DELETED P P M T A F R L Y V s T N DELETED DELETED T A F R L Y V s T N DELETED DELETED M T A F R L Y V s T N DELETED P T A F R L Y V s T N DELETED P M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F R L Y V S T N P DELETED f T A F R L Y V S T N P DELETED M T A F R L Y V S T N P P T A F R L Y V S T N P P M T A F R L Y V G S DELETED DELETED DELETED T A F R L Y V G s DELETED DELETED DELETED M T A F R L Y V G s DELETED DELETED P T A F R L Y V G s DELETED DELETED P M T A F R L Y V G s DELETED P DELETED T A F R L Y V G s DELETED P DELETED M T A F R L Y V G s DELETED P P T A F R L Y V G s DELETED P P M T\ A F R L Y V G s N DELETED DELETED T ' A F R L Y V G s N DELETED DELETED M T/ A F R L Y V G s N DELETED P \| T A F R L Y V G s N DELETED P M i T A F R L Y V i G i S N P DELETED I ] T A F R L Y V ! G I S N P DELETED M T A F R L Y V G j S N P P i i T A F R L Y V G s N P P M T A F R L Y V G T DELETED DELETED DELETED T A F R L Y V G T DELETED DELETED DELETED M T A F R L Y V G T DELETED DELETED P T A F R L Y V G T DELETED DELETED P M T A F R L Y V G T DELETED P DELETED T A F R L Y V G T DELETED P DELETED M T A F R L Y V G T DELETED P P T A F R L Y V G T DELETED P P M T A F R L Y V G T N DELETED DELETED T A F R L Y V G T N DELETED DELETED M T A F R L Y V G T N DELETED P T A F R L Y V G T N DELETED P M T A F R L Y V G T N P DELETED T A F R L Y V G T N P DELETED M T A F R L Y V G T N P P T A F R L Y V G T N P P M T A F R L H Q S S . DELETED DELETED DELETED T A F R L H Q S S DELETED DELETED DELETED M T A F R L H Q S s DELETED DELETED P T A F R L H Q S s DELETED DELETED P M T A F R L H Q S s DELETED P DELETED T A F R L H Q S s DELETED P DELETED M T A F R L H Q S s DELETED P P T A F R L H Q S s DELETED P P M T A F R L H Q S s N DELETED DELETED T A F R L H Q S s N DELETED DELETED M T A F R L H Q s s N DELETED P WO 2008/112003 PCT/US2007/07S117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F R L H Q S S N DELETED P M T A F R L H Q S S N P DELETED T A F R L H Q s ! s N P DELETED M T A F R L H Q s s N P P T A F R L H Q s s N P P M ! T A F R L H Q s T DELETED DELETED DELETED T A F R L H Q s T DELETED DELETED DELETED M T A F R L H Q s T DELETED DELETED P T A F R - L H Q s T DELETED DELETED P M T A F R L H Q s T DELETED P DELETED T A F R L H Q s T DELETED P DELETED M T A F R L H Q s T DELETED P P T A . .p. R L H Q s T DELETED P P M T A F R L H Q s T N DELETED DELETED T A F R L H Q s T N DELETED DELETED M T A F R L H Q s T N iDELETED P T A F R L H j Q S i T N DELETED P M T A F R L H Q S I T N P DELETED T A F R L i H Q s T N P DELETED M T A F R L H Q s T N P P T ■ A F R L H Q s T N P P M T A F R L H Q J G S DELETED DELETED DELETED T A F R L H Q G S DELETED DELETED DELETED M T A F R L H Q G s DELETED DELETED P T A F R L H Q G s DELETED DELETED P M T A F R L H Q G s DELETED P DELETED T A F R L H Q G s DELETED P DELETED T A F R L H Q G s DELETED P P T A F R L H Q G s DELETED P P T A F ' R L H Q G L s N DELETED DELETED T A F R L H Q G s N DELETED DELETED T A F R L H Q G s N DELETED P T A F R L H Q G s N DELETED P T A F R L H Q G s N P DELETED T A F R L H Q G i S . N P DELETED T A F R L H Q G s N P P T A F R L H Q G s N P P T A F R L H Q G T DELETED DELETED DELETED T A F R L H Q G T DELETED DELETED DELETED T A F R L H Q G T DELETED DELETED P T A F R L H Q G T DELETED DELETED P T A F R L H Q G T DELETED P DELETED T A F R L H Q G T DELETED P DELETED t A F R L H Q G T DELETED P P t : A F R L H Q G T DELETED P P T A: - F R L H Q G T N DELETED DELETED \| T A F -. R : ■L:. .. H Q G ! T N DELETED DELETED! M WO 2008/112003 PCT/US2007/0751J7 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F R L H Q G __JL._ T N DELETED P M T A F R L H Q G N DELETED P T A F R L H Q G T N P DELETED T A F R L H Q G T N P DELETED M T A F R L H Q G T N P P T A F R L H Q G T N P P M T A F R L H V s S DELETED DELETED DELETED T A F R L H V s S DELETED DELETED DELETED M T A F R L H V s s DELETED DELETED P T A F R L H V s s DELETED DELETED P M T A F R L H V s \| s DELETED P DELETED T A F R L H V s I s DELETED P DELETED M T A F R L H V s s DELETED P P T A F R L H V s s DELETED P P M T A F R L H V s s N DELETED DELETED T A F R L H V s s N DELETED DELETED M ! T A F R L H V s s N DELETED P i A F R L H V s s N DELETED P M T A F R L H V s s N P DELETED T A F R L H V s s N P DELETED M T A F R L H V s s N P P T A F R L H V s s N P P M T A F R L H V s T DELETED DELETED DELETED T A F R L H V s T DELETED DELETED DELETED M T A F R L H V s T DELETED DELETED P T A F R L H V s T DELETED DELETED P M T A F R L H V s T DELETED P DELETED T A F R L H V s T DELETED P DELETED M T A F R L H V s T DELETED P P T A F R L H V s T DELETED P P M T A F R L H V s T N DELETED DELETED T A F R L H V s T N DELETED DELETED M T A F R L H V s T N DELETED P T A F R L H V s T N DELETED P M T A F R L H V s T N P DELETED T A F R L H V s T N P DELETED M T A F R L H V s T N P P T A F R L H V s T N P P M T A F R L H V G S DELETED DELETED DELETED T A F R L H V G S DELETED DELETED DELETED M T A F R L H V G s DELETED DELETED P T A F R L H V G s DELETED DELETED P M T A F R L H V G s DELETED P DELETED T A F R L H V G s DELETED P DELETED M T A F R L H V G s DELETED P P T A F R L H V G s DELETED P P M T A F R L H V G S j N DELETED DELETED WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 L 49 55 56 ] 91 94 95 96 107 T A F R H V G i S N DELETED DELETED M T A F R L H V G ! S N DELETED P T A F R L H V G s N DELETED P M T A F R L H V G s N P DELETED T A F R L H V G s N P DELETED M T A F R L H V G s N P P T A F R L H V G s N P P M T A F R L H V G T DELETED DELETED DELETED T A F R L H V G T DELETED DELETED DELETED M T A F R L H V G T DELETED DELETED P T A F R L H V G T DELETED DELETED P M T A F R L H V G T DELETED P DELETED T A F R L H V G T DELETED P DELETED M T A F R L H V G T DELETED P P T A F R L H V G T DELETED P P M T A F R L H V G T N DELETED DELETED T A F R L H V G T N DELETED DELETED! M ' T A F : R L H V i G \| T N DELETED P i I T A F R I H V G T N DELETED P M T A F R L H V G T N P DELETED T A F R L H V G T N P DELETED M T A F R L H V G T N P P T A F R L H V G T N P P M T A F R Y Q S ! S DELETED DELETED DELETED T A F R Y Q S i S DELETED DELETED DELETED M T A F R Y Q S : S DELETED DELETED P T A F R Y Q S I S DELETED DELETED P M T A F R Y Q S i S DELETED P DELETED T A F R Y Q s \| s DELETED P DELETED M T A F R Y Q s S DELETED P P T A F R Y Q s S DELETED P P M T A F R Y Q s s N DELETED DELETED T A F R Y Q s s N DELETED DELETED M T A F R Y Q s s i N DELETED P T A F R Y Q s s N DELETED P M T A F R Y Q s s N P DELETED T A F R Y Q s s N P DELETED M T A F R Y Q s s N P ■ P T A F R Y Q s s . N P P M T A F R Y Q s T DELETED DELETED DELETED T A F R Y Q s T DELETED DELETED DELETED M T A F R Y Q s T DELETED DELETED P T A F R Y \| Q s T DELETED DELETED P M T A F R Y Q s T DELETED P DELETED T A F R Y Q s T DELETED P DELETED M T A F R Y Q s T DELETED P P T A F R Y Q s T DELETED P P M WO 2008/112003 PCT/US2007/075U7 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F R Y Q s T N DELETED DELETED T A F R Y Q s T N DELETED DELETED M T A F R Y Q s T N DELETED P T A F R Y Q s T N DELETED P DELETED _ Mj T A F R Y Q s T N P T A F R Y Q s T N P DELETED ■ M ■ T A F R Y Q s T N P P T A F R Y Q s T N P P M T A F R Y Q G S DELETED DELETED DELETED T A F R Y Q G S DELETED DELETED DELETED M T A F R Y Q G s DELETED DELETED P T A F R Y Q G _, s DELETED DELETED P M T A F R Y Q G s DELETED P DELETED T A F R Y Q G s DELETED P DELETED M T A F R Y Q G s DELETED P P T A F R Y Q G s DELETED P P M T A F R Y Q 0 o s N DELETED DELETED T A F R Y Q G s N DELETED DELETED M , T A F R Y Q G _, s N DELETED P T . A F R Y Q G s N DELETED P M T A F R Y Q G s N P DELETED T A F R Y Q G s N P DELETED M T A F R Y Q G s N P P T A F R Y Q G s N P P M T A F R Y Q G T DELETED DELETED DELETED T A F R Y Q G T DELETED DELETED DELETED M T A F R Y Q G T DELETED DELETED P T A F R Y Q G T DELETED DELETED P M T A F R Y Q G T DELETED P DELETED T A F R Y Q G T DELETED P DELETED M T A F R Y Q G T DELETED P P T A F R Y Q G T DELETED P P M T A F R Y Q G T N DELETED DELETED T A F R Y Q G T N DELETED DELETED M T A F R Y Q G T N DELETED P T A F R Y Q G T N DELETED P M T A F R Y Q G T N P DELETED T A F R Y Q G T N P DELETED M T A F R Y Q G T ■ N P -P T A F R Y Q G T N P P M T A F R Y . V S S DELETED DELETED DELETED T A F R Y V S s DELETED DELETED DELETED M T A F R Y V S s DELETED DELETED P T A F R Y V s s DELETED DELETED P M T A F R Y V s s DELETED P DELETED T A F R Y V s s DELETED P DELETED M T A F R Y V s s DELETED P P I WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T A F R Y V s S DELETED P P M T A F R Y V s S N DELETED DELETED T A F R Y V s s N DELETED DELETED M T A F R Y V s S ! N DELETED P T A F R Y V s S i N DELETED P M T A F R Y V s S N P DELETED T A F R Y V s S N P DELETED M T A F R \| Y V s S N P P T A F R Y V s s N P P M T A F R Y V s T DELETED DELETED DELETED T A F R Y V s T DELETED DELETED DELETED M T A F R Y V s T DELETED DELETED P T A F R Y V s T DELETED DELETED P M T A F R Y V s T DELETED P DELETED T A F R Y V s T DELETED P DELETED M T A F R Y V s T DELETED P P I \| T A F R Y V S I T DELETED P P M ! T A F R Y \| V S ; T N DELETED DELETED T A F R Y I V S { T N DELETED DELETED M T A F R Y V s T N DELETED P T A F R Y V s T N DELETED P M T A F R Y V s T N P DELETED T A F R Y V s T N P DELETED M T A F R Y V s T N P P T A F R Y V s T N P P M T A F R Y V G S DELETED DELETED DELETED T A F R Y V G S DELETED DELETED DELETED M T A F R Y V G S DELETED DELETED P T A F R Y V G S DELETED DELETED P M T A F R Y V G s DELETED P DELETED T A F R Y V G s DELETED P DELETED M T A F R Y V G s DELETED P P T A F R Y V G s DELETED P P M T A ■ F R Y V G s N DELETED DELETED T A F R Y V G s N DELETED DELETED M T A F R Y V G s N DELETED P T A F R Y V G s N DELETED P M T A F R Y V G s N P DELETED T A F R Y V G s . N P DELETED M T A F R Y V G s N P P T A F R Y V G s N P P M T A F R Y V G T DELETED DELETED DELETED I T A F R Y V G T DELETED DELETED DELETED M T A F R Y V G T DELETED DELETED P T A F R Y V G T DELETED DELETED P ■ M T A F R Y V G ^ T DELETED P DELETED T A F R Y V G T DELETED P DELETED M WO 2008/112003 PC17US2t»0?/O?Mi7 20 25 29 31 33 49 55 56 91 94 95 96 107 \| T A F R Y V G T DELETED P P T A F R Y V G T DELETED P P M i T A F R Y V G T N DELETED DELETED i ! T A F R Y V G G T T N N DELETED DELETED M j T A F R Y V DELETED P T A F R Y V G T N DELETED P M T A F R Y V G T N P DELETED T A F R Y V G T N P- DELETED M T A F R Y V G T N P P T A F R Y V G T N P P M T A F R H Q S S DELETED DELETED DELETED T A F R H Q S S DELETED DELETED DELETED M T A F R H Q S s DELETED DELETED P T A F R H Q S s DELETED DELETED P M T A F R H Q S s DELETED P DELETED T A F R I I H Q S s DELETED P DELETED M T A F R I \| H Q s s DELETED P P , \| T A F R H Q s s DELETED P ■ P M T A F R H Q s s N DELETED DELETED t T A F R H Q s s N DELETED DELETED M T A F R H Q s s N DELETED P T A F R H Q s s N DELETED P M T A F R H Q s s N P DELETED T A F R H Q s s N P DELETED M T A F R H Q s s N P P T A F R H Q s s N P P M T A F R H Q s T DELETED DELETED DELETED T A F R H Q s T DELETED DELETED DELETED M T A F R H Q s T DELETED DELETED P T A F R H Q s T DELETED DELETED P M T A F R H Q s T DELETED P DELETED T A F R H Q s i T DELETED P DELETED M T A F R H Q S ! T DELETED P P T A F R H Q s T DELETED ■ P P M T A . F R H Q s T N DELETED DELETED T A F R H Q s T N DELETED DELETED M T A F R H Q s T N DELETED P T - A F R H Q s T N DELETED P M T A F R H Q s T N P DELETED T A F R H Q s T N P DELETED M T A F R H Q s T N P P T A F R H Q s T N P P M T A F R H Q G S DELETED DELETED DELETED T A F R H Q G S DELETED DELETED DELETED M T A F R H Q G s DELETED DELETED P T A F R H Q G s DELETED DELETED P M T A F R H Q G s DELETED P DELETED WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 ! 91 94 95 96 107 T A F R H Q G S DELETED P DELETED M T A F R H Q G s DELETED P P i T A F R H Q G \| S DELETED P P M T A F R H Q G ! S N DELETED DELETED I T A F R H Q G ! S N DELETED DELETED M T A F R H Q G [ S N DELETED P I T A F R H Q G ! S N DELETED P M T A F R H Q G \| S N P DELETED I T A F R H Q G s N P DELETED M T A F R H Q G s N P P I T A F R H Q G s N P P M T A F R H Q G T DELETED DELETED DELETED I T A F R 'H Q G T DELETED DELETED DELETED M T A F R H Q G T DELETED DELETED P I T A F R H Q G T DELETED DELETED P M T A F R H Q G T DELETED P DELETED I T A F R H Q \| G T DELETED P JDELETED M T A F R H \| Q G T DELETED P \| P I T A F R I ■ H j Q G T DELETED P P M T A F R H Q G T N DELETED DELETED I T A F R H Q G T N DELETED DELETED M T A F R H Q G T N DELETED P I T A F R H Q G T N DELETED P M T A F R H Q G T N P DELETED I T A F R H Q G T N P DELETED M T A F R H Q G T N P P I T A F R H Q G T N P P M T A F R H V S S DELETED DELETED DELETED I T A F R H V S S DELETED DELETED DELETED M T A F R H V S s DELETED DELETED P I T A F R H V S s DELETED DELETED P M T A F R H V s s DELETED P DELETED I T A F R H V s s DELETED P DELETED M T A F R H V s s DELETED P P I T A F R H V s s DELETED P P M T A F R H V s s N DELETED DELETED I T A F R H V s s N DELETED DELETED M T A F R H V s s N DELETED P I T A F R H V s s N DELETED P M T A F R H V s s N P DELETED I T A F R H V s s N P DELETED M T A F R H V s s N P P t T A F R H V s s N P P M T \| A F R H V s T DELETED DELETED DELETED I T 1 A F R ! I H V s T DELETED DELETED DELETEDJ ' M T 1 A F R H V s T DELETED DELETED P J I T A F R H V s T DELETED DELETED P S M WO 2008/112003 r'CT/vstmvo-7Siii 20 25 29 I 31 33 49 55 56 91 94 95 96 107 T A F R H V s T DELETED P DELETED I T A F Ft H V s T DELETED P DELETED M T A F R H V s T DELETED P P I T A F R H V s T DELETED P P M T A F R H V s T N DELETED DELETED I T A F R H V s T N DELETED DELETED M T A F R H V s T N DELETED P i T A F R H V s T N DELETED P M T A F R H V s T N P DELETED I T A F R H V s T N P DELETED M T A F R H V s T N P P I T A F R H V s T N P P i T A F ■■ R H V G S DELETED DELETED DELETED T A F R H V G S DELETED DELETED DELETED P M '" r T A F R H V G s DELETED DELETED __T T . A ._ A F F _.R„_._ R H V G s DELETED DELETED P M I I H G s DELETED P DELETED T A F R H V G s DELETED P DELETED P T A F R H V G s DELETED P i \| T A F R H V G s DELETED P P M T A F R H V G s N DELETED DELETED I T A F R H V G s N DELETED DELETED M T A F R H V G s N DELETED P i T A F R H V G s N DELETED P M T A F R H V G s N P DELETED I T A L F R H V G s N P DELETED M T A F R H V G s N P P I T A F R H V G s N P P M T A F R H V G T DELETED DELETED DELETED [ T A F R H V G T DELETED DELETED DELETED M T A F R H V G T DELETED DELETED P I T A F R H V G T DELETED DELETED P M T A F R H V G T DELETED P DELETED I T A F R H V G T DELETED P DELETED M T A F R H V G T DELETED P P i T A F R H V G T DELETED P P M T A F R H V G T N DELETED DELETED I T A F R H V G T N DELETED DELETED M 1 T A F R H V G T N DELETED P I T A F R H V G T N DELETED P M T A F R H V G T N P DELETED t T A F R H V G T N P DELETED M T A F R H V G T N P P I T A F R H V G T N P P M T P 1 S L Y Q S S DELETED DELETED DELETED I T P 1 S L Y Q S s DELETED DELETED DELETED M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 \| 107 T P S L Y Q S S DELETED DELETED P T P S L Y Q S S DELETED DELETED P M T P s L Y Q S S DELETED P DELETED T P s L Y Q s S DELETED P P DELETED M T P s L Y Q DELETED P T P s L Y Q S j S DELETED P P M T P s L Y Q s ! s N DELETED DELETED T P s L Y Q s S S N DELETED DELETED M T P s L Y Q s N DELETED P T P s L Y Q s S N DELETED P M T P s L Y Q s s N P DELETED T P s L Y Q s s N P DELETED M T P s L Y 0 s s N P P T P s L Y Q s s N P P M T P s L Y Q s T DELETED DELETED DELETED T P s L Y Q S j T DELETED DELETED DELETED DELETED DELETED _JVL - M T P s L Y 0 s _. T P T P s L Y Q s T DELETED DELETED P T P s L Y Q s T DELETED P DELETED T P s L Y Q s , T DELETED P DELETED M T P s L Y Q s T DELETED P P T P s L Y Q s T DELETED P P M T P s L Y Q s T N DELETED DELETED T P s L Y Q s T N DELETED DELETED M T P s L Y Q s T N DELETED P T P s L Y Q s T N DELETED P M T P s L Y Q s T N P DELETED T P s ■ L Y Q s T N P DELETED M T P s L Y Q s T N P P T P s L Y Q s T N P P M T P s L Y Q G S DELETEDJDELETED DELETED T P s L Y Q G S DELETED DELETED DELETED M T P s L Y Q G s DELETED DELETED P T P s L Y Q G s DELETED DELETED P M T P s L Y Q G s DELETED P DELETED T P s L Y Q G s DELETED P DELETED M T P s L Y Q G j S DELETED P P T P s L Y Q G s DELETED P P M T P s L Y Q G s N DELETED DELETED T P s L Y Q G s N DELETED DELETED M T P s L Y Q G s N DELETED P T P s L Y Q G s N DELETED P M T P s L Y Q G s N P DELETED T P s L Y Q G s N P DELETED M T P s L Y Q G s N P P T P s L Y Q G s H P P M WO 2008/112003 PCT/US2007/075U7 20 25 29 31 33 49 55 56 ! 91 94 95 96 107 T P S L Y Q G T DELETED DELETED DELETED T P S L Y Q G T DELETED DELETED DELETED M T P S L Y Q G T DELETED DELETED P T P S L Y Q G T ' DELETED DELETED P : M T P S L Y Q G T DELETED P DELETED T P S L Y Q G T DELETED P DELETED M T P S L Y Q G T DELETED P P T P S L Y Q G T DELETED P P M T P S L Y Q G T N DELETED DELETED T P S L Y Q G T N DELETED DELETED M T P s L Y Q G T N DELETED P T P s L Y Q G T N DELETED P M T P s L Y Q G T N P DELETED T P s L Y Q G N P DELETED M T P s L Y Q G T N P P T P s L Y Q G T N P P M T P s L Y V V S S DELETED DELETED DELETED T P s L Y S DELETED DELETED DELETED M T P s L Y V s s DELETED DELETED P T P s L Y V s s DELETED DELETED P M T P s L Y V s s DELETED P. DELETED T P s L Y V s s DELETED P DELETED M T P s L Y V s s DELETED P P T P __s_^ L Y V s s DELETED P P M T P s L Y V s s N DELETED DELETED T P 1 s L Y V s s N DELETED DELETED _M-_ T P s L Y V s s N DELETED P T P s L Y V s s N DELETED P M T P s L Y V s s N P DELETED T P s L Y V s s N P DELETED P _Ji... T P s L Y V s s N P T P s L Y V s s N P P DELETED M_ T P s L Y V s T DELETED DELETED T P s L Y V s T DELETED DELETED DELETED M T P s L Y V s T DELETED DELETED P T P s L Y V s T DELETED DELETED P M T P s L Y V s T DELETED P DELETED T P s L Y V s T DELETED P DELETED M T P s L Y V s T DELETED P P T P s L Y V s T DELETED P P M T P s L Y V s T N DELETED DELETED T P s L Y V s T N DELETED DELETED M T P s L Y V s T N DELETED P T P s L Y V s I T N DELETED P M T P s L Y V s i T N P DELETED M T P s L Y V s ! T N P DELETED woaooN/inOos KMTiJgSirtWMKHf 26 23 23 31 35 49 S5 56 91 94 95 06 l 107 T P S L Y V S T N P P i T P s L Y V S T N P P M T P s L Y V G S DELETED DELETED DELETED 1 T P s L Y V G S DELETED DELETED DELETED P 1 T P s L Y V G s DELETED DELETED T P s L Y V G __s s DELETED DELETED P P_ DELETED M T P s L Y V G DELETED 1 T P s L Y V G s DELETED P DELETED 1 T P s L Y V G s DELETED P P T P s L Y V G s DELETED P P M T P s L Y V G s N DELETED DELETED 1 T P s L Y V G s N DELETED DELETED M T P s L Y V G s N DELETED P 1 T P' ' :\'.\) ' ..'■' ■'-"s L Y V G s N DELETED JP__ DELETED 1 T P s L Y V G s N P T ■ P s L Y V G s N \| P N \| P DELETED M T P s L Y V G s P 1 t P s L Y V G s N P P M ■ f p;:; s L Y V G 1 T DELETED DELETED DELETED 1 1 T :- P ' 1 * J ■ S. - L ' ••■ Y-. ; Y -W. i "V . G . ,_.;-T_;.L T DELETED DEIETED DELETED. qBffiiB DELETED M T P 1 " " si "■ f G ■■■: p 1 T P s L Y V G T DELETED DELETED P M T P t s L Y V G T DELETED P DELETED 1 T P' 1 s L Y V G T DELETED P DELETED M t P i s L Y V G T DELETED P P 1 T P 1 S i- Y V G T DELETED p ; p ' U T P 1 i S L Y v G T N DELETEDjDELETED f t P i j s i T_ V G T N DELETEDpELETED M j t P ! i s L Y V G T ' • N. DELETED! P i I t P i ! s j L Y V G t N [DELETED; P : M i t P i ! s t Y V G T N !- - - P-. (DELETED r ! T P i s L Y V G > L_ N ■ ■ t p - DELETED M T P~^ ; s L Y V G T N ';,p ■": ;1 \| T _£_U s i- Y v G t . N p. p ' M i T r^r s L H Q S s DELETED DELETED DELETED i : T p i £ L H Q S s DELETED DELETED DELETED M : T p ^ f s I H ' Q s s DELETED DELETED ■ ; P ' ':} i : T p ! s I H Q s s DELETED DELETED >"■' M ' T p 1 s I H Q s s DELETED ■; P: ' DELETED '•: ' T p j s L H Q s s DELETED ■ ; i R ' :' DELETED M t p i s L H Q s s DELETED! P ■ i ' 9 • ' ■ i- T p i § L H 1 Q s s DELETEDJ P " P : M T p i s L H Q s s N: ' (DELETED DELETED ! t P ! s L H Q s s N IDELETED DELETED M i P i i s L H Q s I s N jDELETED P r T p i i s L H Q s ! S N IDELETED! P ' M WO 2008/112003 PCT/U$2U07/»?5fl7 20 25 29 31 33 49 55 56 91 94 95 96 107 T P - S L H Q s S N P DELETED T P S L H Q S S N P DELETED M T P s L H Q s s N P P P s L H Q s s N P P M T P s L H Q s T DELETED DELETED DELETED T P s L H Q s T DELETED DELETED DELETED M T P s L H Q s T DELETED DELETED P T P s L H Q s T DELETED DELETED P M T P s L H Q s T DELETED P DELETED I I T P s L H Q s T DELETED P DELETED M T P s L H Q s T DELETED P P T P s L H Q s T DELETED P P M T P J 1 s L H_J Q s T N DELETED DELETED T P s L H Q s T N DELETED DELETED M T P s L H Q s T N DELETED P T P s L H Q s T N DELETED P M T T P P s L H Q s T N P DELETED M s L H Q s T N P DELETED . T P s L H Q s T N P P T P s L H Q s T N P P M T P s L H Q G S DELETED DELETED DELETED T P s L H Q G S DELETED DELETED DELETED M T P s L H Q G S DELETED DELETED P T P s L H Q G S DELETED DELETED P M T P s L H Q G S DELETED P DELETED T P s L H Q G S DELETED P DELETED M T P s L H Q G S DELETED P P T P s L H Q G Sv~ DELETED P P ■ M T P s L H Q G S N DELETED DELETED T P s L H Q G S N DELETED DELETED P _ M T P s L H Q G s N DELETED T P s L H Q G s N DELETED P . _M_ T P s L H Q G s N P DELETED T P s L H Q G s N P DELETED M_ T P s L H Q G s- N P P T P s L H Q G s N P P M T P s L H Q G T DELETED DELETED DELETED T P s L H Q G T DELETED DELETED DELETED M T P s L H Q G T DELETED DELETED P T P s L H Q G T DELETED DELETED P M T P s L H Q G T DELETED P DELETED T P s L H Q G T DELETED P DELETED M T P s L H Q G T DELETED P P T P s L H Q G T DELETED P P M T P s L H Q G T N DELETED DELETED T P s L H Q G T N DELETED DELETED M WO 2008/112003 PCT/US2007/075U7 20 25 29 31 33 49 55 56 91 94 95 96 107 T P S L H Q G T N DELETED P I T P S L H Q G T N DELETED P M T P s L H Q G T N P DELETED T P s L H Q G T N P DELETED M T P s L H Q G T N P P T P s L H Q G T N P P M T P s L H V s S DELETED DELETED DELETED T P s L H V s s DELETED DELETED DELETED M T P s L H V s s DELETED DELETED P T P s L H V s s DELETED DELETED P M T P s L H V s s DELETED P DELETED T P s L H V s s DELETED P DELETED M T P s L H V s s DELETED P P T P s L H V s s DELETED P P M T P s L H V s s N DELETED DELETED T P s L H V s s N DELETED DELETED M T T P s L H V s s N DELETED P P s L H V s s N DELETED P M T P s L H V s s N \| P DELETED T P s L H V s s N P DELETED M T P s L H V s s N P P T P s L H V s s N P P M T P s L H V s T DELETED DELETED DELETED T P s L H V s T DELETED DELETED DELETED M T P s L H V s T DELETED DELETED P T P s L H V s T DELETED DELETED P M _ T T p s L H V s T DELETED P DELETED s L H V s T DELETED P DELETED M T p s L H V s s T DELETED P P T p s L H V T DELETED P P M T p s L H V s T N DELETED DELETED T p s L H V s T N DELETED DELETED M T p s L H V s T N DELETED P T p" s L H V s T N DELETED P M T p s L H V s T N P DELETED T p s L H V s T N P DELETED M T p s L H V s T N P P T p s L H V s T N P P M T p s L H V G S DELETED DELETED DELETED T p s L H V G S DELETED DELETED DELETED M T p s L H V G s DELETED DELETED P T p s L H V G s DELETED DELETED P M T p s L H V G s DELETED P DELETED T p s L H V G s DELETED P DELETED M T p s L H V G s DELETED P ! P T p s L H V G s DELETED P I P M WO 200(1/112003 PCT/US2U07/075U7 20 25 29 31 33 49 55 56 91 94 95 96 107 T P S L H V G s N DELETED DELETED T P S L H V G s N DELETED DELETED M T P S L H V G s N DELETED P T P S L H V G s N DELETED P M T P S L H V G s N P DELETED T P S L H V G _i s N P DELETED M T P S L H V G s N P P T P S L H V G s N P P M T P S L H V G T DELETED DELETED DELETED T P S L H V G T DELETED DELETED DELETED M T P s L .H V G T DELETED DELETED P T P s L H V G T DELETED DELETED P M T P s L H V G T DELETED P DELETED T P s L H V G T DELETED P DELETED M T P s L H V G T DELETED P P ■T P s L H V G T DELETED P P M T P s L - L H V G T N DELETED DELETED I i T P s H V G T N DELETED DELETED M T P s L H V G T N DELETED P T P s I H V G T N DELETED P M T P s L H V G _—LJ N P DELETED T P * s L H V G T N P DELETED M T P s L H V G T N P P T P s L H V G \|_I_ N P P M T P s Y Q S S DELETED DELETED DELETED T P s Y Q S s DELETED DELETED DELETED M T P s Y Q S s DELETED DELETED P T P s Y Q S s DELETED DELETED P M T P s Y Q S [ S DELETED P DELETED T P s Y Q S s DELETED P DELETED M T P s Y Q S s DELETED P P T P s Y Q s s DELETED P P M T _ T P s Y Q s s N DELETED DELETED P s Y Q s s N DELETED DELETED M T P s Y Q s s N DELETED P T P s Y Q s s N DELETED P M T P s Y Q s s N P DELETED T P s Y Q s s N P DELETED M T P s Y Q s s . N P P T P s Y Q s J— s N P P M T P s Y Q s T DELETED DELETED DELETED T P s Y Q s J_T DELETED DELETED DELETED M T P s Y Q s T DELETED DELETED P T P s Y Q s T DELETED DELETED P M T P s Y Q s T DELETED P DELETED T P s Y Q s T DELETED P DELETED M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T P S Y Q S T DELETED P P T P S Y Q s T DELETED P P M T P S Y Q s T N DELETED DELETED T P S Y Q s T N DELETED DELETED M T P S Y Q s T N DELETED P T P S Y Q s T N DELETED P M T P S Y Q s T N P DELETED T P S Y Q' s T N P DELETED M T P S Y Q s T N P P T P S Y Q s T N P . P M T P s Y Q G S DELETED DELETED DELETED T P s Y Q G S DELETED DELETED DELETED M T P s Y Q G s DELETED DELETED P T P s Y Q G s DELETED DELETED P _j I M_ T P s Y Q r G s DELETED P DELETED T P s Y Q G s DELETED P DELETED M T P s Y 0 G s DELETED P P T P s Y Q j G s DELETED P P M T P s Y Q G s N DELETED DELETED T P s Y 0 G s N DELETED DELETED M T P s Y Q G s N DELETED P T P s Y Q G s N DELETED P M T P s Y Q G s N P DELETED T P s Y Q G s N P DELETED M T P s Y Q G s N P P T P s Y Q G s N P P M T P s Y Q G T DELETED DELETED DELETED T P s Y Q G T DELETED DELETED DELETED M T P s Y Q G T DELETED DELETED P T P s Y Q G T DELETED DELETED P M T P s Y Q G T DELETED P DELETED T P s Y Q G T T DELETED P DELETED M T P s Y Q G DELETED P P T P s Y Q G T DELETED P P M T P s Y Q G T N DELETED DELETED T P s Y Q G T N DELETED DELETED M T P s Y Q G T N DELETED P " T P s Y Q G T N DELETED P M T P s Y Q G T - N P DELETED T P s Y Q G T N P DELETED M T P s Y Q G T N P P T P s Y Q G T N P P M T P s Y V S S DELETED DELETED DELETED T P s Y V S S DELETED DELETED DELETED M T P s Y V S s DELETED DELETED P T 1 P s Y V S s DELETED DELETED P M WO 2008/112003 PCt/VStodtfdtsm 20 25 29 31 33 49 55 56 91 94 95 96 107 T P S Y V s S DELETED P DELETED T P S Y V s s DELETED P DELETED M T P s Y V s s DELETED P P T P s Y V s s DELETED P P M T P s Y V s s N DELETED DELETED T P 3 Y V s s N DELETED DELETED M T P S Y V s s N DELETED P T ■ P S Y V s s N DELETED P M T P S Y V s s N P DELETED T P S Y V s s N P DELETED M T P S Y V s s N P P T P S Y V s s N P P M T P s Y V s T DELETED DELETED DELETED T P s Y V s T DELETED DELETED DELETED M T P s Y V s T DELETED DELETED P T P s Y V s T DELETED DELETED P M ! T P s Y V s T DELETED P JDELETED [ T P s Y V s T DELETED P DELETED M \|_T P s Y V s T (DELETED P ' P i. T P s Y V s T DELETED P P M T P s Y V s T N DELETED DELETED T P s Y V s T N DELETED DELETED M T P s Y V s T N DELETED P T P s Y V s T N DELETED P M T P s Y V s T N P DELETED T P s Y V s T N P DELETED M T P s Y V s T N P P T P s Y V s T N P P M T P s Y V G S DELETED DELETED DELETED T P s Y V G S DELETED DELETED DELETED M T P s Y V G s DELETED DELETED P T P s Y V G s DELETED DELETED P M T P s Y V G s DELETED P DELETED T P s Y V G s DELETED P DELETED M T P s Y V G s DELETED P P T P s Y V G s DELETED P P M T P s Y V G s N DELETED DELETED T P s Y V G s N DELETED DELETED M T P s Y V G s N DELETED P T P s Y V G s N DELETED P M T P s Y V G s N P DELETED T P s Y V G s N P DELETED U T P s Y V G s ' N P P T P s Y V G s N P P M T P s Y V G T DELETED DELETED DELETED I T P s Y V G T DELETED DELETED DELETED M WO 2008/112003 PCT/US2007/07S117 20 25 29 31 33 49 55 56 91 94 95 96 107 T P S Y V G T DELETED DELETED P T P S Y V G T DELETED DELETED P M T P s Y V G T DELETED P DELETED T P s Y V G T DELETED P DELETED M T P s Y V G T DELETED P P T P s Y V G T DELETED P P M T P s Y V G T N DELETED DELETED T P s Y V G T N DELETED DELETED M T P s Y V G T N DELETED P T P s Y V G T N DELETED P M T P s Y V G T N P DELETED T P s Y V G T N P DELETED M T P _ s Y V G T N P P T P s Y V G T N P P M T P s H Q s S DELETED DELETED DELETED T P s H Q S s DELETED DELETED DELETED M T p ! i s H Q S S s DELETED DELETED P , ! T p s H Q s DELETED DELETED P M i T p s H Q S s DELETED P DELETED T p s H Q S s DELETED P DELETED M T p s H Q S s DELETED P P T p s H Q S s DELETED P P M T p s H Q S s N DELETED DELETED T p s H Q S s N DELETED DELETED M T p s H Q S s N DELETED P T p s H Q S s N DELETED P M T p s H Q S s N P DELETED T p s H Q S s N P DELETED M T p s H Q S s N P P T p s H Q s s N P P M T p s H Q s T DELETED DELETED DELETED T p s H Q s T DELETED DELETED DELETED M T p s H Q s T DELETED DELETED P T p s H Q s T DELETED DELETED P M T p s H Q s T DELETED P DELETED T p s H Q s T DELETED P DELETED M T p s H Q s T DELETED P P T p s H Q s T DELETED P P M T p s H Q s T N DELETED DELETED T p s H Q s T N DELETED DELETED M 1 T p s H Q s T N DELETED P T p s H Q s T N DELETED P M T p s H Q s T N P DELETED T p s H Q s T N P DELETED M T p s H Q s T N P P T p s H Q s T N P P M WO 2008/112003 PCT/US2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T P S H Q G S DELETED DELETED DELETED I T P S H Q G s DELETED DELETED DELETED M T P s I H Q G s DELETED DELETED P I T P s H Q G s DELETED DELETED P M T P s H Q G s DELETED P DELETED I T P s H Q G s DELETED P DELETED M T P s H Q G s DELETED P P I T P s H Q G s DELETED P P M f ' P s H Q G s N DELETED DELETED I T P s H Q G s N OELETED, DELETED M T P s H Q G s N DELETED P I T P s H Q G s N DELETED P M T P . s H Q G s N P DELETED I T P s H Q G s N P DELETED M T P s H Q G s N P P I T P s H Q G s N P P M ' _ T T P s H Q G G T DELETED DELETED DELETED I P 1 s H Q T DELETED DELETED DELETED M T P s H Q G T DELETED DELETED P I I T P s H Q G T DELETED DELETED P M T P s H Q G T DELETED P DELETED I T P s H Q G T DELETED P DELETED M T P s H Q G T DELETED P P I T P s H Q G T DELETED P P M T P s H Q G T N DELETED DELETED I T P s H Q G T N DELETED DELETED M I T P s H Q G T N DELETED P T P S \| I H Q G T N DELETED P M T P S I H Q G T N P DELETED I T P s H Q G T N P DELETED M T P s H Q G T N P P I T P s H Q G T N P P I T P s H V S S DELETED DELETED DELETED T P s H V S S DELETED DELETED DELETED M T P s H V S s DELETED DELETED P I T P s H V S s DELETED DELETED P M T P s H V S s DELETED P DELETED l T P s H V S s DELETED P ■ DELETED M T P s H V S s DELETED P P I T P s H V S s DELETED P P M T P s I H V S s N DELETED DELETED I T P s H V s s ! N DELETED DELETED M T P s H V s s I N DELETED P I T P s H V s s N DELETED P M T P s H V s s N P DELETED I T P s H V i s s N P DELETED M WO 2008/112003 PCMIS2007/075117 20 25 29 31 33 49 55 56 91 94 95 96 107 T P S H V s S N P P I T P s H V s S N P P M r P s H V s T DELETED DELETED DELETED I T P s H ' V s T DELETED DELETED DELETED M T P s H V s T DELETED DELETED P I T P s H V s T DELETED DELETED P M T P s H V s T DELETED P DELETED I T P s H V s T DELETED P DELETED M T P s H V s T DELETED P P I T P s H V s T DELETED P P M T P s H V s T N DELETED DELETED I T P s H V s T N DELETED DELETED M T P s H V s T N DELETED P I T P s H V s T N DELETED P M T P s H v s T N P DELETED I T P s H V s T N P DELETED M T P S I H V s T I N P P i I T P 3 ' H V s T 4 N P P j M T P s H V G S DELETED DELETED DELETED I T P s H V G S pELETED DELETED DELETED M T P s H V G s DELETED DELETED P I T P s H V G s DELETED DELETED P M T P s H V G s DELETED P DELETED I T P s H V G s DELETED P DELETED M T P s H V G s DELETED P P I T P s H V G s DELETED P P M T P s H V G s N DELETED DELETED I T P s H V G s N DELETED DELETED T P s H V G s N DELETED P I T P s H V G s N DELETED P M . T P s H V G s N P DELETED I T P s H V G s N P DELETED M T P s H V G s N P ! P I T P s H V G s N P P M T P s H V G T DELETED DELETED DELETED I T P s H V G T DELETED DELETED DELETED M T P s H V G T DELETED DELETED P I T P s H V G T DELETED DELETED P M T P s H V G T DELETED P DELETED I T P s H V G ' T DELETED P DELETED M T P s H V G T DELETED P P I T P s H V G \| T DELETED P P M T P s H V G ! T N DELETED DELETED I T P s H V G T N DELETED DELETED M T P s H V G T N DELETED P I T P s H v G ; T N DELETED P M WO 200H/112003 PCT/US20U7/H7SiJ7 20 25 29 31 33 49 55 56 91 94 95 96 107 I T P S I H V G T N P DELETED T P S I H V G T N P DELETED M T P s I H V G T N P P I T P s I H V G T N P P M T P R L Y Q S S DELETED DELETED DELETED I T P R L Y Q S S DELETED DELETED DELETED M T P R L Y Q S s DELETED DELETED P I T P R L Y Q S s DELETED DELETED P M T P R L Y Q S s DELETED P DELETED I T P R L Y Q S s DELETED P DELETED M T P R L Y Q S s DELETED P P I T P R L Y Q S s DELETED ' P P M T P R L Y Q s s N DELETED DELETED I T P R L Y Q s s N DELETED DELETED M T P R L Y Q s s N DELETED P I T P R L Y Q s s N DELETED P M T P R L Y Q s s N P DELETED I T P R L Y Q s s N P DELETED M T P R L Y Q s s N P P I T P R L Y Q s s N P P M T P R L Y 0 s T DELETED DELETED DELETED J T P R L Y Q S i T DELETED DELETED DELETED M T P R L Y Q S ! T DELETED DELETED P t T P R L Y Q S T DELETED DELETED P M T P R L Y Q S T DELETEO P DELETED I T P R L Y Q s T DELETED P DELETED M T P R L Y Q s T DELETED P P ! T P R L Y Q s T DELETED P P M T P R L Y Q s T N DELETED DELETED t T P R L Y Q s T \| N DELETED DELETED M T P R L Y Q s T N DELETED P I T P R L Y Q s T N DELETED P M T P R L Y Q s T N P _, DELETED I T P R L Y Q s T N P DELETED M T P R L Y Q s T N P P I T P R L Y Q s T N P P M T P R L Y ■ Q G S DELETED DELETED DELETED I T P R L Y Q G S DELETED DELETED DELETED M T P R L Y Q G s DELETED DELETED P I T P R L Y Q G s DELETED DELETED P M T P R L Y Q G s DELETED P DELETED I T P R L Y Q G s DELETED P DELETED M T P R L Y Q G s DELETED P P I T P R L Y Q G s DELETED P P M T P R L Y Q G s N DELETED DELETED I T P R L Y Q G s N DELETED DELETED M WO 10UW11W03 PCT/US2007/075tl7 ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P R L Y V S T N DELETED DELETED I T P R L Y V s T N DELETED DELETED M T P R L Y V s T N DELETED P I T P R L Y V s T N DELETED P M T P R L Y V s T N P DELETED 1 T P R L Y V s T N P DELETED M T P R L Y V s T N P P 1 T P R L Y V s T N P P M T P R L Y V G S DELETED DELETED DELETED I T P R L Y V G S DELETED DELETED DELETED M T P R L Y V G. s DELETED DELETED P 1 T P R L Y V G s DELETED DELETED P M T P R L Y V G s DELETED P DELETED 1 T P R L Y V G s DELETED P DELETED M T P R L Y V G s DELETED P P 1 T P R L Y V G s DELETED P P M T P R L Y v G , S N DELETED DELETED 1 T P 1 R L Y V i G s N DELETED DELETED M T P R L Y V G s N DELETED P 1 T P R L Y V G s N DELETED P M T P R L Y V G s N P DELETED 1 T P R L Y V G s N P DELETED M T P R L Y V G s N P P 1 T P R L Y V G s N P P M T P R L Y V G T DELETED DELETED DELETED 1 T P R L Y V G T DELETED DELETED DELETED M T P R L Y V G T DELETED DELETED P 1 T P R L Y V G T DELETED DELETED P M T P R L Y V G T DELETED P DELETED ! T P R L Y V G T DELETED P DELETED M T P R L Y V G T DELETED P P 1 T P R L Y V G T DELETED P P M T P R L Y V G T N DELETED DELETED 1 T P R L Y V G T N DELETED DELETED M T P R L Y V G T N DELETED P 1 T P R L Y V G T N DELETED P M T P R L Y V G T N P DELETED 1 T P R L Y V G T N P DELETED M T P R L Y V G T N P P 1 T P R L Y V G T N P P M T P R L H Q S S DELETED DELETED DELETED I T P R L H Q S S DELETED DELETED DELETED M T P R L H Q s s DELETED DELETED P 1 T P R L H Q s s DELETED DELETED P \| M T P R L H Q s s DELETED P DELETED . 1 T P R L H Q s s DELETED P DELETED M 52959 v I/DC' ASTR013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P R L H Q S S DELETED P P T P R L H Q S S DELETED P P M T P R L H Q s s N DELETED DELETED T P R L H Q s s N DELETED DELETED M T P R L H Q s s N DELETED P T P R L H Q s s N DELETED P M T f P R L H Q s s N P DELETED T P R L H Q s s N P DELETED M T P R L H Q s s N P P T P R L H Q s s N P P M T P R L H Q s T DELETED DELETED DELETED T P R L H Q s T DELETED DELETED DELETED M T P R L H Q s T DELETED DELETED P T P R L H Q s T DELETED DELETED P M T P R L H Q s T DELETED P DELETED T P R L H Q s T DELETED P DELETED M T P R L « H Q s T DELETED P P T P R L I H Q s T DELETED P P M T P R L U- H Q s T N DELETED DELETED . T P R L H Q s T N DELETED DELETED M T P R L H Q s T N DELETED P T P R L H Q s T N DELETED P M T P R L H Q s T N P DELETED T P R L H Q s T N P DELETED M T P R L H Q s T N P P T P R L H Q s T N P P M T P R L H Q G S DELETED DELETED DELETED T P R L H Q G S DELETED DELETED DELETED M T P R L H Q G s DELETED DELETED P T P R L H Q G s DELETED DELETED P M T P R L H Q G s DELETED P DELETED T P R L H Q G s DELETED P DELETED M T P R L H Q G s DELETED P P T P R L H Q G s DELETED P P M T P R L H Q G s N DELETED DELETED T P R L H Q G s N DELETED DELETED M T P R L H Q G s N DELETED P . T P R L H Q G s N DELETED P ■ M T P R L H Q G s N P . DELETED T P R L H Q G s N P DELETED M T P R L H Q G s N P P T P R L H Q G s N P P M T P R L H Q G T DELETED DELETED DELETED T P R L ! H Q G T DELETED DELETED DELETED M T P R L H Q G T DELETED DELETED P T P R L H Q G T DELETED DELETED P M 52959 vI/DC ASTR 013/01 WO 20 25 29 31 33 49 55 I 56 91 94 95 96 107 T P R L H Q G T DELETED P DELETED T P R L H Q G T DELETED P DELETED M T P R L H Q G T DELETED P P T P R L H Q G T DELETED P P M T P R L H Q G T N DELETED DELETED T P R L H Q G T N DELETED DELETED M T P R L H Q G T N DELETED P T P R L H Q G T N DELETED P M T P R L H Q G T N P DELETED T P R L H Q G T N P DELETED M T P R L H Q G T N P P T P R L H Q G T N P P M T P R L H V S S DELETED DELETED DELETED T P R L H V S S DELETED DELETED DELETED M T P R L H V s s DELETED DELETED P T P R L H V s s DELETED DELETED P M T P R L H V s '■ s DELETED P DELETED T P R L H V s i 5 DELETED P DELETED M T P R L H V s s DELETED P P T P R L H V s s DELETED P P M T P R L H V s s N DELETED DELETED T P R L H V s s N DELETED DELETED M T P R L H V s s N DELETED P T P R L H V s s N DELETED P M T P R L H V s s N P DELETED T P R L H V s s N P DELETED M T P R L H V s s N P P T P R L H V s s N P . P M T P R L H V s T DELETED DELETED DELETED T P R L H V s T DELETED DELETED DELETED M T P R L H V s T DELETED DELETED P T P R L H V s T DELETED DELETED P M T P R L H V s T DELETED P DELETED T P R L H V s T DELETED P DELETED M ■ T P R L H V s T DELETED P P T P R L H V s T DELETED P P M T . P R L H V s T N DELETED DELETED T P R L H V s T N DELETED DELETED M T P R L H V s T N DELETED P T P R L H V s T N DELETED P M T P R L H V s T N P DELETED T P R L H V s T N P DELETED M T P R L H V s T N P P T P R L H V s T N P P M T P R L H V G S DELETED DELETED DELETED T P R L H V G S DELETED DELETED DELETED M S2959 vt/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P R L H V G s DELETED DELETED P T P R L H V G s DELETED DELETED P M T P R L H V G s DELETED P DELETED T P R L H V G s DELETED P DELETED M T P R L H V G s DELETED P P T P R L H V G s DELETED P P M T P R L H V G s N DELETED DELETED T P R L H V G s N DELETED DELETED M T P R L H V G s N DELETED P T P R L H V G s N DELETED P M T P R L H V G s N P DELETED T P R L H V G s N P DELETED M T P R L H V G s N P P T P R L H V G s N P P M T P R L H V G T DELETED DELETED DELETED T P R L H V G T DELETED DELETED DELETED M T P R L H j V G T DELETED DELETED P T P R L H V G T DELETED DELETED P M T P R L H V G T DELETED P DELETED T P R L H V G T DELETED P DELETED M T P R L H V G T DELETED P P T P R L H V G T DELETED P P M T P R L H V G T N DELETED DELETED T P R L H V G T N DELETED DELETED M T P R L H V G T N DELETED P T P R L H V G T N DELETED P M T P R L H V G T N P DELETED T P R L H V G T N P DELETED M T P R L H V G T N P P T P R L H V G T N P P M T P R Y Q S S DELETED DELETED DELETED T P R Y Q S S DELETED DELETED DELETED M T P R Y Q s s DELETED DELETED P T P R Y Q s s DELETED DELETED P M T P R Y Q s s DELETED P DELETED T P R Y Q s s DELETED P DELETED M T P R Y Q s s DELETED P P T P R Y Q s s DELETED P P M T P R Y Q s s . N DELETED DELETED T P . R Y Q s s N DELETED DELETED M T P R Y Q s s N DELETED P T P R Y Q s s N DELETED P M T P R Y Q s s N P DELETED T P R Y Q s s N P DELETED M T P R Y Q s ! s N P P T P i 1 R Y Q s f s N P P M 52959 v\|/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P R Y Q S T DELETED DELETED DELETED T P R Y Q S T DELETED DELETED DELETED M T P R Y Q S T DELETED DELETED P T P R Y Q S T DELETED DELETED P M T P R Y Q S T DELETED P DELETED T P R Y Q S T DELETED P DELETED M T P R Y Q S T DELETED P P T P R Y Q S T DELETED P P M T P R Y Q S T N DELETED DELETED T P R Y Q S T . N DELETED DELETED M T P R Y Q s T N DELETED P T P R Y Q s T N DELETED P M T P R Y Q s T N P DELETED T P R Y Q s T N P DELETED M T P R Y Q s T N P P T P R Y Q s T N P P M T P R Y Q G S DELETED DELETED DELETED T P R Y Q G s DELETED DELETED DELETED M T P R Y Q G s DELETED DELETED P T P R Y Q G s DELETED DELETED P M T P R Y Q G s DELETED P DELETED T P R Y Q G s DELETED P DELETED M T P R Y Q G s DELETED P P T P R Y Q G s DELETED P P M T P R Y Q G s N DELETED DELETED T P R Y Q G s N DELETED DELETED M T P R Y Q G s N DELETED P T P R Y Q G s N DELETED P M T P R Y Q G s N P DELETED T P R Y Q G s N P DELETED M T P R Y Q G s N P P T P R Y Q G s N P P M T P R Y Q G T DELETED DELETED DELETED T P R Y Q G T DELETED DELETED DELETED M T P R Y Q G T DELETED DELETED P T P R Y Q G T DELETED DELETED P M T P R Y Q G T DELETED P DELETED T P R Y Q G T DELETED P ■ DELETED M T P R Y Q G T DELETED P P T P . R Y Q G T DELETED P P M T P R Y Q G T N DELETED DELETED T P R Y Q G T N DELETED DELETED M T P R Y Q G T N DELETED P T P R Y Q G T N DELETED P M T P R Y Q G T N P DELETED T P R Y Q G T N P DELETED M 52959 vVDC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 R R R Y Q Q V DELETED DELETED DELETED HFLETED DELETED DELETED DELETED DELETED DELETED DELETED M M M R V DEfciUP. DEbETED DELETED DELETED M T R Y Y DEI-ETEP DELETED DELETED DELETED M R R Y DELETED DELETED DELETED DELETED M M DELETED DELETED M T ^ R R R R V V V N DELETED {DELETED DELETED DELETED nFLETED DELETED DELETED. DELETED DELETED HFLETED DELETED nFLETED DELETED^ DELETED DELETED DELETED M M M M M T R R Y Y Y V N N DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED M M M M T R R R R Y Y Y nFLETED DELETED nFLETED nFLETED nFLETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED M M M M R R R Y Y V DELETED DELETED DELETED DELETED DELETED DELETED M M 52953 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P R Y V G s N P DELETED T P R Y V G s N P DELETED M T P R Y V G s N P P T P R Y V G s N P P M T P R Y V G T DELETED DELETED DELETED T P R Y V G T DELETED DELETED DELETED M T P R Y V G T DELETED DELETED P T P R Y V G T DELETED DELETED P M T P R Y V G T DELETED P DELETED T P R Y V G T DELETED P DELETED M T P R Y V G T DELETED P P T P R Y V G T DELETED P .P M T P R Y V G T N DELETED DELETED T P R Y V G T N DELETED DELETED M T P R Y V G T H DELETED P T P R I '■ Y V G T N DELETED! P M T P R I Y V G T N • P IDELETED I T P R I Y V G T N ! P jDELETED M . T P R I Y V G T N { P i P T P R Y V G T N \| P P M T P R H 0 S S DELETED DELETED DELETED T P R H Q S S DELETED DELETED DELETED M T P R H Q S s DELETED DELETED P T P R H Q S s DELETED DELETED P M T P R H Q S s DELETED P DELETED T P R H Q S s DELETED P DELETED M T P R H Q S s DELETED P P T P R H Q S s DELETED P P M T P R H Q S s N DELETED DELETED T P R H Q S s N DELETED DELETED M T P R H Q s s N DELETED P T P R H Q s s N DELETED P M T P R H Q s s N P DELETED T P R H Q s s N P DELETED M T P R H Q s s N P P T P R H Q s s N P P M T P R H Q s T DELETED DELETED DELETED T P R H Q s T DELETED DELETED DELETED M T P R H Q s T DELETED DELETED P T P R H Q s T DELETED DELETED P M T P R H Q s T DELETED P DELETED T P R H Q s T DELETED P DELETED M T P R H Q s T DELETED P P T P R H Q s T DELETED P P M T P R H Q s T N DELETED DELETED T P R H Q s T N DELETED DELETED M 52959 vl/DC ASTRO 13/0 J WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P R H Q S T N DELETED P T P R H Q S T N DELETED P M T P R H Q s T N P DELETED T P R H Q s T N P DELETED M T P R H Q s T N P P T P R H Q s T N P P M T P R H Q G s DELETED DELETED DELETED T P R H Q G s DELETED DELETED DELETED M T P R H Q G s DELETED DELETED P T P R H Q G s DELETED DELETED P M T P R H Q G s DELETED P DELETED T P R H Q G s DELETED P DELETED M T P R H Q G s DELETED P P T P R H Q G s DELETED P P M T P R H Q G s N DELETED DELETED T P R H Q G s N DELETED DELETED M T p i i R H Q G s N DELETED P T p R H Q G S j N DELETED P M~' T p R i I H Q G ; s N P DELETED T p R H Q G s N P DELETED M T p R H Q G s N P P T p R H Q G s N P P M T p R H Q G T DELETED DELETED DELETED T p R H Q G T DELETED DELETED DELETED M T p R H Q G T DELETED DELETED P T p R H Q G T DELETED DELETED P M T p R H 0 G T DELETED P DELETED T p R H Q G T DELETED P DELETED M T p R H Q G T DELETED P P T p R H Q G T DELETED P P M T p R H Q G T N DELETED DELETED T p R H 0 G T N DELETED DELETED M T p R H Q G T N DELETED P T p R H Q G T -N DELETED P M T p R H Q G T N P DELETED T p R H Q G T N P DELETED M T p R H Q G^ T N P P T p R H Q G T N P P M T p R H V S S DELETED DELETED DELETED T p R H V S S DELETED DELETED DELETED M T p R H V S s DELETED DELETED P T p R H V S s DELETED DELETED P M T p R H V S s DELETED P DELETED T p R H V S s DELETED P DELETED M T p R H V S s DELETED P P T p R H V s s DELETED P P M 52959 vi/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P R H V s S N DELETED DELETED T P R H V s S N DELETED DELETED M T P R H V s s N DELETED P T P R H V s s N DELETED P M T P R H V s s N P DELETED T P R H V s s N P DELETED M T P R H V s s N P P T P R H V s s N P P M T P R H V s T DELETED DELETED DELETED T P R H V s T DELETED DELETED DELETED M T P R H V s T DELETED DELETED P T P R H V s T DELETED DELETED P M T P R H V s T DELETED P DELETED T P R H V s T DELETED P DELETED M T P R H V s T DELETED P P T P R H V s T DELETED P P M T P R H VIS T N DELETED DELETED T P R I H V s T N DELETED DELETED M T P R H V s T N DELETED P T P R H V s T N DELETED P M T P R H V s T N P DELETED T P R H V s T N P DELETED M T P R H V s T N P P T P R H V s T N P P M T P R H V G S DELETED DELETED DELETED T P R H V G S DELETED DELETED DELETED M T P R H V G s DELETED DELETED P T P R H V G s DELETED DELETED P M T P R H V G s DELETED P DELETED T P R H V G s DELETED P DELETED M T P R H V G s DELETED P P T P R H V G s DELETED P P M T P R H V G s N DELETED DELETED T P R H V G s N DELETED DELETED M T P R H V G s N DELETED P T P R H V G s N DELETED P M T P R H V G s N P DELETED T P R H V G s N P DELETED M T P R H V G s N P P T P R H V G \| S N P P M T P R H V G T DELETED DELETED DELETED T P R H V G T DELETED DELETED DELETED M T P R H V G T DELETED DELETED P T P R H V G T DELETED DELETED P M T P R H V G T DELETED P DELETED T P R H V G T DELETED P DELETED M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 V V 56 G 91 94 DELETED DELETED 95 DELETED DELETED DELETED DELETED 96 DELETED DELETED DELETED DELETED 107 M M M M Y Y Y _Q_ Q Q Q JL Q Q Q Q Q Q Q ,0-0 Q Q Q Q_ Q Q Q Q Q Q Q Q Q Q .S DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED .DELETED .DELETED .DELETED .DELETED IDELETED DELETED DELETED DELETED N DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED PELETED DELETED DELETED DELETED N DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED M M M M M M M M M M M M M M M M Q DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED DELETED M M M S29S9 vl/OC ASTR 013/01 WO 20 25 29 31 33 49 I 55 \| 56 91 94 95 96 107 T P F S L Y Q I G s DELETED P DELETED T P F S L Y Q G s DELETED P DELETED M T P F s L Y Q G s DELETED P P T P F s L Y Q G s DELETED P P M T P F s L Y Q G s N DELETED DELETED T P F s L Y Q G s N DELETED DELETED M T P F s L Y Q G s N DELETED P T P F s L Y Q G s N DELETED P M T P F s L Y Q G s N P DELETED T P F s L Y Q G s N P DELETED T P F s L Y Q G s N P P T P F s L Y Q G s N P P M T P F s L Y Q G T DELETED DELETED DELETED T P F s L Y Q G T DELETED DELETED DELETED M T P F s L Y Q G T DELETED DELETED P T P F s I Y Q G T DELETED DELETED P M T _PJ__E s L Y Q G T DELETED P DELETED T P F s L Y j Q G T DELETED P DELETED M T P F s L Y Q G T DELETED P P T P F s L Y Q G T DELETED P P M T P F s L Y Q G I T N DELETED DELETED T P F s L Y Q G T N DELETED DELETED M T P F s L Y Q G T N DELETED P T P F s L Y Q G T N DELETED P M T _j P F s L Y Q G T N P DELETED T P F s L Y Q _G__^ T N P DELETED M T P F s L Y Q G I T N P P T P F s L Y Q G ~T I N P P M T P F s L Y y_ S S DELETED DELETED DELETED T P F s L Y _, V S S DELETED DELETED DELETED M T P F s L Y V S s DELETED DELETED P T P F s L Y V S s DELETED DELETED P M T P F s L Y V S s DELETED P DELETED T P F s L Y V S s DELETED P DELETED M T P F s L Y V S s DELETED P P T P F s L Y V s s DELETED P P M T P F s L Y V s s N DELETED DELETED T P F s L Y V s s N DELETED DELETED M T P F s L Y V s s N DELETED P T P F s L Y V s s N DELETED P M T P F s L Y V s s N P DELETED T P F s L Y V s s N P DELETED M T P F s L Y V s s N P P T P F s L Y V s s N P P M T P F s L Y V s T DELETED DELETED DELETED T P F s L Y V s T DELETED DELETED DELETED M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S L Y V s T DELETED DELETED P l T P F S L Y V s T DELETED DELETED P M T P F S L Y V s T DELETED P DELETED I T P F S L Y V s T DELETED P DELETED M T P F s L Y V s T DELETED P P I T P F s L Y V s T DELETED P P M T P F s L Y V s T N DELETED DELETED I T P F s L Y V s T N DELETED DELETED M T P F s L Y V s T N DELETED P i T P F s L Y V s T N DELETED P M T P F s L Y V s T N P DELETED I T P F s L Y V s T N P DELETED M T P F s L Y V s T N P P I T P F s L Y V s T N P P M T P F s L Y V G S DELETED DELETED DELETED I T P F s L Y V G S DELETED DELETED DELETED M T P F s L Y ! V G s DELETED DELETED P I T P F s L Y V G s DELETED DELETED P M T P F s L Y V G s DELETED P DELETED I T P F s L Y V G s DELETED P- DELETED M T P F s L Y 1 V G s DELETED P P I T P F s L Y V G s DELETED P P M T P F s "" L Y V G s N DELETED DELETED I T P F s L Y V G s N DELETED DELETED M T P F s L Y V G s N DELETED P I T P F s L Y 1 V G s N DELETED P M T P F s L Y 1 V G s N P DELETED I T P F s L Y V G s N P DELETED M T P F s L Y V G s N P P I T P F s L Y V G s N P P M T P F s L Y j V G T IDELETED[ DELETED DELETED I T P F s L Y V G T DELETED" DELETED DELETED M T P F s L Y V G T DELETED DELETED P I T P F s L Y V G T DELETED DELETED P M T P F s L Y V G T DELETED P DELETED I T P F s L Y J V G T DELETED P DELETED M T P F s L . Y V G T DELETED P P I T P F s L Y V G T DELETED P P M T P F s L Y V G T N DELETED DELETED I T P F s L Y V G T N DELETED DELETED M T P F s L Y V G T N DELETED P I T P F s L Y V G T N DELETED P M T P F s L Y V G T N P DELETED I T P F s L Y V G T N P DELETED M T P F s L Y V G T N P P I T P F S I L Y V G I J N p I p j M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S L H 0 S S DELETED DELETED DELETED T P F S L H Q S S DELETED DELETED DELETED M T P F s L H Q S S DELETED DELETED P T P F s L H Q S S DELETED DELETED P M T P F s L H Q S S DELETED P DELETED T P F s L H Q S S DELETED P DELETED M T P F s L H Q S S DELETED P P T P F s L H Q S S DELETED P P M T P F s L H Q S S N DELETED DELETED T P F s L H Q S S N DELETED DELETED M T P F s L H Q S S N DELETED P T . P F s L H Q S S N DELETED P M T P F s L H Q S S N P DELETED T P F s L H Q S S N P DELETED M T P F s L H Q s s N P P T P F s L H Q s s N P P __M_ T P F S i L H Q s T DELETED DELETED DELETED T P F s L H Q s T DELETED DELETEDIDELETED M T P F s L H Q s T DELETED DELETED P T P F s L H Q s T DELETED DELETED P M T P F s L H Q s T DELETED P DELETED T P F s L H Q s T DELETED P DELETED M T P F s L H Q s T DELETED P P T P F s L H Q s T DELETED P P M T P F s L H Q s T N DELETED DELETED T P F s L H Q s T N DELETED DELETED M T P F s L H Q s T N DELETED P T P F s L H Q s T N DELETED P M T P F s L H Q s T N P DELETED T P F s L H Q s T N P DELETED M T P F s L H Q S ! T N P P T P F s L H Q s T N P P M T P F s L H Q G S DELETED DELETED DELETED T P F s L H Q G S DELETED DELETED DELETED M T P F s L H Q G s DELETED DELETED P T P F s L H Q G s DELETED DELETED P M T P F s L H Q G s DELETED P DELETED T P F s L H Q G s DELETED P DELETED M T P F s L H Q G s- DELETED P P T P F s L H Q G s DELETED P P M T P F s L H Q G s N DELETED DELETED T P F s L H Q G s N DELETED DELETED M T P F s L H Q G s N DELETED P T P F s L H Q G s N DELETED P M T P F s L H Q G s N P DELETED T P F s L H Q ! G s N P DELETED M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S L H Q G s N P P I T P F S L H Q G s N P P M T P F s L H Q G T DELETED DELETED DELETED T P F s L H Q G T DELETED DELETED DELETED M T P F s L H Q G T DELETED DELETED P T P F s L H Q G T DELETED DELETED P M T P F s L H Q G T DELETED P DELETED T P F s ~i L H Q G T DELETED P DELETED M T P F s L H Q G T DELETED P P T P F s L H Q G T DELETED P P M T P F s L H Q G T N DELETED DELETED T P F s L H Q G T N DELETED DELETED M T P F s L H Q G T N DELETED P T P F s L H Q G T N DELETED P M T P F s I H Q G T N P DELETED T P F s L H Q G T ! N P DELETED M T P F s L H Q G T ; N P P T P F s L H 0 G T N P P M T P F s L H V S S DELETED DELETED DELETED T P F s L H V s S DELETED DELETED DELETED M T P F s L H V s s DELETED DELETED P T P F s L H V s s DELETED DELETED P M T P F s L H V s s DELETED L_ P DELETED T P F s L H V s s DELETED P DELETED M T P F s L H V s s DELETED P P T P F s L H V s s DELETED P P M' T P F s L H V s s N DELETED DELETED T P F s L H V s s N DELETED DELETED M T P F s L H V s s N DELETED P T P F s' L H V s s N DELETED P M T P F s L H V s s N P DELETED T P F s L H V s s N P DELETED M T P F s L H V s s N P P T P F s L H V s s N P P M T P F s L H V s T DELETED DELETED DELETED T P F s L H V s T DELETED DELETED DELETED M T P F s L H V s T DELETED DELETED P T P F s L H V s T DELETED DELETED P M T P F s L H V s T DELETED P DELETED T P F s L H V s T DELETED P DELETED M T P F s L H V s T DELETED P P T P F s L H V s T DELETED P P M T P F s L H V s T N DELETED DELETED T P F s L H V s T N DELETED DELETED M T P F s L H V s T N DELETED P T P F s L H V s T N DELETED P M 52959 v \|/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S L H V S T N P DELETED T P F S L H V S T N P DELETED M T P F s L H V S T N P P T P F s L H V S T N P P M T P F s L H V G S DELETED DELETED DELETED T P F s L H V G S DELETED DELETED DELETED M T P F s L H V G s DELETED DELETED P T P F s L H V G s DELETED DELETED P M T P F s L H V G s DELETED P DELETED T P F s L H V G s DELETED P DELETED M T P F s L H V G s DELETED P P T P F s L H V G s DELETED P P M T P F s L H V G s N DELETED DELETED T P F s L H V G s N DELETED DELETED M T P F s L H V G s N DELETED P T P F s L H V G s N DELETED P M T P F i S L H V G s N P DELETED u_J P F s L H V G s N P DELETED M T P F s L H V G s N P P T P F s L H V G s N P P M T P F s L H V G T DELETED DELETED DELETED T P F s L H V G T DELETED DELETED DELETED M T P F s L H V G T DELETED DELETED P T P F s L H V G T DELETED DELETED P M T P F s ■L H V G T DELETED P DELETED T P F s L H V G T DELETED P DELETED M T P F s L H V G T DELETED P P T P F s L H V G T DELETED P P M T P F s L - H V G T N DELETED DELETEO T P F s L H V G T N DELETED DELETED M T P F s L H ■ V G T N DELETED P T P F s. L H V G T N DELETED P M T P F s L H V G T N P DELETED T P F s L H V G T N P DELETED M T P F s L H V G T N P P T P F s L H V G T N P P M T P F s Y Q S S DELETED DELETED DELETED T P F s Y Q S S DELETED DELETED DELETED M T P F s Y Q s s DELETED DELETED P T P F s Y Q s s DELETED DELETED P M- T P F s Y Q s s DELETED P DELETED T P F s Y Q s s DELETED P DELETED M T P F s Y Q s s DELETED P P T P F s Y Q s s DELETED P P M T P F s Y Q s s N DELETED DELETED T P F s Y Q s s N DELETED DELETED M 52959 vWDC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S Y Q S S N DELETED P I T P F s Y Q S S N DELETED P M T P F s Y Q s s N P DELETED I T P F s Y Q s s N P DELETED M T P F s Y Q s s N P P I T P F s Y Q s s N P P M T P F s Y Q s T DELETED DELETED DELETED I T P F s Y Q s T DELETED DELETED DELETED M T P F s Y Q s T DELETED DELETED P I T P F s Y Q s T DELETED DELETED P M T P F S i Y Q S 1 T DELETED P DELETED: r T P F s Y Q s T DELETED P DELETED M T P F s Y Q s T DELETED P P I T P F s Y Q s T DELETED P P M T P F s Y- Q s T N DELETED DELETED I T P F s Y Q s T N DELETED DELETED M T ; p F s Y Q s T N DELETED P I T \| P F s 1 Y Q s T N DELETED P M T P F s Y Q S T t~ N P DELETED i T P F s Y Q s T L N P DELETED M T P F s Y Q s T N ■P P I T P F s Y Q s T N P P M T P F s Y Q G S DELETED DELETED DELETED I T P F s Y Q G S DELETED DELETED DELETED M T P F s Y Q G s [DELETED DELETED P I T P F s Y Q G s DELETED DELETED P M T P F s ■ 1 Y Q G s DELETED P DELETED I T P F s Y Q G s DELETED P DELETED M T P F s Y Q G s DELETED P P I T P F s Y Q G s DELETED P P M T P F s Y Q G s N DELETED DELETED I T P F s Y Q G s N DELETED DELETED M T P F s Y Q G i S N DELETED P I T P F s Y Q G I S N DELETED P M T P F s Y Q G s N P DELETED I T P F s Y Q G s L N P DELETED M T P F s Y Q G s N P P I T P F s Y Q G s N P P M T P F s Y Q G T DELETED DELETED DELETED I T P F s 1 Y Q G T DELETED DELETED DELETED M T P F s Y Q G T DELETED DELETED P I T P F s Y Q G ■ T DELETED DELETED P M T P F s Y 0 G T DELETED P DELETED I T P F s Y Q G T DELETED P DELETED M T P F s Y Q G ■ T DELETED P P \| I T P. F s Y Q G T DELETED P P \| M 52959 vi/DC ASTR013/0i WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S Y Q G T N DELETED DELETED T P F s Y Q G T N DELETED DELETED M T P F s Y Q G T N DELETED P T P F s Y Q G T N DELETED P M T P F s Y 0 G T N P DELETED T P F s Y Q G T N P DELETED M T P F s Y Q G T N P P T P F s Y Q G T N P P M T P F s Y V S S DELETED DELETED DELETED T P F s Y V S S DELETED DELETED DELETED M T P F s Y V S s DELETED DELETED P T P F s Y V s s DELETED DELETED P M T P F s Y V s s DELETED P DELETED T P F s Y V s s DELETED P DELETED M T P F s Y v ! s s DELETED P P T P F s Y v ! s 3 DELETED N P P M T P F s V V s S DELETED DELETED T P F S i I Y V s ! s N DELETED DELETED M T P F s i i Y V s S N DELETED P T P F s Y V s S N DELETED P M T P F s Y V s S N P DELETED T P F s Y V s S N P DELETED M T P F s Y V s s N P P T P F s Y V s s N P P M T P F s Y V s T DELETED DELETED DELETED T P F s Y V s T DELETED DELETED DELETED M T P F s Y V s T DELETED DELETED P T P F s Y V s T DELETED DELETED P M T P F " s Y V s T DELETED P DELETED T P F s Y V s T DELETED P DELETED M T P F s Y V s T DELETED P P T P F s Y V s T DELETED P P M T P F s Y V s T N DELETED DELETED T P F s Y V s T N DELETED DELETED M T P F s Y V s T N DELETED P T P F s Y V * s T N DELETED P M T P F s Y V s T N P DELETED T P F ' s Y V s T N P DELETED M T P F s Y V s T N P P T P F s Y V s T N P P M T P F s Y V G S DELETED DELETED DELETED T P F s Y V G S DELETED DELETED DELETED M T P F s Y V G s DELETED DELETED P T P F s Y V G s DELETED DELETED P M T P F s Y V G s DELETED P DELETED T P F s Y V G s DELETED P DELETED M 52959 vI/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S Y V G s DELETED P P T P F S 1 Y V G s DELETED P P M T P F s Y V G s N DELETED DELETED T P F s Y V G s N DELETED DELETED M T" P F s Y V G s N DELETED P T P F s Y V G s N DELETED P M T P F s Y V G s N P DELETED T P F s Y V G s N P DELETED M T P F s Y V G s N P P T P F s Y V G s N P P M T P F s Y V G T DELETED DELETED DELETED T P F s Y V G T DELETED DELETED DELETED M T P F s Y V G T DELETED DELETED P T P F s Y V G T DELETED DELETED P M T P F s Y V G T DELETED P DELETED T P F s Y V G T DELETED P DELETED M ! T P F ' s Y V G ; T DELETED P ___ P P T P F S I Y V G j T DELETED P M T P F S j ! Y V G T N DELETED DELETED T P F s Y V G T N DELETED DELETED M T P F s Y ' V G T N DELETED P T P F s Y V G T N DELETED P M T P F s Y V G T N P DELETED T P F s Y V G T N P DELETED M T P F s Y V G T N P P T P F s Y V G T N P P M T P F s H Q S S DELETED DELETED DELETED T P F s H Q S S DELETED DELETED DELETED M T P F s H Q S S DELETED DELETED P T P F s H Q s S DELETED DELETED P M T P F s H Q s S DELETED P ^ DELETED T P F s H Q s S DELETED P DELETED M T P F s H Q s S DELETED P P T P F s H Q s S DELETED P P M T P F s H Q s s N DELETED DELETED T P F s H Q s s N DELETED DELETED M T P F s H Q s s N DELETED P T P F s H Q s s N DELETED P M T P F s H Q s s N P DELETED T P F s H Q s s N P DELETED M T P F s H Q s s N P P I T P F s H Q s s N P P M T P F s t i H Q s T DELETED DELETED DELETED T P F s 1 ! H Q s T DELETED DELETED DELETED M T P F s i i H Q s T DELETED DELETED P T P F s 1 1 H Q s T DELETED DELETED! P M 52939 v\|/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S H Q S T DELETED P DELETED T P F s H Q S T DELETED P DELETED M T P F s I I H Q S T DELETED P P T P F s I ! H Q S T DELETED P P M T P F s I ! H Q S T N DELETED DELETED T P F s H Q S T N DELETED DELETED M T P F s H Q S T N DELETED P T P F s H Q S T N DELETED P M T P F s H Q S T N P DELETED -T P F s H Q S T N P DELETED M T P F s . H Q s T N P P T P F s H Q s T N P P M T P F s H Q G S DELETED DELETED DELETED T P F s H Q G S DELETED DELETED DELETED M T P F s H Q G S DELETED DELETED P T P F s I l H Q G s DELETED DELETED P M T P F s ! i ; H Q G s DELETED P DELETED T P F s . H Q G s DELETED P DELETED M T ~~' P F s H Q G s DELETED P P T P F s H Q G s DELETED, P P M T P F s H Q G s N DELETED DELETED T P F s H Q G s N DELETED DELETED M T P F s H Q G s N DELETED P T P F s H Q G s N DELETED P M T P F s H Q G s N P DELETED T P F s H Q G s N P DELETED M T P F s H Q G s N P P T P F s H j Q G s N P P M T P F s H Q G T DELETED DELETED DELETED T P F s H 0 G T DELETED DELETED DELETED M T P F s H Q G T DELETED DELETED P T P F s H Q G T DELETED DELETED P M T P F s H Q G T DELETED P DELETED T P F s H Q G T DELETED P DELETED M T P F s H Q G T DELETED P P T P F s H Q G T DELETED P P M T P F s H Q G T N DELETED DELETED T P F s H Q G T N DELETED DELETED M T P F s H Q G T N DELETED P T P F s H Q G T N DELETED P M T P F s j H 0 G T N P DELETED T P F s H Q G T N P DELETED M T P F s H Q G T N P P T P F s H Q G T N P P M T P F s H V S S DELETED DELETED DELETED ! T P F s H V S s DELETED DELETED DELETED M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S H V s S DELETED DELETED P T P F S H V s S DELETED DELETED P M T P F s H V s S DELETED P DELETED T P F s H V ■ S S DELETED P DELETED M T P F s H V s S DELETED P P T P F s H V s s DELETED P P M T P F s H V s s N DELETED DELETED T P F s H V s s N DELETED DELETED M T P F s H V s s N DELETED P T . P F s H V s s N DELETED P M T P F s H V s s N " P DELETED T P F s H V s r s N P DELETED M T P F s H V s s N P P T P F s H V s s N P P M T P F s H V s T DELETED DELETED DELETED T P F ^JE^ H V s T DELETED DELETED DELETED M T P F F ^_s H V \| S T DELETED DELETED P T P S i H V I S T DELETED DELETED P DELETED M T P F L s H V S T DELETED P T P F s H V s T DELETED P DELETED M T P F s H V s T DELETED P P T P F s H V s T DELETED P P M T P F s H V s T N DELETED DELETED T P F s H V s T N DELETED DELETED M T P F s H V s T N DELETED P T P F s H V s T N DELETED P M T P F s H V s T N P DELETED T P F s H V - s T N P DELETED M T P F s H V s T N P P T P F s H V s T N P P M T P F s H V G S DELETED DELETED DELETED T P F s H V G S DELETED DELETED DELETED M T P F s H V G s DELETED DELETED P T P F s H V G s DELETED DELETED P M T P F s H V G s DELETED P DELETED T P F s H V G s DELETED P DELETED M T P F s H V G s DELETED P P T P F s H V G s DELETED P P M T P F s H V G s N DELETED DELETED T P F s H V G s N DELETED DELETED M T P F s H V G s N DELETED P T P F s H V G s N DELETED P M T P F s H V G s N P DELETED T P F s H V G s N P DELETED M T P F s H V G s N P P T P F s H V G s N P P M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F S H V G T DELETED DELETED DELETED T P F S H r v G T DELETED DELETED DELETED M T P F s H V G T DELETED DELETED P T P F s H V G T DELETED DELETED P M T P F s H V G T DELETED P DELETED T P F s H V G T DELETED P DELETED M T P F s H V G T DELETED P P T P F s H V G T DELETED P P M T P F s H V G T N DELETED DELETED T P F s H V G T N DELETED DELETED M T P F s. H V G T N DELETED P T P F s H V G T N DELETED P M T P F s H V G T N P DELETED T P F s H V G T N P DELETED M T P F s H V G T N P P T P F s H V G r r N P P M T P F R L Y Q S s DELETED DELETED DELETED M—I T P F R L Y 0 S s DELETED DELETED DELETED T P F R L Y Q S s DELETED DELETED P T P F R L Y Q S s DELETED DELETED P M T P F R L Y Q s s DELETED P DELETED T P F R L Y Q s s DELETED P DELETED M T P F R L Y Q s s DELETED P P T P F R L Y Q s s DELETED P P M T P F R L Y Q s s N DELETED DELETED T P F R L Y Q s s N DELETED DELETED M T P F R L Y Q s s N DELETED P T P F R L Y Q s s N DELETED P M T P F R L Y Q s s N P DELETED T P F R L Y Q s s N P DELETED M T P F R L Y Q s s N P P T P F R L Y Q s s N P P M T P F R L Y Q s T DELETED DELETED DELETED T P F R L Y Q s T DELETED DELETED DELETED M T P F R L Y Q s T DELETED DELETED P T P F R L Y Q s T DELETED DELETED P M T P F R L Y Q s r DELETED P DELETED T P F- R L Y Q s T DELETED P DELETED M T P F R L Y Q s T DELETED P P T P F R L Y Q s T DELETED P P M T P F R L Y Q s T N DELETED DELETED T P F R L Y Q s T N DELETED DELETED M T P F R L Y Q s T N DELETED P T P F R L Y Q s T N DELETED P M T P F R L Y Q s T N P DELETED T P F R L Y Q s T N P DELETED M 52959* I'DC ASTRO 13/0i WO 20 25 29 31 33 49 55 56 91 94 95 i 96 107 I T P F R L Y Q S T N P P • i T P F R L Y Q S T N P P M T P F R L Y Q G S DELETED DELETED DELETED T P F R L Y Q G S [DELETED DELETED DELETED M T P F R L Y Q G s [DELETED DELETED P T P F R L Y Q G s DELETED DELETED P M T P F R L Y Q G s DELETED P DELETED T P F R L Y Q G s DELETED P DELETED M T P F R L Y Q G s DELETED P P T P F R L Y Q G s DELETED P P M T P F R L Y 0. G s N DELETED DELETED T P F R L Y Q G s N DELETED DELETED M T P F R L Y Q G s N DELETED P T P F R L Y Q G s N DELETED P M T P F R L Y Q G \| S N P DELETED T P F R L ! Y Q G ! S N P DELETED M T P F R L Y Q G s N P P I T P F R L Y Q G s ' N P P M T P F R L Y Q G T 'DELETED DELETED DELETED T P F R L Y Q G T DELETED DELETED DELETED M T P F R L Y Q G T DELETED DELETED P T P F R L Y Q G T DELETED DELETED P M T P F R L Y Q G T DELETED P DELETED T P F R L Y Q G T DELETED P DELETED M T P F R L Y Q G T [DELETED P P T P F R L Y Q G T DELETED P P M T P F R L Y Q G T N DELETED DELETED T P F R L Y Q G T N DELETED DELETED M T P F R CI Y Q G T N DELETED P T P F R L Y Q G T N DELETED P M T P F R L Y 0 G T r N P DELETED T P F R L ^ Y Q G T N P DELETED M T P F R L Y Q G T N P P T P F R L Y Q G T N P P M T P F R L Y V S S DELETED DELETED DELETED T P F R L Y V S S DELETED DELETED DELETED M T P F R L Y V S s DELETED DELETED P : T P F R L Y V s s DELETED DELETED P M T P F R L Y V s s DELETED P DELETED T P F R L Y V s s DELETED P DELETED M T P F R L Y V s s DELETED P P T P F R L Y V s s DELETED P P M T P F R L Y V s s N DELETED DELETED T P F R L _, Y V s s N DELETED DELETED M T P F R L Y V s s N DELETED P T P F R L Y V s s N DELETED P M 5259 v!/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F R L Y V s S N P DELETED T P F R L Y V s S N P DELETED M T P F R L Y V s s N P P T P F R L Y V s s N P P M T P F R L Y V s T DELETED DELETED DELETED T P F R L Y V s T DELETED DELETED DELETED M T P F R I Y V s T DELETED DELETED P T P F R L Y V s T DELETED DELETED P M T P F R L Y V s T DELETED P DELETED T P F R L Y V s T DELETED P DELETED M T P F R L Y V s T DELETED P P T P F R L Y V s T DELETED P P M T P F R L Y V s T N DELETED DELETED T P F R L Y V s T N DELETED DELETED M T P F R L Y V s T N DELETED P T P F R L Y V s T N DELETED P M T P F R L : Y i v s T N P DELETED ■ T P F R L Y v , s T N I P DELETED M T P F R L Y V s I N P P T P F R L Y V s T N P P M T P F R L Y V , G S DELETED DELETED DELETED T P F R L Y V G S DELETED DELETED DELETED M T P F R L Y V G s DELETED DELETED P T P F R L Y V G ! S DELETED DELETED P M T P F R L Y V G s DELETED P DELETED I T P F R L Y V G s DELETED P DELETED M T P F R L Y V G s DELETED P P T P F R L Y V G s DELETED P P M T P F R L Y V G s N DELETED DELETED T P F - R L Y V G s N DELETED DELETED M T P F R L Y V G s N DELETED P T P F R L Y V G s N DELETED P M T P F R L Y V G s N P DELETED T P F R L Y V G s N P DELETED M T P F R L Y V G s N P P T P F R L Y V G s N P P M T P F R L Y V G T DELETED DELETED DELETED T P F R L Y 1 V G T DELETED DELETED DELETED M T P F R L Y V G T DELETED DELETED . P T P F R L Y V G T DELETED DELETED P M T P F R L Y V G T DELETED P DELETED T P F R L Y V G T DELETED P DELETED M T P F R L Y V G T DELETED P P T P F R L Y V G T DELETED P P M T P F R L Y V G T N DELETED DELETED T P F R L Y V i G T N DELETED DELETED M 52WV1/DC J0/1GS6ZS Vi d d 0313130 s 9 D H 1 u d d 1 d d 0313130 s 9 0 H 1 a d d 1 w aai3i3a d 0313130 s 9 0 H 1 d d d 1 0313130 d 0313130 s 9 0 H 1 a d d 1 w d O313130 0313130 s 9 0 H 1 H d d 1 d 0313130] 0313130 s 0 D H 1 d d d 1 w 0313130 0313130 0313130 s 9 0 H 1 y d d 1 0313130 0313130 0313130 s 9 0 H 1 y d d 1 w d d N 1 S 0 H 1 M d d 1 d d N 1 S D H 1 y d d 1 w 0313130 d N I s 0 H 1 -a d d 1 0313130 d N 1 s 0 H 1 H d d 1 IAI d 0313130 N 1 s 0 H 1 X d d X d 0313130 N - 1 s D H 1 y d d 1 w 0313130 031313Q N 1 s 0 H 1 d d 1 0313130 0313130 N 1 s D H 1 y d d 1 w d d 0313130 1 s 0 H 1 y d d I d d 0313130 1 s 0 H . 1 y d d 1 !A) 0313130 d 0313130 1 s 0 H 1 y d d 1 0313130 d 0313130 1 s 0 H 1 H d d 1 w d 0313130 0313130 1 s 0 H 1 y d d 1 d 0313130 0313130 1 s 0 H 1 y d d 1 w 0313130 0313130 0313130 1 s D H 1 y d d 1 0313130 0313130 0313130 1 s 0 H 1 y d d 1 w d d N s s 0 H 1 a d d 1 d d N s s 0 H 1 y d d I w 0313130 d N s s 0 H 1 y d d 1 0313130 d N s s 0 H ! 1 y d d 1 L IA( d 03131301 N S s 0 H ; 1 y d d 1 d 0313130 N s s 0 H 1 y d d x w 0313130 0313130 N s s o , H 1 y d d 1 0313130 0313130 N s s 0 H 1 y d d 1 w d d 0313130 s s 0 H 1 y d d 1 d d 0313130 s s 0 H 1 y d d 1 IN Q31313Q d 0313130 s s D H 1 y d d 1 0313130 d 0313130 s S- D H 1 y d d 1 w d 0313130 0313130 s s 0 H 1 a J d 1 d 0313130 0313130 s s 0 H 1 y d d 1 VM 0313130 0313130 0313130 s s 0 H 1 y d d 1 0313130 0313130 0313130 s s D H 1 a d d 1 W d d N 1 9 A A 1 y d d 1 d d N 1 9 A A 1 a d d 1 W 0313130 d N i 9 1 A A 1 y d d 1 0313130 d N 1 9 A A 1 a d d 1 W d 0313130 N 1 9 A A 1 a d d 1 d 0313130 N 1 9 A A 1 a d d 1 i.Ot 96 96 re 1-6 99 95 6fr es l-£ 6Z SZ 02 OMlO/UOtfJLSV ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F R L H Q G s N DELETED DELETED I T P F R L H a G s N DELETED DELETEO M T P F R L H Q G s N DELETED P I T P F R L H Q G s N DELETED P M T P F R L H Q G s N P DELETED I T P F R L H Q G s N P DELETED M T P F R L H Q G s N P P I T P F R L H Q G s N P P M T P F R L H Q G T DELETED DELETED DELETED I T P F R L H Q G T DELETED DELETED DELETED M T P F R L H Q G T DELETED DELETED P I T P F R L H Q G T DELETED DELETED P M T P F R L H Q G T DELETED P DELETED ! T P F R I H Q G T DELETED P DELETED M T P F R L H Q G T DELETED P P I i T P F R L H Q G T DELETED P P M T P F R ; L H Q G : T N DELETED DELETED I T P F R L H Q i G T N DELETED DELETED r" M T P F R L H Q G T N ■ DELETED P i T P F R L H Q G T N . DELETED P M T P F R L H 0 G T N P DELETED [ T P F R L H Q G T N P DELETED M T P F R L H Q G T ■ N P P I T P F R L H Q G T N P P M T P F R L H V S S DELETED DELETED DELETED I T P F R L H V S S DELETED DELETED DELETED M T P F R L H V s s DELETED DELETED P I T P F R L H v ; s s DELETED DELETED P M T P F R I H V s s DELETED P DELETED I T P F R L H V s s DELETED P DELETED M T P F R L H V s s DELETED P P I T P F R L H V s s DELETED P P M T P F R L H V s s N DELETED DELETED I T P F R L H V s s N DELETED DELETED M T P F R L H V s s N DELETED P I T P F R L H V s s N DELETED P M T P F R L H V s s N P DELETED I T P F R L H V s s N P DELETED M T P F R L H V s s N P P 1 T P F R L H V s s N P P M T P F R L H V s T DELETED DELETED DELETED 1 T P F R I H V s T DELETED DELETED DELETED M T P F R L H V s T DELETED DELETED P 1 T P F R L H V s T DELETED DELETED P M T P F R L H V s T DELETED P DELETED 1 T P F R L H V s T DELETED P DELETED M 52959 v I /DC ASTR 013/0] WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F R L H V s T DELETED P P T P F R L H V s T DELETED P P M T P F R L H V s T N DELETED DELETED T P F R L H V s T N DELETED DELETED M T P F R L H V s T i N DELETED P T P F R L H V s T N DELETED P M T P F R L I H V s T N P DELETED T P F R L H V s T N P DELETED M ! T P F R L H 1 V s T N P P i I T P F ■ R L H V s T N P P M T P F R L H V G S DELETED DELETED DELETED T P F R L H V G S DELETED DELETED DELETED M T P j F R L H V G s DELETED DELETED P T P F R L H V G s DELETED DELETED P M T P F R L H V G s DELETED P DELETED T P F R L H V r G s DELETED P DELETED M T P F ! R L H V G s DELETED P P T P F R L H V G s DELETED P P M T P F R L H V G s N DELETED DELETED T P F R L H V G s N DELETED DELETED M T P F R L H V G s N DELETED P T P F R L H V G s N DELETED P M T P F R L H V G s N P DELETED T P F R L H V G s N P DELETED M T P F R L H V G s N P P T P F R L H V G S i N P P M T P F R L H V G T DELETED DELETED DELETED T P F R L H V G T DELETED DELETED DELETED M T P F R L H V G T DELETED DELETED P T P F R L H v G T DELETED DELETED P M T P F R L H V G T DELETED P DELETED T P F R L H V G T DELETED P DELETED M T P F R L H V G T DELETED P P T P F R L H V G T DELETED P P M T P F R L H V G T N DELETED DELETED T P F R L H V G T N DELETED DELETED M T P F R L H V G T N DELETED P T P F R L H V G T N DELETED P - M T P F R L H V G T N P DELETED T P F R L H V G T N P DELETED M T P F R L H V G T N P P T P F R L H V G T N P P M T P F R I Y Q S S DELETED DELETED DELETED T P F R I Y Q S S DELETED DELETED DELETED M T P F R ! Y Q S s DELETED DELETED P T P F R I Y Q S s DELETED DELETED P M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F R Y Q S S DELETED P DELETED T P F R Y Q s S DELETED P DELETED M T P F R Y Q s S DELETED P P T P F R Y Q s S DELETED P P M T P F R Y Q s S N DELETED DELETED T P F R Y Q s S N DELETED DELETED M T P F R Y Q s S N DELETED P T P F R Y Q s S N DELETED P M T P F R Y Q s S N i p DELETED T P F R Y Q s S N P DELETED M T P F R Y Q s S N P P T P F R Y Q s S N P P M T P F R Y Q s T DELETED DELETED DELETED T P ' F R Y Q s T DELETED DELETED DELETED M T P F R Y Q s T DELETED DELETED P T ■P F R Y Q s T DELETED DELETED P M T P ! F R Y Q s T DELETED P DELETED T P F ! R Y Q s T DELETED P DELETED M T P F R Y Q s T DELETED P P T P F R Y Q s T DELETED P P M T P F R Y Q s T N ■ DELETED DELETED T P F R Y Q s T N DELETED DELETED M T P F R Y Q s T N DELETED P T P F R Y Q s T N DELETED P M T P F R Y Q s T N P DELETED T P F R Y Q s T N P DELETED M T P F R Y Q s T N P P T P F R Y Q s T N P P M T P F R Y Q G S DELETED DELETED DELETED T P F R Y ! Q G s DELETED DELETED DELETED M T P F R Y Q G s DELETED DELETED P T P F R Y Q G s DELETED DELETED P M T P F R Y Q G s DELETED P DELETED T P F R Y Q G s DELETED P DELETED M T P F R Y Q G s DELETED P P T P F R Y Q G s DELETED P P M T P F R Y Q G s N DELETED DELETED T P F R Y Q G s N DELETED DELETED M T P F R Y Q G s N DELETED P T ■ P F R Y Q G s N DELETED P M T P F R Y Q G s N P DELETED i T P F R Y Q G s I N P DELETED M T P F R Y Q G s N P P T P F R Y Q G s N P P M T P F R Y Q G T DELETED DELETED DELETED T P F R Y Q G T DELETED DELETED DELETED M S2Q59 vi/OC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 I 95 96 107 T P F R Y Q G T DELETEDIDELETED P T P F R Y Q G T DELETED DELETED P M T P F R Y Q G T DELETED P DELETED T P F R Y Q G T DELETED P DELETED M T P F R Y Q G T DELETED P P T P F R Y Q G T DELETED P P M T P F R Y Q G T N DELETED DELETED T P F R Y Q G T N DELETED DELETED M T P F R Y Q G T N DELETED P T P F R Y Q G T N DELETED P M T P F R Y. Q G T N P DELETED T P F R Y Q G T N P DELETED M T P F R Y Q G T N P P T P F R Y Q G T N P P M T P F R Y V S i S DELETED DELETED DELETED ! T P F R Y V S \| S DELETED DELETED DELETED M : T P F R I : Y V S ! S DELETED DELETED P T P F R I Y V s S DELETED DELETED P M T P F R Y V s S DELETED P DELETED T P F R Y V s s DELETED P DELETED M T P F R Y V s s DELETED P P T P F R Y V s s DELETED P P M T P F R Y V s s N DELETED' DELETED T P F R Y V s s N DELETED DELETED M T P F R Y V s s N DELETED P T P F R Y V s s N DELETED P M T P F R Y V s s N P DELETED T P F R Y V s s N P DELETED M T P F R Y V s s N P P T P F R Y V s s N P P M T P F R Y V s T DELETED DELETED DELETED T P F R Y V s T DELETED DELETED DELETED M T P F R Y V S I T DELETED DELETED P T P F R Y V s T DELETED DELETED P M T P F R ■Y V s T DELETED P DELETED T P F R Y V s T DELETED P DELETED M T P F R Y V s T DELETED P P T P P F R Y V s T DELETED P P M T P F R Y V s T N DELETED DELETED T P F R Y V s T r^ir- DELETED DELETED M T P F R Y V s T N DELETED P T P F R Y V s T N DELETED P M T P F R Y V s T N P DELETED T P F R Y V s T N P DELETED M T P F R Y v i s T N P P T P F R Y v i s T N P P M 52959 vt/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F R Y V G s DELETED DELETED DELETED T P F R Y V G s DELETED DELETED DELETED M T P F R Y . V G s DELETED DELETED P T P F R Y V G s DELETED DELETED P M T P F R Y V G s DELETED P DELETED T P F R Y V G s DELETED P DELETED M T P F R Y V G s DELETED P P T P F R Y v G s DELETED P P M T P F R Y V G s N DELETED DELETED T P F R Y V G s N DELETED DELETED M T P F R Y V G s N DELETED P T P F R Y V G s N DELETED P M T P F R Y V G s N P DELETED T P F R Y V G s N P DELETED M T P F R Y V G s N P P T P F R I Y V G s N P P M T P F R Y V _y V G G T T DELETED DELETED DELETED1DELETED T P F R I i Y DELETED DELETED M T P F R Y G T DELETED DELETED P T P F R Y V G T DELETED DELETED P M ' T P F R Y V G T DELETED P DELETED T P F R Y V G T DELETED P DELETED M T P F R Y V G T DELETED P P T P F R Y V G T DELETED P P M T P F R Y V G T N DELETED DELETED T P F R Y V G T N DELETED DELETED M T P F R Y V G T N DELETED P T P F R Y V G T N DELETED P M T P F R Y V G T N P DELETED T P F R Y V G T N P DELETED M T P F R Y V G T N P P T P F R Y V- G T N P P M T P F R H Q S S DELETED DELETED DELETED T P F R H Q S s DELETED DELETED DELETED M T P F R H Q S s DELETED DELETED P T P F R H Q s s DELETED DELETED P M T P F R H Q s s DELETED P DELETED T P F R H Q s s DELETED P DELETED M T T P F R H Q s s DELETED P . P P F « H Q s s DELETED P P M T P F R H Q s s N DELETED DELETED T P F R H Q s s N DELETED DELETED M T P F R H G s s N DELETED P T P F R H Q s s N DELETED P M T P F R H Q s s N P DELETED T P F R H 0 s s N P DELETED M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T P F R H Q S S- I N P P I T P F R H Q S S N P P M T P F R H Q S T DELETED DELETED DELETED I T P F R H Q S T DELETED DELETED DELETED M T P F R H Q S T DELETED DELETED P I T ,_ P F R H Q S T DELETED DELETED P M T P F R H Q S T DELETED P DELETED I T P F R H Q S T DELETED P DELETED M T P F R H Q S T DELETED P P I T P F R H Q S T DELETED P P M T P F R H Q S T N DELETED DELETED I T P F R H Q s T N DELETED DELETED M T P F R H Q s T N DELETED P I T P F R H Q s T N DELETED P M T P F R H 0 s T N P DELETED I T P F R H Q s T N P DELETED M T P F R ' H Q s i T- N P P I T P F R H Q S T N P P M T P F R H Q G S DELETED DELETED DELETED I T P F R H Q G S DELETED DELETED DELETED M T P F R H Q ; G s DELETED DELETED P I T P F R H Q G s DELETED DELETED P M T P F R H Q G s DELETED P DELETED I T P F R H Q G s DELETED P DELETED M T P F R H Q G s DELETED P P i T P F R H Q G s DELETED P P M T P F R H Q G s N DELETED DELETED I T P F R H Q G s N DELETED DELETED M T P F R H Q G s N DELETED P I T P F R H Q G s N DELETED P M T P F R H Q G s N P DELETED! I T P F R H Q G s N P DELETED! M T P F R H Q G s N P P ! I T P F R H Q G s »N P P M T P F R H Q G T DELETED DELETED DELETED I T P F R H Q G T DELETED DELETED DELETED M T P F R H Q G T DELETED DELETED p I T P F R H Q G T DELETED DELETED p M ' T P F R H Q G T DELETED P DELETED I T P F R H Q G T DELETED P DELETED M T P F R H Q G T DELETED P P I T P F R H Q G T DELETED P P M T P F R H Q G T N - DELETED DELETED I T P F R H Q G T N DELETED DELETED M T \| P ! F R H Q G T N DELETED P I T I P F R H Q G \| T N DELETED P M 52959 vl/QC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 \| 95 96 107 T P F R H Q G T N i P DELETED T P F R H Q G T ' N : P DELETED M T P F R H Q G T ~1 N P P T P F R H Q G T N P P M T P F R H V S S DELETED DELETED DELETED T P F R H V S s DELETED DELETED DELETED M T P F R H V S s DELETED DELETED P T P F R H V S s DELETED DELETED P M T P F R H V S s DELETED P DELETED T P F R H V S s DELETED P DELETED M T P F R H V S s DELETED P P T P F R H V S s DELETED P P M T P F R H V s s N DELETED DELETED T P F R H V s s N DELETED DELETED M T P F R H V s s N DELETED P T P F R H V s s N DELETED P M T P F R H V s s N P DELETED I i T P F R ^ H V s s s N N P DELETED M T P F R H V s P P T P F R H V s s N P P M T P F R H V s T DELETED DELETED DELETED T P F , R H V s T DELETED DELETED DELETED M T P F R H V s T DELETED DELETED P T P F R H V s T DELETED DELETED P M T T P F R H V s T DELETED P jDELETED P F R H V s r T DELETED P IDELETED M T P F R H V s T DELETED P ' P T P F R H V s T DELETED P P M T P F R H V s T N DELETED DELETED T P F R H V s T N DELETED DELETED M T P F R H V s T N DELETED P T P F R H V s T N DELETED P M T P F R H V s T N P DELETED T P F R H V s T N P DELETED M T P F R H V s T N P P T P F R H V ■ s T N P P M T P F R H V G S DELETED DELETED DELETED T P F ■ R H V G s DELETED DELETED DELETED M T P F R H V G s DELETED DELETED P T P F R H V G s DELETED DELETED P M T P F R H V G s DELETED P DELETED T P F R H V G s DELETED P DELETED M T P F R H V G s DELETED P P T P F R H V G s DELETED P P M T P F R H V G s N DELETED DELETED T P F R H V G s N DELETED DELETED M 5295") vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 T p F R H V G s N DELETED P T p F R H V G s N DELETED P M T p F R u_ H V G s N P DELETED T p F R H r v G s N P DELETED M T p F R H V G s N P P T p F R H V G s N P P M T p F R H V G T DELETED DELETED DELETED T p F R H V G T DELETED DELETED DELETED M T p F R H V G T DELETED DELETED P T p F R H V G T DELETED DELETED P M T p F R H V G T DELETED P DELETED T p F R H V G T DELETED P DELETED M T p F R H V G T DELETED P P T p F R H V G T DELETED P P M T p F R H V G T N DELETED DELETED T p F . R H V G T N ~1 DELETED DELETED M T p F R H V G T N DELETED P T p F R H V G T N DELETED P ! M T p F R H V G T N P DELETED I i T p F R H V G T N P DELETED M T p F R H V G T N P P T p F R H V G T N P P M S A S L Y Q S S DELETED DELETED DELETED L S A S L Y 0 S S DELETED DELETED DELETED M S A s L - Y 0 s s DELETED DELETED P s A s L Y Q s s DELETED DELETED P M s A s L Y Q s s DELETED P DELETED s A s L Y Q s s DELETED P DELETED M s A s L Y Q s s DELETED* P P s A s L Y Q s s DELETED P P M s A s L Y Q s s N DELETED DELETED s A s L Y Q s s N DELETED DELETED M s A s L Y Q s s N DELETED P s A s L Y Q s s N DELETED P U s A s L Y Q s s N P DELETED s A s L Y Q s s N P DELETED M s A s L Y Q s s N P P s A s L Y Q s s N P P M s A s L Y Q s T DELETED DELETED DELETED s A s L Y Q s T DELETED DELETED DELETED M s A s L Y Q s T DELETED DELETED P s A s L Y Q s T DELETED DELETED P M s A s L Y Q s T DELETED P DELETED s A s L Y Q s T DELETED P DELETED M s A s L Y Q s T DELETED P P s A s I Y Q s T [DELETED p ; P ! M S29S9vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A S L Y Q S T N DELETED DELETED S A S L Y Q S T N DELETED DELETED M " s A s L Y Q S T N DELETED P s _A__i ._!__ s L Y Q S T N DELETED P M s A s L Y Q s T N P DELETED s A s L Y Q s T N P DELETED M s A s L Y Q s T N P P s A s L Y Q s T N P P M s A s L Y Q G S DELETED DELETED DELETED s A s L Y Q G S DELETED DELETED DELETED M s A s L Y Q G s DELETED DELETED P s A s L Y Q G s DELETED DELETED P M s A s L Y Q G s DELETED P DELETED s A s L Y Q G s DELETED P DELETED M s A s L Y Q G s DELETED P P s A s I Y Q G s DELETED p ! p M s A s ; L Y Q G j S N DELETEDIDELETED s i A s L Y Q G s N DELETED DELETED M S i A s L Y Q G s N DELETED P i I s A s L Y Q G s N DELETED P M s A s L Y Q G S ! N P DELETED s A s L Y Q G s N P DELETED M s . A s L Y Q G s N P P s A s L Y Q G s N P P M s A s L Y Q G T DELETED DELETED DELETED s A s L Y Q G T DELETED DELETED DELETED M s A s L Y Q G T DELETED DELETED P s A s L Y Q G T DELETED DELETED P M s A s L Y Q G T DELETED P DELETED s A s L Y Q G T DELETED P DELETED M s A s L Y Q G T DELETED P P s A s L Y Q G T DELETED P P M s A s L Y Q G T N DELETED DELETED s A s L Y Q G T N DELETED DELETED M s A s L Y Q G T N DELETED P s A s L Y Q G T N DELETED P M s A s L Y Q G T N P DELETED s A s L Y Q G T N P DELETED M s A s L Y Q G T N P P s A s L Y Q G T '" N J P P M s A s L Y V S S JDELETED DELETED DELETED s A s L Y V S S JDELETED DELETED DELETED M s A s L Y V S S DELETED DELETED P s A s L Y V S S DELETED DELETED P M ! s A s L Y V S S DELETED P DELETED ! s A s L Y V S S DELETED P DELETED M 52959 v]/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A S L Y V s S DELETED P P s A S L Y V s s DELETED P P M s A s L Y V s s N DELETED DELETED s A s L Y V s s N DELETED DELETED M s A s L Y V s S j N DELETED! P s A s L Y V s s N DELETED P M s A s L Y V s s N P DELETED s A s L Y V s s N P DELETED M s A s L Y V s s N P P s A s L Y V s s N P P M s A s L Y V s T DELETED DELETED DELETED I s A s L Y V s T DELETED DELETED DELETED M s A s L Y V s T DELETED DELETED P s A s L Y V I S T DELETED DELETED P M s A s L Y V s T DELETED P DELETED s A s L Y V s T DELETED P DELETED M s A s L Y V s T DELETED P P s A s L Y V s T DELETED PPM s A s J L Y V s T ; N DELETEDiDELETED s A s L Y V s T N OELETEO DELETED M s A s L Y V s T N DELETED P s A s L Y V s T N DELETED P M s A s L Y V s T N P DELETED s A s L Y V s T N P DELETED M s A s L Y V s T N P P s A s L Y V s T N P P M s A s L Y V ! G \| S DELETED DELETED DELETED s A s L Y V G S DELETED DELETED DELETED M s A s L Y V G s DELETED DELETED P s A s L Y V G s DELETED DELETED P M s A s L Y V G s DELETED P DELETED s A s I Y V G S DELETED P DELETED M s A s L Y V G S DELETED P ; P s A s L Y V G S DELETED P P M s A s L Y V G s N DELETED DELETED s A s L Y V G s N DELETED DELETED M s A s L Y V G s N DELETED P s A s L Y V G s N DELETED P M s A s L Y V G s N P DELETED s A s L Y V G s N P DELETED M s A s L Y V G s N P P s A s L Y V G I S N P P M s A s L Y V \| G T DELETED DELETED DELETED s A s L Y V G T DELETED DELETED DELETED M s A s L Y V G T DELETED DELETED P s A s L Y V G T DELETED DELETED P M S2959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A S L Y V G T DELETED P DELETED s A S L Y V G T DELETED P DELETED M s A S L Y V G T DELETED P P s A S L Y V G T DELETED P P M s A S L Y V G T N DELETED DELETED s A S L Y V G T N DELETED DELETED M s A S L Y V G T N- DELETED P s A S L Y V G T N DELETED P M s A s L Y V G T N P DELETED s A s L Y V G T N P DELETED M s A s L Y V G T N P P s A s L Y V G T N P P M s A s L H Q S s DELETED DELETED DELETED s A s L H Q S s DELETED DELETED DELETED M s A s L H Q S s DELETED DELETED P s A ■ s L H Q S S iDELETED DELETED P M s A s L H Q s S DELETED P DELETED : s A s L H Q ! S S DELETED P ^DELETED M s A s L H Q SIS DELETED P ■ P s A s L H Q s S iDELETED P P M s A s L H Q s S N DELETED DELETED s A s L H Q S S N DELETED DELETED M s A s L H Q S s N DELETED P s A s L H Q s s N DELETED P M s A s L H 0 s s N P DELETED s A s L H Q s s N P DELETED M s A s L H Q s s N • P P s A s L H Q s s N P P M s A s L H Q s T DELETED DELETED DELETED s A s L H Q s T DELETED DELETED DELETED M s A s L H Q s T DELETED DELETED P s A s L H Q s T DELETED DELETED P M s A s L H 0 S \| T DELETED P DELETED s A s L H Q _, s T DELETED P DELETED M s A s L H Q s T DELETED P P s A s L H Q s T DELETED P P M s A s L H Q s T N DELETED DELETED s A s L H Q s T N DELETED DELETED M s A s L H Q s T- N DELETED P s A s L H Q s T N DELETED P M s A s L H Q s T N P DELETED s A s L H Q s T i N P DELETED M s A s L H Q s T N P P s A s L H Q s T N P P M s A s L H Q G S DELETED DELETED DELETED s A s L H Q G S DELETED DELETED DELETED M SZ'Wvl/DO ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A S L H Q G S DELETED DELETED P I \| s A S L H Q G S DELETED DELETED P M j s A s L H Q G s DELETED P DELETED s A s L H Q G s DELETED P DELETED M s A s L H Q G s DELETED P P s A s L H Q G s DELETED P P M i s A s L H Q G s "1 N DELETED DELETED f I s A s L H Q G s N DELETED DELETED M ! s A s L H Q G s N DELETED P s A s L H Q G s N DELETED P M s A s L H Q G s N P DELETED s A s L H ' Q G s N P DELETED M s A s L H Q G s N P P s A s L H Q G s N P P M s A s L H Q G T DELETED DELETED DELETED s A ' s L H Q G T DELETED DELETED DELETED M s A s L H Q G T DELETED DELETED P s A s L H Q G T DELETED DELETED P M s A s L H Q G T DELETED P DELETED s A s L H Q G T DELETED P DELETED M s A s L H Q G T DELETED P P s A s L H Q G T DELETED P P .M s A s L H Q G T N DELETED DELETED s A s L H Q G T N DELETED DELETED M s A s L H Q G T N DELETED P s A s I H Q G T N DELETED P M s A s L H Q G T "! N P DELETED s A s L H Q G T N P DELETED M s A s L H Q G T N P P s A s L H Q G T N P P M s A s L H V S S DELETED DELETED DELETED s A s L H V S S DELETED DELETED DELETED M s A s L H V S s DELETED DELETED P s A s L H V S s DELETED DELETED P M s A s L H V S s DELETED P DELETED s A s L H V S s DELETED P DELETED M s A s L H V S s DELETED P . P s A s L H V S s DELETED P P M s A s L H V S s N DELETED DELETED s A s L H V S s N DELETED DELETED M s A s L H V S s N DELETED P s A s L H V S s N DELETED P M s A s L H V S s N P DELETED s A s L H V S s N P DELETED M s A s L H V S s N P P s A s L H V S s N P P M 5295'J vf/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 s A S L H V I S T DELETED DELETED DELETED I s A S L H V j S T DELETED DELETED DELETED M s A S L H V S T DELETED DELETED P I s A S_L L H V S T DELETED DELETED P M s A s L H V S T DELETED P DELETED I s A s L H V s T DELETED P DELETED M s A s L H V s T DELETED P P I s A s L H V s T DELETED P P M s A s L H V s T N DELETED DELETED I s A s L H V s T N DELETED DELETED M s A s L H V s T _i N DELETED P I s A s L H V s T N DELETED P M s A s L H V s T N P DELETED I s A s L H V s T N P (DELETED M s A s L H V s T N P i P I s A s L H V s T N ! P ! P M s A s L H V ! G S DELETEDlDELETEDjDELETED ! s A s L ■ H V G S 'DELETED DELETED DELETED M s A sZl L ! H V G S ^DELETED DELETED P I s A s L H V G S DELETED DELETED P M s A s L H V G S DELETED P DELETED I s A s I H V G s DELETED P DELETED M s A s L H V G s DELETED P P I s A j s L J H V G s DELETED P P M s A s L H V G s N DELETED DELETED I s A s L H V G s N DELETED DELETED M s A s L H V G s N DELETED P I s A s L H V G s N DELETED P M s A s L H V G s N P DELETED I s A s L H V G s N P DELETED M s A 1 S 1 L H ■ V ! G s I N P P ' s A s L H V ! G s N P P M s A s L H V ■ G T ^DELETED DELETED DELETED ! s A s L H V I G T DELETED DELETED DELETED M s A s L H V I G T DELETEC DELETEC P I s A s L H V G T DELETEC DELETEC P M s A s L H V G T DELETEC ) P DELETEC ) I s A s L H V G T DELETEE ) P DELETEC ) M s A s L H V G T DELETE: ) P P I s A s L H V G T DELETE: ) P P M s A s L H V G T i N DELETEC )DELETEC ) I s A s L H V G T I N DELETEC )DELETEC ) M s A s L H V G T N DELETEC ) P I I s A s L H V G T N DELETED! P M s A s L ._ H V G T N ! P 'DELETEC 3 s A 1 J S ! L H V G T N P DELETEE D M 52«9 vI/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 T 94 N 95 96 107 S A S L H V G P P s A S L H V G T N P P M s A s Y Q S S DELETED DELETED DELETED s A s Y Q S S DELETED DELETED DELETED M s A s Y Q s s DELETED DELETED P s A s Y Q s s DELETED DELETED P M s A s Y Q s s ■ DELETED P DELETED s A s Y Q s s DELETED P DELETED M s A s Y Q s s DELETED P P s A s Y Q s s DELETED P P M s A s Y Q s s N DELETED DELETED s A s Y Q s s N DELETED DELETED M s A s Y Q s s N DELETED P s A s Y Q s s N DELETED P M s A s Y Q s s N P DELETED s A s Y Q S _\| s N P DELETED M s A S i I j Y Q s __N DELETED P P s A s I ' Y Q \| P P M s A s Y Q T DELETED DELETED s A s Y Q s T DELETED DELETED DELETED M s A s Y Q s T DELETED DELETED P s A s Y Q s T DELETED DELETED P M s A s Y Q s T DELETED P DELETED s A s Y Q s T DELETED P DELETED M s A s Y Q s T DELETED P P s A s Y Q s T DELETED P P M s A s Y Q s T N DELETED DELETED s A s Y Q s ■ T N DELETED DELETED M s A s Y Q s T N DELETED P s A s Y Q s T N DELETED P M s A s Y Q s T N P DELETED s A s Y Q s T N P DELETED M s A s Y Q s T N P P s A s Y Q s T N P P M s A s Y Q G s DELETED DELETED DELETED s A s Y Q G s DELETED DELETED DELETED M s A • s Y Q G s DELETED DELETED P s A s Y Q G s DELETED DELETED P M s A s Y Q G i s DELETED P DELETED s A s Y Q G ! s DELETED P DELETED M S_j A s Y Q G s DELETED DELETED P P s A s Y Q G I s P P M s A s Y Q G : s N DELETED DELETED I s A s Y Q G s N DELETED DELETED M s A s Y Q G s N DELETED P s A s Y Q G s I N DELETED P M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91_ s 94 N 95 96 107 S A S Y Q G P P DELETED S A s Y Q G DELETED M s A s Y Q G s N P P s A s Y Q G s DELETED P P M s A s Y Q G T DELETED DELETED s A s Y Q G T DELETED DELETED DELETED M s A s Y Q G T DELETED DELETED P s A s Y Q G T DELETED DELETED P M s A s Y Q G T DELETED P DELETED s A s Y Q G T DELETED P DELETED M s A s Y Q G T DELETED P P s A s Y Q G T DELETED P P M s A s Y Q G T N DELETED DELETED s A s Y Q G T N DELETED DELETED M s A s Y Q G T N DELETED P s A s Y Q G T N DELETED P M s A I S Y Q G T N_ N P DELETED s A 1 '. S Y Q G G T T P DELETED M s A i : s Y Q N P \| P s A 1 S Y Q G T N P I P M s A s Y V S S DELETED DELETEDiDELETED s A s Y V S S DELETED DELETEDiDELETED M s A s Y V S s DELETED DELETED! P s A s Y V S^ s DELETED DELETED P M s A s Y V s s DELETED P DELETED s A s Y V s s DELETED! P DELETED M s A s Y V s s DELETED! P P s A s Y V s s DELETED P P M s A s Y V s s N DELETED DELETED s A s Y V s s N DELETED DELETED M s A s Y V s s N DELETED P s A s Y V s s N DELETED P M s A s Y V s s N P DELETED s A s Y V s s N ■ P DELETED M s A s Y V s s N P P s A s Y V s s N P P M s A s Y V s T DELETED DELETED DELETED s A s Y V s T DELETED DELETED DELETED M s A s Y V s T DELETED DELETED P s A s Y V s T DELETED DELETED P M s A s Y V s T DELETED P DELETED s A s Y V s T DELETED P DELETED M s A s Y V s T DELETED P P s A s I j Y V s T DELETED N P P M s A s I I Y V V _.__s s T DELETED DELETED s A s I i Y T ..._.. N _ DELETED DELETED M 529S9 vl/IX" ASTR 013/01 WO 20 25 29 31 33 49 55 55 91 94 95 96 107 S A S Y V S T N DELETED P I s A s Y V S T N ' DELETED P M s A s Y V S T N P DELETED s A s Y v 1 S T T N N N P DELETED M s A 1 ' S Y V s P P s A s I Y V s T P P M ,• s A s Y V G S DELETED1DELETED DELETED s A s Y V G S DELETEDIDELETED DELETED M s A s Y V G s DELETED DELETED P s A s Y V G s DELETED DELETED P M s A . s Y V G s DELETED P DELETED s A s Y V G s DELETED P DELETED M s A s Y V G s DELETED P P s A s Y V G s DELETED P P M s A s Y V GH s N DELETED DELETED s A s Y V G s N DELETED DELETED M : S A s Y V G s ' N DELETED P s A s I . Y V G s N jDELETED P M s A s Y V G s N \| P DELETED s A s I i Y V G s N P DELETED M s A s Y V G s N P P s A s Y V G s N P P M s A s Y V G T DELETED DELETED DELETED s A s Y V G T DELETED DELETED DELETED M s A s Y V G .... L DELETED DELETED P s A s Y V G DELETED DELETED P M s A s Y _j V G T DELETED P DELETED s A s Y V G T DELETED P • DELETED M s A s Y V G T DELETED P P s A s Y V G T DELETED P P M s A s Y V G T N DELETED DELETED s A s Y V G T N DELETED DELETED M s A s Y V G T N DELETED P s A s Y V G T N DELETED P M s A s Y V G T N P DELETED s A s Y V G T N P DELETED M s A s Y V G T N P . P s A s Y V G T N P P M s A s H Q S S DELETED DELETED DELETED s A s H Q S S DELETED DELETED DELETED M s A s H Q S s DELETED DELETED P s A s H Q S s DELETED DELETED P M s A s H Q S s DELETED P DELETED s A s H Q s s DELETED P DELETED M s A s H Q s i s DELETED P P s A s H Q s 1 s DELETED P P M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A S H Q S S N DELETED DELETED S A S H Q Fs S N DELETED DELETED M S A s H Q s S N DELETED P S A s H Q__\| s s N DELETED P M s A s H Q s s N ; p DELETED s A s H Q s 1 s N N P DELETED M s A s H Q s s P P s A s H Q s s N P P M s A s H Q s T DELETED DELETED DELETED s A s H 0 s T DELETED DELETED DELETED M s A s H 0 s T DELETED DELETED P s A s H Q s T DELETED DELETED P M s A s H Q s T DELETED P DELETED s A s H Q s T DELETED P DELETED M s A s H Q s T DELETED P P s A s H Q s T DELETED P P M s A s H Q s T T N N DELETED DELETED s A S I H Q s DELETED DELETED M s A s H Q c N BELETED P _l s A s H Q s * T N ;DELETEDj P M s A s H Q s T N P DELETED s A s H Q s T N P DELETED M s A s H Q s T N P P s A s H Q s T N P P M s A s H Q G S DELETED DELETED DELETED s A s H Q G s DELETED DELETED DELETED M s A s H 0 G s DELETED DELETED P s A s H Q G s DELETED DELETED OELETED P M s A s H Q G s P DELETED s A s H Q G s DELETED P DELETED M s A s H Q G s DELETED P P I s A s H Q G s DELETED1 P P M s A s I H 0 G s N 'DELETED DELETED s A s H Q G s N N N DELETED DELETED M s A s H Q G J s DELETED P s A s H Q G s DELETED P M s A s H Q G s N P DELETED s A s H Q G s N P DELETED M s A s H Q G s N P P s A s H Q G s ' N P P M s A s H Q G T DELETED DELETED DELETED s A s H Q G T DELETED DELETED DELETED M s A s H Q G T DELETED DELETED P s A s H Q G T DELETEDIDELETED P M s A s H Q G T DELETED P DELETED s A s H Q G T DELETED P DELETED M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A S H Q G T DELETED P P s A s H Q G T DELETED P P M s A s H Q G T N DELETED DELETED s A s H Q G T N DELETED DELETED M s A ■ s H Q G T N DELETED P s A s H Q G T N DELETED P M s A s H Q G T N P DELETED s A s H Q G T N P DELETED M s A S j I H ■ Q G ! T N P P s A s H Q G T N P P M s A s I H V S s- DELETED DELETED DELETED s A s H V S S DELETED DELETED DELETED M s A s H V s s DELETEDiDELETED P s A s H V s s DELETED DELETED! P M s A , s H V s s DELETED P DELETED s A Ls H __y V s s DELETED DELETED P 'DELETED M s A SSI H S i S P P P S A s H V "s s DELETED P M ! S A s I H V s , s s N DELETED DELETED s A s H V s N DELETED DELETED M s A s H V s s N DELETED P s A s H V s s N DELETED P M s A s H V s s N P DELETED s A s H V s s N P DELETED M s A s H V s s N P P s A s H V s s N P P M s A s H V s T DELETED DELETED DELETED s A s I H V s T DELETED DELETED DELETED M s A s H V c T DELETED DELETED P s A s H V s T DELETED DELETED P M s A s H V s T DELETED P DELETED s A s H V s _J T DELETED P DELETED M s A s H V s T DELETED P P s A s H V s T DELETED P P M s A s H V s i T N DELETED DELETED s A s ' H V s T N DELETED DELETED M s A s H V s T N DELETED P s A s H V s T N DELETED P M s A s H V s T N P DELETED s A s H V s T N P DELETED M s A s H V S ! T N P P s A s H V S I T N P P M s A s H V G S DELETED DELETED DELETED s A s H V u- P S DELETED DELETED DELETED M s A s H V G s DELETED DELETED P s A L s H V G \| S DELETED DELETED P M 52959v l/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A ! i ! s H V _G__ G G s DELETED P DELETED I s A 1 : S I H s DELETED P DELETED M s A 1 \ S H V s DELETED P P I s A S H V [ C3 l s DELETED P P M s A S H V G s N DELETED DELETED I s A s H V G s N DELETED DELETED M s A s H J V G s N DELETED P I s A s H V G s N DELETED P M s A s H V G s N P DELETED t s A s H L_v •G s N P DELETED M s A s H V G s N P P I s A s H V G s N P P- LM s A s H V G T DELETED DELETED DELETED I s A s H V G T DELETED DELETED DELETED M s A s H V G T iDELETED DELETED P I s A s H V G T DELETED DELETED P M s All'S H V V _.. ^. V G _ G G _ G T T DELETED DELETED P DELETED I s A s H P DELETED M s A s H T DELETED P P I s A s H DELETED] P P M s A s H V G G ___G_ G T T T N N DELETED DELETED I s A s H V DELETED DELETED M s A s H , N DELETED P I s A s H V V J__ T N DELETED P M s A s H N P DELETED I s A s H V G T N P DELETED M s A s H V L G_J T N j p P I s A s H V G T N P P M s A R L Y Q S S DELETED DELETED DELETED I s A R L y I G S S j DELETED DELETED DELETED M s A R L Y f~Q S s DELETED DELETED P I s A R L Y Q s s DELETED DELETED P M s A R L Y Q s s DELETED P DELETED I s A R L Y Q s s DELETED P DELETED M s A R L Y Q s s DELETED P P I s A R L Y Q s s DELETED P P M s _, A R L Y Q s s N DELETED DELETED I s A R L Y Q . s s N DELETED DELETED M s A R L Y Q s s . N DELETED P I s A R L Y Q s s N DELETED P M s A R L Y Q s s s N P DELETED I s A R L Y Q s N P DELETED M s A R L Y Q s s N P P t s A R R L Y Q s _s.._. T N P ' P M s A L Y 0 DELETED DELETED DELETED DELETED I s A R L Y G s T DELETED DELETED M 52959 v!,'DC ASTR 013/01 WO 20 25 29 31 _ R 33 49 55 Q - JL .) Q ; 56 s I 9_li 94 "1 TJDELETEO" 95 96 107 S A 1 L Y DELETED P S A 1 ' R Y T DELETED DELETW P M S A R L Y T DELETED P DELETED S A R L Y T DELETED! P P DELETED M s A R L Y s 4 T DELETED P s A R L Y Q s s T DELETED! P P M s A R L Y Q T N DELETED DELETED s A R L Y Q s T N DELETED DELETED M s A R L Y Q s T N DELETED P s A R L Y Q s T N DELETED P M s A R L Y Q s T N P DELETED s A R L Y Q s T N P DELETED M s A R L Y Q s T N P P s A R L Y Q s T N P P M s A R L Y Q G S DELETED1 DELETED DELETED s A R L Y Q G S DELETEDjDELETED DELETED M s A R L L L Y Y Q Q _G_J G G s DELETEDIDELETED P I s A R S _JDELETEDJDELETED P M s A R S DELETED P P DELETED s A R L Y Q S DELETED DELETED DELETED M s A R L Y Q G G S p i P s A R L Y Q s DELETED p DELETED P M s A R L Y Q ~l G "G s N DELETED I s A H L__j Y Q s__] N (DELETED N IDELETED DELETED M s A R L Y Q s P s A R L Y Q G s N DELETED P M s A R ' L Y 0 G n s N P DELETED s. A R L Y Q G s N P DELETED M s A R L Y Q G s N P P s A R L Y Q , G s N P P M s A R L Y i Q G T DELETED DELETED DELETED s A R L Y I 0 G T DELETED DELETED DELETED M s A R L Y Q G T DELETED DELETED P s A R L Y Q G T DELETED DELETED P M s A R L Y Q G T DELETED P DELETED s A R L Y Q G T DELETED P DELETED M s A R L Y Q G T DELETED P P s A R L Y Q G T DELETED P P M s A R L Y Q G T N DELETED DELETED ] s A R L i Y Q _ G G T M DELETED DELETED M s A R L I Y Q T N DELETED P s A R L Y Q G T N [DELETED P M s A R L Y Q G G G T N ! P DELETED s A R R L L I Y I Q ! Q" H- M p DELETED M s I A Y N ■ N i—^—l- p s I A R i L Y I o G L..I . p ■ p M S2951vWDC ASTR 013/01 WO 20 25 29 31 33 49 55 v 56 1 s_ s 91 S 94 95 96 107 S A __R R L _Y_ Y DELETED DELETEDlDELETED I s A s_l DELETED DELETED DELETED M s A R L Y v s s DELETED DELETED P s A R L Y V s ! s DELETED DELETED P M s A R L Y V s s DELETED P DELETED s A . R I Y V s _, s DELETED P DELETED M s A R L Y V s s DELETED P P s A R L Y V s s DELETED P P M s A R L Y V s s N DELETED DELETED s A R L Y V s s N DELETED DELETED M s A R L Y V s s N DELETED P s A R L Y V s s N DELETED P M s A R L Y V s s N P DELETED s A R L Y V s s N P DELETED M s A R L Y V s s N P P s A R L Y V s -I- s N p ! P M s A R L Y__ Y Y Y V V _ V - v- T DELETEDlDELETED DELETED s A 1 _R R R L L L T DELETED DELETEDlDELETED M s A T DELETED DELETED P s A s s T DELETED DELETED! P M s A R L Y T DELETED P JDELETED s A R L Y v s 1 T DELETED p (DELETED M s A R L Y j , V s T DELETED p P s A 1 1 R L Y 1 v n s s T DELETED p P M s A R L Y V T N DELETED DELETED s A R L Y V s T N DELETED DELETED M s A R L Y V s T N DELETED P s A R L Y V s T N DELETED P M s A R L Y V s T N P DELETED s A R L Y V s T N P DELETED M s A R L Y V s T N P P s A R L Y V s T N P P M s A R L Y V G S DELETED DELETED DELETED s A R L Y V G S DELETED DELETED DELETED M s A R L Y V G S DELETED DELETED P s A R L Y V G S DELETED DELETED P M s A R L Y V G S DELETED P DELETED ■ s A R L Y V G S DELETED P DELETED M s A R L Y V G S DELETED P P s A R L Y V G S DELETED P P M s A R L Y V G s N DELETED DELETED I s A R L Y V i G _ ' G i G , G s N DELETED DELETED M s A R L Y V s N DELETED P , s A I i R L Y Y 1 Y y_ V V s s N DELETED P M s A R L N P DELETED I s A R N i P JDELETEDf M 5?.9S9vl/DC ASTR 013/01 WO 20 25 29 31 R 33 49 55 56 91 94 95 96 107 S A L Y V G G s N i P P S A R L Y V s J N P P M S A R j L Y V V G T I DELETED DELETED DELETED S A 1 R L Y G T DELETED DELETED DELETED M S A R L Y V G T DELETED DELETED P S A R L Y V G T DELETED DELETED P M S A R L Y V G T DELETED P DELETED s A R L Y V G T DELETED P DELETED M s A R L Y V G T DELETED P P s A R L Y V G T DELETED P P M s A R L Y V G T N DELETED DELETED s A R L Y V G T N DELETED DELETED M s A R L Y V G T N DELETED P s A R L Y V G T N DELETED P M s A R L Y V G T N P DELETED s A R L Y V G T N P DELETED M L_S A ,_R R L_ L Y Y V IY, Q S T T N P P 3 A 1 N P P M s A R L H S DELETED DELETED DELETED s A L _j H Q S s DELETED DELETED DELETED M s A R R L H 0 s s DELETED DELETED P s A L H Q s s DELETED DELETED P M s A 1 R L 1 H Q j 0 s s DELETED P DELETED s A R L H s s DELETED P DELETED M s A R L H Q s s DELETED P P s A \|R L H Q s s DELETED P P M s A R L H Q s s N DELETED DELETED s A R L H Q s s N DELETED DELETED M s A R L H Q s s N DELETED P s A R L H Q s s N DELETED P M s A R L H Q s s N P DELETED s A R L H 0 s s N P DELETED M s A R L H Q s ■ s N P P s A R L H Q s s N' P P M s A R L H Q s T DELETED DELETED DELETED s A R L H Q s T DELETED DELETED DELETED M s A R L H Q s T DELETED DELETED P s A R . L H 0 s T DELETED DELETED P M s A R L H 0 s T DELETED P DELETED s A R L H 0 s T DELETED P DELETED M s A L H Q s T DELETED P P s A R L H 0 s T DELETED P P M s A R L H o s T N DELETED DELETED s A ' R L H Q s T N DELETED DELETED M s A t R L H Q s s -7 N DELETED P s A ■ 1 R L H 0 T N DELETEDl P M 52959v \|/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 \| 96 107 s A R L H Q s T H N p IDELETED s A R L H Q s T p DELETED M s A R L H Q s T N p P s A R L H a~1 s T N p P L_M "s A R L H Q G S DELETED DELETED DELETED , s A R L H . Q G S DELETED DELETED DELETED M s A R L H Q G s DELETED DELETED P s A R L H Q G s DELETED DELETED P M s A R L H Q G s DELETED P DELETED s A R L H Q G s DELETED P DELETED M s A R L H Q G s DELETED P P s A R L H Q G s DELETED P ~~1 P M s A R L H Q G s N DELETED DELETED s A R I. H G G s N DELETED DELETED M s A R L H Q G s N DELETED P s A R L H Q G s N _j DELETED P M s A L R L L H H G Q ___Q G G .A... G s s N N N P DELETED s A "■' 1 ■-R- f _j R P DELETED M s A L L H P p s A j ___R_ R G s N P P M s A L H Q G T DELETED DELETED DELETED s A I ! R L H Q G T DELETED DELETED DELETED M s A I I R L H Q G T DELETED DELETED P s A R L H Q G T DELETED DELETEDl P M s A R L H Q G T DELETED p DELETED s A R L H Q G T DELETED p DELETED M s A I R_^ L H Q G T DELETED p P s A _i. R L H Q G T DELETED p P M s A R L H Q G T N DELETED DELETED s A R L H Q G _\ T N DELETED DELETED M s A R L H Q G T N DELETED P s A I ! R L H Q G T N DELETED P M s A 1 i R L H Q G T N P DELETED s A R L H Q G T N P DELETED M s A R L H Q G T N P P s A R L. H Q G T N P P M s A R L H V S S DELETED DELETED DELETED s A R L H V s s DELETED DELETED DELETED M s A R L H V s s DELETED DELETED P s A R L H V s s DELETED DELETED P M s A R L Hi V s s DELETED P DELETED s A R L H~1 H V s s DELETED P DELETED M s A R L 1 v s s DELETED P P s A R L H V s s DELETED P P M s A I ; R I H V 1 S s N N DELETED DELETED s A 1 ! R L H V s s DELETED DELETED M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A R L H V V _ s s S N DELETED P s A R L H H Si N DELETED; P M s A R L V s S N i P i DELETED s A R L H V s s N P DELETED ■ M s A R L H V s N P I P s A R L H V s s N P P M s A R L H V s T DELETED DELETED DELETED s A R L H V s T DELETED DELETED DELETED M s A R L H V s T DELETED DELETED P s A R L H V s T DELETED DELETED P M s A R L H V s T DELETED . P DELETED s A R L H V s T DELETED P DELETED M s A R L H V s T DELETED P P s A R L H V s T DELETED P P M s A 1 R L H V V v V J s T N JDELETED DELETED s A R L_ __L L __L L H hi ~:^: H H s s I S T T T N N DELETED DELETED M s A I R DELETED! P M s A 1 R N DELETED P s A ! I R N ' P DELETED s A 1 1 R V rs T N N P DELETED M s A l R L Is T P P s A ' R L H V I s T h N P P M s A R L H V G S DELETED DELETED DELETED s A R L H V G S DELETED DELETED DELETED t M s A R L H V G s DELETED DELETED P s A R L H V G s DELETED DELETEDl P M s A R L H V G s DELETED P '.DELETED s A R L H V G s DELETED P DELETED M s A R L H V G s DELETED P P s A R L H V G s DELETED P P M s A R L H V G s . N DELETED DELETED s A R L ; H V G s N DELETED DELETED M s A R L H V G s N DELETED P s A R L H V G s N DELETED P M s A R L H V G s N P DELETED s A R L H V G s N P DELETED M s A R L H V G s N P P s A R L H V G s N P P M s A R L H V G r~T DELETED DELETED DELETED s A R L H H V G T DELETED DELETED DELETED M s A R L V V G \|_ G G T T DELETED DELETED P s A R i H DELETEDIDELETED P M s A R L T T DELETED DELETED P DELETED s A R L ! H y_ i V ; G I G I P DELETED M s A 1 j R L i H JDELETED (DELETED P P s A .' 1 R „ t- I H i v ' G ! P P M 52959 vl/DC ■ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A R L H H H V V G G T N DELETED DELETED s A R R - L T N DELETED DELETED M s A L V G T N DELETED P s A R L V G T N DELETED P M s A i R L H V G I T N P DELETED s A i R L H V G T N P DELETED M s A R L H V G T H P P s A R L H V G T N P P M s A R Y 0 S S DELETED DELETED DELETED s A R Y Q S S DELETED DELETED DELETED M s A R Y Q S S DELETED DELETED P s A R Y Q s S DELETED DELETED P M s A R Y Q s S DELETED P DELETED s A R Y Q s s DELETED P DELETED M s A R Y 0 s s DELETED P P s A \| R Y _Q _ Q s s '"'s ~ s DELETED P P M s A ' R ! I ■ Y -I— s N DELETED DELETED s A -.— 3.1 —L_ Y N DELETED DELETED M s r^A R Y „3„_ s lid s N DELETED P s A R Y Q DELETED P M s A R Y . Q ,s N P {DELETED s A R Y Q s s N P DELETED M s A R I Y Q s s N P P s A R Y Q s s N P P M s A R Y Q s T DELETED DELETED DELETED s A R Y Q s T DELETED DELETED DELETED M s A I R Y Q s T DELETED DELETED P s A R Y Q s T DELETED DELETED P M s A R Y Q s T DELETED P DELETED s A R Y Q s T DELETED P DELETED M s A R Y Q s T OELETED P P s A R Y Q s T DELETED P P M- s A R Y Q s T N DELETED DELETED s A R Y Q s T N DELETED DELETED M s A R I i Y Q s T N DELETED P s A R Y Q s T N DELETED P M s A R Y Q s T N P DELETED s A R Y Q s T N P DELETED M s A 1 !' R Y Q s T ■ N- P P s A R Y Q s T ' N P P M s A R Y Q G S DELETED DELETED DELETED s A 1 j R . I Y Q __G G s DELETED DELETED DELETED M s A t j R 1 Y Q s DELETED DELETED' P s A Y Q G s DELETEDlDELETED P M s A i ' Y Q G s DELETED p DELETED s A 1 i R Y Q G s DELETED p DELETED M 52959 v! 'DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A R Y Q G s DELETED P P S A R Y Q G s DELETED P P M s A R Y Q G s N DELETED DELETED s A ^ R Y Q G s N DELETED DELETED M s A R Y Q G s N DELETED P s A R Y Q_i G s N DELETED P M s A R Y Q G s N P DELETED s A R Y Q G s N P DELETED M s A R Y Q G s N P P s A R Y Q G s N P P M s A R Y Q G T DELETED DELETED DELETED s A R Y Q G T DELETED DELETED DELETED M s A R Y Q G T DELETED DELETED P s A R Y _Q.__ 0 G T DELETED DELETED P M s 1 A R Y T DELETED P DELETED s A K I I Q_ Q G G~ "~G T DELETED P P p DELETED M _s s A 1 R i I Y T T DELETED DELETED P A 1 ! K ! 1 j Y P M__ s A , R 1 ' Y N OELETEDIDELETED s A R Y Q U G N DELETEDJDELETED M s A R Y Q G T N DELETED! P s A R Y Q G T N DELETED P M s A R Y Q G T N P DELETED s A R Y Q G T N P DELETED M s A R Y Q G T N P P s A R Y Q G T N P P M s A R Y V S S DELETED] DELETED DELETED s A R Y V s s DELETED DELETED DELETED M s A R Y V s s DELETED DELETED P s A R Y V s s DELETED DELETED P M s A R Y V s s DELETED P DELETED s A R Y V s s DELETED P DELETED M s A R Y V s s DELETED P P s A R Y V s s DELETED P P M s A R Y V s s N DELETED DELETED s A R Y Y V s s N DELETED DELETED M s A R I V s s N DELETED P s A R i I Y V s s N DELETED P M s A R i 1 Y , V s s N P DELETED s A 1 R Y v s s N ^_ P DELETED M s A R Y V s s N P P s A R Y V s s N P P M s A 1 1 R Y V s 1 T DELETED DELETED DELETED s A 1 ! R Y V s T DELETED DELETED DELETED M s A i : R Y V s T DELETED DELETED P s A . 1 R Y •"V s T .DELETED .DELETED P M 52959 vl/DC ASTR 013/01 WO 20 25 29 \| 31 33 49 55 56 ] 91 94 95 P 96 107 S A I ! R Y V s T DELETED DELETED I s A ! \| R Y V s T DELETED P DELETED M s A ^J I R Y Y V V s T DELETED P P I s A ^TR S T DELETED P P M s A I rri \| Y V s T N DELETED DELETED I s A I R Y V s T N DELETED DELETED M s A R Y V s T N DELETED P I s A R Y V s T N DELETED P M s A R Y V s T N P DELETED I s A R Y V s T N P DELETED M s A R Y V s T N P P I s A R Y V s T N P P M s A R Y V V V G S DELETED DELETED DELETED I s A R Y 1 G ' G S ^ DELETED DELETED DELETED M s A R Y s DELETED DELETED P I s A R I Y v -v- _y_ V __G __G _ G s DELETED DELETED1! P M s A I R i y s "^ """ s DELETED; P DELETED I s A \| I __J R ] \ [ Y. DELETED P DELETED M s A R \| Y DELETED P P I s A R I"Y s DELETED P P M s A R Y V G s N DELETED DELETED I s A R Y^ V G s N DELETED DELETER M s A R Y V G s N DELETED P I s A R Y V G s N DELETED P M s A R Y V G s N P DELETED t s A R Y V G s N P DELETED M s A R Y V G s N P P I s A R I \| Y V G s N P 1 P M s A R I \| Y V G T DELETED DELETED DELETED I s A R I ! Y V G T DELETED DELETED DELETED M s A R I i Y V 1 G T DELETED DELETED P I s A R i i Y V ! G T DELETED DELETED! P M s A R r TTT~ V G T DELETED: P JDELETED I s A R I \| Y V 1 G T DELETED P DELETED M s A R I ! Y V i G T DELETED P P I s A R Y V G ' T DELETED P P M s A R I j Y V G hh N DELETED DELETED I s A R I Y V G N DELETED DELETED M s A R Y V I G ! T- N DELETED P 1 s A R I l Y V I G i T ' N DELETED P M s A R 1 I Y v ! G ! T N P DELETED 1 s A R Y , v 1 G i T N P DELETED M s A R Y 1 v ; G T N P P 1 s A R Y 1 v ! G j T N P P M s A R — - H ' Q s S DELETED DELETED DELETED I s A i i R !_H i Q i s i s DELETED DELETED FDELETED M S29S9v[/f>C ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A r R -——- H Q S S DELETED DELETED P s A 1 R H Q S S DELETED DELETED P M s A R H i Q s S DELETED P DELETED s A R H i Q s S DELETED P DELETED M s A LJLH H f Q S J S DELETED P P s A R H Q s S DELETED P P M s A R H Q s S N DELETED DELETED s A R H 0 s S N DELETED DELETED M s A R H Q s S N DELETED P s A R H Q s s N DELETED P M s A R H Q s s N P DELETED s A R j H Q s s N P DELETED M s A R H Q s s N P P s A ! 1 , R_ H Q 1 S s N P P M s A R H Q s T DELETED DELETEDiDELETED s A R"" __R_ R H ! 0 s T JDELETED DELETEDlDELETED M ! s A \| _J±_J.__0 H Q s T JDELETED DELETED P s A 1 s___ s T DELETED DELETED; P M s A i : H Q DELETED P DELETED! I s A R j 1 1 H Q s T JDELETED P DELETED M s A R 1 1 1 H Q s T iDELETED P P s A R 1 \| H Q s T DELETED P P M s A R J \| H 0 S T N DELETED DELETED s A R H Q s T N DELETED DELETEDI M s A R H Q s T N DELETED P s A R H Q s T N DELETED P M s A R H Q s T N P DELETED s A R H Q s T N P DELETED M s A R H Q s T N P P s A R H Q s T N P P M s A ! 1 R H Q G S DELETED DELETED DELETED s Ail ! R H Q .G S DELETED DELETED DELETED M s A R H Q ; G S DELETED DELETED P s A R H ! G ; G ■ S DELETED DELETED P M s A R —J H , Q j G f S DELETED P DELETED s A ■ R H Q G S DELETED P DELETED M s A R H Q G s DELETED P P s A R H " Q G s DELETED P P M s A R H Q G s N DELETED DELETED s A R H Q G s N DELETED DELETED M s A R H Q G s N DELETED P s A R H Q G s N DELETED P M s A R - H Q G s N P DELETED s A R 4 1 H Q G 1 S N P DELETED M s A R i ; H Q G s s N P P s A R 1 i ! H Q G N P P M 52959 vl/OC ASTR 013/01 WO 20 25 \| 29 31 33 49 55 56 91 94 95 96 107 S A i i r £ —L__ H Q G T DELETED DELETED DELETED s A R H Q G T DELETED DELETED DELETED M s A R H Q G T DELETED DELETED P s A R H Q G T DELETED DELETED P M s A R H Q G T DELETED P DELETED s A R H Q G T DELETED P DELETED M s A R H Q G T DELETED P P s A ! 1 R H Q G T DELETED P P M s A i 1 R H Q G T N DELETED DELETED s A R H Q G T N DELETED DELETED M s A R H Q G T N DELETED P s A R H Q G T N DELETED P M s A R H Q G T H P DELETED s A R H Q G T N P DELETED M s A R H Q G T N ! P ! p s A _ R R H 0 G T N _ _P_ DELETED P M I s A i H V_ V S s s DELETED DELETED j ; s A 1 i R 1 ; R : \| H DELETED'DELETED.DELETED M s A ! M V s _ s s DELETEDIDELETED; P s A R H s DELETEDIDELETED! P M s A R H V s s DELETED P DELETED s A R H V s s DELETED P DELETED M s A R H V s s DELETED P P s A R H V s s DELETED P P M . s A R H V s s N DELETED DELETED s A R H V s s N DELETED DELETED M s A R H V s s N DELETED P s A R H V s s N DELETED P M s A R H V s s N P DELETED s A R H V s s N P DELETED M s A R H V s s N P P s A R H V s s N P P M s A R H V s T DELETEDIDELETED DELETED s A R H V s T DELETED DELETED DELETED M s A R H V s T DELETED DELETED P s A- R H V s T DELETED DELETED P M s A R i ; H V s T DELETED .P ' DELETED s A R I S H V s T DELETED P DELETED M s A R I ! H V s T DELETED P P s A R ! ! H^ V s T OELETED P P M s A R I ; H V s T N DELETED DELETED s A R I i H V s T N DELETED DELETED M s A R I ! H V s T N DELETED P s A R ■ I H V s T N DELETED P M s A R ! I H V. s T N P DELETED s A R ! I H V s T N j P DELETED M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A R H V S T N P P s A R H V S T N P p M s A R H V G S DELETED DELETED DELETED s A R H V G s DELETED DELETED DELETED "M s A R H V G s DELETED DELETED p s A R H V G s DELETED DELETED p M s A R H V G s DELETED P DELETED s A R H V G s DELETED P DELETED M s A R H V G s DELETED P p s A R H V G s DELETED P p M s A R H V G s N DELETED DELETED s A R H V G s N DELETED DELETED M s A R H V G s N DELETED P s A R V G s N DELETED P M s A R H H H V G s N P DELETED s A R -:■ V V G s N P DELETED M s A _ __ i_ _R_ .._JL_. R s N P P s __Y_ V G G G s T T N '; P P __M_ s A A H DELETEDIDELETED DELETED s R H V DELETED OELETED DELETED M s A R I H V G T DELETED DELETED P s A R H V G T DELETED DELETED P M s A R H V G T DELETED P DELETED s A R I H V G T DELETED P DELETED M s A R . H V G T DELETED P P s A R H V G T DELETED P P M s A R \| H V G T N DELETED DELETED s A R H V G T N DELETED DELETED M s A R H V G T N DELETED P s A R H V G T N DELETED P M s A R H V G T N P DELETED s A R H V G T N P DELETED M s A R H V G T N \| P P s A R H V G T N I P P M s A F S L L Y Y Q Q S S DELETED DELETED DELETED s A F s S S DELETED DELETED DELETED M s A F s L __Y Y Q S S DELETED DELETED P s A F s L Q S S DELETED DELETED P M s A F s L Y Q S s DELETED P ' DELETED s A F s L Y Q S s DELETED P DELETED M s A F s L Y Q S s DELETED P I P s A F s L Y Q s s DELETED P ! P M s A F s s L Y Q s s N DELETEDIDELETED s A F L _Y_. Y Q s s N DELETEDJDELETED M s A F s L s s N DELETEDI P s A F s L Y 0 , s s N DELETEDI P M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A F S L Y Q S S N P DELETED s A F S L Y Q S s N P DELETED M s A F S L Y Q s s N P P s A F S L Y Q s s N P P M s A F S L Y Q s T DELETED DELETED DELETED s A F s L Y Q s T DELETED DELETED DELETED M s A F s L Y Q s T DELETED DELETED P s A F s L Y Q s T DELETED DELETED P M s A F s L Y Q s T DELETED P DELETED s A F s L Y Q s T DELETED P DELETED M s A F s L Y Q s T DELETED P P s A F s L Y Q s T DELETED P P M s A F s L Y Q s T N DELETED DELETED s A F s L L Y Q s T N DELETED DELETED M s A F s Y Q s T N DELETED P s A F s L Y Q s T N DELETED P M s A j F F s s L L Y Q Q s s _ s. , G T T T N NJ N N __ _P __ P DELETED s A Y 0 DELETED M s A F s L __Y__ Y Y __L_L P P ■ i s A F s L P P M s A F s S DELETED DELETED DELETED s A F s L Y Q G S DELETED DELETED DELETED M s A F s L Y Q G s DELETED DELETED P s A F s L Y 0 G s DELETED DELETED P M s A F s L Y Q G s DELETED P DELETED s A F s L Y 0 G s DELETED P DELETED M s A F s L Y Q G s DELETED P P s A F s L Y Q G s DELETED P P M s A F ' s L Y Q G s N DELETED DELETED s A F s L Y Q G s N DELETED DELETED M s A F s L Y Q G s N DELETED P s A F s L Y Q G s N DELETED P M s A F s L Y Q G s N P DELETED s A F s L Y Q G s N P DELETED M s A F s L Y Q G s N P P s A F s L Y Q G s N P P M s A F s L Y Q G T DELETED DELETED DELETED s A F s L Y Q G T DELETED DELETED DELETED M s A F s L Y Q G T DELETED DELETED P s A F s L Y Q G T DELETED DELETED P M s A F s L L Y Q G T DELETED P DELETED s A F s Y Q G T DELETED P DELETED M s A F s L Y 0 G T T DELETED P \| P s A F s L Y 0 G DELETED P \| P M s A F s L Y Q G t_T_ T N DELETEDlDELETED s A F s L Y Q G N DELETEDiDELETED M 52959 vl/iX' ASTR 013/01 WO 20 25 29 31 33 49 55 56 ! 91 94 95 96 107 S A F i- L __ L Y Y 0 G ■ T ! N DELETED P S A F Q G T N DELETED P M s A F : s L V Q G T N P DELETED s A F s L Y Q G T N P DELETED M s A F L Y Q G r N P P s A F s L Y Q G T N P P M s A F s L Y ! V S s DELETED DELETED DELETED s A F s L Y ! V S s DELETED DELETED DELETED M . s A F s L Y V s s DELETED DELETED P s A . F s L Y V s s DELETED DELETED P M s A F s L Y V s s DELETED P DELETED s A F s . L Y V s s DELETED P DELETED M s A F s L Y V s s DELETED P P s A F s L Y V s s DELETED P P M s A F s L Y V s s N DELETED DELETED s A F s L Y V s s N DELETED DELETED M s A F s L Y V S ! S N DELETED P s A F s L L Y V s_J S N DELETED P M s A F . S y V s s N P DELETED s A F s i Y V : S s _^ I— N P DELETED M s A F s L Y V : S s N P P s A F s L Y V S : S N P P M s A F s _L L Y V S '■ T DELETED DELETED DELETED s A F s Y V S T [DELETED DELETED DELETED M s A F s L Y V s T DELETED DELETED P s A F s L Y V s T DELETED DELETED P M s A F s L Y V s T DELETED P DELETED s A F s L Y V s T DELETED P DELETED M s A F s L Y V s T DELETED P P s A F s L Y V s T DELETED P P M s A F s L Y V s T ' N DELETED DELETED s A F s L ! Y V s T N DELETED DELETED M s A F s L Y V s T N DELETED P s A F s L Y V s T N DELETED P M s A F s L Y V s T N " P DELETED s A F s L Y V s T N P ■ DELETED M s A F s L Y . V s T N P P s A F s L ' Y V s . T N . - P P M s A F s L Y V G ' S DELETED DELETED OELETED s A F s L Y V G s DELETED DELETED DELETED M s A F s L Y V G s DELETED DELETED P s A F s L Y V \| G s DELETED DELETED P M s A F s L Y V ! G s \|D£LETED P DELETED s A F s ■ L Y V G s DELETED P DELETED M s A F s s 1 -L- Y V G s .DELETED P P s A : L Y V ! G s DELETED P P M S295t)v\nx ASTK 0)3/01 WO 20 25 29 \| 31 ! 33 49 55 56 ! 91 \| 94 95 96 107 S A F I S L Y v ; G S N DELETED DELETED s A F I S L Y v ! G ; s N DELETED DELETED M s A F S L Y v ; G s N DELETED P s A F S L Y V G s N DELETED P M s A F s L Y V G J s N P DELETED s A F s L Y V G s N P DELETED M s A F s L Y V G s N P P s A F I S L Y V G s N P P M s A F s L Y V G T DELETED DELETED DELETED s A F s L Y V G T DELETED DELETED DELETED M s A F s L Y V G T DELETED DELETED P s A F s L Y V G T DELETED DELETED P M s A F s L Y V G T DELETED P DELETED s A F s L Y V G T DELETED P DELETED M s A F s L Y V G T DELETED P P s _ __A A LL \| U. U_ s L Y V G T DELETED P P M s L Y V T u . I N (DELETED DELETED s A L Y V i G T I N IDELETED DELETED M s A F s L Y V G T i N DELETED P s A F J s L Y V G T N DELETED P M s A F s L Y V G T N P DELETED s A F s L Y V G T N P DELETED M s A F s L Y V G G T T N P P s A F s L Y V N P P M s A F s L H Q S S DELETED DELETED DELETED s A F s L H Q S S DELETED DELETED DELETED M s A F s L H Q s S DELETED DELETED P s A F s L H Q s S DELETED DELETED P M s A F s L H Q s S DELETED P DELETED s A F s L H 0 s S DELETED P DELETED M s A F s L H Q s S DELETED P P s A F s L H Q s s DELETED P P M s A F s L H Q s S N DELETED DELETED s A F s L H Q s S N DELETED DELETED M s A F s L H Q S I S N DELETED P s A F s L H Q s S N DELETED P M s A F s L H Q s s N P DELETED s A F s L H Q s s N P . DELETED M s A F s L H Q s s N P P s A F s L H Q s s N P P M s A ! F \| S L H Q s T DELETED DELETED DELETED s A . F j S L H Q s T DELETED DELETED DELETED M s A i F s s L H Q s T DELETED DELETED P s A F A F L H Q S ! T DELETED DELETED P M s s L H Q S j T DELETED P DELETED s A F ST r H Q S i T DELETED P DELETED M 52950 i ASTR 013/01 WO 20 25 29 31 33 49 55 56 \| 91 94 95 96 107 S A F S L- H Q S _L T _, DELETED P P S A F S L L H H 0 S T DELETED P P fvl S A j F S G s T N DELETED DELETED S A F S L H ! 0 s T N DELETED DELETED M S A F s L H Q s T N DELETED DELETED P S A F L H G s T N P M S A F s L H G s T N P DELETED s A F s L H Q s T N P DELETED M s A F s L H Q s T N P P s A F s L H Q s T N P P M s A F s L H Q G S DELETED DELETED DELETED s A F s L H 0 G s DELETED DELETED DELETED M s A F s L H Q G s DELETED DELETED P s A F s L H Q G s DELETED DELETED P M s A F s L H Q G s DELETED P DELETED s A F s L H Q G s DELETED P DELETED M s A F __s s L H o ; G 3 DELETED P P S i A c L L H G G s DELETED P P M S ; A F s H 0 G s N DELETED DELETED S A F s L H Q ! G s N DELETED DELETED M s A F s L H Q ! G s N DELETED P s A F s L ; H G I G s N DELETED P M s A F s L ' H i Q ! G s N P DELETED s A F s L I H ! Q \| G \| S N ! P DELETED M s A F s L j H 0 ! G S N P P I I s A F s L i H G ! G s N i P ! P ! M s A F s L ; H ' Q , G ! T DELETED!DELETED!DELETED! I s A r~ F s L i H i Q : G ; T DELETED DELETED DELETED M s A F s L ■ H \| Q G l T DELETED DELETED P s A F s L H Q G ] T DELETED DELETED P M s A F s L H 0 G I T DELETED P DELETED s A F s L H Q G T DELETED P DELETED M s A F s L H Q G T DELETED P P s A F s L H Q G T DELETED! P ■ P M s A F s L H G G T N DELETED DELETED s A F s L H Q G T N DELETED DELETED M s A F s L H Q G T N DELETED P s A F s L H 0 G T N DELETED P M s A F s L H Q G T N P DELETED s A F s L H Q G T N P DELETED M s A F s L H G G T N P P s A F s L H Q G T N P P M s A F s L H V S S DELETED DELETED DELETED s A F s L L K V s s DELETED DELETED DELETED M s A F s H V s s DELETED DELETED P s A F s L H V s s DELETED DELETED P M S2)59 vl/i)C ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A F S L H V s S DELETED P DELETED S A F s L H V s S DELETED P DELETED M S A F s L L H V s S DELETED P P s A F s H V S \| S DELETED P P M s A F s L H v s : s N N DELETED DELETED s A F s L H V S i S DELETED DELETED M s A F s L H V s ; s N DELETED P s A F s L H V s ! s N DELETED P M s A F s L H V , S s N P DELETED s A F s L H V s s N P DELETED M s A F s L H V s s N P P s A F s L H V s s N P P M s A F s L H V S ■ . T DELETED DELETED DELETED s A F s I H V s T DELETED DELETED DELETED M s A F s L H V s T DELETED DELETED P s A F s L H V s T DELETED DELETED P M s A F ! S F I S L H V s T DELETED P DELETED j s A L H v S I I DELETED; P DELETED M s A F s L H j V s T DELETED P P s A F s L H V s T DELETED P P M s A F s L H V s T N DELETED DELETED s A F s I H V s T N DELETED DELETED M s A F s L H V s T N DELETED P s A F s L H V s T N DELETED P M s A F s I H V s T N P DELETED s A F s L H V \| S T N P DELETED M s A F F s L H V I S T N P P s A s L H v ! s T N P P M s A F s L H V G I S DELETED DELETED! DELETED s A F s L H V G S DELETED DELETED DELETED M s A F s L H V G : S DELETED DELETED P I s A F s L H V G S DELETED DELETED P M s A F s L H V G : S DELETED P DELETED s A F s L H V G I S DELETED P DELETED M s A F s L H V G S DELETED ■p P s A F s L H V G S DELETED P P M s A F s L H V G ■ s ■N . DELETED DELETED s A F s L H V G s N DELETED DELETED M s A F s L H V G s N DELETED P s A F s L H V G s N DELETED P M s A F s L H V G ! S N P DELETED s A F s L H V G i S N P DELETED M s A F s L H V G ! S N P P s A F s L H V G I S N P P M s A F s L H V G I T DELETED DELETED DELETED s A F s L H V G T DELETED DELETED DELETED M 52959 v [/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A F S L H V V G T DELETED DELETED P S A F S L H G T DELETED DELETED P M S A F _JLJ L H V G T DELETED P DELETED s A F i s L H V G T DELETED P DELETED M s A F s L H V G T DELETED P P s A F s L H V G T DELETED P P M s A F s L H V G T N DELETED DELETED s A F s L H V " G T N DELETED DELETED M s A F s !_ H V ' G T N DELETED P s A F s L H V G T N DELETED P M s A F s L H V G T N P DELETED s A F s L H V G T N P DELETED M s A F ■ s L H V G T N P P s A F s L H V G T N P P M s A F s Y Q l S S DELETED DELETED DELETED s A F s Y Q S S DELETED DELETED DELETED M s A A F s Y Q s s DELETED DELETED P I i s Y Q s s DELETED DELETED P M s A F s Y Q s s DELETED P DELETED s A F s Y Q s s DELETED P DELETED M s A F s Y Q s s DELETED P P s A F s Y Q s s DELETED P P M s A F s r Y 0 s s N DELETED DELETED s A F s Y Q s s N DELETED DELETED M s A F s Y Q s s N DELETED P i \| i s A F s Y Q s s N DELETED P M s A F s Y Q s s N P DELETED s A F s Y Q s s N ■ - P DELETED M s n A F s Y Q s s N P P s A F s Y Q s s N P P M s A F s Y Q s T DELETED DELETED DELETED s A F n s Y Q s T DELETED DELETED DELETED M s A F s Y Q s T DELETED DELETED P s A F s Y Q s T DELETED DELETED P M s A F s Y Q s T DELETED P DELETED s A F s Y Q s T DELETED P DELETED M s A F s Y Q s T DELETED P P s A F s Y Q s T DELETED P P M s A F s Y Q s T N DELETED DELETED s A F s Y Q s T N DELETED DELETED M s A F s Y Q s T N DELETED P s A F s Y Q s T N - DELETED P M s A F s j \| Y Q s T N P DELETED s A F s \| \| Y Q s T N P DELETED M s A A F s i I Y Q s T N P P ! s F s ■ i Y 0 s T N j P P M $vm VI'DC ASTR 013/01 WO 20 25 29 \| 31 33 49 55 56 91 94 95 I 96 107 S A F ■ S Y Q G S DELETED DELETED DELETED s A F S Y Q G s DELETED DELETED DELETED M s A F S Y Q" G S (DELETED DELETED P s A F s Y Q i G s IDELETED DELETED P M s A F s I __, Y Q G s DELETED P [DELETED s A F s Y Q G s DELETED P j'OELETED M s A F s Y Q G s DELETED P P s A F s Y Q G s DELETED P P M s A F s I ! Y Q G s N DELETED DELETED s^ A F s Y ! Q G s N DELETED DELETED M s ! A F s Y Q G s N DELETED P s A F s Y Q G s N DELETED! P M s A F s Y I Q G S N P DELETED s A ; F s Y Q G Si N P DELETED M s A i F' "1 s Y Q G S I N P P s _ _A_ A F s Y 0 G S N P P M s F s I Y ■ Q G T DELETEOlDELETECiDELETED s A F S i Y i Q G T DELETED DELETED DELETED M s A F s Y Q G T DELETED DELETED' P s A F J us Y Q G T DELETED DELETED P M s A F s Y Q G T DELETED P DELETED S '■ A F s Y Q G T DELETED P DELETED M s : A F __S\| I ■ Y Q G I T [DELETED p i p s A F ~~s Y Q G T DELETED P j P M s A F ] s Y Q G T N DELETED DELETED s A F s Y Q G T N DELETED DELETED M s A F s Y Q G T N DELETED P s A F s Y Q G T N DELETED P M s A F s Y Q G T N P DELETED s A : F s Y Q G T N P DELETED M s A F s Y Q G T N P P S ! A F S I Y Q ' G T N P P M S A F s ■ Y v : s S DELETED DELETED DELETED s A F s Y V S S DELETED DELETED DELETED M (/> A F s Y V S S DELETED DELETED P s A F s Y V I S s DELETED DELETED P M s A F J_ s Y V S S DELETED P DELETED I s A F s Y ' V S S DELETED P DELETED M s A F s Y V s s DELETED P P s A F s Y V s s DELETED P P M s A F s i ; Y v s s N DELETED DELETED s A F s Y V s s N DELETED DELETED M S j A F s Y V s s N DELETED P s A F s Y V s s N DELETED P M s A F s y V s s N P DELETED j s A F s 5205'. ■'IX ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 ! 96 107 S A F S Y V s S N P P s A F S Y V s s N p P M s A F S Y V s T DELETED DELETED DELETED s A F F s s Y V s T DELETED DELETED DELETED M s A Y V s T DELETED DELETED P I 1 s A F s Y V s T DELETED DELETED P M \| s A F s Y V s T DELETED P DELETED s A F s Y V s T DELETED P DELETED M s A F s Y V s T DELETED P P s A F IS Y V s T DELETED P P M s A F s Y V s T N DELETEDJDELETED s A F s Y V s T N DELETED-DELETED M s A F s Y V s T N DELETED! P s A F s Y V s T N jDELETEDi P M s A F s Y V s T N p DELETED s A s Y V s _s_._ s T N p DELETED M s A s I Y V T M p P P s A F s I Y V "" T N p M s A F s Y V I G S DELETED DELETED!DELETED s A F s Y V G S DELETED DELETED;DELETED M s A F s Y V G s DELETED DELETED P s A F s Y V G s DELETED DELETED! P M s A F s Y V G s DELETED p DELETED s A F s Y V G s DELETED p DELETED M s A F s Y V G s DELETED p P s A F s Y V G s DELETED p P ^ M s A F s Y V G s N DELETED DELETED s A F s Y V G s N DELETED DELETED M s A F s Y V G s N DELETED P s A F s Y V G s M DELETED P M s A F s Y V G s N ; P DELETED s A F s Y "V G s N P iDELETED M s A F s Y V G s N P P s A F s Y V G s N P P M s A F s Y V G T DELETED DELETED DELETED s A F s Y v G T DELETED DELETED DELETED M s A F s Y V G T DELETED DELETED P s A F s Y V G T DELETED DELETEO P M s A F s Y V G T DELETED P DELETED s A F s n Y V G T DELETED P DELETED] M s A F s Y V G T DELETED P P s A F s Y V G T DELETED P P M s A F s Y V G T N DELETED DELETED s A F s Y V G T N DELETED DELETED M s A F s Y V G T N DELETED P s A F s Y V G T N DELETED P M 52(JS9 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A F S i Y V G T N P P DELETED s A F s Y V G T N OELETED M s A F s Y V G T N P P s A F s Y V G T N P P M s A F s H Q S S DELETED DELETED DELETED s A F s H Q S s DELETED DELETED DELETED M s A F s H Q s s DELETED DELETED P P s A F s H Q s s DELETED DELETED M s A F s H Q s s DELETED P DELETED s A F s H Q s s DELETED P DELETED M s A F s H Q s s DELETED P P s A F s i t H Q s s DELETED P P M s A F S I H Q s s N DELETEDiDELETED s A PF s i I H ■ 0 s s N DELETED DELETED M s A F s I H Q s s N DELETED P s A A A F • F s s I ! H Q s L_ s s N DELETED P M s H a s N P DELETED s s ! ; H Q s 3 N P DELETED M i s A r s H Q s s N P P s A F s H Q s s N P P M s A F s H Q s T DELETED DELETED DELETED s A F s J H Q s T OELETED DELETED DELETED M s A F s H Q s T DELETED DELETED P s A F s H Q s T DELETED DELETED P M s A F s H Q s T DELETED P DELETED] s A F s H Q s T DELETED P DELETED M s A F s H Q s T DELETED P P s A F s H Q s T DELETED P P M s A F s H Q s T N DELETED DELETED s A F s H Q s T N DELETED DELETED M s A F s H 0 s T N DELETED P s A F s H Q s T N DELETED P M s A F s H a s T N P DELETED s A F s H Q s T N . P DELETED M s A F s H Q s T N P P s A F s H Q s T N P P M s A F s H Q G S DELETED DELETED DELETED s A F s H Q G s DELETED DELETED DELETED M s A F s H Q G s DELETED DELETED P s A F s H a G s DELETED DELETED P M s s A F s . H Q G s DELETED P DELETED A F s H Q G s DELETED P DELETED M s A F s H Q G s DELETED P P s A F s H Q G s DELETED P P M s s A F s H a G s N OELETED DELETED A F s H Q G s N DELETED DELETED M 52')yi v\|/DC ASTK. 013/01 WO 20 25 j 29 31 33 ■ ) 49 55 56 91 94 95 \| 96 107 S A \| F S I ! H Q G s N DELETED! P I s A... F S ■ H Q G S I N DELETEJJj P M s A F s H ! Q G S I N P DELETED i s A F s H Q G S I N P DELETED M s A F s I i H Q G s N P P I s A F s H 0 G s N P P M s A F s H ! Q G T DELETED DELETED DELETED I s A F s H Q G T DELETED DELETED DELETED M s A F 1 S H Q G T DELETED DELETED P I s A F 1 S i 1 H Q G T DELETED DELETED! P M s A F s H Q G r T DELETED P DELETED I s A F s H Q G T DELETED p DELETED M s A F s H G G T DELETED p ■ p I s A F s H G G—I- T DELETED p p M S \| A F s H Q G T j N DELETED:DELETED i s A F s H ; Q G T N DELETEDjDELETED M s A A F s H G ! G T N DELETED] P i i_-Ji F j S ! 1 H Q G T N DELETED': P M r~s "1 A ! F j S \ 1 H G G T : N P iDELETED I ! s^ A F s H Q G T N P DELETED M I s A F s H Q G T N P P I s A F s H Q G_^ T ' N P P M s A F s H V S S DELETED DELETED DELETED I s A F s H V 5 s DELETED DELETED DELETED M s A F s H V S s DELETED DELETED P i s A F- s H V S s DELETED DELETED P M s A F s H V s s DELETED P DELETED i s A F S I H V s s DELETED P DELETED M _s . A F s H V s s DELETED P P I s A F s H V s s DELETED P P M s A F s H V s s N DELETED DELETED t s A F s K V s s N DELETED!DELETED M s A IF i S H V s s N DELETED P 1 s A F s H V s s N DELETED P M s A F s H V s s N P DELETED 1 s A F s H V s s N P DELETED M S i A F s H ! V s s N P P 1 S 1 A F s H V s s N P P M S i A F s H i V s T DELETED DELETED DELETED 1 s A F s H V s T DELETED DELETED DELETED M s A F S H V s T DELETED DELETED P 1 s A F s H V s ; T DELETED DELETED P M s A F s H V s ! T DELETED P DELETED 1 s A F s H V S T DELETED P DELETED M s A r s I ! H V s T DELETED P P 1 1 S A ! F ' S I ! H V s T DELETED P P M 52')50 vi.'DC ASTR 013/01 WO 20 25 \| 29 31 33 49 H 55 56 91 94 95 96 107 \| S A F S V s T N DELETED DELETED S A F s H V s T N DELETED DELETED M S A F s H V s T N DELETED P S A F s H V s T N DELETED P M S A F s H V s T N P iDELETED S A F 3 H V s T N P [DELETED M s A F s I j H V s T N P I P s A F s H V s T N P I P M s A F s H V G S DELETED DELETEDiDELETED s A F s H V G s DELETED DELETED DELETED M s * A F s H V G s DELETED DELETED P s A F s H V G s DELETED DELETED P M s A F s H V G s DELETED P 'DELETED s A F s I ! H v I G s DELETED P P ■ P DELETED DELETED DELETED M s A F s H V G s DELETED P s s A A F S ' I H V G s DELETED P M s ] H G G G s s N DELETED s s i \| H V DELETED P M s A F s I K V s N DELETED s A F s H V G s N DELETED! P M s A F s I ! H V G s N P DELETED s A h s H V G s N P DELETED M s A F s H V G s N P P s A F s H V G s N P P M s A F s H V G T DELETED DELETED DELETED s A F s H V G T DELETED DELETED DELETED M s A F s H V G T DELETED DELETED P s A F s H V G T DELETED DELETED P M s A F s H V G T DELETED P DELETED s A F s H V G T DELETED P DELETED M s A F s H V G T DELETED P P s ' A F S i I H V G T DELETED! P P M s A F s H V G T N DELETEDIDELETED s A F s H V G T N DELETEDiDELETED M s A F s H V G T N DELETEDL P s A F s I H V G T N DELETEDI P M s A F s H V G T N p DELETED s A F s H V G T N p DELETED M s A F s H V G T . N p P s ■ A F s H V G ■T N p : p M s A F R L Y Q S S DELETED DELETED DELETED s A F R L Y Q S s DELETED DELETED DELETED M s A F R L Y Q I S s DELETED DELETED P s A F ! R r L Y Q s s DELETED DELETED P M s A F i R L Y Q s s DELETED P DELETED I s A F I R L Y Q s s bELETEO' P DELETED M ASTR 013/01 WO 20 25 29 31 33 __49__ Y 55 56 91 94 95 96 107 S A F R L Q S S DELETED P P s A F R L i Y 0 S S DELETED P P M s A F R L i Y Q S . s N DELETED DELETED s A F R L Y Q S s 1 N DELETED DELETED M s A F RZJ L Y Q S s N DELETED P s A p R L Y Q S s N [DELETED! P M s A F R L Y Q s s N P {DELETED s A F R L Y Q s s N P DeLETEO M s A F R L Y Q s s N P P s A F R L Y Q s s N P P M s A F R L Y Q s T DELETED DELETED DELETED s A F R L Y Q s T DELETED DELETED DELETED M s A F R I L Y Q s T DELETED DELETED P s A F R L Y Q s T DELETED DELETED! P M s A F R I. L I. Y Y Q s T DELETED P IDELETED s A F F — 1 R i 0 Q Q s T DELETED' P !DELETED M ; s A A A 1 Y I Y S ! s I T T ■ DELETEa P P \|s F R L DELETED p P M \| S F B—J L Y Ql S ] T 1 N ~1 DELEIED] DELETED s A 1 F R L Y Q s T N DELETED DELETED M s A F R L Y Q s T 1 N DELETED P s A F R L Y Q s T N DELETED P M s A F R L Y Q s T N P DELETED s A F R L Y Q s T N P DELETED M s A F R L Y Q s T N P P s A F R L k Y Q s T N P P M s A F R L Y Q G S DELETED DELETED DELETED s A F R L Y Q G s [DELETED DELETED DELETED M s A F R L Y Q G s DELETED DELETED P s A F R L Y Q G s DELETED DELETED P M s A F R L Y Q G s DELETED P _, DELETED s s A F R L Y Q G s DELETED P DELETED M A F R L Y Q G s DELETED P P s A F R L Y Q G s JD6LETED P P M s A F R L Y Q G s N DELETED DELETEC I s A F R L Y Q G s N DELETED DELETEC M s A F R L Y Q G s N DELETED P s A F R L Y Q G «_ s N DELETED P M s A F R L Y Q G s . N P DELETEC I s A F R L Y Q G s 1 N P iDELETEC M s A F R L Y Q G s i N P i p s A F R i L Y Q G 4_5 J N P P M s A F R L Y 0 G T DgLETEC DELETEC DELETE: ) I A F R L Y Q G T DgLETEC DELETEC DELETEC ) M s A F R L Y i Q G T DELETEC DELETEC P s A F R L Y I Q G T DELETED DELETEC P M 52<.>5'1 vl/\|)C ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 \| 96 107 S A ■F R L Y Q G T DELETED P (DELETED s A F R L Y 0 G T DELETED P .DELETED M S A F R L V Q G T DELETED [PiP S \| A F R L Y Q G T DELETED P ! P M S A F R L Y Q G T \| N DELETED DELETED S A F R L : Y Q G T \| N DELETED DELETED M s A F R L Y Q G T \| N DELETED P s A F R L Y Q G T i N DELETED P M s A F R L Y Q G T N P DELETED s A F R L Y Q G T N P DELETED M s A F R L Y Q G T N P P s A F- R L Y Q G T N P P M s A F R L Y V S S DELETED DELETED DELETED s A F R L Y V S S DELETED DELETED DELETED M s A F R L Y V S s DELETED DELETED P s A F R L I Y L Y V s. s DELETED DELETEDi P M s A F R V s s DELETED P JDELETED A F R L Y V s S IDELETED P DELETED M S 1 A F R ' L Y v , s n S DELETED P } 1 1 s__ s A F R ; L Y V s S DELETED P ! P j M A F R i L Y V s S N DELETEDlDELETEDi I s A F j ■ R ! L i Y V s s N DELETEDJDELETEDl M s A F ! R L Y V s s N DELETED\| P s A F R L Y V s s N DELETEDi P M s A F R L Y V s s N P (DELETED S \| A F R L \| Y V s s N "~ P JDELETED M S J A F R L l Y V s S N P P s A F R L ! Y V s s N P P M s A F R L Y V s T DELETED DELETED DELETED s A F R L Y V s T DELETED DELETED DELETED M s A F R L Y V s T DELETED DELETED P s A F R L Y V s T DELETED DELETED P M §___ s A F R L Y V s T OELETED P DELETED A F R L Y V s T DELETED P DELETED M s A F R L Y V s T DELETED P P s A F R L Y V s T DELETED P P M s A F R L Y V s T N . DELETED DELETED s A F R L Y V s T N DELETED DELETED M s A F R L Y V s T N DELETED P s A F R L Y V s T N DELETED P M s A F R L Y V \| S T N P DELETED s A _ A F R L Y V j S T N P I DELETED M s F R L_ L Y V S ; T N P P s A F I R I V V S ; T ! N P p : M s A F 1 R L Y j V G ! S DELETED DELETED DELETED; 1 s A F ! R L Y } V G I S JDELETED DELETED DELETEDi M 52959 vl/DC ASTR 013/01 WO 20 25 29 31 33 __L L 49 Y Y 55 56 91 94 95 96 P 107 S A F R V G~l s DR'LETED DELETED I s_ s A F R V G s DRLETED DELETED P M A F R I L Y V G s DELETED P DELETED I s A F R L Y V G s DFt-ETED P DELETED M s A F R L Y V G s nFLETED P P ! s A F R L Y V ■ G s DFLETED P P M s A F R L Y V G s N DELETED DELETED I s A F R L Y V G s N DELETED DELETED M s A F R L Y v G s N DELETED P I s A F R L Y V G s N DELETED) P M s A F R L Y V G s N P DELETED I s A F R L Y V G s N P DELETED M s A F R L Y V G s N P P ! s A A F R L Y V G s N P P M s F R L Y v G T HFLETED DELETED DELETED I s A F — — -i -H R I. L Y V G T DELETED DELETEDiDELETED M s I * s A A ! R J Y Y""\| X V G T -1F.LETED, DFLETED DELETED] P I R L ! V M T DELETED' I? P M ? 9. T w,u=Tea 1ELETE.Q i. A F R L Y V G T OFiLETED P DELETED M s A A F R L Y V G T DELETED P P 1 b F R L Y V G T DELETED P DELETED P M s A F R L L Y V G T N DELETED 1 s A F R Y V G T _^- DELETED DELETED M s A F R L Y V G T N DELETED P 1 s A F R L Y V G T N DELETED P M s A F R L Y V G T i N P DELETED 1 s A F R L Y V G T N P DELETED M s A F R L Y V G T N P P 1 s A F R L Y V G T N P P M s A F R L H Q S S DIETED DELETED DELETED 1 s A F R L H Q S S DELETED DELETED DELETED M s A F R L H Q ' S S DIETED DELETED P 1 s A -F R L H a s s Hf?LETED DELETED P M s A F R L H Q s s DELETED P DELETED 1 s A F R L H Q s s n^LETED P DELETED M s A F R L H Q s s nfSLETEO P P 1 s A F R L H " Q s s DELETED P . ■ P M s A F R L H Q s s t~^ N DELETED DELETED t s A F R L H Q s s N DELETED DELETED M s A F ; R L H Q s s N DELETED P 1 s A F i R L i H . Q s s N DELETED P M s A F R R L L L H Q s s N P DELETED 1 s i A F H H Q s s N P DELETED M s A A p i R Q s s T~ N P P 1 s ! F ! R "- H Q f s f S N P P \| M 52451! vl/DC ASTRO 13/0J WO 20 25 29 31 33 49 55 56 91 94 95 \ 96 107 S_ s A A F R L H Q S T DFLETED DELETEDIDELETED I F R L H s T DENTED DELETED DELETED M s A F R L H s T DELETED DELETED P I s A F R L H 0 s T DEl-ETED DELETED: P M s A F R L H Q s T DEI-ETED P iDELETED I s A F R L H Q s T DFI-ETED P DELETED M s A F R L H Q s T DFJ-ETED P P I s A F R L H Q s T DFUETED P P M s i A F R L_\| H Q s T N DELETED DELETED I S I A F R L H Q s T N DELETED DELETED M S \| A F R L H - Q s T N DELETED P I S 1 A F R L H Q s T N DELETED P M S A F R L H Q s T N P DELETED I S A F R L H Q s T N P DELETED M S A F R L H Q s T ! N P i P I s A F R L H Q s T N P P M ! S I A c R i L H Q ! G 3 DEl-ETED DELETED DELETED I S 1 A F L i H Q G S DEf-ETED DELETED DELETED M S A F R \| L H Q G s DENTED DELETED P I S A F R L H Q G s InFLETED DELETED! P M s A F R L H Q G s DELETED P* DELETED s A F R L H Q G s DFLETEO P DELETED M s A F R L H Q G s DELETED P P s A F R L H Q G __s s DFLETED P P M s A F R L H Q G N DELETED DELETED s A i F R L H Q G s N DELETEDIDELETED M s A F R L H Q G s N DELETED; P s A F R L H Q G s N DELETED P M s A F R L H Q G s N p DELETED s A F R L H Q G s N p DELETED M s A F R L H Q G s N p P s A F R L H Q G s N p P M s A F R L H Q G T DFLETED DELETED DELETED s A F R L H Q G T OFLETED DELETED DELETED M s A F R L H Q G T DFLETED DELETED P s A F R L H Q G T DELETED DELETED P M s A F R L H Q G T- DELETED P DELETED s A F R L H Q G T DELETED P DELETED M s A F R L H Q G T DELETED P P s A F R L H Q G T OFLETED P P M s A F R L H Q G T N DELETEDIDELETED I s A F R L H Q G T N DELETED'DELETEO M s A F R L H Q G T N iDELETED! P s A F R t. H Q G T N JDELETEDj P M s A F \| R L ! H i Q G T N \| P IDELETEC s A F j R L ! H : 0 j_ T N P DELETEC M 52W vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 r 94 95 ! 96 107 S i A F R : R j L \| H Q G T N P P S j s 1 A F L H Q G T N I P P M A F R ' L 1 H V S S DELETED DELETED DELETED s A F F R 4 L H V s s DELETED DELETED' DELETED P M s ' A R L H V s s DELETED DELETED s A F R L H V s s OEXETEOiOELETED P M s A F R L H V s s DELETED P DELETED s A F ' R L H V s s DELETED P DELETED M s A F R L H V s s DELETED P P s A F R L H V s s DELETED P P M s A F R L H V s s N DELETED DELETED s A F R L H V s s N DELETED DELETED M s A F R L H V s s N DELETED P s A F R L H V s s N DELETED P M s A F R L H V s s N P DELETED s s s __ A A A F F R L H V s s N P DELETED M R L L H H V s s N P P F R V s s N I P P M i s A ? \| H \ V tt \ s T otv-t^o DELETE s A F R I H V s T JDJLETED DELETED DELETED s _A \| F R L . H V s T DELETED DELETED P s A F R I. H V s T DELETED DELETED P M s A F R 1. H V s T DELETED P DELETED s s A F R L H V s T DELETED P DELETED A F R L H V s T DELETED P P s A F R I H V s T JDJLETED P P s A F R I H V s T N DELETED DELETED s i_ A F R I H V s T N DELETED DELETED M s A F R I H V s T N DELETED P s A F R L H V s T N DELETED P s A F R L H V s T N P DELETED s A F R L H V s T N P DELETED s A F R L H V s T N ■ P P s A F R L H V s T I N P P M s A F R L H V G S DgLETED DELETED DELETED s A F R L H V G S DELETED DELETED DELETED M s A F R L H V G s DELETED DELETED P s A F R L H V G s DELETED DELETEDl P M s A F R L H V G s D£LETEC P DELETED j s A F R L H V G s DELETED P DELETED M s A F R L H V G s DELETED P P s A F R L H V G s DELETED P P M s A F R L i H V G s N DELETED DELETED I s A F R L H V 1 G~~ s N DELETED DELETED M s A F R L H V G s N DELETED P s A F ! R L i H V G ! s N DELETED P M S:M$ ASTRO33/01 WO 20 25 29 31 33 49 55 56 91 94 95 ( 96 107 S S A F R ' L H V G ^ s N P DELETED I A F R L H V G s N P DELETED M s s A F R L H V G s N P P P DELETED A F R L H V GJ s N P M s A F R L H v G T DELETED DELETED s A F R L H V G T DELETED DELETED DELETED M s A F R L H V G T DELETED DELETED P s A F R L H V G T DELETED DELETED P M s A F R L H V G T DELETED P DELETED s A F R L H V G T DELETED P DELETED M s A F R L H V G T DELETED P P s A r~F R L H V G T DELETED P P M s A F R L H V G T N DELETED DELETED s A F R L H V G T M DELETED DELETED M s A F R L H V G T . N DELETED P _s__ s s~" s A F R L H V G T N DELETED P M . _A__ A A ""'"F"~ R h—L __hL. H V V G J T N P P DELETED I i G T N DELETED M F R L H V G T N ! P P s A F R l H V G "I T N P P M s A U_F___ R Y Q S S DELETED DELETED DELETED s A F R Y Q s s DELETED DELETED DELETED M _s_„ s A F R Y Q s s DELETED DELETED P A F R Y Q s s DELETEDlDELETED P M s A F R Y Q s 3 DELETED P DELETED s ~ A F R Y Q s s DELETED P DELETED M A F R Y Q s s DELETED P P s 1 A F l R Y Q s s DELETED P P M s A -- -F R Y Q s s N DELETED DELETED s A F R Y Q s s N DELETED DELETED M s A F R Y Q s s N DELETED P s A F R Y Q s s N DELETED P M s A F R Y Q s s N P DELETED s A F R Y Q s s N P DELETED M s A F R Y Q s s N P P s A F R Y Q s s N P P M s A F R Y Q s T DELETED DELETED DELETED s A F R Y Q s T DELETED DELETED DELETED M s A F R Y Q s T DELETED DELETED P s A F R Y Q s T DELETED DELETED P M s A F R Y Q s T DELETED P DELETED s A ' F R Y Q s T DELETED P DELETED M s A , F R Y Q s T DELETED P P s A F R Y Q s T DELETED P P M s__ s A F R Y Q s T N DELETED DELETED A c R Y Q s T N DELETEDlDELETED M S2WJ vi-'DC ASTR. 013/03 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A F R Y Q s T N (DELETED P s A F R Y Q s T N jDELETED P M s A F R I Y Q s T N P DELETED s s A F R Y Q s T N P DELETED M A F R \| Y Q s T N P P s A F R Y Q s T N P P M s A F L R Y Q G S DELETED DELETEDIDELETED s A F R Y Q G s DELETED DELETED DELETED M s A F R Y Q G s DELETED DELETED P s A F R Y Q G s DELETED DELETED P M s A F R Y Q G s DELETED P DELETED s A F R Y- Q G s DELETED P DELETED M s A F R Y Q G s DELETED P P s A F R Y Q G s DELETED P P M s A F R Y Q G s N DELETED DELETED s A F R Y Q G ^_s N DELETED DELETED M __s_ s A F R I \| Y Q G s N DELETED'! P A F R i i Y Q G s N DELETED P M s A F R I ' Y Q G s N P DELETED s A F R J 1 1 Y Q G s N P DELETED M s A F R 1 1 Y Q G s N P P s A F R Y Q G s N P P M s A F R Y Q G T DELETED DELETED DELETED s A F R Y Q G T DELETED DELETED DELETED M s A F R Y Q G T DELETED DELETED! P s A F R Y Q G T DELETED DELETED P M s A F R Y Q G T DELETED P DELETED s A F R I Y Q G T DELETED P DELETED M s A F R Y Q G T DELETED P P s A F R Y Q G T DELETED P P M s A F R Y Q G T N DELETED DELETED s A F R Y Q G T N DELETED DELETED M s A F R Y Q G T N DELETED P s A F R Y Q G T N DELETED P M s A F R Y Q G T N P DELETED s A F R Y Q G T N P DELETED M s A F R Y Q G T N P P s A F R Y Q G T N P P M s A F R Y V S S DELETED DELETED DELETED s A F R Y V S S DELETED DELETED DELETED M s A F R Y V S s DELETED DELETED P s A F R Y V s s DELETED DELETED P M s A F R Y V s s DELETED P DELETED s A F R Y V 3 S s DELETED P DELETED M s A F R Y V s DELETED I P ■■ p s A F R i Y ' V S s DELETED! P ■ P \| M 1295v\|.>DC ASTR 013/01 WO 20 25 ! 29 31 33 49 55 j 56 91 94 95 96 I 107 S A F R Y ! V ) S S N DELETED DELETED \| S A F R Y VjS s N DELETED DELETED M S A F R Y v ! s s N DELETED P S A F R Y V S s N DELETED P M s A F R Y V S s N P DELETED s A F R Y V s s N P DELETED M s A F R Y V s s N P P s A F R Y V s s N P P M s A F R Y V S T DELETED DELETED DELETED s A F R Y V s T DELETED DELETED DELETED M s A F R Y V s T DELETED DELETED P s A F R Y V S T DELETED DELETED P M s A F R Y V s T DELETED P DELETED s A F R Y V S T DELETED P DELETED M s A F R Y V S T DELETED P P s ■ A F R Y V i S T DELETED P P M j S j A f F R I J Y V I S ,' T N DELETED, DELETED\|_ _J DELETED] M k" " A T F R V \| S T N DELETED A TF R ■ I i Y V j S T N DELETED P ' —I )s_ A LJL_ R \| I Y V I S \| T N DELETED P ! Ml s A F R j I Y V I S j T N P DELETED I s A F R I I Y V S ' T N P DELETED) M s A F R Y V s ! T N P P ' I s A F R Y V S \| T i N P P ! M s A F R Y V G S DELETED DELETED DELETED I s A F R Y V G s DELETED DELETED DELETED', M s A F R Y V G S DELETED DELETED p ! s A F R Y V G s DELETED DELETED p M s A F R Y V G s DELETED P DELETED s A F R Y V G s DELETED P DELETED M s A F R Y V G s DELETED P P s A F R Y V G s DELETED! P P M s A F R Y V G s N (DELETED DELETED s A F R Y V G s N DELETED DELETED M s A F R Y V G s N DELETED P s A ■ F R Y V G s N DELETED P M s A F R Y V G s N P DELETED s A F R Y . V G s N P DELETED M s A F R Y V G s N P P s A F R Y V G s N P P M s A F R Y V G T DELETED DELETED DELETED s A F R Y V G T DELETED DELETED DELETED M s A F r R Y V G T DELETED DELETED P I _s s A F R Y ( V G T DELETED DELETED P M A F R Y I V G T DELETED] P DELETED s A F j R Y I V G i T (DELETED I ? DELETED M 52159 vl.'DC ASTR 013/03 WO _20_ S 25 29 31 33 j 49 55 56 91 94 95 96 107 A F R ■^7 i VL-1 V G T DELETED P P s A F R 1 Y V G T DELETED P P M_j s A F R y V G T N DELETED DELETED s A F u R Y V G T N DELETED DELETED M s A F R Y V G T N DELETED P s A F R Y V G T N DELETED P M s A F i R Y V G T N P DELETED s A F R ' Y V G T N P DELETED M s A F R Y V G T N P P s A F R Y V G T N P P M s A F R H Q S S DELETED DELETED DELETED s A F R H Q S S DELETED DELETED DELETED M s A F R H Q s s DELETED DELETED P s A F R ■ H Q s s DELETED DELETED P M s A F R H Q s s DELETED P DELETED J'iZ s A F R H Q s s DELETED P DELETED M A A A F 1 R 1 ! H 0 s s DELETED p P __F F R H Q s s DELETED P P J M \| R H Q s s N ^ DELETED DELETED s A F R H Q s s N DELETED DELETED M s A F R I H Q s s N DELETED P 3 A F R H Q s s N DELETED P M s A F R H Q s s N P DELETED s A F R H Q s s N P 'DELETED M s A F L_6_J H Q s s N P P s A F R -l H 0 s s N P P M s A F R H Q s T DELETED DELETED DELETED s A F R H Q s T DELETED DELETED DELETED M s A F I R_ H Q s T DELETED DELETED P s A F _JLJ H Q s T DELETED DELETED P M s A u. F R H Q s T DELETED P DELETED __s s A F R H Q s T DELETED P DELETED M A F R_J H Q s T DELETED P P s A F R H Q s T DELETED P P M s A F R H Q s T N DELETED DELETED s A F R H Q s T N DELETED DELETED M s A F R H Q s T N DELETED P s A F R H Q s T N DELETED P M s A F R H Q s T N P DELETED s A F R H ' Q s T N P DELETED M i__s - A F R H Q s T N P P ! s A F R H ■ Q s T N P P M s s A F R H G G S DELETED DELETED DELETED A F R H 0 G s DELETED DELETED DELETED M s A 1 F R i j H 0 G s DELETED DELETED P ..._s A F R 1 H 0 G s DELETED DELETED P M 52959 vl/IX' ASTR 013/01 WO 20 i 25 29 J 31 4 33 49 55 56 91 94 95 j 96 107 S \| A F ! R H Q G s DELETED p IDELETED I S A F j R H Q G j s DELETED P DELETED M S A F J R I ! H Q G s DELETED p P I ^S A F R H Q G s s DELETED p P M s A F R H ! Q G N IDELETED DELETED! t s A F R H - Q G s N DELETEDiDELETED M s A F R H Q G s N DELETED P l s A F R I 1 H Q G s N DELETED P M s A F R i H Q G s N P DELETED I s A F R H Q G s N P DELETED M s A F R H Q G s N P P ) s A F R H Q G s N P P M s A F R H Q G T DELETED DELETED DELETED I s A F R H Q G T DELETED DELETED DELETED M s A F R H Q G T DELETED DELETED P I s A F R ! I ! H Q G T DELETED DELETED! P M s A F R j i \| H ; Q T DELETED P {DELETED s A A F R I H 0 G T DELETED P IDELETED M s F R H Q I G T DELETED P P f ! s A F j_ R H Q G T DELETED P P M r s A F I R H Q G T N DELETED DELETED I S ' A F R H \| Q G T N DELETEDiDELETED M S I A F R I ! H Q G T I i N DELETED P ! S I A F R I j H Q G T N DELETED P M s A F R I i H Q "I G T N P DELETED I s A F R I ! H Q G i_l_ N P ^DELETED M s A j F R H O G T N P ! P i s A F ! R H Q G T N P P M s A F R H v i s S DELETED DELETED DELETED I s A F R H V S S DELETED DELETED DELETED M s A F R H V S S DELETED DELETED , P I s A F R H V s S DELETED DELETED P M s A F R H V s S DELETED P DELETED I s A F R H V s s DELETED P DELETED M s A F R H V s s DELETED P P t s A F R H V s s DELETED P P M s A F R H V s s N DELETED DELETED I s A F R H V s s N DELETEDiDELETED M s A F R H V s s N DELETED P I s A F R H V s s N DELETED P M s A F R H V s s N p DELETED I s A F R H V s s i N P iDELETEDi M s A F R 'I \| H \| V s s N P \| P ! M j s A : F R I H V l s i s N P ! P j S A F i R _JL - H V S ' T DELETED DELETED iDELETED. I i s ! A F \| R I ! H V I S IT DELETED DELETED (DELETED i M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S A F R H V s T DELETED DELETED P S A F R H V s T DELETED DELETED P ! M S A F R i r i H V s T DELETED P DELETED! S A F H -] H V s T DELETED P DELETED M S A F R H V s T DELETED P ' P S A F R H V s T DELETED P P M S A F R H V s T N DELETED DELETED S A P R H V s T N DELETEDJDELETED M s A F R H V s T N DELETED P s A F R H V s T N DELETED P M s A F R H V s T N P DELETED s A F R H V s T N P DELETED M s A F R H V s T N P P s A F R ' H V s T N P P M s A F R H V G S DELETED DELETED DELETED s A F R H V G S DELETED DELETED DELETED M s s A A p F R H V G s s s DELETED DELETED P p DELETED M R I ; H V G DELETED DELETED A F R i ; H V G DELETED P s A F R H V G s DELETED P DELETED M s A F __R H V G s DELETED P P s A F R -i H V G s DELETED P P M s A F R H v G s N DELETED DELETED s A F R H V G s N DELETED DELETED M t_ s A F R H V G s N DELETED P . i s A F . R H V G s N DELETED P M s A F \|fL H V G s N P DELETED s A F R H V G s N P DELETED M s A F R H V G s N P P s A F R H V G s N P P M s A F R H V G T DELETED DELETED DELETED s A F R H V G T DELETED DELETED DELETED M s A F R H V G T DELETED DELETED P s A F R H V G T DELETED DELETED P M s A F R H V G T DELETED P DELETED s A r F R H V G T DELETED P DELETED M s A F R H V G T DELETED P P s A F R" H V G T DELETED P P M s A F R H V G T N DELETED DELETED s A F • R H V G T N DELETED DELETED M s A F R H V G T N DELETED P s A F R H V G , T N DELETED P M s A F R H V G T N P DELETED ( s A F R H V G T N P DELETED M s A F R i j H v G T N P P s A F R I I H i v G T N i P P M 52()59 vl/DC ASTR 013/01 WO 20 25 29 I 31 33 49 55 56 91 94 DELETED 'T 95 96 DELETED: 107 1 S p I i S L Y Q S S DELETED, s p I \| S L V J Q s S DELETED! DELETEDlDELETED M s p I I S L Y Q s s DELETED DELETED P 1 s p s L Y Q s s DELETED DELETED P M s p s L 1 Y Q s s DELETED P DELETED: I s 1 p s L Y Q s s DELETED P DELETED M s p s L Y Q s s DELETED P P 1 s p s L Y Q s s DELETED P P M s p 1 1 L V Q s s N DELETED DELETED t s p s L Y Q s s N DELETED DELETED M s p s L Y Q s s N DELETED P 1 s p s L Y Q s s N DELETED P M s p s L Y Q s s N P DELETED 1 s p s L Y 0 [ s s N P DELETED M s p s L Y Q s s N P P 1 j s p s L Y Q s s N P P M i s P ! i s L V Y 0 s T DELETEDlDELETED DELETED DELETEDlDELETED DELETED 1 I s p I S Q s T M_J \|_ S p s L Y Q s T DELETEDlDELETED P t s p s L Y Q s T DELETED DELETED P M s p s L Y Q s T DELETED P DELETED 1 p ' s L Y Q s T [DELETED P DELETED M s p s L Y Q s T DELETED P P 1 s p s L Y Q s T DELETED P P M s t p s L Y 0 s T N DELETED DELETED 1 s p s L Y Q s T N- DELETED DELETED M s p s L Y Q s T N DELETED P i s p i I s L Y Q s T N DELETED P M s p s L Y Q s T N P DELETED 1 s p s L Y Q s T N P DELETED M p s L Y Q s T N P P 1 s p s L Y Q s T N P P M s p s L Y Q G S DELETED DELETED DELETED 1 s p s L Y Q G S DELETED DELETED DELETED M s p s L Y Q G s DELETED DELETED P 1 s p s L Y Q G s DELETED DELETED P M s p s L Y Q G s DELETED P DELETED 1 s p s L Y Q G s DELETED P DELETED M s p s L Y Q G s DELETED P P I (__§_ p s L Y Q G s DELETED P P M s p s L Y Q G s N DELETED DELETED I (_ s p s L ! Y Q G s N DELETED DELETED M s p s L i Y Q G s N DELETED P s p s L Y Q G s N DELETED P j M i s I p s L Y Q G s N P [DELETED 1 > I s I p s L Y L_Q G s I N P [DELETED \ M 52959-'l.'DC ASTR 013/01 WO 20 25 _ 29__ 31 33 49 Y 55 56 91 94 95 96 107 S p s s L Q G s N P P s p L Y G s N P P M s p i S L Y Q G T DELETED DELETED DELETED s p s L Y Q G T DELETED DELETED DELETED M s p _l s L Y 0 G T DELETED DELETED P s p s L Y Q G T DELETED DELETED P M s p s L Y Q G T DELETED P DELETED s p s L Y Q G T DELETED P DELETED M s p s L Y Q G T DELETED P P s p s L Y Q G T DELETED, P P M s p s L Y Q G T N DELETED DELETED s p s L Y Q G T N DELETED DELETED M s p s L Y Q G T N DELETED P s p s L Y Q G T N DELETED P M s p s L Y Q G T N P DELETED s p s L L L Y Q G T N \| P DELETED M s p : i S Y Y __Q_ 0 G G J T N ' P , P s p s T N P P M s p s L Y V S S DELETED DELETED DELETED M s p i s L Y V s S DELETED DELETED DELETED s p s^ L Y V s S DELETED DELETED P o p s L Y V s s DELETED DELETED P M s p s L Y V s s DELETED P DELETED s p s L Y V s s DELETED P DELETED M s p s L Y V s s DELETED P P s p s L Y V s s DELETED P P M s p s L Y V s s . N DELETED DELETED s p s L Y V s s N DELETED DELETED M s p s L Y V s s N DELETED P s p s L Y V s s N DELETED P M s p s L Y V s s N P DELETED s p s L Y V s s N P DELETED M s p 1 S L Y V s s N P P s p I i S L Y V s s N P P W s p i i s L . Y V s T DELETED DELETED DELETED s p 1 S L Y. V s T DELETED DELETED DELETED M s p s L Y V s T DELETED DELETED P s p s L Y V s T DELETED DELETED P M s p s L Y V s T DELETED P DELETED s p s L Y V s T DELETED P DELETED M s p s L Y V s T DELETED P P s p s L Y V s T DELETED P P M s p s L Y V s T N DELETED DELETED s p s L Y V s T N DELETED DELETED M s p 1 S L Y V s T N DELETED P s P \| ! \| S L Y V s N DELETED P M S2l?59vl/!)C ASTR 013/01 WO 20 25 29 31 33 49 55 56 ! 91 I 94 95 96 ; 1.07 1 S p S L Y V , S T N P DELBTEDj I s P S L Y V S T N P DELETED! M s P s L Y V S T N P p I s p s I L Y V S T N P P j M s p s L Y V G s DELETED DELETED DELETED! I s p s L Y V G S DELETED DELETED DELETED M s p s L Y V G s DELETED DELETED p I s p s L Y V G s DELETED DELETED p M s p s L Y V G s DELETED P DELETED 1 s p s L Y V G s DELETED P DELETED M s p s L Y V G s DELETED P p 1 s p s L Y V G s DELETED P p M s p s L Y V G s N DELETED DELETED 1 s p si L Y V G s N DELETED DELETED M s p s L Y V G s N DELETED P 1 s p S ' L Y__ Y Y V G s f N DELETED P M , s -£- — p p —1 S _\| _L__^ V V "G " s"~r _N " N P DELETEDi I J DELETED! M ; s P 1 1 { S { L Y I V G s i N P P '. I s P s L Y ! V G S \| N P P M 1 s p s L Y V G T (DELETED DELETED;DELETED 1 s P . s L Y V G T DELETED DELETED\|DELETED M s p s L Y V G T DELETED DELETEDi P S ! P s L Y V G T DELETED DELETED P M S j P s L Y V G T DELETED P DELETED 1 I S j P s L. Y V G T DELETED P DELETED M 1 s p s L Y V G T DELETED P P i s p s L Y V G T DELETED P P M s p s L Y V G T N DELETED DELETED 1 s p s L Y V G T N DELETED DELETED M s p s L Y V G T N DELETED P i s p s L Y V G T N jDELETED P M s p s L . Y V G T N P DELETED 1 s p s L Y V G T N P DELETED M s p s L Y V G T N P P I s p s L" Y V G T N P P M s p s L H Q S S DELETED DELETED DELETED 1 s p s L H Q S S DELETED DELETED DELETED M s p s L H Q S s DELETED DELETED P 1 s p s L H 0 S s DELETED DELETEDi P M s p s L H Q S s DELETED p [DELETED 1 s p s L H Q S S DELETED P DELETED M s P ! 1 s L H Q s s DELETED P P p i s p s L H 0 s s DELETED P M s p s L H Q S j S N DELETEDJDELETED ■ i s p s L i H Q S ! S j N DELETED.'DELETED! M 52959 vl.'DC ASTR 013/01 WO 20 25 29 ! 31 33 49 55 56 91 94 95 96 107 S p I S L H 0 S j S N DELETED\| P t s p s L H Q s s N DELETED P M s p s L H Q s s N P DELETED I s p s L H Q s s N P DELETED M s p s L H Q s s N P P I s p s L H Q s s N P P M s p s L H L_Q s T DELETED DELETED DELETED I s p s L H Q s T DELETED DELETED DELETED M s p s L H Q s T DELETED DELETED P I s p s L H Q s T DELETED DELETED P M ! cT" p s L . H Q s T DELETED P DELETED I s p s L H Q s T DELETED P DELETED M s p - s L H Q s T DELETED P P I l_ s p s L H Q s T DELETED P P M s p I S L H Q s T N DELETED DELETED I s p s L H Q s T N DELETED DELETED M Q p ; i s L L H_ _ H H _Q__ Q s._ T N JDElETEp DELETED P P _ P P DELETED I M s p "T"r-S T T N N s p I s I I S 1 p s L Q s N DELETED M s p s L H Q s T N P P I s p s L H Q s T N P P M s p s L H Q G S DELETED DELETED DELETED I s p s L r H Q G S DELETED DELETED DELETED M s p s L H Q G s DELETED DELETED P I s p I s L H Q G s DELETED DELETED P M s p s L H Q G s DELETED P DELETED I s p s ' L H Q G s DELETED P DELETED M s p s L H Q G s DELETED P P I s p s L H Q G s DELETED P P M s p s L H Q G s N DELETED DELETED I s p s L H Q G s N DELETED DELETED M s p s L H Q G s N DELETED P I s p s L H Q G s N DELETED P M s p s L H Q G s N P DELETED I s f p s L H Q G s N P DELETED M S _j p s L H Q G s N P P I s p s L H Q G s N P P M s p s L H Q G T OELETED DELETED DELETED I s p s L H Q G T DELETED DELETED DELETED M s p s L H Q G T DELETED DELETED P s p s L H f_Q G T DELETED DELETED P M s p- s L H Q G T DELETED P DELETED i S_J p s L H Q G T DELETED P DELETED M s p s L H Q G T DELETED P P I s p s L ' H 1 Q G T DELETED P j P M 5295'.'KIX" ASTR 013/01 WO 20 25 29. 31 33 49 55 56 91 94 95 96 107 S p s L H Q Q G T N ^ DELETED DELETED S p s L . H G T N DELETED DELETED M s s p s L H Q G T N DELETED P p s L H Q G T N DELETED P M s p s L H Q G T H P DELETED r s p s L H Q G T N ■P. DELETED M s p 1 s L H Q G T N P P s p 1 1 s L H Q G T N P P M s p s L H V s S DELETED DELETED DELETED s p s L H V S s DELETED DELETED DELETED M s p s L H V s s DELETED DELETED P s p s L H V s s DELETED DELETED P M s p s L H V s s DELETED P DELETED s p s L H V s s DELETED P DELETED M s p s L H V s s DELETED P P s p \| i i s L H v s s DELETED P P M P,! !_._ _s . L L H V s s -I N DELETED DELETED "_pj 1 s H V s s ' N DELETED DELETED M 1 S p s L H V s s N DELETED P p s J L H V 3 s N DELETED P M s~l p s L H V S s N P DELETED s p s L H V s s N P DELETED M s p s L H V s s N P P s p 1 s L H V s s N P P M s p s L H V s T DELETED DELETED DELETED s p S \| L H V s T DELETED DELETED DELETED M s p s L H V s T DELETED DELETED P s p —£—I L H V s T DELETED DELETED P M s p s L H V s T DELETED P DELETED s p s L H V s T DELETED P DELETED M s_ s p 3 L H V s T DELETED P P p s L H V s T DELETED P P M s p s L H V s T N DELETED DELETED s p s L H V s T N DELETED DELETED M s p s L H V s T N DELETED P s p s L H V s T N DELETED P M s p s L H V s T N P DELETED s p s L H V s T N P DELETED M s p s L H V s T N P P s p s L H V s T ' N P P M s UP— s L H V G S DELETED DELETEDjDELETED s p s L H V G S DELETED DELETED\|DELETED M \| s p s L H V G S DELETED DELETED! P s p s L H V G S DELETED DELETED P P M s p s L H V G s DELETED DELETED s i p s L I H f v G s DELETED P jDELETED M 5295') vUDC ASTR013/01 WO 20 25 29 ~31 33 49 55 56 91 s 94 95 96 107 j__S p s L H V G DELETED P P s p s L h H V G s DELETED P P M s p s L H V G s N DELETED DELETED s p s L \| H V G s N DELETED DELETED M s p s L H V G s N DELETED P s p s L H V G s N DELETED P M s p s L H V G s N P DELETED s p s L H V G s N P DELETED M s p s L FH V ' G s N P P s p I S L H V G s N P _, P M s p s L H V G T DELETED DELETED DELETED s p s L H V G T DELETED DELETED DELETED M s p s L H V G T DELETED DELETED P s p s L H V G T DELETED DELETED P M s p s L H V G T DELETED P DELETED s p i ! s I. L H V \| G T DELETED P DELETED s p H H G ™G " T T T DELETED P j P DELETED! P \ 9 s p 1 s M s p s L H V G N (DELETED DELETED s p s -I L H V G T N DELETED DELETED M s p s L H V G T N DELETED P s p s L H V G T N DELETED P M s p s L H V G T N P DELETED s p s L H V G T N P DELETED M s p s L H V G T N P P s p s L H V G T N P P M s p s Y Q S S DELETED DELETEDlDELETED s p s Y Q S s DELETED DELETED DELETED M s p s Y Q S s DELETED DELETED P s p s Y Q s s DELETED DELETED P M s p s Y Q s s DELETED P [DELETED s p s Y Q s s DELETED P DELETED M s p s Y Q s s DELETED P P s p s Y Q s s DELETED P P M s p s Y Q s s N DELETED DELETED ■ s p s Y Q s s N DELETED DELETED M s p s Y Q s s N DELETED P I s p - s Y Q s s N DELETED P M s p s Y Q s s N P DELETED s p s Y Q s s N P DELETED M s p s Y Q s s N P P s p s Y Q s s N p : P M s p s Y Q s T DELETED DELETED DELETED s p s Y Q s ' T DELETED DELETED DELETED M s p i s ] Y Q s T DELETED DELETED P s p s Y Q ' s T DELETED DELETED! P { M 52M9 vl/DC ASTR 013/01 WO 20 25 29 31 ! 33 49 55 56 91 94 95 P 96 107 S p s Y 0 S T DELETED DELETED I S p s Y Q S T DELETED P DELETED M ! S p 1 S Y Q S T DELETED P P s ' p s Y Q s T DELETED P P M . s p s t i : Y Q s T N DELETED DELETED s p S Y Q s r- T N DELETED DELETED M s p s Y Q s T N DELETED P s p s Y Q s T N DELETED P M s p s Y Q s T N P jDELETED s p s Y Q s T N P DELETED M s p s , I Y Q s T N P P s p s Y Q s T N P P M s p s Y Q G S DELETED DELETED DELETED s p s Y Q G S DELETED DELETED DELETED M s p s Y Q G s DELETED DELETED P s p 1 i S Y Q ^G s DELETED DELETED P M s _ ^ p i i s i I Y Q G s DELETED P DELETED p 1 J S i 1 ! Y Q G s DELETED P DELETED M ; c p i i S I Y Q G s DELETED P ! P I s p s I Y Q G s DELETED P P M s p s Y Q G s N DELETED DELETED s p s Y Q G s N DELETED DELETED M s p s Y Q G s N DELETED P s 1 p s Y Q G s N DELETED P M s p s Y Q G s N P DELETED s p s Y 0 G s N P DELETED M s p s Y Q G s N P P s p S ! I Y Q G s N P P M s p s j Y Q G T DELETED DELETED DELETED s p s Y Q G T DELETED DELETED DELETED M s p s Y Q G T DELETED DELETED P s p s Y Q G T DELETED DELETED P M s p s Y Q G T DELETED P iDELETED s p s Y Q G T DELETED P DELETED M s p s Y - Q G T DELETED P P s p s Y Q G T DELETED P P M s p s Y Q G T N DELETED DELETED s p s : Y Q G T N DELETED DELETED M s p s Y Q G T H DELETED P s p s Y Q G T N DELETED! P M s p s Y Q G T N P jDELETED s p s Y Q G T N P DELETED M s p s Y Q G T N P [ P I s p s i i Y Q G T N P i P M s p s Y V S S DELETED DELETED DELETED s p 3 I ! Y V s I s DELETEDiDELETED DELETED M 52959 v],'DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S p s Y V V s S DELETED DELETED DELETED DELETED _f P M s p s Y s p s Y V s S DELETED P DELETED s L_P s Y V s s DELETED P DELETED M s p s Y V s S DELETED P P s p s Y V s s DELETED P P M s p s Y V s s N DELETED DELETED s p s Y V s s N DELETED DELETED1 M s p s Y V s s N DELETED P s p s Y V s s N DELETED P M s p s Y V s s N P DELETED s p s Y V s s N P DELETED M s p s Y V s s N P P s p s i i \| Y V s s N P P M s p S i I I Y V s T DELETED DELETED DELETED s p s ! i : Y V s T DELETEDiDELETED DELETED M __s___ —s_. s p s I i : Y V s T DELETEDIDELETED P p 1 s ; i ; Y V __s„ s T DELETED DELETED! P M ■ p 1 j S ! 1 i Y V T DELETED P [DELETED s p . S I I Y V s T DELETED P DELETED M s p s i i Y V s T DELETED P ! P s p s ! i Y V s T DELETED P P M s p s ! i Y V s T N DELETED DELETED s p s i i Y V s T N DELETED DELETED M s p s I i Y V s T N DELETED P s p S I Y V s T N DELETED P M s p s Y V s T N P DELETED s p s Y V s T N P DELETED M ~s p s Y V s T N P P s p s Y V s T N P P M s p s Y V G S DELETED DELETED DELETED s p s Y V G S DELETED DELETED DELETED M s p s Y V G s DELETED DELETED P s p s Y V . G s DELETED DELETED P M s^ p s Y V G s DELETED P DELETED s p s Y V G s DELETED P DELETED M s p s Y V G s DELETED P P s p s Y V G s DELETED P P M s p s Y V G s N DELETED DELETED s p s Y V G s N DELETED DELETED M s p s Y V G s N DELETED P s p s Y V G s N DELETED P M s p s Y V G s N P DELETED s p S I I Y V G s N P DELETED M s p S \ I Y V G s N p ! p s p s : i Y V G s N p ! p M 5^'J59 vl/DC ASTR 013/01 WO 20 S 3 25 j 29 31 33 49 55 56 91 94 95 96 107 P S Y V G T DELETED DELETED DELETED P s Y V G T DELETED DELETED DELETED M s ,. P [ . S Y V G T DELETED DELETED P 5 P 1 S Y V G T DELETED DELETED P M S P s Y V G T DELETED P DELETED S P s Y V G T OeLETEDi P DELETED M I s P , s Y V G T DELETED P P s P s Y V G T DELETED P P M s P s Y V G . T N DELETED DELETED S ' P s Y^ V G T N DELETED DELETED M s P s Y V G T N DELETED P s P s Y V G T N DELETED P M s P s Y V G T N P DELETED s P s Y V G T N \| P DELETED M s P 1 s Y V G T N P P h s P s Y V i G T N P P M s P ! S H i Q s S DELETED DELETED DELETED DELETED I \| s P ! : 3 i H Q s . s DELETED DELETED M s Pi 1 ■ S H Q s S DELETED DELETED P s P IS H Q s S DELETED DELETED P M s P s H Q s s DELETED P DELETED s P 1 s H Q s s DELETED P DELETED M s P s H Q s s DELETED P P s P s H Q s s DELETED P P ! M I s P s H Q s s N DELETED DELETED Is P s H Q s S : N DELETED DELETED M s P 1 S H Q s s N DELETED P 5 "! P 1 S H Q s s N DELETED P M S ! P s H Q s s N P DELETED S i P s H Q s s N P DELETED M s P s H Q s s N P P s P s H Q s s N P P M s P s H Q s T DELETED DELETED DELETED s P s H Q s T DELETED DELETED DELETED M s P s H Q s T DELETED DELETED P s P s H Q s T DELETED DELETED P M s P s H Q s T DELETED P DELETED s P s H Q s T DELETED P DELETED M s P s H Q s T DELETED P P s P s H Q s T DELETED P P M s P s H Q s T N DELETED DELETED s P s H Q s T N DELETED DELETED M s P s H Q s T N DELETED P ! S I P s H Q s T N DELETED P M s P s H Q ! S T N P DELETED P s 1 H Q \| S T N P DELETED M 5295 vMiVJ ASTR 013/01 WO 20 25 i 29 31 33 49 j 55 56 91 94 95 96 107 S P 1 S H i Q s T N P P s P S H Q s T N P P M s P s H Q G S DELETED DELETEDJDELETED s P s H Q G S DELETED DELETED DELETED M s P s H Q G s DELETED DELETED P s P s H 0 G j s DELETED DELETED P M s P s H Q G s DELETED P DELETED s P s H Q G s DELETED P DELETED M s P s H Q G s DELETED P P s P s H Q G s DELETED P P M s P s H Q G s N DELETED DELETED s P s H Q G S N DELETED DELETED M s P s H Q G s N DELETED P s P s H Q G s N DELETED P M s P S I H Q s N P DELETED s P ] s H Q G s ! N P p DELETED M 3 P \| 1 s H H 0 G s N P s P \| 1 s Q —I G s N P M s P ! i s I H Q ~~l G T DELETED DELETED DELETED s p s H Q G T DELETED DELETED DELETED M s p s H Q G T DELETED DELETED P 1 S ! P i s H Q G T DELETED DELETED: P M s p s H Q G T DELETED P JDELETED s p s H Q G T DELETED P DELETED M s p s H Q G T DELETER p P s p s H Q G T DELETED p P M s p s H Q G T N DELETED DELETED s p s H Q G T N DELETED DELETED M s p s H Q G T N DELETED P s p s H Q G T N DELETED! P M s p s H Q G T N P DELETED s p s H Q G T N P DELETED M s p s H Q G T N P P s p s H Q G T N P P M s p s H V S S DELETED DELETED DELETED s p s H V S S DELETED DELETED DELETED M s ■ p s H V S s DELETED DELETED P % p s H V s s DELETED DELETED P M s p s H V s s DELETED P DELETED s . p s H V s s DELETED P DELETED M s p 3 H V s s DELETED P P ! 1 s p s H V s s DELETED P P M s p I ! S H V s s N DELETED OELETED s p t s H V s s N DELETED DELETED M s p s H V s s N DELETED1 P S P s H V s s N DELETED\| P M ASTR013/01 WO 20 25 29 31 L 33 49 55 56 91 94 95 96 107 S p s H V s S N P DELETED S __p 1 s H V s s N "" P DELETED M S p s H V s s N P P S p s H V s s N P P M S p s H V I S T DELETED DELETED DELETED S p s H V s T DELETED DELETED DELETED M S p s H V s T DELETED DELETED P 3 p s H V S T DELETED DELETED P M s p ' s I H V s T DELETED P DELETED \| j s p s H V s T DELETED P DELETED M s p s H V s T DELETED P P s p s H V s T DELETED P P M s p s H V s T N DELETED DELETED s p s H V s T N DELETED DELETED M s p s H V s T N DELETED P s p s H V s T N DELETED P M s i p s I H V s T N P DELETED s p s H V s T N P DELETED M s ■ p s H V s T N P P s p s H V s T . N P P M s p s H V G S DELETED DELETED DELETED s p s H V G s DELETED DELETED DELETED M s p s H V G s DELETED DELETED P s p s H V G s DELETED DELETED P M s p s H V G s DELETED P DELETED s p s H V G s DELETED P DELETED M s p s H V G s DELETED P P I s p s H V G s DELETED P P M s p s H V G s N DELETED DELETED s p s H V G s N DELETED DELETED M s p s H V G . s N DELETED P s p s H V G s N DELETED P M s p s H V G S I N P DELETED s p s H V G s N P DELETED M s p s H V G s N P P s p s H V G s N P P M s p s H V G T DELETED DELETED DELETED s p s - H V G T DELETED DELETED DELETED M s p s H V G T DELETED DELETED P s p s H V G T DELETED DELETED P M s p s H V G T DELETED P DELETED s p s H V G T DELETED P DELETED M s p s H V G T DELETED P P s p 1 I S H V G T DELETED P P M s p i!s!) H V G T N DELETED DELETED s p 1 j S 1 H V G T j N DELETED DELETED M S^S9 vl/IX" ASTR 013/01 WO 20 \| 25 \| 29 31 ! 33 49 55 56 91 94 95 96 107 s p ! i s ! H V G T N DELETED P s p S ! H V G T N DELETED P M s p s 1 H V G T N P DELETED s p s H- V G T N P DELETED M s p s H V G T N P P s p s 1 H V G T N P P M S J p R L Y Q S S DELETED] DELETED DELETED s p R L Y Q S S DELETED DELETEDj DELETED M s p R L Y Q S s DELETED DELETED P s p R L Y 0 s s DELETED DELETED P M S J p R L Y Q s s DELETED P DELETED s p R L Y Q s s DELETED P DELETED M S _j p R L Y Q s s DELETED P P _-JL_\| p R L Y Q s s DELETED P P M s p R L Y Q s s N DELETED DELETED s p R L Y 0 s s N DELETED DELETED M s p R L V Q 1 s s N DELETED P s P ; 1 ! R L Y Q s s N IDELETED P M s p : i R L Y G s s N \| P DELETED s P ! i R L Y Q s s N ! P DELETED M s p R L Y Q s s N P P s p R L Y Q s s N P P M s p R L Y Q s T DELETED DELETED DELETED s p R L Y Q s T DELETED DELETED DELETED M s p R L Y Q s T DELETED DELETED P s p R L Y Q s T DELETED DELETED P M s p R L Y Q s T DELETED P DELETED s p JR. L Y 0 s T DELETED P DELETED M s p R L Y 0 s T DELETED P P s p R L Y Q s T DELETED P P M s p R L Y Q s T N DELETED DELETED s p R L Y Q s T N DELETED DELETED M s p R L Y Q s T N DELETED P s p R L Y a s T N DELETED P M s p R L Y a s T N P DELETED L_s_ p R L Y Q s T N P DELETED M s p R L Y Q s T N .P P s p R L Y Q s T N P P M s p R L Y Q G S DELETED DELETED DELETED s p R L Y Q G s DELETED DELETED DELETED M s p R L Y a G s DELETED DELETED P s p R L Y 0 G s DELETED DELETED P M s p R L Y Q G s DELETED P DELETED s p R L Y Q G s DELETED P DELETED M s p R L Y Q G s DELETED P P s p R L Y Q G . 1 s DELETED P P M 5333 vi/DC" ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 \| 95 96 107 S p R L Y Q G s N DELETED DELETED s p R L ! Y Q G s N DELETED DELETED M s p R L Y Q G s I N DELETED P s p R L Y Q G s N DELETED P M s p R L Y Q G s N P DELETED s p R L Y Q G s N P IDELETED M s p R L Y Q G s N P P s p R L Y Q G s N P P M s p R L Y Q G T DELETED DELETED DELETED s p '. R L Y Q G T nFlETED DELETED DELETED M s p R L Y Q G T DELETED DELETED P s p R L Y Q G T DELETED DELETED P M s p R L Y Q G T DELETED P DELETED s p R L Y Q G T DELETED P DELETED M s s p 1 R L i V Q G T DELETED P P p R L I Y y y Y 0 G T DELlliP P P M '■■ s p 1 1 R . L L I Q G T N DELETED DELETED DELETED M r~_s p ! J p : R R Q Q G T N 4 DELETED DELETED L_S_„ v s i G ■ T I N ~f P T* R 1 k V Q G 7 l io ' IDEVETEd "P "M s p R L Y Q G T N P DELETED s p R L Y Q G T N P DELETED M s p R L Y Q G T N P P s p R L Y Q G T N P P M s p R L Y V S S DELETED DELETED DELETED s p R L Y V S S DFLETED DELETED DELETED M s p R L Y V S s DELETED DELETED P s p R L Y V s s DELETED DELETED P M s p R L Y V s s DELETED P DELETED s p R L Y V s s DELETED P DELETED M s p R L Y V s s DELETED P P __s s p R L Y V s s DELETED P P M p 1 R L Y V s s N DELETED DELETED s p R L Y V s s N DELETED DELETED M s p R L Y V s s N DELETED P s p R L Y V s s N DELETED P M s p R L Y V s s N P DELETED I s p R L Y V s s N P DELETED M s p R L Y V s s N P P s p R ]_ L Y V s s N P P M s p R L ■Y V s i T DEIFIED DELETED DELETED DELETED I s p R L Y V s 1 T DELETEDJDELETED M s p 1 R L Y V s ! T DELETED DELETED! P s p R I. Y V s T DELETED DELETED! P M s i P R L Y V s T DELETED P IDELETEC I s J p R L Y V s T DELETED P (DELETED M ASTR 013/01 WO 20 25 29 31 33_l49\| 55 56 91 94 95 ! 96 107 S p R L I Y V s T DELETED P p i i s p R L Y v s T DELETED P P M s p R L Y V s T N DELETED DELETED s p ■ R L Y V s T N DELETED DELETED M s p R L Y V s T N DELETED P s p R L Y V s T N DELETED P M s p R L Y V s T N P DELETED s p R L Y V S _\| T N P DELETED M s p R L Y V s T N P P s p R L Y V s T N P P M s p R L Y V G S DELETED DELETED DELETED s p R L Y V G s DELETED DELETED DELETED M s p R L Y V G s DELETED DELETED P s P ! ! R L Y V G s IDELETED DELETED P M J s p ! i R L Y V G s DELETED P DELETED s p R L Y ! V G s DELETED P DELETED M s p R L Y I V G s DELETED P p s j P R L Y V ' G I S (DELETED1. P P M s ; p ! i R L Y V G s N DELETEOlDELETED I I s p i i R L Y V G s N DELETED DELETED M s p R J L Y V G [_S N DELETED P s p R L Y V G s N DELETED p M S ' P R L Y V G s N P DELETED S ? P ! R L Y V G ~ s N P DELETED M s ! P R L Y V G s N P P s p R L Y V G s N P P ! M s p R L Y V G T 'DELETED DELETED DELETED s p R L Y- V G T DELETED DELETED DELETED M s p _5lJ L Y V G T DELETED DELETED P s p R L Y V G- T DELETED DELETED • P M s p R L Y V G T DELETED P DELETED s p R L Y V G T DELETED P DELETED M s p R L Y V G T DELETED P P I s p R L Y V G T DELETED P P M s p R L Y V G T N DELETED DELETED s p R L Y V G T N DELETED DELETED M s p R L Y V G T N DELETED P s p R L Y V G T N DELETED P M s p R L Y V G • T N P DELETED s p R L Y V G T N P DELETED M s p R L Y V G T N P P s p R L Y V G T N P P M s p I ! R L H Q S S DELETED DELETED DELETED s p i 1 R _J^J H Q s i s DELETED DELETED DELETED M s p R L H Q S f S :DELETEDiDELETED P 1 S \| P ! 1 [ R L \| H Q s I s IDELETEDIDELETED; P j M 52159 vl/DC ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S p R L H Q S S DELETED P DELETED I s P R L H Q s s DELETED P DELETED M s p R L H Q s s DELETED P P P I M s p I R L H Q s s DELETED P s p i I R L H Q s s N DELETED DELETED t s p ( 1 R L H Q s s N DELETED DELETED M s • p 1 1 R L H Q s s N DELETED P I s p R L H Q s s N DELETED P M s p R L H Q s s N P DELETED I s p R L H Q s s N P DELETED M s p R L H Q s s N P P 1 s p R I H Q s s N P P M s p R L H Q s T DELETED DELETED DELETED 1 s p R~~1 L H Q s T DELETED DELETED DELETED M s p R L H Q s T DELETED DELETED P 1 s p R L H Q s T DELETED DELETED P M 1 S P_ S 1 P ~~R _ L_ j ..H Q s T DELETED P DELETED 1 R \| L !- H Q s T DELETED J> P DELETED! M s p 1 R i L H Q ! S T DELETED P ! ! s p R L H Q s T DELETED P P M s p R L H Q s T N DELETED DELETED 1 s p R L H Q s T N DELETED DELETED M S \| P R L H Q s T N .'DELETED p 1 S 1 P R L H Q s T N DELETED p M S j P R L H Q s T N i P DELETED 1 S 1 P R L H Q s T N P DELETED M S \| P R L H Q s T N P P 1 s ! p R L H Q s T N P \| P M s p R L H Q G S DELETED DELETED DELETED t s ■p R IS H Q G S DELETED DELETED DELETED M s p R L , H Q G s DELETED DELETED P 1 s p R L H Q G s DELETED DELETED P M S P R L H Q G s DELETED P DELETED 1 s p R L H Q G s DELETED P DELETED M s p R L H Q G s DELETED P P 1 s p R L H Q G s DELETED P P • M s p R L H Q G s N DELETED DELETED 1 s p R L H Q G s N DELETED DELETED M s p R L H Q G s N DELETED P 1 s p R L H Q G s N DELETED P M s p R L H Q G s N P DELETED 1 s p R L H Q G s N P DELETED M s p R L H Q G s N P P 1 s p R L H Q G s N P P M s p R I L H I Q G T DELETED DELETED DELETED ! L> j p R f L H Q G T DELETED DELETED DELETED M 52951 vl/DC" ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S p R L H Q G G T DELETED DELETED p s p R J L H Q T DELETED DELETED p M s p R L H Q G T DELETED P DELETED s p R_j L H 0 G T DELETED L_ P DELETED M s p R L H Q G T DELETED P p s p R __\| L H Q T DELETED P p M s p R L H Q G T N DELETED DELETED s p R L H 0 G T N DELETED DELETED M s p - R L H Q G T N DELETED P s p R L H Q G T N DELETED P M s p R L H Q G T N P DELETED s p R L H s p R L H 0 G T N P P s p R L H 0 G T N P P M s p i \| R L H V S S DELETEDj DELETED DELETED s p 1 i R L H v ] S S DELETED DELETED DELETED M s s p 1 ! R L H V S s DELETEDiDELETED P P M p 1 \ ~R~^ i H V s s DELETED DELETED s p I i R L H V s s DELETED P DELETED s p [ ! R L H V s s DELETED P DELETED M s p 1 ! R L H V s s DELETED P P I s p I ( R L H V s s DELETEO P P M s p 1 ! R L ^ H V s s N DELETED DELETED ■ s p R L H V s s N DELETED DELETED M s p R L H V s s N DELETED P s p R L H V s s N DELETED! P M s p R L H V s s N p DELETED s p R L H V s s N p DELETED fv'i s p R L H V s s N p ! p s p R L H V s s N p i P M ' s p 1 1 R L H V s T DELETED DELETED!DELETED s p t 1 R L H V s T DELETED DELETED DELETED M s p 1 1 R I. H V s T DELETED DELETED P s p L R L H V s T DELETED DELETED , P M s p R L H V s T DELETED p DELETED s p R \ L H V s T DELETED P DELETED M s p R L H V s T DELETED ' p P s p R L H V s T DELETED p P M s p R L H V s T N DELETED DELETED s p R L H V s T N DELETED DELETED M s p \|_R__ L H V s T N DELETED P I s p R L H • V s T N DELETED P M s p R L H V s T N p DELETED f ( s p 1 i R L H V s T N p DELETED M s p 1 1 R L H V s T N p P s p 1 ! R L H . v s T N p P M 52W9 vVUC ASTR 013/01 WO 20 I 25 29 31 33 I 49 55 56 91 94 ! .95 96 107 S "1 p R L H V G S DELETE DpELETEO DELETED s i p R L H V G s DELETED DELETED DELETED M S ! p R L H V G s DELETEDIDELETED P s p R I H V G s DELETED DELETED P M s p R L H V G s DELETED P DELETED s p R L H v G s DELETED P DELETED M s p R L H V G s DELETED P P s p R L H V G s DELETED P P M s p I i R L H ^ V G s N DELETED DELETED s p R L H V G s N DELETED DELETED M s p ■ R L H V G s N DELETED P s p R L H V G s N DELETED P M s p R L H V G s N P DELETED s p I R L H V G s N P DELETED M s p R L H V G s N P P I s p R L H v ■ G s N ! P P M s p R L H V G T DELETEDiDELETED DELETED s p 1 R L i H V G T DELETED DELETED DELETED M s p R L H V G 1 T DELETED DELETED: P s p R L H V G T DELETEDIDELETED; P M s p R L H V G T DELETED! P DELETED s p R L H V G T DELETED P DELETED s p R L H V G T DELETED! P P s p R L H V G T DELETED P i P M s p R i H V G T N DELETED DELETED s p R L H V G T N DELETED DELETED M s p R L H J V G T N DELETED P s p R L H V G T N DELETED P M s p R L H V G T N P OELETED s p R L H V G T N P DELETED s p R L H V G , T N P" P s p R L H V G ! T N ! P ! P M s p R Y Q S S DELETED DELETED DELETED s p R Y Q S s DELETED DELETED DELETED M s p R Y Q S s DELETED DELETED P s p R Y Q S s DELETED DELETED P M s p R Y Q S s pELETED P DELETED s p R - Y Q S s DELETED P DELETED M s p R Y Q s s DELETED P P s p R Y Q s s DELETED P P M s p R Y Q s s I N DELETED DELETED s p R Y Q ; s s j N DELETEDiDELETED M s p R ■ ; Y Q 1 s s i_ N DELETED P s p R Y Q 3 s i N DELETED P M s PH"'~! R Y i Q i 3 s ^ s I N P DELETED I s P 1 i I R Y ! Q i S I N ' P 'DELETED I M 52Wv]/nc AST& 0(3^01 Wd 20 ] 25 \| 29 31 33 49 55 \| 56 91 94 95 96 107 s i p R Y Q s S N -i P \| P " * "1 p R y Q s s N P I P M s ! p R Y Q S T DELETED DELETED DELETED 1 s p i i R Y Q s T DELETED DELETED DELETED M s , p 1 ' R y Q J s T DELETED! DELETED! P s p 1 R Y Q s "* T DELETED DELETED P M s p R Y Q s T DELETED! P DELETED s p R Y Q s 4 T DELETED! P DELETED] M s p R I Y Y 0 s T DELETED P ] P s p R Q s T DELETED P j P M s p R Y Q s T N DELETED DELETED s p R Y Q s T N DELETED DELETED M s p 1 1 R ' Y Q s T N DELETED P s p 1 1 R Y Q s T N DELETED P M s p 1 1 L_R__L_L_ Y Q s T N P DELETED s p 1 1 t~~R~l Y Y Q s T N P DELETED __M__J s s P ! I __R i _\| i Y R ! i i Y _Q Q 5 s .N J P -P. - i _] p '■ 1 P 1 ! .N P P M R I I Y Q G s DELETED DELETED DELETED o~l •> n; i i r R Y Q G __JLJ DELETED DELETED DELETED M s p i i R Y Q G s DELETED p€LETED\| P s p 1 i R Y 0 G s DELETED DELETED P M s p 1 1 R Y Q G s DELETED P DELETED s p i i R Y Q G s DELETED P DELETED M s p i i R Y 0 G s DELETED P P s p ! i R Y Q G s DELETED P P M s p R Y Q G s N DELETED DELETED s p R Y Q G s N DELETED DELETED M s p R Y Q G s N DELETED P s p R —!— Y Y 0 G s N DELETED P M s p 1 R Q G s N P DELETED ' s p '"R l ! Y Q G s N P DELETED M s p R I i Y Q G s N P P s p R Y Q L_G_ s N P P I M ' s p R Y Q G T DELETED DELETED DELETED I s p R Y Q G T DELETED DELETED DELETED M s p R Y 0 G T DELETED DELETED P s p R Y Q G T DELETED DELETED P M s p R Y Q G T DELETED P DELETED s p R Y Q G T DELETED P DELETED M s p R Y Q G T DELETED L p i p s p R Y Q G T [DELETED p P I M s p R Y Q G T I N DELETED DELETED I s F R Y 0 G T ! N DELETED DELETED M s p R Y Q G T I N [DELETED P I 1 s p R Y 0 G T I N JDELETED P ! M S2959vi/iX" ASTR 013/01 WO 20 25 1 29 31 33 49 55 56 91 94 95 96 107 s p 1 1 L_R Y Q G T N P DELETED s p R^ 1 Y Q G T N P DELETED M s p j I R Y Q G T N P P s p j i R Y 0 G T N P P M s P ! 1 1 R Y V S S DELETED DELETED DELETED s P \| 1 ! R 1 1 Y V S S DELETED DELETED DELETED M s P ! 1 j R 1 ! Y v s s DELETED DELETED P s , P 1 1 j R 1 I Y V s s DELETED DELETED P M s P R " 7■" Y V s s DELETED P DELETED M s P R Y V s s DELETED P DELETED s P R Y V s s DELETED P P s P R Y V s s DELETED P P M s P R Y V s s N DELETED DELETED s P R Y V s s N DELETED DELETED M s P 1 R Y V s s N DELETED P s P _ ' R _i .J - Y V s s N DELETED P M s P R^ i ' Y v ! s v T s s N P P DELETED s 1 i R s N DELETED P M I s P ■ I ! R 1 ! Y V s s N P ! i s P 1 R Y V s s N P P M s P R Y V s T DELETED DELETED DELETED s P R Y V s T DELETED DELETED DELETED M s P R Y V s T DELETED DELETED P s P j R Y V s T DELETED DELETED P M s P R Y V s T DELETED P DELETED s P i i R Y V s T DELETED P DELETED M s P 1 1 R Y V s T DELETED P P s P R Y V s T DELETED P P M s P R l_Y__ V s T N DELETED DELETED s P R 1 Y V s T N DELETED DELETED M s P R 1 ! Y V s T N DELETED P s P R 1 i Y V s T N DELETED P M s P R 1 \| Y V s T I N -4 P „ DELETED s P R i i Y V s T N I P DELETED M s P R 1 1 Y V 3 T N P P s P R 1 ! Y V s T N P P M s P R t \| Y V G S DELETED DELETEDiDELETED s P R t i Y V G S DELETED DELETED DELETED M s P R Y V G s DELETED DELETED P s P R Y V G s DELETED DELETED* P M s P R Y V G s DELETED p IDELETED s P R Y V G s DELETED p DELETED M ! s P R i i Y V G s DELETED p P 1 s P R 1 \| Y v G s DELETED p P M f s P R 1 ! Y v G s N DELETED DELETED I 1 s . P_J ' R 1 '■ Y V G s N DELETED DELETED M 52591,'Of ASTR 013/01 WO 20 1 25 29 31 I 33 49 55 56 91 ! 94 95 1 96 107 s .p - 1 R \| i Y 1 V G 1 S N DELETED' P p R j: r. Y 1 V G S \| W DELETED P ■Vi S j P R Y V G S I N P (DELETED S 1 P R \ I Y_j V G S \| N P DELETED M S ! P R _\| I Y V , G S j N I P P \| 1 c p R j Y ! V "] G -t £ N P P i (vi 1 1 § p R Y \| V G T DELETF.oioELETED DELETED 1 J s^ p R Y V G T jDELETEDJDELETED DELETED M G 1 p R Y V G T IDELETEDIDELETED P s p R Y V G T DELETED DELETED P M s p R Y V G T DELETED P DELETED s p R Y v G T DELETED P DELETED M s p R Y V G T DELETED P P s p R Y V G T DELETED P P M s p R Y V G ' T N DELETED DELETED s p R Y V G T N DELETED DELETED M 1 S p i i R ' »"] Y" V G T N DELETED) P , l 1 s p ' 1 R i i Y V 3 r N. . DELETED P M ! 1 S p j-J_' R Y V G T N P DELETED DELETED i i i s p R Y V G T N P M 1 s p R Y V G T N P P 1 S p R Y V G T N P P ^ rM s p R H Q 1 S S- DELETED DELETED DELETED s p R H Q j S S DELETED DELETED DELETED M s p R H Q ] S S DELETED DELETED P I S p R H Q { S S DELETED DELETED P M 1 s p R H Q S i S DELETED P DELETED L5^ p R H Q 1 S ! S DELETED P DELETED M i s p R H Q 1 S \| S DELETED P P s p R H Q j S j S DELETED U p M i S p R 1 H Q 1 S ! S N DELETEDlDELETED s p R I i H Q S S N DELETE D'DELETED M 1 s p R I ! H Q s S N DELETED! P i s p H H Q s S N DELETED! P M s p R H Q s s N p IDELETED s p R H Q s s N P JDELETED M s p R H Q s s N P P s p R H Q s s N P P M s p R H Q s T DELETEDIDELETED DELETED s" p R H Q s T DELETED (DELETED DELETED M s p R H Q s T DELETED DELETED P s p R H 0 s T DELETED DELETED P M s p j 1 R ' jJL Q s T DELETED! P JDELETED s p R 1 j H Q s T DELETED! P [DELETED M i s i p R _J±_i ° S ! T DELETED! P i P ! s i p j i R ! I ~H , Q s T DELETED ! p 1 P M A&Tit(H3/0l WO 2G 25 [ 29 , 31 33 f 49 55 56 91 94 «^ 96 , 107 i s p T i-1 R -I I [ H Q s T N DELETED DELETED! I s p 1 1 R I j H Q s T N DELETED DELETED M s p R ' L"-, Q s T N DELETED P I ! o p R i TH Q s T N DELETED P ! M H- p R 1 ! H Q s T N P DELETED! I p R l ! H Q s T N P DELETED! M s p R 1 \| H Q s T N P P i I s p ■ R 1 ! H Q s T N P P ( M s p R H Q G S DELETED DELETED DELETED) _J___\| s p R H Q G S DELETED DELETED DELETED M s p R H Q G s DELETED DELETED P i s p R 1 H Q G s DELETED DELETED P M s p R 1 ! H Q G s DELETED P. DELETED I s p R 1 I H Q G s DELETED p !DELETED M s p R 1 H 0 G s DELETED p I p I s p R H Q G s DELETED p _J P DELETED M j 1 S p _ R I R \| s 0 G _ 6""1 _s_„ s —$- N TJELETED t i 1 S i s p p- p H Q Q N 4DELETED\|DELETED N DELETED P M ! '■ s [ ' R 1 H r Q G s N DELETED, P 1 M ! : s p 1 R , H Q G s N P "^ DELETED I s p 1 R H 0 G s _, N p DELETED M s p 1 R H 0 G s N n p P I r* s p 1 r R H 0 G s N p P M : s p 1 R H Q G T DELETED DELETED DELETED I ! s p 1 R _H_j Q G T DELETED DELETED DELETED M ) s p \ R H Q G T DELETED DELETED P I—!— s p' R H Q G T OELETED DELETED P M s p R H Q G T DELETED P DELETED I s p R H Q G T DELETED P DELETED M s p R H Q G T DELETED P P I s p R H 0 G T DELETED P P M s p R H Q G T N DELETED DELETED I s p R H Q G T N DELETED DELETED M s p R H Q G T N DELETED P t s p R H . Q G T N DELETED P M i s p R H Q G T N P DELETED I s p R H Q G T N P DELETED M s p R H Q G T N P P I 1 s ■p R H Q G T N P P M 1 S p R H V S S DELETED DELETED DELETED L ' J s p I™T~R~" H V S s DELETED DELETED DELATED DELETED L M s p i i i R 1 I H V s s DELETED P I s p i i R _±_l H V s s IDELETED DELETED J p~ i_M s P j 1 R 1 ! H V s s DELETED P DELETED \ i s P } 1 1 R 1 ! H V s s DELETED P DELETED M 529S)vl/OC ASTR 013/01 WO 20 25 29 I 31 33 49 55 56 91 94 95 96 107 ( S p i R H V s S DELETED P P I ! S p 1 .. I J_ R H V s s DELETED P P M I s P ! 1 j R H V s s N DELETED DELETED] i ! s P ! 1 R H V S _j 3 N DELETED DELETED M i s p I 1 R j H V s s N DELETED P I I s P ! 1 R H V s s N DELETED) P I M s P ! l R H V s s N P DELETED i ! s p 1 1 R I H V s s N P DELETED M i s p i i -R I I H v-1 s s N P P I s p 1 1 R H V s s N P P M s p i i R i i H V s T DELETED DELETED DELETED I s p i i R I I H v s T DELETED DELETED DELETED M s p j 1 R I I H V s T DELETED DELETED P I 1 s p ! i I R H v s T DELETED DELETED D P DELETED1 M [ r s P j 1 \| R . 1 j H j v s T DELETED 1 s p ! i R j I I H . V s T DELETED P DELETED M i S p l_JL_« L-..R_Lj.„i_._li„ R ! I _, H V g T DELETEDI P P ..l.p_r_ DELETED I i ! s V s s T DELETED P OELETED ( s -1 T N i s p R r , H V s T N DELETED DELETED M ! s p R H V s T N DELETED P I i S , p R H V s T N DELETED P M s p R H V 1 s T N P DELETED ! s p R H' V s T N P DELETED M ! s F ,R_ H V s T N P P I 1 s P R H V s T N P P M I I s P 1 R H V G S DELETED DELETED DELETED 1 s p ! i R H V G S DELETED DELETED DELETED M i s "~p~i i R H V G s DELETED DELETED P 1 s p R H V G s DELETED DELETED P M s p R H V G s DELETED P DELETED » ! s p R H V G s DELETED P DELETED M ! s p R H V G s OELETED P P 1 ! S p R H V G s DELETED) P ! P M j s p R H V G s N DELETEDJDELETED 1 1 s p R •I ! H V G s . N DELETED DELETED . M s p R l I H V G s N DELETED P 1 s p R I j H V G s N DELETED P M 1 s p R , H V G s N P DELETED 1 1 s p R I ... H V G s N P DELETED M 1 s p __J I ! H V G s N P P 1 1 s p R I I H V i G s N P P M s p R t f H V G T DELETED DELETED DELETED 1 s i p i I R kiTH V i G T DELETED DELETED DELETED M ■' S rrr i' i R_ I I H i v G T DELETED DELETED p 1 1 s __p_. R I I H V G T DELETED DELETED P 1 M S2SS5 vI/HC ASH R 013/01 WQ 20 T 25 29 \| 31 33 49 55 56 91 94 \| 95 96 107 ^ s p 1 1 R ] H V G T DELETED! P DELETED I s p 1 1 R 1 ' i H V G T DELETEDj P DELETED M s p ! i R i ! H V cT^ T DELETEDj P p ! t s p 1 1 1 R j 1 1 H V \J T DELETED! P p i M s p ' f R 1 ; H V G T N ! DELETED DELETED DELETED! s ^ p [ DELETED] M C; p i R i ! H j V G T N JDELETED . .p i \ s p i i R i 1 H i V G T N IDELETED p 1 M .• s p i j R I H 1 1\ V "* G T N P DELETED] ■ s p R 1 V G T N P DELETED M ' s p R [ H V G T N N P p . 1 s p R 1 H V G T P p M i S "p F S L Y Q S S DELETEDj DELETED DELETED ! s p F S L Y Q S s DELETED DELETED DELETED M I s p F S L Y Q s s DELETED DELETED p 1 s p J F S L ~^r\ Q s s DELETED DELETED p M i Q p ' f __S_, S ' !_ L j Y 1 0 s s DELETED .__ P_ [p_ELE_TE.D f S Y \| Q S 1 s DELETED1 P (DELETEDJ M 1 f s p 1 F 1 s L 1 _Ht Q s ( s -1- DELETEDj P ! P j * s I p F s L V 1 Q PHA-HIED P \ P ' . Wi s p F s L Y"1 Q s s N n DELETED DELETED s 1 p F s L Y 0 s s N DELETED DELETED DELETED M r s p F s L Y Q s s N p 3 p F s I L_Y Q s s N N DELETED p M s L_P F s L Y Q s s P DELETED s P F s L , Y Q s s N P (DELETED M i i p F s L " L-JL_ Q s s 1-N P p i s p F s 1 L Y Q s s ] N j P.J P I M "* s p F s ! L Y Q "S T D'ELETEDDELETEDIDELETED !Hs p F s L Y Q s T DELETEDPELETED DELETED M I S p i F s L Y Q s T DELETEDlDELETEO j P s p 1 p s L ' Y Q 1 S T DELETEDIDELETEO P M CI§__ p ! F s , Y 0 LJL T DELETED[_ P DELETED' P DELETED] P DELETED L_S p t F s L 1 Y 0 i s T DELETED M s p ! F s L Y Q s T P s p j F s L Y Q s T DELETED P P M s p ! F s L L Y Q s T N DELETED DELETED s p ) F s L Y Q s T N DELETED DELETED M 1 s p I F s L Y Q s T N DELETED P 1 s p ! F s L Y Q s T N DELETED P M i s p L F ! F s L Y Q s T N P - DELETED 1 S p 1 s ' i Y 0 s T N P DELETED M 1 s p ! F ! s \| L Y Q s i T N 1 P P ' i s p ! F ( S f L Y Q s T DELETED P ! P M ! S p i F i s ', L Y Q G S DELETEDJDELETED 1 ! s p i F 1 s i L Y Q G s DELETED DELETED\|DELETED M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 s p F S L Y Q G S DELETED DELETED P i s p F S L Y Q G s \ DELETED DELETED P—I M s p F S L Y Q G s DELETED P DELETED I ! s p F S L Y Q G _J s DELETED P DELETED M I s p F S i_ Y Q G I S JDELETED „_p !_p I I s p F i S L Y Q ! G \| S DELETED p i p M I s p F I S L Y Q i G I S N DELETED DELETED i j s p F f S 1 L Y Q I G s N DELETED DELETED M s p F S L Y Q G s N DELETED P :- t s p F s L Y Q G s N DELETED P I M s p F s L Y Q G s N P DELETED 1 s p F s L Y Q G s N P DELETED M s p F s L Y Q G j S N P P 1 s p F s L Y Q G i S N ! P P M I S p F s L Y Q G \| T DELETEDJDELETED DELETED E ■ s P F s L Y 0 G ! T DELETED\|DELETED!DELETED M 3 p F F S i L Y Q i G i T DELETED DELETED P i : : s p S ! L Y Q I G T DELETED DELETED P P M ' S p F S L Y Q G T DELETED DELETED! I s p F s L Y Q G T DELETED P DELETED M s p F ' s L Y Q G T DELETED P. P 1 s p F s L Y Q G T DELETED P P M s p F s L Y Q G T N DELETED DELETED f s p F s L Y Q G T N DELETED DELETED M : s p F s L Y Q G T N DELETED P i : s p F s L Y Q G T N DELETED P M , s p F s L Y Q G T N P DELETED 1 s p F s L Y Q G T N p DELETED M s p F s L Y Q G T N P P P 1 s p F s L Y Q G T N P i M s p F s L Y V S S DELETED DELETED DELETED ) s p F s L Y V S S DELETED DELETED DELETED M s p ■ F s L Y v \| s s DELETED DELETED DELETED DELETED! P 1 s p F s L Y V S s DELETED P M s p F s L Y V S s p DELETED 1 s p F s L Y V S s DELETED p DELETED M s p F s L Y V S s DELETED P P 1 s p F s L Y V S s DELETED P. P M s p F s L Y V S s N DELETED DELETED 1 s p F s L Y V S s N DELETED DELETED M s P 1 F s L Y V S s ! N DELETED P i I s p i F s L Y V S s M DELETEp P P M s P ! F s L Y V S s N DELETED 1 s p ; F s I Y V S s N P DELETED M s P ! F J S L Y V S s N P P 1 s p F ! S L Y V s s _ _N ... P P M ;29.s ASTR013AM WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S p F S L Y v s T DELETED DELETED DELETED S p F S L Y V s T DELETED! DELETED DELETED M S p F S L Y V s T DELETED DELETED P S p F S i Y V s T DELETE!? DELETED P M s p F s L Y V s T DELETED P DELETED f~ s p F s L Y V s T DELETED P DELETED M s p F s L Y V s T DELETED P P s p F s L Y V s T DELETED P P M s p F s i L_ Y V s T N DELETED DELETED s p F s L Y V s T N DELETED DELETED M s p F s L Y V s T N DELETED P s p F s L Y V s T N DELETED P M s p F s L Y V s T N P DELETED s p F s L Y V s T N P DELETED M s p F s L Y V s T N P P s p F s L Y V S j T N P P M s p F s s L Y V G S DELETEDDELETED DELETED s p F Y V G S DELETED DELETEDDELETED M s p F s L Y V G S DELETED DELETED P s p F s L Y V G S DELETED DELETED P M s p F s L Y V G s DELETED P DELETED s p F s L Y V G s DELETED P DELETED M s p F s L Y V G s DELETED P P s p F s L Y V G s DELETED P P M s p F s L Y V G s N DELETED DELETED s p F s L Y V G s N DELETED DELETED M s p F s L Y V G s N DELETED P s p F s L Y V - G s N DELETED P M s p F s L Y V" G s N P DELETED s p F s L Y V G s N P DELETED M s p F s L Y V G s N P P s p F s L Y V G s N P P M s p F s L Y V G T DELETED DELETED DELETED s p F s L Y V G T DELETED DELETED DELETED M s p F s L Y V G T DELETED DELETED P 1 s p F s L Y V G T DELETED DELETED P M s p F s L Y V G T DELETED P DELETED s p F s L Y V G T DELETED P DELETED M s p F s L Y V G ' T DELETED P P s p F s L Y V G T DELETED P P M s p F s L Y V G T N DELETED DELETED s p F s L Y V G T N DELETED DELETED M s p F s L Y V G T N DELETED P 1 s p F s L Y V G T N DELETED P M s p F s L Y V G T L.._N . p DELETED s p F s L V r v G T : N P DELETED M 52'j.v.' vi/nr ASTR 013/01 WO 20 25 29 31 33 ! 49 55 56 91 94 95 96 107 S p F S L Y V G T N P P s p J F S L J Y V G T N P P W __j s p F s L ! H G S S DELETED DELETED DELETED 5 p F s L ! H Q S s DELETED DELETED DELETED M s p F s L H Q S s DELETED DELETED P s p F s L : H Q s s DELETED DELETED P M s p F S L i H Q s s DELETED P DELETED s p F S L H Q s s DELETED P DELETED M s P F S L H 0 s s DELETED P P s p F s L H 0 s s DELETED P P M s p F s L H Q s s N [DELETED DELETED s p F 3 L H Q s s N (DELETED DELETED M s p F S L H Q s s N DELETED P s p F s L H Q s s N DELETED P M s p F s L H Q s s -N P DELETED s p F S L H 0 I S s N P DELETED M S P L F S [_ H 0 s s N p P s p F , S L H' Q s S N P M s P \ F s L H Q s T DELETED DELETED DELETED \| s p F s L H Q s T DELETED DELETED DELETED M s p F s L H Q s T DELETED DELETED P s p F s L H Q s T DELETED DELETED P M s p F s L H Q s T 'DELETED P DELETED s p F s L H Q s T IDELETED P DELETED! M s p F s L H Q s T JDELETED P P s p F s L H Q s T DELETED P P M L_s p F s ! L H Q s T N iDELETED DELETED s p F \| S i L H Q s T N DELETED DELETED M 1 S ! P i F S L H Q s T N DELETEDF P M S I P F s L H Q . s T P iDELETED s ! p F s L H 0 s T N P DELETEDI __M s p F s L H Q s T N P N I P P s p F s L H Q s T P M s p F s L H Q G S DELETEDiDELETED DELETED s p F s L H Q G s DELETED DELETED DELETED M s p F s L H 0 G S DELETED DELETED P s p F s L H Q G S DELETED DELETED P M s p F s L ! H Q G s DELETED P DELETED g p F s L I H Q G s DELETED P DELETED M s p F s L I H Q G s DELETED P P I I s p F s L i H Q G s DELETED P P M s p F s L H Q G s N N DELETED DELETED s P F s L H a G s DELETED DELETED DELETED! M s P \| F s L H Q G s N P s P ! F s L H Q G s ■DELETED P M AS'rii on/OS wo 20 25 29 31 33 49 55 56 91 94 95 96 107 S p F S L H 0 G s N P DELETED I S p F S L H 0 G s N p ~~! DELETED M s p F s I H J 0 G s N p P I s p F s ! H 0 G s N P P M s p F s L H Q G T DELETED DELETED DELETED I s p F s L H Q G T DELETED DELETED DELETED M s p F s I H Q G T DELETED DELETED P I s p F s L - H 0 G T DELETED DELETED P P M s , p F s 1_ H Q G T DELETED DELETED 1 s p F s L H Q G T DELETED P DELETED M s p F s L H Q G T DELETED p P 1 1 s p F s L H Q G T DELETED P P M s p F s L H Q G T N DELETED DELETED 1 s p F s L H Q G T N DELETED DELETED DELETED M s p F s L H Q G T N P 1 ; s p F F F s L _ _.L L H 0 G j T N DELETED P M rl- p p s _JL_„ s _ H H H 0 G i N ! P N ! P DELETED DELETED P 1 G M 1 1 ^- F ^"Q G ' N P 1 s p F s L H Q G T N P P M 1 s p F s L H V S S DELETED DELETED DELETED 1 s p l F s L H V S S DF.LETEDIDELFTED DELETED M s p F s L H V s S ' DELETED (DELETED P 1 s p F s L H V s s [DELETED DELETED P M s p F s L H V s s DELETED DELETED P DELETED 1 s p F s L H V s s P DELETED M s p F s L H V s s DELETED P P { s p F s L H V 3 s DELETED P P M s p F s L H V S s N DELETED DELETED 1 s p F s L _, H V s s N DELETED DELETED M \| S p F s L H V s s _..M N DELETED P 1 ! s p r s L H V s s DELETED P M 1 s p F s i H V s 3 N I P N I P ' DELETED 1 s p F s L H V . s s DELETED M s p F I S L H V s s N P P 1 s p F s L H V s s N P P M s p F s L H V s T DELETED DELETED DELETED i s p F s L H V s T DELETED DELETED DELETED DELETED M s p F s L H V s T DELETED P 1 s p F s L H V s T DELETED DELETED ' P M s p F s L H V s T DELETED DELETED P DELETED 1 s p F s L H V s T P DELETED M s p F s L , H V s T DELETED P P 1 s p F s l_ H V s T DELETED p P M s p F s L H V s T N DELETED DELETED 1 s p F s L H V s T U DELETED DELETED M 53959'-■].'!)(• ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 \| 95 96 107 S p F S L H V S T N iDELETED P s p F s L H V S T N DELETED P M s p F s L H V S T N P DELETED s p F s L H V S T N P DELETED M s p F s L H V s J T N P P s p F s L H V s T N P P M I s p F S ■ L H V G S DELETED DELETED DELETED s~1 p F s L H V G S DELETED DELETED DELETED M s p F s L H V G S DELETED DELETED P s p F s L H V G s DELETED DELETED P M s p F s L H V G s DELETED P DELETED I s p F s L H V G s DELETED P DELETED M s p F s L H V G s DELETED P P s p F s L H V G s DELETED P P M s p F s L H V G s N DELETED DELETED s p F 3 L H V G s u— N DELETED DELETED M \| s p F F ____§ !_ L H V G s N DELETED P M s p __JH H V G s N DELETED P s p F s L V G s N ! P DELETED s p^ F s i L- H V G s N P DELETED M s p F s L H V G s H P P s p F s L H V G s N P P M i s p F s L H V G T DELETEDJDELETEDIDELETED i ; S p F s L H V G T DELETEDlDELETED DELETED M s p . F s L H V G T DELETED;DELETED P i S p F s L H V ' G T DELETED DELETED P M s p F s L H V G T DELETED P DELETED s p F s L H V G T„ DELETED P DELETED ■M : s p p s L ^H V G T DELETED P j P ■ s p F s L H V G T DELETED P P M s p F s L H V G T N DELETED DELETED 5 p F s L H v G T N DELETED DELETED M s p F s L H V G T N DELETED P s p F s L H V. G T N DELETED P M s p F s L H v. G T N N P DELETED s p F s L H V G T P DELETED M s p F s L H V G T N P P s p F s L H V G T N P P M s p F s Y 0 S S DELETED DELETED DELETED s p F s Y 0 s ■ S ^DELETED DELETED DELETED M s p F s Y Q S s DELETED DELETED P s p F s Y Q S s DELETED DELETED P M s p F s Y Q S s DELATED P DELETED s p F s Y Q S s DELETED P DELETED M 5 p F s Y O S s DELETED; P P i s p F s Y Q s s DELETED P_.._ P M stwjvuiic ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S p F S Y 0 S S j N iDELETED DELETED I s p F _JL_J Y Q S S N JDELETED DELETED M ' s p F s Y Q S S N N DELETED P I ! s p F s i i Y 0 S s DELETED __P, M s p F S h ' Y Q S s N N P DELETED I s p F s Y Q S s P DELETED M s p F s Y Q S s M P P ] s p F LJL Y Q s s I N P P j M s p F s Y Q s T (DELETED DELETED DELETED I s P ! F s V -I Q s T DELETED DELETED DELETED M s p F s Y ~1 Q s T DELETED DELETED P I s p F ■ s Y Q s T DELETED DELETED P M s p F s Y Q s T DELETED P DELETED I s p F s Y Q s T DELETED P DELETED M s p F s Y Q s T DELETED P P I s p F s Y 0 S i T DELETED P P M s p_ F j S i 1 Y 0 S i N DELETED DELETED I 1 s p F s Y Q s T M _ N N DELETEDlDELETED M s P ■ F s Y Q s T DELETED[_ P I s P F s I Y Q s T DELETRDi P M s __PI F s Y Q s T P DELETED I s P F s Y Q s T N P DELETED M s P F s Y Q s T N P P I s P F s Y Q s T N P P M s P F s Y Q G S DELETED DELETED DELETED I s P F s Y Q G S DELETF.n DELETED DELETED M » s P F s Y Q G s DELETED DELETED P I s P i F s Y Q G s DELETED DELETED P M s p F i S Y Q G s DELETED P DELETED I s p F s Y Q G s DELETED P DELETED! M s p F s I Y Q G s DELETED, DELETED P P I , s p F S ! I i Y Q G s P P M s p F ! s Y Q G s N DELETED DELETED I s p F s Y Q G s N DELETED DELETED M s p F s Y Q G s N DELETED P i s p F s Y Q G s N DELETED P M s p F - s Y Q G s N P DELETED I s p F s Y Q G s N P DELETED M s p F s Y Q G s P P I s p F s Y 0 G s P P M s ■ p F s Y Q G T DELETED DELETED DELETED I i s p F s Y Q G ! T DELETED DELETED DELETED M s p—i F s Y a G I T OGLU.TEO OELETEO P f s p F S J i Y G G T DELETED DELETED P M s P , F s Y Q G T DELETED! P DELETED ] s P j F s Y Q G T DELETED P DELETEDi M ■^ ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 \| 95 ! 96 107 s p F S Y Q G T DELETED! P l p I s p F s Y Q G T DELETED P P M s p F s Y Q G T N DELETED DELETED s p F s I ! Y 0 G T N ' DELETED DELETED M S J p F s I Y Q G T N DELETED P [ ! s p F s Y Q G T N DELETED P M 1 s p F s I \| Y Q G T N P DELETED s p F s i : Y Q G i T N P DELETED M s p F s~i Y Q G T N P P s p F s Y Q G T N P P M s p F s Y V S S DELETED DELETED DELETED s p F s Y V s S DELETED DELETED DELETED M s p F s Y V s s DELETED DELETED P s p F s Y V s s DELETED DELETED P M s p F s I i Y V s s DELETED DELETED P DELETED s p F s I ' Y V s s P DELETED M ; s p c s Y Y V V s s s s DELETED' P P P s p s DELI/TED P M s p p s V V s s N DELETEDIDELETED s p F s Y V s s N N DELETED DELETED M s p F s Y V s s DELETED P s p F s Y V s s tt iOELETED P M s p F s Y V s s K N P DELETED s p F s Y V s s P DELETED M s p F s Y V s s W P P s p F is Y V s s N P P M s p F s L Y V s T DELETED DELETED DELETED DELETED I i p F S i I Y V s T DELETED DELETED M s p F s Y V s T DELETEDJDELETED P s p F s Y V s T DELETED DELETED P M s p F s I Y V s T DELETED P DELETED s p F s I Y V s T DELETED; P DELETED M "" s p F s I ; Y V s T DELETED' P P s p F s Y V s T DFI..FTED P P M s p F s Y V s T N DELETED DELETED s p F s Y V s T N DELETED DELETED M s p F s Y V s T N DELETED P s p F s Y V s T N DELETED P P M s p F s Y V s T N DELETED I s p F s I Y V s T N P DELETED M s p F s Y V s T N ! P N \| P P s p F s Y V s T P M s p F s Y v G S DELETEDIDELETED DELETED s p F s Y V G s DELETED DF.LETED DELETED DELETED M S : p F S I ! Y V G s {DELETED P s p F s i i Y V G s DELETEDIDELETED P M 5?59v\|:r)C ASTRO 13/0J WO 20 S 25 29 31 33 ! 49 55 56 91 94 95 j 96 107 p F s ~n Y " V G s DELETED P DELETED i s p F I ! Y V G ' s DELETED P DELETED M s p F s I Y V G s DELETED P P I „_s._._ s p F s Y V G s DELETED P I P M p F s Y V G s . N DELETEDjDELETED i £ p F s Y V G s N DELETED DELETED M s p__j F s Y V G s N DELETED P I s p F s I \ Y V G s N DELETED P M ! s P F s I Y V G s N P P DELETED I s p F s Y V G s N DELETED M s p F s Y V G s N P P 'I s p F s Y V G s N P P M s p F s Y V G T DELETED DELETED DELETED [ s p F s Y v G T DELETED DELETED DELETED M s p F s Y V G T DELETED DELETED DELETED P I s p F s Y V G T DELETED P M s p F s V V G T DELETED P P DELETED I I s p F F s ._ i Y V G T DELATED DELETED M s p s Y V G T DELETED P I s p F s Y V G T DELETED P P M s p F s I ! Y V G T N DELETED DELETED I s p F s i : Y V G J T N N DELETED DELETED M J s p F s Y V G T DELETED P P I s p F s Y V G T _ _N N DELETED M s p F s Y V G T P DELETED I s p F s Y V G T _N P DELETED M 1 s p 1 'p s ' _r . V G T P P { s p F s Y V ■ G T N P P M s p- F s H Q S S DELETED DELETED DELETED I s p F s i H Q S s DELETED DELETED DELETED ■M s p F s H Q s s DELETED DELETED DELETED P I s p c s H Q s s DELETED P M s p F s H Q s s DELETED! P DELETED I s p __F\| s H Q s " s DELETED P DELETED M s p F s H Q s s DELETED P P I s - p F s H Q s s DELETED P P M s p F s H Q s s N DELETEDIDELETED I s p F s H Q s s N DELETED DELETED M s p F - s H Q s s N IDELETED P I s p F s H Q s s N DELETED P M s p F s H Q s s - N P DELETED i s p F s H Q s s N P DELETED M s p F s H Q s s _.__N N P P I s p F s H 0 s 3 P DELETED P V, s p p F s H Q s T DELETED DELETED ! s F s i \| H Q s T DELETED; DELETED DELETED M S295l> v\|/i)C ASTR 013/01 WO 20 25 29 31 I 33 49 55 56 91 S4 \| 95 96 107~' S p F S j J j W 0 S T DELETED)DELETED P ■ > 1 S p F S \| I ! H Q s T DELETED DELETED DELETED P M \| s s s p F , S_ ! I H Q s T P DELETED] ! 1 P ! F S „L_U^ 0 s T DELETED P DELETED M \| p F s \ ! H 0 s T DELETED DELETED , P_ -I ■ i i i s p F 5 \ ' H Q s T ...P P M s p F S i ! H Q s T N DELETED DELETED s p F S I I H 0 s T N DELETED DELETED h-M s p F s" ] i ■ H Q s T . " DELETED! P s p F s H Q s T N H DELETED P L w , s p r s H Q s T P DELETED s p F s H Q s T N P DELETED M s p F s i H Q s T N i p P s p F S i I H Q s T N P P M s p F s ! i H 0 G S DELETED DELETED DELETED s p F s ; i H Q G s DELETED DELETEDiDELETED M s p F F s H Q G s DELETED DELETED! P M s p __s„_ " s I I H Q G s s DELETED ■DELETED P 1 s p F ] i H 0 G DELETED. p DELETED! P DELETED s p F s H 0 G s DELETED M s p F s H Q G s DELETED p P S , p F s H Q s DELETED! P P M L s„i p F s I j H 0 G s N ^DELETED DELETED i j f s_n p F s I I H Q G_J s r-,i DELETED DELETED M s p F s I i H Q G s N DELETED P s p F s I ! H Q J G s N DELETED P M s p F s i i H 0 G s N D DELETED s p F S j I H Q G s -M P DELETED M s p F S ! H Q G s N P P s p F S I I H Q G s P P M s p F S I Ft 0 G T DELETEDiDELETED DELETED s p F S ! ! i H Q G T DELETED DELETED DELETED M ■ s p F s ! H 0 G T DELETED DELETED DELETED P s ,p_ F s H Q G T DELETED P M s p F s H Q G T DELETED . P DELETED s p F s H Q G T DELETED! p DELETED M s p F s H 0 G T DELETED P P s p F s H Q G T DELETED P P M s p F s H Q G T r"j DELETEDiDELETED s p F s H Q G T N DELETEDiDELETED M s p F s > . H Q G T N DELETED DELETED P s p F S i I j H Q G T N P M s —£L_i F S I \| H 0 G T N p N P DELETED . s p F s H Q G y DELETED M s p F s H Q G T N P P si p F s H Q G T N P L_ P M 5295!J vl/f>r ASTfc 013/01 WO 20 25 29 31 33 ! 49 55 56 91 94 95 96 107 1 p F S I H V s S DELETEDiDELETED DELETED p 1 F s H V s s DELETEDiDELETED DELETED M SI p F s H V s s DELETED DELETED DELETED P s p F s H V j s s DELETED P M s p F s I H V s s DELETED! P DELETED] s p r s t ! H V s s DELETED P DELETED M S _j p F s_ ! ! H V s s DELETED DELETED P P S_J p F s i ! H V s s P c M s p F s—\ H V s s N N N DELETED DELETED s p F s H V 3 s DELETED DELETED M s p F s I H V s s DELETED P s p F s I i H V s s N N DELETED P M s p F s ! i i H V s s P DELETED s p F s I ! H V s s __._P P DELETED M s p F s t \| H V s s N P s p F s I ! H V s s N; p P M s p F I i H v__ V s s T T CI-i.ETED DF.-LETED DELETEDiDELETED s p F s DELETED DELETED DELETED DELETED M ! s p F s i : H V s T DELETED P I s p F s I j H V s T DELETED P M \| s p F s ! H V s T TJELETED P DELETED \| s p F s H V s T DELETED DELETED P DELETED M s p F s H V s T P P s p F s H V s T DELETED P DELETED DELETED P M s p F s H V s T i'i DELETED s p F s H V. s T N DELETED M ; s ^ p F ^p I H V s n T N jDELETED P f s p F I H V s T N DELETED P P M _S \| p F S ! H V s T N / J DELETED , : s p F s I H V s T P DELETED M s p F s H V s i P s p F s H V s -r P P M s p F s H V G s DELETED DELETED DELETED s p r s I H V VJ s DELETED DELETED DELETED DELETED M s p F s '• ' I ! H V G s DEL ETED P s p F s I ! H V G s DELETED DELETED P M s p F s I i H V G s DELETED P. DELETED s p F s I i H V G s DELETED P DELETED M s p F s H V G s DELETED! P \| P s p F s H V G s DEIETED! P i P M 1 S p F s H V G s \t .DELETED DELETED . s p F s H V G s N DELETED DELETED M s p F •s H V G s N \ • i DELETED P s p c s I H V G s DELETED P M s p F s I 3 DELETED s p F s H V G s I ,. P DELETED M s^yj-.-i/ijc ASTR 013/01 WO i 20 25 29 . 31 33 49 55 56 91 94 ...__95_ P P 96 107 ! S p F S H V G s__ s "N P , s p F s H V G N ■ P M ! s p F s H V G T DELETEDjOELETED DELETED i i s p F s I H V G T DELETEDiDELETED DELETED M~l i S p F s H V G T DELETED'DELETED P I I s p F s H V G T DELETEDiDELETED P M s p F s H V G T DELETED DELETED P P P P DELETED s p F s , H V G T DELETED M s p F s H v G T DELETED P s p F s H V L G T DELETED P M "1 s p F s H V ' G T N DELETED DELETED s p F s H V G T N DELETED DELETED M s p F s H v G T N N DELETED! P s p F s H v G T DELETED p P M s p F s H v G T N DELETED s p F s H V G T N P DELETED v M s'" p F s I L H V ___G__ T i'.: P p F s H V T DELETEDiDELETED D __M__ s p F R Y Q S S DELETED s p F R L Y Q s s DELETED DELETEDIDELETED M s p F R __\| Y Q 1 s s DELETED DELETED! P s p F R L L Y Q s s DELETED:DELETE:M P M s p F R Y Q s s DELETED P IDELETED s p F R L Y Q s s DELETED P IDELETED M ' s p F R L Y Q s s DELETED P P s p F R L Y Q s s DELETED P P M s p F R L Y 0 s s N DELETE?-DELETE0 DELETED s 1 p F R L Y Q s s M DELETED M s p F R L Y Q s s N [DELETED P s p F R L Y Q s s N DELETED p P M 5 p F R L Y 0 s s \- DELETED 1 s p F R L Y 0 s s :■-: '. P DELETED M s p F R L Y Q s s P s p F R L Y 0 s s W F I P M s p F R L Y Q s T DELETED DELETEL DELETED s p F R L Y Q s T DELETED DELETED DELETED DELETED M s p F R L Y Q s T DELETEC DELETED P s p F R L Y 0 s T DELETED ! P M s p F R L Y Q s T DELETED P IDELETED s p F R L Y Q s T DELETED --~.P__ P DELETED M s p F \| R L Y Q 3 T DELATED DELETED ! P s p F R L Y Q s T : P M s p F R L Y Q s T DELETE!":[OELETED s p F R L Y Q s T M (DELETE!" _DELET=:: DELETE:' 'DELETED ( M s p F R L Y Q s T W P 1 s p F R L Y Q s T N P i M 52^' vl/MC ASTR 013/01 WO 20 25 29 31 33 49 55 56 S 91 94 95 P 96 107 S p F R L L Y Y 0 T N DELETED s p F R Q S T N DELETED P P P DELETED M s p F R L Y Q S T P s p F R L Y 1 Q e T P M 3 p F R L Y r~Q G S DELETED DELETED DELETED S p F R L L " Y Q G S DELET£DiQEL£TED M S p F R Y 0 G s DELETEDIDELETEO P s p F R L Y Q "" G s DELETEDIDELETED P M s p F R L Y Q G s DELETED! P DELETED s p F R L Y Q G s DELETED P DELETED M s p F R L Y Q G s DELETED; P P s p F R L Y Q G s DELETEDi P P M s p F R L Y Q G s N DELETED.DELETED s p F R L Y Q G s N DELETED-DELETED M s p F R L Y Q G s N DELETED: P s p F R L Y Q G s __N„ DELETED ■;■ P M P N P P M s p F F R R L L Y 0 G s DELETED s p Y Q G s DELETED M s p F R L Y Q G s P s p F R L Y Q G s K P ! P M s p F R L Y Q G T DELETED DELETED DELETED DELETED s p F R L Y Q G T DELETED DELETED M s p F R L Y Q G T DELETED DELETED P s p F R L Y Q G T DELETED'DELETED P M s p F R L Y Q G T DELETED: P DELETED1 _P.._. DELETED: ' P DELETED s p F R L Y Q G T DELETED M s p ~" F R L Y Q G T P s p F R L Y Q G T DELETED p P M s p F R L Y Q G T ■_ rj jOELETED N (DELETED DELETED s p F R L Y Q G T DELETED M s p F R L Y Q G T t-l (DELETED P 5 p F R L Y Q G T s p F R L Y Q G T .'. P DELETED s p F R L Y Q G T ;-; : p DELETED M s p F R L Y Q G T N ; P P s p F R L Y Q G T N P P M s p F R L Y V S S DELETED DELETED DELETED DELETED DELETED s p F R L Y V S S DELETED DELETED DELETED DELETED M s p F R L Y V S s P s. p F R L Y V S s DELETED P M s p F F R L Y V S s DELETED- P DELETED s p R I L~ Y V S s DELETED P DELETED M s p F R L Y V S s DELETED P P P s p F R L Y V s s DELETED P M s p F R L Y V s s N ;DELETE-: „_M .DELETED DELETED s p R L Y V 5 s DELETED M I ASTRO! 3/01 WO 20 25 29 31 33 49 55 56 91 94 DELETED 96 107 I S 4 p F R L Y V s S P ! I i S p F R L Y V V s S PELETED _P__ P p _^ M s p F R L Y s S N DELETED s p _l F R L Y V s S N DELETE? M ! s p F R Y V s S N P P__ DELETED P p 4 s p F R L Y V s s N S/i s p F L—R— L Y V s T DELETED DELETED DELETED s p F R L Y V I s T DELETEDJDELETED M s p F R L Y V s T DELETED:DELETED DELETED'DELETED P s p F R L Y V s T P M s p F R L Y V s T DELETED P P P DELETED s p F R L Y V s T DELETED DELETED M s p F R L Y V s T DELETED P s p F R L Y V s T DELETED P DELETED DELETED P M s p F R L Y V s T N DELETED s p c r R L_ L _ "~L Y_ Y V V s T N DELETED M ' 5 p r R V s_ f N .DELETED P I I 1 s -1 p P M DELETE:"' P M s p F R Y V s T N ■ P .-■LLETED s p F R L Y V s T N P P DELETED M s p F R L Y V s T N P s p F R L Y V s T M P P M s p F R L Y V G S DELFT EDjCELETED DELETL'p'UELETEn DELETEDJDELETED DELETED s p F R L Y V G S DELETED M s p F R L Y V G s P s p F R i_ Y V G s DELETED DELETED P_ P P DELETED DELETED DELETED OELETEL: P M s p F R L Y V G s DELETED DELETED, s s p F • R L Y V G s DELETED DELETED M p F R L Y V G s DELETED P s p F R L Y V G ■ s DELETED N P M s p F R L Y V G s DELETED s p F R L Y V G s N DELETED M s p F R L Y V G s N P I s p F R L Y V G s M P M s p F R L Y V G s N p DELETED s p F R L Y V G s N P P DELETED M s p F R L Y V G s N P s p F R L Y V G s N p ! p M s p F R L Y V G T DELETED DELETEDDELETED s p F R L Y V G T DELETEDlDELETED D^LETEO"DEL_ETE_D DELETED;DELETEr ;DELETED M s p F R L Y V G T P s p F R L Y V G T p M s p F R L Y V G T DELETED p P _ P DELETED \| s p F R L Y V d T jDELETED DELETED ! M p p" f F R R _L_ L Y . Y y V f T IDEL^TE;: P t T !OELETF.O; P P ! M 5291; vl.'DC" ASTRO!VOS WO 1- 20 25 29 31 33 L 49 — , ... 55 56 91 94 95 ! 96 l 107 ] s p F P. V V G i N JDELETEDbGLETED I s s s p r R R V" L__ L, L . Y V G T__ T T T T N iOELETEDjOELETED _____N iDELETEpj P.. _ _,J!_ JlLELEJiP; P __j N j P :DELETED M t p F Y V G p _J F 1 _Y Y — _J?_. -G M ! p__ p F R R i j Y V G N N N P 'DELETED M j s—i p F R L L Y V G T P j P I s __P_J F R Y V G ■• P . P M s p _l F R j L H Q S S DELETEDJDELETEDJDCLETED I s p F R L H Q S s DELATED DELETED: DELETED'DELETED M s p F R L H . Q S s DELETED: P I s p F R L H Q S s DELETED'DELETED P M s p F R L H Q S s DELETED] P DELETED I s p F R L H Q s s DELETED P DELETED M s p F R L H Q s s DELETEDj P P I s p F R R _ J. L L H H H Q s 5 s s DELETED P P DELETED HLETED _M__ I s p F s Q s s DELETED DELETED M fi p F R H Q s s DELETED, P I s p P _R R " L H 0 5 j s DELETED; P M s p F L H Q s 1 s r-:_ J p pPLETiP I s p F R L L j H H Q s 1 s P Ob'LETEO M ~* s p F ~~F R R 0 0 s s s ! V p p -J.....J s__ s p__ p 1-1 N ' P P DELETED "ELETED M F R L H Q s ! T DELF.TED DELETED DELETED ' s p F R »_ H Q s [ T DELETEU'DELETED M s p F R L H Q s s j >" 1 T DELETED P I s p .- F R L H Q DELETED DELETE!." P M s p F R L H Q s i T DELETED P DELETED i s p c R \ H Q s ! T DELETED DELETED P DELETED M s s p F R L H Q s ! T P P I p F R L H Q s i T DELfTED i N P P M s p F ■ R L r H Q s i I DELETED DELETED ! s p F R L H Q s ! T DELETED. "ELETED U s p F R i H Q s I T DELETED P 1 s p„_ F R L H Q s ! T ! N !_ N [ M DELETED P M s p F R L H Q s I T P DELETED 1 s p F R L H Q s ! T P DELETED M s L_JL_ F R L H Q s 1 T !"' M P P t s . p ! F R L H Q 8 1 T T" N p ; p M s p J F R L H Q G s iDEI.ETED ■DELE TEC iOELrTL=D :OELi"TEC .DEU1TEL DELIMHC DELETE:/DELETED ! s p F 1 R L ! H Q G ! s iDELETEr.OELETEC 1 M ! S p I F j _R i I\ L L i ! H 1 n 0 G 1 S 1 S ■ 3 JDELETED P \ ! i C p i F Q G_._ G .... ^ _. i \_3 'DELETED P 4 M : S I p ! F ; F \ R 1 R n ^lE'rEL ! P " . ^ELETEC i i s p L ! H M 52i/5 ASTRO 13/01 WO 1 20 25 29 31 33 49 55 56 91 94_ DELETED 95 96 107 S p F R L L H „ H __Q__ Q Q _J3 G S P P PJLETEp DELETED P i rs p F R R s DELETED P M I s p F _ L_ i H G s N DELETED s p P R H Q s >'i DELETE"? P s p F H G s N DELETED s p h \| R L H 0 G s N DELETED P P i s p F R L H Q G s N DELETED s p F R t_ H Q G s N p DELETED M s p F R L H Q G s N P p I s p c R L H Q G s N p p M s p F R L H Q G T DELETED DELETED.DELETED I s p F R L L H Q G T DELETED DELETEDDELETED M s p F R L H Q G T DELETED DELETED P I s p F R L H Q G T DELGTEDIOELETEP P M s p F R L H Q G T DELETED! P {DELETED I s p F R L L H Q G T DELATED P _ DELETED M ! S p p R H ..a Q G T DEL-TED DELilTED P P i s p IT R R L L H r . .P . M __s s p F H G G T N JDELETEC -ELETED I p F R L H Q G T N !DELETED:!:ELETED M s p F R L H Q G T ^_ N OELETED DELETED __P P P I s p F R L H Q G T N M P M s p F R L H Q G T DELETED I s p F R L__ H 0 T fc - DELETED P M s p F_, R H 0 G T ._....P_„_ P D~ELETEC: I s p F L L H Q V __G 3 T F M s p F R H S DELL TED DELETED I s p F R L H V S s DELETED DELATED DELETEDiDELETED M s p F R- L H V S s DELETEDl P I s p F R L H V s 's DELETED DELETED P P.. M s p F R L H V s s DELETED DELETED I s p F R L H V s s DELETED P DELETED M s p F R L H V s s DELETED P I s p F R L H V s s DEU.HTCiD P M s p F R L H V s s '-! DELETED DELETED I s p ■ F R L H V s s N DELETED DELETED DELETE/-' P DELETED M s p F R L H V s s N P i s p F R L H V s s N P M s J p F R L H V s s N DELETED I s p F R L H V 5 s N P DELETED P M i s , p F R L H V s s -j P J S_J p F R i- H V s s DELETED DELETED P M s p F R L H V 3 T DELETED I s p c R H V s T DE!. =TEC DELETED DELETED DELETE" CELETEJJ P M I s p F R L H H V s T DEl.FTF.r; I s p F R t_ V s T DELETED P M S2';S ASTRO\3A)i WO 20 25 29 31 33 49 55 56 91 94 \| 95 96 107 S p F R L _H H V s T DELETED P DELETED I s p F R S j T DELETED p DELETED I s~1 p F R _k__ L H H V V s s T. DELETED! P ' p s p F R T DELETED P DELETED DELETED P s P F R L H V s T N DELETED I s p F R L H V T N DELETED M s p F R L H V s T N DELETED P I s p F R L H V s T N DELETED P P M s p F R L H V s T N DELETED I s p F R L H v s T N p DELETED M s p F R L H V s T N P \| P I s p F R L H V s T N P P M s p F R L H V G S DELETED DELETED DELETED I s p F R L H V G S DELETED DELETED DELETED M s p F R L H V G s DELETED DELETED P i S ! p F R L H V G s DELETED DELETE!"' P P M s p F F R R ._J- _ L H V G s DELETED DELETED DELETED i s p_ p s DELETED P_ _ DELETED; P M s F R L H V G s P I s p F R L H V G s DELETED P \ P M s p F R L H V G s N N DELETED DELETED "ELETED i 1 * L s p F R L H V G s DELETED M__j s __p _ p F R L H V G s N DELETED P i s F R L H V G s N DELETE!' P P M r s p F R L H V G s N DELETED I s p F R L H V G s \i P P DELETED M L s p F R L H V G s N P I I s p F R L H V G s N P P M s p F R L H V G T DELETED DELETED DELETED DELETED DELETED I s p F R L H V G T DELETED DELETED M s p F R L H V G T DELETED P I s p F R L H V G T DELETF:D:DELl:THD P M s p F R L H v G T DELETED ill DELETED I s p F R L H V G T DELETED P DELETED M s p F R L H V G T DELETED -■> p I s p F R L H V G T DELETED P ' p M s p F R L H V G T N DELETE^.DELETED i t s p F R L H .v G T N DELETEDiDELETED M I s p F R L H V G T N DELETED DELETEr P I s p F R L H V G T M P M s p F R L H V G T N P .DELETED I s ! P i F R L H V G T N i P__ ! P__ p DELETEr DELETE: DELETED M ! S ! P i F R L ' H V G T N N P I ' S p F R L H V G T P M 1 s p : F R I Y Q S S DELETED DELETED I 1 £ p R I Y Q s s DELETED DELETED M 52'5'i viroC ASTR 013/111 WO 20 25 29 31 33 I 49 55 56 91 94 DELETED 95 96 107 S p F R I I Y Q S S DELETF.P- P "M" s p F R \|_J-J. v Q s s DELETED DELETEM P s p F R Y Q s s DELETED P iDELETED C-, p F o Q s s s DELETED P DELETED M s p F R I [ Y Q 3 DELETED P 1 P s p F R ._L_ Y Q s . S DELETED P P M s p F R Y Q s s ~l N DELETEDJDELETED s p F R I Y Q s s N DELETED DELETED M s p F R Y Q s s N DELETED! P \| s p F R I Y. Q s s N DELETED! P M s p F R Y Q s s ."J P DELETED s p F R Y Q s s M P iDELETED M s s p F R Y Q s s N ' P j p p F R I j Y Q s s 1 T N DELETED P : P M s p F R I I Y Q s DELETE:;-;DELETED s p p R I Y G Q s T DELETED OCldjllD DELETED DELETED DELETED DELETED M s s" p p - R Y Y s s "1 T DELETt." P M ■ R R —- T " T DELETE -> P s p F Y Q s P DELETED s p F R I i Y Q s T DELETED1 P DELETED M s p F R I ! Y Q s T DELETED! P ! P s p F R I Y Q s T DELETED N N P j P M s p F' R Y Q s T DELETEDJDELETED s p F R ! I Y Q s T DELETER-DELETED M s p F R \ I Y Q s T ■± DELETED. P s p F " R l'l Y Q s T DELETE:: P M s p F R i I __Y_ Y Q s T r,! \| P DELETED s p F R ; I Q s T M P ,DELETED M s p F R ! I Y Q , s T N P i P s p F R ! I Y__ Y Q s T N S P P M s p p R i i Q S DELETED'DELETEC'.DELETED s p F R R I t Y Q G S DELE_TF_D DELETED DELETE;;-DELETED M s p F I [ Y Q G s DELETEL; P s p F H J Y Q 1 G s DELETED DELETED DELETfH P M s p F R Y Q G s P iDELETED s p F R Y Q G s DELETEDl P . JDELETED M s p F R Y Q G s DELETED! P ! P s p p R Y Q G s DELETED! P i P M ' S p F R V Q G s N iDELETE-'[DELETED s p F R I j Y Q G s N IDELFTEDIDELETED M s p F R I i Y Q G s N DELETED! P s p F R Y Q G s N DELETE;;1 P M s p F R Y Q G s N P DELETED s p F R ! Y Q G 1 s s ^ i P ^DELETED M s s p = R I Y Q G ^ p P p r R I y Q G s \\ p ■ p M S295 ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 95 95 107 S p F R Y 0 G T DELETED DELETE:) DELETED I p F R 1 1 i Y Q G T DELETED DELETED DELETED M s p F R _j 1 ' Y 0 G T DELETED DELETED P I s p F R Y Q G T DELETED DELETED P M s p F R Y Q Q G T DELETED P !D£LETED I s p F ■ R J J_J Y G T DELETED P JDELETED M s p F R 1 ' . Y Q G T DELETED P P I s p F R 1 I Y Q G u T DELETED P N jDELETED P M s p F R .1 Y Q G T DELETED I s p F R 1 Y 0 G T N DELETED DELETED M s p F R Y Q .6 T N DELETED P I s p F R Y Q G T N DELETED! P M s p F R Y Q G T N P 1DELETED I s p F _R_i Y \| 0 _, G T iv ; P DELETED M s p F R~^ Y Q _ G T K P P I s p F R V Q G T V P ! P M s s p F R Y V S s DEi.rTED DELETED DEL Em DELETED DELETED I p F R —- Y v s DELETED M s p F R Y V s 3 DELETEDiOEL-'fTEi: P I s p F R i i Y V s s DELETED'DELETED P M s p F R Y V s s DELETED 7J DELETED i s p F R Y V s s DELETED ro OELETED M s p F R Y V s s DEL ETED P P I s p F R 1 Y V s s DELETED P P M s p F R Y V s s M DELETED DELETED I s p F " R . Y V s s s DELETED DELETED M s p F R 1 Y V s N DELL-TED P I s p F R 1 ; Y V s s ■■: ^DELETE.:' P M s p F R Y V u S s s f.' f,1 P DELETED '—I s p F R Y V s p DELETED M s p F R \| ! Y V s 1 s s '!' P I s p F R j I Y V s U DELETED P DELETED M I s p F R 1 1 ! Y V s T DELETED DELETED s p F R \ ; Y V s T DELETO DELETED M s p F R Y V s T DELATED DELETED DELETED P I s p F _Ji_^ ) • Y V s T DELETED P M s p F R . Y V s T DELETED P DELETED I s p F R Y V s T DELETED P DELETED M s p F R Y V s T DELEXI2 DELETED p P i s p F R Y V s T P M s p F R Y V s s T tJ DELrOi'J DELETED I s p F R j I Y V T N DELETED DELETED M s p F , R\| I Y V s T DELETED DELETED .... ll P I s p F R j 1 Y V s T P M s p F R j 1 Y V s T ' J DELETED I s p F R i Y V s T \' DELETED M ASTRO HA) I WO 20 25 29 31 33 49 55 56 91 94 95 96 107 S p F R Y V 5 T N P P s p F R Y V s T N P P M c p F R I I Y V G c DELETED DELETED DELETED s p F R R _Y__ Y V G c DELETED DELETED DELETED DELETED M j s p F V G s n DELETED P s p F R Y V G s DELETED DELETED P M s p p F R Y Y V G j s DELETED P DELETED F R I V G s DELETED P DELETED M s p F R Y V G c DELETED P p DELETED P s p F R Y V G s s DELETED N P M s s p F R i I Y V G DELETED p F R Y V G s N DELETED DELETED M s p F R I I Y V G s N DELETED P s p F R ! I V V G s N DELETED P M s p F R t I ! Y V G s N P DELETED i i s p F R l I R , I V V V3 3 .' p DELETED M ! s s p p p F F __ Y Y V V 'J P i P R R I O 8 P P M i I Y V G T DELETED DELETED DELETED DELETED DELETED s p F R Y V G T DELETED DELETED DELETED M s p F R Y V G T P s p F R Y V G T DELISTED DELETED "-—- P M s p F R Y V G T DELETED DELETED s p F R i i Y V G T DELETED P P P DELETED M s p F R I Y V G T DEI.F TED P s__ s ' p F R I I I Y V G T DELETED P M I p F R ,_I ! Y I V G T M DELETED DELETED DELETED p F-- R I I Y V G T N DELETED M s p F R I j Y V G T i'i DELETED DELETED P s p F R ' t ! v V G T f.; P M s p p R j I i Y V G T _ P DELETED i i s p F R i I i Y V G T M DELETED M i s p F R ! i ; Y V G T ■j P P i ' i s p F R I Y V G T i-i P M "I s p F R H Q S s DELETED.DELETEDlDELETED s p F R H Q S s OELETED!OELETEO;OELETEO ■ M s p F R H Q S s DELETED DELETED 'DELETEDi P s p F R H Q s s IDELETED1. P M s p F R H Q s s DELETED P iDELETED s p F R H Q s s DELETED P ^DELETED M s p F R H Q s s DELETED P P s p F R H Q s s DELETED N P i P M s p F R H Q s s :DELETED!DELETED 1 — p F R ._ I ._ H Q s > s M :DE LETEDiOELETED M s p p F R i I l H Q s s ■ i DELETED P ! Q L „_Y. F R I I I H Q s s N iDELETED P M S2'>>')vi/nc.- ASTRO J 3/01 WO 20 25 29 31 33 49 55 56 91 94 j 95 i 96 107 S p 1= R H Q S S N i P DELETED ! s p F R H 0 S S_ N j P IDELETED M . s p F rL_j H Q S s N ... P P_ P I s p p F R H i. ° ^ s s N P M F R , I H i_0_ s T DELETED DELETEDlDELETED I ! s p F R H Q s T DELETED DELETED DELETED M s p c R H 0 s T DELETED DELETED P 1 s p f- R H 0 s T DELETED! DELETED P M 3 p F R i J H Q Q s T DELETED. P JQELETED 1 s p F R i ; H s T DELETED P iDELETED M s p F R H 0 s T DELETED P i P i s p F R ■ H Q s _, T DELETED P 1 P M s p F R H Q s T N DELETED DELETED DELETED DELETED i s , p F R 1 i H 0 5 T N N M DELETED M s p F R " I 1 H Q s s T P I s p F f f R ! I H Q T DELETED P M 1 s _._p_. JJ F R_ _ R H Q s s s T ...ii i_--p i !-j ! P DELETED 1 s 1 hi Q T DELETED P IVl s F R H Q T "■•-, ' P 1 s p F R H Q s T N P P M s p F R H Q G S DELETETJI DELETED DELETED t s p F R I I H Q G j S DELETED DELETED;DELETED M s p F R ! I H Q G 1 _ s DELETED DELETED DELETED DELETED P 1 _JL s* p F R s H Q G s P M p F R H Q G s DELETED P DELETED s p F R H Q G s DELETED DLL-lTfiO DELETED P DELETED M i s p F F R & — ■ H Q G s ._ _ DELETED p i s p H Q G s P M s p F R i ! H Q s M DELETED s p F R \ I H 0 G s DHLETEDlDELETED M p r- R I 1 H Q G s N DELETED! P I p F R 1 ! H Q « s 'nULETrD P M s p R ! i H Q G s '■ P P DELETED i s p 1= R 1 H Q G s .... ^ DELETED M s p F R i H Q G s p P 1 i s p F R i i H Q G s P DELETED P M ■ s p F R H Q G T DELETED OELETED I s p F R H Q G T DELETED DELETED DELETED M s p F R H Q G T DEj.EJEip DELETED DELETED P 1 s p F R H Q G T pELETED P M s p F R H Q G T DELETED DELETED 1 s p F R H Q G T DELETED DELETED p OELETED M s p F R H Q G T ;-■ P 1 3 ? F R hi Q G T DEI r.TED\| P P M s p F R ; 1 H Q G T N DELETED DELETED DELETED 1 ! s p > R i I H Q G T i.i DELETED M ASTR 013/01 WO 20 25 29 31 33 49 55 56 91 94 i 95 i 96 107 S s p F R H Q G T N N DELETED! P p F R i i H Q L_ G T DELETED! P M s p F R H Q G G ^G T M P P DELETED I s p F R H Q T N DELETED M s F R H I Q T P s p F R H Q T N p P M s p F R i ! H V s S DELETED DELETEDiDELETED s p F R I I H V s S DELETED DELETEDiDELETED M s p F R i ; H V s s DELETEDiDELETED: P I i S \| p F R —J— H V s s DELETEDIDELETED1 P M _, s p F R H V s s DELATED; p DELETED s p F R H V s s DELETED! P DELETED M s p F R I H V s s DELETED DELETED p P s p F R H V s s p P M s p F R H V s s f.l DELETED DELETED s p F R H V V s s s L_ :"' DELETED DELETED M s s " -i- F F R H H s '.' DELETED P R V l__s s P M s p F R j ) H V s s DELETED s p F R i I H V s s ■:i l"J P DELETED M s p F R ! I H V s s M P s p F R i i H V s s I! ; P P M s p F R I I \| H V s T DEl.HTEDjDELETEDjDELETED s p F R i I H V s T DELATED DELETED DELETED DELETED M s p F R H V s T DELETED P s p F R H V s T DELETEDiDELETED DELETED! P DELIlTEDi P P M s p F R H V s T DELETED DELETED s p F R H V s T M s p F R H V s T DELETED DELETED I-' P s p F R H V s T P DELETED P M s p F R H V s T : J DELETED I s„ s p p F F R -— H V s T DELETED DELETED DELETED M R __H H V V 3 T P s p F R T DELF1E- P M s p F R H V s T H P DELETED s p F R H V s T N j P DELETED M s p F R H V s T P P s p F . R H V s T P P M s- p F R H V G S D-tFT^D DELETED DELETED s p F R H V G S L"i:LET^'D:DELETKD DELETED M s p F R H V G S DEL ET-D DELETED P-arTEDTELETED i)F.l.i:.'IED: !"■ P s p F R H V G s P M s p F R H V G s DELETED c- s p P R H V G s 3 DEL!-TED. E DELETED M p r R —I— V G PE! r-~rDi P P s p P R H V G s P . M 1 521^ vi/iX" ASTR 013/01 WO 20 25 29 31 : 33 49 55 V 56 G G 91 S-1 95 ;;::LE;;E!) DELETED 96 107 S P F R I H S M i'J DELETED t S P F R I I H H V s DELETED M s P F R ; i V G s " ! [DELETED P I s P F R I I H V G s .'J DELETED ? P M s P F F R L— H V G s DELETED I s P R H V G s '■.' P DELETED M s P F R H V G J s M P P I s P F R I i H V G s N P P M s 1 P \| F R I I H V G T DELETED'TJELEJED1 DELETEDIDELETED DELETED ! s P F R I I H V l_G T DELETED M s P F R H V G T DELETED DELETED P I s P F R H V G T DELETED DELETED DELETED P P M s P F R H V G T DELETED I s P F R ! I H V G T DELETED DELETED r p DELETED M s P F R ! I I H V G T P ! s P F R ■ H V G T T DELETED p DF.LFTEr-7)FA : r.PD P M ! S P F R H V G DELETED i s _ p F R H V G T DELETED M P F R H G T '.' JDELETED \> :rsr ELITE* •: P " >~1 I s P F R H V G T P M c P F R I! V G T DELETED I s P t— R —L— H v G T DELETED M s P F « H v G T -. ■. - V r P I s P F R H v G T ;; P M Table 10. Exemplary Mutations of mAb 2.998.2 Heavy Cluin (SGQ ID NO: 1^1) to Germline at the Indicated Residue Nuwln-r. 27 32 33 52 ss H)M DI ■LI-1 ED AMjLE'i'hp DELETED 103 112 G S s s s DEIJ-Ti-.M DELETED L G S s s s DEU-T:H DELETED Q G s s s s DELETi-:-) V L G s s s s DELlITf!), DELETED V Q G s s s s DELETED 11 DELETED L G s s s s DELE'ITD !I DELETED Q G -. s s s s DELETED V L G s s s s DELETED V 0 G s s c s II DEI.ETi-:!) DI:LE'iED '.)\ '.E'i'EEj DEE;.: !'! DELETED L G s s s s !; DELETED 0 G s s s s (! V L G s s s s s s V Q G s s 1 i DELETED L G s s s s ]] DELETED 0 SSWvi/'X-" *^jj1^ l$l ASTR 013/0! WO 27 32 \| 33 52 85 100 101 1: 103 \| U2 G S s s S i! V L G S s s s H V 0 G s s s R DELETE!) DELETED'DELETED L G s s s R DELETED DELETED DELETED DELETED Q G s s s R DELETED V V L G s s s R DELETED DELETED Q G s s s R DELETED H DELETED L G s s s R DELETED Tl DELETED Q G s s s R DELETED V L G s s s R DELETED 11 \| V Q G s s s R H DELETED (DELETED L G s s s R 'i! DELETED DELETED 0 G s s ~^ s R !i DELETED DELE'IED v L G s s s R V ! Q ^ G s s s k )i D DELETED: L S i S s R \| \\ DELETED, Q G s s s ^ J '] -. V L G s s s R I-l V Q G s s ' T s DELETED DELETED DELETED L G s ! s T s DELETED DELETED DELETED Q G s ! s T s DELETED DELETED V L G s s T s DELETED DELETED u V Q G s ! s T s DELETED DELETED L G s s T s ^DELETED i i DELETED Q G s s T s DELETED V L G s s T s DELETED ;! V 0 G s s T s H DELETED DELETED L G s s T s i-j DELETED DELETED EEI.ETED i 1 DELETED 0 G s s T s i! V L G s s T s !! V Q G s s T s li DELETED L G s s T s !l if DELETED 0 G s s T _ s 11 li I V L G s S \| T s 11 !■ j V 0 G s s T R jDELETr.D DELETED" DELETED L G S i S T R DELETED DELETED Q G s \| s T R DELETE!) Oll\ ETED DE;.E'IE:D ! ; i ; V L G s \| s T R DELETED v Q G S ! S T R DELETED DELETED L G S j S T R DELETED DELETED Q G r^s \| s T R DELETED V L G sis x R DELETED V Q 5205'; vi,'!X" ASTR 013/01 WO ASTR 033/01 WO u- 21 i 32 1 33 ; 52 85 10> iPJDELETEDj V i Pi DELETED! v ! 112 L 0 G s i T s DELE'P G s i i T s DEI.E'ti G ! s ! T s DELE'1"' -P" I! .DELETED! -:P, ii 'DELETED! L 0 G s T s DELE'i! G G s s DELE'l" ■:P; II I v j L s T s DELEl'i ■:P FT j v 1 Q i G s T s 11 1 DELETED iDELETED! L i G s T_J s H .J.lMiil^ii^LETED; iDELETED! V ! 0 J L G s T s 11 G s T s II !DELETED\| V 0 G s T s H H .'DELETED, L G s T s II i K 'DELETED! 0 G s T s il 1-1 1 V L G s T s H : H v ■ DELETEpJPELnTEPj L 0 1 G 4 s s s s T T T R_ K R DEI.E'i' DVAM'-DELE"" r~ r. jDELETED-DELETED [ G , ■P PEi.ETEP' V i ■:D-DELETED V L "1 0 G r T R DELiP" G s T R DELE •- :D! [-1 {DELETED L G s . T R DELI-; ' ■:P: H DELETED Q G s i ! T R DELE"" -"!"■« ■ IE V L G s ' T R DI-.1 E1 ■;■'. :•! v Q G s ' i T R li jDELETED DELETED L G s T R j J DGLETEP.iDELETED Q G s i T R 1-1 ;DELETED' V T V G s T 7 R \\ iDELETEDj V Q ' G s T R il II : DELETED , L_ G G s T R i-i ! H ..DELETED Q s T R -1 II ! V , L G s T R 11 V .-P DELETED:DKLETED 0 J L G r 5 S S DELE" G r S S 1 S DEEiP .-.,"'iDl-ll ETEP DELETED 0 G F s s S DELFT ED1DELETED: V L G F 1 s 1 S s DELE'l EP1DELETED! V Q G F s 1 s 1 s iDELL- FP. I-l DELETED L G F s s 1 s s jj)E_LE_! IDE!/:; jDELl7-' LP; H j DELETED Q G F 1 s s LP. !! V L G F ! S s s '■P! H V Q G G F 1 s 1 s s I ;' iOE! ETEP'DELETED L r ! S '■ S ■ s : S : s 1 ■■ IDE! ETEP-DELETED Q G F r s DELETED V i L ! „ 52->5 ASTR 013/01 WO 27 32 33 : 52 f 85 U>« (01 M H 103 112 C F S S '• s ii DELETED L G F ' S j s s H DELETED Q G F S i s s i! ! M V T 1^ G F S s s !! ; H V Q G F S s R DELFT;.;) DELETED DELETED DELETED L G F s s R DELETED DELETED Q G F s s R DELE: ;■!> DELETED V L 0 F- s s R DELE'iED DELETED V Q G F s s R DELE'! ED DELE': ED !J ]] M DELETED L G F s s R DELETED Q G F s s R DELETED V L G F s s R DEI.!-"'! ID 1-1 V Q G F s s R ;\| DELETED1DELETED L G F s s R i: DELETED r;YiLET>':P DELETEDl 0 G p s s R _ R. •■ i v L G C F F r —"—■ ~"— F s s >'• 1 DELETED V Q s s s - R ii DELETED L G s R ! ' DELETED Q "1 G F s s R ! i ! :-i V L G F .- ^ s R ": ! 11 V Q G F s T S DELETED DELETED DELETED DELETED 'DELETED L G F s T s DE; .:■.■:-. :) DELETED Q G F s T s DELETED v L G F s T s DELETED DELETED V Q G F s T s DELETED L G F s T s DELETED II !■[ DELETED Q G F s T s DEEE'i ED V L G F s T s DEI ET.-Di H V Q G F s T s ii I DEI ETEP DELETED L G F s T ^1 DELETED DELETED jDELETED DELETED Q G F s T s i; V L G F s . T s : V Q G F s T s !; ! i-I 1 V~~" i ~"H .DELETED L G F s T s li tDELETED Q G F s T s !i i V L G F s T s DE; ■:':;■:• DEI "IED V Q G F s T R !PH ETED j ot-:i ETED \| PJ;E ETE D \|DE: ETED : I DELETED L G F .. s T R iDELETED Q G F s T R DE! ETEP V L G F s T R IDF! : ■' !■.;? V Q G i F ■ s T R IDE! ■-'■.D ■ DELETED L Ci ! F L s-. T R JDEI P :i DELETED Q 52Wv;'Or A.STR 013/01 WO 27 32 33 52 85 \| i MO ifn :-;n":,rT\|"" ~;f" " 103 112 G '■' 3 T R DP.: V L G F s T R DEi ! M V _5ZT G F S s T R pi"l -Ti-p DELETED L G F T R il (DELETED DELETED Q G l: s T R j ! V L G F s T R i! DELETED U ! il A j I! v n Q "• G F s T R ■DELETED L G F s T R DELETED Q G F s 1 T R ETED H . ; V L G F s T K V Q ~G~~] F I S S DO! DELETED DELETED L 1 G F I s S DEi E'i ED [DELETED DELETED _fi— G F I [ s S DE: :TLP\|nL!_Ej;[:!' ETEDJDELETED ■ViiiD'" u V L G F I s S DEI V Q G F F -1 s S DE! DELETED L G 1 s G F 1 s s DE! H V L G F r s s DE: '{TED! II is DEi ETED V Q G F i s s DELETED L ' G F i S \| s ( DEI ETED'DELETED Q G L r 1 s "~i s I1!-:: ETED V L G F 1 s s :i -DELETED V Q G rr L 1 s s 'i !i DELETED h—L—1 G F 1 s s ■; ii DELETED 0 G F I s s ! i Li; n j i V Q G F 1 _s , R DF' DELETED DELETED L Ci 1 p- J s R DE-1 ETED.DE! ETED ■TED' i .;Li:.l i-.Il DELETED Q G F 1 s R DF! V [__k_ G F 1 S 1 R DF: V "~Q~ G • J* 1. s R Or1 -:"!-■•"'") \| i ; DELETED 1_ L G F 1 s R Dr.: DELETED Q Ci F 1 s R DE; ETED I 1! V L G F I s R DE! ETED i-i v Q G F 1 s R DELETED'DELETED L G F 1 I s R DELETED DELETED Q G F I \~ s R •i 1 DEi ETED V L G F I s R i i -E:- ETED V Q G F I s R DELETED L G F F I s R i i ; .DELETED Q \G i 1" S R J V ' L G F I s R V ! o 52'>59 v-i/DC r^T^ ASTRO! 3/0 i WO 1 27 32 33 ; 52 85 {fi't iHi / ; 103 f7n ~ G p i T s DEPPPHD DELETED DELETED DELETED ; DELETED , L G F 1 T s DELETED 1 DELETED Q G F 1 / T s DELETED V L 1- G F 7 s D£J.:.n':> ■)-.:\ i: "i.n p V Q G F 7 s DFJP-PEP DELETED L , G F T s DEi PTEPJ ii DELETED Q G F T S !DEI :;TEL"> n V L G p T S IDE!, PTPP )! DELETED V Q G F T S !f DELETED L G F T S i : DFEU'HD DELETED P..E':TED DELETED . Q G F T S 1 ; V , L G F T s .. p V Q G F f T j; DELETED L G F 1 T . . DELETED £ G p i T s 1 ' V L G i; 1 T .,■ V -Q P, 0 G G F l "J K Pi. PP.! PEE.. PEP-DELETED F —__ T R DF:I .;:-.!■ DELETED PI-!! ETED DELETED DELETED G F 7 ii (DEL.-.TED V L G F '1 K DHL ■'!■.': V Q . G F ' '1' R DPI.: TED : i DELETED t L G F T R DEE. TFP DELETED .. Q G F T R DEEP PEP V L G F 7 R uDP.i .' i'!-P V Q 1 G F 7 R :; PELD1TD 1) EL:/TED DELETED L G F ■ - T R DELETED Q G F T R DELi.EED DELETED V L G F T R ! : V Q G F i 1 T R ! DELETED L G F i 1 T R ■.'. DELETED Q G~ F f r f V L IT T R .; :;i::..pi;BD^ DELETED DELETED V Q D .s s s S DPI.., ;■;:;> DELETED L D s s s s DPI :.::'P DELETED Q 0 s s s s DEL! TED V L D s s s s !DP: Ti p DEI TED 1 t V Q D s s s s DP. TP:: DELETED , L 0 s s s s DEI r;-!' DELETED Q D s s s s OF.!. TED ' --.-A !'ED ' '■: PEP V L D s s" <: s dpp r- p> V LQ b s s s ! )ELETED L D s ~ s s s ' JELETED Q SjtiS'i vi/or ^-s^-J ^2— ASTR 013/01 WO 27 32 33 52 85 Ml Wi \| 103 m D S s s s ■-! DELID'ED! V "\- DELETED L D s s s s 1—-—1 0 ! o s s s s ■r "" ' ■ • j L ! D s s s s : i D -DELETED Q i D s s s s ii ! !i ; V L ! 1 S 1 s ' s s ! ! ! ;; j v o ! D s s s R DELETED! DELETEDiDELETEDj L j D s s s L R DELETED! Di:LETEDjDELETED 0 ! D s s s R DELETED! DELETED! v L D s s s K DELATED! DELETED! V 0 D s s s R DELETED; DEI ETED, II ! DELETED L D s s s R ! 'DELETED Q D s s s K DEI.LTPD- D V L D s s s s s R DELETED' - i V Q D s s R l-l 1 [ ""-.LETED'DELETED L D " D s s R D-..L LTD DELETED EEL1 -:.'" V 0 S s s R L r D s s s R '■ i D"LI- :'ED D s s s R I i ! DELETED L D s s s R L 'DELETED Q D s s s H "I D V L D \| S s s R ' i i' V 0 D s s T S DELETE!'1 DELETED DELETED L D s s T S JJEUHT; : DELETED' DELETEDIDELETED ' 'ELE'ELD1 V __S i D s s T S L ' D s s T s DELETED. D LETED' V Q D s s T s DELETED !! 'DELETED !i DELETED L D s s T s DELETED Q D D s s ■[■ s DELETED DELETED H V L s s ■I" s ;. v 0 D s s T 5 DELETED-DELETED L D s s T s ■I DEL! !ED [DELETED Q D s s T s DELL LED! V L D s s T s DELETED; V 0 D s s T s i ! D :DELETED L D s s T s il M DED.-TED DELETED Q D s s T s V L D s s T s : v Q D s s T R DE!. ;":-D:DELETED L D s s T ■R ]):■! ■■"i'i.'n DELETED 0 D ' S s T R . :u .'E;D v L D s s T R DE! ■"'!■; D '.-LTD,: V 0 529s u vi/nr T=^ A STR 013/01 WO A.-TR 013/01 WO A;STR 013/01 WO 27 32 33 52 85 !"' 101 103 ' DELETED "' DELETED 112 i I) F S s S i- !DELETE L ! D I7 S s S M ;DL JVi'l-1 !' 'M:.l l-'l"! o i D F s s s V L ; D F s s s i! jDELHTt- !; » r f L ... V ' 'ELETED '•■ELETED Q i D F s s s L D F s s s H ; n 0 ' D F s s s li ! H V L ! D F s s s 15iTrrfi:!)!bn"nTfE DELETED!DELETE V A .'DELETED El DELETED Q i 1) F s s K 1 i D F 1 s R o ! D F s s R DEL: TEDjOELE'l \|; V DELETED DELETED L i D f s s R ED_EL: TED D!;: !•;;'- o ! D F s s R DELVED ;■ L D 0 F s s " s s s s s R K" R R DEI'. ri:'D_ ^ (! ni-!.■■':■■ '• DEL ii-.:' :: ,Dr;,.ET ■■ 0. J L 0 F ' ELETED '■ DELETED — ■ ■ V V 'DELETED ELETED v 1 Q i D F L : D F s s R ■i 'ii!-:: ETE Q ! D F s s R L 1 D F s s R Q " 0 P s s. R ! 1 L 1 D F s s R i II Q : D F s s R L D F s s R V Q i D F s T s DELr;E! D;DELETE DEUTi-.D'DELETE :■ '-ELETED L- , D F s T s A DELETED V o ! D F s T S DELETED! DE1 FT1-' L D F s T s DELETED.'E i.E"! !■ DELETED !! DEL. 'ED' ii V 0 D F s T s DELETED L D F s T s .AT.ETED V V 0 ! D I7 s T s DEL: ■'■I'-:). !■! DEL1 i'l-D' li L ! D F s T s 0 i U F s T s i. ,DEI 1"!' . ■ DELETED L ! D F s T s E .DELETE D DELETED Q j D F s T s ;. !DELET! V V t~T~! D F s T s 0 i D t—F s T s i! DEL'"":;.."'; >EEE'"E a%6 ELETED DELETED V" L ! D F s T s o ; D F s T s L 1 o F s L_J s ■ : ELETED ': LETED Q : D i. s T R L i J) F s T R 0 ! 529S9V1/]JC • -^yr-0 I'R 013/01 WO '-•R Q13/01 WO .__._ 1- ' "\ 1 T s D J: i T' 1 s D F i T s . D l: 1 T s D L F I T u DEI. 1) F I T R DEL ~D F 1 T R DEI D 1- ! T U DEI. ~D F J T R DEI. D F_ I T R DLL 0 F I 1 T R OLE D 1; F T R DEL i !■> T K A D T 1 ELETED L i ELETED o 1 V L i V 1 o '■ DELETED I DELETED o 1 V_J L V Q 'ELETED I n DELETED Q V L \r $ 1 ^LETEDi i- i DELETED 0 ! V Q : "■ "LE'reo i _ :'ELETED o i V L ! V Q ELETED L '"■ELETED 0 V L V Q DELETED E ! DELETED o 1 v L V 0 \| ' E;i.Ei'ED L ' ELETED Q , Y ! L V Q >ELETED L DELETED 0 v i L V Q r>2«'}-.-i/Dr TR0!3/0f WQ Table ! 1. Exemplary Mutations of mAb 2.99S.2 Light f' ,ii: at The Indicated Residue N---^. to Germiinc 57^9 vl.'DC" ■■■SYR 0(3/01 WO .9y'i vi,TK AST#GiM«i WO " 1 "" 7 SO 92 «?3 I ':i)f j D I S V 1 T l I i I j D S s V T D s V A S D ■S V A S s , . v i D 1 S V A S ! I ! i 1 0 s V A s 1 I V D s v A T s D D S V A T s ! v ! S ! V A T i ! j 1 1 i'.) i s V A T i 1 v D s V V S j S j 1 1 0 s s V V s S ! V D _1 v _J v s s „ I - — 1 D \| S V V p s V V V r Is : i . 1. .L.J ^ -L 1 0 u v D i" ^ V v T ! i ' v : n s A s : s i i 1 n , F r~s A s i s ■ ^ i D !■• ! s A s i J j_ i n :: 1 S A 1 S ! 1 ' "'" ; D D I 1 S A '[' 1 .s ■ i ■ V j S A T S : o ' i; ! s A T I._ ' : _ i-' D V ' S A T : 1 !') [) 1) ' b I- s r v r s" v; i s F i S V V 1 S - F ! S ; S f S F v j s ;,_. ; ' o r s V ! T s '■■ ___ i__ I ■ ] i i' v u i !■■ ! s v ; r n \| F i s V i T „ _ ( ....__ 1 s V 1 r"„ V rh. L i„ ! V A ! s s D .. i; ! V ' A ■ i) ! F_ , V . A s 1 0 F ' V A ! T i_ »L !.__ F I v' A ~ T ' ■ i- v A T \| ; _. I- V A j T _ J _ ■ . ' __ 52^59 vl.'Dr ^00=- 20 ;9i-i/ic 30^ ASTRO 13/01 WO ASTR^W'WO TAL1LE 12 A.K'll-rDGFR-Al.PHA ANTIBODY HEAVY CHAIN SEQUENCES o3 ■JO rO Z ID 3 a V 23 I £ i>"; 2: c- a H ^ w a^V ASTROiM)! WO EXAMPLE g Al-TINITY DETERMINATION UV Bl/- : '■' ■" '■- VSIS \|00241 [ Biaeore experiments were performed . i: '— TioO instrument at 22 °C. Stand:]!-;! aldehyde coupling of the biosensor suri ' ■ ;!' ' -:'libony was utilized. Specifically, 50 fig of each mAb was reacted wiih -1 ml. ""«" : NaOAc, pH 5.5. and then the oxidation reaction was si..fi: ■'.■■::■ nng die sample on a Sephadex G-25 Nucleic Acid Purification-5 column (N/ ' • ' : '■i-'-~iences) with 10 mM NaOAC, pH 4.0. The mAbs were then flowed over a C: '-" "~i reacted with EDC/NHS, carbohydrazide, and ethano! . "" '"'"" ,5lc desired surface capacity had been reached, the hydrazone bonds heiv., ' :;u! '-"nc surface were reduced by flawing 0.1 M NaBH3CN in 0.1 M NaOAc, r" " -' ,;'!'-' immobilized mAbs u.'i S.KJ '.,',! {0(1241\ Mate 2.993.2 (SEQ IO Nos:!4 and K ' '■' ':-' & ^os: 5 anJ 4). 2.375.3 variant A (SEQ ID NO: 2 with 3Q, 80Y (SEQ 11) ':-,;0 D NO: 4 with 46L, 77S (SEQ ID NO: 135)). 2.449.1 (SEQ ID NO: 10 and r' - !-'° I variant A (SEQ ID NO: 10; SBO !D NO: 12 with 49Y, 1071 (SEQ ID NO- ' ' " ■'obili/.ed on a CMS biosensor ehi-. RcconVomnnt human sPDGFR-alpha ■' ' -" 322-PR/CF; ioi« QY056081) was injected for 90 seconds at a concent r;" ■ ' J ^-6 - 0.806 nM (2x serial dilution) followed by a 3 minute dissociation. -' ■'■" ''-' ■' -sociation phase was obviously extremely slow for all the interactions studied. ■"■' ": injections, three at 25.S nM and three blank buffer injections, were perform ",iwi injection with a dissociation phase of 14.^00 seconds (4 hrs.) after ■': completed. The samples were prepared in Hepes-buiTen-: "' '■'■'■ ""' ' '• polysorbate 20. phi 7.4 (HBS-P) with 100 ug/ml of BSA added. All samples ■ - - " ■ •' ejected in triplicate with over ten buffer injections interspersed for double re' ' ■vnsorgram data were processed will: Scrubber 2.0 and globally fit to a l:i inte' - ■ deluding a tenri for mass transpon using CLAMP. The resulting binding cc- " ' f ' '■ in the table below. MAbs are liste:! in order from highest to lowest affinity. ASTR 013/01 WO Tabic 14. AFFINITY OF SELECT!: -->:iiliiii C ka(MV) 2.175.3 variant A\ 3.55 X !05 2.53 pVl! t I 2.449.1 variant A I 4.40 X 10' 3. SO 2.175.3 5.16 X 10' 2.59 so 2.449.1 4.40 X \Q 6A6> 140 2.998.2 2.98 X 30' 4.S9 ;■■ 164 iOft'243; The results in Table 14 show that tl-2.449.1 showed increased affinity for soluble PDGFR; compared in 'he respective non-gcmiiincd antibodies reduced di-.> -'-•v-s of 2.175.3 and y Biacore analysis '■! antibodies show "'•e!: contributes to ■isU-Sny in TshJo )4 e 2 and an MG-63 '.ivies are lisied in Antibody H753- Table ;5. ACTIVITY OF SELECTED ANTnv ELISA AND KECEPTOR PHOSPHORYLATION ASS. sPDGFRa Elisa IC50 (n- 38 2.175.3 Wiv.-. A 46 2.449.1,3 44 2.449.!.3 Vn.-i::;!l A 45 DGFRa BINDING ';-■ 1C50 (ng/ml) EXAMilLTL'" EVALUATION1 OF ANTITUMOR EFFF XENOGRAFI"MODF b'MOR A.STK0(3/0i WO J0OZ---SJ Tiic anliiuaior efficacy of two of the ;P xenograft model of non small celi king carcinoma. Calu-6. a cross bcU'.i H BlackO':^ mice that had tiic murk;,: . human iMXi!;Ra by homologous recombination and S* expressed ru-. human i'OGFRa receptor and no-, knookin/knaek^ui truce 19 weeks of aye (KVgroup) were : OJ ml of mairigci into the right Hank. When the tumors : size, the an'Todics in a phosphate buffered saline ve! ;. adminislered ^trapcritoncally at 10 mg of antibody per '•■" duration of;!- ^tusly. Figure 2a shows the average timir- ~ while Fi^i.rc "'; shows the average body weight over tin reduce;! ':IL- = ■ ;-J:" r_;r-.)v.:h ,ac significantly; treatment v ■ growth ip-'Q. '■' i while i:v.;:me:i! with 2.449.1.3 prodir' ; 0.001). The; ■ was no ^g!:i:lcan[ difference between •.:>:• change durin-.' :ho, studv {F'g.ure 2b). f0024': The ?.niii'.i:iior effiency of 2.449.1.3 :■ evaluated m ,:u- U; !S glioma xenograft model. SOD n.u:-. injected w\'\\ "XI06 ceils in 0,1 ml of matrige! into the :'■-tumors reached an average of 2SQ mm3 in size, the described abr-c i'ov the Caiu-6 model. The results an' ■ 2.449.!.3 re.-: vd growth of the U11S tumors by 9--'"-2.449.1.3 red- ed t>rn\vth by 101%. Therefore both 2,"-highly aeto.e : ■ reducing growih of this glioma xenogra:: , not reduce in \ .vo activiiv in tins model. ■ vo evaluated in a = ■ -vere derived from replaced with the .ie requiting mice receptor. These .' age of 170 mnij in :;i:nc vehicle were r s per week for the "•: {.-.roup over time, 'h both antibodies vd ;■ 55% reduced . growth rate (y: - ci in body weight i A was further e -:' 10/group) were :: rials. When the ■• .'dininistercd as ;. The antibody ■•'.). Variant A of .1.'}. Variant A are :s .f Variant A do INCORPORATION BY REF:"-. ^ \fH)24i ' All re fere: tecs cited herein, including ;■>:■■ text books, a:- tlit: 'ike. ami the references cited llie: ',. aircadv. ;v.\- f ■ .-he mc:iroor;:;ed herein by reference in f- '-v:c;itions, p;ipcrs, '■laf they are not ASTKOlVOi WO EQUIVALENTS ;(i:}2--r'\| The tbjv.jiiiin.u wr-IUen ypceirjwiilo-i ;:■ ;■■'.-Ofit sklik-d !i. '.tie voi. to practice die invention. '! he :- i>e ;• invention should be construed in accordance with 'die ap ■ -thereof. .-i:"":kioiii te Diablo '.» :: iiiid Exatr.piys '- die besf mode .;,;er h<:nvr detailed :-iv ways and the :.ii any equivalents> 52-J50 ■-■■,">;"■ SEQUENCE LISTING AstraZeneca AB Targeted Binding Agents Directed to PDGFR-Alpha and Uses Thereof ASTR-013/01WO US 60/835,647 2006-08-03 136 Patentln version 3.4 1 360 DNA Homo sapiens 1 cacgtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60 ccctgtgcag cctctgcatt cacctrcagt gactactaca tccactggat ccgccagcct 120 ccagggaagg gcctggagtg ggtttcatac attagtagaa gtggcagtct catatactac ISO gtagactctg tgaagggccg attcaccatc tccagggaca aegecaagaa ctcactgaat 240 ctgcaaatga acagectgag agecgaggae acggccgtgt actactgtgc gagaggggcg 300 ccgtatagtg ggagcccctt tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 2 120 PRT Homo sapiens 2 Gin Val His Leu Val Glu Ser Gly Gly Giy Leu Val Lys Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 'yr Met His Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 15 Ser Tyr lie Ser Arc Ser Gly Ser Leu lie Tyr Tyr Val Asp Ser Val 50 55 60 Lys GLy Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu ASP 65 70 " 75 B0 JHUGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys ^ B5 90 95 Ala Arg Gly Gly Pro Tyr Ser Gly Ser Pro Phe Asp Tyr Trp Gly Gin 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 3 324 DNA Homo sapiens 3 gacatccaga tgacccagcc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc ggccaagtca gagaattagc aggtatttaa attggtatca gcagaaacca 120 gggaaagccc ctaagttcct gatctatgct ccatccagtt tgccaagtgg ggtcccatca 180 aggttcagtg gcagcggacc tgggacagat ttcaccctca ccatcagcac .ttacaacct 240 gaagattttg caactnacta ctgtcaacag agttacagta cccctccgtg gacgttcggc 300 caagggacca aggtggaaat caaa 324 4 108 PRT Homo sapiens 4 Asp lie Gin Met Thr Gin Ser Pro Ser Ser-Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Pro Ser Gin Arg He Ser Arg Tyr 20 25 30 Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Phe Leu lie 35 40 45 Tyr Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Thr Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pro 95 90 95 T?P'Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 5 360 DNA Homo sapiens 5 cagatgcagc tggtggagtc tcggggaggc ttggtcaagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggatt caccttcagt gactactaca tgaactggat ccgccaggct 120 ccagggaagg ggctggagtg ggtttcattc atragtagta gtggtagcac catatactac ISO gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtgt atnactgtgc gagagatggt 3GC caratagcag ctcgtqgcat ggacgtctgg ggccaaggga ccacggtcac cgtctcctce 360 6 120 ?RT Komo sapiens 6 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Asn Trp lie Arc Gin Ala Pre Gly Lys Gly Leu Glu Trp Vai 35 " " 40 45 Ser Phe lie Ser Ser Ser Gly Ser Thr He Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 7 0 7 5 30 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly His He Ala Ala Arg Gly Met Asp Val Trp Gly Gin 100 105 lib Gly Thr Thr Val Thr Val Ser Ser 115 120 7 336 DMA Homo sapiens 7 gtcatccaca Cgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcgagtca ggtcattacc aattatttag cctggtatca gcagaaacca 120 gggaaagttc ctaagctcct gatctttgct ^icatccactt tgcaatcagg ggtcccatct 180 cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 24C gaagatgttg cgacttatta ctgtcagaag tataacagtg cccctccaag gactcgatcg 300 atcaccttcg gccaagggac acgactggag attaaa 336 8 112 PRT Homo sapiens 8 Val lie Gin Met Thr Gin Ser Pro Set Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Val lie Thr Asn Tyr 20 25 30 Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pro Lys Leu Leu lie 35 40 45 Phe Ala Ser Ser Thr Leu Gin Ser Gly Val Pro-Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 65 70 7 5 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gin Lys Tyr Asn Ser Ala Pre Pro 35 '90 95 Arg Thr Arg Ser lie Thr Phe Gly Gin Gly Thr Arc Lsu Glu lie Lys 100 105 110 9 360 DNA Homo sapiens caggtgcagc cggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgaggctc 60 tcctgtgcag cctctggatt caccttcagt gactactaca tgaactggat ccgccagcct 120 ccagggaagg ggctggagtg ggtttcatac attagtagta gtggtagtat catatactac 180 gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gacagaaggg 300 cgtatagcag ctcgtggtat ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360 10 120 PRT Homo sapiens 10 Gin Val Gin Leu Val Glu Ser Gly Glv Gly Leu Val Lys Pro Gly Gly 1 5 1C 15 Ser Leu Arg Leu Ser Cys Ala Ma Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Asn Trp He Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr He Ser Ser Ser Gly Ser He He Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Arg He Ala Ala Arg Gly Met Asp Val Trp Gly Gin 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 11 324 DNA Homo sapiens 11 gacatccaga tgacccagtc tccatcctcc ctctccgcat ctctaqgaaa cagagtctcc 6C aAiscttgcc ggccaagtca gagctttagc aggtatataa attggtatca gcagaaacca 120 gggaaagccc ctaagctcct gatccatgCt gcatccagtt rggtaggtgg ggtcccatca 180 aggttcagtg gcagtggatc cgggacagat ttcactctca ccatcagcac tctgcaacct 240 gaagattttg caacttacta ctctcaacag acttacagta accccccgat caccttcggc 300 caagggacac gactggagat gaaa 324 12 109 PRT Homo sapiens «J00> 12 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Acq Val Ser He Thr Cys Arc Pro Ser Gin Ser Phe Ser Arc Tyr 20 2 5 30 He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 40 45 His Ala Ala Ser Ser Leu Val Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 90 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Asn Pro Pro 85 90 95 :ie Thr Phe Gly Gin Gly Thr Arg Leu Glu Met Lys 100 105 13 351 DNA Homo sapiens 13 cagctgcagc tgcaggagcc gggcccagca ctggtgaagc cttcggagac cctgtccctc 60 acctgcactg tctctggtga ctccaccagc agttttattt actactgggg ccgcatccgc 120 cagcccccag ggaaggggct cgagtqcaut gggactattc a~tatagtgg gagcacctac j.3C tacaacccgr ccctcaagag tccagtcacc atatccgtag acacgtccas gaaccagttc 24C tccctgaagc cgaggtctgt caccgccgca gacacggctg cgtattactg tgcgagacat 30C :actg cacTgggttt ttgactactg gggccaggga acccaggtca ccgtctcccc a 351 14 111 PRT Homo sapiens 14 Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Lea Val Lys Pro Ser Glu 15 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser lie Ser Ser Phe 20 25 30 lie Tyr Tyr Trp Gly Trp He Arg Gin Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp He Gly Thr lie Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe 65 70 75 80 Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg His His Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Gin 100 105 110 Val Thr Val Ser Ser 115 15 321 DNA Homo sapiens 15 gacattgtgc tgactcagtt tccagacttt cagtctgtga ctccaaagga gaaagtcacc 60 atcacttqcc gggccagtca ggtcattgqt agtagcttac actggtacca gcagaaacca 120 gatcagtctc cgaagctcct catcaagtat gcttcccagt ccttctcagg ggtcccctcc 180 aggttcagtg gcagtggatc taggacagat ttcaccctca ccatcaataq cctggaagtt 2^0 gaagatgctg caacgtatta ctgtcatcag actactattt taccgtggac gttcqgccaa 300 gqgaccaagg tggaagtcaa a 32; 16 10"? PRT Homo sapiens 16 Asp He Val Leu Thr Gin Phe Pro Asp Phe Gin Ser Val Thr Pro Lys 15 10 15 llu Lys Val Thr He Thr Cys Arg Ala Ser Gin Vai lie Gly Ser Ser 20 25 30 Leu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pre Lys Leu Leu He 35 40 45 Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Sec Gly Ser Gly Thr Asp Phe Thr Leu Thr He Asn Ser Leu Glu Val 65 70 7 5 80 Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Thr lie Leu Pro Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu Val Lys 100 105 17 35', DNA Homo sapiens 17 cagctgcagc tgcaggagtc gggcccagga ctggcgaagc etteggagae cctgcccctc 6C acccgcactg cccctggtgg ctccatcagc agtagtagtt actactgggc ctggatccgc 120 cagcccccag ggaagggact ggagtggatt gggaccatcc actatagtgg gaccacctac 180 tacaattcgt ccctgaagag tcgagtcacc atatccgtag acacgtccca gaaccagttc 240 rccctgaagc zgaqczctgz gaccgccgca gataeggctg tgtattactg tgegagacat 3C0 cactgggtt- ttgac^acxg gggccaggga accctggtca ccgtctcctc a 351 18 117 PRT Homo sapiens 1.8 ;JS !,eu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Phe lie Ser Ser Se; 20 25 30 Ser Tyr Tyr Trp Gly Trp lie Arg Gin Pro Pro Gly Lys Gly Leu Glu 35 * 40 45 Trp lie Gly Thr He Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn Ser Ser 50 55 60 Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Gin Asn Gin Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg His His Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 19 321 DNA Hoino sapiens 19 gaagttgtgc tgactcagtc tccagacttt cagtctgtga ctccaaagga gaaaatcacc 60 atcacctgcc gggccagtca catcatrggt actagcttac actggtatca gaagaaacca 120 gatcagtctc caaagctcct catcaactac gcttcccagt ccttctcagg ggtcccctcg 190 aggttcagtg gcagtggatc tgggacagaa ttcaccctca ccatcaatag cctggaagct 24 0 gaagatactg caacgtatta ctgtcatcag agtactaatt taccgtggac gttcgaccaa 300 gggaccaagg tggaaatcaa a 321 2C 107 PR? Homo sapiens 20 Glu Val Val Leu Thr Gin Ser Pro Asp Phe Gin Ser Val Thr Pro Lys 15 10 15 Glu Lys lie Thr He Thr Cys Arg Ala Ser Gin lie lie Gly Thr Ser 20 ' 25 30 Leu His Trp Tyr Gin Lys Lys Pro Asp Gin Ser Pro Lys Leu Leu lie 35 40 45 Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Ar9 Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Asn Ser Leu Glu Ala 65 70 75 80 Glu Asp Thr Ala Thr Tyr Tyr Cys His Gin Ser Thr Asn Leu Pro Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 21 324 DNA H omo sapiens 21 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggcaagrca cagcattacc aggtatazaa attggtatca gcagaaacca gggaaagccc ctaacctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccttca aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tccgcaacct gaagattttc caacttacta ctgtcaacag agctacagtc cccctc^gat caccttccgc caagggacac gactggagat taaa 22 108 PRT Homo sapiens 22 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser His Ser lie Thr Arg :yr 20 25 30 lie Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Asn Leu Leu He 35 40 45 Tyr Ala Ala Ser S^r Leu Gin Ser Gly Vai Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Pro Gin Pro 65 7G 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Ser Pro Pro 85 90 95 lie Thr Phe Gly Gin Gly Thr Arg Leu Glu lie Lys 100 105 23 372 DMA Homo sapiens «S00> 23 gaggtgcagc tagtgg-agtc tgggggaggc ctggtccagc ctggggcgtc cctcagactc 60 tcctgtgcag cctctggatt cacctttagt agctactgca zgagctgggt ccgccaggct 12C ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaagtga gaagtactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 24C ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagatggggg 300 gtttttggtt cggggagtta ttatatccct tttgactact ggggccaggg aaccctggtc 36G accgtctcct ca 372 24 124 PRT B.ora.Q sapie-fia 24 Glu Val Gin Leu val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 15 10 15 Ser Leu Arg Leu ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp val Arc Gin Ala Pro Gly Lys Gly Lei: Glu Trp Val 35 40 45 Ala Asn lie Lys Gin Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Vai Tyr Tyr Cys 85 9C 95 Ala Arg Trp Gly Val Phe Gly Ser Gly Ser Tyr Tyr lie Pro Phe Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 115 120 25 321 DNA Homo sapiens 25 gp.catccaga tcacccagcc tccatcctca ctgtctccat ctgtgcgaga cagagtcace 6C atcacttgtc gggegagtea gggcattagg aattatttag cctggtttca gcagaaacca 12C gggaaagece ctaagtccct gatctatgct gcatccagtt tgcaaagtgg cgtcccatca 180 acgttcsgcg gcagtggatc tgggacacat tccactctca ccatcagtag tttgeagect 200 gaagattttg caagttatnc ctgccaacag tatgagattt atcctctcac tttcggcgga 300 gggaccaagg tggagaicaa a 321 26 107 PRT Homo sapiens 26 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Arg Asn Tyr 20 25 30 Leu Ala Trp Phe Gin Gin Lys Pro Gly Lys Ala Pro Lys Ser Leu lie 35 AG 15 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Thr Phe Ser Gly 50 55 6C Ser Gly Ser Gly Thr His Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 70 75 80 Glu Asp Phe Ala Ser Tyr Phe Cys Gin Gin Tyr Glu He Tyr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu He Lys 100 105 27 354 DNA Homo sapiens 27 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaacg ggctggagtg ggtggcagtt atatggtatg atagaagtaa taaatactat 180 gcagactccg tgaagggccg gutcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatgg acagcctgag agccgaggac acggcrgtgt attactgtgc ggggggacgs 300 tcccggggag cctttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354 28 118 PRT Homo sapiens 28 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 15 10 15 Ser Leu Arc Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gin Mer Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cy- 35 90* 95 Airily Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thr ~^* i_00 105 110 Leu Val Thr Val Ser Ser 115 29 321 DNA Homo sapiens 29 gacatccaga tgacccagtc tccatcttcc ctgtctgcat ctgtagtf^ga cagagtcacc 60 atcacttgtc gggcgagtca gggtattagc agctggttag cctggtsitca gcagaaaccc 120 gggaaagccc ctaagctcct gatctatgct gcatccagct tgcaaacjtgg gqtcccatca 180 agattcagcg gcagtggccc tgggacagat ttcactctca ccatcadcag cctgcagcct 240 gaagattttg caacttacta ttgccaacgg actaacagcc tccctcdgac gtccggcnaa 300 gggaccaagg cggaaatcaa a 321 30 107 PRT Homo sapiens 30 Asp He Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ai 15 10 15 Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Ly5 Leu Leu He 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg" Phe Ser Gly 50 55 6G Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Sei^ ^=u Gin Pro 65 70 75 20 Glu ASD Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Set ?-ie Pro Arc 85 SO 95 Thr Phe Gly Gin Gly Thr Lys Val Glu lie Lys 100 105 31 351 DNA Homo sapiens 31 cagctgcagt tgcagg^gtc gggcccagga ctggtgaacc cttcggagac cctgtccctc 60 acctgcactg tctctggtgg ctccatcagc agtagtaatt actactgggg ctggatccgc 12G cagcccccac ggaagg^gct ggagtggatt gggactatat attatactgg gagtacctac 18C tacaacccgt ccctca^gag tcgagtcacc atatccgtag acacgtccaa gaaccagttc 240 tccctgaagt tgagct^tgt gaccgccgca gacacggctg tg-attactg tgcgagacat 300 cactgggttt ttgact^ctg gggccaggga accctggtca ccgtctcctc a 351 32 117 ?HT Honio sapiens 32 Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pre Ser Glu 15 10 15 Thr Leu Ser Leu Tar Cys Thr Val Ser Gly Gly Ser lie Ser Ser Ser 20 25 30 Asn Tyr Tyr Trp Gly Trp He Arq Gin Pro Pro Gly Lys Gly Leu Glu 35 4 0 4 5 Trp He Gly Thr lie Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Vqi Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe 65 TO 75 80 Ser Leu Lys Leu St>r Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 8$ 90 95 :ys Ala Arg His H.i_s Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Leu 100 105 110 'ai Thr Vai Ser S^r 115 33 321 :2l5V 33 gaaattgtgc tgactcagtc tccagacttt ctgtctgtga ctccaaagga gaaacticacc 60 atcacctgcc gggccagtca gatcattggt agtagcttac actggtacca acagaaacca 120 gatcagtctc caaaactcct catcaagtat gcttcccagt ccttctcagg ggtcccctca LEO aggttcagtg gcagtggatc tgggacagat ttcaccctca ccctcaatag cctggaagct 240 gaagatgctg caacgtatta ctgtcatcag agtactattt tiaccgtggac gtucggccaa 300 gggaccaagg tggaaatcaa a 321 34 107 PRT Homo sapiens 34 Giu lie Val Lea Thr Gin Ser Pro Asp Phe Leu Ser Val Thr Pro Lys 15 10 15 Glu Lys Val Thr He Thr Cys Arg Ala Ser Gin He He Gly Ser Ser 20 25 3C Leu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Lys Leu Leu He 35 40 45 Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Leu Asn Ser Leu Glu Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Thr He Leu Pre Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 35 351 DNA Homo sapiens 35 cagengcage tgcaggagtc gggcccagqa ctggugaagc cctcggagac cc^gtccctc 60 acctgcactg tctctggtgc ctccaccagc agtagtacci: actacteggg ctggatccgc 120 cagcccccag ggaaggggct ggagtggatt gggactatat attatagtgg gagcacctac ISO tacaacccgt ccctcaaaag tcgagtcacc atarccgtag acacgtccaa gaaccagttc 240 tccctgaagc tgaactctgt gaccgccgca gacacggctg tgtattactg tgcgagacat 300 cactgggttt ttgactactg gggccaggga accctggtca ccgtctccrc a 351 36 117 PRT Homo sapiens 36 Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GIu 15 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser He Ser Ser Ser 20 25 30 Thr Tyr Tyr Trp Gly Trp lie Arg Gin Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp He Gly Thr He Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe 65 70 75 80 Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 65 90 95 :ys Ala Arg His His Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 37 321 DNA Homo sapiens 37 gaaattgtgc tgactcagtc ~ccagacttt ctgtctgtga ctccaaagga gaaagtcacc 60 atcacctgcc gggccagtca caccattiggt agtagtttac acteg-acca acagaaacca 120 gatcagtctc caaacctcct caccaagtat gctcctcagt ccgtc-cagg ggtcccctcg Ifid L ^■fcttcagtg gcagtgggtc tgggacagat ttcaccctca ccctc^atag cctggaagct 240 gaagatgctg caacgtatta ctgtcatcag agtactattt taccgCggac gctcggccaa 300 gggaccaagg tggaaatcaa a 321 38 107 FRT Homo sapiens 30 Glu He Val Leu Thr Gin Ser Pro Asp Phe Leu Ser V#l Thr Pre Lys 15 10 15 Glu Lys Val Thr He Thr Cys Arg Ala Ser Gin He He Gly Ser Ser 20 25 30 .eu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Asn Leu Leu He 35 4 0 4 5 jys Tyr Ala Ser Gin Ser Val Ser Gly Val Pro Ser Al~g Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Leu Asn Ser Leu Glu Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Thr He Leu Pro Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu lie Lys 100 105 35 360 DNA Homo sapiens 39 caggtgcagc tggtggagtc tgggggaggc tcggtcaagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggatt caccttcagg gactattaca tgagctggat ccgccaggct 120 ccagggaagg ggctggagtg ggttgcattc attagtagta gtggtagtat tatatactac 130 gcagactctg tgaagggccg atucaccatc tccagggaca aegec^agaa ctcactgttt 240 ccgcaaatga acagectgag agecgaggae acggccgtgt attaccgtgc gagagatgeg 300 catatagcag ctcgtggcac ggacgtctgg cgccaacgga ccacggtcac cqzctcc.tza 36C ^,0> 4 0 '9m> i2o PRT Homo sapiens 40 Gin Vai Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asp Tyr 20 25 30 Tyr Met Ser Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Phe lie Ser Ser Ser Gly Ser tie lie Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg phe Thr lie Ser -Arg Asp Asn Ala Lys Asn Ser Leu Phi 65 7 0 7 5 30 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly His He Ala Ala Arg Gly Met Asp Val Trp Gly Gin 100 105 11C Gly Thr Thr Val Thr Val Ser Ser 115 120 41 324 DNA Homo sapiens 41 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 63 atcacttgcc gggcaagtca gagcattaac aagtatataa attggtatca gcagaaacca 120 gggaaagece ctaagctcct gatttatgct gcatccagtt tgcaaagtgq ggtcccatca 180 aggttcaatg gcagtggatc tggcacagat ttcactttca ccatcaacac cctgcaacct 240 gaagattttg caacttacta ctgtcagcag acttacagta cccccccgat caccttcggc 300 caagggacac gactggagat: taaa 32 4 42 108 PRT ^% * Homo sapiens 42 Asp He Gin Met Thr Glr. Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Ser lie Asn Lys Tyr 20 25 30 He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 40 4S Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Asn Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr He Asn Thr Leu Glr. Pre 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Thr Fro Pro 85 90 95 He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys 100 105 43 360 DNA Homo sapiens 43 caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggatt cacctccagt gactactaca tgaactggat ccgccaggct 120 ccagggaagg cgctggagtg ggtttcattc attagtagta gtggtagtac catatactac 180 gcagactctg tgaagggccg attcaccatc tccagggaca aegecaagaa ctcactgtat 240 ctgcaaatga acagcctgag aaccgaggac acggccgtgt attactgtgc gagagatggg 300 catatagcag ctcgtggtat ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360 14 120 PRT Homo sapiens 44 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Giy Gly 1 5 10 15 Se^Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Asn Trp lie Arg Glr. Ala Pre Gly Lys Gly Leu GIu Trp Val 35 40 45 Ser Phe lie Ser Ser Ser Gly Ser Thr lie tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 "JO 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly His lie Ala Ala Arg Gly Met Asp Val Trp Gly Gin 100 1C5 110 ;iy Thr Thr Val Thr Val Ser Ser 115 120 45 324 DNA Homo sapiens 45 gacarccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc ' 6G atcacttgcc gggcaagtca gagttttagc aggtatataa attggtatca gcagaaacca 120 gggaaagccc ctaaactcct gatctatgct gcatccagtt tgcaaggtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagat ttcactctcg ccatcagcag tctgcaacct 240 gaagattttg caacttacta ctgtcaacag acttacagta cccctccgat caccttcggc 300 caagggscac gactggagat taaa 324 46 108 PRT Homo sapiens 46 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Ser Phe Ser Arg Tyr 20 25 30 lie 7isn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie 35 10 45 Tyr Ala Ala Ser Ser Leu Gin Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Ala lie Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Thr Pro Pro 85 90 95 lie Thr Phe Giy Gin Gly Thr Arg Leu Glu lie Lys 100 105 47 360 DNA Homo sapiens 47 caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60 tcctg~gcag cctctggatt caccttcagt gactactaca Cgaactggat ccgccaggct 120 ccagggaagg ggctggagtg ggtttcatat attagtagta gtggtagtat tatatactac 180 gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcacngtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gagagatggg 300 cgtatagtag ctcgtggtat gcacgtctgg ggccaaggga ccacggtcac cgtctcctca 360 48 120 PRT Homo sapiens 48 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 * 25 30 Tyr Met Asn Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp VaZ 35 A0 45 Ser Tyr lie Ser Ser Ser Gly Ser He He Tyr Tyr Ala Asp Sar Val t 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 ' 70 " 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Arg He Val Ala Arg Gly Met Asp Val Trp Gly Gin 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 49 324 <:2i2> DNA Hnrao sapiens 4 9 gacacccaga tgacccagtc tccatcctcc ctgtgtgcat ctgtaggaga cagagtcacc 6C atcacttgcc gggcaagtcg gagcattacc aggtatttaa attggtatca gcagaaacca 12G gggaaagccc ctaagctcct gatccatggt gcatccagtt tgcaaagtgg ggtcccatcc 180 aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240 gaagattttg caacttacta ctgtcaacag agttacagta cccctccgat caccttcggc 300 caagggacac gactggagat taaa 324* 50 108 PRT Homo sapiens 50 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Cys Ala Ser Val Gly 15 1C 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Arg Ser lie Thr Arg Tyr 20 25 30 Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie 35 40 45 Tyr Gly Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arc Phe Ser Gly 50 55 60 SfiAtGly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 6^ 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser T'hr Pro Pro 95 90 95 He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys 100 105 51 363 DNA Homo sapiens 51 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggcc cctgagactc 60 tcctgrgcag cgtctggatt ctccttcagt atctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atttggtttg atggtagtaa taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 cLC gcgtcttact atggttcggg gatggactac tggggccagg gaacccCggt caccgtctcc 360 tea 3 63 52 121 PRT Homo sapiens 52 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro GTy Arg 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser He Tyr 20 25 30 Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu QJ_U Trp Val 35 40 45 Ala Val He Trp Phe Asp Gly Ser Asn Lys Tyr Tyr Aia }\Sp ser val 50 55 60 Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ser Lys Asn -r^r LSU Ty3 65 70 75 go Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Arg Asp Lys Ala Ser Tyr Tyr Gly Ser Gly Met Asp Tyr Trp Gly 100 105 110 Gin Gly Thr Leu Vai Thr Vai Ser Ser 115 120 53 327 DNA Homo sapiens 53 gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60 ctctcctgca gggccagtca gagtgttacc agcacctact taccctggta ccagcacaga 120 cctggccagg ctcccaggct cctcatctct ggtgcatcca ggagggccac tggcatccca 180 gacacg'tca gzggcagtgg gtctgggaca gacttcacr.c ccaccatcaq cagaccgcag 24C cctgaagatt ttgcagtgta ttactgtcag cactatgcta gctcattcac gtggacgttc 300 ggccagggga ccaaggtgga aatcaaa 327 54 109 ?RT Homo sapiens 54 Glu He Vai Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 15 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Vai Ser Ser Thr 20 25 30 Tyr Leu Ala Trp Tyr Gin His Arg Pro Gly Gin Ala Pro Arg Leu Leu 35 40 45 lie Ser Gly Ala Ser Arg Arg Ala Thr Gly lie Pro Asp Arg Phe Ser 50 55 6C Giy Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Arg Leu Glu 65 70 73 30 Pro Glu Asp Phe Ala Vai Tyr Tyr Cys Gin His Tyr Gly Ser Ser Phe 35 90 95 TtJkrrp Thr Pbe Gly Gin Gly Thr Lys Val Glu He iys ^ 100 105 55 351 DNA Homo sapiens «900> 55 gaggtgcagt tggtggagag tgggggaggc ttggtccagc ctggggggtc cctgagactc 6C tcctgtgcag cctctggatt cacctttagt aacttttgga tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccaac ataaagcacg gtggaagtga gaaatactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 ctgcaaatga acacactgag agccgaggac acggctgtgt attactgtgc gagagatcct 300 atgtactact ttgactactg gggccaggga accctggtca ccgtctcctc a 351 56 117 PRT Homo sapiens 56 Giu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Trp Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 15 Ala Asn He Lys His Gly Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gin Met Asn Arg Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Met Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 57 321 DNA Homo sapiens 57 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcaagtca ggacattaga aatgatttag actggtatca gcagaaacca 120 gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180 aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240 gaagattttg caacttatta ctgtctacag cataatggtt accctcccag ttttggccag 300 gggaccaagc tggagatcaa a 321 53 107 FRT Hcrr.c sapiens 58 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Glv 15 10 15 Asp Arg Val Thr lie Thr Cys Arg Ala Sec Gin Asp lie Arg Asn Asp 20 25 * 30 Leu Asp Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pre Lys Arg Leu He 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gin His Asn Gly Tyr Pro Arg 85 90 95 Ser Phe Gly Gin Gly Thr Lys Leu Glu He Lys 100 105 59 354 DNA Komo sapiens 59 CM^tgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctgqagtg ggtgqcagtt atatggtatg atagaagtaa caaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgrat 240 ctgcaaatga acagcctgag agccgaggac acggctgrgt attactgtgc ggggggacga 300 tcccggggag cctttgacta ctggcgccag ggaaccctgg tcaccgtctc ctca 354 60 ne PRT Hono sapiens 60 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ty: 20 25 30 Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp val 35 4 0 4 5 Ala Val He Trp Tyr Asp Arg Ser Asri Lys Tyr Tyr Ala Asp Ser Val 50 " 55 60 Lys Gly-Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 " 75 80 Leu Gin Mei Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thi 100 105 110 Leu Val Thr Val Ser Ser 115 61 321 DNA Homo sapiens 61 gacarccaca r.gacccagrc tccatcntcc g-gtctgcat ctgtaggaga cagaqtcacc 60 at;cacttgLC qcqcgagtca gggtattagc agttggttag cctggtatca qcagaaacca 12C gggl^agccc ctaagctcct gatctttgct ccatccagtt tgcaaagtgg ggtcccatca 160 agattcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240 gaagattttg caacttacta ttgtcaacgg actaacagtt tccctcggac gttcggccaa 300 gggaccaagg tggaaatcaa a 321 62 107 FRT Homo sapiens 62 Asp lie Gin Met Thr Gin Ser Fro Ser Ser Val Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr lie Thr Cys Arc Ala Ser Gin Gly He Ser Ser Trp 20 2 5 30 Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Tie 35 40 45 Phe Ala Ala Ser Ser Leu Gin Ser Giy Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 90 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Ser Phe Pro Arg 85 ' 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 63 363 DNA Homo sapiens 63 gaggtgcagc tggtggagtc fcgggggaggc tcggtacagc ctagggggtc cctgagaccc 50 tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct 120 ccagggaagg ggctggagtg ggrttcattc attagtggta gtagtactac car.gr.acnac ISO gcagactctg tgaagggccg attcaccatc tccagagaca angccaagaa ctcaccg~ae 240 ctgcaaatga acagcctgag agacgaggac acggctgtgt atractgtgc gagattacga 300 tjjkttgact ggtcatatgc ttttgatatc tggggccaag ggacaatggt caccgtctct 360 tea 363 64 121 PR? Homo sapiens 64 Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Giu Trp Val 35 40 45 Ser Phe lie Ser Gly Ser Ser Ser Thr Men Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr j.Ie Ser Arg Asp Asn Ala Lys Asp. Ser Leu Tyr 65 10 75 80 Leu Gin Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 ALa Arg Leu Arg Tyr Phe Asp Trp Ser Tyr Ala Phe Asp lie Trp Gly 100 " 105 110 Gin Gly Thr Met Val Thr Val Ser Ser 115 120 65 321 DNA Homo sapiens 65 gacatccaga tgacccagtc tccaccttcc gtgtctacat ctgtaggaga cagagtcacc 60 atcacttgtc gggcgagtca gggtattege agctggttag cctggtatca gcagagacca 120 gggaaagece ctaagctcct gatctatget gcatccagtt tacaa^atgc ggtcccatca 130 aggttcagcg gcagtggatc tgggacagat ttcactctca ccatc^gcag cctgcagcct 240 gaagattttg caacttactt ttgtcaacag gctaccagtt tcccatccac ttccggccct 300 gggaccaaag tggatatcaa c 321 66 10"? PRT Homo sapiens 66 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Tbr Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arc Ala Ser Gin Gly lie Arg Ser Trj 20 25 30 Leu Ala Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Lys Leu Leu lie 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Asn Gly Val Pro Ser Acg Phe Ser Gly 50 55 ■ 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin lJro 65 "7 0 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gin Gin Ala Thr Ser Phe Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp He Asn 100 105 6"? 354 DNA Homo sapiens 67 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atagaagtaa taaatactat 160 gtagactccg tgaagcgccg attcaccatc tccagagaca attccaagaa cacgttgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgrgc gqggggscga 300 tcccggggag cctttgacta czggggccag ggaaccctgc tcaccgcctc ctca 35 4 68 118 PRT Homo sapien; •4 68 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 "70 7$ 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 69 321 DNA Homo sapiens 69 gacacccaga tgacccagtc tccatcttcc gtgtctccac ctgtaggaga cagagtcacc 60 ancacttgtc gggcgagtca ggatattagc agctggttac cctggtatca gcacaaacca 120 gggaaagccc ctaagctcct gatctttgct gcatccagct -gcaaagtgg ggtcccacca 180 agattcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240 gaagattttg caacttacta ttgtcaacgg actagcagtt tccctcggac gttcggccaa 300 gggaccaagg tggaaatcaa a 321 70 107 PRT Homo sapiens 70 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly 5 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp He Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 40 45 Phe Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Ser Ser Phe Pro Arg 85 90 95 Thr ?he Gly Gin Gly Thr Lys Val Glu He Lys 100 105 71 " 354 DNA Homo sapiens 71 caggtgcagc Cggtggagtc rgggggaggc gtggtccagc ctgggaggtc cctcagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactcggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtcgcagtt atatggtatg atagaagtaa taaatactat 180 gcagactccg -gaagggccg attcaccatc tccagagaca attccaagaa cacgctgta'c 240 ctgcaaatga acagcctgag agccgaggac acggctgtat attactgtgc gggggcacga 300 tcccggggag cctttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354 72 118 PRT Homo sapiens 72 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 2C 2 5 30 4 Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 73 321 DN'A Homo sapiens 73 gacatccaga tgacccagtc tccatcttcc gtg^ctgcat ctgttggaga cagagtcacc 60 atcacttgtc gggcgagtca gggtattagc aqctggttag cctggtatca gcagaaaccc 120 gggaaagccc ctaacctcct gatttatgct gcatccagtt tgcaaagtgg ggtcccatca 180 agattcagcg gcagtggatc tgggacagat ttcactctce ccatcagcag cctgcagcct 240 gaagattttg caacttacca ttgtcaacgg actaacaatt tccctcggac gttcggccaa 300 gggaccaagg tggaaatcaa a 321 74 107 PRT Homo sapiens 74 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala .Ser Val. Gly I 5 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Gly He Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Asn Leu Leu He 35 40 45 Ty^Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly '5C 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Asn Phe Pro Arg 85 " 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 75 363 DNA Homo sapiens 7 5 gaggtgcagc tgccggagte tegqgqaggc ttggcacagc ctggggggtc cctgaqactc GO tcctgtgcag cctctggat" caccttcact agctatagca tgaactgggr ccgccaggct 120 ccagggaagg ggctqgagtg ggtttcatac attagtggta gtagtactac catgtactac 180 gcagactctg tgaagggccg attcaccatc tccagagaca atgccaagaa ctcactytat 210 ctgcaaatga acagcctgag agacgaggac acggctgtgt attactgtgc gaqattacga 300 cattttgact ggtcatatgc ttttgatatc tggcgccaag ggacaatgct caccgtctct 360 tea 363 76 121 PRT Homo sapiens 76 Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly phe Thr Phe Ser Ser Tyr 20 25 3C Ssr Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly LQ.J Glu Trp Vei 35 10 45 Ser Tyr lie Ser Gly Ser Ser Thr Thr Met Tyr Tyr Ala ASD Ser Val 50 55 60 4 Lj^^Sly Arg Phe Thr He Ser Arg Asp Asr. Ala Lys Asn Ser Leu Tyr 70 75 80 Leu Gin Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Vai Tyr Tyr Cys 85 90 95 Ala Arg Leu Arg His Phe Asp Trp Ser Tyr Ala Phe Asp He Trp Gly 100 105 110 Gin Gly Thr Met Val Thr Vai Ser Ser 115 120 77 321 DNA Homo sapiens 77 gacatccaqa tgacccagtc tccatcttcc gtctctacat ctgtaggaga cacagtcacc 60 atcacttgrc gggccagtca gggtattagc agccggtzaq cctggcatca gcagagacca 120 gggaaagccc ctaagctcct gatcratgct gcatccagtt rgcaaagtgg ggtcccatca 180 aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240 gaagattttg caacttactt ttgtcaacag gctaccagtt tcccattcac tttcggccct 300 gggaccaaag tgggtatcaa a 321 79 107 PRT Homo sapiens 78 Asp He Gin Met Thr Gin Ser Pro Ser Ser Val Ser Thr Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Gly He Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Lys Leu Leu lie 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 7C 75 80 iflRs GHTOsp Phe Ala Thr Tyr Phe Cys Gin Gin Ala Thr Ser Phe Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Gly lie Lys 100 105 79 366 DNA Homo sapiens 79 caggtgcagc tggtgcagtc tggggctgag gtgaagaaac ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggata caccttcacc ggctaccata tgcactgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcaacccta acagtggtgg cacaaactat 130 gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctac 240 atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagagatagg 300 gctttttgga gtggttatca cggttcggac gtctggggcc aagggaccac ggtcaccgtc 360 tcctca 366 80 122 PRT Homo sapiens 80 Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 15 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 His Met His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met 35 40 45 Gly Trp lie Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gin Lys Phe 50 55 60 C-ln Gly Arg Val Thr Mat Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 8C Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Al.a Val Tyr Tyr Cys 85 90 95 Arg Asp Arg Ala Phe Trp Ser Gly Tyr His Gly L§u Asp Val Trp 100 105 110 Gly Gin Gly Thr Thr Val Thr Val Ser Ser 115 120 81 321 DNA Homo sapiens 81 gacatccaga tgacccagcc tccatcctcc ctgtctgcat ctgtacjgaga cagagtcacc 60 atcacttgcc gggcgagtca ggtcattgcc aattatttag cctggtatca gcagaaacca 129 ggaaaagttc ctaaactcct gatctatgct gcatccactt tgcaat;Cagg ggtcccatct 180 cggttcagtg gcagtggatc cgggacagat ttcactctca ccatc^gcag cctgcagcct 240 gaagatgttc caacttatta ctgtcacacg tataagagtg ccccgt^ggac gttcggccaa 3C0 gggaccaagg tggaaatcas a 321 82 107 PRT Homo sapiens 82 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Val IIe Ala Asn Tyr 20 25 30 Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pre Lys Leu Leu He 35 40 4$ Tyr Ala Ala Ser Thr Leu Gin Ser Gly Val Pro Ser Atg phe Ser Gly 50 55 ' 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser S&r Leu Gin Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys His Thr Tyr Lys S^r Ala Pro Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu tie Lys 100 105 > 83 . 357 DNA Homo sapiens 83 caggtgcagc tggtgcagtc tggggctgag gtcaagaagc ctggggcctc agtgaaggtt 60 tcctgcaagg cttctggata caccttcacc aqttatgata tcaactgggt gcgacagccc 120 actggacaac ggcttgagtg gatgggatgg atgaacccta acagtggtaa cacaggctat 160 gcacagcagt tccagggcag agtcaccatg accaggaaca cctccataac tacagcctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagaaaag 300 tatagcagtt cgctctttga ctcctggggc cagggaaccc tggtcaccgt ctcctca 357 34 119 PRT Horr.c sapiens 34 Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 15 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp lie Asn Trp Val Arg Gin Ala Thr Gly Gin Gly Leu Glu Trp Met 35 4 0 .. .-_ 4 5 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gin Gin Phe 50 55 60 Gin Gly Arg Val Thr Met Thr Arg Asn Thr Ser lie Thr Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Glu Tyr Ser Ser Ser Leu Phe Asp Ser Trp Gly Gin Gly 1C0 105 110 Thr Leu Val Thr Val Ser Ser 115 85 321 4 DNA I3> Homo sapiens 85 gacatccaga tgacccagcc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcactrgcc gggcaagtca gggcattaga aataatttag gctggtttca gcagaagcca 120 gggaaagccc ctaagcgcct aatctatgct gcatccagtt tgcaaagtgg ggtcccatca 18C aggttcagcg gcagtggatc tggcacaaaa ttcactctca caatcagcag cctgcagcct 240 gaagattttg caacttattt ctgtctacag cataataggt accctctcac tttcggcgga 300 gggaccaagg tggagatcaa a 321 86 107 PRT Homo sapiens 86 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Aia Ser Val Gly 1 5 10 15 Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Arg Asn Asn 20 25 30 Leu Gly Trp Phe Gin Gin L-ys pro Gly Lys Ala Pro Lys Arg Leu lie 35 40 45 Tyr Ala Aia Ser Ser Leu Gin Ser Gly Vai Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Lys Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 10 IS 80 Glu Asp Phe Ala Thr Tyr Phe Cys Leu Gin His Asn Arg Tyr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys val Glu He Lys 100 105 87 372 ON'A Home sapiens 87 cagctccagc tgg'ggagtc zgggggaggc gtcgtccagc ctgggaggtc cctgacaccc 60 tcctgtgcag cctctggatt caccttcagt agctaccgca tgcactggct cecccaggct 120 ^Rggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtac 240 ctgcaaatga acagcctgag agctgaggac acggctgtgt tttactgtgc gagagataga 300 tattgtagta gtaccagctg ctataggggg ctaggctact ggggccaggg aaccctggtg 360 acggtttcat ca 372 88 124 PRT Homo sapiens 88 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Scr Gly Phe Thr Phe Ser Ser Tyr 20 ' 25 30 Gly Met His Trp Val Arg Gin Ala Fro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val lie Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 " 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Asp Arg Tyr Cys Ser Ser Thr Ser Cys Tyr Arg Gly Leu Gly 100 ~ 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Se^ 115 120 89 321 DNA Home sapiens 89 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgcaggaaa cagag'ccagc 60 atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatcu gcagaaacca 120 A* goMLaagccc ctacgcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240 gaagattttg caagttatta ctgtctacag cataatagtt tcccgtggac gttcggccaa 300 gggaccaagg tggaaatcaa a 321 90 107 PRr Homo sapiens 90 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Ser lie Thr Cys Arg Ala Ser Gin Gly He Arg Asn Asp 20 25 30 Leu Gly Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Thr Arg Leu Hi 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 8G Glu Asp Phe Ala Ser Tyr Tyr Cys Leu Gin His Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 91 360 DNA Homo sapiens 91 caggtgcagc tggtggagtc tggggaaggc ttggtcaagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggatt caccrtcagt gactactaca rgaactggat ccgccacgct 120 ccagggaagg ggctggagtg gqtttcatac attegtagta gtggcag-iat tatatactac ISC gcagactctg tgaagggccc attcaccatc tccagggaca accccaagaa ctcactgr.at 2^.0 ctgcaaarga acagcctgag agccgaggac acggccgtgt atcactgLgc gagagar.ggg 30C cacatagcag ctcgtggtat ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360 92 120 PRT Homo sapiens 92 Gin Vai Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Giy 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ty: 20 25 30 Tyr Met Asn Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 4S Ser Tyr lie Ser Ser Ser Gly Ser lie lie Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arc Asp Asn Ala Lys Asn Ser Leu Tyr 65 " 70 75 80 Leu Gin Met Asn Ser Leu Arg Ala Giu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly His lie Ala Ala Arg Gly Met Asp Val Trp Gly Gin 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 93 324 DNA Homo sapiens 93 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggcaagtca gagctttagc aggtatataa attggtatca gcagaaacca gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaggtgg ggtcccatca aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct gaagattccg caacctacta ctgccaacag actcacagta accctccgat cacctccggc caagggacac gactggagat taaa 9d OjL> PRT Homo sapiens 91 Asp lie Gin Met Tbr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Ser Phe Ser Arg Tyr 20 25 30 He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly ?hr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 65 70 75 30 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Asn Pro Pro 85 90 95 He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys 100 105 95 360 DNA Homo sapiens 95 caggcgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagaccc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggcg 120 ccaggcaagg ggctggagCg ggtggcagtt atatggtatg atagaagtaa taaatactat 180 gcagactccg tgaagggCCg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcttgag agccgaggac acggctgtgt attactgtgc ggggggacga 300 tcccggggag cctttgac:t ctggggccag ggaaccctgg tcaccgtctc ctcagccccc 360 96 118 PRT Homo sapiens 96 Gin Val Gin Leu vai G-__u Ser Gly Gly Gly Val Val Gin Pro Gly Arg b 10 15 Ser Leu Arg Leu Ser Cys Ma Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Gly Gly Arg Ser Arq Gly Ala Phe Asp Phe Trp Gly Gin Gly Thr 100 " 105 110 Leu Val Thr Val Ser Ser 115 97 321 DNA Homo sapiens 97 gacatccaga tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60 atcacttgtc gggcgaatca agacattagc agctggctag cctggtatca gcagaaaqca 120 gggaaagccc ctaaactcct catctatgct gcatccagtt tgcaaagtgg ggtcccatca 180 agattcagcg gcagcggatc tgggacagat ttcactctca ccatcagcag cctgcagccr 240 gaagattttc caacttacta ttgtcaacgg actaacagtt ttcctcggac gttcggccaa 300 gggaccaagg tggaaatcaa a 321 9B 107 PRT <:213> Homo sapiens 98 Asp lie Gin Met Thr Gin Ser Pre Ser Ser Val Ser Ala Ser Vsl Gly 1 5 10 15 4 A^^Arg Val Thr lie Thr Cys Arg Ala Ser Gin Asp Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gin Gin Lys Ala Gly Lys Ala Pro Lys Leu Leu lie 35" 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 65 70 75 60 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Ser Phe Pro Arg 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys 100 105 99 351 DNA Homo sapiens 99 caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60 tcctgcaagg catctggata caccttcacc agctactata tgtactgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggaata atcaacccta gtcgtggCag cacaacctac 180 gcacagaagt tccagggcag agtcaccatg accagggaca cgtccaCgag cacagtctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt antactgtgc gagagqcagc 300 tcgccgttct ctgactactg gggccaggga accctggtca ccgtctCctc a 351 100 117 PRT Homo sapiens 100 Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys pro Gly Ala 15 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr ?he Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Arc Gin Ala Pro Gly Gin Gly Leu Glu Trs Met 35 40 45 Giy""rie He Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gin Lys Phe 50 55 60 Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyj 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Ser Pro Phe Phe Asp Tyr Trp Gly Gin Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 101 321 DNA Homo sapiens 101 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcactitgcc gggcaagtca gatcattagc cactttttaa attggtatca gcagaaacca 12C gggaaagccc ctaagctcct ggtctatgtt gcatccagtt tgcaaagtgq ggtcccatca 180 agattcagng gcagtggatc tgggactgat ttcactctca ccatcagcag -ictgcaacct 240 gaacattttg caacttacta ttgtcaacag agtttcagta taccgctcac tttcggcgga 300 gggaccaagg tggagatcaa a 321 102 107 PRT Homo sapiens 102 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin He He Ser His Phe 20 25 30 Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Va'. 35 40 45 Tyr Val Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser S£r ^eu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Phe S«?r Ile Pro ^eu 85 90 35 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 103 361 DNA Homo sapiens 103 caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctggga^gtc cctgagagtc 60 tcctgtgcag cgtctggatt tatgttcaga agctatggca tqcact-9QQz ccgccaggcr 120 ccaggcaagg ggctggagtg ggtggcagtt atatcgcatg atggaa^taa taaaaatca:: 1SD ggagactccg tgaagggccg attcaccatc tccagagaca attcc#a9aa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgrgt attact9t9c gagagggaga 300 ctggcagggg ggggccccta ttactattac tactacggta tggaccjtct(3 gggccaacgg 360 accacggtca ccgtctcctc a 331 104 127 PRT Homo sapiens 104 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro G1y Ar 15 10 15 Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Met PJ»e Arg Ser Tyr 20 25 3° Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly L 35 Ala Val He Trp His Asp Gly Ser Asn Lys Asn His GJ-Y AsP Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys A^ ?h- Leu Ty; 65 70 75 RO .■sw^bxn Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Va1 TVr TYr CYS 85 90 95 Ala Arg Gly Arg Leu Ala Gly Gly Gly Pro Tyr Tyr Tyf Tvr Tyr TYr 100 105 1X0 Gly Met Asp Val rrp Gly Gin Gly Thr Thr Val Thr Va1 Ser Ser 115 120 125 105 333 DNA Homo sapiens 105 gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctg^a?a gccggcctcc 60 atctcctgca ggtctagtca gagcctcctg catagtaatg gataca?cta tttggattgg 120 tacctgcaga agccagggca gtcrccacag ctcctgatct atttgg zccggggtcc ctgacaggtt cagtggcact ggatcaggca cagattt-tac actgaaaatc 240 300 accttcggcc aagggacacg actggagatt aaa 333 agcagagtgg aggctgagga tgttgggctt tattactgca tgcaatctct acaaactatc 106 111 PRT Homo sapiens 106 Asp Ile Val Met Thr Gin Ser Pro Leu Ser Leu Pro Va* Thr pro GIY ; 5 10 15 Glu Pro Ala Ser lie Ser Cys Arg Ser Ser Gin Ser Le 20 25 Li Leu His Ser 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gin Lys Pr° GiY Gin Ser 35 40 45 Fro Gin Leu Leu He Tyr Leu Gly Ser His Arg Ala Se" G1y Val pco 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Th Leu L^'s Ile 55 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met Gin Ser 85 90 95 Leu Gin Thr lie Thr Phe Gly Gin Gly Thr Arg Leu Glu lie Lys 100 105 110 107 360 DNA Homo sapiens 107 caggtgcagc tggcggagtc tgggggaggc ttggtcaagc ctggagggcc cctgagactc 60 tcctgtgcag cctctggatt caccttcagt gactactaca tgaactggat ccgccaggct 120 ccagggaagg ggctggagtg ggtttcatac attagT:agta ctggtagtat catatactac 180 gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactcxat 2 ctacaaatga acagcctgag agccgaggac acggccgtgt actactgtgc gagaga-ggg 300 cgtatagtag ctcgtggtat cgacgtctgg ggccaaggca ccacggtcac cgtczcctca 360 108 120 PRT Homo sapiens 108 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Asn Trp He Arc Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 ' 40 45 Ser Tyr lie Ser Ser Ser Gly Ser He He Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 7C 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Arg He Val Ala Arg Gly Met Asp Val Trp Gly Gin 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 109 324 DMA Homo sapiens 109 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 ctcacttgcc gggcaagtca cagcattaac aggtatataa attggtatca gcagaaacca 120 gggaaagccc ctaaactcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatct 180 aggttcagtg gcaatggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 230 gaagattttg caacttacta ctgtcaacag agttacagta cccctccgat caccttcggc 300 caagggacac gactggagat tact 323 110 108 PRT Homo sapiens 110 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr Leu Thr Cys Arg Ala Ser His Ser He Asn Arg Tyr 20 25 30 He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser -Gly 50 55 60 Asn Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pro 85 90 95 He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Thr 100 105 111 360 DNA Homo sapiens 111 caggtgcagc tggtggagtc tgggggaggc gcggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt aga~atggca tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatggtacg atggaagaaa taaatactat 180 gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggctgtgt attartgtgt gggagtgggt 300 ataacagtga ctggtgcctt tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 112 120 PRT Homo sapiens 112 Gin Val Gin Leu Val Glu Ser Gly Gly Giy Val Val Gin Pro Gly Arc 5 ■ 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val lie Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Val Asp Ser Val 50 55 " 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 l "75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Gly Val Gly He Thr Val Thr Gly Ala Phe Asp Tyr Trp Gly Gin 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 113 321 DNA Homo sapiens 113 gaaatagtga tgacgcagtc tccacccacc ctgcctgtgt ctccagggga aagagccacc 60 cTt^Kcctgca gggcca9tca gagtgttcgc agcaacttag cctggtacca acagaaacct 120 aqccaqgctc ccagqctcct- catctatggt gcatccacca gggccactga catcccaacc 180 aqgttcaqtq gcagtq'99tc tgggacagag ttcactccct ccatcagcag cccgcagtct 24C caagattttg cagtttatta ttgtcagcag tataataact ggcctcggac gtttggccaa 300 gggaccaagg tggaa#tcaa a 321 114 107 PRT Homo sapi 114 Glu He Val Met l'hr Gin Ser Pro Ala Thr Leu Ser Val Ser Pro G1y 1 5 ' 10 15 Jlu Arg Ala ?h>- l>eu $ez Cys Arg Ala Ser Gin Ser Val Arg Ser Asn 20~ 25 30 Leu Ala Trp Tyr (5ln dn Lys pro G^V G^n A^a Pro Ar9 Leu Leu H-e 35 40 45 Tyr Gly Ala Ser fnr Ar9 Vai Tnr AsP Ile Pro Thr Ar9 p^e Ser G1V 50 55 60 Ser Gly Ser Gly t"r G^-u phe ^r Leu Ser le Ser Ser Leu G-n Ser 65 TO 75 80 ilu Asp Phe Ala Vai Tyr Tyr CYS Gin Gin Tyr Asn Asn Trp Pro Arg g5 90 35 T\i V\\t Q,Y$ ^\T, €>Vi "^ V}* ^"^ ^» Wfc \}-& 100 105 115 354 DNA Homo sapi^ns 115 caggtgcagc tggr.g3a9tc c99g99aggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtct#9at- caccttcagc agctatggca rgcactgggt ccgccaggct 120 ccaggcaagc ggccgga9t9 ggtggcagtc atatggtatg atacaagtaa taaaCactat 180 qcagactccg tgaagg9cc9 attcaccatc tccagagaca attccaagaa cacgctgtat 2-50 cicaaatga acagcctgag agccgaggac acggctgtgt attactgtgc ggggggacga tcciggggag cctttgactt ctggggccag ggaaccctgg tcaccgtctc ctca 116 118 PRT Homo sapiens 116 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg 15 10 15 Ser Leu Arg Leu Ser- Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val lie Trp Tyr Asp Arg Ser Asn l.ys Tyr Tyr Ala Asp Ser Val 50 " 55' 60 Lys Gly Arg Phe Thr lie Ser Arc Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 V5 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Phe Trp Gly Gin Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 117 306 DNA Homo sapiens 117 cagtctccat cttccgtgtc tgcatctgta ggacacagag tcaccatcac ttgtcgggcg agtcagggta ttagcagctg gttagcctgg tatcagcaga aagcagggaa agcccctaaa ctcctgatct attctgcatc cagr.ttgcaa agtggggtcc catcaagatt cagcggcagt ggatctggga cagatttcac tctcaccatc agcagcctgc agcctgaaga ttttgcaact cactatt-gcc aacggactaa cagttttcct cggacgttcg cccaagggac caaggtggaa atcaaa A 118 107 PRT Homo sapiens 118 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Ser Ser Trp 20 25 30 Lea Ala Trp Tyr Gin Gin Lys Ala Gly Lys Ala Pro Lys Leu Leu He 35 40 45 Tyr Ser Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 30 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Ser Phe Pro Arg 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 119 351 DNA Homo sapiens 119 cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60 acctgcactg tctctggtgg cttcatcagc agtagtagtt actactgggg ctggatccgc 120 cagcccccag ggaagggact ggagtggatt gggaccatct attatagtgg gaccacctac 180 tacaattcgt ccctgaagag tcgagtcacc atatccgtag acacgtccca gaaccaqttc 24C tccctgaagc tgagctctgt gaccgccgca gatacggctg tgtattactg tgcgagacat 30C cactgggttt ttgactactg gggccaggga accctggtca ccgtctcctc a 351 120 117 PRT Homo saniens A M$> 120 Glrv Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val L/s pro Ser Giu 15 10 ^5 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Phe lj-e Ser Ser Se^ 20 25 30 Ser Tyr Tyr Trp Gly Trp lie Arg Gin Pro Pro Gly L^s G1V Leu Glu 35 40 4? Trp lie Gly Thr He Tyr Tyr Ser Gly Thr Thr Tyr T/r Asn Ser Ser 50 55 60 Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser G±n Asn Gln Phe 65 70 75 so Ser Leu Lys Leu Ser Ser val Thr Ala Ala Ass Thr A>a Val TV"r Tyr 8 5 90 95 Cys Ala Arg ttis nis Trp Val Phe Asp Tyr Trp Gly G>n "^V "1'nr '^eu 100 105 u0 Val Thr Val Ser Ser 115 121 321 DMA Homo sapiens 121 gaagttgtgc tgactcagtc tccagacttt cagtctgtga ctcca^a99a gaaaatcacc 6C atcacctgcc gggccagtca gatcattggt actagcttac actgg^atca gaagaaacca 120 gatcagtctc caaagctcct catcaactat gcttcccagt ccttctcai39 ggtcccctcg 180 aggttcagtg gcagtggatc tgggacagaa ttcaccctca ccatc^ata9 cctggaagct 240 gaagatactg caacgtatta ctgtcatcag agtactaatt taccgOS30 gttcggccaa 300 gggaccaagg tggaaatcaa a 321 122 107 PRT Homo sapiens 122 Glu Val Val Leu Thr Gin Ser Pro Asc Phe Gin Ser V^1 Thr Pre Lys 5 10 15 Glu Lys He Thr He Thr Cys Arg Ala Ser Gin He He Gly Thr Ser 20 25 3G Leu His Trp Tyr Gin Lys Lys Pro Asp Gin Ser Pro Lys Leu Leu He 35 40 45 Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Asn Ser Leu Glu Ala 65 70 75 80 Glu Asp Thr Ala Thr Tyr Tyr Cys His Gin Ser Thr Asn Leu Pro Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys IOC 105 123 381 DNA Homo sapiens 123 caggtgcagc tggcgcagcc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggata caccttcatc ggctactatc ttcactgggt gcgacaggcc 120 cctggacaag ggcttgaatg gatgggatcg atcaacccta acagtggtgg cacaaactat 180 gcacagaagt ttcagggcag ggtcaccatg atcagggaca cgtccatcaa cacagcctac 240 atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagacataaa 300 cgtatcacta tggttcgggg agtccactat ctctactacg gttgggacgt ctggggccaa 360 gggaccacgg tcaccgtctc ctca 384 124 128 PRT Homo sapiens 124 Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe He Gly Tyr 20 25 30 Tyr Leu His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met 35 40 45 Gly Ser lie Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gin Lys Phe 50 55 60 Gin Gly Arg Val Thr Met lie Arg Asp Thr Ser He Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 . 90 95 Ala Arg Asp Lys Arg He Thr Met Val Arg Gly Val His Tyr Leu Tyr 100 105 HO Tyr Gly Trp Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser 115 120 125 125 321 DNA Homo sapiens 125 gacatccaga tgacccagtc tccatccccc ctgtctgcat ctgtaggaga cagagtcacc 6C atcacttgcc gggcgagtca ggtcattagc aattatttag cctggtiatca gcagaaacca 12C gggaaagttc ctcagctccc gatctatgct gcatccactt tgcaa'cagg ggtcccatcc 180 cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240 gaagatgtug caacttatta ctgtcaaaac tataaaagtg ccccgtggac gtccggccaa 300 gggaccaagg tggaaatcaa a 321 126 107 PRT Homo sapiens 126 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 ASD Arg Val Thr He Thr Cys Arg Ala Ser Gin Val lie Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pro Gin Leu Leu He 35 40 45 Tyr Ala Ala Ser Thr Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gin Asn Tyr Lys Ser Ala Pro Trp 8S 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu lie Lys 100 105 127 116 PRT Homo sapiens 127 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ser Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 43 Ser Tyr He Ser Ser Ser Gly Ser Thr He Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 " 75 80 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Ser Gly Ser Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val 100 105 HO Thr Val Ser Ser 115 128 118 PRT i\3> Homo sapiens 128 Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ser Trp He Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr lie Ser Ser Ser Gly Ser Thr He Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 * 75 60 Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 35 90 95 Ala Arg Ser He Ala Ala Arg Gly Met Asp Val Trp Gly Gin Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 129 114 PRT Homo sapiens 129 Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 15 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser He Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp He Arg Gin Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp He Gly Ser He Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val 100 105 110 Ser Ser 130 108 PRT Homo sapiens 130 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Ser lie Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pre 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pro 85 90 95 Trp Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 131 107 PRT Homo sapiens 131 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Gly He Ser Asn Tyr 20 25 30 Lea Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pro Lys Leu Leu He 35 40 Tyr Ala Ala Ser Thr Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gin Lys Tyr Asn Ser Ala Pro He 85 90 95 Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys 100 105 132 107 PRT Homo sapiens «300> 132 Glu He Val Leu Thr Gin Ser Pro Asp Phe Gin Ser Val Thr Pro Lys 1 5 10 15 Glu Lys Val Thr He Thr Cys Arg Ala Ser Gin Ser He Gly Ser Ser 20 25 30 Leu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Lys Leu Leu He 35 40 45 Lys Tyr Ala Ser Gin Ser Fhe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Asn Ser Leu Glu Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Ser Ser Leu Pro Trp 85 90 95 Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 133 105 PRT Homo sapiens 133 Aso lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 * 5 10 IS Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Ser He Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 40 45 Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 "?5 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser He Thr Phe 55 90 95 Gly Gin Gly Thr Arg Leu Glu He Lys 100 105 134 120 PRT Homo sapiens 134 Gin Vai Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 15 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met His Trp He Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val 35 " 40 45 Ser Tyr He Ser Arg Ser Gly Ser Leu He Tyr Tyr Val Asp Ser Val 50 55 60 Lys Giy Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 ,eu Gin Ket Asn Ser Leu Arq Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Air. Arg Gly Gly Pro Tyr Ser Gly Ser Pro Phe Asp Tyr Trp Gly Gin 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 135 108 PRT Homo sapiens 135 Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Thr He Thr Cys Arg Pro Ser Gin Arg He Ser Arg Tyr 20 25 30 Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 ' 40 15 Tyr Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 €0 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pre 85 90 95 Trp Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys 100 105 136 108 PRT Homo sapiens 136 Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 15 10 15 Asp Arg Val Ser He Thr Cvs Arg Pro Ser Gin Ser Phe Ser Arg Tyr 20 25 30 He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He 35 40 45 Tyr Ala Ala Ser Ser Leu Val Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Asn Pro Pro 65 90 95 lie Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys 100 105 -6^3** 1. / A targeted binding agent that specifically binds to PDGFR-alpha and ^ inhibits the growth of cells that express PDGFR-alpha, wherein the targeted binding agent binds PDGFR-alpha with a KD less than about 40pM. 2. The targeted binding agent of claim 1, wherein said targeted binding agent binds to PDGFR-alpha and at a concentration of 2 g/ml inhibits greater than or equal to 90% of tyrosine phosphorylation of PDGFR-alpha on MG-63 cells incubated with 25ng/ml PDGF-AA. 3. The targeted binding agent according to any one of the preceding claims, wherein said targeted binding agent inhibits the proliferation of MG-63 cells incubated with 3.45nM PDGF-AA with an IC50 of less than 3.2nM. 4. The targeted binding agent according to any one of the preceding claims, wherein said targeted binding agent binds to PDGFR-alpha and inhibits binding of PDGF-AA, PDGF-AB, PDGF-BB, and/or PDGF-CC iigands to PDGFR-alpha; inhibits downstream cell signaling implicated in cell growth; does not cross-react with PDGFR-beta receptor; and/or does not cross react with other Class III receptor tyrosine kinase family members. 5. The targeted binding agent according to any one of the preceding claims wherein said targeted binding agent inhibits tumor growth and metastasis in a mammal. 6. The targeted binding agent according to any one of the preceding claims, wherein said targeted binding agent comprises a polypeptide comprising the sequence of i. SEQIDNO. :2; ii. SEQ ID NO.: 2, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 6; iii. SEQIDNO. : 10; iv. SEQ ID NO. : 10, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 8; v. SEQIDNO.: 14; vi. SEQ ID NO. : 14, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 10; vii.SEQIDNO. : 4; viii. SEQ ID NO. : 4, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 7; ix. SEQ ID NO. : 12; x. SEQ ID NO. : 12, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 9; xi. SEQ ID NO. : 16; or xii. SEQ ID NO. : 16, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 11. 7. A targeted binding agent according to any one of the preceding claims comprising an amino acid sequence comprising a CDR3 sequence as shown in Table 12 or Table 13; a CDR3 sequence as shown in Table 12 and a CDR3 sequence as shown in Table 13; a CDRI, CDR2 and CDR3 sequence as shown in Table 12; a CDRI, CDR2 and CDR3 sequence as shown in Table 13; or a CDRI, CDR2 and CDR3 sequence as shown in Table 12 and a CDRI. CDR2 and CDR3 sequence as shown in Table 13. 8. A targeted binding agent according to any one of the preceding claims wherein said targeted binding agent is an antibody; a monoclonal antibody; a fully human monoclonal antibody; a binding fragment of a fully human monoclonal antibody; or a binding fragment of a fully human monoclonal antibody selected from the group consisting of Fab, Fab', F(ab') 2, Fv and dAb. A targeted binding agent according to any one of the preceding claims wherein said targeted binding agent is i. any one of the monoclonal antibodies as shown in Tabic 1; ii. monoclonal antibody 2 .175 .3; iii. monoclonal antibody 2 .175 .3 variant A; iv. monoclonal antibody 2 .449.1 .3; v. monoclonal antibody 2.449 .1 .3 variant A; vi. monoclonal antibody 2 .449.1 .3 wherein the antibody comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 12, wherein the sequence comprises the unique combination of germline and non-germline residues indicated by row 3968 of Table 9; or monoclonal antibody 2.998 .2. 10. A targeted binding agent wherein said targeted binding agent comprises an antibody which comprises variants or derivatives of the monoclonal antibodies of any one of claims 6 to 9: and/or has at least 80% amino acid sequence identity with the monoclonal antibody of any one of claims 6 to 9. 11. A targeted binding agent which competes for binding to PDGFR-alpha with any one of the targeted binding agents of claims 1-10; and/or binds to the same epitope on PDGFR-alpha as any one of the targeted binding agents of claims 1-10. 12. A nucleic acid molecule encoding the targeted binding agent of any one of the preceding claims. 13. A vector comprising the nucleic acid molecule of claim 12. 14. A host cell comprising the vector of claim 13. 15. A method of producing an antibody by culturing the host cell of claim 14 under conditions wherein a nucleic acid molecule is expressed to produce the antibody, followed by recovering the antibody. 16. A method of treating a neoplastic disease in an mammal, comprising : selecting an animal in need of treatment for a neoplastic disease ; and ^ ^ administering to said animal a therapeutically effective dose of the targeted binding agent of any one of claims 1 to 11. 17. The method of claim 16, wherein said neoplastic disease is selected from the group consisting of. melanoma, small cell lung cancer, non-small cell lung cancer, glioma, hepatocellular (liver) carcinoma, thyroid tumor, gastric (stomach) cancer, prostate cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, esophageal carcinoma, head and neck cancers, mesothelioma, sarcomas, biliary (cholangiocarcinoma), small bowel adenocarcinoma, pediatric malignancies, epidermoid carcinoma and gastrointestinal stromal tumor (GIST). 18. A method of treating a non-neoplastic disease, comprising : selecting an animal in need of treatment for a non-neoplastic disease; and administering to said animal a therapeutically effective dose of the targeted binding agent of any one of claims 1 to 11. 19. The method of claim 18, wherein the non-neoplastic disease is selected from fibrotic or immune system diseases. ■ Dated this 05th day of January, 2009 (&MRISH TTWARI) T)F K & S PARTNERS AGENT FOR THE APPLICANTS)

Full Text

FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
(Sec section 10, rule 13)
"TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF"

ASTRAZENECA AB, SE -151 85 Sodertalje, Sweden.

The following specification particularly describes the invention and the manner in which it is to be performed.

WO 2008/112003

PCT/US2007/075117

TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES
THEREOF
BACKGROUND OF THE INVENTION Cross Reference to Related Applications
|001j This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application Serial No. 60/835,647, filed August 3, 2006, the entirety of which is hereby incorporated by reference.
Field of the Invention
[002] The invention relates to targeted binding agents against the largci antigen PDGFR-alpha and uses of such agents. In some embodiments, the invention relates lo fully human monoclonal antibodies directed to PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such targeted binding agents or antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
Description of the Related Art
[003} Platelet derived growth factor (PDGF) is a protein that regulates cell growth and division. There are five different isoforms of PDGF (A, B. C. D, and an AB helerodimer) that exist as dimers and activate the cellular response through two different receptors (PDGFR-alpha and PDGFR-beta). Specifically, PDGF dimers bind lo two receptors simultaneously to induce receptor dimerization, autophosphorylation and intracellular signaling.
|004] Platelet derived growth factor receptor-alpha (PDGFR-alpha, also known as CDJ40a.) is a type HI receptor tyrosine kinase characterized by an extracellular domain having Five lgG-like domains, a transmembrane domain and a catalytic intracellular domain. PDGFR-alpha can form homodimers or heterodimers with the structurally similar PDGFR-beta. PDGF-AA activates only alpha-alpha receptor dimers, PDGF-AB and PDGF-CC

WO 2008/112003

PCT/US2007/075117

activate alpha-alpha and/or alpha-beta receptor diniers and PDGF-BB activates ail three combinations of receptor dimers.
J005] PDGFR-alpha has been linked to tumorigenesis and has been implicated in a number of cancers including breast, lung, ovarian, prostate, colon and endometrial cancers. as well as hepatocellular carcinoma, glioblastoma, melanoma, and gastrointestinal stromal tumor (GIST)).
J006] Several companies have developed therapeutic agents that target PDGFR-alpha. Gleevec® (Novartis®) and SUTENT/SU1124S (sunitinib malate, Pfizer®) are small molecule drugs that target PDGFR-alpha as well as other receptor tyrosine kinases. In addition, monoclonal antibodies that target PDGFR-alpha have been reported. International publication number WO 1992/013867 describes that mouse or rabbit monoclonal and/or polyclonal antibodies may be prepared to PDGF receptor constructs. international publication number WO 1995/000659 relates to a monoclonal antibody, specific for PDGFR-alpha, characterized in that it binds PDGFR-alpha and does not bind PDGFR-beta. The application discloses two antibodies; characterized as having half maximal binding affinity oi~ 50pM and 75pM as measured by solid phase enzyme linked immunosorbent assay. International publication number WO2006/138729 discloses a fully human monoclonal antibody, tenned 3G3 (ImClone Systems, Inc.), that targets PDGFR-alpha. This antibody has" a reported affinity for soluble PDGFR-alpha of 40 pM as measured in a bivalent affinity assay; in which soluble PDGFR-alpha was immobilized on a sensor chip and antibody was injected at various concentrations. As discussed herein, in a bivalent assay, experimental artefacts may affect the measured affinity.
[0071 An antibody with an affinity higher than 40 pM, may be desirable as such an antibody may produce a greater extent and/or duration of PDGFR-alpha inhibition when administered to humans at standard doses. An antibody with an affinity higher than 40pM may be administered at a lower effective dose than an antibody with a lower affninity, or may be administered at longer dosing intervals in comparison with a standard dosing interval for an antibody with a lower affinity.
3

WO 2008/112003

PCTYUS2007/075117

SUMMARY OF THE INVENTION
[008] Embodiments of the invention relate to targeted binding agents that specifically bind to PDGFR-alpha and inhibit the growth of cells that express PDGFR-alpha. Mechanisms by which this can be achieved can include, and are not limited to, blocking ligand binding and/or inhibiting cell signaling implicated in tumor cell growth as weil as inhibition of the stromal fibroblast component leading to reduced angiogenesis. The targeted binding agents are useful for reducing tumour growth and angiogenesis.
[009] In one embodiment of the invention, the targeted binding agent is a fully human antibody that binds to PDGFR-alpha and inhibits binding of PDGF-AA, PDGF-AB. PDGF-BB, and/or PDGF-CC ligands to PDGFR-alpha. Yet another embodiment of the invention is a fully human monoclonal antibody that binds to PDGFR-alpha and inhibits receptor autophosphorylation. Another embodiment of the invention is a fully human monoclonal antibody that binds to PDGFR-alpha and inhibits downstream cell signaling implicated in cell growth.
(0010J In some embodiments, the targeted binding agent binds to PDGFR-alpha and does not cross-react with PDGFR-beta receptor, that is, the agent is mono-specific. In some embodiments, the targeted binding agent binds to PDGFR-alpha and docs not cross react with other Class III receptor tyrosine kinase family members, such as. for example, FLT3. c-kit, and/or CSF-1R.
J0011] Another embodiment of the invention is a targeted binding agent that competes for binding with any of the targeted binding agents or antibodies described herein.
|0012] In one embodiment, the targeted binding agent binds PDGFR-alpha with a KD of less than about 500 picomolar (pM). In another embodiment, the targeted binding agent binds with a KD less than about 400, 300, 200 or 100 pM. In one embodiment, the targeted binding agent binds with a KD of less than about 75, 60, 50: 40, 30, 20, 10 or 5 pM. Affinity and/or avidity measurements can be measured by FMAT, FACS, KinExA® and/or BIACORE®, as described herein.
|00131 In another embodiment, the targeted binding agent binds PDGFR-alpha with a KD less than about 400, 300, 200, or 100, 75, 60, 50, 40, 30. 20, 10, or 5 pM as measured in a monovalent affinity assay. Monovalent affinity may be measured in a BIACORE® assay in which soluble receptor is flowed over immobilized antibody. In comparison with a

WO 2008/112003

PCT/US2007/0751I7

bivalent affinity assay, the KD as reported by a monovalent affinity assay is much less likely to be affected by experimental artefacts and is thus able to report a KD much closer lo the true monovalent affinity of the antibody. In a bivalent affinity assay, the density of immobilized receptor influences the extent to which single antibody molecules bind twice and/or rebind immobilized receptor as they are flowed over. As such, in a bivalent affinity assay, the density of receptor can directly affect the reported KD. Thus, a monovalent affinity assay provides a much more biologically-relevant measurement of affinity.
|00141 In another embodiment, the targeted binding agent inhibits ligand-induced transphosphorylation within the receptor dimer with an IC50 less than about 400, 300. 200, or 100, 75, 60, 50, 40, 30, 20, 10, or 5 pM when performed at close to saturating ligand levels.
|0015| In another embodiment, the targeted binding agent inhibits ligand-induced receptor autophosphorylation with an IC50 less than about 400, 300, 200, 100, 75, 60, 50. 40. 30, 20, 10 or 5 pM when performed at close to saturating ligand levels.
|0016] In one embodiment of the invention, the targeted binding agent is an antibody. In one embodiment of the invention, the targeted binding agent is a monoclonal antibody. In one embodiment of the invention, the targeted binding agent is a fully human monoclonal antibody. In another embodiment of the invention, the targeted binding agent is a fully human monoclonal antibody of the IgGl, IgG2, IgG3 or IgG4 isotype. In another embodiment of the invention, the targeted binding agent is a fully human monoclonal antibody of the IgG2 isotype. This isotype has reduced potential to elicit effector function in comparison with other isotypes, which may lead lo reduced toxicity.
10017| A further embodiment is an antibody that binds to PDGFR-alpha and comprises a heavy chain amino acid sequence having one, two or three of the complementarity determining regions (CDR) sequences shown in Table 12 and a light chain amino acid sequence having one, two or three of the CDR sequences shown in Table 13. In certain embodiments the antibody is a fully human monoclonal antibody. In some embodiments, the invention provides an antibody thai binds Ihe same epitope as any of the antibodies disclosed herein.
[0018} In one embodiment, the heavy chain of antibody 2.175.3, 2.451.1, 2.449.1.3, 2.998.2 or 2.84.3 is paired with a heterologous light chain. Lighl-chain promiscuity is well

WO 2008/112003

PCT/US2007/075117

established in the art. Thus, the heavy chain of any of antibodies 2.175.3, 2.451.1, 2.449.1.3, 2.998.2 or 2.84.3 or another antibody as disclosed herein may be paired with the light chain of any of antibodies 2.175.3. 2.451.1, 2.449.1.3, 2.998.2, 2.84.37 or other antibody as disclosed herein.
[0019] In one embodiment an antigen binding site may comprise a heavy chain CDRl, CDR2 and CDR3 and a light chain CDRl, CDR2 and CDR3 of any of antibodies 2.175.3, 2.451.1, 2.449.1.3, 2.998.2, 2.84.3 with as many as twenty, sixteen, ten, nine or fewer, e.g. one, two, three, four or five, amino acid additions, substitutions, deletions, and/or insertions within the disclosed CDRs. Such modifications may potentially be made at any residue within the CDRs.
(0020] In another embodiment the targeted binding agent or antibody may comprise a sequence comprising any one. two. three, four, five or six of the CDRl. CDR2 or CDR3 sequences as shown in Table 12 or Table 13. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence as shown in Table 12. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence as shown in Table 13. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence as shown in Table 12 and a CDRl, CDR2 and CDR3 sequence as shown in Table !3. It is noted that those of ordinary skill in the art can readily accomplish CDR detenninations. See for example, Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bcthesda MD (1991), vols. 1-3.
}0021] In another embodiment the targeted binding agent or antibody may comprise a sequence comprising any one, two, three, four, five or six of the CDRl, CDR2 and CDR3 sequences of any one of the fully human monoclonal antibodies 2.175.3, 2.449.1.3 or
2.998.2, as shown in Table ! 2 or in Table 13. In one embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3, 2.449.1.3 or 2.998.2, as shown in Table 12. In another embodiment the targeted binding agent or antibody may comprise a sequence comprising a CDRl, CDR2 and CDR3 sequence of fully human monoclonal antibody
2.175.2, 2.449.1.3 or 2.998.2, as shown in Table 13. In another embodiment the targeted

WO 2008/112003

PCT/US2007/075II7

binding agent or antibody may comprise a sequence comprising a CDR1, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3, 2.449.1.3 or 2.998.2 as shown in Table 12, and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3, 2.449.1.3 or 2.998.2 as shown in Table 13.
[0022] In another embodiment the targeted binding agent or antibody comprises a sequence comprising a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3 as shown in Table 12 and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.175.3 as shown in Table 13. In another embodiment the targeted binding agent or antibody comprises a sequence comprising a CDRI. CDR2 and CDR3 sequence of fully human monoclonal antibody 2.449-1.3 as shown in Table 12 and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.449.1.3 as shown in Table 13. In another embodiment the targeted binding agent or antibody comprises a sequence comprising a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.998.2 as shown in Table 12 and a CDRI, CDR2 and CDR3 sequence of fully human monoclonal antibody 2.998.2 as shown in Table 13.
[0023J A further embodiment of the invention is a targeted binding agent which competes for binding to PDGFR-alpha with the targeted binding agent or antibodies of the invention. In another embodiment of the invention there is an antibody which competes for binding to PDGFR-alpha with the targeted binding agent or antibodies of the invention. In another embodiment the targeted binding agent or antibody competes for binding lo PDGFR-alpha with any one of fully human monoclonal antibodies 2-175.3, 2.449.1.3 or 2.998.2. In one embodiment of the invention there is provided an antibody which competes with any one of fully human monoclonal antibodies 2.175.3, 2.449.1.3 of 2.998.2 for binding to PDGFR-alpha.
|0024| A further embodiment of the invention is a targeted binding agent or antibody • that binds to the same epitope on PDGFR-alpha as the targeted binding agent or antibodies of the invention. In another embodiment of the invention there is an antibody that binds to the same epitope on PDGFR-alpha as the targeted binding agent or antibodies of the invention. In one embodiment of the invention there is provided a targeted binding agent that binds to the same epitope on PDGFR-alpha as any one of fully human monoclonal antibodies 2.175.3. 2.449.1.3 or 2.998.2. In one embodiment of the invention there is provided an antibody that

WO 2008/112003

PCT/US2007/075117

binds to the same epitope on PDGFR-alpha as any one of fully human monoclonal antibodies 2.175.3, 2.449.1.3 or 2.998.2.
J0025J A further embodiment of the invention is a targeted binding agent or antibody comprising the contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 of any one of the monoclonal antibodies as shown in Table ] 2 or Table 13.
[0026| One embodiment provides a targeted binding agent, or antigen-binding portion thereof, wherein the agent, or binding portion, comprises a heavy chain polypeptide having the sequence of SEQ ID NO.:2. In one embodiment, the agent, or binding portion thereof, further comprises a light chain polypeptide having the sequence of SEQ ID NO.:4. Another embodiment is a targeted binding agent, or antigen-binding portion (hereof, wherein the agent, or binding portion, comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 10. In one embodiment, the agent, or binding portion thereof, further comprises a light chain polypeptide having the sequence of SEQ ID NO.: 12. Still another embodiment is a targeted binding agent, or antigen-binding portion thereof, wherein the agent, or binding portion, comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 14. In one embodiment, the agent, or binding portion thereof, further comprises a light chain polypeptide having the sequence of SEQ ID NO.: 16.
|0027) In one embodiment, the targeted binding agent comprises one or more of fully human monoclonal antibodies 2.175.3, 2.449.1.3 or 2.998.2.
|0028| In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 2, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 6. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 10, wherein the sequence comprises any one of the unique combinations of germline and non-germiine residues indicated by each row of Table 8. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 14, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 10. In one embodiment, the targeted binding agent of the invention comprises a

WO 2008/112003

PCT/US2007/075117

polypeptide comprising the sequence of SEQ ID NO.: 4, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 7. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 12, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 9. In one embodiment, the targeted binding agent of the invention comprises a polypeptide comprising the sequence of SEQ ID NO.: 16. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 11.
[0029] In one embodiment, the antibody of the invention comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 2. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 6. In one embodiment, the antibody of the invention comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 10. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 8. In one embodiment, the antibody of the invention comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 14. wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by eacli row of Table 10. In one embodiment, the antibody of the invention comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 4, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 7. In one embodiment, the antibody of the invention comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 12, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 9. In one embodiment, the antibody of the invention comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 16, wherein the sequence comprises any one of the unique combinations of germline and non-germline residues indicated by each row of Table 11.
(0030) In one embodiment, the targeted binding agent or antibody of the invention comprises a heavy chain sequence according to SEQ ID NO: 2, 6 or 10, wherein the residue at position 30 is selected from: S or R;

WO 2008/112003

PCT/US2007/075U7

the residue at position 31 is selected from: S, N or D;
the residue at position 33 is selected from: G or Y;
the residue at position 35 is selected from: S, H or N;
the residue at position 50 is selected from: Y, V or F;
the residue at position 53 is selected from: Y, S or R;
the residue at position 54 is selected from: S or D;
the residue at position 57 is selected from: T, L, N or I;
the residue at position 58 is selected from: K or I;
the residue at position 61 is selected from: V or A:
the residue at position 99 is selected from: G, D or E or the residue is deleted;
the residue at position 100 is selected from: G or the residue is deleted;
the residue at position 101 is selected from: S, H, P or R;
the residue at position 102 is selected from: Y or I;
the residue at position 103 is selected from: S, V or A;
the residue at position 104 is selected from: G or A;
the residue at position 105 is selected from: S or R;
the residue at position 106 is selected from: P or G;
the residue at position 107 is selected from: F or M; and
the residue at position 109 is selected from: Y or V. This group of'Tieavy chain sequences is named "'Group A".
(0031 ] In one embodiment, the targeted binding agent or antibody of the invention comprises a heavy chain sequence according to SEQ ID NO: 14 or 18, wherein
the residue at position 27 is selected from: G or D;
the residue at position 28 is selected from: S or F;
the residue at position 32 is selected from: S or F;
the residue at position 33 is selected from: S, N, T or 1;
the residue at position 52 is selected from: S or T;
the residue at position 56 is selected from: S or T;
the residue at position 58 is selected from: S or T;
the residue at position 63 is selected from: S or P;
the residue at position 100 is selected from: H or the residue is deleted;

WO 2008/112003

PCT/US2007/075117

the residue at position 101 is selected from: H or the residue is deleted; and
the residue at position 103 is selected from: V or the residue is deleted. This group of heavy chain sequences is named "Group B".
(003J2J In one embodiment, the targeted binding agent or antibody of the invention comprises aflight chain sequence according to SEQ ID NO: 4, 8 or 12, wherein
the residue at position 25 is selected from: A or P;
the residue at position 27 is selected from: Q, R or H;
the residue at position 28 is selected from: G, V, S, I, D or R;
the residue at position 29 is selected from: I or F; 1 the residue at position 30 is selected from: S, N. A, R or T;
the residue at position 31 is selected from: S, H. K, T or R;
the residue at position 32 is selected from: S. T, Y, D. N or F:
the residue at position 33 is selected from: L or 1;
the residue at position 50 is selected from: A. G, L, Y, S or V;
the residue at position 51 is selected from: A, G or S;
the residue at position 53 is selected from: T, Q, N, H, R or S;
the residue at position 54 is selected from: L, R or S;
the residue at position 55 is selected from: Q, P. F, A or V:
the residue at position 56 is selected from: S, N, T or G;
the residue at position 91 is selected from: S orT;
the residue at position 92 is^*lected from: Y or F;
the residue at position 94 is selected from: N, T, S or the residue is deleted;
the residue at position 95 is selected from: F, W, P, 1, A. L or the residue is
deleted;
the residue at position 96 is selected from: P or the residue is deleted; and [0033] the residue at position 97 is selected from: W, L, R, I or the residue is deleted. This group of light chain sequences is named "Group C'[0034] In one embodiment, the targeted binding agent or antibody of the invention comprises a light c hain sequence according to SEQ ID NO: 16 or 20, wherein
the residue at position 28 is selected from: S, I, G, D, R or V;
the residue at position 29 is selected from: F, 1 or V;

WO 2008/112003

PCT/US2007/075U7

the residue at position 30 is selected from: S, A, T. G, R or N;
the residue at position 31 is selected from: S, R. K, N orT;
the residue at position 32 is selected from: Y, F. W, N, D or S:
the residue at position 33 is selected from: L or I;
the residue at position 34 is selected from: N, A or H;
the residue at position 50 is selected from: A, Y, G, L or V;
the residue at position 51 is selected from: A, G or S;
the residue at position 52 is selected from: A, Y, G, L or V;
the residue at position 54 is selected from: L, R or S;
the residue at position 55 is selected from: Q, F, V. A or P;
the residue at position 56 is selected from: S. N, T or G:
the residue at position 92 is selected from: S or T; and
the residue at position 93 is selected from: S, N or 1. This group of light chain sequences is named "Group D".
(0035] In one embodiment the targeted binding agent or antibody of the invention comprises any one of the Group A heavy chain sequences and any one of the Group C or Group D light chain sequences.
|0036] In one embodiment the targeted binding agent or antibody of the invention comprises any one of the Group B heavy chain sequences and any one of the Group C or Group D light chain sequences.
|0037] In one embodiment, the targeted binding agent comprises an antibody which comprises variants or derivative of the CDRs disclosed herein or the light or heavy chain sequences disclosed herein or the monoclonal antibodies disclosed herein. Variants include antibodies comprising light or heavy chain sequences which have at least about 60, 70, 80, 85, 90, 95, 98 or about 99% amino acid sequence identity with any of the CDRI, CDR2 or CDR3s as shown in Table 12 or Table 13, or with the light or heavy chain sequences disclosed herein, or with the monoclonal antibodies disclosed herein. In one embodiment variants comprise changes in the the CDR sequences or light or heavy chain sequences disclosed herein that are naturally occuning or are introduced by in vitro engineering of native sequences using recombinant DNA techniques or mutagenesis techniques. Naturally occurring variants include those which are generated in vivo in the corresponding gennline

WO 2008/112003

PCT/US2007/075117

nucleotide sequences during the generation of an antibody to a foreign antigen. In one embodiment the derivative may be a heteroantibody, that is an antibody in which two or more antibodies are linked together. Derivatives include antibodies which have been chemically modified. Examples include covalent attachment of one or more polymers, such as water-soluble polymers, N-linked, or O-linked carbohydrates, sugars, phosphates, and/or other such molecules. The derivatives are modified in a manner that is different from naturally occurring or starting antibody, either in the type or location of the molecules attached. Derivatives further include deletion of one or more chemical groups which are naturally present on the antibody.
[0038) Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH3-I! genu line sequence. Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH4-39 germ line sequence. Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a Dl-26, D6-6 or D7-27 germ line sequence. Some embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a VK light chain. Still other embodiments of the invention include a monoclonal antibody that comprises a VK light chain paired with a heavy chain encoded by, or derived from, a VH3-11 or VH4-39 heavy chain gene. In some embodiments, the VK light chain polypeptide is encoded by, or derived from, a JK1 light chain gene. In other embodiments, the VK light chain polypeptide is encoded by, or derived from, a JK5 light chain gene.
[0039| Other embodiments of the invention include human monoclonal antibodies that bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH3-11 germ line sequence, and a Vk light chain polypeptide derived from a 012 light chain gene. Additional embodiments of the invention include human, monoclonal antibodies that, bind PDGFR-alpha and comprise a heavy chain polypeptide derived from a VH3-11 genii line sequence, and a Vk light chain polypeptide derived from the 012 germline sequence light chain wherein the second amino acid in CDR1 of the light chain encodes proline. This combination of VH3-11 heavy chain gene usage in combination with 012 light chain gene usage along with proline encoded for at the second amino acid position of CDR1 of the light

WO 2008/112003

PCT/US2007/075117

chain is exemplified in antibodies derived from two antibodies from independent lineages with diverse CDR3 heavy chain and light chain sequences, namely 2.449.1.3 and 2.175.3 {see Tables 12 and 13).
100401 Monoclonal antibodies 2.175.3 and 2.449.1.3 are both high affinity antibodies to PDGFRa, and block PDGF-driven cellular responses with high potency in vitro. Although these two antibodies share VH (VH3-11) and Vk (012) usage, they diverge in D, JH and Jk usage. Thus, they are derived from different B-cell lineages. They do, however, share unusual sequence patterns in Vk. Residue 25 is a proline in both antibodies, mutated from the germline alanine. Proline is not used by any of the Vk germline genes, and occurs at this location in only 0.2% of human sequences in the Kabat database. Proline at position 25 would insert a rigid peptide bond and a sharp angle in the peptide backbone, and would therefore produce unique structural characteristics wiihin this Vk region of the lisjhi chain of both of these antibodies. Similarly, a mutant arginine is used by both 2.175.3 and 2.449.1.3 in position 27e (Kabat numbering) of CDR1 of Vk. Arginine is not used in this canonical location in any Vk germline genes, and occurs in only 0.4% of human sequences in the Kabat database. In one embodiment of the invention there is provided a human monoclonal antibody that binds PDGFR-alpha and comprises a proline at residue 25. In one embodiment of the invention there is provided a human monoclonal antibody that binds PDGFR-alpha and comprises an arginine at position 27e of CDR1.
[0041] In other embodiments the invention provides compositions, including a targeted binding agent of the invention or binding fragment thereof, and a pharmaceutically acceptable carrier. In other embodiments the invention provides compositions, including an antibody of the invention or binding fragment thereof, and a pharmaceutical^ acceptable carrier.
|0042| Still further embodiments of the invention include methods of effectively treating an animal suffering from a neoplastic disease, including selecting an animal in need of treatment for a neoplastic disease, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds to PDGFR-alpha. In certain embodiments, the animal is human. In certain embodiments, the targeted binding agent is a fully human monoclonal antibody. In certain embodiments, the targeted binding agent is an

WO 2008/112003

PCT/US2007/075117

antibody of the invention and may be selected from the group consisting of 2.175.3, 2.449.1.3, or 2.998.2.
J0043J Treatable neoplastic diseases, include, for example, cancers including, melanoma, small cell lung cancer, non-small cell lung cancer, glioma, hepatocellular (liver) carcinoma, thyroid tumor, gastric (stomach) cancer, prostate cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, esophageal carcinoma, head and neck cancers, mesothelioma, sarcomas, biliary (cholangiocarcinoma), small bowel adenocarcinoma, pediatric malignancies, epidermoid carcinoma, and gastrointestinal stromal tumor (GIST).
(0044] In one embodiment the present invention is suitable for use in antagonizing PDGFR-alpha, in patients with a tumour which is dependent alone, or in part, on a PDGFR-alpha.
|004S| Additional embodiments of the invention include methods of inhibiting tumor cell growth in an animal. These methods include selecting an animal in need of treatment for tumor cell growth, and administering to the animal a therapeutically effective dose of a targeted binding agent, wherein said agent specifically binds to PDGFR-alpha. In another embodiment the method includes selecting an animal in need of treatment for tumor cell growth, and administering to the animal a therapeutically effective dose of a fully human monoclonal antibody, wherein said antibody specifically binds to PDGFR-alpha.
[00461 Further embodiments of the invention include the use of a targeted binding agent in the preparation of medicament for the treatment of diseases involving PDGFR-alpha expression in an animal, wherein the agent specifically binds to PDGFR-alpha. In another embodiment the invention includes the use of an antibody in the preparation of medicament for the treatment of diseases involving PDGFR-alpha expression in an animal, wherein the monoclonal antibody specifically binds to PDGFR-alpha.
[0047| In other embodiments, the targeted binding agents or antibodies described herein can be used for the preparation of a medicament for the treatment of neoplastic diseases in an animal, wherein the antibody specifically binds to PDGFR-alpha.
{0048] Embodiments of the invention described herein relate to monoclonal antibodies that bind PDGFR-alpha and affect PDGFR-alpha function. Other embodiments relate to fully human anti-PDGFR-alpha antibodies and anti-PDGFR-alpha antibody

WO 2008/112003

PCT/US2007/075117

preparations with desirable properties from a therapeutic perspective, including high binding affinity for PDGFR-alpha, high selectivity for inhibition of PDGFR-alpha signaling, low toxicity, the ability to block PDGF-AA ligands from binding to PDGFR-alpha, the ability lo block PDGF-AB ligands from binding to PDGFR-alpha, the ability to block PDGF-BB ligands from binding to PDGFR-alpha, the ability to block PDGF-CC ligands from binding to PDGFR-alpha. and/or the ability to inhibit tumor cell growth in vitro and in vivo. Some embodiments relate to fully human anti-PDGFR-alpha antibodies that do not substantially cross react with PDGFR-beta. Still other embodiments relate to fully human anti-PDGFR-alpha antibodies and anti-PDGFR-alpha antibody preparations that do not result in a significant Human Anti-Chimeric Antibody (HACA) response, thereby allowing for repeated administration.
[0049) In one embodiment, the invention includes antibodies that bind to PDGFR-
alpha with very high affinities (Kd). For example a human, rabbit, mouse, chimeric or
humanized antibody that is capable of binding PDGFR-alpha with a Kd less than, but not
limited to, 10-5, 10-6, 10-7, 10-8, 10-9, 10-10 or 10-11M, or any range or value therein.
Affinity and/or avidity measurements can be measured by KinExA® and/or BIACORE®, as
described herein.
[0050) Accordingly, one embodiment described herein includes isolated antibodies,
or fragments of those antibodies, that bind to PDGFR-alpha. As known in the art, the
antibodies can advantageously be, for example, polyclonal, oligoclonal, monoclonal,
chimeric, humanized, and/or fully human antibodies. Embodiments of the invention
described herein also provide cells for producing these antibodies.
[0051] It will be appreciated that embodiments of the invention arc not limited to any particular form of an antibody or method of generation or production. For example, the anti-PDGFR-alpha antibody can be a full-length antibody (e.g., having an intact human Fc region) or an antibody binding fragment (e.g., a Fab, Fab' or F(abr)2, FV or dAb). In addition, the antibody can be manufactured from a hybridoma that secretes the antibody, or from a recombinantly engineered cell that has been transformed or transfected with a gene or genes encoding the antibody. In addition, the antibodies can be single-domain antibodies such as camelid or human single VH or VL domains that bind lo PDGFR-alpha, such as a dAb fragment,

WO 2008/112003

PCT/US2007/075117

10052] Other embodiments of the invention include isolated nucleic acid molecules encoding any of the targeted binding agents or antibodies described herein, vectors having isolated nucleic acid molecules encoding anti-PDGFR-alpha antibodies or a host cell transformed with any of such nucleic acid molecules. In addition, one embodiment of the invention is a method of producing an anti-PDGFR-alpha antibody by culturing host cells under conditions wherein a nucleic acid molecule is expressed to produce the antibody followed by recovering the antibody.
[0053] A further embodiment herein includes a method of producing high affinity antibodies to PDGFR-alpha by immunizing a mammal with cells expressing human PDGFR-alpha, isolated cell membranes containing human PDGFR-alpha, purified human PDGFR-alpha, or a fragment thereof, and/or one or more orthologous sequences or fragments thereof.
|0U54| Other embodiments are based upon the generation and identification of isolated antibodies that bind specifically to PDGFR-alpha. PDGFR-alpha is expressed on a number of tumor types. Antibodies that neutralize PDGFR-alpha can prevent PDGFR-alpha induced tumor growth and other desired effects.
J0055J Another embodiment of the invention includes a method of diagnosing diseases or conditions in which an antibody prepared as described herein is utilized to detect the level of PDGFR-alpha in a patient or patient sample. In further embodiments, methods for the identification of risk factors, diagnosis of disease, and staging of disease is presented which involves the identification of the expression and/or overexpression of PDGFR-alpha using anti-PDGFR-alpha antibodies. In some embodiments, the methods comprise administering to a patient a fully human antibody conjugate that selectively binds to a PDGFR-alpha protein on a cell. The antibody conjugate comprises an antibody that selectively binds to PDGFR-alpha and a label. The methods further comprise observing the presence of the label in the patient. A relatively high amount of the label will indicate a relatively high risk of the disease and a relatively low amount of the label will indicate a relatively low risk of the disease. In one embodiment, the label is a green fluorescent protein.
[0056] The invention further provides methods for assaying the level of PDGFR-alpha in a patient sample, comprising contacting an anti-PDGFR-alpha antibody with a biological sample from a patient, and detecting the level of binding between said antibody

WO 2008/112003

PCT/US2007/075117

and PDGFR-alpha in said sample. In more specific embodiments, the biological sample is blood or serum.
|0057] Another embodiment of the invention includes a method for diagnosing a condition associated with the expression of PDGFR-alpha in a cell by contacting serum or a cell with an anti-PDGFR-alpha antibody, and thereafter detecting the presence of PDGFR-alpha.
{0058] In another embodiment, the invention includes an assay kit for detecting PDGFR-alpha in mammalian tissues, cells, or body fluids to screen for diseases involving cells that express PDGFR-alpha. The kit includes an antibody that binds to PDGFR-alpha and a means for indicating the reaction of the antibody with PDGFR-alpha, if present. Preferably the antibody is a monoclonal antibody. In one embodiment, the antibody that binds PDGFR-alpha is labeled. In another embodiment the antibody is an unlabeled primary antibody and the kit further includes a means for detecting the primary antibody, in one embodiment, the means includes a labeled second antibody that is an antiimmunoglobulin. Preferably the antibody is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radiopaque material.
J0059] Yet another embodiment includes methods for treating diseases or conditions associated with the expression of PDGFR-alpha in a patient, by administering to the patient an effective amount of an anti-PDGFR-alpha antibody. The anti-PDGFR-alpha antibody can be adminislercd alone, or can be administered in combination with additional antibodies or chemotherapeutic drug or radiation therapy. For example, a monoclonal, oligoclonal or polyclonal mixture of PDGFR-alpha antibodies that inhibit tumor growth can be administered in combination with a drug shown to inhibit tumor cell proliferation directly. The method can be performed in vivo and the patient is preferably a human patient.
|0060] In some embodiments, the anli-PDGFR-alpha antibodies can be modified lo enhance their capability of fixing complement and participating in complement-dependent cytotoxicity (CDC). In other embodiments, the anli-PDGFR-alpha antibodies can be modified to enhance their capability of activating effector cells and participating in antibody-dependent cytotoxicity (ADCC). In yet other embodiments, the anti-PDGFR-alpha antibodies can be modified both to enhance their capability of activating effector cells and

WO 2008/112003

PCT/US2007/075117

participating in antibody-dependent cytotoxicity (ADCC) and to enhance their capability of fixing complement and participating in complement-depend£nt cytotoxicity (CDC).
[0061] In another embodiment, the invention provides an article of manufacture including a container. The container includes a composition containing an anti-PDGFR-alpha antibody, and a package insert or label indicating that the composition can be used to treat diseases characterized by the expression or overexpression of PDGFR-alpha.
[0062] In other embodiments, the invention provides a kit for treating diseases involving the expression of PDGFR-alpha, comprising anti-PDGFR-alpha monoclonal antibodies and instructions to administer the monoclonal antibodies to a subject in need of treatment
[0063] In another aspect, a method of selectively killing a cancerous cell in a patient is provided. The method comprises administering a fully human antibody conjugate to a patient. The fully human antibody conjugate comprises 3" antibody that can bind to the extracellular domain of PDGFR-alpha and an agent. The agent is either a toxin, a radioisotope, or another substance that will kill a cancer cell. The antibody conjugate thereby selectively kills the cancer cell. The agent can be saporin.
10064] In one aspect, a conjugated fully human antibody that binds to PDGFR-alpha is provided. Attached to the antibody is an agent, and the binding of the antibody to a cell results in the delivery of the agent to the cell. In one embodiment, the above conjugated fully human antibody binds to an extracellular domain of PDGF^-alpha. In another embodiment, the antibody and conjugated toxin are internalized by a cell that expresses PDGFR-alpha. In another embodiment, the agent is a cytotoxic agent. In another embodiment, the agent is, for example saporin, or auristatin. pseudomonas exotoxin, gelonin, ricin, calicheamicin or maytansine-based lmmunoconjugates, and the like. In still another embodiment, the agent is a radioisotope.
[0065] In some embodiments of the invention, tfie glycosylation patterns of the antibodies provided herein are modified to enhance ADCC and CDC effector function. See Shields RL et al., (2002) JBC. 277:26733; Shinkawa T e* al., (2003) JBC. 278:3466 and Okazaki A et al., (2004) J. Mol. Biol., 336: 1239.

WO 2008/112003

PCT/US2007/075117

BRIEF DESCRIPTION OF THE DRAWINGS (0066) Figure 1 is a graph showing the dose responses for 5 selected monoclonal antibodies for % inhibition of PDGF-AA-induced proliferation of MG-63 tumor cells against antibody in ng/ml. Cell stimulation was conducted using 100 ng/ml (3.45nM) PDGF-AA.
[0067] Figures 2a-2b show the results of in vivo antitumor evaluation of 2.175.3 and 2.449.1.3 in the Calu-6 non-small cell lung carcinoma xenograft model. Figure 2a shows the average tumor size (mm3) vs. time (days) and Figure 2b shows the average body weight (g) vs. time (days). The square points represent the vehicle treatment group; the circular points represent the 2.175.3 10 mg/kg treatment group; the triangular points represent the 2.449.1.3 lOmg/kg treatment group.
[0068J Figure 3 shows the results of in vivo evaluation of the antibodies in the UI IS glioma xenograft model in SCID mice. Tumor size (mm3) versus lime (days) of treatment with antibodies is graphed. The square points show the vehicle treatment group; the circular points show the 2.175.3 10 mg/kg treatment group; the triangular points show the 2.449.1.3 10 mg/kg treatment group.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT |0069] Embodiments of the invention described herein relate to targeted binding agents that bind lo PDGFR-alpha. In some embodiments, the targeted binding agents are antibodies that bind to PDGFR-alpha and inhibit tumor cell growth. Other embodiments of the invention include fully human anti-PDGFR-alpha antibodies, and antibody preparations that are therapeutically useful. Such anti-PDGFR-alpha antibody preparations preferably have desirable therapeutic properties, including strong binding affinity for PDGFR-alpha, high selectivity for inhibition of PDGFR-alpha signaling, low toxicity, the ability to block PDGF-AA ligands from binding to PDGFR-alpha, the ability to block PDGF-AB ligands from binding to PDGFR-alpha or PDGFR-alpha/beta heterodimers, the ability to block PDGF-BB ligands from binding to PDGFR-alpha or PDGFR-alpha/beta heterodimers, the ability to bock PDGF-CC ligands from binding to PDGFR-alpha or PDGFR-alpha/beta heterodimers, and/or the ability to inhibit tumor cell growth in vitro and in vivo. Some

WO 2008/112003

PCT/US2007/075117

embodiments relate to fully human anti-PDGFR-atpha antibodies that do not cross-react with PDGFR-beta.
|0070j Embodiments of the invention also include targeted binding agents which are isolated binding fragments of anti-PDGFR-alpha antibodies. Preferably, the binding fragments are derived from fully human anti-PDGFR-alpha antibodies. Exemplary fragments include Fv, Fab' dAb or other wel-known antibody fragments, as described in more detail below. Embodiments of the invention also include cells that express fully human antibodies against PDGFR-alpha. Examples of cells include hybridomas, or recombinantly created ceils, such as Chinese hamster ovary (CHO) cells that produce antibodies against PDGFR-alpha.
10071] In addition, embodiments of the invention include methods of using these antibodies for treating diseases. Anti-PDGFR-alpha antibodies arc useful for inhibiting tumor growth. The mechanism of action can include, but is not limited to, blocking ligand binding and/or inhibiting cell signaling implicated in cell growth. Diseases that are treatable through this mechanism include, but are not limited to, neoplastic diseases, such as, cancers including, lung cancer, ovarian cancer, prostate cancer, colon cancer, glioblastoma, melanoma and gastrointestinal stromal tumor (GIST).
J0072] Other embodiments of the invention include diagnostic assays for specifically determining the presence and/or quantity of PDGFR-alpha in a patient or biological sample. The assay kit can include anti-PDGFR-alpha antibodies along with the necessary labels for detecting such antibodies. These diagnostic assays are useful lo screen for PDGFR-alpha-related diseases including, but not limited to, neoplastic diseases, such as cancers including, breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, glioblastoma, melanoma and gastrointestinal stromal tumor (GIST).
|0073] Another embodiment is an antibody comprising a heavy chain polypeptide comprising the sequence of SEQ ID NO.:2. In one embodiment, the antibody further comprises a light chain polypeptide comprising the sequence of SEQ ID NO.:4. Another embodiment includes an antibody comprising a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 10. In one embodiment, the antibody further comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 12. Still another embodiment is an antibody comprising a heavy chain polypeptide comprising the sequence of SEQ ID

WO 2008/112003

PCT/US2007/075117

NO.: 14. In one embodiment, the antibody further comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 16.
(0074] Yet another embodiment is a hybridoma that produces the light chain and/or the heavy chain of antibody as described hereinabove. The hybridoma may produce a light chain and/or a heavy chain of a fully human monoclonal antibody. In one embodiment, the hybridoma produces the light chain and/or the heavy chain of the fully human monoclonal antibody 2.175.3, 2.449.1.3, and 2.998.2. Alternatively the hybridoma may produce an antibody that binds to the same epitope or epitopes as fully human monoclonal antibody 2.175.3, 2.449.1.3, and 2.998.2. Alternatively the hybridoma may produce an antibody that competes for binding to PDGFR-alpha with fully human monoclonal antibody 2.175.3, 2.449.1.3, and 2.998.2.
[0075[ Still another embodiment is a nucleic acid molecule encoding the light chain or the heavy chain of the antibody as described hereinabove. In this embodiment, the nucleic acid molecule may encode the light chain or the heavy chain of a fully human monoclonal antibody. In one embodiment, the nucleic acid molecule encodes the light chain or the heavy chain of one of the fully human monoclonal antibodies 2.175.3, 2.449.1.3, or 2.998.2.
1007.6] An additional embodiment is a vector comprising a nucleic acid molecule or molecules as described hereinabove, wherein the vector encodes a light chain and/or a heavy chain of an antibody as defined hereinabove.
[0077] One embodiment of the invention includes a host cell comprising a vector as described hereinabove. Alternatively the host cell may comprise more than one vector.
|0078| In addition, one embodiment of the invention is a method of producing an antibody by culturing host cells under conditions wherein a nucleic acid molecule is expressed to produce the antibody, followed by recovery of the antibody.
(0079] In one embodiment the invention includes a method of making a targeted binding agent by transfecting at least one host cell with at least one nucleic acid molecule encoding the targeted binding agent as described hereinabove, expressing the nucleic acid molecule in the host cell and isolating the targeted binding agent. Another embodiment of the invention is a method of making an antibody by transfecting at least one host cell with at least one nucleic acid molecule encoding the antibody as described hereinabove, expressing the nucleic acid molecule in the host cell and isolating the antibody.

WO 2008/112003

PCTYUS2007/075117

[0080J Another aspect of the invention is a method of inhibiting the growth of cells that express PDGFR-alpha by administering a targeted binding agent as described hereinabove. The method may include selecting an animal in need of treatment for disease-related to PDGFR-alpha expression, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds to PDGFR-alpha.
[0081] Still another aspect is a method of treating a neoplastic disease in a mammal by administering a therapeutically effective amount of a targeted binding agent that specifically binds PDGFR-alpha. The method may include selecting an animal in need of treatment for a neoplastic disease, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds PDGFR-alpha. The agent can be administered alone, or can be administered in combination with a second anti-neoplastic agent selected from an antibody, a chemotherapeutic drug, or a radioactive drug.
[0082J One other aspect is a method of treating cancer in a mammal by administering a therapeutically effective amount of a targeted binding agent that specifically binds PDGFR-alpha. The method may include selecting an animal in need of treatment for cancer, and administering to the animal a therapeutically effective dose of a targeted binding agent that specifically binds PDGFR-alpha. The agent can be administered alone, or can be administered in combination with a second anli-neoplastic agent selected from an antibody, a chemotherapeutic drug, or a radioactive drug.
[0083] According to another aspect of Ihe invention a targeted binding agent can be used that specifically binds PDGFR-alpha for the manufacture of a medicament for the treatment of a neoplastic disease.
[0084] One embodiment the invention is particularly suitable for use in inhibiting tumor growth in patients with a tumor that is dependent alone, or in part, on PDGFR-alpha expression.
[0085] Another embodiment of the invention includes an assay kit for detecting PDGFR-alpha in mammalian tissues, cells, or body fluids to screen for neoplastic and/or fibrotic and/or immune system diseases. The kit includes a targeted binding agent thai binds to PDGFR-alpha and a means for indicating the reaction of the targeted binding agent with PDGFR-alpha, if present. The targeted binding agent may be a monoclonal antibody. In one embodiment, the antibody that binds PDGFR-alpha is labeled. In another embodiment the

WO 2008/112003

PCT/US2007/075117

antibody is an unlabeled primary antibody and the kit further includes a means for detecting the primary antibody. In one embodiment, the means includes a labeled second antibody that is an anti-immunoglobulin. Preferably the antibody is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radio-opaque material.
[0086] Further embodiments, features, and the like regarding anti-PDGFR-alpha antibodies are provided in additional detail below.
Definitions
J0087J Unless otherwise defined, scientific and technical terms used herein shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless othenvise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the art.
I0088J Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofeclion). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook ct al. Molecular Cloning: A Laboratory Manual (3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001)), which is incorporated herein by reference. The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

WO 2008/112003

PCT/US2007/075I17

[0089] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
|0090] A compound refers to any small molecular weight compound with a molecular weight of less than about 2000 Daitons.
(0091] The term "'PDGFR-alpha" refers to the platelet derived growth factor tyrosine kinase receptor-alpha encoded by the PDGFR-alpha gene. PDGFR-alpha is also known as CD140aandPDGFR-a.
[0092] The term "neutralizing" when referring to a targeted binding agent such as an antibody relates to the ability of said agent to eliminate, or significantly reduce, the activity of a target antigen. Accordingly, a "neutralizing" anti-PDGFR-alpha antibody of the invention is capable of eliminating or significantly reducing the activity of PDGFR-alpha. A neutralizing PDGFR-alpha antibody may, for example, act by blocking the binding of ligand to its receptor PDGFR-alpha.
[0093] The term "isolated polynucleotide" as used herein shall mean a polynucleotide that has been isolated from its naturally occurring environment. Such polynucleotides may be genomic, cDNA, or synthetic. Isolated polynucleotides preferably are not associated with all or a portion of the polynucleotides they associate with in nature. The isolated polynucleotides may be operably linked to another polynucleotide that it is not linked to in nature. In addition, isolated polynucleotides preferably do not occur in nature as part of a larger sequence.
[0094J The term "isolated protein"' referred to herein means a protein that has been isolated from its naturally occurring environment. Such proteins may be derived from genomic DNA, cDNA, recombinant DNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g. free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.
[0095] The term "'polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus. Preferred polypeptides in accordance with the invention comprise the human heavy chain immunoglobulin molecules and the human

WO 2008/112003

PCT/US2007/075117

kappa light chain immunoglobulin molecules, as well as antibody molecules formed by combinations comprising the heavy chain immunoglobulin molecules with light chain immunoglobulin molecules, such as the kappa or lambda light chain immunoglobulin molecules, and vice versa, as well as fragments and analogs thereof. Preferred polypeptides in accordance with the invention may also comprise solely the human heavy chain immunoglobulin molecules or fragments thereof.
[0096] The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. - For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring.
|0097| The term "operably linked" as used herein refers to positions of components so described that are in a relationship permitting them to function in their intended manner. For example, a control sequence "operably linked" to a coding sequence is connected in such a way that expression of the coding sequence is achieved under conditions compatible vith the control sequences.
|0098] The term "control sequence" as used herein refers to polynucleotide sequences that are necessary either to effect or to affect the expression and processing of coding sequences to which they are connected. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences may include promoters, enhancers, introns, transcription termination sequences, polyadenylation signal sequences, and 5' and '3 untranslated regions. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
10099] The term "polynucleotide" as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, or RNA-DNA hetero-duplexes. The term includes single and double stranded forms of DNA.

WO 2008/112003

PCT/US2007/075117

[00100] The term "oligonucleotide" referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring linkages. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g. for probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant. Oligonucleotides can be either sense or antisense oligonucleotides.
[00101] The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleo tides and ribonucleotides. The term "'modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "oligonucleotide linkages" referred to herein includes oligonucleotides linkages such as phosphorothioatc, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate: phosphoroanilothioate, phosphoraniiadate, phosphoroamidate, and the like. See e.g., LaPlanche et al. Nucl. Acids Res. 14:9081 (1986); Stec et al. J. Am. Chem. Soc. 106:6077 (1984); Stein et ai. Nucl. Acids Res. 16:3209 (1988); Zon et al. Anti-Cancer Drug Design 6:539 (1991); Zon et at. Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al. U.S. Patent No. 5,151,510; Uhlmann and Peyman Chemical Reviews 90:543 (1990), the disclosures of which are hereby incorporated by reference. An oligonucleotide can include a label for detection, if desired.
[00102] The term "selectively hybridize" referred to herein means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments thereof selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, or antibody fragments and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%.

WO 2008/112003

PCT/US2007/075117

100103} The term i:CDR region" or "'CDR" is intended lo indicate the hypervariable regions of the heavy and light chains of the immunoglobulin as defined by Kabat et al. 1991 (Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest, 5lh Edition. US Department of Health and Human Services, Public Service, NIK Washington), and later editions. An antibody typically contains 3 heavy chain CDRs and 3 light chain CDRs. The term CDR or CDRs is used here in order to indicate, according to the case, one of these regions or several, or even the whole, of these regions which contain the majority of the amino acid residues responsible for the binding by affinity of the antibody for the antigen or the epitope which it recognizes.
[00104] The third CDR of the heavy chain (HCDR3) has a greater size variability (greater diversity essentially due to the mechanisms of arrangement of the genes which give rise to it). It may be as short as 2 amino acids although the longest size known is 26- CDR length may also vary according to the length that can be accommodated by the particular underlying framework. Functionally, HCDR3 plays a role in part in the determination of the specificity of the antibody (Segal et al., PNAS, 71:4298-4302, 1974, Am it et al., Science. 233:747-753, 1986, Chothia et al., J. Mol. Biol., 196:901-917, 1987, Chothia ct al., Nature. 342:877- 883, 1989, Caton et al., J. Immunol, 144:1965-1968, 1990. Sharon et al., PNAS, 87:4814-4817, 1990, Sharon et al., J. Immunol., 144:4863-4869, 1990, Kabat ct al., J. Immunol., 147:1709-1719, 1991).
[00105] The term a ;*set of CDRs" referred to herein comprises CDR1, CDR2 and CDR3. Thus, a set of HCDRs refers to HCDRI, HCDR2 and HCDR3, and a set of LCDRs refers to LCDR1, LCDR2 and LCDR3. Unless otherwise stated, a "set of CDRs" includes HCDRs and LCDRs.
{00106) Two amino acid sequences are 'homologous" if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least about 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN

WO 2008/112003

PCT/US2007/075117

with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M.O., in Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or pails thereof are more preferably homoJogous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. It should be appreciated that there can be differing regions of homology within two orthologous sequences. For example, the functional sites of mouse and human orthologues may have a higher degree of homology than non-functional regions.
(00107] The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence.
|00108j In contradistinction, the term '"complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".
[00109] The term 'sequence identity" or "'identity' with reference to a sequence means that two polynucleotide or amino acid sequences are identical (i.e.. on a nucleotide-by-nucleotide or rcsidue-by-residuc basis) over the comparison window. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more preferably at least 99 percent sequence identity, as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of

WO 2008/112003

PCT/US2007/075117

sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence.
|001101 As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology - A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. Stereoisomers (e.g., P-amino acids) of the twenty conventional amino acids, unnatural amino acids such as a-, a-di substituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional arAino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, y-carboxyglutamate, c-N,N,N-trimethyilysine, e-N-aceiyllysine. O-phosphoserine. N-acetylserine. N-formylm£thionine. 3-melhylhisiidine. 5-hydroxylysine, a-N-methylarginine, and other similar aminc> acids and imino acids (e.g.. 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.
|00111| Similarly, unless specified otherwise, the left-hand end of single-stranded polynucleotide sequences is the 5' end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as 'upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as ^downstream sequences1'.
[00112] As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of

WO 2008/112003

PCT/US2007/075117

amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxy 1 side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine.
[00113| As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present invention, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%. 90%; 95%, and most preferably 99% sequence identity to the antibodies or immunoglobulin molecules described herein. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that have related side chains. Genetically encoded amino acids are generally divided into families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are an aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding function or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Assays are described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains.

WO 2008/112003

PCIYUS2007/075117

Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequencee databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et al. Science 253:164 (1991). Thus, the foregoing examples demonstrate lhal those of skill in the art can recognize sequence motifs a.nd structural conformations that may be used to define structural and functional domains in accordance with the antibodies described herein.
|001141 Preferred amino acid substitutions a.re those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation. (3) alter binding affinity for forming protein complexes. (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs, Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular Contacts. A consen'ative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend tQ break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide seminary and tertiary structures are described in Proteins, Structures and Molecular Principles fCreinhlon. Ed,, W. H. Freeman and Company, New York (1984)); Introduction to Proteih Structure (C. Branden and J. Tooze, eds.. Garland Publishing, New York, N.Y. (1991)); and Thornton el at. Nature 354:105 (1991), which are each incorporated herein by reference.
[001151 Variants of the VH and VL domains and CDRs of the present invention, -including those for which *mino acid sequences are set out herein, and which can be employed in targeting agents and antibodies for PDGFR-alpjha can be obtained by means of methods of sequence alteration or mutation and screening for antigen targeting with desired characteristics. Examples of desired characteristics include but are not limited to: increased binding affinity for antigen relative to known antibodies which are specific for the antigen;

WO 2008/112003

PCT/US2007/075117

increased neutralization of an antigen activity relative to known antibodies which are specific for the antigen if the activity is known; specified competitive ability with a known antibody or ligand to the antigen at a specific molar ratio; ability to immunoprecipitalc ligand-receptor complex; ability to bind to a specified epitope; linear epitope, e.g. peptide sequence identified using peptide-binding scan, e.g. using peptides screened in linear and/or constrained conformation; conformational epitope, formed by non-continuous residues; ability to modulate a new biological activity of PDGFR-alpha, or downstream molecule; ability to bind and/or neutralize and/or for any other desired property.
(00116] The techniques required to make substitutions within amino acid sequences of CDRs. antibody VH or VL domains and antigen binding sites are available in the art. Variants of antibody molecules disclosed herein may be produced and used in the present invention. Following the lead of computational chemistry in applying multivariate data analysis techniques to the . structure/prop erty-activity relationships (Wold, et al. Multivariate data analysis in chemistry. Chemometrics -Mathematics and Statistics in Chemistry (Ed.: B. Kowalski), D. Reidel Publishing Company, Dordrecht, Holland, 1984) quantitative activity-property relationships of antibodies can be derived using well-known mathematical techniques, such as statistical regression, pattern recognition and classification (Norman et ai. Applied Regression Analysis. Wiley-Intcrscience; 3rd edition (April 1998); Kandel, Abraham & Backer, Eric. Computer-Assisted Reasoning in Cluster Analysis. Prentice Hall PTR, (May II, 1995); Krzanowski, Wojtek. Principles of Multivariate Analysis: A User's Perspective (Oxford Statistical Science Series, No 22 (Paper)). Oxford University Press; (December 2000); Witten, Ian H. & Frank, Eibe. Data Mining: Practical Machine Learning Tools and Techniques with Java Implementations. Morgan Kaufmann; (October 11, 1999);Denison David G. T. (Editor), Christopher C. Holmes, Bani K. Mallick, Adrian F. M. Smith. Bayesian Methods for Nonlinear Classification and Regression (Wiley Series in Probability and Statistics). John Wiley & Sons; (July 2002); Ghose, Amp K. & . Viswanadhan, Vellarkad N. Combinatorial Library Design and Evaluation Principles, Software, Tools, and Applications in Drug Discovery). The properties of antibodies can be derived from empirical and theoretical models (for example, analysis of likely contact residues or calculated physicochemical property) of antibody sequence, functional and three-dimensional structures and these properties can be considered singly and in combination.

WO 2008/112003

PCT/US2007/075117

[00117) An antibody antigen-binding site composed of a VH domain and a VL domain is typically formed by six loops of polypeptide: three from the light chain variable domain (VL) and three from the heavy chain variable domain (VH). Analysis of antibodies of known atomic structure has elucidated relationships between the sequence and three-dimensional structure of antibody combining sites. These relationships imply that, except for the third region (loop) in VH domains, binding site loops have one of a small number of main-chain conformations: canonical structures. The canonical structure formed in a particular loop has been shown to be determined by its size and the presence of certain residues at key sites in both the loop and in framework regions.
[001181 This study of sequence-structure relationship can be used for prediction of those residues in an antibody of known sequence, but of an unknown three-dimensional structure, which are important in maintaining the three-dimensional structure of its CDR loops and hence maintain binding specificity. These predictions can be backed up by comparison of the predictions to the output from lead optimization experiments. In a structural approach, a model can be created of the antibody molecule using any freely available or commercial package, such as WAM. A protein visualisation and analysis software package, such as Insight II (Accelrys, Inc.) or Deep View may then be used to evaluate possible substitutions at each position in the CDR. This information may then be used to make substitutions likely to have a minimal or beneficial effect on activity or confer other desirable properties.
(00119| The term "polypeptide fragment" as used herein refers to a polypeptide that has an ammo-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full-length cDNA sequence. Fragments typically are at least 5. 6, 8 or 10 amino acids long, preferably at least 14 amino acids long, more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long. The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has at least one of the following properties: (1) specific binding to a PDGFR-aipha, under suitable binding conditions, (2) ability to inhibit binding of PDGF-AA, (3) ability to inhibit binding of PDGF-AB, (4) ability to inhibit

WO 2008/112003

PCT/US2007/075117

binding of PDGF-BB, and/or (5) ability to inhibit binding of PDGF-CC. Typically, polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.
|00120] Peptide analogs are commonly used in the pharmaceutical industry as non-peplide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed 'peptide mimetics" or "peplidomimetics". Fauchere, J. Adv. Drug Res. 15:29 (1986); Veber and Freidinger TINS p.392 (1985); and Evans et al. J. Med. Chem. 30:1229 (1987), which are incorporated herein by reference. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH2NH--, --CH2S-, -CH2-CH2-, ~ CH=CH~(cis and trans), --COCH2-, --CH(OH)CH2~, and -CH2SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch Ann. Rev. Biochem. 61:387 (J992), incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.
[00121] As used herein, the term "antibody" refers to a polypeptide or group of polypeptides that are comprised of at least one binding domain that is formed from the folding of polypeptide chains having three-dimensional binding spaces with internal surface shapes and charge distributions complementary to the features of an antigenic determinant of an antigen. An antibody typically has a tetrameric form, Comprising two identical pairs of polypeptide chains, each pair having one '"light" and one "heavy" chain. The variable regions of each light/heavy chain pair form an antibody binding site.

WO 2008/112003

PCT/US2007/075117

[00122) As used herein, a "targeted binding agent" is an agent, e.g. an antibody, or binding fragment thereof, that binds to a target site. In one embodiment, the targeted binding agent is specific for only one target site. In other embodiments, the targeted binding agent is specific for more than one target site. In one embodiment, the targeted binding agent may be a monoclonal antibody and the target site may be an epitope. As described below, a targeted binding agent may comprise at least one antigen binding domain (e.g. a CDR) of an antibody, wherein said domain is fused or contained within a heterologous protein scaffold, e.g. a non-antibody protein scaffold.
|00123] "Binding fragments" of an antibody are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab'. F(ab,)2, Fv, dAb and single-chain antibodies. An antibody other than a "bispecific" or "bi functional" antibody is understood to have each of its binding sites identical. An antibody substantially inhibits adhesion of a receptor to a counter-receptor when an excess of antibody reduces the quantity of receptor bound to counter-receptor by at least about 20%, 40%, 60% or 80%, and more usually greater 'han about 85% (as measured in an in vitro competitive binding assay).
(00124] An antibody may be oligocional, a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a multi-specific antibody, a bi¬specific antibody, a catalytic antibody, a chimeric antibody, a humanized antibody, a fully human antibody, an anti-idiotypic antibody and antibodies that can be labeled in soluble or bound form as well as fragments, variants or derivatives (hereof, either alone or in combination with other amino acid sequences provided by known techniques. An antibody may be from any species. The term antibody also includes binding fragments of the antibodies of the invention; exemplary fragments include Fv, Fab, Fab7, single stranded antibody (svFC), dimeric variable region (Diabody) and disulphide stabilized variable region (dsFv).
100125] It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments arc (Ward, E.S. et al., (1989) Nature 341, 544-546) the Fab fragment consisting of VL, VH, CL and CHI domains; (McCafferty et al (1990) Nature, 348, 552-554) the Fd fragment consisting of the VH and CHI domains; (Holt et al (2003) Trends in Biotechnology 21, 484-490) the Fv fragment

WO 2008/112003

PCT/US2007/075117

consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989), McCafferty et al (1990) Nature, 348, 552-554, Holt et al (2003) Trends in Biotechnology 21, 484-490], which consists of a VH or a VL domain; (vj iso/afeo1 CDR regions; (yi'j F(ab')2 fragments, a bfvatent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird et al, (1988) Science, 242, 423-426, , Huston et al, (1988) PNAS USA, 85, 5879-5883); (viii) bispecific single chain Fv dingers (PCT/US92/09965) and (ix) "diabodies", multivalent or multi specific fragments constructed by gene fusion (WO94/13804; Holliger, P. (1993) et al, Proc. Natl. Acad. Sci. USA 90 6444-6448,). Fv, scFv or diabody molecules may be stabilized by the incorporation of disulphide bridges linking the VH and VL domains (Reiler, Y. et al. Nature Biotech. 14, 1239-1245, 1996). Minibodies comprising a scFv joined to a CH3 domain may also be made (Hu, S. ei al, (1996) Cancer Res., 56, 3055-3061). Other examples of binding fragments are Fab', which differs from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CHI domain, including one or more cysteines from the antibody hinge region, and Fab'-SH, which is a Fab' fragment in which the cysteine residue(s) of the constant domains bear a free thiol group.
(001261 The term 'epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and may, but not always, have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is (00127] The tenn "agent" is used herein to denote a'chemical compound, a mixture of chemical compounds, a biological macromolecuie, or an extract made from biological materials.
(00128] "Active" or 'activity1' in regard to a PDQFR-alpha polypeptide refers to a portion of a PDGFR-alpha polypeptide that has a biological or an immunological activity of a native PDGFR-alpha polypeptide. "Biological" when used herein refers to a biological

WO 2008/112003

PCTYUS2007/075117

function that results from the activity of the native PDGFR-alpha polypeptide. A preferred PDGFR-alpha biological activity includes, for example, autophosphorylation.
|00129] 'Mammal" when used herein refers to any animal that is considered a mammal. Preferably, the mammal is human.
|00130] Digestion of antibodies with the enzyme, papain, results in two identical antigen-bin ding fragments, known also as "Fab" fragments, and a "Fc1" fragment, having no antigen-binding activity but having the ability to crystallize. Digestion of antibodies with the enzyme, pepsin, results in the a F(ab')2 fragment in which the two anus of the antibody molecule remain linked and comprise two-antigen binding sites. The F(ab')2 fragment has the ability to crosslink antigen.
J001311 "Fv" when used herein refers to the minimum fragment of an antibody that retains both antigen-recognition and antigen-binding sites.
[00132[ "Fab" when used herein refers to a fragment of an antibody that comprises the constant domain of the light chain and the CH1 domain of the heavy chain.
[00133] A i(dAb" is a single domain antibody and comprises either the variable domain of an antibody heavy chain (VH domain) or the variable domain of an antibody light chain (VL domain). Each dAb contains three of the six naturally occurring CDRs (Ward et al.s Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544-546 (1989); Holt, et al., Domain antibodies: protein for therapy, Trends Biotechnol. 21, 484-^9 (2003)). With molecular weights ranging from 11 to 15 kDa, they are four times smaller than a fragment antigen binding (Fab)2 and half the size of a single chain Fv (scFv) molecule.
[00134] The term "mAb" refers to monoclonal antibody.
|00135| "Liposome" when used herein refers to a small vesicle that may be useful for delivery of drugs that may include the PDGFR-alpha polypeptide of the invention or antibodies to such a PDGFR-alpha polypeptide to a mammal.
|00136J 'Label" or "labeled" as used herein refers to the addition of a detectable moiety to a polypeptide, for example, a radiolabel, fluorescent label, enzymatic label chemiluminescent labeled or a biotinyl group. Radioisotopes or radionuclides may include 3H, 14C, 15N, 35S, 90Y, 99Tc, lllln, 125L 1311, fluorescent labels may include rhodamine.

WO 2008/112003

PCT/US2007/075U7

lanthanide phosphors or FITC and enzymatic labels may include horseradish peroxidase, P-galactosidase, luciferase, alkaline phosphatase.
[00137] Additional labels include, by way of illustration and not limitation: enzymes, such as glucose-6-phosphate dehydrogenase ("G6PDH"), alpha-D-galactosidase, glucose oxydase, glucose amylase, carbonic anhydrase. acetylcholinesterase, lysozyme, maiate dehydrogenase and peroxidase; dyes; additional fluorescent labels or fluorescein include, such as fluorescein and its derivatives, fluorochrome, GFP (GFP for "Green Fluorescent Protein"), dansyl, umbel liferone, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine; fluorophores such as lanthanide cryptates and chelates e.g. Europium etc (Perkin Elmer and Cis Biointernational); chemoluminescent labels or chemiluminescerSj such as isoluminol, luminol and the dioxetanes; sensitizers: coenzymes; enzyme substrates; particles, such as latex or carbon particles; metal sol; crystallite; liposomes; cells, etc., which may be further labelled with a dye, catalyst or other detectable group; molecules such as biotin, digoxygenin or 5-bromodeoxyuridine; toxin moieties, such as for example a toxin moiety selected from a group of Pseudomonas exotoxin (PE or a cytotoxic fragment or mutant thereof), Diptheria toxin or a cytotoxic fragment or mutant thereof, a botulinum toxin A, B, C, D, E or F, ricin or a cytotoxic fragment thereof e.g. ricin A, abrin or a cytotoxic fragment thereof, saporin or a cytotoxic fragment thereof, pokeweed antiviral toxin or a cytotoxic fragment thereof and bryodin I or a cytotoxic fragment thereof.
|001381 The term "pharmaceutical agent or drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (Parker, S., Ed., McGraw-Hill, San Francisco (1985)), (incorporated herein by reference).
[00139] As used herein, "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of ail macromolecular species present in the

WO 2008/112003

PCT/US2007/O-?sm

composition, more preferably more than about 85%, 90%. 95%, and 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.
|00140] "Antibody-dependent cell-mediated cytotoxicity" and "ADCC refer to a
cell-mediated reaction in which non-specific cytotoxic cells that express Ig Fc receptors
(FcRs) (e.g. Natural Killer (NK) cells, monocytes, neutrophils, and macrophages) recognize
bound antibody on a target cell and subsequently cause lysis of the target cell. The primary
cells for mediating ADCC, NK cells, express FcyRIII only, whereas monocytes express
FcyRI, FcyRII and FCYRIII. FcRs expression on hematopoietic cells is summarized in Table
3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess
ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in
U.S. Patent No. 5,500,362, or 5,821,337 can be performed. Useful effector cells for such
assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
Alternatively, or additionally, ADCC activity of the molecule of interest can be assessed in
vivo, e.g., in an animal model such as that disclosed in Clynes el al. PNAS (USA) 95:652-
656(1988). ■ '
[00141J 'Complement dependent cytotoxicity" and "CPC" refer to the mechanism by which antibodies carry put their cell-killing function. It is initiated by the binding of Clq, a constituent of the first component of complement, to (he Fc domain of Igs. IgG or IgM, which are in complex with antigen (Hughs-Jones, N.C., and B. Gardner. 1979. Mol. Immunol. 16:697). Clq is a large, structurally complex glycoprotein of-410 kDa present in human serum at a concentration of 70 ug/ml (Cooper, N.R. 1985. Adv. Immunol. 37:151). Together with two serine proteases, Clr and Cls, Clq forms the complex CI, the first component of complement. At least two of the N-terminal globular heads of Clq must be bound to the Fc of Igs for CI activation, hence for initiation of the complement cascade (Cooper. N.R. 1985. Adv. Immunol, 37:151).
[00142] 'Whole blood assays" use unfractionated blood as a source of natural effectors. Blood contains complement in the plasma, together with FcR-expressing celjular effectors, such as polymorphonuclear cells (PMNs) and mononuclear cells (MNCs). Thus,

WO 2008/112003

PCT/US2007/075117

whole blood assays allow simultaneous evaluation of the synergy of both ADCC and CDC effector mechanisms in vitro.
(00143] The term "patient" includes human and veterinary subjects.
|00144] The term "and/or': as used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example "A and/or B" is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.
Antibody Structure
|00145J The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light' (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The ammo-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-teiminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as lgM, lgD. IgA. and igE, respectively. Within light and heavy chains, the variable and constant regions are joined by a *\J" region of about 12 or more amino acids, with the heavy chain also including a "D:' region of about 10 more amino acids. See generally, Fundamental Immunology Ch. 7 (Paul. W., ed„ 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair form the antibody binding site.
100146] Thus, an intact antibody has two binding sites. Except in bifunclional or bispecific antibodies, the two binding sites are the same.
[00147] The chains ail exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR 1, CDR1, FR2, CDR2. FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of

WO 2008/112003

PCT/US2007/075U7

Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. Mo!. Biol. 196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989).
(00148J A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmatm Clin. Exp. Immunol. 79: 315-321 (1990), Kostelny et al. J. Immunol. 148:1547-1553 (1992). Bispecific antibodies do not exist in the form of fragments having a single binding site (e.g., Fab, Fab', and Fv).
[00149| Typically, a VH domain is paired with a VL domain to provide an antibody antigen-binding site, although a VH or VL domain alone may be used to bind antigen. The VH domain (see Table 12) may be paired with the VL domain (see Table 13). so that an antibody antigen-binding site is formed comprising both the VH and VL domains.
Human Antibodies and Humanization of Antibodies
[00150] Human antibodies avoid some of the problems associated with antibodies that possess murine or rat variable and/or constant regions. The presence of such murine or rat derived proteins can lead to the rapid clearance of the antibodies or can lead to the generation of an immune response against the antibody by a patient. In order to avoid the utilization of murine or rat derived antibodies, fully human antibodies can be generated through the introduction of functional human antibody loci into a rodent, other mamma! or animal so that the rodent, other mammal or animal produces fully human antibodies.
[001511 One method for generating fully human antibodies is through the use of XenoMousc® strains of mice that have been engineered lo contain up to but less than 1000 kb-sized germ line configured fragments of the human hea.vy chain locus and kappa light chain locus. See Mendez et al. Nature Genetics 15:146-156 (1997) and Green and Jakobovils J. Exp. Med. 188:483-495 (1998). The XenoMouse® strains are available from Amgen, Inc. (Fremont, California, U.S.A).
[001521 Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in U.S.

WO 2008/112003

PCT/US2007/075117

Patent Application Serial No. 08/759,620, filed December 3, 1996 and International Patent Application Nos. WO 98/24893, published June 11. 1998 and WO 00/76310, published December 21, 2000, the disclosures of which are hereby incorporated by reference. See also Mendez et ai. Nature Genetics 15:146-156 (1997), the disclosure of which is hereby incorporated by reference.
100153| The production of the XenoMouse® strains of mice is further discussed and delineated in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30, 1992, 08/031,801, filed March 15, 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995, 08/430, 938, filed April 27, 1995, 08/464,584. filed June 5, 1995, 08/464,582. filed June 5. 1995, 08/463.191. filed June 5, 1995, 08/462.S37, filed June 5, 1995, 08/486.853, filed June 5, 1995. 08/486,857, filed June 5, 1995, 08/486,859. filed June 5, 1995. 08/462,513, filed June 5,
1995, 08/724,752, filed October 2, 1996. 08/759,620, filed December 3, 1996, U.S. Publication 2003/0093820, filed November 30, 2001 and U.S. Patent Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598 and Japanese Patent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2. See also European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No.. WO 96/34096, published October 31,
1996, WO 98/24893, published June 11, 1998, WO 00/76310, published December 21, 2000. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirely.
J00154J In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces {individual genes) from the Ig locus. Thus, one or more VH genes, one or more DH genes, one or more JH genes, a mu constant region, and usually a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani et al. and U.S. Patent Nos. 5,545,806, 5,625,825, 5.625,126, 5,633.425. 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,877,397, 5,874,299, and 6,255,458 each to Lonberg and Kay, U.S. Patent No. 5,591,669 and 6,023.010 to Krimpenfort and Bems, U.S.

WO 2008/112003

PCT/US2007/075117

Patent Nos. 5,612,205, 5,721,367, and 5,789,215 to Bems et al., and U.S. Patent No. 5,643,763 to Choi and Dunn, and GenPhann Internationa] U.S. Patent Application Serial Nos. 07/574,748, filed August 29, 1990. 07/575,962, filed August 31,1990. 07/810,279. filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,068, filed June 23. 1992. 07/990,860, filed December 16, 1992, 08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 3 994, the disclosures of which are hereby incorporated by reference. See also European Patent No. 0 546 073 BK International Patent Application Nos. WO 92/03918, WO 92/22645. WO 92/22647. WO 92/22670, WO 93/J2227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884 and U.S. Patent No. 5.981.175, the disclosures of which are hereby incorporated by reference in their entirety. See further Taylor et al., 1992, Chen et al., 1993, Tuaillon et al., 1993, Choi et al.. 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuaillon et al., (1995), Fishwild et al., (1996), the disclosures of which are hereby incorporated by reference in their entiiety,
(001551 Kirin has also demonstrated the generation of human antibodies from mice in which, through microcell fusion, large pieces of chromosomes, or entire chromosomes, have been introduced. See European Patent Application Nos. 773 2S8 and 843 961. the disclosures of which are hereby incorporated by reference. Additionally. ICMTM- mice, which are the result of cross-breeding of Kirin's Tc mice with Medarex's minilocus (Humab) mice have been generated. These mice possess the human IgH iranschromosome of the Kirin mice and the kappa chain transgene of the Genpharm mice (Ishida et al.. Cloning Stem Cells. (2002)4:91-102).
(00156] Human antibodies can also be derived by in vitro methods. Suitable examples include but are not limited to phage display (CAT, Morphosys, Dyax, Biosite/Medarex, Xoma, Symphogen, Alexion (formerly Proliferon), Affimed) ribosome display (CAT), yeast display, and the like.
(00157] In another embodiment, the antibodies of the invention the compete with the disclosed antibodies. Competition between antibodies may be assayed easily in vitro, for example using ELISA and/or by tagging a specific reporter molecule to one binding member which can be detected in the presence of one or more other untagged antibodies, to enable

WO 2008/112003

PCT/US2007/075117

identification of antibodies which bind the same epitope or an overlapping epitope. Such methods are readily known to one of ordinary skill in the art, and are described in more detail herein. Thus, a further aspect of the present invention provides an antigen binding site comprising a human antibody antigen-binding site that competes with an antibody molecule, for example especially an antibody molecule comprising a VH and/or VL domain. CDR e.g. HCDR3 or set of CDRs of the parent antibody or any of antibodies disclosed herein that bind to PDGFR-alpha. In one embodiment, the an antibody of the invention competes with 2.175.3, 2.449.1.3 and /or 2.998.2.
Preparation of Antibodies
[001581 I" general, antibodies produced by the fused hybridomas were human lgG2 or IgG4 heavy chains with fully human kappa or lambda light chains. Antibodies can also be of other human isotypes, including IgGl heavy chains. The antibodies possessed high affinities, typically possessing a Kd of from about 10-6 through about 10-12 M or below, when measured against cells in FACS-based affinity measurement techniques. The affinity can also be measured by solid phase and solution phase techniques. In one embodiment, the antibodies described herein bind CD PDGFR-alpha 20 with a Kd of less than about 500, 400, 300, 200 or 100 picomolar (pM) and inhibit tumor growth. In some embodiments, the antibodies bind PDGFR-alpha with a Kd of less than about 75, 60, 50. 40. 30,25,20, 10,or5pM.
[001591 As will be appreciated, anti-PDGFR-alpha antibodies can be expressed in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies can be used to transform a suitable mammalian host cell. Transfonnation can he by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfeclion procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents arc hereby incorporated herein by reference). The transfonnation procedure used depends upon the host to be transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include dcxtran-mediated transfeclion, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation,

WO 2008/112003

PCT/US2007/075117

encapsulation of the polynucleotide(s) In liposomes, and direct microinjection of the DNA into nuclei.
[00160] Mammalian ceil lines available as hosts for expression are weil known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK.) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), human epithelial kidney 293 cells, and a number of other ceil lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels and produce antibodies with constitutive PDGFR-alpha binding properties.
|00161| Anti-PDGFR-alpha antibodies are useful in the detection of PDGFR-alpha in patient samples and accordingly are useful as diagnostics for disease states as described herein. In addition, based on their ability to inhibit tumor growth, anti-PDGFR-alpha antibodies have therapeutic effects in treating symptoms and conditions resulting from PDGFR-alpha expression. In specific embodiments, the antibodies and methods herein relate lo the treatment of symptoms resulting from PDGFR-alpha induced tumor growth. Further embodiments involve using the antibodies and methods described herein to treat neoplastic diseases, such as cancers including, lung cancer, ovarian cancer, prostate cancer, colon cancer, glioblastoma, melanoma and gastrointestinal stromal tumor (GIST).
Antibody Sequences
[001621 Embodiments of the invention include the specific anli-PDGFR-alpha antibodies listed below in Table 1. This table reports the identification number of each anti-PDGFR-alpha antibody, along with the SEQ ID number of variable regions of the corresponding heavy chain and light chain genes.
[00163] Each antibody has been given an identification number that includes either two or three numbers separated by one or two decimal points. In some cases, only two identification numbers separated by one decimal point are listed. However, in some cases, several clones of one antibody were prepared. Although the clones have the identical nucleic acid and amino acid sequences as the parent sequence, they may also be listed separately, with the clone number indicated by the number to the right of a second decimal point. Thus,

WO 2008/112003

PCT/US2007/075117

for example, the nucleic acid and amino acid sequences of antibody 2.84 are identical to the sequences of antibody 2.84.1, 2.84.2, and 2.84.3.
TABLE J

mAblD
No.: Sequence SEQID NO:
2.175.3 Nucleotide sequence encoding the variable region of the heavy chain 1

Amino acid sequence encoding the variable region of the heavy chain 2

Nucleotide sequence encoding the variable region of the light chain

Amino acid sequence encoding the variable region of the light chain 4
2.451.1.1 Nucleotide sequence encoding the variable region of the heavy chain 5

Amino acid sequence encoding the variable region of the heavy chain 6

Nucleotide sequence encoding the variable region of the light chain 012/JK5 7

Amino acid sequence encoding the variable region of the light chain 012/JK5 8

Nucleotide sequence encoding the variable region of the light chain A20/JK5 21

Amino acid sequence encoding the variable region of the light chain A20/JK5 22
2.449.1.3 Nucleotide sequence encoding the variable region of the heavy chain 9

Amino acid sequence encoding the variable region of (he heavy chain 10

Nucleotide sequence encoding the variable region of the light chain 11

Amino acid sequence encoding the variable region of the light chain 12
2.998.2 Nucleotide sequence encoding the variable region of the heavy chain 13

Amino acid sequence encoding the variable region of the heavy chain 14

Nucleotide sequence encoding the variable region of the light chain 15

Amino acid sequence encoding the variable region of the light chain 16

WO 2008/112003 PCT/(iS2007/075II7

2.84.3 Nucleotide sequence encoding the variable region of the heavy chain 1 17

Amino acid sequence encoding the variable region of the heavy chain 18

Nucleotide sequence encoding the variable region of the light chain 19

Amino acid sequence encoding the variable region of the light chain 20
2.1576.1.
2 Nucleotide sequence encoding the variable region of the heavy chain 23

Amino acid sequence encoding the variable region of the heavy chain 24

Nucleotide sequence encoding the variable region of the light chain 25

Amino acid sequence encoding the variable region of the light chain 26
3.625.1 Nucleotide sequence encoding the variable region of the heavy chain 27

Amino acid sequence encoding the variable region of the heavy chain 28

Nucleotide sequence encoding the variable region of the light chain 29

Amino acid sequence encoding the variable region of the light chain 30
2.414.2 Nucleotide sequence encoding the variable region of the heavy chain 31

Amino acid sequence encoding the variable region of the heavy chain 32

Nucleotide sequence encoding the variable region of the light chain T -1

Amino acid sequence encoding the variable region of the light chain 34
2.542.2 Nucleotide sequence encoding the variable region of the heavy chain 35

Amino acid sequence encoding the variable region of the heavy chain 36

Nucleotide sequence encoding the variable region of the light chain 37

Amino acid sequence encoding the variable region of the light chain 3S
2.737.1.4 Nucleotide sequence encoding the variable region of the heavy chain 39

Amino acid sequence encoding the variable region of the heavy chain 40

Nucleotide sequence encoding the variable region of the light chain 41

Amino acid sequence encoding the variable region of the light chain 42
2.1623.2 Nucleotide sequence encoding the variable region of the heavy chain 43

Amino acid sequence encoding the variable region of the heavy chain 44

Nucleotide sequence encoding the variable region of the light chain 45

Amino acid sequence encoding the variable region of the light chain 46
2.1853.3 Nucleotide sequence encoding the variable region of the heavy chain 47

Amino acid sequence encoding the variable region of the heavy chain 4S

Nucleotide sequence encoding the variable region of the light chain 49

Amino acid sequence encoding the variable region of the light chain 50
2.1954.2 Nucleotide sequence encoding the variable region of the heavy chain 51

Amino acid sequence encoding the variable region of the heavy chain 52

Nucleotide sequence encoding the variable region of the light chain 53

Amino acid sequence encoding the variable region of the light chain 54
3.23.2 Nucleotide sequence encoding the variable region of the heavy chain 55

Amino acid sequence encoding the variable region of the heavy chain 56

Nucleotide sequence encoding the variable region of the light chain 57

Amino acid sequence encoding the variable region of the light chain 58
3.87.1.1 Nucleotide sequence encoding the variable region of the heavy chain 59

Amino acid sequence encoding the variable region of the heavy chain 60

Nucleotide sequence encoding the variable region of the light chain 61

Amino acid sequence encoding the variable region of the light chain 62

WO 2008/112003

PCT/US2007/075117

3.341.1 Nucleotide sequence encoding the variable region of the heavy chain 63

Amino acid sequence encoding the variable region of the heavy chain 64

Nucleotide sequence encoding the variable region of the light chain 65

Amino acid sequence encoding the variable region of the light chain 66
3.472.1.1 Nucleotide sequence encoding the variable region of the heavy chain 67

Amino acid sequence encoding the variable region of the heavy chain 68

Nucleotide sequence encoding the variable region of the light chain 69

Amino acid sequence encoding the variable region of the light chain 70
3.805.13 Nucleotide sequence encoding the variable region of the heavy chain 71

Amino acid sequence encoding the variable region of the heavy chain 72

Nucleotide sequence encoding the variable region of the light chain 73

Amino acid sequence encoding the variable region of the light chain 74
3.818.4 Nucleotide sequence encoding the variable region of the heavy chain 75

Amino acid sequence encoding the variable region of the heavy chain 76

Nucleotide sequence encoding the variable region of the light chain 77

Amino acid sequence encoding the variable region of the light chain 78
4.16.2 Nucleotide sequence encoding the variable region of the heavy chain 79

Amino acid sequence encoding the variable region of the heavy chain 80

Nucleotide sequence encoding the variable region of the light chain 81

Amino acid sequence encoding the variable region of the light chain 82
5.1.1.1 Nucleotide sequence encoding the variable region of the heavy chain 83

Amino acid sequence encoding the variable region of the heavy chain S4

Nucleotide sequence encoding the variable region of the light chain 85

Amino acid sequence encoding the variable region of the light chain 86
5.9.3 Nucleotide sequence encoding the variable region of the heavy chain 87

Amino acid sequence encoding the variable region of the heavy chain 88

Nucleotide sequence encoding the variable region of the light chain S9

Amino acid sequence encoding the variable region of the light chain 90
2.796.2 Nucleotide sequence encoding the variable region of the heavy chain 91

Amino acid sequence encoding the variable region of the heavy chain 92

Nucleotide sequence encoding the variable region of the light chain 93

Amino acid sequence encoding the variable region of the light chain 94
3.772.2 Nucleotide sequence encoding the variable region of the heavy chain 95

Amino acid sequence encoding the variable region of the heavy chain 96

Nucleotide sequence encoding the variable region of the light chain 97

Amino acid sequence encoding the variable region of the light chain 98
5.16.1 Nucleotide sequence encoding the variable region of the heavy chain 99

Amino acid sequence encoding the variable region of the heavy chain 100

Nucleotide sequence encoding the variable region of the light chain 101

Amino acid sequence encoding the variable region of the light chain 102
2.2002.3 Nucleotide sequence encoding the variable region of the heavy chain 103

Amino acid sequence encoding the variable region of the heavy chain 104

Nucleotide sequence encoding the variable region of the light chain 105

Amino acid sequence encoding the variable region of the light chain 106

WO 2008/112003

PCIYUS2O07/075117

2.2071.1.
3 Nucleotide sequence encoding the variable region of the heavy chain 107

Amino acid sequence encoding the variable region of the heavy chain 10S

Nucleotide sequence encoding the variable region of the light chain 109

Amino acid sequence encoding the variable region of the light chain no
3.23.3 Nucleotide sequence encoding the variable region of the heavy chain in

Amino acid sequence encoding the variable region of the heavy chain 112

Nucleotide sequence encoding the variable region of the light chain 113

Amino acid sequence encoding the variable region of the light chain 114
3.457.3.1 Nucleotide sequence encoding the variable region of the heavy chain 115

Amino acid sequence encoding the variable region of the heavy chain U6

Nucleotide sequence encoding the variable region of the light chain 117

Amino acid sequence encoding the variable region of the light chain 118
2.84.1 Nucleotide sequence encoding the variable region of the heavy chain i(9

Amino acid sequence encoding the variable region of the heavy chain 120

Nucleotide sequence encoding the variable region of the light chain 121

Amino acid sequence encoding the variable region of the light chain 122
2.35 i.3 Nucleotide sequence encoding the variable region of the heavv chain 123

Amino acid sequence encoding the variable region of the heavy chain 124 ,

Nucleotide sequence encoding the variable region of the light chain 125

Amino acid sequence encoding the variable region of the light chain 126 |
|00164| Antibodies, as described herein in the Examples, were prepared through the utilization of the XenoMouse® technology, as described below. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in the patents: applications, and references disclosed in the background section herein. In particular, however, a preferred embodiment of transgenic production of mice and antibodies therefrom is disclosed in U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996 and International Patent Application Nos. WO 98/24893, published June 11, 1998 and WO 00/76310, published December 21, 2000, the disclosures of which are hereby incorporated by reference See also Mendez et a!. Nature Genetics 15:3 46-156 (1997), the disclosure of which is hereby incorporated by reference.
|00I65J Through the use of such technology, fully human monoclonal antibodies to a variety of antigens have been produced. Essentially^ XenoMouse® lines of mice are immunized with an antigen of interest (e.g. PDGFR-alpha), lymphatic cells (such as B-cells) are recovered from the hyper-immunized mice, and the recovered lymphocytes are fused with a myeloid-type cell line to prepare immortal hybridoma cell lines. These hybridoma

WO 2008/112003

PCT/US2007/075117

cell lines are screened and selected to identify hybridoma eel! lines that produced antibodies specific to the antigen of interest. Provided herein are methods for the production of multiple hybridoma cell lines that produce antibodies specific to PDGFR-alpha. Further, provided herein are characterization of the antibodies produced by such cell lines, including nucleotide and amino acid sequence analyses of the heavy and light chains of such antibodies.
[00166] Alternatively, instead of being fused to myeloma cells to generate hybridomas, B cells can be directly assayed. For example, CD19+ B cells can be isolated from hyperimmune XenoMouse© mice and allowed to proliferate and differentiate into antibody-secreting plasma cells. Antibodies from the cell supematants are then screened by ELISA for reactivity against the PDGFR-alpha immunogen. The supematants might also be screened for immunoreactivity against fragments of PDGFR-alpha to further map the different antibodies for binding to domains of functional interest on PDGFR-alpha. The antibodies may also be screened other related human receptors and against the rat, the mouse, and non-human primate, such as Cynomolgus monkey, orthologues of PDGFR-alpha, the last to determine species cross-reactivity. B cells from wells containing antibodies of interest may be immortalized by various methods including fusion to make hybridomas either from individual or from pooled wells, or by infection with EBV or transfection by known immortalizing genes and then plating in suitable medium. Alternatively, single plasma cells secreting antibodies with the desired specificities are then isolated using a PDGFR-alpha-specific hemolytic plaque assay (see for example Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-48 (1996)). Cells targeted for lysis are preferably sheep red blood cells (SRBCs) coated with the PDGFR-alpha antigen.
[00167J 'n {he presence of a B-cell culture containing plasma cells secreting the immunoglobulin of interest and complement, the formation of a plaque indicates specific PDGFR-alpha-mediated lysis of the sheep red blood cells surrounding the plasma cell of interest. The single antigen-specific plasma cell in the center of the plaque can be isolated and the genetic information that encodes the specificity of the antibody is isolated from the single plasma cell. Using reverse-transcription followed by PCR (RT-PCR), the DNA encoding the heavy and light chain variable regions of the antibody can be cloned. Such cloned DNA can then be further inserted into a suitable expression vector, preferably a vector cassette such as a pcDNA, more preferably such a pcDNA vector containing the constant

WO2008/U20U3

PCT/US2007/075117

domains of immunoglobulin heavy and light chain. The generated vector can then be transfected into host cells, e.g., HEK293 cells, CHO cells, and cultured in conventional nutrient media modified as appropriate for inducing transcription, selecting transformants. or amplifying the genes encoding the desired sequences.
(00168) Anti-PDGFR-alpha antibodies can have therapeutic effects in treating symptoms and conditions related to PDGFR-alpha expression. For example, the antibodies can inhibit growth of cells expressing PDGFR-alpha, thereby inhibiting tumor growth, or the antibodies can be associated with an agent and deliver a lethal toxin to a targeted cell. Anti-PDGFR-alpha antibodies can have therapeutic effects in treating fibrotic diseases, such as cardiac, lung, liver, kidney or skin fibrosis. Anti-PDGFR-alpha antibodies can also have therapeutic effects in the treatment of allograft vasculopathy or restenosis. In addition, the anti-PDGFR-alpha antibodies are useful as diagnostics for the disease states, especially neoplastic, fibrotic and immune system diseases.
|001691 If desired, the isotype of an anti-PDGFR-alpha antibody can be switched, for example to take advantage of a biological property of a different isotype. For example, in some circumstances it can be desirable in connection with the generation of antibodies as therapeutic antibodies against PDGFR-alpha that the antibodies be capable of fixing complement and participating in complement-dependent cytotoxicity (CDC). There are a number of isotypes of antibodies that are capable of the same, including, without limitation, the following: murine lgM, murine IgG2a, murine lgG2b, murine lgG3, human IgM, human JgA, human IgGl, and human lgG3. In other embodiments it can be desirable in connection with the generation of antibodies as therapeutic antibodies against PDGFR-alpha that the antibodies be capable of binding Fc receptors on effector cells and participating in antibody-dependent cytotoxicity (ADCC). There are a number of isotypes of antibodies that are capable of the same, including, without limitation, the following: murine lgG2a, murine IgG2b, murine IgG3, human IgGl, and human lgG3. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, ratlier, the antibody as generated can possess any isotype and the antibody can be isotype switched thereafter using conventional techniques that are well known in the art. Such techniques include the use of direct recombinant techniques (see e.g., U.S. Patent No. 4,816,397), cell-cell fusion techniques (see e.g., U.S. Patent Nos. 5,916,771 and 6,207,418), among others.

WO 2008/112003

PCT/US20UTWI7SH*

[00170} By way of example, the anti-PDGFR-alpha antibodies discussed herein are fully human antibodies. If an antibody possessed desired binding to PDGFR-alpha, it could be readily isolype switched to generate a human lgM, human JgGl, or human IgG3 isotype, while still possessing the same variable region (which defines the antibody's specificity and some of its affinity). Such molecule would then be capable of fixing complement and participating in CDC and/or be capable of binding to Fc receptors on effector cells and participating in ADCC.
[00171] In the cell-cell fusion technique, a myeloma, CHO cell or other cell line is prepared that possesses a heavy chain with any desired isotype and another myeloma, CHO cell or other cell line is prepared that possesses the light chain. Such cells can, thereafter, be fused and a cell line expressing an intact antibody can be isolated.
[00172] Accordingly, as antibody candidates are generated thai meet desired ■'structural1' attributes as discussed above, they can generally be provided with at least certain of the desired "functional" attributes through isotype switching.
Therapeutic Administration and Formulations
[00173j Embodiments of the invention include sterile pharmaceutical formulations of anti-PDGFR-alpha antibodies that are useful as treatments for diseases. Such formulations would inhibit cell growth, thereby effectively treating pathological conditions where, for example, PDGFR-alpha expression is abnormally elevated or PDGFR-alpha expressing cells mediate disease states. Anti-PDGFR-alpha antibodies preferably possess adequate affinity to specifically bind PDGFR-alpha, and preferably have an adequate duration of action to allow for infrequent dosing in humans. A prolonged duration of action will allow for less frequent and more convenient dosing schedules by alternate parenteral routes such as subcutaneous or intramuscular injection.
[00174J Sterile formulations can be created, for example, by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution of the antibody. The antibody ordinarily will be stored in lyophilized form or in solution. Therapeutic antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having an adapter that allows retrieval of the formulation, such as a stopper pierceable by & hypodermic injection needle.

WO 2008/H2003

PCT/US2Q07/075U7

J00175] The route of antibody administration is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, intrathecal, inhalation or intralesional routes, or by sustained release systems as noted below. The antibody is preferably administered continuously by infusion or by bolus injection.
|00176] An effective amount of antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it is preferred that the therapist titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. Typically, the clinician will administer antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays or by the assays described herein.
[001771 Antibodies, as described herein, can be prepared in a mixture with a pharmaceutically acceptable carrier. This therapeutic composition can be administered intravenously or through the nose or lung, preferably as a liquid or powder aerosol (lyophilized). The composition can also be administered parenterally or subcutaneously as desired. When administered systemically, the therapeutic composition should be sterile, pyrogen-free and in a parenterally acceptable solution having due regard for pH, isotonieity, and stability. These conditions are known to those skilled in the art. Briefly, dosage formulations of the compounds described herein are prepared for storage or administration by mixing the compound having the desired degree of purity with physiologically acceptable carriers, excipienls, or stabilizers. Such materials are non-toxic to the recipients at the dosages and concentrations employed, and include buffers such as TR1S HC1, phosphate, citrate, acetate and other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidinone; amino acids such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA: sugar alcohols such as mannitol or sorbitol; counterions such as sodium and/or nonionic surfactants such as TWEEN. PLURONiCS orpolyethyleneglycol.

WO 2008/112003

PCT/US2007/073H7

(00178) Sterile compositions for injection can be formulated according to conventional pharmaceutical practice as described in Remington: The Science and Practice of Pharmacy (20th ed, Lippincott Williams & Wilkens Publishers (2003)). For example, dissolution or suspension of the active compound in a vehicle such as water or naturally occurring vegetable oil like sesame, peanut, or cottonseed oil or a synthetic fatty vehicle like ethyl oleate or the like can be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
[00179] Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-mctbacrylate) as described by Langer et al., J. Biomed Mater. Res.. (1981) 15:167-277 and Langer. Chem. Tech., (1982) 12:98-105, or poly(vinylalcohol)), polylaclides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers, (1983) 22:547-556), non-degradable ethylene-vinyl acetate (Langer et al., supra), degradable lactic acid-glycolic acid copolymers such as the LUPRON Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988).
100180) While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins lor shorter time periods. When encapsulated proteins remain in the body for a long time, they can denature or aggregate as a result of exposure to moisture at 37°C? resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for protein stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be inlermolecular S-S bond formation through disulfide interchange, stabilization can be achieved by modifying sulfhydryl residues., lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
J00181] Sustained-released compositions also include preparations of crystals of the antibody suspended in suitable formulations capable of maintaining crystals in suspension. These preparations when injected subcutaneously or intraperitonealy can

WO 2008/112003

PCT/US2007/075117

produce a sustained release effect. Other compositions also include liposomaliy entrapped antibodies. Liposomes containing such antibodies are prepared by methods known per se: U.S. Pat. No. DE 3,218,121; Epstein et a], Proc. Natl. Acad. Sci. USA. (1985) S2:36S8-3692; Hwang et al., Proc. Natl. Acad. Sci. USA, (1980) 77:4030-4034; EP 52,322: EP 36,676; EP 88,046; EP 143,949; 142,641; Japanese patent application 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324.
|00182J The dosage of the antibody formulation for a given patient will be determined by the attending physician taking into consideration various factors known to modify the action of drugs including severity and type of disease, body weight, sex, diet, time and route of administration, other medications and other relevant clinical factors. Therapeutically effective dosages can be determined by either in vitro or in vivo methods.
f001831 An effective amount of the antibodies, described herein, to be employed therapeutically will depend, for example, upon the therapeutic objectives, the rouie of administration, and the condition of the patient. Accordingly, it is preferred for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about O.OOlmg/kg to up to lOOmg/kg or more, depending on the factors mentioned above. Typically, the clinician will administer the therapeutic antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays or as described herein.
(00184| It will be appreciated that administration of therapeutic entities in accordance with the compositions and methods herein will be administered with suitable cairiers, excipicnis, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures can be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the

WO 2008/112003

PCT/US2007/075117

route of administration. See also Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance.1* Regul. Toxicol. Pharmacol. 32(2):2I0-S (2000), Wang W. :'Lyophilization and development of solid protein pharmaceuticals." Int. J. Pharm. 203(1-2):I-60 (2000), Channan WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts:' J Pharm Sci .89(8):967-78 (2000), Powell el a!. "Compendium of excipients for parenteral formulations" PDA J Pharm Sci Technol, 52:233-311 (1998) and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.
Design and Generation of Other Therapeutics
[001851 In accordance with the present invention and based on the activity of the antibodies that are produced and characterized herein with respect to PDGFR-alpha. the design of other therapeutic modalities is facilitated and disclosed to one of skill in the an. Such modalities include, without limitation, advanced antibody therapeutics, such as bispecific antibodies, immunotoxins, radiolabeled therapeutics, and single antibody V domains, antibody-like binding agent based on other than V region scaffolds, generation of peptide therapeutics, gene therapies, particularly intrabodies. antisense therapeutics, and small molecules.
(00186) An antigen binding site may be provided by means of arrangement of CDR.S on non-antibody protein scaffolds, such as fibronectin or cytochrome B etc. (Haan & Maggos (2004) BioCentury, 12(5): A1-A6; Koideel al. (1998) Journal of Molecular Biology, 284: 1141-1151; Nygren et al. (1997) Current Opinion in Structural Biology, 7: 463-469) or by randomising Or mutating amino acid residues of a Joop vyjthm a protein scaffoJd to confer binding specificity for a desired target. Scaffolds for engineering novel binding sites in proteins have been reviewed in detail by Nygren et al. (Nygren et al. (1997) Current Opinion in Structural Biology, 7: 463-469). Protein scaffolds for antibody mimics are disclosed in WO/0034784, which is herein incorporated by reference in its entirety, in which the inventors describe proteins (antibody mimics) that include a fibronectin type III domain having at least one randomised loop. A suitable scaffold into which to graft one or more CDRs, e.g. a set of HCDRs, may be provided by any domain member of the immunoglobulin gene superfamily. The scaffold may be a human or non-human protein. An advantage of a

WO 2008/112003

PCT/US2007/075117

non-antibody protein scaffold is that it may provide an antigen-binding site in a scaffold molecule that is smaller and/or easier to manufacture than at least some antibody molecules. Small size of a binding member may confer useful physiological properties, such as an ability to enter cells, penetrate deep into tissues or reach targets within other structures, or to bind within protein cavities of the target antigen. Use of antigen binding sites in non-antibody protein scaffolds is reviewed in Wess, 2004 (Wess. L. In: BioCentury, The Bernstein Report on BioBusiness, 12(42), A1-A7, 2004). Typical are proteins having a stable backbone and one or more variable loops, in which the amino acid sequence of the loop or loops is specifically or randomly mutated to create an antigen-binding site that binds the target antigen. Such proteins include the IgG-binding domains of protein A from S. aureus, transferrin, albumin, tetranectin, fibronectin (e.g. 10th fibronectin type III domain), lipocalins as well as gamma-crystalline and other Affilin™ scaffolds (Sal Proteins). Examples of other approaches include synthetic "Microbodies" based on cyclotides - small proteins having intra-molecular disulphide bonds. Microproteins (Versabodies™, Amunix) ?nd ankyrin repeat proteins (DARPins, Molecular Partners).
|00187] In addition to antibody sequences and/or an antigen-binding site, a targeted binding agent according to the present invention may comprise other amino acids, e.g. forming a peptide or polypeptide, such as a folded domain, or to impart to the molecule another functional characteristic in addition to ability to bind antigen. Targeted binding agent s of the invention may carry a detectable label, or may be conjugated to a toxin or a targeting moiety or enzyme (e.g. via a peptidyl bond or linker). For example, a targeted binding agent may comprise a catalytic site (e.g. in an enzyme domain) as well as an antigen binding site, wherein the antigen binding site binds to the antigen and thus targets the catalytic site to the antigen. The catalytic site may inhibit biological function of the antigen, e.g. by cleavage.
1.00188) 'n connection with the generation of advanced antibody therapeutics, where complement fixation is a desirable attribute, it can be possible to sidestep the dependence on complement for cell killing through the use of bispecifics. immunotoxins, or radiolabels, for example.
(00189] For example, bispeciftc antibodies can be generated that comprise (i) two antibodies, one with a specificity to PDGFR-alpha and another to a second molecule, that are

WO 2008/112003

PCT/US2007/075117

conjugated together, (ii) a single antibody that has one chain specific to PDGFR-alpha and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to both PDGFR-alpha and the other molecule. Such bispecific antibodies can be generated using techniques that are well known; for example, in connection with (i) and (ii) see e.g., Fanger el al. Immunol Methods 4:72-81 (1994) and Wright and Hams, supra, and in connection with (iii) see e.g., Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992). In each case, the second specificity can be made as desired. For example, the second specificity can be made to the heavy chain activation receptors, including, without limitation, CD 16 or CD64 (see e.g., Deo et al. 18:127 (1997)) or CD89 (see e.g., Valerius et al. Blood 90:4485-4492(1997)).
(00190] Antibodies can also be modified to act as immunotoxins utilizing techniques that are well known in the an. See e.g., Vitetta Immunol Today 14:252 (1993). See also U.S. Patent No. 5,194,594. In connection with the preparation of radiolabeled antibodies, such modified antibodies can also be readily prepared utilizing techniques that are well known in the art. See e.g., Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafher and Longo, eds., Lippincott Raven (1996)). See also U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules would be likely to kill cells expressing the desired multimeric enzyme.._subunit oligomenzation domain. In some embodiments, a pharmaceutical composition comprising an effective amount of the antibody in association with a pharrnaceutically acceptable carrier or diluent is provided.
|00191j m some embodiments, an anti-PDGFR-alpha antibody is linked to an agent (e.g., radioisotope, pharmaceutical composition, or a toxin). Preferably, such antibodies can be used for the treatment of diseases, such diseases can relate cells expressing PDGFR-alpha or cells overexpressing PDGFR-alpha. For example, it is contemplated that the drug possesses the pharmaceutical property selected from the group of antimitotic, alkylating, antimetabolite, antiangiogenic, apoptotic, alkaloid, COX-2. and antibiotic agents and combinations thereof. The drug can be selected from the group of nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogs, anthracyc lines, taxanes, COX-2 inhibitors, pyrimidine analogs, purine analogs, antimetabolites, antibiotics, enzymes, epipodophyllotoxins, platinum coordination

WO 2008/112003

PCT/US2007/075117

complexes, vinca alkaloids, substituted ureas, methyl hydrazine derivatives, adrenocortical suppressants, antagonists, endostatin, taxols. camptothecins, oxaliplalin, doxorubicins and their analogs, and a combination thereof.
[00192] Examples of toxins further include gelonin, Pseudomonas exotoxin (PE). PE40, PE38, diphtheria toxin, ricin, ricin, abrin, alpha toxin, saporin, ribonuclease (RNase): DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, Pseudomonas endotoxin, as well as derivatives, combinations and modifications thereof.
[00193] Examples of radioisotopes include gamma-emitters, positron-emiIters, and x-ray emitters that can be used for localization and/or therapy, and beta-emitters and alpha-emitters that can be used for therapy. The radioisotopes described previously as useful for diagnostics, prognostics and staging are also useful for therapeutics. Non-limiting examples of anti-cancer or anti-leukemia agents include anthracyclines such as doxorubicin (adriamycin), daunorubicin (daunomycin), idarubicin, detorubicin, carminomycin, cpirubicin, esorubicin, and morpholino and substituted derivatives, combinations and modifications thereof. Exemplary pharmaceutical agents include cis-platinum, taxol, calicheamicin, vincristine, cytarabine (Ara-C), cyclophosphamide, prednisone, daunorubicin, idarubicin. fludarabine, chlorambucil, interferon alpha, hydroxyurea, temozolomide, thalidomide, and bleomycin, and derivatives, combinations and modifications thereof. Preferably, the anti¬cancer or anti-leukemia is doxorubicin, morpholinodoxorubicin, or morpholinodaunorubicin.
[00194] The antibodies of the invention also encompass antibodies that have half-lives (e.g., serum half-lives) in a mammal, preferably a human, of greater than that oi" an unmodified antibody. In one embodiment, said antibody half life is greater than about 15 days, greater than about 20 days, greater than about 25 days, greater than about 30 days, greater than about 35 days, greater than about 40 days, greater than about 45 days, greater than about 2 months, greater than about 3 months, greater than about 4 months, or greater than about 5 months. The increased half-lives of the antibodies of the present invention or fragments thereof in a mammal, preferably a human, result in a higher serum titer of said antibodies or antibody fragments in the mammal, and thus, reduce the frequency of the administration of said antibodies or antibody fragments and/or reduces the concentration of said antibodies or antibody fragments to be administered. Antibodies or fragments thereof having increased in vivo half-lives can be generated by techniques known to those of skill in

WO 2008/112003

PCT/US2007/075117

the art. For example, antibodies or fragments thereof with increased in vivo half-lives can be generated by modifying (e.g., substituting, deleting or addisjg) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor (see. e.g.. International Publication Nos. WO 97/34631 and WO 02/060919, which are incorporated herein by reference in their entireties). Antibodies or fragments thereof with increased in vivo half-lives can be generated by attaching to said antibodies or antibody fragments polymer molecules such as high molecular weight poiyethyleneglycol (PEG). PEG can be attached to said antibodies or antibody fragments with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of said antibodies or antibody fragments or via epsilon-amino groups present on lysine residues. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used. The degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography.
|00195| As will be appreciated by one of skill in the art, in the above embodiments, while affinity values can be important, other factors can be as important or more so, depending upon the particular function of the antibody. For example, for an immunotoxin (toxin associated with an antibody), the act of binding of the antibody lo the target can be useful; however, in some embodiments, it is the internalization of the toxin imo the cell that is the desired end result. As such, antibodies with a high percent internalization can be desirable in these situations. Thus, in one embodiment, antibodies with a high efficiency in internalization are contemplated. A high efficiency of internalization can be measured as a percent internalized antibody, and can be from a low value to 100%. For example, in varying embodiments, 0.1-5, 5-10, 10-20, 20-30, 30-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-99, and 99-100% can be a high efficiency. As will be appreciated by one of skill in the art, the desirable efficiency can be different in different embodiments, depending upon, for example, the associated agent, the amount of antibody that can be administered to an area, the side effects of the antibody-agent complex, the type (e.g., cancer type) and severity of the problem to be treated.

WO 2008/112003

PCT/US2007/075I17

[00196| In other embodiments, the antibodies disposed herein provide an assay kit for the detection of PDGFR-alpha expression in mammalian tissues or cells in order to screen for a disease or disorder associated with changes in expression °f PDGFR-alpha. The kit comprises an antibody that binds PDGFR-alpha and means for indicating the reaction of the antibody with the antigen, if present.
[00197] in some embodiments, an article of manufacture is provided comprising a container, comprising a composition containing an antrPDGFR-alpha antibody, and a package insert or label indicating that the composition can be used to treat disease mediated by PDGFR-alpha expression. Preferably a mammal and, more preferably, a human, receives the anti-PDGFR-alpha antibody.
Combinations
(00198| The anti-neoplastic treatment defined herein may be applied as a sole therapy or may involve, in addition to the compounds of the invention, conventional surgery, bone marrow and peripheral stem cell transplantations or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti tumor agents:
(i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-plalin, oxaliplatin. carboplatin, cyclophosphamide, nitrogen mustard, melpMan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimi dines like 5-fluorouracil and tegafur, raltilrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumor antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin. epirtfbicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and tabids like taxol and taxotere and polokinase inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and leniposide, amsacrine, topotecan and camptothecin);
(ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene). anliandrogens (for example bicalutamide, flulamide, nilutamide and cyproteronc acetate), LHRH antagonists or LHRH

WO 2008/112003

PCT/US2007/075117

agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole. vorazole and exemestane) and inhibitors of 5ct-reductase such as finasteride;
(iii) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6-chloro-2,3-niethylenedioxyanilino)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazolme (A2D0530; International Patent Application WO 01/94341) and iV-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-l-yl]-2-methylpyrimidin-4-ylamino}lhiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem.. 2004, 47, 6658-6661), and metalloproteinase inhibitors like rnarimastat, inhibitors of urokinase plasminogen activator receptor function or, inhibitors of cathepsins, inhibitors of serine proteases for example matriptase, hepsin, urokinase, inhibitors of heparanase);
(iv) cytotoxic agents such as fludarabine, 2-chlorodeoxyadenosine, chlorambucil or doxorubicin and combination thereoff such as Fludarabine + cyclophosphamide, CVP: cyclophosphamide + vincristine + prednisone, ACVBP: doxorubicin + cyclophosphamide + vindesine + bleomycin + prednisone, CHOP: cyclophosphamide + doxorubicin + vincristine + prednisone, CNOP: cyclophosphamide + mitoxanlrone + vincristine. + prednisone, m-BACOD: methotrexate + bleomycin + doxorubicin + cyclophosphamide + vincristine + dexamethasone + leucovorin., MACOP-B: methotrexate + doxorubicin + cyclophosphamide + vincristine + prednisone fixed dose + bleomycin + leucovorin, or ProMACE CylaBOM: prednisone + doxorubicin + cyclophosphamide + etoposide + cytarabine + bleomycin + vincristine + methotrexate + leucovorin.
(v) inhibitors of growth factor function, for example such inhibitors include
growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2
antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbBl
antibody cetuximab [Erbitux, C225] and any grovvlh factor or growth factor receptor
antibodies disclosed by Stem et al. Critical reviews in oncology/haematology, 2005, Vol. 54,
ppl 1-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the
epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as
A'-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
(gefitinib, ZD1839). A'-(3-ethyny!phenyl)-6,7-bis(2-methoxycthoxy)quinazolin-4-amine
(erlotinib, OS1-774) and 6-aciylamido-A/-(3-chloro-4-fluoroplienyl)-7-(3-

WO 2008/i 12003

PCT/US2007/07511?

morpholinopropoxy)-quinazolin-4-amine (CI 1033)T erbB2 tyrosine kinase inhibitors such as lapatinib, inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-derived growth factor family such as imatinib. inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as famesyl transferase inhibitors, for example sorafcnib (BAY 43-9006)), inhibitors of cell signalling through MEK. and/or AKT kinases, inhibitors of the hepatocyte growth factor family, c-kit inhibitors, abl kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors, aurora kinase inhibitors (for example AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 and AX39459), cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors, and inhibitors of survival signaling proteins such as BcI-2, Bcl-XL for example ABT-737;
(vi) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(l-methylpiperidin^_yiniethoxy)quina2oline (Z06474; Example 2 within WO 01/32651), 4-(4-fluoro-2-methylindoI-5-yloxy)-6-methoxy-7-(3-pyrrolidin-l-ylpropoxy)quinazoline (A2D2171; Exarnple 240 within WO 00/47212). vatalanib (PTK787; WO 98/35985) and SU11248 (sunitimb; WO 01/60814), compounds such as those disclosed in International Patent Applications W097/22596, WO 97/30035, WO 97/32856. WO 98/13354, WO00/47212 and WO01/32651 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin avB3 function and angioslatin)] or colony stimulating factor I (CSF1) orCSFl receptor.;
(vii) vascular damaging agents such as Combretast^tin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;
(viii) antisense therapies, for example those which are directed to the targets listed above, such as G-3139 (Genasense), an anti bcl2 antisense;
(ix) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA^ GDEPT (gene directed enzyme pro drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi drug resistance gene therapy; and

WO 2008/112003

PCT/US2007/075117

(x) immunotherapy approaches, including for example treatment with Alemtuzumab (campath-lH™), a monoclonal antibody directed at CD52, or treatment with antibodies directed at CD22. ex vivo and in vivo approaches lo increase the immunogenicity of patient tumour cells, transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte macrophage colony stimulating factor, approaches to decrease T cell anergy such as treatment with monoclonal antibodies inhibiting CTLA-4 function, approaches using transfected immune cells such as cytokine trans feet ed dendritic cells, approaches using cytokine transfected tumour cell lines and approaches using anti idiotypic antibodies.
(xi) inhibitors of protein degradation such as proteasome inhibitor such as Velcade (bortezomid).
(xii) biotherapeutic therapeutic approaches for example those which use peptides or proteins (such as antibodies or soluble external receptor domain constructions) which either sequester receptor ligands, block ligand binding to receptor or decrease receptor signalling (e.g. due to enhanced receptor degradation or lowered expression levels).
(00199] Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or phamiaceulically acceptable salts, thereof, within the dosage range described hereinbefore and the other pharmaceutically active agent within its approved dosage range.
(00200] In one embodiment of the invention the anti-neoplastic treatments of the invention are combined with agents which inhibit the effects of vascular endothelial growth factor (VEGF), (for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin®), anti-vascular endothelial growth factor receptor antibodies such anti-KDR antibodies and anti-fltl antibodies, compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/3285, WO 98/13354, WOOO/47212 and WOOl/32651) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin avb3 function and angiostalin); In another embodiment of the invention the anti-angiogenic treatments of the invention are combined agents which inhibit the tyrosine kinase activity of the vascular endothelial growth factor receptor, KDR (for example AZD2171 or AZD6474). Additional details on AZD2171 may be found in Wedge et al (2005) Cancer Research. 65(10):43S9-400. Additional details on

WO 2008/112003

PCT/US2007/075117

A2D6474 maybe found in Ryan & Wedge (2005) British Journal of Cancer. 92 Suppl l:S6-13. Both publications are herein incorporated by reference in their entireties. In another embodiment of the invention, the fully human antibodies 1.1.2, 1.5.3, 2.1.2 are combined a\one or in combination with Avastin™, AZD2i 1 \ or AZD6474.
[002011 Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or pharmaceutical ly acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically active agent within its approved dosage range.
EXAMPLES [00202| The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as limiting upon the teachings herein.
EXAMPLE i IMMUNIZATION AND TITERfNG immunogen
[00203) Recombinant soluble PDGFR-alpha extracellular domain was obtained
from R&D Systems (Minneapolis, MN. Catalog #: 322-PR/CF) and used as an immunogen.
In addition, recombinant human PDGFR-alpha expressed in BHK (baby hamster kidney)
cells was used as an antigen for immunization. The BHK cells were obtained from the
American Type Tissue Collection, catalog no. CCL-10.
Immunization
(00204) Monoclonal antibodies against PDGFR-alpha were developed by
sequentially immunizing XenoMouse® mice (XenoMouse strains: XMG2 (lgG2 kappa) and
XM3C-1 (IgG4 kappa) Amgen, Inc. Fremont. CA) with the extracellular domain of PDGFR-
alpha (R&D Systems, Catalog #: 322-PR/CF). XenoMouse animals were immunized via
footpad route for all injections by conventional means. The total volume of each injection
was 50 pi per mouse containing 10 micrograms of PDGFR-alpha extracellular domain, 25 pi

WO 2008/112003

PCT/US2007/075117

per footpad. Adjuvants included Titermax GoldTM (Sigma, cat. T2684), aluminum phosphate gel adjuvant, HCL Biosecior (cat 1452-250) and ImmuneEasy mouse adjuvant (qCpG, Qiagen cat. No 303105). The first injection was administered with Titermax GoldTM (Day 0). Boosts were administered as 5 ul of aluminum phosphate gel adjuvant (5ul) and qCpG (15 ul) along with 10 ug of PDGFRalpha extracellular domain on days 3,6,10,13,20,24,27,31 and 34.
EXAMPLE 2
RECOVERY OF LYMPHOCYTES, B-CELL ISOLATIONS, FUSIONS AND GENERATION OF HYBRIDOMAS
[00205} Immunized mice were sacrificed by cervical dislocation and the draining lymph nodes were harvested and pooled from each cohoit. The lymphoid cells were dissociated by grinding in DMEM to release the cells from the tissues, and the colls were suspended in DMEM. The ceils were counted, and 0.9 ml DMEM per 100 million lymphocytes was added to the ceil pellet to resuspend the cells gently but completely. Using 100 u:l of CD90+ magnetic beads per 100 million cells, the cells were labeled by incubating the cells with the magnetic beads at 4°C for 15 minutes. The magnetically-labeled cell suspension containing up to 108 positive cells (or up to 2x109 total cells) was loaded onto an LS+ column and the column washed with DMEM. The total effluent was collected as the CD90-negative fraction (most of these cells were expected to be B cells).
[00206] A fusion was performed by mixing washed enriched B cells from above and nonsecretory myeloma P3X63Ag8.653 cells purchased from ATCC (cat. no. CRL 1580) (Kearney et al, J. Immunol. 123, 1979, 1548-1550) at a ratio of 1:1. The cell mixture was gently pelleted by centrifugation at 800 x g. After complete removal of the supernatant, the cells were treated with 2-4 mL of Pronase solution (CalBiochem, cat. # 53702; 0.5 mg/mL in PBS) for no more than 2 minutes. Then 3-5 ml of FBS was added to stop the enzyme activity and the suspension was adjusted to 40 mL total volume using electro cell fusion solution, ECFS (0.3 M Sucrose, Sigma, Cat# S7903, 0.1 mM Magnesium Acetate, Sigma, Cat# M2545, 0.1 mM Calcium Acetate, Sigma, Cat# C4705). The supernatant was removed after centrifugation and the cells were resuspended in 40 mL ECFS. This wash step was repeated and the cells again were resuspended in ECFS to a concentration of 2x106 cells/mL.

WO 2008/112003

PCT/US2007/075117

|00207] Electro-cell fusion was performed using a fusion generator, model ECM2001, Genetronic, Inc., San Diego, CA. The fusion chamber size used was 2.0 mL, using the following instrument settings: Alignment condition: voltage: 50 V, time: 50 seconds; membrane breaking at: voltage: 3000 V, time: 30 uscconds; post-fusion holding time: 3 seconds.
(00208] After ECF, the cell suspensions were carefully removed from the fusion chamber under sterile conditions and transferred into a sterile tube containing the same volume of Hybridoma Culture Medium (DMEM (JRH Biosciences), 15% FBS (Hycione): supplemented with L-glutamine, pen/strep, OP1 (oxaloacetate, pyruvate, bovine insulin) (all from Sigma) and IL-6 (Boehringer Mannheim). The cells were incubated for 15-30 minutes at 37°C, and then centrifuged at 400 x g (1000 rpm) for five minutes. The cells were gently resuspended in a small volume of Hybridoma Selection Medium (Hybridoma Culture Medium supplemented with 0.5x HA (Sigma, cat. # A9666)), and the volume was adjusted appropriately wilh more Hybridoma Selection Medium, based on a final plating of 5x106 B cells total per 96-well plate and 200 JIL per well. The cells were mixed gently and pipetted into 96-well plates and allowed to grow. On day 7 or 10, one-half the medium was removed, and the cells were re-fed with Hybridoma Selection Medium.
ELISA screening
|00209] For ELISA analysis, recombinant human PDGFR-alpha (R&D systems, cat#322-PR7CF ), at a concentration of 4ug/ml, was used as a capture reagent. ELISA plates were coated with recombinant human PDGFR-alpha in a volume of 50 (il/well in antigen coating buffer (0.1 M Carbonate Buffer, pH 9.6 NaHC03 (MW 84) 8.4 g/L) and incubated overnight at 4°C. The following day, the ELISA plate was washed 3 times with washing buffer (0.05% Tween 20 in lx PBS) and subsequently blocked wilh 200 (.il/well of blocking buffer (1% BSA, 0.1% Tween 20, 0.01% Thimerosal in lx PBS) for 1 hour at room temperature. Upon completion of the blocking step, 50 ul/welt of hybridoma supernatant was incubated at room temperature for 2 hours. After incubation, the ELISA plate was washed 3 times in washing buffer. Following the wash step, 50 pJ/well of detection antibody was added to the wells and incubated at room temperature for 1 hour. The ELISA plale was subsequently washed 3 times with washing buffer and TMB substrate was added (50

WO 2008/112003

PCT/US2007/075117

uJAvell). Following the addition of the stop solution (50 ul/well). the ELISA plate was read at GSOnm with an ELISA plate reader. The supematants deemed positive by ELISA were subsequently evaluated by FMAT and FACS.
EXAMPLE 3 SELECTION OF CANDIDATE ANTIBODIES BY FMAT AND FACS
[002101 After 14 days of culture, hybridoma supematants were screened for PDGFR-alpha-specific monoclonal antibodies by Fluorometric Microvolume Assay Technology (FMAT) by screening against either the human osteosarcoma MG-63 cell line or recombinant HEK293 cells that were transfected with human PDGFR-alpha and counter-screening against parental HEK293 cells.
[002111 The culture supematants from the positive hybridoma cells growth wells based on the primary screen were removed and the PDGFR-alpha positive hybridoma cells were suspended with fresh hybridoma culture medium and were transferred to 24-well plates. After two days in culture, these supematants were ready for a secondary confirmation screen. In the secondary confirmation screen, the positives in the first screening were screened by FACS with two sets or three sets of detection antibodies used separately: 1.25ug/ml GAH-Gamma Cy5 (JIR# 109-176-098) for human gamma chain detection: 1.25ug/ml GAH-Kappa PE (S.B.#2063-09) for human kappa light chain detection and ].25ug/ml GAH-lambda PE (S.B.#2073-09) for human lambda light chain detection in order to confirm that the anli-PDGFR-alpha antibodies were fully human.
EXAMPLE 4 PDGFR TYROSINE PHOSPHORYLATION ASSAY [00212] 791 antibody lines were interrogated using a PDGFR tyrosine phosphorylation (pTyr) assay to determine whether the antibody lines inhibited the phosphorylation of PDGFR-alpha in tumor cells.
[00213] Briefly, human osteosarcoma MG-63 cells were seeded at 10,000 cells per well in a 96-well FMAT assay plate in 100 \i\ Starvation Media (1% charcoal/dextran treated FBS) and incubated at 37°C for approximately 20 hours. Starvation Media was removed and 37.5 u.1 of media was added to all wells receiving sample and 12.5 ul was added to wells

WO 2008/112003

PCT/US2O07/075117

receiving control (mouse mAb anti-PDGFRa (BD PharMingen catalog # 556001) or mouse IgG2a (serotech, 2X final concentration)) and incubated for 30 minutes at 37°C. 50ul of PDGF-AA (R&D) in 1% assay media at 2X final concentration (50ng/m!) was added to all plates and media added to column 12 of the control plate. Plates were incubated for 10 minutes at 37°C. Media was removed and 100 ul of 3.7% formaldehyde in PBS/3%BSA was added and incubated for 20 minutes at room temperature. Plates were washed two times with PBS and 100 ul permeabilization buffer (0.1% Triton-X in 3%BSA/PBS) was added to each well, incubated at room temperature for 10 minutes, and discarded. 100 ml of 0.6% hydrogen peroxide in PBS/3% BSA was added to inactivate any endogenous peroxidase activity and incubated at room temperature for 20 minutes. Plates were washed three times with PBS/0.1% Tween-20 and blocked with 100 u! 10% FBS in PBS/0.1% Tween-20. Plates were incubated for 1 hour ai room temperature, blocking buffer removed, and 50 ul anti-phospho PDGFa antibody (sc-12910-R) (1 ug/ml) was added to each well in 10% FBS/PBS-T. Plates were incubated for 2 hours at room temperature, then washed three times with PBST, soaking for 5 minutes between each wash. 50 ul of Goat anti-Rabbit IgGFc-HRP secondary antibody diluted in Blocking Buffer was added and incubated at room temperature for 1 hour. Plates were washed three times for 5 minutes with PBST and tapped dry. 50 u.1 of ECL reagent (LumiGLO Reserve, KPL catalog # 54-71-01) was added and RLUs read immediately. Plates were washed two times with PBST and tapped dry. Plates where then frozen at -80°C for 30-60 minutes. Plates were brought to room temperature and 100 ul of CyQuant added to each well. Plates were read at 485 run excitation and 530 nm emission on a fluorescence reader.
[00214] 103 lines were selected based on a greater than or equal to 90% neutralization in the pTyr assay, i.e. the selected antibody lines inhibited tyrosine phosphorylation of PDGF receptor-alpha by greater than or equal to 90%. (Data not shown.)
EXAMPLE 5
AFFINITY AND CONCENTRATION ANALYSIS OF HYBR1DOMA SUPERNATANTS
HIGH ANTIGEN (HA) / LIMITED ANTIGEN (LA) ANALYSIS
[00215] 103 antibody lines were interrogated using a high antigen (HA) / limited
antigen (LA) analysis as described below. HA is an antibody concentration dependent

WO 2008/112003

PCT/US2007/075117

reaction, and is thus a measure of antibody concentration. LA is largely an antibody affinity dependent reaction and thus, can be a measure of antibody affinity.
High Antigen Quantitation Assay
[00216] Briefly, EL1SA plates were coated with a greater amount of human PDGFR-alpha antigen (R&D Systems, Inc., Minneapolis, MN Cat. No. 322-PR-050/CF) in comparison with the Limited Antigen Quantitation Assay described below. Antibody-containing hybridoma supematants were titrated over a dilution range of 1:51 to 1:1656. A control of a known mouse anti-human PDGFR-alpha-specific antibody (PharMingen Catalog No. 556001) was used to define the linear range of the assay. Data within the linear range were then used to derive the relative concentration of the PDGFR-specific antibody in each titrated sample.
Limited Antigen Quantitation Assay
100217] Microliter plates were coated with a lower amount of human PDGFR-alpha antigen in comparison with the High Antigen Quantitation Assay described above. Fifty microliters (50 uX) of human PDGFR-alpha at 64, 32, 16, 8, 4, and 2 ng/ml (covering a range of 8.5 nM to 0.26 nM) in 1% skim milk / IX PBS pH 7.4 / 0.5% azidc was added to each well. The plate was incubated for 30 minutes.
(00218J Plates were washed four limes with water, and 50uL of hybridoma supernatant containing test antibodies diluted 1:25 in 1% skim milk / IX PBS pH 7.4 / 0.5% azide were added to the wells. Plates were wrapped tightly with plastic wrap or paraffin film, and incubated overnight with shaking at room temperature.
[002191 O" me following day, ali plates were washed five times and 50 uL goat anti-Human IgG Fc HRP polyclonal antibody at a concentration of 0.5 ug/ml in 1% milk, IX PBS pH 7.4 was added to each well. The plates were incubated for \ hour at room temperature.
[00220| Plates were washed at least five times with tap water. Fifty microliters (50) uL of HPR substrate TMB was added to each well, and the plate were incubated for 30 minutes. The HRP-TMB reaction was stopped by adding 50 uL of 1M phosphoric acid to each well. Optical density (absorbance) at 450 ran was measured for each well of the plate.

WO 2008/112003

PCT/US2007/075117

(00221] Thirty-four (34) antibody lines were selected based on relative binding affinity. Selection was based on titration of antigen at 16 ng/ml and 2 ng/ml. Selected cut¬offs were LA greater than 0.3 OD units and 3.3 ug/ml. Lines thai exhibited weak reactivity at antigen concentration of 2 ng/ml of antigen were de-selected.
(00222] Nine (9) additional lines were added to increase the candidate pool based on inhibition of PDGFR-alpha phosphorylation in MG-63 cells, such that a total of 43 antibody lines that exhibited potent inhibition of tyrosine phosphorylation and high relative affinity based on HA/LA analysis were carried forward. The aforementioned nine additional lines exhibited complete inhibition of PDGFR-alpha phosphorylation (i.e 100%). None of the lines cross-reacted with PDGFR-beta or homologs (FLT3, c-kit, CSF-1R).
TABLE 2
SUMMARY OF 43 ANTIBODY LINES SELECTED BASED ON ABILITY TO
POTENTLY INHIBIT PDGFR-ALPHA PHOSPHORYLATION IN MG-63 CELLS

WO 2008/112003

PCT/US2007/0751I7

2.1696 >100%
2.45] >I00%
3.457 >100%
2.175 99%
2.259 99%
2.998 99%
2.449 99%
2.414 98%
2.84 98%
3.268 98%
2.351 97%
2.S50 95%
3.472 95%
2.886 94%
2.415 94%
3.23 94%
2.10 93%
2.737 93%
2.796 93%
2.565 92%
2.32 92%
2.624 92%
2.862 92%
3.805 92%
2.542 91%
3.289 91%
3.772 91%
2.889 90%

WO 2008/112003

PCT/US2007/075117

EXAMPLE 6 IN VITRO SCREENIMG AND DATA ANALYSIS OF CLONED MONOCLONAL
ANTIBODIES [00223| Thirty (30) antibody lines were cloned and interrogated further as follows. pTvr Assay
|00224| PDGFR Tyrosine Phosphorylation (pTyr assay) was performed using MG-63 cells as described above in Example 4. Results are shown in Table 3.
Proliferation Assay
[002251 Inhibition of MG-63 cell growth by the purified monoclonal antibodies against PDGFR-alpha was evaluated using a PDGF-AA Proliferation Assay Screen.
[00226| Briefly, MG-63 cells were seeded at 5,000 cells per well in 100 ul full growth media in the inner wells of black clear bottom plates and incubated at 37°C, 5% C02 for 3-4 hours. Cells were washed with PBS IX with media and replaced with growth starvation culture media (MEM, 1% NEAA, 0.1% NaBicarb, 1% L glut) and stai-ved overnight. Media was removed from plates and 50 ui of 2X mAb or media added lo appropriate wells. 50 ul of PDGF-AA titration, 200 ng/ml PDGF-AA or media alone was added and plates incubated for 3 days. Plates were read out with Alamar Blue at 530 excitation and 580 nm emission (100 ul per well/100 ul).
|00227| Data for the lop 15 monoclonal antibodies, i.e. exhibiting the lowest 1C50 values, for a cell stimulation using 100 ng/ml (3.45 nM) PDGF-AA are summarized below in Table 3. Monoclonal antibodies selected for further analysis are shown in bold. The dose response curves for 5 of the selected antibodies are shown in Figure 1. The preparation of 2.451.1.1 may contain two different antibodies, with the same heavy chain but different light chains, since there were two different light chain sequences detected during sequencing of the DNA for this monoclonal antibody.
TABLE 3 PROLIFERATION ASSAY: MG-63 CELLS

mAb ICso (ng/ml)
2.175.3 56.1 (0.37 nM)

WO 2008/112003

PCT/US2007/075117

2.414.2 349.1 (2.3 nM)
2.451.1.1 283.1 (1.9 nM)
2.542.2 651.6 (4.35 nM)
2.737.1.4 558.5 (3.72 nM)
2.1623.2 981.7 (6.5 nM)
2.1853.3 2679.2 (18 nM)
3.341.2 471.0 (3.1 nM)
2.796.2 756.8 (5nM)
5.16.1 422.7 (2.8 nM)
2.2071.1.3 492.0 (3.3 nM)
2.449.1.3 236.6 (1.57 nM)
2.84.3 480.8 (3-2 nM)
2.998.2 315.5(2.1 nM)
2.351.3 648.6 (4.3 nM)
BD556001 2857.6 (19 nM)
Hu lgG2 >10ug/mL
Hu lgG4 >10 ug/mL
FACS Kd Affinity Determination
(00228J The affinity of purified monoclonal antibodies (mAbs 2.175.3, 2.449.1.3, 2.451.1.1, 2.998.2. 2.84.3) against PDGFR-alpha was determined by FACS analysis.
[00229| Briefly, MG-63 cells expressing PDGFR-alpha were resuspended in FACS buffer (2% FBS, 0.05% NaN3) at a concentration of approximately 3 to 5 million cells/mL. Cells were kept on ice. Purified antibodies and CD 140a control were serially diluted in filtered IxPBS (2x) across 11 wells in 96-well plates. The twelfth well in each row contained buffer only. Ix PBS and cells were added to each mAb well such that the final volume was 30 uL/well and each well contained approximately 100,000 cells. The final molecular concentration ranges for the mAbs were as follows:

WO 2008/112003

PCT/US2007/075117

mAb Concentration
2.451.1.1 = 19.1-0.019nM
2.175.3 = 10.8-0.021 nM
2.449.1.3 = 10.7-0.021 nM
2.449.1.3 = 9.2-0.009 nM
2.84.3 = 4.4-0.009 nM
2.449.1.3 = 9.2 - 0.009 nM
2.998.2 = 4.6-0.009 nM
CD 140a = 20.2 - 0.020 nM
[00230] Plates were placed on a plate shaker for 5 hours at 4°C. then spun and washed 3x with PBS. 200 u.L of 100 or 131 nM Cy5 goat a-human polyclonal antibody (Jackson Laboratories, #109-175-008) was added to each well, and 200 uL of 100 nM Cy5 goat cc-mouse polyclonal antibody was added to the cells complexed with CD140a antibody. Plates were then placed on a shaker for 40 minutes at 4°C, then spun and washed 3x with PBS.
J00231J The Geometric Mean Fluorescence (GMF) of 15,000 to 20,000 cell 4ievents'r for each mAb concentration was determined using a FACSCalibur instrument. For each mAb, the GMF data was normalized for both replicate titrations relative to an identical mAb concentration point in each titration. Corresponding normalized titration points were averaged to give one normalized GMF point for each mAb concentration. Only one titration data set for mAb 2.351.3 was of acceptable quality for analysis. A nonlinear plot of GMF as a function of molecular mAb concentration was fit using Scientist software using the equation:
2
(00232] In the above equation, F = Geometric mean fluorescence, LT = total molecular mAb concentration, P' = proportionality constant that relates arbitrary lluorescence units to bound mAb, and KD = equilibrium dissociation constant. For each

WO 2008/112003

PCT/US2007/075117

mAb an estimate for KD was obtained as Pr and KD were allowed to float freely in the nonlinear analysis. Table 4 below lists the resulting KDs for each mAb along with the 95% confidence interval of the fit. MAbs are listed in order of decreasing affinity.
TABLE 4

Sample K0(pM) 95% CI (pM)
2.175.3 328 ±202
2.451.1.1 389 ±196
2.449.1.3 (control) 52 ±51
2.449.1.3 53 ±49
2.998.2 57 ±68 (upper CI only)
CD140a 146 ±99
2.84.3 j 227 ±121
Mouse cross-reactivity
|00233| To set up animal xenograft studies, mouse cross-reactivity was determined using FACS analysis performed with N1H3T3 cells, a murine fibroblast line which expresses endogenous PDGFRa. N1H3T3 cells were incubaled at 0.5 X 106 cells/ml with 10 ug/ml of test antibodies on ice for lh, rinsed and then resuspended in PBS with 5 ug/ml of goat-anti-human IgG antibodies labeled with Cy5. Cells were rinsed and analyzed by FACS for the presence of Cy5. Only 3 of the tested monoclonal antibodies exhibited mouse cross-reactivity. Results are summarized in Table 5.
Percent Internalization
[00234] The percentage of antibody being internalized in cells was determined using a standard internalization protocol. Percent internalization results a( 10 ug/ml are summarized in Table 5.
Results
J002351 Results of in vitro screening and data analysis of the 30 cloned monoclonal antibodies are summarized in Table 5. mAbs are listed in order of increasing

WO 2008/112003

PCT/US2007/0751I7

IC50 values. mAbs in italics were selected as the top ten mAbs and antibodies, in boldface were selected as the three lead candidates. "()"denotes ranking in Table 5.
[00236] As can be seen from Table 5, mAb 2.175.3 exhibited exceptional inhibition of PDGF-AA proliferation of MG-63 cells as well as exceptional inhbition of phosphorylation of PDGFR-alpha on MG-63 cells. MAbs 2.449.1.3 and 2.998.2 also inhibited phosphorylation of PDGFR-alpha on MG-63 cells and inhibited PDGF-AA proliferation of MG-63 cells. In addition, mAbs 2.449.1.3 and 2.998.2 also had a high binding affinity for PDGFR-alpha.

WO 2008/112003

PCT/US2007/075117

TABLE 5
PDGFR-ALPHA MONOCLONAL ANTIBODY SUMMARY

Antibody pTyr Assay: % Inhibition
@ 2 ng/ml Proliferation Assay: IC50 ng/ml (1-6-06) Proliferation Assay: IC50 ng/ml (1-23-06) /o
Internalization @ lOpg/ml Mouse-Cross Reactivity Affinity 2.175.3 100 67.3(1) (0.45nM) 56.1(1) (0.37nM) 19% Yes 328pM
2.449.1.3 99 178.6(2) (1.2nM) 236.6 (2) (1.57nM) 20% - 52pM
2.451.J.1 100 399.0 (6) (2.67nM) 283.1 (3) (1.9nM) 21% - 389pM
2.998.2 99 307.6(4) (2.05nM) 315.5(4) (2.1nM) 25% - 57pM
2.84.3 98 192.3(3) (1.3nM) 4S0.9 (8) (3.2nM) 26% - 227pM
2.414.2 99 657.7 (9) (4.4nM) 349.1 (5) (2.3nM) 28% -
5.16.1 99 385.5 (5) (2.57nM) 422.7 (6) (2.8 InM) ' 31% -
3.341.2 100 403.6 (7)
(2.7nM) 471.0(7) (3. InM) 22% -
2.2071.!.3 99 1,276.4(10)
(S.5nM) 492.0 (9) (3.3nM) 21% -
2.737.1.4 99 550.8 (8) (3.7nM) 558.5(10) (3.73nM) 22% -
2.796.2 99 497.7 756.8 19% -
2.542.2 99 1037.5 651.6 26% -
2.351.3 97 1,078.9 648.6 21% -
2.1623.2 97 755.1 981.7 46% Yes
2.1853.3 98 1,122.0 2679.2 30% Yes
3.818.4 92 4,602.6 -
3.457.3.1 85 - -
3.23.3 84 61.9 -
5.1.1.1 77 > 10 ng/mL -
4.16.2 74 > 10 Mg/niL -
3.87.1.1 69 6,237.3 -
2.1576.1.2 65 > 10 ng/mL -
3.472.1.1 61 - -
3.805.1.3 58 1,016.2 -
3.772.2 56 167.9
5.9.3 31 2.2 1
!

WO 2008/112003 PCT/US2007/075117

3.23.2 26 150.3 -
2.1954.2 -3 - -
3.625.1.7 -3 3819.44 -
2.2002.3 -9 - -

WO 2008/112003

PCT/US2007/075U7

EXAMPLE 7 STRUCTURAL ANALYSIS OF ANTI-PDGFR-ALPHA ANTIBODIES
(00237] The heavy and light chain variable domains of the antibodies were sequenced to detennine their DNA sequences. The complete sequence information for the anti-PDGFR-alpha antibodies is provided in the sequence listing with nucleotide and amino acid sequences for each gamma and kappa chain combination. The variable heavy sequences were analyzed to detennine the VH family, the D-region sequence and the J-region sequence. The sequences were then translated to determine the primary amino acid sequence and compared to the germline VH, D and J-region sequences to assess somatic hypermutations. "-" indicates identity with the germline sequence. ll#:; indicates an additional amino acid in the antibody sequences that is not found in the germline.
(00238[ Tabic 12 is a table comparing the antibody heavy chain regions to their cognate germline heavy chain region. Table 13 is a table comparing the antibody kappa light chain regions to their cognate germline light chain region.
[00239] The variable (V) regions of immunoglobulin chains are encoded by multiple germline DNA segments, which are joined into functional variable regions (VHDJH or VKJK) during B-cell ontogeny.
(00240) It should also be appreciated that where a particular antibody differs from its respective germline sequence at the amino acid level, the antibody sequence can be mutated back to the germline sequence. Such corrective mutations can occur at one, two, three or more positions, or a combination of any of the mutated positions, using standard molecular biological techniques. By way of non-limiting example. Table 12 shows thai the heavy chain sequence of mAb 2.175.3 (SEQ ID NO.: 2) differs from the corresponding germline sequence inter alia through a Q to H mutation (mutation 1) in the FR1 region, a S to H mutation (mutation 2) in die CDRl region, and a S to R mutation (mutation 3) in the CDR2 region. Thus, the amino acid or nucleotide sequence encoding the heavy chain of mAb 2.175.3 can be modified to change mutation 1 to yield the germline sequence at the site of mutation 1. Further, the amino acid or nucleotide sequence encoding the heavy chain of mAb 2.175.3 can be modified to change mutation 2 or mutation 3 to yield the genu line sequence at the site of mutation 2 or mutation 3. Indeed the amino acid or nucleotide sequence encoding the heavy chain of mAb 2.175.3 can encompass any combination of two

WO 2008/112003

POVUS2007/075117

or more mutations lo yield the germline sequence at those particular sites. Tables 6-11 below illustrate the position of such variations from the germline for mAb 2.175.3, 2.449.1.3 and 2.998.2. Each row represents a unique combination of germline and non-gennline residues at the positions indicated. In the event of a discrepancy between the sequence listing and tables 6-1 J, the information provided in the table takes precedence.
Table 6. Exemplary Mutations of mAb 2.175.3 Heavy Chain (SEQ ID NO: 2) to Germline at
the Indicated Residue Number.

3 35 53 57 61 80 99 100 101 106
0 S s T A Y DELETED DELETED DELETED DELETED
0 s ! s T A Y DELETED DELETED DELETED P
0 s s T A | Y DELETED DELETED P JDELETED
0 s s T A Y DELETED DELETED P P
0 s s T A Y DELETED G DELETED DELETED
0 s s T A Y DELETED G DELETED P
0 s s T A Y DELETED G P DELETED
0 s s T A Y DELETED G P P
0 s s T A Y G DELETED DELETED DELETED
0 s s T A Y G DELETED DELETED P
0 s s T A Y G DELETED P DELETED
0 s s T A Y G DELETED P P
0 s s T A Y G G DELETED DELETED
Q s s T A Y G G DELETED P
0 s s T A Y G G P DELETED
0 s s T A Y G G P P
0 s s T ■A | N DELETED DELETED DELETED DELETED
0 s s T A ! N DELETED DELETED DELETED P
0 s s T A ! N DELETED DELETED P DELETED
0 s s T A N DELETED DELETED P P
0 s s T A N DELETED G DELETED DELETED
0 s s T A N DELETED G DELETED P
0 s s T A N DELETED G P DELETED
0 s s T A N DELETED G P P
0 s s T A N G DELETED DELETED DELETED
0 s s T A N G DELETED DELETED P
0 s s T A N G DELETED P DELETED
Q s s T A N G DELETED P P
0 s s T A N G G DELETED DELETED
Q s s T A N G ! G DELETED P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 i 106
0 S s T A N G G P (DELETED
0 S s T . A N G G p ! P
0 S s T V Y DELETED DELETED DELETEDIDELETED
0 s s T V Y DELETED DELETED DELETED P
0 s s T V Y DELETED DELETED P DELETED
0 s s T V Y DELETED DELETED P P
0 s s T V Y DELETED G DELETED DELETED
0 s s T V Y DELETED G DELETED P
0 s s T V Y DELETED G P DELETED
0 s s T V Y DELETED G P P
0 s s T V Y G DELETED DELETED DELETED
0 s s T V Y G DELETED DELETED P
0 s s T V Y G DELETED P DELETED
0 s s T V Y G DELETED P P
0 s s T i V Y G G DELETED DELETED
0 s S _| T V Y G G DELETED P
0 s s T V Y G G P DELETED
Q s s T V Y G G P P
0 s s T V N DELETED DELETED DELETED DELETED
0 s s T V N DELETED DELETED DELETED P
Q s s T V N DELETED DELETED P DELETED
0 s ■s T V N DELETED DELETED P P
0 s s T V 1 N DELETED G DELETED DELETED
0 s s T v ! N DELETED G DELETED P
0 s ' S T V N DELETED G P DELETED
0 s s T V N DELETED G P P
0 s s T V N G DELETED DELETED DELETED
Q s s T V N G DELETED DELETED P
0 s s T V N G DELETED P DELETED
0 s s T V N G DELETED P P
0 s s T V N G G DELETED DELETED
0 s s T V N G G DELETED P
0 s s T V N G G P DELETED
0 s s T V N G G P P
0 s s L A Y DELETED DELETED DELETED DELETED
0 s s L A Y DELETED DELETED DELETED P
Q s s L A Y DELETED DELETED P DELETED
Q s s L A Y DELETED DELETED P P
Q s ■ s L A Y DELETED G DELETED DELETED
Q s s L A Y DELETED G DELETED P
Q s s L A Y DELETED G P IDELETED
Q s s L A Y DELETED G P | P

WO 2008/1120(13

PCI7US2007/075117

3 35 53 57 61 80 99 100 101 i 106
0 S s L A Y G DELETED DELETED DELETED
0 S s L A Y G DELETED DELETED P
0 S s L A Y G DELETED P DELETED
0 S s L A Y G DELETED P P
Q S s L A Y G G DELETED DELETED
0 S s L A Y G G DELETED P
0 s s L A Y G G P DELETED
Q s s L A Y G G P P
0 s s L A N DELETED DELETED DELETED DELETED
0 s s L A N DELETED DELETED DELETED P
0 s s L A N DELETED DELETED P DELETED
0 s s L A N DELETED DELETED P P
0 s s L A N DELETED G DELETED DELETED
0 s s L A N DELETED G DELETED P
0 s s L A N DELETED G I P DELETED]
0 s s L A N DELETED G | P P !
0 s s L A N G DELETED DELETED DELETED!
0 s s L A N G DELETED DELETED P
0 s s L A N G DELETED P DELETED
0 s s L A N G DELETED P P
0 s s L A N G G DELETED DELETED
0 s s L A N G G DELETED P
Q s s L A N G G P DELETED
0 s s L A N G G P ; P
Q s s L V Y DELETED DELETED DELETEDiDELETED
0 s s L V Y DELETED DELETED DELETED P
0 s s L V Y DELETED DELETED P DELETED
0 s s L V Y DELETED DELETED P P
0 s s L V Y DELETED G DELETED DELETED
Q s s L V Y DELETED G DELETED P
0 s s L V Y DELETED G P DELETED
0 s s . L V Y DELETED G P P
0 s- s L V Y G DELETED DELETED DELETED
Q s s L V Y G DELETED DELETED P
0 s s L V Y G DELETED P DELETED
0 s s L V Y G DELETED P P
0 s s L V Y G G DELETED DELETED
0 s s L V Y G G DELETED P
Q s s L V Y G G P DELETED
0 s s L V Y G G P P
0 s s L V N DELETED DELETED DELETED DELETED
Q s s L V N DELETED DELETED DELETED P

PCT/OS2rt07/O75li7

3 35 53 57 61 80 99 100 101 106
0 s s L V N DELETED DELETED P DELETED
0 s s L V N DELETED DELETED P P
0 s s L V N DELETED G DELETED DELETED
0 s s L V N DELETED G DELETED P
0 s s L V N DELETED G P DELETED
0 s S L V N DELETED G P P
0 s S L V N G DELETED DELETED DELETED
0 s S L V N G DELETED DELETED P
0 s S L V N G DELETED P DELETED
0 s S L V N G DELETED P P
Q - ■ s . S L V N G G DELETEDDELETED
0 s S L V N G G DELETED; P
Q s s L V N G G P DELETED
0 s s L V ! N G G P P
0 s R T A J Y DELETED|DELETED DELETED DELETED
0 s R T A i Y DELETED DELETED DELETED P
0 s R T A | Y DELETED DELETED P DELETED
0 s R T A t Y DELETED DELETED P P
0 s R T A ! Y DELETED G DELETED DELETED
0 s R T A Y DELETED G DELETED P
0 s R T A Y DELETED G P DELETED
0 s R T A Y DELETED G P P
0 s R T A Y G DELETED DELETED DELETED
0 s R T A Y G DELETED DELETED P
0 s R T A Y G DELETED P DELETED
0 s R T A Y G DELETED P P
0 s R T A Y G G DELETED DELETED
0 s R T A Y G G DELETED P
0 s R T A Y G G P DELETED
0 s R T A Y G G P P
0 s R T A N ' DELETED DELETED DELETED DELETED
0 s R T A N DELETED DELETED DELETED P
0 s R T A N DELETED DELETED P iDELETED
0 s R T A N DELETED DELETED P P
0 s R T A N DELETED G DELETED DELETED
0 s R T A N DELETED G DELETED P
0 s R T A N DELETED G P DELETED
0 s R T A N DELETED G P P
0 s R T A N G DELETED DELETED DELETED
0 s R T A N G DELETED DELETED P
0 s R T A N G DELETED P DELETED
0 s R T A N G DELETED P P

WO 2008/112003

PCTAJS2007/075117

3 35 53 57 61 80 99 100 101 106
0 S R T A N G G DELETED DELETED
0 S R T A N G G DELETED P
0 s R T A N G G P DELETED
Q s R T A N G G P P
0 s R T V Y DELETED DELETED DELETED DELETED
0 s R T V Y DELETED DELETED DELETED P
0 s R T V Y DELETED DELETED P DELETED
0 s R T V Y DELETED DELETED P P
0 s R T V Y DELETED G DELETED DELETED
0 s R T V Y DELETED G DELETED P
0 s R T V Y DELETED G P DELETED
0 S 1 R T V Y DELETED G P P
0 S | R T V Y G DELETED DELETED DELETED
0 S _j R T V Y G DELETED DELETED P
0 s R T V Y G DELETED P DELETED
0 s R T V Y G DELETED P P
0 s R T V Y G G DELETED DELETED
Q s R T V Y G G DELETED P
0 s R T V Y G G P DELETED
0 s R T V Y G G P P
0 s R T V N DELETED DELETED DELETED DELETED
Q s R T V N DELETED DELETED DELETED P
0 s R T V | N DELETED DELETED P DELETED
0 s R T V 1 N DELETED DELETED P P
0 s R T V ! N DELETED G DELETED DELETED
0 s R T V N DELETED G DELETED P
0 s R T V N DELETED G P DELETED
0 s R T V N DELETED G P P
0 S ! R T V 'N G DELETED DELETED DELETED
0 s ! R T V N G DELETED DELETED P !
0 S ! R T V N G DELETED P DELETED
0 s R T V N G DELETED P P
0 s R T V N G G DELETED DELETED
0 s R T V N G G DELETED P
Q s R T V N G G P DELETED
0 s R T V N G G P P
0 s R L A Y DELETED DELETED DELETED DELETED
0 s R L A Y DELETED DELETED DELETED P
0 s R L A Y DELETED DELETED P DELETED
Q s R L A Y DELETED DELETED P P
0 s R L A 1 Y DELETED G DELETED DELETED
Q s R L A | Y DELETED G DELETED P

WO 2008/112003

PCT/US2007/075117

3 35 S3 57 61 80 99 100 101 | 106
0 S R L A Y DELETED G P JDELETED
0 S R L A Y DELETED G P P
0 S R L A Y G DELETED DELETED DELETED
0 S R L A Y G DELETED DELETED P
0 S R L A Y G DELETED P DELETED
0 S R L A Y G DELETED P P
0 S R L A Y G G DELETED DELETED
0 S R L A Y G G DELETED P
0 S R L A Y G G P DELETED
Q S R L A Y G G P P
0 S R L A N DELETED DELETED DELETED DELETED
0 S R L A I N DELETED DELETED DELETED P
0 S R L A ! N DELETED DELETED P DELETED
0 S R
"R" L A N DELETED DELETED P P
0 S
L A 1 N DELETED G DELETED DELETEDj
0 S R . L A N DELETED G DELETED P
0 S R L A N DELETED G P DELETED
0 S R L A N DELETED G P P
0 s R L A N G DELETED DELETED DELETED
0 s R L A N G DELETED DELETED P
0 S j R L A N G DELETED P DELETED
0 S R L A N G DELETED p ! p
0 s R L A N G G DELETEDIDELETED
0 s R L A N G G DELETED: P
0 s R L A N G G P jDELETED
0 s R L A N G G P P
0 s R L V Y DELETED DELETED DELETED DELETED
9 s R L V Y DELETED DELETED DELETED P
0 s R L V Y DELETED DELETED P jDELETED
Q s R L V Y DELETED DELETED P P
0 s R L V Y DELETED G DELETED DELETED
0 s R L V Y DELETED G DELETED P
0 s R L V Y DELETED G P DELETED
0 s R L V Y DELETED G P P
0 s R L V Y G DELETED DELETED DELETED
0 s R L V Y G DELETED DELETED P
Q s R L V Y G DELETED P DELETED
0 s R L V Y G DELETED P P
0 s R L V Y G G DELETED DELETED
Q s R L V Y G G DELETED P
0 s R L V Y G G P DELETED
Q s R L V Y G G P j P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 106
0 s R L V N DELETED DELETED DELETED DELETED
0 s R L V N DELETED DELETED DELETED P
0 s R L V N DELETED DELETED P DELETED
0 s R L V N DELETED DELETED P P
0 s R L V N DELETED G DELETED DELETED
0 s R L V N DELETED G DELETED P
0 s R L V N DELETED G P DELETED
0 s R L V N DELETED G P P
0 s R L V N G DELETED DELETED DELETED
0 s R L V N G DELETED DELETED , P
0 s R L V N G DELETED P DELETED
0 s R L V N G DELETED P P
0 s R L V N G G DELETED DELETED
0 s R
R L L V N G G DELETED! ' p
0 s

V N G G p IDELETED
0 s R L V | N G G p P
0 H S T A Y DELETED DELETED DELETED DELETED
0 H S T A Y DELETED DELETED DELETED P
0 H s T A Y DELETED DELETED p DELETED
Q H s T A 1 Y DELETED DELETED p P
0 H s T A ! Y DELETED G DELETED DELETED
0 H s T A Y DELETED G DELETED P
0 H s T A Y DELETED G P DELETED
0 H s T A Y DELETED G P P
0 H s T A Y G DELETED DELETED DELETED
0 H s T A Y G DELETED DELETED P
0 H s T A Y G DELETED P DELETED
0 H s T A Y G DELETED P P !
0 H s T A Y G G DELETED DELETED:
0 H s T A Y G G DELETED P .
0 H s T A Y G G P DELETED
0 H s T A Y G G P P
0 H s T A N DELETED DELETED DELETED DELETED
0 H S - T A N DELETED DELETED DELETED P
0 H s T A N DELETED DELETED P DELETED
0 H s T A N DELETED DELETED P P
0 H s T A N DELETED G DELETED|DELETED
0 H s T A N DELETED G DELETED! P
0 H s T A N DELETED G P IDELETED
0 H s T A N DELETED G P ip
0 H s T A N G DELETED DELETED|DELETED
Q H s T A N G DELETED DELETED P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 106
Q H S T A N G DELETED P DELETED
0 H S T A N G DELETED P P
0 H S T A N G G DELETED DELETED
0 H s T A N G G DELETED P
0 H s 1 T_ A N G G P DELETED
0 H s T A N G G P P
Q H s T V Y DELETED DELETED, DELETED DELETED,
0 H s T V Y DELETED DELETED DELETED P
0 H s T V Y DELETED DELETED P DELETED
0 H s T V Y DELETED DELETED P P
0 H s T V Y DELETED G DELETED DELETED
0 H s T V Y DELETED G DELETED P
0 H s T V Y DELETED G P DELETED
0 H s T V Y DELETED G P P
0 H s T V Y G DELETED DELETED DELETED
0 H s T V Y G DELETED DELETED P
0 H s T V Y G DELETED P DELETED
0 H s T V Y G DELETED P P
Q H s T V Y G G DELETED DELETED
0 H s T V Y G G DELETED P
0 H s T V Y G G P DELETED
Q H s T V Y G G P P
Q H s T V N DELETED DELETED DELETED DELETED
0 H s T V N DELETED DELETED DELETED P
0 H s T V N DELETED DELETED P DELETED
0 H s T V N DELETED DELETED P P
0 H s T V N DELETED G DELETED|DELETED
Q H s T V N DELETED G DELETED! P
0 H s T V N DELETED G P DELETED
Q H s T V N DELETED G P P
■Q H s T V N G DELETED DELETED DELETED
0 H s T V N G DELETED DELETED P
0 H s T V N G DELETED P DELETED
Q H s T V N G DELETED P P
0 H s T V N G G DELETED DELETED
0 H s T V N G G DELETED P
0 H s T V N G G P DELETED
Q H s T V N G G P P
Q H s L A Y DELETED DELETED DELETED DELETED
Q H s L A Y DELETED DELETED DELETED ■ P
0 H s _L_J A Y DELETED DELETED P DELETED
Q H ! S L A Y DELETED DELETED P P

WP P*/J J ?oO? F£?/i|$W»W»wt i 1

WO 2008/112003

PCT/US2007/07S117

3 35 53 57 61 80 99 100 101 106
0 H S L V Y G G P DELETED
0 H s L V Y G G P P
0 H s L V N DELETED DELETED DELETED DELETED
0 H s L V N DELETED DELETED DELETED P
0 H s L V N DELETED DELETED P DELETED
0 H s L V N DELETED DELETED P P
0 H s L V N DELETED G DELETED DELETED
0 H s L V N DELETED G DELETED P
0 H s L V N DELETED G P DELETED
0 H s L V N DELETED G P . P
0 H s L V N G DELETED DELETED DELETED
0 H s L V N G DELETED DELETED P
0 H s L V N G DELETED P DELETED
0 H s L V | N G DELETED P P
0 H s L V N G G DELETED DELETED:.
0 H s L V : N G G DELETED p I
0 H s L V j N G G P DELETED
0 H s L V j N G G P P
0 H R T A Y DELETED DELETED DELETED DELETED
0 H R T A Y DELETED DELETED DELETED P
0 H R T A Y DELETED DELETED P DELETED
Q H R T A Y DELETED DELETED P P
0 H R T A Y DELETED G DELETED DELETED
0 H R T A Y DELETED G DELETED P
0 H R T A Y DELETED G P DELETED
0 H R T A Y DELETED G P P
0 H R T A Y G DELETED DELETED DELETED
0 H R T A Y G DELETED DELETED P
0 H R T A Y G DELETED P DELETED
0 H R T A Y G DELETED P P
0 H R T A Y G G DELETED DELETED
0 H R T A Y G G DELETED P
Q H R T A Y G G P DELETED
0 ' H R T A Y G G P P
0 H R T A N DELETED DELETED DELETED DELETED
0 H R T A N DELETED DELETED DELETED P
0 H R T A N DELETED DELETED P DELETED
Q H R T A N DELETED DELETED P P
0 H R T A N DELETED G DELETED DELETED
Q H R T A N DELETED G DELETED P
0 H R T A N DELETED G P DELETED
Q H R T A N DELETED G P P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 106
Q H R T A N G DELETED DELETED DELETED
Q H R T A N G DELETED DELETED P
Q H R T A N G DELETED P DELETED
Q H R T A N G DELETED P P
Q H R T A N G G DELETED DELETED
Q H R T A N G G DELETED P
Q H R T A N G G P DELETED
Q H R T A | N G G P P
Q H R T V | Y DELETED DELETED DELETED DELETED
Q H R T V Y DELETED DELETED DELETED P
Q H R T V Y DELETED DELETED P DELETED
0 H R T V Y DELETED DELETED P P
0 H R T V Y DELETED G DELETED DELETED
Q H R T V Y DELETED G DELETED P !
0 H R T V Y DELETED G P DELETED-
Q H R T V Y DELETED G p i P
Q H R T V Y G DELETED DELETEDiDELETED
Q H R T V Y G DELETED DELETED! P
Q H R T V Y G DELETED P DELETED
Q H R T V Y G DELETED P P
Q H R T V Y G G DELETED DELETED
Q H R T V Y G G DELETED P
Q H R T V Y G G P DELETED
Q H R T V Y G G P P
Q H R T v ..- N DELETED DELETED DELETED DELETED
Q H R T 'V N DELETED DELETED DELETED P
Q H R T V N DELETED DELETED P DELETED
Q H R T V N DELETED DELETED P P
Q H R T V 1 N DELETED G DELETED DELETED
Q H R T V t N DELETED G DELETED P
0 H R T V N DELETED G P DELETED
Q H R T V N DELETED G P P
Q H R T V N G DELETED DELETED DELETED
Q H R T V N G DELETED DELETED P
Q H R T V N G DELETED P DELETED
Q H R T V N G DELETED P P
Q H R T V N G G DELETED DELETED
Q H R T V N G G DELETED P
Q H R T V N G G P DELETED
Q H R T V N G G P P
Q H R L A Y DELETED DELETED DELETEDiDELETED
Q 1 H R L A Y DELETED DELETED DELETED! P

PCT/US2007/075U7

3 35 53 57 61 80 99 100 101 106
0 H R L A | Y DELETED DELETED P DELETED
Q H R L A Y DELETED DELETED P P
0 H R L A Y DELETED G DELETED DELETED
0 H R L A Y DELETED G DELETED P
0 H R L A Y DELETED G P DELETED
Q H R L A Y DELETED G P P
0 H R L A Y G DELETED DELETED DELETED
0 H R L A Y G DELETED DELETED P
Q H R L A Y G DELETED P DELETED
Q H R L A Y G DELETED P P
0 H R L A Y G G DELETED DELETED
Q H R L A Y G G DELETED P
0 H R L A Y G G P DELETED
0 H R L A Y G G P P
0 H R L A N DELETED DELETED DELETED DELETED
Q H R L A N DELETED DELETED DELETED: p
0 H R L A N DELETED DELETED P DELETED
0 H R L A N DELETED DELETED P P
0 H R L A N DELETED G DELETED DELETED
0 H R L A N DELETED G DELETED P
0 H R L A N DELETED G P DELETED
0 H R L A N DELETED G P P
0 H R L A N G DELETED DELETED DELETED
0 H R L A N G DELETED DELETED P
0 H R L A N G DELETED P DELETED
0 H R L A N G DELETED P P
0 H R L A N G G DELETED DELETED
Q H R L A N G G DELETED P
0 H R L A N G G P DELETED
Q H R L A N G G P P
0 H R L V Y DELETED DELETED DELETED DELETED
0 H R L V Y DELETED DELETED DELETED P
0 H R L V Y DELETED DELETED P DELETED
Q H R L V Y DELETED DELETED P P
0 H R L V Y DELETED G DELETED DELETED
0 H | R L V Y DELETED G DELETED P
Q H R L V Y DELETED G P DELETED
0 H R L V Y DELETED G P P
0 H R L V Y G DELETED DELETED DELETED
0 H R L V Y G DELETED DELETED P
0 H R L V Y G DELETED P DELETED
Q H R L V Y G DELETED P P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 | 106
0 H R L V Y G G DELETEDJDELETED
0 H R L V Y G G DELETED P
0 H R L V Y G G P DELETED
0 H R L V Y G G P P
0 H R L V N DELETED DELETED DELETED DELETED
0 H R L V N DELETED|DELETED DELETED P
0 H R L V N DELETED DELETED P DELETED
0 H R L V N DELETED DELETED P P
0 H R L V N DELETED G DELETED DELETED
0 H R L V N DELETED G DELETED P
0 H R L V N DELETED G P DELETED
0 H ' R L V N DELETED G P P
Q H R L V N G DELETED DELETED DELETED
0 H R L L V N G DELETED DELETED P
0 H i R
V N G DELETED P DELETED'
0 H j R L V N ! G DELETED P P ;
0 H ! R L V N G G DELETED DELETED
0 H ! R L V N G G DELETED P
0 H R L V N G G P DELETED
0 H R L V N G G P P
H S S T A Y DELETED DELETED DELETED DELETED
H S S T A Y DELETED DELETED DELETED P
H s S T A Y DELETED DELETED P DELETED
H s S T A Y DELETED DELETED P P
H s s T A Y DELETED G DELETED DELETED
H s s T A - Y DELETED G DELETED P
H s s T A | Y DELETED G P DELETED
H s s T A \ Y DELETED G j P P
H s s T A j Y G DELETEDjDELETED DELETED
H s s T A j Y G DELETED DELETED P
H s s T A Y G DELETED P DELETED
H s s T A Y G DELETED P, P
H s s T A Y G G DELETED DELETED
H s s T A Y G G DELETED P
H s s T A Y G G P DELETED
H s s T A Y G G P P
H s s T A N DELETED DELETED DELETED DELETED
H s s T A N DELETED DELETED DELETED P
H s s T A N DELETED DELETED P DELETED
H s s T A N DELETED DELETED P P
H s s T A N DELETED G DELETED DELETED
H s s T A N DELETED G DELETED P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 106
H S s T A i N DELETED G P DELETED
H S s T A N DELETED G P P
H s s T A N G DELETED DELETED DELETED
H s s T A N G DELETED DELETED P
H s s T A N G DELETED P DELETED
H s s T A N G DELETED P P
H s s T A N G G DELETED DELETED
H s s T A N G G DELETED P
H s s T A N G G P DELETED
H s s T A N G G P P
H s s T V Y DELETED DELETED DELETED DELETED
H s s T V Y DELETED DELETED DELETED P
H s s T V Y DELETED DELETED P DELETED
H s s T V Y DELETED DELETED P P
H s s T V Y DELETED G DELETEDJDELETED
H s s T ; v Y DELETED G DELETEDj P
H s s T V Y DELETED G P (DELETED
H s s T V Y DELETED G P ' P
H s s T V Y G DELETED DELETED DELETED
H s s T V Y G DELETED DELETED P
H s s T V Y G DELETED P DELETED
H s s T V Y G DELETED P P
H s s T V Y G G DELETED DELETED
H s s T V Y G G DELETED P
H s s T V Y G G P DELETED
H s s T V Y G G P P !
H s s T V N DELETED DELETED DELETED DELETED
H s s T V N DELETED DELETED DELETED P
H s s T V N DELETED DELETED P DELETED
H s s T V N DELETED DELETED P P
H s s T V N DELETED G DELETED DELETED
H s s • T V N DELETED G DELETED P
H s s T V N DELETED G P DELETED
H s s T V N DELETED G P P
H s s T V N G DELETED DELETED DELETED
H s s T V N G DELETED DELETED P
H s s T V N G DELETED P DELETED
H s s T V' N G DELETED P P
H s s T V N G G DELETEDJDELETED
H s s T V N G G DELETED! P
H s s T V N G G P DELETED
H s s T V N G G P P

WO 2008/112003 PCT/US2007/075117

3 35 53 57 61 80 99 100 101 106
H S s L A Y DELETED DELETED DELETED DELETED
H S s L A Y DELETED DELETED DELETED P
H s s L A Y DELETED DELETED P DELETED
H s s L A Y DELETED DELETED P P
H s s L A Y DELETED G DELETED DELETED
H s s L A Y DELETED G DELETED P
H s s L A Y DELETED G P DELETED
H s s L A Y DELETED G P P
H s s L A Y G DELETED DELETED DELETED
H s s L A Y G DELETED DELETED P
H s s L A Y G DELETED P DELETED
H s s L A Y G DELETED P P
H s s L A Y G G DELETED DELETED
H s s L A Y G G DELETED P
H s s L A Y G G P DELETED
H s s L A ! Y G G P P
H s s L A N DELETED DELETED DELETED DELETED
H s s L A N DELETED DELETED DELETED P
H s s L A N DELETED DELETED P DELETED
H s s L A N DELETED DELETED P P
H s s L A N DELETED G DELETED DELETED
H s s L A N DELETED G DELETED P
H s s L L_ A N DELETED G P DELETED
H s s L A N DELETED G | P P
H s s L A N G DELETED DELETED DELETED
H s s L A N G DELETED DELETED P
H s s L A N G DELETED P DELETED
H s s L A N G DELETED P P
H s s L A N G G DELETED DELETED
H s s L A N G G DELETED P
H s s L A N G G P DELETED
H s s L A N G G P P
H s s L V Y DELETED DELETED DELETED DELETED
H s s L V Y DELETED DELETED DELETED P
H s s L V Y DELETED DELETED P DELETED
H s s L V Y DELETED DELETED P P
H s s L V Y DELETED G DELETED DELETED
H s s L V Y DELETED G DELETED P
H s s L V Y DELETED G P DELETED
H s s L V Y DELETED G P P
H s s L V Y G DELETED DELETED DELETED
H s s L V Y G DELETED DELETED P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 106
H S s L V Y G DELETED P DELETED
H S s L V Y G DELETED P P
H s s L V j Y G G DELETED DELETED
H s s L V Y G G DELETED P
H s s L V 1 Y G G P DELETED
H s s L V Y G G P P
H s j s L V N DELETED DELETED DELETED DELETED
H s s L V N DELETED DELETED DELETED P
H s s L V N DELETED DELETED P DELETED
H s s L V N DELETED DELETED P P
H s s L V N DELETED G DELETED DELETED
H s s L V N DELETED G DELETED P
H s s L V N DELETED G P DELETED
H s s L V N DELETED G P i P
H ! S s L V N G DELETED DELETE DlDELETED
H I S j S L V N G DELETED DELETED; P
H|S S L V N G DELETED P iDELETED
H s s L V N G DELETED p ! p
H s s L V N G G DELETED DELETED
H s s ' L V N G G DELETED P
H s s L V N G G P DELETED
H s s L V N G G P P
H s R T A Y DELETED DELETED DELETED DELETED
H s R T A Y DELETED DELETED DELETED! P
H s R T A Y DELETED DELETED P DELETED
H s R T A Y DELETED DELETED P P
H s R T A Y DELETED G DELETED DELETED
H s R T A Y DELETED G DELETED P
H s R T A Y DELETED G P DELETED
H s R T A Y DELETED G P P
H s R T A Y G DELETED DELETED DELETED
H s R T A Y G DELETED DELETED ■P
H s R T A ■ Y - -G -- DELETED P DELETED
H s R T A Y G DELETED P P
H s R T A Y G G DELETED DELETED
H s R T A Y G G DELETED P
H s R T A Y G G P DELETED
H s R T A Y G G P P
H s R T A N DELETED DELETED DELETED DELETED
H s R T A N DELETED DELETED DELETED P
H s R T A N DELETED DELETED P DELETED
H s R T A N DELETED DELETED P P

WO2008/H2003

PCT/US2007/0751I7

3 35 53 57 61 80 99 100 101 106
H S R T A N DELETED G DELETED DELETED
H S R T A N DELETED G DELETED P
H s R T A N DELETED G P DELETED
H s R T A N DELETED G P P
H S 1 R T A N G DELETED DELETED DELETED
H s R T A N G DELETED DELETED P
H s R T A N G DELETED P DELETED
H s R T A N G DELETED P P
H s R T A N G G DELETED DELETED
H s R . T A N G G DELETED P
H s R T A N G G P DELETED
H s R T A N G G P P
H s R T V Y DELETED DELETED DELETED DELETED
H s R T V Y DELETED DELETED DELETED P !
H s R T V Y DELETED DELETED P DELETED!
H S ! R T V j Y DELETED DELETED P P
H s R T V Y jDELETED G DELETED DELETED
H s R T V Y DELETED G DELETED p
H s R T V Y DELETED G P DELETED
H s R T V Y DELETED G P P
H s R T V Y G DELETED DELETED DELETED
H s R T V Y G DELETED DELETED P
H s R T V Y G DELETED P DELETED
H s R T V Y G DELETED P P
H s R T V Y G G DELETED DELETED
H s R T V Y G G DELETED P
H s R T V Y G G P DELETED
H s R T V Y G G P P
H s R T V N DELETED DELETED DELETED DELETED
H s R T V N DELETED DELETED DELETED P
H s R T V N DELETED DELETED P DELETED
H s R T V N DELETED DELETED P P
H s R T V N DELETED G DELETED DELETED
H s R T V N DELETED G DELETED! P
H • s R T V N DELETED G P !DELETED
H s R T V N DELETED G P I P
H s R T V N G DELETED DELETED|DELETED
H s R T V N G DELETED DELETED P
H s R T V N G DELETED P DELETED
H s R T V N G DELETED P P
H s R T V i N G G DELETED DELETED
H s R T V N G G DELETED P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 I 99 | 100 101 | 106
H S R T V N G G P JDELETED
H S R T V N G G P P
H s R L A Y DELETED DELETED DELETEDlDELETED
H s R L A Y DELETED DELETED DELETED P
H s R L A Y DELETED DELETED P DELETED
H s R L A Y DELETED DELETED P P
H s R L A Y DELETED G DELETED DELETED
H s R L A Y DELETED G DELETED P
H s R L A Y DELETED G P DELETED
H s R L A Y DELETED G P P
H s R L A Y G DELETED DELETED DELETED
H s R L A Y G DELETED DELETED P
H s R L A Y G DELETED P DELETED
H s R L A Y G DELETED P P !
H s R L A Y G G DELETED DELETED
H s R L A ! Y G G DELETED! P
H s R L A Y G G P DELETED
H s R L A Y G G P P
H s R L A N DELETED DELETED DELETED DELETED
H s R ' L A N DELETED DELETED DELETED P
H s R L A N DELETED DELETED P DELETED
H s R L A N DELETED DELETED P i P
H s R L A N DELETED G DELETEDlDELETED
H s R L A N DELETED G DELETED! p
H s R L A N DELETED G P DELETED
H s R L A N DELETED G P P
H s R L A N G DELETED DELETED DELETED
H s R L A N G DELETED DELETED P
H s R L A N G DELETED P DELETED
H s R L A N G DELETED P P
H s R L A N G G DELETED DELETED
H s R L A N G G DELETED P
H s R L A N G G P DELETED
H s R L A N G G P. P
H s R L V Y DELETED DELETED DELETED DELETED
H s R L V Y DELETED DELETED DELETED P
H s R L V Y DELETED DELETED P DELETED
H s R L V Y DELETED DELETED P P
H s R L V Y DELETED G DELETED DELETED
H s R L V Y DELETED G DELETED P
H s R L V Y DELETED G P DELETED
H s R L V Y DELETED G P P

WO 2008/112003

PCT/US2007/075117

wo Hmnmm

PCt/US20df/0?Sl1f

3 35 53 57 61 80 99 100 101 106
H H S T A N DELETED DELETED P DELETED
H H S T A N DELETED DELETED P P
H H S T A N DELETED G DELETED DELETED
H H S T A N DELETED G DELETED P
H H S T A N DELETED G P DELETED
H H S T A N DELETED G P P
H H S T A N G DELETED DELETED DELETED
H H S T A N G DELETED DELETED P
H H S T A N G DELETED P DELETED
H H s T A N G DELETED P P
H H s T A N G G DELETED DELETED
H H s T A N G G DELETED P
H H s T A N G G P DELETED
H H s T A N G G P 1 P
H H s T V Y DELETED DELETED DELETEDDELETED
H H s . T V Y DELETED DELETED DELETED: P
H H s T V Y DELETED DELETED P (DELETED
H H s T V Y DELETED DELETED P P
H H s T V Y DELETED G DELETED DELETED
H H s T V Y DELETED G DELETED P
H H s T V Y DELETED G P DELETED
H H s T V Y DELETED G P P
H H s T V Y G DELETED DELETED DELETED
H H s T V Y G DELETED DELETED P
H H s T V Y G DELETED P DELETED
H H s T V Y G DELETED P P
H H s T V Y G G DELETED DELETED
H H s T V Y G G DELETED P
H H s T V Y G G P DELETED
H H s T V Y G G P P ■
H H s T V N DELETED DELETED DELETED DELETED
H- H s T V N DELETED DELETED DELETED P
H H s T V N DELETED DELETED P DELETED
H H s T V N DELETED DELETED P P
H H s T V N DELETED G DELETED DELETED
H H s T V N DELETED G DELETED P
H H s T V N DELETED G P DELETED
H H s T V N DELETED G P P
H H s T V N G DELETED DELETED DELETED
H H s T V N G DELETED DELETED P
H H s T V N G DELETED P DELETED
H H s T V N G DELETED P P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 I 61 80 99 100 101 106
H H S T V N G G DELETED DELETED
H H S T V N G G DELETED P
H H s T V N G G P DELETED
H H s T V N G G P P
H H s L A _, Y DELETED DELETED DELETED DELETED
H H s L A Y DELETED DELETED DELETED P
H H s L A Y DELETED DELETED P DELETED
H H s L A Y DELETED DELETED P P
H H s L A Y DELETED G DELETED DELETED
H H s L A Y DELETED G DELETED P
H H s L A Y DELETED G P DELETED
H H s L A Y DELETED G P P
H H s L A Y G DELETED DELETED DELETED
H H s L A Y G DELETED DELETED P
H H ! S L A Y ! G DELETED p DELETED
H H S L A Y G DELETED p ! p
H H | S L A Y G G DELETEDlDELETED
H H s L A Y G G DELETED! P
H H s L A Y G G P DELETED
H H s L A Y G G P ! P
H H s L A N DELETED DELETED DELETEDlDELETED
H H s L A N DELETED DELETED DELETED! p
H H s L A N DELETED DELETED P DELETED
H H s L A N DELETED DELETED P P
H H s L A N DELETED G DELETED DELETED
H H s L A N DELETED G DELETED P
H H s L A N DELETED G P DELETED
H H s L A N DELETED G P P
H H s L A N G DELETED DELETED DELETED
H H s L A N G DELETED DELETED P
H H s L A N G DELETED P DELETED
H H s L A N G DELETED P P
H H s L A N G G DELETED DELETED
H H s L A N G G DELETED P
H H s L A N G G P DELETED
H H s L A N G G P P
H H s L V Y DELETED DELETED DELETED DELETED
H H s L V Y DELETED DELETED DELETED P
H H s L V Y DELETED DELETED P DELETED
H H s L V Y DELETED DELETED P p
H H s L V Y DELETED G DELETED DELETED
H H s L V Y DELETED G (DELETED P

WO 2008/112003

PCT/US2007/07S117

3 35 53 57 61 80 99 100 101 106
H H S L V Y DELETED G P DELETED
H H S L V Y DELETED G P P
H H S L V Y G DELETED DELETED DELETED
H H S L V Y G DELETED DELETED P
H H S L V Y G DELETED V DELETED
H H s L V Y G DELETED P P
H H s L V Y G G DELETED DELETED
H H s L V Y G G DELETED P
H H s L V Y G G P DELETED
H H s L V Y G G P P
H H s L V N DELETED DELETED DELETED DELETED
H H s L V N DELETED DELETED DELETED P
H H s L V N DELETED DELETED P DELETED
H H s L V N DELETED DELETED P P
H H ; S L V N DELETED G DELETED DELETED
H H i S L V N DELETED G DELETED P
H H s L V N DELETED G P DELETED
H H s L V N DELETED G P P
H H s L V N J G DELETED DELETED DELETED
H H s L V N G DELETED DELETED P
H H s L V N G DELETED P DELETED
H H s L V N G DELETED P P
H H s L V N G G DELETED DELETED
H H s L V N G G DELETED P
H H s L V N G G P DELETED
H H s L V | N G G P P
H H R T A Y DELETED DELETED DELETED DELETED
H H R T A Y DELETED DELETED DELETED P
H H R T A Y DELETED DELETED P DELETED
H H R T A Y DELETED DELETED P P
H H R T A Y DELETED G DELETED DELETED
H H R T A Y DELETED G DELETED P
H H R T A Y DELETED G P DELETED
H H R T A Y DELETED G P P
H H R T A Y G DELETED DELETED DELETED
H H R T A Y G DELETED DELETED P
H H R T A Y G DELETED P DELETED
H H R T A Y G DELETED P ! P
H H R T A Y G G DELETEDlDELETED
H H R T A Y G G DELETED P
H H R T A Y G G P DELETED
H H R T A ! Y G G P P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 ! 106
H H R T A N DELETED DELETED DELETED^ DELETED
H H R T A N DELETED DELETED DELETED P
H H R T A N DELETED DELETED P DELETED
H H R T A N DELETED DELETED P P
H H R T A N DELETED G DELETED DELETED
H H R T A N DELETED G DELETED P
H H R T A N DELETED G P DELETED
H H R T A N DELETED G P P
H H R T A N G DELETED DELETED DELETED
H H R T A N G DELETED DELETED P
H H R T A N G DELETED P DELETED
H H R T A N G DELETED P P
H H R T A N G G DELETED DELETED
H H R T A N G G DELETED P
H H R T A N G G P DELETED,
H H i R T A N G G P P
H H R T V Y DELETED DELETED DELETED DELETED
H H R T V Y DELETED DELETED DELETED P
H H R T V Y DELETED DELETED P DELETED
H H R T V Y DELETED DELETED P P
H H R T V Y DELETED G DELETED DELETED
H H R T V Y DELETED G DELETED P
H H R T V Y DELETED G P DELETED
H H R T V Y DELETED G P P
H H R T V Y G DELETED DELETED DELETED
H H R T V Y G DELETED DELETED P
H H R T V Y G DELETED P DELETED
H H R T V Y G DELETED P P
H H R T V Y G G DELETED DELETED
H H R T V Y G G DELETED P
H H R T V Y G G P DELETED
H H R T V Y G G P P
H H R T V N DELETED DELETED DELETED DELETED
H H R T V N DELETED DELETED DELETED P
H H R T V N DELETED DELETED P DELETED
H H R T V N DELETED DELETED P P
H H R T V N DELETED G DELETED DELETED
H H R T V N DELETED G DELETED P
H H R T V N DELETED G P DELETED
H H R T V N DELETED G P - P
H H R T V N G DELETED DELETED DELETED
H H j R T V N G DELETED DELETED P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 80 99 100 101 106
H H R T V N G DELETED P DELETED
H H R T V N G DELETED P P
•H H R T V N G G DELETED DELETED
H H R T V N G G DELETED P
H H R T V N G G P (DELETED
H H R T V N G G P P
H H R L A Y DELETED DELETED DELETED DELETED
H H R L A Y DELETED DELETED DELETED P
H H R L A Y DELETED DELETED P DELETED
H H R L A Y DELETED DELETED P P
H H R L A Y DELETED G DELETED DELETED
H H R L A Y DELETED G DELETED P
H H R L A Y DELETED G P DELETED
H H H
"H " R R L A Y DELETED G P P

L A Y G DELETED DELETED DELETED
H H R L A Y G DELETED DELETED P
H H R L A Y G DELETED P IDELETED
H H R L A Y G DELETED P P
H H R L A Y G G DELETED DELETED
H H R L A Y G G DELETED P
H H R L A Y G G P DELETED
H H R L A Y G G P P
H H R L A N DELETED DELETED DELETED DELETED
H H R L A N DELETED DELETED DELETED P
H H R L A N DELETED DELETED P DELETED
H H R L . A N DELETED DELETED P P
H H R L A N ■ DELETED G DELETED DELETED
H H R L A N DELETED G DELETED P
H H R L A N DELETED G P DELETED
H H R L A N DELETED G P P
H H R L A N G DELETED DELETED DELETED
H H R L A N G DELETED DELETED P
H H R L A N G DELETED P DELETED
H H R L A N G DELETED P P
H H | R L A N G G DELETED DELETED
H H ! R L A N G G DELETED P
H H R L A N G G P DELETED
H H R L A N G G P P
H H R L V Y DELETED DELETED DELETED DELETED
H H R L V Y DELETED DELETED DELETED P
H H R L V Y DELETED DELETED P DELETED
H H R L V Y DELETED DELETED P P

WO 2008/112003

PCT/US2007/075117

3 35 53 57 61 so 99 100 101 106
H H R L V Y DELETED G DELETED DELETED
H H R L V Y DELETED G DELETED P
H H R L V Y DELETED G P DELETED
H H R L V Y DELETED G P P
H H R L V Y G DELETED DELETED DELETED
H H R L V Y G DELETED DELETED P
H H R L V Y G DELETED P DELETED
H H R L V Y G DELETED P P
H H R L V Y G G DELETED DELETED
H H R L V Y G G DELETED P
H H R L V Y G G P DELETED
H H R L V Y G G P P
H H R L V N DELETED DELETED DELETED DELETED
H H R L v N DELETED DELETED DELETED P
H H R L V | N DELETED DELETED P DELETED
H H R L V N DELETED DELETED P j P
H H R L V N DELETED G DELETEDJDELETED
H H R L V -N DELETED G DELETED P
H H R I V N DELETED G P DELETED
H H R L V N DELETED G P P
H H R L V N G DELETED DELETED DELETED
H H R L V N G DELETED DELETED P
H H R L V N G DELETED P DELETED
H H R L V ! N G DELETED P P
H H R L V i N G G DELETED DELETED
H H R L V N G G DELETED P
H H R L V N G G P DELETED
H H R L V N G G | P P
Table 7. Exemplary Mutations of mAb 2.175.3 Light Chain (SEQ ID NO: 4) to Germline at
the Indicated Residue Number.

25 28 31 46 55 77
A S s L o S
A S s L 0 T
A s s L p S
A s s L P T
A s s F 0 g
A s s F 0 T
A s s F P S
A s s F p T

WO 2008/112003

PCT/US2007/075117

25 28 31 46 55 77
A S R L Q S
A S R L Q T
A S R L p S
A s R L P_[ T
A s R F Q S
A s R F Q T
A s R F p , S
A s R F P_j T
A R S L Q S
A R S L Q T
A R s L p S
A R s L P T
A R s F Q S
A R s F Q 1 T
A R s F 1 P I S
A R s F P T
A R R L Q\ s
A R R L Q T
A R R L p S
A R R L p T
A R R F Q S
A R R F Q T
A R R F p S
I A R R F P T
P- S S L Q S
P s s L Q T
P s s L p S
P s s L p T
P s s F Q S
P s s F Q T
P s s F P S
P s s F P T
P s R L ■Q S
P s R L 0 T
P s R L p S
P s R L p T
P s R F Q S
P s R F _Q_ T
P s R F p S
P s R F p T
P R S L _Q_ S
! P R S L 0 T

•j3qiun,M 3npiS3-y paiEDtptq sqj je 3ui|UU3r) o» (01 :ONOI D3S)U!RMDXA^H i'\'6WZ qv™.P suoiiemw £re|durax3 "3 o\qs±

X d 3 H a d
s d 3 a a d
X 0 3 a tt d
s 0 3 y a d
X d 1 a tf d
s d 1 a H d
X 0 1 a y d
s 0 1 a a d
1 d 3 s a d
s d 3 s a d
X 0 3 s a d
s 0 3 s a d
X d 1 s a d
s a 1 S" a d
LL ss 9P I£ 8Z sz

Z.USZ.O/Z,OOZSfl/XJd .

COOZU/800Z OAV

WO 2008/1120(13

PCT/US2007/075117

35 57 99 100 101
N T E G S
N T E G R
N I DELETED DELETED S
N I DELETED DELETED R
N I DELETED G S
N I DELETED G R
N I E DELETED S
N I E DELETED R
N I E G S
N 1 E G R
Table 9. Exemplary Mutations of mAb 2.449.! .3 Light Chain (SEQ ID NO: 12) to Gemiline
at the Indicated Residue Number.

20 25 29 31 33 49 55 56 i 91 94 95 96 I 107
T A S L Y Q S ! S DELETED DELETED DELETED I
T A S L Y Q s s DELETED DELETED DELETED M
T A s L Y Q s s DELETED DELETED P I
T A s L Y Q s s DELETED DELETED P M
T A s L Y Q s s DELETED P DELETED I
T A s L Y Q s s DELETED P DELETED M
T A s L Y Q s s DELETED P P I
T A s L Y Q s s DELETED P P M
T A s L Y Q s s N DELETED DELETED I
T T A
A s s L L Y Y 0 Q s
s s s ISI DELETED DELETED DELETED P M I
T A s L Y Q s s N DELETED P M
T A s L Y. Q s s N P DELETED I
T A s L Y Q s s N P DELETED M
T A s L Y Q s s N P P I
T A s L Y Q s s N P P M
T A s L Y Q s T DELETED DELETED DELETED I
T A s L Y Q s T DELETED DELETED DELETED M
T A s L Y Q s T DELETED DELETED P I
T A s L Y Q s T DELETED DELETED P M
T A s L Y Q s T DELETED P DELETED I
T A s L Y Q s T DELETED P DELETED M
T A s L Y Q s T DELETED P P I
T A s L Y Q s T DELETED P . P M
T A s L Y Q s T N DELETED DELETED I
T A s L Y Q s T N DELETED DELETED M
T A s L Y Q s T N DELETED P I
T A s L Y Q s T N DELETED P M
T A s L Y Q s T j N P DELETED I
T A s L Y Q s T I N P DELETED M

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A S L Y Q S T N P P
T A S L Y Q^ s T N P P M
T A S L Y Q G S DELETED DELETED DELETED
T A S L Y Q G S DELETED DELETED DELETED M
T A S L Y Q G s DELETED DELETED P
T A S L Y Q G s DELETED DELETED P M
T A S L Y Q G s DELETED P DELETED
T A S L Y Q G s DELETED P DELETED M
T A S L Y Q G s DELETED P P
T A S L Y Q G s DELETED P P M
T A S L Y Q G s N DELETED DELETED
T A S L Y Q G s N DELETED DELETED M
T A S L Y Q G s N DELETED P
T A S L Y Q G s N DELETED P M
T A S L Y Q G s N P DELETED
T A s L Y j Q G s N P DELETED M
T A s L Y | Q G s N P | P
T A s L Y ! Q j G s N P P N4
T A s L Y Q l G r DELETED DELETED DELETED
T A s L Y Q G T DELETED DELETED DELETED M
T A s L Y Q G T DELETED DELETED P
T A s L Y Q G T DELETED DELETED P M
T A s L Y Q G T DELETED P DELETED
T A s L Y Q G T DELETED P DELETED M
T A s L Y Q G T DELETED P P
T A s L Y Q G T DELETED P P M
T A s L Y Q G T N DELETED DELETED
T A s L Y Q G T N- DELETED DELETED M
T A s L Y Q G T N DELETED P
T A s L Y Q G T N DELETED P M
T A s L Y 0 G T N P DELETED
T A s L Y Q G T N P DELETED M
T A s L Y Q G T N P P
■ T A s L Y Q G T N P P M
T A s L Y V S S DELETED DELETED DELETED
T A s L Y V S S DELETED DELETED DELETED M
T A s L Y V S s DB.ETED DELETED P
T A s L Y V S s DEI ETED DELETED P M
T A s L Y V S s DELETED P DELETED
T A s L Y V S s DELETED P DELETED M
T A s L Y i V S s DELETED P P
T A s L Y V S s DELETED P P M
T A s L Y V S s N DELETED DELETED
T A s L Y V S s N DELETED DELETED M
T A s L Y V s s N DELETED P
T A s L Y V s s N DELETED P M
T A s L Y V s s N P DELETED

WO 2008/112003 PCT/CJS2007/0751I7

20 25 29 31 33 49 55 | 56 91 94 | 95 96 107
T A S L Y V s S N P DELETED M
T A S L Y V | S S N P P
T A S L Y V s S N P P M
T A S L Y V s ! T DELETED DELETED DELETED
T A S L Y V s i T DELETED DELETED DELETED M
T A S L Y V S ! T DELETED DELETED P
T A S L Y V s T DELETED DELETED P M
T A S L Y V s T DELETED P DELETED
T A S L Y V s T DELETED P DELETED M
T A s L Y V s T DELETED P P
T A s L Y V s T DELETED P P M
T A s L Y V s T N DELETED DELETED
T A s L Y V s T N DELETED DELETED M
T A s L Y V s T N DELETED P
T A s L Y V s T N DELETED P M
T A s L Y V s T N P DELETED I !
i T A s L | Y V S I T N P DELETED M !
T A s L Y j V s ! T N P ! P
T A s L Y V s T N P P M
T A s L Y V G S DELETED DELETED DELETED
T A s L Y V G S DELETED DELETED DELETED M
T A s L Y V G s DELETED DELETED P
T A s L Y V G s DELETED DELETED P M
T A s L Y V G i S DELETED P DELETED
T A s L Y V G s DELETED P DELETED M
T A s L Y V G s DELETED P P
T A s L Y V G s DELETED P P M
T A s L Y V G s N DELETED DELETED
T A s L Y V G s N DELETED DELETED M
T A s L Y V G s N DELETED P
T A s L Y V G s N DELETED P M
T A s L Y V G s N P DELETED
T A s L Y V G s N P DELETED M
T A s L Y V G s N P P
T A s L Y V G s N P P M
T A s L Y V G T DELETED DELETED DELETED
T A s L Y V G T DELETED DELETED DELETED M
T A s L Y V G T DELETED DELETED P
T A s L Y V G T DELETED DELETED P . M
T A s L Y V G T DELETED P DELETED
T A s L Y V G T DELETED P DELETED M
T A s L Y V G T DELETED P P
T A s L Y V G T DELETED P P M
T A s L Y V G T N DELETED DELETED
T A s L Y V G T N DELETED DELETED M
T A s L Y V G T N IDELETED P
T A S | L Y V G T N DELETED P M

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A S L Y ■V G T . N P DELETED I
T A S L Y V G T N P DELETED M
T A S L Y V G T N P P I
T A S L Y V G T N P P M
T A s L H Q S S DELETED DELETED DELETED i
T A s L H Q s S DELETED DELETED DELETED M
T A s L H Q s s DELETED DELETED P !
T A s L H Q s s DELETED DELETED P M
T A s L H Q s s DELETED P DELETED I
T A s L H Q s s DELETED P DELETED M
T A s L H Q s s DELETED P P I
T A s L H Q s s DELETED P P M
T A s L H Q s s N DELETED DELETED I
T A s L H Q s s N DELETED DELETED M
T A s L H Q s s N DELETED P I
T A s L H Q s s N DELETED P M
T A s L i H Q s s N P DELETED I
T A s L H Q s s N P DELETED M
T A s L H Q s s N P P i
T A s L H Q s I s N P P M
T A s L H Q s T DELETED DELETED DELETED I
T A s L H Q s T DELETED DELETED DELETED M
T A s L H Q s T DELETED DELETED P I
T A s L H Q s T DELETED DELETED P M
T A s L H Q s T DELETED P DELETED I
T A s L H Q s T DELETED P DELETED! M
T A s L H Q s T DELETED P P f
T A s L H Q s T DELETED P P M
T A s L H Q s T N DELETED DELETED I
T A s L H Q s T N DELETED DELETED M
T A s L H Q s T N DELETED P I
T A s L H Q s T N DELETED P M
T A s L H Q s T N P DELETED I
T A s L H . Q s T N P DELETED M
T A s L H Q s T N P P I
T A s L H Q s T N P P M
T A s L H Q G S DELETED DELETED DELETED I
T A s L H Q G S DELETED DELETED DELETED M
T A s L H Q G s DELETED DELETED P I
T A s L H Q G s DELETED DELETED P M
T A s L H Q G s DELETED P DELETED [
T A s L H Q G s DELETED P DELETED M
T A s L H Q G s DELETED P P I
T A s L H Q G s DELETED P P M
T A s L H Q G s N DELETED DELETED i
T A s L H Q G s N DELETED DELETED M
T A s L H Q G s N DELETED P I

WO 2008/112003 PCT/US2O07/O7SH7

20 25 29 31 33 49 | 55 56 91 94 95 96 107
T A S L H Q G s N DELETED P M
T A S L H Q G s N P DELETED
T A s L H Q G s N P DELETED M
T A s L H Q G s N P P | I
T A s L H Q G s N P P M
T A s L H Q G T DELETED DELETED DELETED
T A s L H Q G T DELETED DELETED DELETED M
T A s L H Q G T DELETED DELETED P
T A s L H Q G T DELETED DELETED P M
T A s L H Q G T DELETED P DELETED
T A s L H Q G T DELETED P DELETED M
T A ■ s L H Q G T DELETED P P
T A s L H Q G T DELETED P P M
T A s L H Q G T N DELETED DELETED
T A s L H Q G T N DELETED DELETED M
T ~~' A s L H Q G T N DELETED P
T ! A i 1 s L H Q i G T N DELETED P M
T A s L ! H Q G T N P JDELETED
T A s L H Q G T N P JDELETED M
T A s L H Q G T N P | P
T A s L H Q G T N P P M
T A s L H v- S S DELETED DELETED DELETED
T A s L H V S S DELETED DELETED DELETED M
T A s L H V S s DELETED DELETED P
T A s L H V S s DELETED DELETED P M
T A s L H V S s DELETED P DELETED
T A s L H V S s DELETED P DELETED M
T A s L H V S s DELETED P P
T A s L H V S s DELETED P P M
T A s L H V S s N DELETED DELETED
T A s L H V S s N DELETED DELETED M
T A s L H V s i s N DELETED P
T A s L H V s s N DELETED P M
T A s L H V s s N P DELETED
T A s L H V s s N P DELETED M
T A s L H . V s s N P P
T A s L H V s s N P P M
T A s L H V s T DELETED DELETED DELETED
T A s L H V s T DELETED DELETED DELETED M
T A s L H V s T DELETED DELETED P
T A s L H V s T DELETED DELETED P M
T A s L H V s T DELETED P DELETED
T A s L H V s T DELETED P DELETED M
T A s L H V s T DELETED P P
T A s L H V s T DELETED P P M
T A s L H V s T N DELETED DELETED
T A s L H V s T N DELETED DELETED M

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A S L H V S T N DELETED P
T A S L H V s T N DELETED P M
T A S L H V s T N P DELETED
T A S L H V s T N P DELETED M
T A S L H V s T N P P
T A S L H V s T N P P M
T A S L H V G S DELETED DELETED DELETED
T A S L H V G S DELETED DELETED DELETED M
T A s L H V G s DELETED DELETED P
T A s L H V G s DELETED DELETED P M
T A s L H V G s DELETED P DELETED
T A s L H V G s DELETED P DELETED M
T A s L H V G s DELETED P P
T A s L H V G s DELETED P P M
T A s L H V G s N DELETED DELETED
T A s L H V G s N DELETED DELETED M
T A ! 1 s L H V G s N DELETEDJ P
T A s L H V G s N DELETED P M T A s L H V G 3 N P DELETED . i ' i
T A s L H V G s N P DELETED M I
T A s L H V G s N P P
T A s L H V G s N P P M
T A s L H V G T DELETED DELETED DELETED
T A s L H V G T DELETED DELETED DELETED M
T A s L H V G T DELETED DELETED P
T A s L H V G T DELETED DELETED P M
T A s L H V G T DELETED P DELETED
T A s L H V G T DELETED P DELETED M
T A s L H V G T DELETED P P
T A s L H V G T DELETED P P M
T A s L H V G T N DELETED DELETED
T A s L H V G T N DELETED DELETED M
T A s L H V G T N DELETED P
T A s L H V G T N DELETED P M
T A s L H V G T N P DELETED
T A s L H V G T N P DELETED M
T A s L H V G T N P P
T A s L H V G T N P P M
T A s Y Q S S DELETED DELETED DELETED
T A s Y Q S S DELETED DELETED DELETED M
T A s Y Q S s DELETED DELETED P
T A s Y Q S s DELETED DELETED P M
T A s Y Q S s DELETED P DELETED
T A s Y Q S s DELETED P DELETED M
T A s Y Q S s DELETED P P
T A s Y Q S s DELETED P P M
T A s Y Q s s N DELETED DELETED ! I

WO 2008/112003

PCT/US2O0?/U?SU7

20 25 29 31 33 49 55 56 91 94 95 96 107
T A , S Y Q S S N DELETED DELETED M
T A S Y Q S S N DELETED P
T A s Y Q S S N DELETED P M
T A s Y Q s ! s N P DELETED
T A s Y Q S i S N P DELETED M
T A s Y Q s S N P P
r A s Y Q s S N P P M
T A s Y Q s T DELETED DELETED DELETED
T A s Y Q s T DELETED DELETED DELETED M
T A s Y Q s T DELETED DELETED P
T A s Y Q s T DELETED DELETED P M
T A s Y Q s T DELETED P DELETED
T A "S Y Q s T DELETED P - DELETED M
T A s Y Q s T DELETED P P
T A s Y Q s T DELETED P P M j
T A s Y Q s T N DELETED DELETED
T A s Y Q s T N DELETED DELETED M
T A s Y Q i S T N DELETED P
T A ^s I Y Q s T N DELETED P M
T A s Y Q s T N P DELETED
T A s Y Q s T N P DELETED M
T A s Y Q s T N P P
T A s Y Q s T N P P M
T A s Y Q G S DELETED DELETED DELETED
T A s Y Q G s DELETED DELETED DELETED M
T A s Y Q G s DELETED DELETED P
T A 5 Y Q G s DELETED DELETED P M
T A s Y Q G s DELETED P DELETED
T A s Y Q G s DELETED P DELETED M
T A s Y Q G s DELETED P P '
T A s Y Q G s DELETED P P M
T A s Y Q G s N DELETED DELETED
T A s Y Q G s N DELETED DELETED M
T A s Y Q G s N DELETED P
T A s Y Q -G s N DELETED P M
T A s Y Q G s N P DELETED
T A s Y Q G s N P DELETED M
T A s Y Q G s N- P P
T A s Y Q G s ' N P P M
T A s Y Q G T DELETED DELETED DELETED
T A s Y Q G T DELETED DELETED DELETED M
T A s Y Q G T DELETED DELETED P
T A s Y Q G T DELETED DELETED P M
T A s Y Q G T DELETED P DELETED
T A s Y Q G T DELETED P DELETED M
T A s Y Q G T DELETED P P
T A s Y Q G T DELETED P P M

WO 2008/112003

PCT/US2(Ht7/075m

20 25 j 29 31 33 49 55 56 j 91 94 95 j 96 107
T A S Y Q G I T N DELETED DELETED I
T A S Y Q G ! T N DELETED DELETED M
T A S Y Q G ! T N DELETED P I
T A S Y Q G I T N DELETED P M
T A S Y Q G j T N P DELETED I
T A S Y Q G ! T N P DELETED M
T A S Y Q G ! T N P P I
T A S Y Q G ! T N P P M
T A S Y V S S DELETED DELETED DELETED I
T A S Y V S S DELETED DELETED DELETED M
T - A S Y V S S DELETED DELETED ' P I
T A s Y V S S DELETED DELETED P M
T A s Y V S S DELETED P DELETED I
T A s Y V S S DELETED P DELETED M
T A s Y V S S DELETED P P I
T A s Y V S s DELETED P P M
T A s Y V S j S N DELETED DELETED I
T A s Y V s s N DELETED DELETED M
T A s Y V s s N DELETED P I
T A s Y V s s N DELETED P M
T A s Y V s s N P DELETED I
T A s Y V s s N P DELETED M
T A s Y v" s s N P P I
T A s Y V s s N P P M
T A s Y v ■ s T DELETED DELETED DELETED I
T A s Y V s T DELETED DELETED DELETED M
T A s Y V s T DELETED DELETED P ! I
T A s Y V s T DELETED DELETED P | M
T A s Y V s T DELETED P DELETED! I
T A s Y V s T DELETED P DELETED! M
T A s Y V s T DELETED P ■ P I I
T A s Y V s T DELETED P P M
T A s Y V s T N DELETED DELETED I
T A s Y V s T N DELETED DELETED M
T A s Y V s T N DELETED p I
T A s Y V s T N DELETED p M
T A s Y V s T N P DELETED I
T A s Y V s T N P DELETED M
T A s Y V s T - N P P I
T A s Y V s T N P P M
T A s Y V G S DELETED DELETED DELETED I
T A s Y V G S DELETED DELETED DELETED M
T A s Y V G | S DELETED DELETED P I
T A s Y V G S DELETED DELETED P M
T A s Y V G S DELETED P DELETED I
T A s Y V G S DELETED P DELETED M
T A s Y V G S DELETED P P !

WO 2008/112003

PCT/US2007/075H7

20 25 29 31 33 I 49 55 56 91 94 95 96 107
T A S Y V G s DELETED P P M
T A S Y V G s N DELETED DELETED
T A s Y V G s N DELETED DELETED M
T A s i i Y V G s N DELETED P
T A S I Y V G s N DELETED P M
T A s Y V G s N P DELETED
T A s Y V G s N P DELETED M
T A s Y V G s N P P
T A s , Y V G s N P P M
T A s Y V G T DELETED DELETED DELETED
T A s Y V G T DELETED DELETED DELETED M
T A s Y V G T DELETED DELETED P
T A s Y V G T DELETED DELETED P M
T A s Y V G T DELETED P DELETED
T A s Y V G T DELETED P DELETED M
T A s Y V G T DELETED P P
T A s Y V G T DELETED P P M
T A s Y V G T N DELETED DELETED
T A s Y V G T N DELETED DELETED M
T A s Y V G T N DELETED P
T A s Y V G T N DELETED P M
T A s Y L V G T N P DELETED
T A s Y V G T N P DELETED M
T A s Y V G T N P P
T A s Y V G T N P P M
T A s H Q S S DELETED DELETED DELETED
T A s H Q S S DELETED DELETED DELETED M
T A s H Q s S DELETED DELETED P
T A s H Q s s DELETED DELETED P M
T A s H Q s s DELETED P DELETED I i
T A s H Q s s DELETED P DELETED M
T A s H Q s s DELETED P P
T A s H Q s s DELETED P P M
T A s H Q s s N DELETED DELETED
T A s H Q s s N DELETED DELETED M
T A s H 0 s L S N DELETED P
T A s H Q s s N DELETED P M
T A s H Q s s N P DELETED
T A s H Q s s N P DELETED M
T A s H Q s s N P P
T A s H Q s s N P P M
T A s H Q s T DELETED DELETED DELETED
T A s H Q s T DELETED DELETED DELETED M
T A s H Q s T DELETED DELETED P
T A s H Q s T DELETED DELETED P M
T A s H Q s T DELETED P DELETED
T A s H Q s T DELETED! P DELETED M

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A S H Q S T DELETED P P I
T A S H Q S T DELETED P P M
T A S H Q s T N DELETED DELETED I
T A S H Q s T N DELETED DELETED M
T A S H Q s T N DELETED P I
T A S H Q s T N DELETED P M
T A S H Q s T N P DELETED i
T A S H Q s T N P DELETED M
T A S H Q s T N P P I
T A S H Q s T N P P M
T A S H Q G S DELETED DELETED DELETED I
T A S H Q G s DELETED DELETED DELETED M
T A S H Q G s DELETED DELETED P I
T A s H Q G s DELETED DELETED P M
T A s H Q G s DELETED P DELETED I i
T A s H Q G s DELETED P DELETED M ;
T A s ' H Q G s DELETED P P ' !
T A s I j H Q G s DELETED P P M
T A s H Q G s N DELETED DELETED I
T A s H Q G s N DELETED DELETED M
T A s H Q G s N DELETED P I
T A s H Q" G s N DELETED P M
T A s H Q G s N P DELETED I
T A s H Q G s N P DELETED M
T A s H Q G s N P P I
T A s H Q G s N P P M
T A s H Q G j T DELETED DELETED DELETED I
T A s H Q G | T DELETED DELETED DELETED M
T A s H Q G T DELETED DELETED P I
T A s H Q G T DELETED DELETED P M
T A s H Q G T DELETED P DELETED I
T A s H Q G T DELETED P DELETED M
T A s H Q G T DELETED P P I
T A s H Q G T DELETED P P M
T A s H Q G T N DELETED DELETED I
T A s H Q G T N DELETED DELETED M
T A s H Q G T N DELETED P I
T A s H Q G T N DELETED P M
T A s H Q G T N P DELETED I
T A s H Q G T N P DELETED M
T A s H Q G T N P P I
T A s H Q G T N P P M
T ' A s H V S S DELETED DELETED DELETED I
T A s H V S s DELETED DELETED DELETED M
T A s H V S s DELETED DELETED P I
T A s H V S s DELETED DELETED p i M
T A s H V S s DELETED P DELETED! I

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 ) 95 96 DELETED 107
T A S H V s S DELETED P
M
T A S H V s S DELETED P P
T A S H V s S DELETED P P M
T A S H V s S N DELETED DELETED
T A S H V s S N DELETED DELETED M
T A s H V s s N DELETED P
T A s H V s s N DELETED P M
T A s H V s s N P DELETED
T A s H V s s N P DELETED M
T A s H V s s N P P
T A s H V s s N P P M
T A s H V s T DELETED DELETED DELETED
T A s H V s T DELETED DELETED DELETED M
T A s H V s T DELETED DELETED P
T A s H V s T DELETED DELETED P M
T A s H V s T DELETED P DELETED I i
T A s H V s T DELETED P DELETED M
T A s H V s T DELETED P P
T A s H V s T DELETED P P M
T A s H V s T N DELETED DELETED
T A s H V s T N DELETED DELETED M
• T A s H V s T N DELETED P
T A s H V s T N DELETED P M
T A s H V s T N P DELETED
T A s H V s T N P DELETED M
T A s H V s T N P P
T A s H V s T N P P M
T A s H V G S DELETED DELETED DELETED
T A s H V G S DELETED DELETED DELETED M
T A s H V G s DELETED DELETED P
T A s H V G s DELETED DELETED P M
T A s H V G s DELETED P DELETED
T A s H V G s DELETED P DELETED M
T A s H V G s DELETED P P
T A s H V G s DELETED P P M
T A s H V G s N DELETED DELETED
T A s H V G s N DELETED DELETED M
T A s H V G s N DELETED P
T A s H V G s N DELETED P M
T A s H V G s N P DELETED
T A s H V G s N P DELETED M
T A s H V G s N P P
T A s H V G s N P P M
T A s H J V G T DELETED DELETED DELETED
T A s H V G T DELETED DELETED DELETED M
T A s H V G T DELETED DELETED P
T A s H V G T DELETED DELETED! P M

WO 2008/112003

VCT/V&lWtfflSll'T

20 25 29 31 33 49 55 56 91 94 95 96 107 i
T A S H V G T DELETED P DELETED
T A s H V G T DELETED P DELETED M
T A s H V G T DELETED P P
T A s H V G T DELETED P P M
T A s H V G T N DELETED DELETED
T A s H V G T N DELETED DELETED M
T A s H V G T N DELETED P
T A s H V G T N DELETED P M
T A s H V G T N P DELETED
T A s H V G T N P DELETED M
T A s H V G T N P P
T A s H V G T N P P M
T A R L Y Q S S DELETED DELETED DELETED
T A R L Y Q S s DELETED DELETED DELETED M
T A R L Y Q S s DELETED DELETED P
T A R L Y Q S s DELETED DELETED P M
T A R L Y Q s s DELETED P DELETED
T A R L Y Q s s DELETED P DELETED M
T A R L Y Q s s DELETED P P
T A R L Y Q s s DELETED P P M
T A R L Y Q s s N DELETED DELETED
T A R L Y Q s s N DELETED DELETED M
T A R L Y Q s s N DELETED P
T A R L Y Q s s N DELETED P M I
T A R L Y Q s s N P DELETED . i
T A R L Y Q s s N P DELETED M
T A R L Y Q s s N P P
T A R L Y Q s s N P P M
T A R L Y Q s T DELETED DELETED DELETED
T A R L Y Q s T DELETED DELETED DELETED M
T A R L Y Q s T DELETED DELETED P
T A R L Y Q s T DELETED DELETED P M
T A R L Y Q s T DELETED P DELETED
T A R L Y Q s T DELETED P DELETED M
T A R L Y Q s T DELETED P P
T A R L Y Q s T DELETED P P M
T A R L Y Q s T N DELETED DELETED
T A R L Y Q s T N DELETED DELETED M
T A R L Y Q s T N DELETED P
T A R L Y Q s T N DELETED P M
T A R L Y Q s T N P DELETED
T A R L Y Q s T N P DELETED M
T A R L Y Q s T N P P
T A R L Y Q s T N P P M
T A R L Y Q G S DELETED DELETED DELETED I
■T A R L Y Q G S DELETED DELETED DELETED M
T A R L Y Q G s DELETED DELETED P

WO 2008/1121)03

wrTrtJSiooMrtsm

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R L Y Q G S DELETED DELETED P M
T A R L Y Q G S DELETED P DELETED
T A R L Y Q G S DELETED P DELETED M
T A R L Y Q G s DELETED P P
T A R L Y Q G s DELETED P P M
T A R L Y Q G s N DELETED DELETED
T A R L Y Q G s N DELETED DELETED M
T A R L Y Q G s N DELETED P
T A R L Y Q G s N DELETED P M
T A R L Y Q G s N P DELETED
T A R L Y Q G s N P . DELETED M
T A R L Y Q G s N P P
T A R L Y Q G s N P P M
T A R L Y Q G T DELETED DELETED DELETED I I
T A R L Y Q G T DELETED DELETED DELETED M
T A R L Y 0 G T DELETED DELETED P
T A R L Y Q G T DELETED DELETED P M
T A R L Y Q G T DELETED P DELETED
T A R L Y Q G T DELETED P DELETED M
T A R L Y Q G T DELETED P P
T A R L Y Q G T DELETED P P M
T A R L Y Q G T N DELETED DELETED
T A R L Y Q G T N DELETED DELETED M
T A R L Y Q G T N DELETED P
T A R L Y Q G T N DELETED P M
T A R L Y Q G T N P DELETED
T A R L Y Q G T N P DELETED M
T A R L Y Q G T N P P
T A R L Y Q G T N P P M
T A R L Y V S S DELETED DELETED DELETED
T A R L Y V S S DELETED DELETED DELETED M
T A R L Y V S s DELETED DELETED P
T A R L Y V S s DELETED DELETED P M
T A R L Y V S s DELETED P DELETED
T A R L Y V S . s DELETED P DELETED M
T . A R L Y V S s DELETED P P
T A R L ' Y V S s DELETED P P M
T A R L Y V S s N DELETED DELETED
T A R L Y V S s • N DELETED DELETED M
T A R L Y V S s N DELETED P
T A R L Y V S s N DELETED P M
T A R L Y V S s N P DELETED I
T A R L Y V S s N P DELETED M
T A R L Y V S s N P P
T A R L Y V S s N P P M
T A R L Y V S T DELETED DELETED DELETED
T A R L Y V s T DELETED DELETED DELETED M

WO 2008/112003 FCT/US2007/07S117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R L Y V s T DELETED DELETED P i
T A R L Y V s T DELETED DELETED P M
*V Ps ] R L Y V S \ T DELETED P DELETED T A R L Y V S I T DELETED P DELETED M
T A R L Y V S i T DELETED P P I
T A R L Y V S I T DELETED P P M
T A R L Y V S i T N DELETED DELETED I
T A R L Y V S T N DELETED DELETED M
T A R L Y V S T N DELETED P I
T A R L Y V s T N DELETED P M
T A R L Y V s T N P DELETED I
T A R L Y V s T N P DELETED Wl
T A R L Y V s T N P P I
T A R L Y V s T N P P M
T A R L Y V G S DELETED DELETED DELETED I
T A R L Y V G s DELETED DELETED DELETED M
T ! A R L Y V G s DELETED DELETED P I
1 T | A R L Y V G s DELETED DELETED P M
T i A R L Y V G s DELETED P DELETED I
T i A R L Y V G s DELETED P DELETED M
T A R L Y V G s DELETED P P I
T A R L Y V G s DELETED P P M
T A R L Y V G s N DELETED DELETED I
T A R L Y V G s N DELETED DELETED M
T A R L Y V G s N DELETED P I
T A R L Y V G s N DELETED P M
T A R L Y V G s N P DELETED I
T A R L Y V G s N P DELETED M
T A R I L Y V G s N P P I
T A R \ L Y V G s M P P Wi
T A R L Y V G T DELETED DELETED DELETED I
T A R L Y V G T DELETED DELETED DELETED M i
T A R L Y V G T DELETED DELETED P I
T A R L Y V G T DELETED DELETED P ' M
T A R L Y V G T DELETED P DELETED i
T A R L Y V G T DELETED P DELETED M
T A R L Y V G T DELETED P P I
T A R L Y V G T DELETED P P M
T A R L Y V G T N DELETED DELETED I
T A R L Y V G T N. DELETED DELETED M
T A R L Y V G T N DELETED P I
T A R L Y V G T N DELETED P M
T A R L Y V G T N P DELETED i
T A R L Y V G T N P DELETED M
T A R L Y V G T N P P ■ I
T A R L Y V G T N P P _M_J
T A R L H Q S | S DELETED DELETED DELETED I

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 ! 91 94 95 96 107
T A
R L H Q S . S DELETED DELETED DELETED M
T A R L H Q S i S DELETED DELETED P
T A R L H Q s S DELETED DELETED P M
T A R L H Q s S DELETED P DELETED
T A R L H Q s s DELETED P DELETED M
T A R L H Q s s DELETED P P
T A R L -H Q s s DELETED P P M
T A R L H Q s s N DELETED DELETED
T A R L H Q s s N DELETED DELETED M
T A R L H Q s s N DELETED P
T A R L H Q s s N DELETED P M
T A R L H Q s s N P DELETED
T A R L H Q s s N P DELETED M
T A R L H Q s s N P P
T A R L H Q s s N P P M
T A R L H Q s T DELETED DELETED DELETED
T A R L H Q S : T DELETED DELETED DELETED M !
T A R L H 0 S T DELETED DELETED P
T A R L H Q S T DELETED DELETED P M
T A R L H Q S T DELETED P DELETED
T A R L H Q S T DELETED P DELETED M
T A R L H Q S j T DELETED P P
T A R L H Q s T DELETED P P M
T A R L H Q s T N DELETED DELETED
T A R L H Q s T N DELETED DELETED M
T A R L H Q s ! T N DELETED P | j
T A R L H Q s T N DELETED P M
T A R ■ L H Q s T N P DELETED
T A R L H Q s T N P DELETED M
T A R L H Q s T N P P
T A R L H Q s T N P P
T A R L H Q G S DELETED DELETED DELETED
T A R L H Q G j S DELETED DELETED DELETED M
T A R L H Q G ! S DELETED DELETED P
T A R L H Q G I S DELETED DELETED P
T A R L H Q G S DELETED P DELETED
T A R L H Q G s DELETED P DELETED M
T A R L H Q G s DELETED P P
T A R L H Q G s DELETED P P M
T A R L H Q G s N DELETED DELETEDJ I
T A R L H Q G s N DELETED DELETED M
T A R L H Q G s N DELETED P ■
T A R L H Q G s N DELETED P M
T A R L H Q G s N P DELETED
T A R L H Q G s N P DELETED M
T A R L H Q G s N P P 1
T A R L H Q G s N P P M

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R L H Q G T DELETED DELETED DELETED !
T A R L H Q G T DELETED DELETED DELETED M
T A R L H Q G T DELETED DELETED P
T A R L H Q G T DELETED DELETED P M
T A R L H Q G T DELETED P DELETED
T A R L H Q G T DELETED P DELETED M
T A R L H Q G T DELETED P P
T A R L H Q G T DELETED P P M
T A R L H Q G T N DELETED DELETED
T A R L H Q G T N DELETED DELETED M
T A R L H Q G T N DELETED P
T A R L H Q G T N DELETED P M
T A R L H Q G T N P DELETED
T A R L H Q G T N P DELETED M
T A R L H Q G ! T N P P
T A R L H Q G ! T N P P M |
T A R L H V S : S DELETED DELETED DELETED , i
■ |
T A R L _j H V s ! s DELETED DELETED DELETED fv',
T A R L H V s S DELETEO DELETED P
T A R L H V s s DELETED DELETED P M
T A R L H V s s DELETED P DELETED
T A R L H V s s DELETED P DELETED M
T A R L H V s s DELETED P P
T A R L H V s s DELETED P P M
T A R L H V s s N DELETED DELETED
T A R L H V s s N DELETED DELETED M
T A R L H V s s N DELETED P
T A R L H V s s N DELETED P M
T A R L. H V s s N P DELETED
T A R L H V s s N P DELETED M
T A R L H V s s N P P
T A R L H V s s N P P M
T A R L H V s T DELETED DELETED DELETED
T A R L H V s T DELETED DELETED DELETED M
T A R L H V s T DELETED DELETED P
T A R L H V s T DELETED DELETED P M
T A R L . H V s T DELETED P DELETED
T A R L H V s T DELETED P DELETED M
T A R L H V s T DELETED P P
T A R L H V s T DELETED P P M
T A R L H V s T N DELETED DELETED
T A R L H V s T N DELETED DELETED M
T A R L H V s T N DELETED P
T A R L H V s T N DELETED P M
T A R L H V s T N P DELETED
T A R L H V s T N P DELETED M
T A R L H ! V s T N P P

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R L H V S T N P P M
T A R L H V G s DELETED DELETED DELETED
T A R L H V G s DELETED DELETED DELETED M
T A R L H V G s DELETED DELETED P
T A R L H V G s DELETED DELETED P M
T A R L H V G s DELETED P DELETED
T A R L H V G s DELETED P DELETED M
T A R L H V G_i s DELETED P P
T A R L H V G s DELETED P P M
T A R L H V G s N DELETED DELETED
T A R L H V G s N DELETED DELETED M
T A R L H V G s N DELETED P
T A R L H V G s N DELETED P M
T A R L H V G s N P DELETED
T A R L H V f G j S N P DELETED M
T A R L H V G S N P P
T A R L H V G s S N P P M :
T A R L H V G T DELETED DELETED DELETED
T A R L H V G T DELETED DELETED DELETED M
T A R L H V G T DELETED DELETED P
T A R L H V G T DELETED DELETED P M
T A R L H V G T DELETED P DELETED
T A R L H V G T DELETED P DELETED M
T A R L H V G T DELETED P P
T A R L H V G T DELETED P P M
T A R L H V G T N DELETED DELETED
T A R L H V G T N DELETED DELETED M
T A R L H V G T N DELETED P
T A R L H V G T N DELETED P M
T A R L H V G T N P DELETED
r A R I H V G T N P DELETED M
T A R L H V G | T N P P
T A R L H V G ! T N P P M
T A R Y Q S S DELETED DELETED DELETED
T A R Y Q S S DELETED DELETED DELETED M
T A R Y Q s s DELETED DELETED P
T A R Y Q s s DELETED DELETED P M
T A R Y Q s s DELETED P ■ DELETED
T A R Y Q s s DELETED P DELETED M
T A R Y Q s s DELETED P P
T A R Y Q s s DELETED P P M
T A R Y Q s s N DELETED DELETED
T A R Y Q s s N DELETED DELETED M
T A ■ R Y Q s s N DELETED P
T A R Y Q s s N DELETED P | M
T A R Y Q s s N P DELETED) I
T I A R Y Q s s N P DELETED| M

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 | 95 96 107
T A R Y Q S S N P P

T A R Y 0 S S N P P M
T A R Y Q s T DELETED DELETED DELETED
T A R Y Q s T
T DELETED DELETED DELETED M
T A R Y Q s
DELETED DELETED P
T A R Y Q s T DELETED DELETED P M
T A R Y Q s T DELETED P DELETED
T A R Y Q s T DELETED P DELETED M
T A R Y Q s T DELETED P P
T A R Y Q s T DELETED P P M
T A R Y Q s T N DELETED DELETED
T A R Y Q s T N DELETED DELETED M
T A R Y Q s T N DELETED P
T A R Y Q s T N DELETED P M
T A R Y Q S I T N P DELETED
T A R Y Q S : T N i p DELETED M
T A R Y Q S ' T | N j P P I |
T A R Y Q S i T N | P P M
T A R Y Q G ! S DELETED DELETED DELETED
T A R Y Q G S DELETED DELETED DELETED M
T A R Y Q G s DELETED DELETED P
T A R Y Q G s DELETED DELETED P M
T A R Y Q G s DELETED P DELETED
T A R Y Q G s DELETED P DELETED M
T A R Y Q G s DELETED P P
T A R Y Q G s DELETED P P M
T A R Y Q G s N DELETED DELETED
T A R Y Q G s N DELETED DELETED M
T A R Y Q G s N DELETED P
T A R Y Q G s N DELETED P M
T A R Y Q G s N P DELETED
T A R Y Q G s N P DELETED M
T A R Y Q G s N P P
T A R Y Q G s N P P- M
T A R Y Q G T DELETED DELETED DELETED
T A R Y Q G T DELETED DELETED DELETED M
T A R Y Q G T DELETED DELETED P
T A R Y Q G T DELETED DELETED P M
T A R Y Q G T DELETED P DELETED
T A R Y Q G T DELETED P DELETED M
T A R Y Q G T DELETED P P
T A R Y Q G T DELETED P P M
T A R Y Q G T N DELETED DELETED
T A R Y Q G T N DELETED DELETED M
T A R Y Q G T N DELETED P
T A R Y Q G T N DELETED P M
T A R Y Q G T N P DELETED

WO 2008/112003 PCT/U32007/07M17

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R Y Q G T N P DELETED M
T A R Y Q G T N P P t
T A I R Y Q G T N P P M
T A R Y V S S DELETED DELETED DELETED I
T A R Y V s s DELETED DELETED DELETED M
T A R Y V s s DELETED DELETED P I
T A R Y V s s DELETED DELETED P M
T A R Y V s s DELETED P DELETED I
T A R Y V s s DELETED P DELETED M
T A R Y V s s DELETED P P I
T A R Y V s s DELETED P P M
T A R Y V s s N DELETED DELETED I
T A R Y V s s N DELETED DELETED M
T A R Y V S ! S N DELETED P !
T A R Y V S I S N DELETED P M
T A R Y ! V S S N P DELETED I
T A R I ! Y I V ( S . S N P DELETED M
T A R I | Y ! V ! S ■ S ; N P P I
T A R I Y V ( S i S i N P P M. 1
T A R Y V s T DELETED DELETED DELETED 1
T A R Y V s T DELETED DELETED DELETED M
T A R Y V s T DELETED DELETED P 1
T A R Y V s T DELETED DELETED P M
T A R Y V s T DELETED P DELETED 1
T A R Y V s T DELETED P DELETED M
T A R Y V s T DELETED P P 1
T A R Y V s T DELETED P P M
T A R Y V s T N DELETED DELETED 1
T A R Y V s T N DELETED DELETED M
T A R Y V s T N DELETED P 1
T A R Y V s T N DELETED P M
T A R Y V s : T N P DELETED 1
T A R Y V S T A R Y V S : T , N P P 1
T A R Y V s T N P P M
T A R Y V G S DELETED DELETED DELETED 1
T A R Y V G S DELETED DELETED DELETED . M
T A R Y V G s DELETED DELETED P 1
T A R Y V G s DELETED DELETED P M
T A R Y V G s DELETED P DELETED 1
T A R Y V G s DELETED P DELETED M
T A R Y V G s DELETED P P 1
T A R Y V G s DELETED P P M
T A R Y V G s N DELETED DELETED 1
T A R Y V G s N DELETED DELETED M
T A R Y V G s N DELETED P 1
T A R Y V G s N DELETED P M

WO 2008/112003

PCT/US20O7/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R Y V G s N P DELETED
T A R Y V G s N P DELETED M
T A R Y V G s N P P
T A R Y V G s N P j P M
T A R Y V G T DELETED DELETEDlDELETED I f
T A R Y V G T DELETED DELETED DELETED M :
T A R Y V G T DELETED DELETED P i i
T A R Y V G T DELETED DELETED P M I
T A R Y V G ! T DELETED P DELETED 1 I
T A R Y V G T DELETED P DELETED IV.
T A R Y V G T DELETED P P
T A R Y V G T DELETED P P M
T A R Y V G T N DELETED DELETED
T A R Y V G T N DELETED DELETED M
T A R Y V G T N DELETED P
T A R Y V G T N DELETED P M
T A R Y V G i T N P DELETED
T A R Y V G T N P DELETED M
T A R Y V G T N P P
T A R Y V G T N P P M
T A R H Q S S DELETED DELETED DELETED
T A R H Q S S DELETED DELETED DELETED M
T A R H Q s s DELETED DELETED P
T A R H Q s s DELETED DELETED P M
T A R H Q s s DELETED P DELETED
T A R H Q s s DELETED P DELETED M
T A R H Q s s DELETED P P
T A R H Q s s DELETED P P M
T A R H Q s s N DELETED DELETED
T A R H Q s s N DELETED DELETED M
T A R H Q s s N DELETED P
T A R H Q s s N DELETED P M
T A R H Q s s N P DELETED
T A R H Q s s N P DELETED M
T A R H Q s s N P P
T A R H Q s s N P P M
T A R H Q s T DELETED DELETED DELETED
T A R H Q s T DELETED DELETED DELETED! M
T A R H Q s T DELETED DELETED P
T A R H Q s T DELETED DELETED P M
T A R H Q s T DELETED P DELETED
T A | R H Q s T DELETED P DELETED M
T A R H Q s T DELETED P P
T A R H Q s T DELETED P P M
T A R H Q s T N DELETED DELETED |
T A R H Q s T N DELETED DELETED M
T A R H Q s T N DELETED P

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R H Q s T • N DELETED P M
T A R H Q s T N P DELETED
T A R H Q s T N P DELETED M
T A R H Q s T N P P
T A R H Q s T N P P M
T A R H Q G S DELETED DELETED DELETED
T A R H Q G S DELETED DELETED DELETED M
T A R H Q G s DELETED DELETED P
T A R ■ H Q G s DELETED DELETED P M
T A R H Q G s DELETED P DELETED
T A R H Q G s DELETED P DELETED M
T A R H Q G s DELETED P P
T A R H Q G s DELETED P P M
T A R H Q G s N DELETED DELETED
T A R H Q G s N DELETED DELETED M
T A R H Q G s N DELETED P
T A R H Q G s N DELETED P M
T A R H Q G s N P DELETED
T A R H Q G s N P DELETED M
T A R H Q G s N P P
T A R K Q G s N P P M
T A R H Q G T DELETED DELETED DELETED
T A R H Q G T DELETED DELETED DELETED M
T A R H Q G T DELETED DELETED P
T A R H Q G T I DELETED1 DELETED P M
T A R H Q G T DELETED P DELETED
T A R H Q G T DELETED P DELETED M
T A R H Q G T DELETED P P
T A R H Q G T DELETED P P M
T A R H Q G T N DELETED DELETED
T A R H Q G T N DELETED DELETED M
T A R H Q G T N DELETED P
T A R H Q G T N DELETED P M
T A R H Q G T N P DELETED
T A R H Q G T N P DELETED M
T A R H Q G T N P P
T A R H Q G T N P P M
T A R H V S S DELETED DELETED DELETED
T A R H V S S DELETED DELETED DELETED M
T A R H V S s DELETED DELETED P
T A R H V S s DELETED DELETED P M
T . A R H V s s DELETED P DELETED
T A R H V s s DELETED P DELETED M
T A R H V s s DELETED P P
T A R H V s s DELETED P P M
T A R H V s s N DELETED DELETED
T A ! 1 R H V s s N DELETED DELETED M

WO 2008/112003

PCTYUS2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A R H V s S N DELETED P M
T A R H V s s N DELETED P

T A R H V s s N P DELETED
T A R H V s s N P DELETED M
T A R H V s s N P P i I
T A R H V s s N P P M
T A R H V s T DELETED DELETED DELETED
T A R H V s T DELETED DELETED DELETED M
T A R H V s T DELETED DELETED P
T A R H V s T DELETED DELETED P M
T A R H V s T DELETED P DELETED
T A R H V s T DELETED P DELETED M
T A R H V s T DELETED P P
T A R H V s T DELETED P P M
T A R H V S ! T N DELETED DELETED
T A R H V S ! T N DELETED DELETED M
T A R H V S ! T N DELETED P i I
T A R H V S ': T N DELETED P M
T A R H V S i T N P DELETED
T A R H V S T N P DELETED M
T A R H V s T N P P
T A R H V s T N P P M
T A R H V G S DELETED DELETED DELETED
T A R H V G s DELETED DELETED DELETED M
T A R H V G s DELETED DELETED P
T A R H V G s DELETED DELETED P M
T A R H V G s DELETED P DELETED
T A R H V G s DELETED P DELETED M
T A R H V G s DELETED P P
T A R H V G s DELETED P P M
T A R H V G s N DELETED DELETED
T A R H V G s N DELETED DELETED M
T A R H V G s N DELETED P
T A R H V G s N DELETED P M
T A R H V G s N P DELETED
T A R H V G s N P DELETED M
T A __n R H V G s N P P
T A R H V G s N P P M
T A R H V G T DELETED DELETED DELETED f
T A R H V G T DELETED DELETED DELETED M
T A R H V G T DELETED DELETED P
T A R H V G T DELETED DELETED P M
T A R H V G T DELETED P DELETED
T A R H V G T DELETED P DELETED M
T A R H V G T DELETED P P
T A R H V G T DELETED P P M
T A R H V G T N DELETED DELETED

n d d 3313130 S 9 0 A 1 S d V 1
i d d 3313130 s 9 0 A 1 s d V 1
\M 0313130 d 3313130 s 9 0 A 1 s d V 1
i 0313130 d 3313130 s 9 0 A 1 s d V 1
lAj d 0313130 3313130 s 9 D A 1 s d V 1
i d Q313130 3313130 s 9 0 A 1 s d V 1
irti 0313130 0313130 0313130 s ^ o A 1 s d V 1
i 0313130 0313130 0313130 s 9 0 A 1 s d V 1
w d d N 1 S D A 1 s d V 1
i d d N 1 s D A 1 s 3 V 1
w 0313130 d N 1 s 0 A 1 s d V 1
[ 0313130 d N 1 s 0 A 1 s d V 1
irti d 0313130 N 1 s 0 A 1 s 3 V 1
1 d 0313130 N 1 s 0 A 1 s d V 1
n 0313130 0313130 N 1 s 0 A 1 s 3 V 1
i 0313130 0313130 N 1 s 0 A 1 s d V 1
1AI d d 0313130 1 s D A 1 s 3 V 1
1 d d 0313130 1 s 0 A 1 s 3 V 1
IAI 0313130 d 0313130 1 s 0 A 1 s d V 1
1 0313130 d 0313130 1 s D A 1 s d V 1
IN d 0313130 0313130 1 s D A 1 s d V 1
1 d 0313130 0313130 1 s 0 A 1 s d V 1
(A] 0313130 0313130 0313130 1 s 0 A 1 s d V 1
I 0313130 0313130 0313130 1 s 0 A 1 s d V 1
IAI d d N s s 0 A 1 s d V 1
i d d N s s 0 A T s d V 1
w 0313130 d N s s D A 1 s d V 1
i 0313130 d N s s 0 A 1 s d V 1
1 w d 0313130 N s s 0 A 1 s d V 1
i i d 0313130 N s ; s 0 A 1 s d I V x
[A| 0313130 0313130 N s s 0 A i 1 s d V 1
1 0313130 0313130 N S i S D A 1 s 3 V 1
W d d 0313130 S ! S 0 A 1 s d V 1
1 d d 0313130 S | S D A 1 s d V 1
W 0313130 d 0313130 s s D A 1 s d V 1
1 0313130 d 0313130 s s 0 A 1 s d V 1
W d 0313130 0313130 s s D A 1 s d V 1
1 d 0313130 0313130 s s 0 A 1 s d V 1
n 0313130 0313130 0313130 s s 0 A 1 s d V 1
i 0313130 0313130 0313130 s s 0 A 1 s d V 1
w d d N 1 9 A H y V 1
i d d N 1 9 A H y V 1
w 031313G d N 1 9 A H y V 1
t 0313130 d N 1 9 A H y V 1
w d 0313130 N 1 9 A H y V 1
1 d 0313130 N 1 9 A H y V 1
w 0313130 0313130 N 1 9 A H y V 1
m 96 96 P6 V6 95 SS 6* C£ te GZ sz oz
tusuvioossntfoj toommooi O/A

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F S L Y Q G s N DELETED DELETED
T A F S L Y Q G s N DELETED DELETED M
T A F S L Y Q G s N DELETED P
T A F S L Y Q G s N DELETED P M
T A F s L Y Q G s N P DELETED
T A F s L Y Q G j S N P DELETED M
T A F s L Y | Q G s N P P
T A F s L Y Q G s N P P M
T A F s L Y Q G T DELETED DELETED DELETED
T A F s L Y Q G T DELETED DELETED DELETED M
T A F s L Y Q G T DELETED DELETED P
T A F s L Y Q G T DELETED DELETED P M
T A F s L Y Q G T DELETED P DELETED
T A F s L Y Q G T DELETED P DELETED M
T A F s L Y Q G T DELETED P P
T A F s L I Y Q G T [DELETED P P M
T A F i 3 L ! Y Q G T N DELETEDiDELETED
T A F | S L i Y Q G T N DELETED DELETED M
T A F i S L Y Q G T N DELETED P
T A F s L Y Q G T N DELETED P M
T A F s L Y Q G T N P DELETED
T A F s L Y Q G T N P DELETED M
T A F s L Y Q G T N P P ! I
T A F s L Y Q G T N P P i M
T A F s L Y V S S DELETED DELETED DELETED
T A F s ■ L Y V S s DELETED DELETED DELETED M
T A F s L Y V s s DELETED DELETED P
T A F s L Y V s s DELETED DELETED P M
T A F s L Y V s s DELETED P DELETED
T A F s L Y V s s DELETED P DELETED M
T A F s L Y V s s DELETED P P
T A F s L Y V s s DELETED P P M !
T A F s L Y V s s N DELETED DELETED
T A F s L Y V s s N DELETED DELETED M
T A F s L Y V s s N DELETED P
T A F s L Y V s s N DELETED P M
T ■ A ■ F s L Y V s s N P DELETED
T A F s L Y V s s N P DELETED M
T A F s L Y V s s N P P
T A F s L Y V s s N P P M
T A F s L Y V s T DELETED DELETED DELETED
T A F s L Y V s T DELETED DELETED DELETED M
T A F s L Y V s T DELETED DELETED P
T A F s L Y V s T DELETED DELETED P M
T A F s L Y V s T DELETED P DELETED
T A F s L Y V s T DELETED P DELETED M
T A F s L Y V s T DELETED P P

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 | 56 j 91 94 95 96 107
M
T A F S L Y V s T DELETED P P

T A F S L Y V s T N DELETED DELETED M
T A F S L Y V s T N DELETED DELETED

T A F S L Y V s T N DELETED P
T A F S L Y V s T N DELETED P M
T A F S L Y V s T N P DELETED
T A F S L Y V s T N P DELETED M
T A F S L Y V s T N P P
T A F s L Y V s T N P P M
T A F s L Y V G S DELETED DELETED DELETED
T A F s L Y V G S DELETED DELETED DELETED M
T A F s L Y V G s DELETED DELETED P
T A F s L Y V G s DELETED DELETED P M
T A F s L Y V G s DELETED P DELETED
T A F s L Y V G s DELETED P DELETED M
T A F s L Y V G i S DELETED P P
T A F s L Y V G : S DELETED P P M !
T A F s L Y V G j S N DELETED DELETED i i
T A F s L Y V s N DELETED DELETED M
T A F s L Y V G S i N DELETED P
T A F s L Y V G S N DELETED P M
T A F s L Y V G s N P DELETED
T A F s L Y V G s N P DELETED M
T A F s L Y V G s N P P
T A F s L Y V G s N P P M
T A F s L Y V G T DELETED DELETED DELETED
T A F s L Y V G T DELETED DELETED DELETED M
T A F s L Y V G T DELETED DELETED P
T A F s L Y V G T DELETED DELETED P M
T A F s L Y V G T DELETED P DELETED
T A F s L Y V G T DELETED P DELETED M
T A F s L Y V G T DELETED P P-
T A F s L Y V G j T DELETED P P M
T A F s L Y V G I T N DELETED DELETED
T A F s L Y V G T N . DELETED DELETED M
T A F s L Y V G T N DELETED P
T A F s L Y V G T N DELETED P M
T A F s L Y V G T N P DELETED
T A F s L Y V G T N P DELETED M
T A F s L Y V G T N P P
T A F s L Y V G T N P P M
T A F s L H Q S S DELETED DELETED DELETED
T A F s L H Q S s DELETED DELETED DELETED M
T A F s L H Q S s DELETED DELETED P
T A F s L H Q S s DELETED DELETED P ■ M
T A F s L H Q S s DELETED P DELETED
T A F s L H Q s s DELETED P DELETED M

WO 2008/112003 PCT/US2007/075U7

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F S L H Q S S DELETED P P I I
T A F S L H 0 S S DELETED P P M i
T A F S L H Q S S N DELETED DELETED I
T A F S L H Q S S N DELETED DELETED M
T A F S L H Q S S N DELETED P
T A F S L H Q S S N DELETED P M
T A F S L H Q S s N P DELETED
T A F S L H Q S s N P DELETED M
T A F S L H Q S s N P P
T A F S L H Q S s N P P M
T A F S L H Q S T DELETED DELETED DELETED
T A F S L H Q S T DELETED DELETED DELETED M
T A F S L H Q s T DELETED DELETED P
T A F S L H Q s T DELETED DELETED P M
T A F S L H 0 s T DELETED P DELETED
T A F S L H Q s ■ T DELETED P DELETED M
T A F a L H Q s T DELETED P P
T A F s L H Q s T DELETED P P M
X A ,F s I H O s T ' N DELETED DELETED} }
T A F s L H 0 s T N DELETED DELETED M
T A F s L H Q s T N DELETED P
T A F s L H Q s T N DELETED P M
T A F s L H Q s T N P DELETED
T A F s L H Q s T N P DELETED M
T A F s L H Q s T N P P
T A F s L H Q s : T N P P M
T A F s L H Q G S DELETED DELETED DELETED
T A F s L H Q G ■ S DELETED DELETED DELETED M
T A F s L H Q G ! S DELETED DELETED P
T A F s L H Q G | S DELETED DELETED P M
T A F s L H Q G S DELETED P DELETED
T A F s L H Q G S DELETED P DELETED M
T A F s L H Q G s DELETED P P
T A F s L H Q G s DELETED P P M
T A F s L H Q G s N DELETED DELETED
T A F s L H Q G s N DELETED DELETED M
T A F s L H Q G s N DELETED P
T A F s L H Q G s N DELETED P M .
T A F s L H Q G s N P DELETED
T A F s L H Q G s N P DELETED M
T A F s L H Q G s N" P P
T A F s L H Q G s N P P M
T A F s L H Q G T DELETED DELETED DELETED
T A F s L H Q G T DELETED DELETED DELETED M
T A F s L H Q G T DELETED DELETED P
T A F s L H Q G T DELETED DELETED! P M
1 T A F s L H Q G T DELETED P IDELETED

WO 2008/112003 PCT/US2007/075U7

20 25 29 31 33 49 55 56 [ 91 94 95 96 107
T A F S L H Q G T DELETED P DELETED M
T A F S L H Q G T DELETED P P
T A F S L H Q G T DELETED P P M
T A F S L H Q G T N DELETED DELETED
T A F s L H Q G T N DELETED DELETED M
T A F s L H Q G T N DELETED P
T A ,_ F s L H Q G T N DELETED P M
T A F s L H Q G T N P DELETED
T A F s L H Q G T N P DELETED M
T A F s L H Q G T N P P
T A F s L H Q G T N P P M
T A .F s L H V S S DELETED DELETED DELETED
T A F s L H V S S DELETED DELETED DELETED M
T A F s L H V S s DELETED DELETED P
T A F s L H V s s DELETED DELETED P M
T A F s L H V S S DELETED P DELETED
T A F s L H V S ' S DELETED P DELETED M !
T A F s L H v s s DELETED P P
T A F s L H V s s DELETED P P M
T A F s L H V s s N DELETED DELETED
T A F s L H V s s N DELETED DELETED M
T A F s L H V s s N DELETED P
T A F s L H V s s N DELETED P M
T A F s L H V s s N P DELETED
T A F s L H V s s N P DELETED M
T A F s L H V s s N P P ,
T A F s L H V s s N P P M
T A F s L H V s T DELETED DELETED DELETED
T A F s L H V s T DELETED DELETED DELETED M
T A F s L H V s T DELETED DELETED P
T A F s L H V s T DELETED DELETED P M
T A F s L H V s ! T DELETED P DELETED
T A F s L H V s ! T DELETED P DELETED M
T A F s L H V s T DELETED P P
T A F s L H V s T DELETED P P M
T A F s L H V s T N DELETED DELETED .
T- A F s L H V s T N DELETED DELETED M
T A F s L H V s T N DELETED P
T A F s L H V s T N DELETED P M
T A F s L H V s T N P DELETED
T I A F s L H V s T N P DELETED M
T A F s L H V s T N P P
T A F s L H V s T N P P M
T A F s L H V G S DELETED DELETED DELETED
T A F s L H V G S DELETED DELETED DELETED M
T A | F s L H V G I S DELETED DELETED P
T A F s L H V G | S DELETED DELETED P M

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F S L H V G s DELETED P DELETED
T A F S L H V G s DELETED P DELETED M
T A F s L H V G s DELETED P P
T A F s L H V G s DELETED P P M
T A F s L H V G s N DELETED DELETED
T A F s L H V G s N DELETED DELETED M
T A F s L H V G s N DELETED P
T A F s L H V G s N DELETED P M
T A F s L H V G s N P DELETED
T A F s L H V G s N P DELETED M
T A F s L H V G s N P P
T A F . s L H V G s N P P M
T A F s L H V G T DELETED DELETED DELETED
T A F s L H V G T DELETED DELETED DELETED M
T A F s L H V G T DELETED DELETED P
T A F s L H V G T DELETED DELETED P M !
T A F s L H V G T DELETED P DELETED I i I I
T A F s L H V G T DELETED P DELETED M
T A F s L H V G T DELETED P P
T A F s L H V G T DELETED P P M
T A F s L H V G T N DELETED DELETED
T A F s L H V G T N DELETED DELETED M
T A F s L H V G T N DELETED P
T A F s L H V G T N DELETED P M
T A F s L H V G T N P DELETED
T A F s L H V G T N P DELETED M
T A F s L H V G T N P P I I
T A F s L H V G T N P P J M
T A F s Y Q S S DELETED DELETED DELETED
T A F s Y Q S S DELETED DELETED DELETED M
T A F s Y Q S s DELETED DELETED P
T A F s Y Q S s DELETED DELETED P M
T A F s Y Q S s DELETED P DELETED
T A F s Y Q S s DELETED P DELETED M
T A F s Y Q S s DELETED P P
T A F s Y Q S s DELETED P P M
T A F s Y Q s s N DELETED DELETED
T A F s Y Q s s N. DELETED DELETED M
T A F s Y Q s s ■ N DELETED P
T A F s Y Q s s N DELETED P M
T A F s Y Q s s N P DELETED
T A F s Y Q s s N P DELETED M
T A F s Y Q s s N P P
T A F s I I Y Q s s N P P M
T A F s Y Q s T DELETED DELETED DELETED
T A F s Y Q s T DELETED DELETED DELETED M
T A F S Y Q s T DELETED DELETED P

WO 2008/112003 PCT/US2007/0751I7

20 25 29 31 33 49 55 56 i 91 94 95 96 107
T A F S I Y Q s ! T DELETED DELETED P M
T A F S Y Q s T DELETED P DELETED
T A F s Y Q s T DELETED P DELETED M
T A F s I Y Q s T DELETED P P
T A F s Y 0 S ! T DELETED P P M
T A F s Y Q S I T N DELETED DELETED
T A F s Y Q S ! T N DELETED DELETED M
T A F s Y Q s ! T N DELETED P
T A F s Y Q s T N DELETED P M
T A F s Y Q s T N P DELETED
T A F s Y Q s T N P DELETED M
T A F s Y Q s T N P P
T A F s Y Q s i T N P P M
T A F s Y Q G | S DELETED DELETED DELETED
T A F s Y Q G i S DELETED DELETED DELETED M
T A F s Y Q G : S DELETED DELETED P
T A F s Y Q G '- S DELETED DELETED P M '
T A F s Y Q G | S DELETED P DELETED
T A F s Y Q G ! S DELETED P DELETED M
T A F s Y Q G ! S DELETED P P
T A F s Y Q G S DELETED P P M
T A F s Y Q G S N DELETED DELETED
T A F s Y Q G s N DELETED DELETED M
T A F s Y Q G s N DELETED P
T A F s Y Q G s N DELETED P M
T A F s Y Q G i S N P DELETED i
I i
T A F s Y Q G i S N P DELETED M
T ... A F s Y Q G s N P P ■
T A F s Y Q G s N P P M
T A F s Y Q G T DELETED DELETED DELETED
T A F s Y Q G T DELETED DELETED DELETED M
T A F s Y Q G T DELETED DELETED P
T A F s Y Q G T DELETED DELETED P M
T A F s Y Q G T DELETED P DELETED
T A F s Y Q G T DELETED P DELETED M
T A F s Y Q * G T DELETED P P
T A F s Y Q G T DELETED P P M
T A F s Y Q G T N DELETED DELETED
T A F s Y Q G T - N DELETED DELETED M
T A F s Y Q G T N DELETED P
T A F s Y Q G T N DELETED P M
T A F s Y Q G T N P DELETED
T A F s Y Q G T N P DELETED M
T A F s Y Q G T N P P .
T A F s Y Q G T N P P ■ M
T A F s Y V S S DELETED DELETED DELETED
T A F s I ! Y V S S DELETED DELETED DELETED M

WO 2008/112003 PCT/US2007/0751I7

20 25 29 31 33 49 55 56 91 94 95 96 107 .
T A F S Y V s S DELETED DELETED P
T A F S Y V s S DELETED DELETED P M
T A F S Y V s S DELETED P DELETED
T A F s Y V s s DELETED P DELETED M
T A F s Y V s s DELETED P P
T A F s Y V s s DELETED P P M
T A F s Y V s s N DELETED DELETED
T A F s Y V s s N DELETED DELETED M
T A F s Y V s s N DELETED P
T A F s Y V s s N DELETED P M
T A F s Y V s s N P DELETED
T A F s Y V s s N P DELETED M
T A F s Y V s s N P P
T A F s Y V s s N P P M
T A F s Y V s T DELETED DELETED DELETED
T A F s Y V S ! T DELETED DELETED DELETED M j
T A F s Y V S ! T DELETED DELETED P I I
T A F s Y V s : T DELETED DELETED P M !
T A F s Y V S i T DELETED P DELETED [ i
T A F s Y V S ! T DELETED P DELETED M
T A F s Y V s T DELETED P P
T A F s Y V s T DELETED P P M
T A F s Y V s T N DELETED DELETED
T A F s Y V s T N DELETED DELETED M
T A F s Y V s T N DELETED P
T A F s Y V s T N DELETEDI P M
T A F s Y V s T N p (DELETED
T A F s Y V s T N p DELETED M
T A F s Y V s T N p P
T A F s Y V s T N p P M
T A F s Y V G S DELETED DELETED DELETED I
T A F s Y V G S DELETED DELETED DELETED M
T A F s Y V G s DELETED DELETED P
T A F s Y V G s DELETED DELETED P M
T A F s Y V G s DELETED P DELETED
T A F s Y V G s DELETED P DELETED M
T A F s Y V G s DELETED P P
T A F s Y V G s DELETED P P M
T A F s Y V G s N DELETED DELETED
T A F s Y V G s N DELETED DELETED M
T A F s Y V G s N DELETED P
T A F s Y V G s N DELETED P M
T A F s Y V G s N P DELETED
T A F s Y V G s N P DELETED M
T A F s Y V G s N P P
T A F s Y V G s N P P M
T A F s Y V G i T DELETED DELETED DELETED

WO 2008/112003 PCT/US2007/075117

20 25 29 31 | 33 49 55 56 91 94 95 96 107
T A F S I Y V G T DELETED DELETED DELETED M
T A F S Y V G T DELETED DELETED P
T A F S Y V G T DELETED DELETED P M
T A F S Y V G T DELETED P DELETED

A F S Y V G T DELETED P DELETED M
T A F S Y V G T DELETED P P
T A F S Y V G T DELETED P P M
T A F S Y V G T N DELETED DELETED
T A F s Y V G T N DELETED DELETED M
T A F s Y V G T N DELETED P
T A F s Y V G T N DELETED P M
T A F s Y V G T N P DELETED
T A F s Y V G T N P DELETED M
T A F s Y V G T N P P
T A F s Y V G i T N P P M
T A F s H Q s s DELETED DELETED DELETED
T A F s H Q S : S DELETED DELETED DELETED M '■
T A F s H Q S S DELETED DELETED P
T A F s H Q s s DELETED DELETED P M
T A F s H Q s s DELETED P DELETED
T A F s H Q s s DELETED P DELETED M
T * F s H Q s s DELETED P P
T A F s H Q s s DELETED P P M
T A F s H Q s s N DELETED DELETED
T A F s H Q s s N DELETED DELETED M
T A F s H Q s s N DELETED P
T A F . s H Q s s N DELETED P M
T A F s H 0 s s N P DELETED
T A F s H Q s s N P DELETED M
T A F s H Q s s N P P
T A F s H Q s s N P P M
T A F s H Q s T DELETED DELETED DELETED
T A F s H Q s T DELETED DELETED DELETED M
T A F s H Q s T DELETED DELETED P
T A F s H Q s T DELETED DELETED P M
" T A m F s H Q s T DELETED P DELETED
T A F s H Q s T DELETED P DELETED M
T A F s H Q s T DELETED P P
T A F s H 0 s T DELETED P P M
T A F s H Q s T N DELETED DELETED
T A F s H Q s T N DELETED DELETED M
T A F s H Q s T N DELETED P
T A F s H Q s T N DELETED P M
T A F s H Q s T N P DELETED
T A F s H Q s T N P DELETED M
T A F s H Q s T N P P ]
T i A | F | S H Q s T N p ! p M

WO 200H/112003 PCY/USSoaMlWi H

20 25 29 31 33 49 55 ! 56 91 94 95 96 107
T A F S H Q G s DELETED DELETED DELETED
T A F S H Q G s DELETED DELETED DELETED M
T A F s H Q G s DELETED DELETED P
T A F s H Q G s DELETED DELETED P M |
T A F s H Q G s DELETED P DELETED I !
T A F s H Q G s DELETED P DELETED M
T A F s H Q G s DELETED P P
T A F s H Q G s DELETED P P M
T A F s H Q G s N DELETED DELETED
T A F s H Q G s N DELETED DELETED M
T A F s H 0 G s N DELETED P
T A F s H Q G s N . DELETED P M
T A F s H Q G s N P DELETED
T A F s H Q G s N P DELETED M
T A F s H Q G s N P P
T A F s H Q G s N P | P M
T A F s i | H Q G T DELETED DELETED DELETED
T A F s H •Q G T DELETED DELETED DELETED M
T A F s H Q G T DELETED DELETED P
T A F s H 0 G T DELETED DELETED P M
T A F s H Q G T DELETED P DELETED
T A F s H .Q G T DELETED P DELETED M
T A F s H Q G T DELETED P P
T A F s H Q G T DELETED P P M
T A F s H Q G T N DELETED DELETED
T A F s H Q G T N DELETED DELETED M
T A F s H Q G T N DELETED P
T A F s H Q G T N DELETED P M
T A F s H Q G T N P . DELETED
T A F s H Q G T ] N P DELETED M
T A F s H Q G T N P P
T A F s H Q G T N P P M
T A F s H V S S DELETED DELETED DELETED! 1
T A F s H V s S DELETED DELETED DELETED M
T A F s H V s s DELETED DELETED P
T A F s H V s s DELETED DELETED P M
T A F s H V s s DELETED P . DELETED
T A F s H V s s DELETED P ■ DELETED M
T A F s H V s s DELETED P P
T A F s H V s s DELETED P P M
T A F s H V s s N DELETED DELETED
T A F s H V s s N DELETED DELETED M
T A F s H V s s N DELETED P
T A F s H V s s N DELETED P M
T A F s H V s s N P DELETED
T A F s H v s s N P DELETED M
T A F s H ! V s ! s N P P

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F S H V s S N P P M
T A F S H V s T DELETED DELETED DELETED
T A F s H V s T DELETED DELETED DELETED M
T A F s H V s T DELETED DELETED P
T A F s H V s T DELETED DELETED P M
T A F s H V s T DELETED P DELETED
T A F s H V s T DELETED P DELETED M
T A F s H V s T DELETED P P
T A F s H V s T DELETED P P M
T A F s H V s T N DELETED DELETED
T A F s H V s T N DELETED DELETED M
T A F s H V s T N DELETED P
T A F s H V s T N DELETED P M
T A F s H V s T N P DELETED
T A F s H V s T N P DELETED M
T A F s H V s T N P P
T A F s H V s T N P P | M
T A F s H V | G ! S DELETED DELETED DELETED
T A F s H V | G S DELETED DELETED DELETED M
T A F s H V G S DELETED DELETED P
T A F s H V G s DELETED DELETED P M
T A F s H V G s DELETED P DELETED
T A F s H V G s DELETED P DELETED M
T A F s H V G S S DELETED P P
T A F s H V G | S DELETED P P M
T A F s H V G I S N DELETED DELETED
T A F s H V G ! S N DELETED DELETED M
T A F s H V G s N DELETED P
T A F s H V G s N DELETED P M
T A F s H V G s N . P DELETED
T A F s H V G s IS] P DELETED M
T A F s H V G s N P P
T A F s H V G , s N P P M
T A F s H V G T DELETED DELETED DELETED
T A F s H V G T DELETED DELETED DELETED M
T A F s H V G T DELETED DELETED P
T A F s H V G T DELETED DELETED P M
T A F s H V G T DELETED P DELETED
T A F s H V G T DELETED P DELETED M
T A F s H V G T DELETED P P
T A F s H V G T DELETED P P M
T A F s H V G T N DELETED DELETED
T A F s H V G T N DELETED DELETED M
T A F s H V G T N DELETED P
T A F s H V G T N DELETED P M
T A F s I H V G T N P DELETED
T A F s I ! H V G T N P DELETED M

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 | 107
T A F S I H V G T N P P i i
T A F s I H V G T N P P ! M
T A F R L Y Q S S DELETED DELETED DELETED
T A F R L Y Q S S DELETED DELETED DELETED M
T A F R L Y Q s S DELETED DELETED P
T A F R L Y Q s S DELETED DELETED P M
T A F R L Y Q s S DELETED P DELETED
T A F R L Y Q s S DELETED P DELETED M
T . A F R L Y Q s S DELETED P P
T A F R L Y Q s S DELETED P P M
T A F R L Y Q s S N DELETED DELETED
T A F R L Y Q s S N DELETED DELETED M
T A F R L Y Q s S N DELETED P
T A F R L Y Q s s N DELETED P M
T A F R L Y Q s s N P DELETED
T A F R L Y Q s s N P DELETED M
T A F R L Y Q s s N P 9 i I
T A F R L Y Q s s ! N P P M
T A F R L Y Q s T DELETED DELETED DELETED
T A F R L Y Q s T DELETED DELETED DELETED M
T A F R L Y Q s T DELETED DELETED P
T A F R L Y Q s T DELETED DELETED P M
T A F R L Y Q s T DELETED P [DELETED
T A F R L Y Q s T DELETED P iDELETED M
T A F R L Y Q s T DELETED P P
T A F R L Y Q s T DELETED P P M
T A F R L Y Q s T N DELETED DELETED
T A F R L Y Q s T N DELETED DELETED M .
T A F R L Y Q s T N DELETED P
T A F R L Y Q s T N DELETED P M
T A F R L Y Q s T N P DELETED
T A F R L Y Q s T N P DELETED M
T A F R L Y Q s T N P P
T A F R L Y Q s T N P P M
T A F R L Y Q G S DELETED DELETED DELETED
T A F R L Y Q G S DELETED DELETED DELETED M
T A F R L Y Q G S DELETED DELETED P
T A F R L Y Q G S DELETED DELETED P M
T A F R L Y Q G S DELETED P DELETED
T A F R L Y Q G S DELETED P DELETED M
T A F R L Y Q G S DELETED P P
T A F R L Y Q G S DELETED P P M
T A F R L Y Q G S N DELETED DELETED
T A F R L Y Q G ! S N DELETED DELETED M
T .A F R L Y Q G S N DELETED P
T A F R L Y Q G s N DELETED P M
T A F R L Y Q G s N P DELETED i

WO 2008/112003 PCT/US2007/075I17

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F R L Y Q G S N P DELETED M
T A F R L Y Q G s N P P
T A F R L Y Q G ! S N P P M
T A F R L Y Q G T DELETED DELETED DELETED
T A F R L Y Q G T DELETED DELETED DELETED M
T A F R L Y Q G T DELETED DELETED P
T A F R L Y Q G T DELETED DELETED P M
T A F R L Y Q G T DELETED P DELETED
T A F R L Y Q G T DELETED P DELETED M
T A F R L Y Q G T DELETED P P
T A F R L Y Q G T DELETED P P M
T A F R L Y Q G T ' N DELETED DELETED
T A F R L Y Q G T N DELETED DELETED M
T A F R L Y Q G T N DELETED P
T A F R L Y Q G T N DELETED P M
T A F R L Y Q G ! T N | P DELETED
T A F R L Y 0 G ! T N P DELETED M
T A F R L Y Q G ! T N P P
T A F R L Y Q G j T N P P M
T A F R L Y V S | S DELETED DELETED DELETED
T A F R L Y V s S DELETED DELETED DELETED M
T A F R L Y V s S DELETED DELETED P
T A F R L Y V s s DELETED DELETED P M
T A F R L Y V s s DELETED P DELETED
T A F R L Y V s s DELETED P DELETED M
T A F R L Y V s s DELETED P P
T A F R L Y V s s DELETED P P M
T A F R L Y V s s N DELETED DELETED
T A F R L Y V s s. N DELETED DELETED M
T A F R L Y V s s N DELETED P
T A F R L Y V s s N DELETED P M
T A F R L Y V s s N P DELETED
T A F R L Y V s s N P DELETED M
T A F R L Y V s s N P P
T A F R L Y V s s N P P M
T A F R L Y V s T DELETED DELETED DELETED
T A F R . L Y V s T DELETED DELETED DELETED M
T A F R L Y V s T DELETED DELETED P
T A F R L Y V s T DELETED DELETED P M
T A F R L Y V S i T DELETED P DELETED
T A F R L Y V S ; T DELETED P DELETED M
T A F R L Y V s T DELETED P P
T A F R L Y V s T DELETED P P M
T A F R L Y V s T N DELETED DELETED
T A F R L Y V s T N DELETED DELETED M
T A F R L Y V s T N DELETED P
T A F R L Y V s T N DELETED P M

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F R L Y V S T N P DELETED f
T A F R L Y V S T N P DELETED M
T A F R L Y V S T N P P
T A F R L Y V S T N P P M
T A F R L Y V G S DELETED DELETED DELETED
T A F R L Y V G s DELETED DELETED DELETED M
T A F R L Y V G s DELETED DELETED P
T A F R L Y V G s DELETED DELETED P M
T A F R L Y V G s DELETED P DELETED
T A F R L Y V G s DELETED P DELETED M
T A F R L Y V G s DELETED P P
T A F R L Y V G s DELETED P P M
T\ A F R L Y V G s N DELETED DELETED
T ' A F R L Y V G s N DELETED DELETED M
T/ A F R L Y V G s N DELETED P
| T A F R L Y V G s N DELETED P M
i T A F R L Y V i G i S N P DELETED I ]
T A F R L Y V ! G I S N P DELETED M
T A F R L Y V G j S N P P i i
T A F R L Y V G s N P P M
T A F R L Y V G T DELETED DELETED DELETED
T A F R L Y V G T DELETED DELETED DELETED M
T A F R L Y V G T DELETED DELETED P
T A F R L Y V G T DELETED DELETED P M
T A F R L Y V G T DELETED P DELETED
T A F R L Y V G T DELETED P DELETED M
T A F R L Y V G T DELETED P P
T A F R L Y V G T DELETED P P M
T A F R L Y V G T N DELETED DELETED
T A F R L Y V G T N DELETED DELETED M
T A F R L Y V G T N DELETED P
T A F R L Y V G T N DELETED P M
T A F R L Y V G T N P DELETED
T A F R L Y V G T N P DELETED M
T A F R L Y V G T N P P
T A F R L Y V G T N P P M
T A F R L H Q S S . DELETED DELETED DELETED
T A F R L H Q S S DELETED DELETED DELETED M
T A F R L H Q S s DELETED DELETED P
T A F R L H Q S s DELETED DELETED P M
T A F R L H Q S s DELETED P DELETED
T A F R L H Q S s DELETED P DELETED M
T A F R L H Q S s DELETED P P
T A F R L H Q S s DELETED P P M
T A F R L H Q S s N DELETED DELETED
T A F R L H Q S s N DELETED DELETED M
T A F R L H Q s s N DELETED P

WO 2008/112003 PCT/US2007/07S117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F R L H Q S S N DELETED P M
T A F R L H Q S S N P DELETED
T A F R L H Q s ! s N P DELETED M
T A F R L H Q s s N P P
T A F R L H Q s s N P P M !
T A F R L H Q s T DELETED DELETED DELETED
T A F R L H Q s T DELETED DELETED DELETED M
T A F R L H Q s T DELETED DELETED P
T A F R - L H Q s T DELETED DELETED P M
T A F R L H Q s T DELETED P DELETED
T A F R L H Q s T DELETED P DELETED M
T A F R L H Q s T DELETED P P
T A . .p. R L H Q s T DELETED P P M
T A F R L H Q s T N DELETED DELETED
T A F R L H Q s T N DELETED DELETED M
T A F R L H Q s T N iDELETED P
T A F R L H j Q S i T N DELETED P M
T A F R L H Q S I T N P DELETED
T A F R L i H Q s T N P DELETED M
T A F R L H Q s T N P P
T ■ A F R L H Q s T N P P M
T A F R L H Q J G S DELETED DELETED DELETED
T A F R L H Q G S DELETED DELETED DELETED M
T A F R L H Q G s DELETED DELETED P
T A F R L H Q G s DELETED DELETED P M
T A F R L H Q G s DELETED P DELETED
T A F R L H Q G s DELETED P DELETED
T A F R L H Q G s DELETED P P
T A F R L H Q G s DELETED P P
T A F ' R L H Q G L s N DELETED DELETED
T A F R L H Q G s N DELETED DELETED
T A F R L H Q G s N DELETED P
T A F R L H Q G s N DELETED P
T A F R L H Q G s N P DELETED
T A F R L H Q G i S . N P DELETED
T A F R L H Q G s N P P
T A F R L H Q G s N P P
T A F R L H Q G T DELETED DELETED DELETED
T A F R L H Q G T DELETED DELETED DELETED
T A F R L H Q G T DELETED DELETED P
T A F R L H Q G T DELETED DELETED P
T A F R L H Q G T DELETED P DELETED
T A F R L H Q G T DELETED P DELETED
t A F R L H Q G T DELETED P P
t : A F R L H Q G T DELETED P P
T A: - F R L H Q G T N DELETED DELETED |
T A F -. R : ■L:. .. H Q G ! T N DELETED DELETED! M

WO 2008/112003 PCT/US2007/0751J7

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F R L H Q G __JL._
T N DELETED P M
T A F R L H Q G
N DELETED P

T A F R L H Q G T N P DELETED
T A F R L H Q G T N P DELETED M
T A F R L H Q G T N P P
T A F R L H Q G T N P P M
T A F R L H V s S DELETED DELETED DELETED
T A F R L H V s S DELETED DELETED DELETED M
T A F R L H V s s DELETED DELETED P
T A F R L H V s s DELETED DELETED P M
T A F R L H V s | s DELETED P DELETED
T A F R L H V s I s DELETED P DELETED M
T A F R L H V s s DELETED P P
T A F R L H V s s DELETED P P M
T A F R L H V s s N DELETED DELETED
T A F R L H V s s N DELETED DELETED M !
T A F R L H V s s N DELETED P
i A F R L H V s s N DELETED P M
T A F R L H V s s N P DELETED
T A F R L H V s s N P DELETED M
T A F R L H V s s N P P
T A F R L H V s s N P P M
T A F R L H V s T DELETED DELETED DELETED
T A F R L H V s T DELETED DELETED DELETED M
T A F R L H V s T DELETED DELETED P
T A F R L H V s T DELETED DELETED P M
T A F R L H V s T DELETED P DELETED
T A F R L H V s T DELETED P DELETED M
T A F R L H V s T DELETED P P
T A F R L H V s T DELETED P P M
T A F R L H V s T N DELETED DELETED
T A F R L H V s T N DELETED DELETED M
T A F R L H V s T N DELETED P
T A F R L H V s T N DELETED P M
T A F R L H V s T N P DELETED
T A F R L H V s T N P DELETED M
T A F R L H V s T N P P
T A F R L H V s T N P P M
T A F R L H V G S DELETED DELETED DELETED
T A F R L H V G S DELETED DELETED DELETED M
T A F R L H V G s DELETED DELETED P
T A F R L H V G s DELETED DELETED P M
T A F R L H V G s DELETED P DELETED
T A F R L H V G s DELETED P DELETED M
T A F R L H V G s DELETED P P
T A F R L H V G s DELETED P P M
T A F R L H V G S j N DELETED DELETED

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33
L 49 55 56 ] 91 94 95 96 107
T A F R
H V G i S N DELETED DELETED M
T A F R L H V G ! S N DELETED P
T A F R L H V G s N DELETED P M
T A F R L H V G s N P DELETED
T A F R L H V G s N P DELETED M
T A F R L H V G s N P P
T A F R L H V G s N P P M
T A F R L H V G T DELETED DELETED DELETED
T A F R L H V G T DELETED DELETED DELETED M
T A F R L H V G T DELETED DELETED P
T A F R L H V G T DELETED DELETED P M
T A F R L H V G T DELETED P DELETED
T A F R L H V G T DELETED P DELETED M
T A F R L H V G T DELETED P P
T A F R L H V G T DELETED P P M
T A F R L H V G T N DELETED DELETED
T A F R L H V G T N DELETED DELETED! M
' T A F : R L H V i G | T N DELETED P i I
T A F R I H V G T N DELETED P M
T A F R L H V G T N P DELETED
T A F R L H V G T N P DELETED M
T A F R L H V G T N P P
T A F R L H V G T N P P M
T A F R Y Q S ! S DELETED DELETED DELETED
T A F R Y Q S i S DELETED DELETED DELETED M
T A F R Y Q S : S DELETED DELETED P
T A F R Y Q S I S DELETED DELETED P M
T A F R Y Q S i S DELETED P DELETED
T A F R Y Q s | s DELETED P DELETED M
T A F R Y Q s S DELETED P P
T A F R Y Q s S DELETED P P M
T A F R Y Q s s N DELETED DELETED
T A F R Y Q s s N DELETED DELETED M
T A F R Y Q s s i N DELETED P
T A F R Y Q s s N DELETED P M
T A F R Y Q s s N P DELETED
T A F R Y Q s s N P DELETED M
T A F R Y Q s s N P ■ P
T A F R Y Q s s . N P P M
T A F R Y Q s T DELETED DELETED DELETED
T A F R Y Q s T DELETED DELETED DELETED M
T A F R Y Q s T DELETED DELETED P
T A F R Y | Q s T DELETED DELETED P M
T A F R Y Q s T DELETED P DELETED
T A F R Y Q s T DELETED P DELETED M
T A F R Y Q s T DELETED P P
T A F R Y Q s T DELETED P P M

WO 2008/112003

PCT/US2007/075U7

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F R Y Q s T N DELETED DELETED
T A F R Y Q s T N DELETED DELETED M
T A F R Y Q s T N DELETED P
T A F R Y Q s T N DELETED P DELETED _ Mj
T A F R Y Q s T N P

T A F R Y Q s T N P DELETED ■ M ■
T A F R Y Q s T N P P
T A F R Y Q s T N P P M
T A F R Y Q G S DELETED DELETED DELETED
T A F R Y Q G S DELETED DELETED DELETED M
T A F R Y Q G s DELETED DELETED P
T A F R Y Q G _, s DELETED DELETED P M
T A F R Y Q G s DELETED P DELETED
T A F R Y Q G s DELETED P DELETED M
T A F R Y Q G s DELETED P P
T A F R Y Q G s DELETED P P M
T A F R Y Q 0 o s N DELETED DELETED
T A F R Y Q G s N DELETED DELETED M ,
T A F R Y Q G _, s N DELETED P
T . A F R Y Q G s N DELETED P M
T A F R Y Q G s N P DELETED
T A F R Y Q G s N P DELETED M
T A F R Y Q G s N P P
T A F R Y Q G s N P P M
T A F R Y Q G T DELETED DELETED DELETED
T A F R Y Q G T DELETED DELETED DELETED M
T A F R Y Q G T DELETED DELETED P
T A F R Y Q G T DELETED DELETED P M
T A F R Y Q G T DELETED P DELETED
T A F R Y Q G T DELETED P DELETED M
T A F R Y Q G T DELETED P P
T A F R Y Q G T DELETED P P M
T A F R Y Q G T N DELETED DELETED
T A F R Y Q G T N DELETED DELETED M
T A F R Y Q G T N DELETED P
T A F R Y Q G T N DELETED P M
T A F R Y Q G T N P DELETED
T A F R Y Q G T N P DELETED M
T A F R Y Q G T ■ N P -P
T A F R Y Q G T N P P M
T A F R Y . V S S DELETED DELETED DELETED
T A F R Y V S s DELETED DELETED DELETED M
T A F R Y V S s DELETED DELETED P
T A F R Y V s s DELETED DELETED P M
T A F R Y V s s DELETED P DELETED
T A F R Y V s s DELETED P DELETED M
T A F R Y V s s DELETED P P I

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T A F R Y V s S DELETED P P M
T A F R Y V s S N DELETED DELETED
T A F R Y V s s N DELETED DELETED M
T A F R Y V s S ! N DELETED P
T A F R Y V s S i N DELETED P M
T A F R Y V s S N P DELETED
T A F R Y V s S N P DELETED M
T A F R | Y V s S N P P
T A F R Y V s s N P P M
T A F R Y V s T DELETED DELETED DELETED
T A F R Y V s T DELETED DELETED DELETED M
T A F R Y V s T DELETED DELETED P
T A F R Y V s T DELETED DELETED P M
T A F R Y V s T DELETED P DELETED
T A F R Y V s T DELETED P DELETED M
T A F R Y V s T DELETED P P I |
T A F R Y V S I T DELETED P P M !
T A F R Y | V S ; T N DELETED DELETED
T A F R Y I V S { T N DELETED DELETED M
T A F R Y V s T N DELETED P
T A F R Y V s T N DELETED P M
T A F R Y V s T N P DELETED
T A F R Y V s T N P DELETED M
T A F R Y V s T N P P
T A F R Y V s T N P P M
T A F R Y V G S DELETED DELETED DELETED
T A F R Y V G S DELETED DELETED DELETED M
T A F R Y V G S DELETED DELETED P
T A F R Y V G S DELETED DELETED P M
T A F R Y V G s DELETED P DELETED
T A F R Y V G s DELETED P DELETED M
T A F R Y V G s DELETED P P
T A F R Y V G s DELETED P P M
T A ■ F R Y V G s N DELETED DELETED
T A F R Y V G s N DELETED DELETED M
T A F R Y V G s N DELETED P
T A F R Y V G s N DELETED P M
T A F R Y V G s N P DELETED
T A F R Y V G s . N P DELETED M
T A F R Y V G s N P P
T A F R Y V G s N P P M
T A F R Y V G T DELETED DELETED DELETED I
T A F R Y V G T DELETED DELETED DELETED M
T A F R Y V G T DELETED DELETED P
T A F R Y V G T DELETED DELETED P ■ M
T A F R Y V G ^ T DELETED P DELETED
T A F R Y V G T DELETED P DELETED M

WO 2008/112003

PC17US2t»0?/O?Mi7

20 25 29 31 33 49 55 56 91 94 95 96 107 |
T A F R Y V G T DELETED P P
T A F R Y V G T DELETED P P M i
T A F R Y V G T N DELETED DELETED i !
T A F R Y V G G T
T N N DELETED DELETED M j
T A F R Y V

DELETED P
T A F R Y V G T N DELETED P M
T A F R Y V G T N P DELETED
T A F R Y V G T N P- DELETED M
T A F R Y V G T N P P
T A F R Y V G T N P P M
T A F R H Q S S DELETED DELETED DELETED
T A F R H Q S S DELETED DELETED DELETED M
T A F R H Q S s DELETED DELETED P
T A F R H Q S s DELETED DELETED P M
T A F R H Q S s DELETED P DELETED
T A F R I I H Q S s DELETED P DELETED M
T A F R I | H Q s s DELETED P P , |
T A F R H Q s s DELETED P ■ P M
T A F R H Q s s N DELETED DELETED t
T A F R H Q s s N DELETED DELETED M
T A F R H Q s s N DELETED P
T A F R H Q s s N DELETED P M
T A F R H Q s s N P DELETED
T A F R H Q s s N P DELETED M
T A F R H Q s s N P P
T A F R H Q s s N P P M
T A F R H Q s T DELETED DELETED DELETED
T A F R H Q s T DELETED DELETED DELETED M
T A F R H Q s T DELETED DELETED P
T A F R H Q s T DELETED DELETED P M
T A F R H Q s T DELETED P DELETED
T A F R H Q s i T DELETED P DELETED M
T A F R H Q S ! T DELETED P P
T A F R H Q s T DELETED ■ P P M
T A . F R H Q s T N DELETED DELETED
T A F R H Q s T N DELETED DELETED M
T A F R H Q s T N DELETED P
T - A F R H Q s T N DELETED P M
T A F R H Q s T N P DELETED
T A F R H Q s T N P DELETED M
T A F R H Q s T N P P
T A F R H Q s T N P P M
T A F R H Q G S DELETED DELETED DELETED
T A F R H Q G S DELETED DELETED DELETED M
T A F R H Q G s DELETED DELETED P
T A F R H Q G s DELETED DELETED P M
T A F R H Q G s DELETED P DELETED

WO 2008/112003 PCT/US2007/075117

20 25 29 31 33 49 55 56 ! 91 94 95 96 107
T A F R H Q G S DELETED P DELETED M
T A F R H Q G s DELETED P P i
T A F R H Q G | S DELETED P P M
T A F R H Q G ! S N DELETED DELETED I
T A F R H Q G ! S N DELETED DELETED M
T A F R H Q G [ S N DELETED P I
T A F R H Q G ! S N DELETED P M
T A F R H Q G | S N P DELETED I
T A F R H Q G s N P DELETED M
T A F R H Q G s N P P I
T A F R H Q G s N P P M
T A F R H Q G T DELETED DELETED DELETED I
T A F R 'H Q G T DELETED DELETED DELETED M
T A F R H Q G T DELETED DELETED P I
T A F R H Q G T DELETED DELETED P M
T A F R H Q G T DELETED P DELETED I
T A F R H Q | G T DELETED P JDELETED M
T A F R H | Q G T DELETED P | P I
T A F R I ■ H j Q G T DELETED P P M
T A F R H Q G T N DELETED DELETED I
T A F R H Q G T N DELETED DELETED M
T A F R H Q G T N DELETED P I
T A F R H Q G T N DELETED P M
T A F R H Q G T N P DELETED I
T A F R H Q G T N P DELETED M
T A F R H Q G T N P P I
T A F R H Q G T N P P M
T A F R H V S S DELETED DELETED DELETED I
T A F R H V S S DELETED DELETED DELETED M
T A F R H V S s DELETED DELETED P I
T A F R H V S s DELETED DELETED P M
T A F R H V s s DELETED P DELETED I
T A F R H V s s DELETED P DELETED M
T A F R H V s s DELETED P P I
T A F R H V s s DELETED P P M
T A F R H V s s N DELETED DELETED I
T A F R H V s s N DELETED DELETED M
T A F R H V s s N DELETED P I
T A F R H V s s N DELETED P M
T A F R H V s s N P DELETED I
T A F R H V s s N P DELETED M
T A F R H V s s N P P t
T A F R H V s s N P P M
T | A F R H V s T DELETED DELETED DELETED I
T 1 A F R ! I H V s T DELETED DELETED DELETEDJ ' M
T 1 A F R H V s T DELETED DELETED P J I
T A F R H V s T DELETED DELETED P S M

WO 2008/112003

r'CT/vstmvo-7Siii

20 25 29 I 31 33 49 55 56 91 94 95 96 107
T A F R H V s T DELETED P DELETED I
T A F Ft H V s T DELETED P DELETED M
T A F R H V s T DELETED P P I
T A F R H V s T DELETED P P M
T A F R H V s T N DELETED DELETED I
T A F R H V s T N DELETED DELETED M
T A F R H V s T N DELETED P i
T A F R H V s T N DELETED P M
T A F R H V s T N P DELETED I
T A F R H V s T N P DELETED M
T A F R H V s T N P P I
T A F R H V s T N P P i
T A F ■■ R H V G S DELETED DELETED DELETED

T A F R H V G S DELETED DELETED DELETED
P M
'" r
T A F R H V G s DELETED DELETED

__T
T . A ._ A F
F _.R„_._ R H V G s DELETED DELETED P M I

I H
G s DELETED P DELETED

T A F R H V G s DELETED P DELETED P

T A F R H V G s DELETED P
i |
T A F R H V G s DELETED P P M
T A F R H V G s N DELETED DELETED I
T A F R H V G s N DELETED DELETED M
T A F R H V G s N DELETED P i
T A F R H V G s N DELETED P M
T A F R H V G s N P DELETED I
T A L F R H V G s N P DELETED M
T A F R H V G s N P P I
T A F R H V G s N P P M
T A F R H V G T DELETED DELETED DELETED [
T A F R H V G T DELETED DELETED DELETED M
T A F R H V G T DELETED DELETED P I
T A F R H V G T DELETED DELETED P M
T A F R H V G T DELETED P DELETED I
T A F R H V G T DELETED P DELETED M
T A F R H V G T DELETED P P i
T A F R H V G T DELETED P P M
T A F R H V G T N DELETED DELETED I
T A F R H V G T N DELETED DELETED M 1
T A F R H V G T N DELETED P I
T A F R H V G T N DELETED P M
T A F R H V G T N P DELETED t
T A F R H V G T N P DELETED M
T A F R H V G T N P P I
T A F R H V G T N P P M
T P 1 S L Y Q S S DELETED DELETED DELETED I
T P 1 S L Y Q S s DELETED DELETED DELETED M

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 | 107
T P S L Y Q S S DELETED DELETED P
T P S L Y Q S S DELETED DELETED P M
T P s L Y Q S S DELETED P DELETED
T P s L Y Q s S DELETED P P DELETED M
T P s L Y Q

DELETED
P
T P s L Y Q S j S DELETED P P M
T P s L Y Q s ! s N DELETED DELETED
T P s L Y Q s S S N DELETED DELETED M
T P s L Y Q s
N DELETED P
T P s L Y Q s S N DELETED P M
T P s L Y Q s s N P DELETED
T P s L Y Q s s N P DELETED M
T P s L Y 0 s s N P P
T P s L Y Q s s N P P M
T P s L Y Q s T DELETED DELETED DELETED
T P s L Y Q S j T DELETED DELETED DELETED
DELETED DELETED _JVL -
M
T P s L Y 0 s _. T

P

T P s L Y Q s T DELETED DELETED P

T P s L Y Q s T DELETED P DELETED
T P s L Y Q s , T DELETED P DELETED M
T P s L Y Q s T DELETED P P
T P s L Y Q s T DELETED P P M
T P s L Y Q s T N DELETED DELETED
T P s L Y Q s T N DELETED DELETED M
T P s L Y Q s T N DELETED P
T P s L Y Q s T N DELETED P M
T P s L Y Q s T N P DELETED
T P s ■ L Y Q s T N P DELETED M
T P s L Y Q s T N P P
T P s L Y Q s T N P P M
T P s L Y Q G S DELETEDJDELETED DELETED
T P s L Y Q G S DELETED DELETED DELETED M
T P s L Y Q G s DELETED DELETED P
T P s L Y Q G s DELETED DELETED P M
T P s L Y Q G s DELETED P DELETED
T P s L Y Q G s DELETED P DELETED M
T P s L Y Q G j S DELETED P P
T P s L Y Q G s DELETED P P M
T P s L Y Q G s N DELETED DELETED
T P s L Y Q G s N DELETED DELETED M
T P s L Y Q G s N DELETED P
T P s L Y Q G s N DELETED P M
T P s L Y Q G s N P DELETED
T P s L Y Q G s N P DELETED M
T P s L Y Q G s N P P
T P s L Y Q G s H P P M

WO 2008/112003

PCT/US2007/075U7

20 25 29 31 33 49 55 56 ! 91 94 95 96 107
T P S L Y Q G T DELETED DELETED DELETED
T P S L Y Q G T DELETED DELETED DELETED M
T P S L Y Q G T DELETED DELETED P
T P S L Y Q G T ' DELETED DELETED P : M
T P S L Y Q G T DELETED P DELETED
T P S L Y Q G T DELETED P DELETED M
T P S L Y Q G T DELETED P P
T P S L Y Q G T DELETED P P M
T P S L Y Q G T N DELETED DELETED
T P S L Y Q G T N DELETED DELETED M
T P s L Y Q G T N DELETED P
T P s L Y Q G T N DELETED P M
T P s L Y Q G T N P DELETED
T P s L Y Q G
N P DELETED M
T P s L Y Q G T N P P
T P s L Y Q G T N P P M
T P s L Y V V S S DELETED DELETED DELETED
T P s L Y

S DELETED DELETED DELETED M
T P s L Y V s s DELETED DELETED P
T P s L Y V s s DELETED DELETED P M
T P s L Y V s s DELETED P. DELETED
T P s L Y V s s DELETED P DELETED M
T P s L Y V s s DELETED P P
T P __s_^ L Y V s s DELETED P P M
T P s L Y V s s N DELETED DELETED
T P 1 s L Y V s s N DELETED DELETED _M-_
T P s L Y V s s N DELETED P

T P s L Y V s s N DELETED P M
T P s L Y V s s N P DELETED
T P s L Y V s s N P DELETED P _Ji...
T P s L Y V s s N P

T P s L Y V s s N P P DELETED M_
T P s L Y V s T DELETED DELETED

T P s L Y V s T DELETED DELETED DELETED M
T P s L Y V s T DELETED DELETED P
T P s L Y V s T DELETED DELETED P M
T P s L Y V s T DELETED P DELETED
T P s L Y V s T DELETED P DELETED M
T P s L Y V s T DELETED P P
T P s L Y V s T DELETED P P M
T P s L Y V s T N DELETED DELETED
T P s L Y V s T N DELETED DELETED M
T P s L Y V s T N DELETED P
T P s L Y V s I T N DELETED P M
T P s L Y V s i T N P DELETED M
T P s L Y V s ! T N P DELETED

woaooN/inOos

KMTiJgSirtWMKHf

26 23 23 31 35 49 S5 56 91 94 95 06 l 107
T P S L Y V S T N P P i
T P s L Y V S T N P P M
T P s L Y V G S DELETED DELETED DELETED 1
T P s L Y V G S DELETED DELETED DELETED P 1
T P s L Y V G s DELETED DELETED

T P s L Y V G __s
s DELETED DELETED P P_
DELETED M
T P s L Y V G
DELETED

1
T P s L Y V G s DELETED P DELETED 1
T P s L Y V G s DELETED P P

T P s L Y V G s DELETED P P M
T P s L Y V G s N DELETED DELETED 1
T P s L Y V G s N DELETED DELETED M
T P s L Y V G s N DELETED P 1
T P' ' :\'.\) ' ..'■' ■'-"s L Y V G s N DELETED JP__
DELETED 1
T P s L Y V G s N P

T ■ P s L Y V G s N | P N | P DELETED M
T P s L Y V G s
P 1
t P s L Y V G s N P P M
■ f p;:; s L Y V G 1 T DELETED DELETED DELETED 1
1 T :- P ' 1 * J ■ S. - L ' ••■ Y-. ; Y -W. i
"V . G . ,_.;-T_;.L
T DELETED
DEIETED DELETED.
qBffiiB DELETED M
T P 1 " " si "■ f

G

■■■: p 1
T P s L Y V G T DELETED DELETED P M
T P t s L Y V G T DELETED P DELETED 1
T P' 1 s L Y V G T DELETED P DELETED M
t P i s L Y V G T DELETED P P 1
T P 1 S i- Y V G T DELETED p ; p ' U
T P 1 i S L Y v G T N DELETEDjDELETED f
t P i j s i T_ V G T N DELETEDpELETED M j
t P ! i s L Y V G T ' • N. DELETED! P i I
t P i ! s j L Y V G t N [DELETED; P : M i
t P i ! s t Y V G T N !- - - P-. (DELETED r !
T P i s L Y V G > L_ N ■ ■ t p - DELETED M
T P~^ ; s L Y V G T N
';,p ■": ;1 |
T _£_U s i- Y v G t . N p. p ' M i
T r^r s L H Q S s DELETED DELETED DELETED i :
T p i £ L H Q S s DELETED DELETED DELETED M :
T p ^ f s I H ' Q s s DELETED DELETED ■ ; P ' ':} i :
T p ! s I H Q s s DELETED DELETED >"■' M '
T p 1 s I H Q s s DELETED ■; P: ' DELETED '•: '
T p j s L H Q s s DELETED ■ ; i R ' :' DELETED M
t p i s L H Q s s DELETED! P ■ i ' 9 • ' ■ i-
T p i § L H 1 Q s s DELETEDJ P " P : M
T p i s L H Q s s N: ' (DELETED DELETED !
t P ! s L H Q s s N IDELETED DELETED M
i P i i s L H Q s I s N jDELETED P r
T p i i s L H Q s ! S N IDELETED! P ' M

WO 2008/112003

PCT/U$2U07/»?5fl7

20 25 29 31 33 49 55 56 91 94 95 96 107
T P - S L H Q s S N P DELETED
T P S L H Q S S N P DELETED M
T P s L H Q s s N P P

P s L H Q s s N P P M
T P s L H Q s T DELETED DELETED DELETED
T P s L H Q s T DELETED DELETED DELETED M
T P s L H Q s T DELETED DELETED P
T P s L H Q s T DELETED DELETED P M
T P s L H Q s T DELETED P DELETED I I
T P s L H Q s T DELETED P DELETED M
T P s L H Q s T DELETED P P
T P s L H Q s T DELETED P P M
T P J 1 s L H_J Q s T N DELETED DELETED
T P s L H Q s T N DELETED DELETED M
T P s L H Q s T N DELETED P
T P s L H Q s T N DELETED P M
T T P P s L H Q s T N P DELETED M

s L H Q s T N P DELETED

. T P s L H Q s T N P P
T P s L H Q s T N P P M
T P s L H Q G S DELETED DELETED DELETED
T P s L H Q G S DELETED DELETED DELETED M
T P s L H Q G S DELETED DELETED P
T P s L H Q G S DELETED DELETED P M
T P s L H Q G S DELETED P DELETED
T P s L H Q G S DELETED P DELETED M
T P s L H Q G S DELETED P P

T P s L H Q G Sv~ DELETED P P ■ M
T P s L H Q G S N DELETED DELETED
T P s L H Q G S N DELETED DELETED
P _ M
T P s L H Q G s N DELETED

T P s L H Q G s N DELETED P . _M_
T P s L H Q G s N P DELETED

T P s L H Q G s N P DELETED M_
T P s L H Q G s- N P P

T P s L H Q G s N P P M
T P s L H Q G T DELETED DELETED DELETED
T P s L H Q G T DELETED DELETED DELETED M
T P s L H Q G T DELETED DELETED P
T P s L H Q G T DELETED DELETED P M
T P s L H Q G T DELETED P DELETED
T P s L H Q G T DELETED P DELETED M
T P s L H Q G T DELETED P P
T P s L H Q G T DELETED P P M
T P s L H Q G T N DELETED DELETED
T P s L H Q G T N DELETED DELETED M

WO 2008/112003

PCT/US2007/075U7

20 25 29 31 33 49 55 56 91 94 95 96 107
T P S L H Q G T N DELETED P I
T P S L H Q G T N DELETED P M
T P s L H Q G T N P DELETED
T P s L H Q G T N P DELETED M
T P s L H Q G T N P P
T P s L H Q G T N P P M
T P s L H V s S DELETED DELETED DELETED
T P s L H V s s DELETED DELETED DELETED M
T P s L H V s s DELETED DELETED P
T P s L H V s s DELETED DELETED P M
T P s L H V s s DELETED P DELETED
T P s L H V s s DELETED P DELETED M
T P s L H V s s DELETED P P
T P s L H V s s DELETED P P M
T P s L H V s s N DELETED DELETED
T P s L H V s s N DELETED DELETED M
T
T P s L H V s s N DELETED P

P s L H V s s N DELETED P M
T P s L H V s s N | P DELETED
T P s L H V s s N P DELETED M
T P s L H V s s N P P
T P s L H V s s N P P M
T P s L H V s T DELETED DELETED DELETED
T P s L H V s T DELETED DELETED DELETED M
T P s L H V s T DELETED DELETED P
T P s L H V s T DELETED DELETED P M
_ T
T p s L H V s T DELETED P DELETED

s L H V s T DELETED P DELETED M
T p s L H V s s T DELETED P P
T p s L H V
T DELETED P P M
T p s L H V s T N DELETED DELETED
T p s L H V s T N DELETED DELETED M
T p s L H V s T N DELETED P
T p" s L H V s T N DELETED P M
T p s L H V s T N P DELETED
T p s L H V s T N P DELETED M
T p s L H V s T N P P
T p s L H V s T N P P M
T p s L H V G S DELETED DELETED DELETED
T p s L H V G S DELETED DELETED DELETED M
T p s L H V G s DELETED DELETED P
T p s L H V G s DELETED DELETED P M
T p s L H V G s DELETED P DELETED
T p s L H V G s DELETED P DELETED M
T p s L H V G s DELETED P ! P
T p s L H V G s DELETED P I P M

WO 200(1/112003

PCT/US2U07/075U7

20 25 29 31 33 49 55 56 91 94 95 96 107
T P S L H V G s N DELETED DELETED
T P S L H V G s N DELETED DELETED M
T P S L H V G s N DELETED P
T P S L H V G s N DELETED P M
T P S L H V G s N P DELETED
T P S L H V G _i s N P DELETED M
T P S L H V G s N P P
T P S L H V G s N P P M
T P S L H V G T DELETED DELETED DELETED
T P S L H V G T DELETED DELETED DELETED M
T P s L .H V G T DELETED DELETED P
T P s L H V G T DELETED DELETED P M
T P s L H V G T DELETED P DELETED
T P s L H V G T DELETED P DELETED M
T P s L H V G T DELETED P P
■T P s L H V G T DELETED P P M
T P s L
-
L H V G T N DELETED DELETED I i
T P s
H V G T N DELETED DELETED M
T P s L H V G T N DELETED P
T P s I H V G T N DELETED P M
T P s L H V G _—LJ N P DELETED

T P * s L H V G T N P DELETED M
T P s L H V G T N P P
T P s L H V G |_I_ N P P M
T P s Y Q S S DELETED DELETED DELETED
T P s Y Q S s DELETED DELETED DELETED M
T P s Y Q S s DELETED DELETED P
T P s Y Q S s DELETED DELETED P M
T P s Y Q S [ S DELETED P DELETED
T P s Y Q S s DELETED P DELETED M
T P s Y Q S s DELETED P P
T P s Y Q s s DELETED P P M
T _ T P s Y Q s s N DELETED DELETED

P s Y Q s s N DELETED DELETED M
T P s Y Q s s N DELETED P
T P s Y Q s s N DELETED P M
T P s Y Q s s N P DELETED
T P s Y Q s s N P DELETED M
T P s Y Q s s . N P P
T P s Y Q s J— s N P P M
T P s Y Q s T DELETED DELETED DELETED
T P s Y Q s J_T DELETED DELETED DELETED M
T P s Y Q s T DELETED DELETED P
T P s Y Q s T DELETED DELETED P M
T P s Y Q s T DELETED P DELETED
T P s Y Q s T DELETED P DELETED M

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T P S Y Q S T DELETED P P
T P S Y Q s T DELETED P P M
T P S Y Q s T N DELETED DELETED
T P S Y Q s T N DELETED DELETED M
T P S Y Q s T N DELETED P
T P S Y Q s T N DELETED P M
T P S Y Q s T N P DELETED
T P S Y Q' s T N P DELETED M
T P S Y Q s T N P P
T P S Y Q s T N P . P M
T P s Y Q G S DELETED DELETED DELETED
T P s Y Q G S DELETED DELETED DELETED M
T P s Y Q G s DELETED DELETED P
T P s Y Q G s DELETED DELETED P _j I M_
T P s Y Q r G s DELETED P DELETED
T P s Y Q G s DELETED P DELETED M
T P s Y 0 G s DELETED P P
T P s Y Q j G s DELETED P P M
T P s Y Q G s N DELETED DELETED
T P s Y 0 G s N DELETED DELETED M
T P s Y Q G s N DELETED P
T P s Y Q G s N DELETED P M
T P s Y Q G s N P DELETED
T P s Y Q G s N P DELETED M
T P s Y Q G s N P P
T P s Y Q G s N P P M
T P s Y Q G T DELETED DELETED DELETED
T P s Y Q G T DELETED DELETED DELETED M
T P s Y Q G T DELETED DELETED P

T P s Y Q G T DELETED DELETED P M
T P s Y Q G T DELETED P DELETED
T P s Y Q G T T DELETED P DELETED M
T P s Y Q G
DELETED P P
T P s Y Q G T DELETED P P M
T P s Y Q G T N DELETED DELETED
T P s Y Q G T N DELETED DELETED M
T P s Y Q G T N DELETED P
" T P s Y Q G T N DELETED P M
T P s Y Q G T - N P DELETED
T P s Y Q G T N P DELETED M
T P s Y Q G T N P P
T P s Y Q G T N P P M
T P s Y V S S DELETED DELETED DELETED
T P s Y V S S DELETED DELETED DELETED M
T P s Y V S s DELETED DELETED P
T 1 P s Y V S s DELETED DELETED P M

WO 2008/112003

PCt/VStodtfdtsm

20 25 29 31 33 49 55 56 91 94 95 96 107
T P S Y V s S DELETED P DELETED
T P S Y V s s DELETED P DELETED M
T P s Y V s s DELETED P P
T P s Y V s s DELETED P P M
T P s Y V s s N DELETED DELETED
T P 3 Y V s s N DELETED DELETED M
T P S Y V s s N DELETED P
T ■ P S Y V s s N DELETED P M
T P S Y V s s N P DELETED
T P S Y V s s N P DELETED M
T P S Y V s s N P P
T P S Y V s s N P P M
T P s Y V s T DELETED DELETED DELETED
T P s Y V s T DELETED DELETED DELETED M
T P s Y V s T DELETED DELETED P
T P s Y V s T DELETED DELETED P M
! T P s Y V s T DELETED P JDELETED
[ T P s Y V s T DELETED P DELETED M |_T P s Y V s T (DELETED P ' P i.
T P s Y V s T DELETED P P M
T P s Y V s T N DELETED DELETED
T P s Y V s T N DELETED DELETED M
T P s Y V s T N DELETED P
T P s Y V s T N DELETED P M
T P s Y V s T N P DELETED
T P s Y V s T N P DELETED M
T P s Y V s T N P P
T P s Y V s T N P P M
T P s Y V G S DELETED DELETED DELETED
T P s Y V G S DELETED DELETED DELETED M
T P s Y V G s DELETED DELETED P
T P s Y V G s DELETED DELETED P M
T P s Y V G s DELETED P DELETED
T P s Y V G s DELETED P DELETED M
T P s Y V G s DELETED P P
T P s Y V G s DELETED P P M
T P s Y V G s N DELETED DELETED
T P s Y V G s N DELETED DELETED M
T P s Y V G s N DELETED P
T P s Y V G s N DELETED P M
T P s Y V G s N P DELETED
T P s Y V G s N P DELETED U
T P s Y V G s ' N P P
T P s Y V G s N P P M
T P s Y V G T DELETED DELETED DELETED I
T P s Y V G T DELETED DELETED DELETED M

WO 2008/112003

PCT/US2007/07S117

20 25 29 31 33 49 55 56 91 94 95 96 107
T P S Y V G T DELETED DELETED P
T P S Y V G T DELETED DELETED P M
T P s Y V G T DELETED P DELETED
T P s Y V G T DELETED P DELETED M
T P s Y V G T DELETED P P
T P s Y V G T DELETED P P M
T P s Y V G T N DELETED DELETED
T P s Y V G T N DELETED DELETED M
T P s Y V G T N DELETED P
T P s Y V G T N DELETED P M
T P s Y V G T N P DELETED
T P s Y V G T N P DELETED M
T P _ s Y V G T N P P
T P s Y V G T N P P M
T P s H Q s S DELETED DELETED DELETED
T P s H Q S s DELETED DELETED DELETED M
T p ! i s H Q S S s DELETED DELETED P , !
T p s H Q
s DELETED DELETED P M i
T p s H Q S s DELETED P DELETED
T p s H Q S s DELETED P DELETED M
T p s H Q S s DELETED P P
T p s H Q S s DELETED P P M
T p s H Q S s N DELETED DELETED
T p s H Q S s N DELETED DELETED M
T p s H Q S s N DELETED P
T p s H Q S s N DELETED P M
T p s H Q S s N P DELETED
T p s H Q S s N P DELETED M
T p s H Q S s N P P
T p s H Q s s N P P M
T p s H Q s T DELETED DELETED DELETED
T p s H Q s T DELETED DELETED DELETED M
T p s H Q s T DELETED DELETED P
T p s H Q s T DELETED DELETED P M
T p s H Q s T DELETED P DELETED
T p s H Q s T DELETED P DELETED M
T p s H Q s T DELETED P P
T p s H Q s T DELETED P P M
T p s H Q s T N DELETED DELETED
T p s H Q s T N DELETED DELETED M 1
T p s H Q s T N DELETED P
T p s H Q s T N DELETED P M
T p s H Q s T N P DELETED
T p s H Q s T N P DELETED M
T p s H Q s T N P P
T p s H Q s T N P P M

WO 2008/112003

PCT/US2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T P S H Q G S DELETED DELETED DELETED I
T P S H Q G s DELETED DELETED DELETED M
T P s I H Q G s DELETED DELETED P I
T P s H Q G s DELETED DELETED P M
T P s H Q G s DELETED P DELETED I
T P s H Q G s DELETED P DELETED M
T P s H Q G s DELETED P P I
T P s H Q G s DELETED P P M
f ' P s H Q G s N DELETED DELETED I
T P s H Q G s N OELETED, DELETED M
T P s H Q G s N DELETED P I
T P s H Q G s N DELETED P M
T P . s H Q G s N P DELETED I
T P s H Q G s N P DELETED M
T P s H Q G s N P P I
T P s H Q G s N P P M '
_ T
T P s H Q G G T DELETED DELETED DELETED I

P 1 s H Q
T DELETED DELETED DELETED M T P s H Q G T DELETED DELETED P I I
T P s H Q G T DELETED DELETED P M
T P s H Q G T DELETED P DELETED I
T P s H Q G T DELETED P DELETED M
T P s H Q G T DELETED P P I
T P s H Q G T DELETED P P M
T P s H Q G T N DELETED DELETED I
T P s H Q G T N DELETED DELETED M
I
T P s H Q G T N DELETED P

T P S | I H Q G T N DELETED P M
T P S I H Q G T N P DELETED I
T P s H Q G T N P DELETED M
T P s H Q G T N P P I
T P s H Q G T N P P I
T P s H V S S DELETED DELETED DELETED

T P s H V S S DELETED DELETED DELETED M
T P s H V S s DELETED DELETED P I
T P s H V S s DELETED DELETED P M
T P s H V S s DELETED P DELETED l
T P s H V S s DELETED P ■ DELETED M
T P s H V S s DELETED P P I
T P s H V S s DELETED P P M
T P s I H V S s N DELETED DELETED I
T P s H V s s ! N DELETED DELETED M
T P s H V s s I N DELETED P I
T P s H V s s N DELETED P M
T P s H V s s N P DELETED I
T P s H V i s s N P DELETED M

WO 2008/112003 PCMIS2007/075117

20 25 29 31 33 49 55 56 91 94 95 96 107
T P S H V s S N P P I
T P s H V s S N P P M
r P s H V s T DELETED DELETED DELETED I
T P s H ' V s T DELETED DELETED DELETED M
T P s H V s T DELETED DELETED P I
T P s H V s T DELETED DELETED P M
T P s H V s T DELETED P DELETED I
T P s H V s T DELETED P DELETED M
T P s H V s T DELETED P P I
T P s H V s T DELETED P P M
T P s H V s T N DELETED DELETED I
T P s H V s T N DELETED DELETED M
T P s H V s T N DELETED P I
T P s H V s T N DELETED P M
T P s H v s T N P DELETED I
T P s H V s T N P DELETED M
T P S I H V s T I N P P i I
T P
3 ' H V s T 4 N P P j M
T P s H V G S DELETED DELETED DELETED I
T P s H V G S pELETED DELETED DELETED M
T P s H V G s DELETED DELETED P I
T P s H V G s DELETED DELETED P M
T P s H V G s DELETED P DELETED I
T P s H V G s DELETED P DELETED M
T P s H V G s DELETED P P I
T P s H V G s DELETED P P M
T P s H V G s N DELETED DELETED I
T P s H V G s N DELETED DELETED

T P s H V G s N DELETED P I
T P s H V G s N DELETED P M
. T P s H V G s N P DELETED I
T P s H V G s N P DELETED M
T P s H V G s N P ! P I
T P s H V G s N P P M
T P s H V G T DELETED DELETED DELETED I
T P s H V G T DELETED DELETED DELETED M
T P s H V G T DELETED DELETED P I
T P s H V G T DELETED DELETED P M
T P s H V G T DELETED P DELETED I
T P s H V G ' T DELETED P DELETED M
T P s H V G T DELETED P P I
T P s H V G | T DELETED P P M
T P s H V G ! T N DELETED DELETED I
T P s H V G T N DELETED DELETED M
T P s H V G T N DELETED P I
T P s H v G ; T N DELETED P M

WO 200H/112003 PCT/US20U7/H7SiJ7

20 25 29 31 33 49 55 56 91 94 95 96 107
I
T P S I H V G T N P DELETED

T P S I H V G T N P DELETED M
T P s I H V G T N P P I
T P s I H V G T N P P M
T P R L Y Q S S DELETED DELETED DELETED I
T P R L Y Q S S DELETED DELETED DELETED M
T P R L Y Q S s DELETED DELETED P I
T P R L Y Q S s DELETED DELETED P M
T P R L Y Q S s DELETED P DELETED I
T P R L Y Q S s DELETED P DELETED M
T P R L Y Q S s DELETED P P I
T P R L Y Q S s DELETED ' P P M
T P R L Y Q s s N DELETED DELETED I
T P R L Y Q s s N DELETED DELETED M
T P R L Y Q s s N DELETED P I
T P R L Y Q s s N DELETED P M
T P R L Y Q s s N P DELETED I
T P R L Y Q s s N P DELETED M
T P R L Y Q s s N P P I
T P R L Y Q s s N P P M
T P R L Y 0 s T DELETED DELETED DELETED J
T P R L Y Q S i T DELETED DELETED DELETED M
T P R L Y Q S ! T DELETED DELETED P t
T P R L Y Q S T DELETED DELETED P M
T P R L Y Q S T DELETEO P DELETED I
T P R L Y Q s T DELETED P DELETED M
T P R L Y Q s T DELETED P P !
T P R L Y Q s T DELETED P P M
T P R L Y Q s T N DELETED DELETED t
T P R L Y Q s T | N DELETED DELETED M
T P R L Y Q s T N DELETED P I
T P R L Y Q s T N DELETED P M
T P R L Y Q s T N P _, DELETED I
T P R L Y Q s T N P DELETED M
T P R L Y Q s T N P P I
T P R L Y Q s T N P P M
T P R L Y ■ Q G S DELETED DELETED DELETED I
T P R L Y Q G S DELETED DELETED DELETED M
T P R L Y Q G s DELETED DELETED P I
T P R L Y Q G s DELETED DELETED P M
T P R L Y Q G s DELETED P DELETED I
T P R L Y Q G s DELETED P DELETED M
T P R L Y Q G s DELETED P P I
T P R L Y Q G s DELETED P P M
T P R L Y Q G s N DELETED DELETED I
T P R L Y Q G s N DELETED DELETED M

WO 10UW11W03 PCT/US2007/075tl7

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P R L Y V S T N DELETED DELETED I
T P R L Y V s T N DELETED DELETED M
T P R L Y V s T N DELETED P I
T P R L Y V s T N DELETED P M
T P R L Y V s T N P DELETED 1
T P R L Y V s T N P DELETED M
T P R L Y V s T N P P 1
T P R L Y V s T N P P M
T P R L Y V G S DELETED DELETED DELETED I
T P R L Y V G S DELETED DELETED DELETED M
T P R L Y V G. s DELETED DELETED P 1
T P R L Y V G s DELETED DELETED P M
T P R L Y V G s DELETED P DELETED 1
T P R L Y V G s DELETED P DELETED M
T P R L Y V G s DELETED P P 1
T P R L Y V G s DELETED P P M
T P R L Y v G , S N DELETED DELETED 1
T P 1 R L Y V i G s N DELETED DELETED M
T P R L Y V G s N DELETED P 1
T P R L Y V G s N DELETED P M
T P R L Y V G s N P DELETED 1
T P R L Y V G s N P DELETED M
T P R L Y V G s N P P 1
T P R L Y V G s N P P M
T P R L Y V G T DELETED DELETED DELETED 1
T P R L Y V G T DELETED DELETED DELETED M
T P R L Y V G T DELETED DELETED P 1
T P R L Y V G T DELETED DELETED P M
T P R L Y V G T DELETED P DELETED !
T P R L Y V G T DELETED P DELETED M
T P R L Y V G T DELETED P P 1
T P R L Y V G T DELETED P P M
T P R L Y V G T N DELETED DELETED 1
T P R L Y V G T N DELETED DELETED M
T P R L Y V G T N DELETED P 1
T P R L Y V G T N DELETED P M
T P R L Y V G T N P DELETED 1
T P R L Y V G T N P DELETED M
T P R L Y V G T N P P 1
T P R L Y V G T N P P M
T P R L H Q S S DELETED DELETED DELETED I
T P R L H Q S S DELETED DELETED DELETED M
T P R L H Q s s DELETED DELETED P 1
T P R L H Q s s DELETED DELETED P | M
T P R L H Q s s DELETED P DELETED . 1
T P R L H Q s s DELETED P DELETED M
52959 v I/DC'

ASTR013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P R L H Q S S DELETED P P
T P R L H Q S S DELETED P P M
T P R L H Q s s N DELETED DELETED
T P R L H Q s s N DELETED DELETED M
T P R L H Q s s N DELETED P
T P R L H Q s s N DELETED P M
T f P R L H Q s s N P DELETED
T P R L H Q s s N P DELETED M
T P R L H Q s s N P P
T P R L H Q s s N P P M
T P R L H Q s T DELETED DELETED DELETED
T P R L H Q s T DELETED DELETED DELETED M
T P R L H Q s T DELETED DELETED P
T P R L H Q s T DELETED DELETED P M
T P R L H Q s T DELETED P DELETED
T P R L H Q s T DELETED P DELETED M
T P R L « H Q s T DELETED P P
T P R L I H Q s T DELETED P P M
T P R L U- H Q s T N DELETED DELETED .
T P R L H Q s T N DELETED DELETED M
T P R L H Q s T N DELETED P
T P R L H Q s T N DELETED P M
T P R L H Q s T N P DELETED
T P R L H Q s T N P DELETED M
T P R L H Q s T N P P
T P R L H Q s T N P P M
T P R L H Q G S DELETED DELETED DELETED
T P R L H Q G S DELETED DELETED DELETED M
T P R L H Q G s DELETED DELETED P
T P R L H Q G s DELETED DELETED P M
T P R L H Q G s DELETED P DELETED
T P R L H Q G s DELETED P DELETED M
T P R L H Q G s DELETED P P
T P R L H Q G s DELETED P P M
T P R L H Q G s N DELETED DELETED
T P R L H Q G s N DELETED DELETED M
T P R L H Q G s N DELETED P .
T P R L H Q G s N DELETED P ■ M
T P R L H Q G s N P . DELETED
T P R L H Q G s N P DELETED M
T P R L H Q G s N P P
T P R L H Q G s N P P M
T P R L H Q G T DELETED DELETED DELETED
T P R L ! H Q G T DELETED DELETED DELETED M
T P R L H Q G T DELETED DELETED P
T P R L H Q G T DELETED DELETED P M
52959 vI/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 I 56 91 94 95 96 107
T P R L H Q G T DELETED P DELETED
T P R L H Q G T DELETED P DELETED M
T P R L H Q G T DELETED P P
T P R L H Q G T DELETED P P M
T P R L H Q G T N DELETED DELETED
T P R L H Q G T N DELETED DELETED M
T P R L H Q G T N DELETED P
T P R L H Q G T N DELETED P M
T P R L H Q G T N P DELETED
T P R L H Q G T N P DELETED M
T P R L H Q G T N P P
T P R L H Q G T N P P M
T P R L H V S S DELETED DELETED DELETED
T P R L H V S S DELETED DELETED DELETED M
T P R L H V s s DELETED DELETED P
T P R L H V s s DELETED DELETED P M
T P R L H V s '■ s DELETED P DELETED
T P R L H V s i 5 DELETED P DELETED M
T P R L H V s s DELETED P P
T P R L H V s s DELETED P P M
T P R L H V s s N DELETED DELETED
T P R L H V s s N DELETED DELETED M
T P R L H V s s N DELETED P
T P R L H V s s N DELETED P M
T P R L H V s s N P DELETED
T P R L H V s s N P DELETED M
T P R L H V s s N P P
T P R L H V s s N P . P M
T P R L H V s T DELETED DELETED DELETED
T P R L H V s T DELETED DELETED DELETED M
T P R L H V s T DELETED DELETED P
T P R L H V s T DELETED DELETED P M
T P R L H V s T DELETED P DELETED
T P R L H V s T DELETED P DELETED M
■ T P R L H V s T DELETED P P
T P R L H V s T DELETED P P M
T . P R L H V s T N DELETED DELETED
T P R L H V s T N DELETED DELETED M
T P R L H V s T N DELETED P
T P R L H V s T N DELETED P M
T P R L H V s T N P DELETED
T P R L H V s T N P DELETED M
T P R L H V s T N P P
T P R L H V s T N P P M
T P R L H V G S DELETED DELETED DELETED
T P R L H V G S DELETED DELETED DELETED M
S2959 vt/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P R L H V G s DELETED DELETED P
T P R L H V G s DELETED DELETED P M
T P R L H V G s DELETED P DELETED
T P R L H V G s DELETED P DELETED M
T P R L H V G s DELETED P P
T P R L H V G s DELETED P P M
T P R L H V G s N DELETED DELETED
T P R L H V G s N DELETED DELETED M
T P R L H V G s N DELETED P
T P R L H V G s N DELETED P M
T P R L H V G s N P DELETED
T P R L H V G s N P DELETED M
T P R L H V G s N P P
T P R L H V G s N P P M
T P R L H V G T DELETED DELETED DELETED
T P R L H V G T DELETED DELETED DELETED M
T P R L H j V G T DELETED DELETED P
T P R L H V G T DELETED DELETED P M
T P R L H V G T DELETED P DELETED
T P R L H V G T DELETED P DELETED M
T P R L H V G T DELETED P P
T P R L H V G T DELETED P P M
T P R L H V G T N DELETED DELETED
T P R L H V G T N DELETED DELETED M
T P R L H V G T N DELETED P
T P R L H V G T N DELETED P M
T P R L H V G T N P DELETED
T P R L H V G T N P DELETED M
T P R L H V G T N P P
T P R L H V G T N P P M
T P R Y Q S S DELETED DELETED DELETED
T P R Y Q S S DELETED DELETED DELETED M
T P R Y Q s s DELETED DELETED P
T P R Y Q s s DELETED DELETED P M
T P R Y Q s s DELETED P DELETED
T P R Y Q s s DELETED P DELETED M
T P R Y Q s s DELETED P P
T P R Y Q s s DELETED P P M
T P R Y Q s s . N DELETED DELETED
T P . R Y Q s s N DELETED DELETED M
T P R Y Q s s N DELETED P
T P R Y Q s s N DELETED P M
T P R Y Q s s N P DELETED
T P R Y Q s s N P DELETED M
T P R Y Q s ! s N P P
T P i 1 R Y Q s f s N P P M

52959 v|/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P R Y Q S T DELETED DELETED DELETED
T P R Y Q S T DELETED DELETED DELETED M
T P R Y Q S T DELETED DELETED P
T P R Y Q S T DELETED DELETED P M
T P R Y Q S T DELETED P DELETED
T P R Y Q S T DELETED P DELETED M
T P R Y Q S T DELETED P P
T P R Y Q S T DELETED P P M
T P R Y Q S T N DELETED DELETED
T P R Y Q S T . N DELETED DELETED M
T P R Y Q s T N DELETED P
T P R Y Q s T N DELETED P M
T P R Y Q s T N P DELETED
T P R Y Q s T N P DELETED M
T P R Y Q s T N P P
T P R Y Q s T N P P M
T P R Y Q G S DELETED DELETED DELETED
T P R Y Q G s DELETED DELETED DELETED M
T P R Y Q G s DELETED DELETED P
T P R Y Q G s DELETED DELETED P M
T P R Y Q G s DELETED P DELETED
T P R Y Q G s DELETED P DELETED M
T P R Y Q G s DELETED P P
T P R Y Q G s DELETED P P M
T P R Y Q G s N DELETED DELETED
T P R Y Q G s N DELETED DELETED M
T P R Y Q G s N DELETED P
T P R Y Q G s N DELETED P M
T P R Y Q G s N P DELETED
T P R Y Q G s N P DELETED M
T P R Y Q G s N P P
T P R Y Q G s N P P M
T P R Y Q G T DELETED DELETED DELETED
T P R Y Q G T DELETED DELETED DELETED M
T P R Y Q G T DELETED DELETED P
T P R Y Q G T DELETED DELETED P M
T P R Y Q G T DELETED P DELETED
T P R Y Q G T DELETED P ■ DELETED M
T P R Y Q G T DELETED P P
T P . R Y Q G T DELETED P P M
T P R Y Q G T N DELETED DELETED
T P R Y Q G T N DELETED DELETED M
T P R Y Q G T N DELETED P
T P R Y Q G T N DELETED P M
T P R Y Q G T N P DELETED
T P R Y Q G T N P DELETED M

52959 vVDC

ASTR 013/01 WO

20

25

29

31

33

49

55

56

91

94

95

96

107

R
R
R

Y

Q
Q
V

DELETED
DELETED
DELETED
HFLETED

DELETED
DELETED
DELETED
DELETED

DELETED
DELETED

M
M
M

R

V

DEfciUP.
DEbETED

DELETED
DELETED

M

T

R

Y
Y

DEI-ETEP
DELETED

DELETED

DELETED

M

R
R

Y

DELETED
DELETED
DELETED

DELETED

M
M

DELETED

DELETED

M

T

^
R
R
R
R

V
V
V

N
DELETED
{DELETED
DELETED
DELETED
nFLETED
DELETED
DELETED.
DELETED
DELETED
HFLETED
DELETED
nFLETED

DELETED^
DELETED
DELETED
DELETED

M
M
M
M
M

T

R
R

Y
Y
Y

V

N
N

DELETED
DELETED
DELETED
DELETED

DELETED
DELETED
DELETED
DELETED

M
M
M

M

T

R
R
R
R

Y
Y
Y

nFLETED
DELETED
nFLETED
nFLETED
nFLETED
DELETED
DELETED
DELETED

DELETED
DELETED
DELETED
DELETED

DELETED
DELETED
DELETED
DELETED

M
M
M
M

R
R
R

Y
Y

V

DELETED
DELETED
DELETED
DELETED

DELETED
DELETED

M
M

5295*3 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P R Y V G s N P DELETED
T P R Y V G s N P DELETED M
T P R Y V G s N P P
T P R Y V G s N P P M
T P R Y V G T DELETED DELETED DELETED
T P R Y V G T DELETED DELETED DELETED M
T P R Y V G T DELETED DELETED P
T P R Y V G T DELETED DELETED P M
T P R Y V G T DELETED P DELETED
T P R Y V G T DELETED P DELETED M
T P R Y V G T DELETED P P
T P R Y V G T DELETED P .P M
T P R Y V G T N DELETED DELETED
T P R Y V G T N DELETED DELETED M
T P R Y V G T H DELETED P
T P R I '■ Y V G T N DELETED! P M
T P R I Y V G T N • P IDELETED I
T P R I Y V G T N ! P jDELETED M .
T P R I Y V G T N { P i P
T P R Y V G T N | P P M
T P R H 0 S S DELETED DELETED DELETED
T P R H Q S S DELETED DELETED DELETED M
T P R H Q S s DELETED DELETED P
T P R H Q S s DELETED DELETED P M
T P R H Q S s DELETED P DELETED
T P R H Q S s DELETED P DELETED M
T P R H Q S s DELETED P P
T P R H Q S s DELETED P P M
T P R H Q S s N DELETED DELETED
T P R H Q S s N DELETED DELETED M
T P R H Q s s N DELETED P
T P R H Q s s N DELETED P M
T P R H Q s s N P DELETED
T P R H Q s s N P DELETED M
T P R H Q s s N P P
T P * R H Q s s N P P M
T P R H Q s T DELETED DELETED DELETED
T P R H Q s T DELETED DELETED DELETED M
T P R H Q s T DELETED DELETED P
T P R H Q s T DELETED DELETED P M
T P R H Q s T DELETED P DELETED
T P R H Q s T DELETED P DELETED M
T P R H Q s T DELETED P P
T P R H Q s T DELETED P P M
T P R H Q s T N DELETED DELETED
T P R H Q s T N DELETED DELETED M

52959 vl/DC

ASTRO 13/0 J WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P R H Q S T N DELETED P
T P R H Q S T N DELETED P M
T P R H Q s T N P DELETED
T P R H Q s T N P DELETED M
T P R H Q s T N P P
T P R H Q s T N P P M
T P R H Q G s DELETED DELETED DELETED
T P R H Q G s DELETED DELETED DELETED M
T P R H Q G s DELETED DELETED P
T P R H Q G s DELETED DELETED P M
T P R H Q G s DELETED P DELETED
T P R H Q G s DELETED P DELETED M
T P R H Q G s DELETED P P
T P R H Q G s DELETED P P M
T P R H Q G s N DELETED DELETED
T P R H Q G s N DELETED DELETED M
T p i i R H Q G s N DELETED P
T p R H Q G S j N DELETED P M~'
T p R i I H Q G ; s N P DELETED
T p R H Q G s N P DELETED M
T p R H Q G s N P P
T p R H Q G s N P P M
T p R H Q G T DELETED DELETED DELETED
T p R H Q G T DELETED DELETED DELETED M
T p R H Q G T DELETED DELETED P
T p R H Q G T DELETED DELETED P M
T p R H 0 G T DELETED P DELETED
T p R H Q G T DELETED P DELETED M
T p R H Q G T DELETED P P
T p R H Q G T DELETED P P M
T p R H Q G T N DELETED DELETED
T p R H 0 G T N DELETED DELETED M
T p R H Q G T N DELETED P
T p R H Q G T -N DELETED P M
T p R H Q G T N P DELETED
T p R H Q G T N P DELETED M
T p R H Q G^ T N P P
T p R H Q G T N P P M
T p R H V S S DELETED DELETED DELETED
T p R H V S S DELETED DELETED DELETED M
T p R H V S s DELETED DELETED P
T p R H V S s DELETED DELETED P M
T p R H V S s DELETED P DELETED
T p R H V S s DELETED P DELETED M
T p R H V S s DELETED P P
T p R H V s s DELETED P P M

52959 vi/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P R H V s S N DELETED DELETED
T P R H V s S N DELETED DELETED M
T P R H V s s N DELETED P
T P R H V s s N DELETED P M
T P R H V s s N P DELETED
T P R H V s s N P DELETED M
T P R H V s s N P P
T P R H V s s N P P M
T P R H V s T DELETED DELETED DELETED
T P R H V s T DELETED DELETED DELETED M
T P R H V s T DELETED DELETED P
T P R H V s T DELETED DELETED P M
T P R H V s T DELETED P DELETED
T P R H V s T DELETED P DELETED M
T P R H V s T DELETED P P
T P R H V s T DELETED P P M
T P R H VIS T N DELETED DELETED
T P R I H V s T N DELETED DELETED M
T P R H V s T N DELETED P
T P R H V s T N DELETED P M
T P R H V s T N P DELETED
T P R H V s T N P DELETED M
T P R H V s T N P P
T P R H V s T N P P M
T P R H V G S DELETED DELETED DELETED
T P R H V G S DELETED DELETED DELETED M
T P R H V G s DELETED DELETED P
T P R H V G s DELETED DELETED P M
T P R H V G s DELETED P DELETED
T P R H V G s DELETED P DELETED M
T P R H V G s DELETED P P
T P R H V G s DELETED P P M
T P R H V G s N DELETED DELETED
T P R H V G s N DELETED DELETED M
T P R H V G s N DELETED P
T P R H V G s N DELETED P M
T P R H V G s N P DELETED
T P R H V G s N P DELETED M
T P R H V G s N P P
T P R H V G | S N P P M
T P R H V G T DELETED DELETED DELETED
T P R H V G T DELETED DELETED DELETED M
T P R H V G T DELETED DELETED P
T P R H V G T DELETED DELETED P M
T P R H V G T DELETED P DELETED
T P R H V G T DELETED P DELETED M

52959 vl/DC

ASTR 013/01 WO

20

25

29

31

33

49

55
V
V

56
G

91

94
DELETED DELETED

95
DELETED DELETED DELETED DELETED

96
DELETED DELETED
DELETED DELETED

107
M
M
M
M

Y
Y
Y

_Q_
Q Q
Q
JL
Q Q Q Q Q Q Q
,0-0
Q
Q
Q
Q_
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q

.S

DELETED DELETED DELETED DELETED
DELETED
DELETED DELETED DELETED .DELETED .DELETED .DELETED .DELETED
IDELETED DELETED
DELETED DELETED
N
DELETED DELETED DELETED DELETED
DELETED DELETED DELETED DELETED PELETED DELETED DELETED DELETED
N
DELETED DELETED DELETED DELETED

DELETED DELETED
DELETED DELETED
DELETED DELETED
DELETED DELETED
DELETED DELETED
DELETED DELETED
DELETED DELETED
DELETED DELETED

M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M

Q

DELETED DELETED DELETED DELETED

DELETED DELETED DELETED
DELETED

DELETED DELETED

M
M
M

S29S9 vl/OC

ASTR 013/01 WO

20 25 29 31 33 49 I 55 | 56 91 94 95 96 107
T P F S L Y Q I G s DELETED P DELETED
T P F S L Y Q G s DELETED P DELETED M
T P F s L Y Q G s DELETED P P
T P F s L Y Q G s DELETED P P M
T P F s L Y Q G s N DELETED DELETED
T P F s L Y Q G s N DELETED DELETED M
T P F s L Y Q G s N DELETED P
T P F s L Y Q G s N DELETED P M
T P F s L Y Q G s N P DELETED
T P F s L Y Q G s N P DELETED

T P F s L Y Q G s N P P
T P F s L Y Q G s N P P M
T P F s L Y Q G T DELETED DELETED DELETED
T P F s L Y Q G T DELETED DELETED DELETED M
T P F s L Y Q G T DELETED DELETED P
T P F s I Y Q G T DELETED DELETED P M
T _PJ__E s L Y Q G T DELETED P DELETED
T P F s L Y j Q G T DELETED P DELETED M
T P F s L Y Q G T DELETED P P
T P F s L Y Q G T DELETED P P M
T P F s L Y Q G I T N DELETED DELETED
T P F s L Y Q G T N DELETED DELETED M
T P F s L Y Q G T N DELETED P
T P F s L Y Q G T N DELETED P M
T _j P F s L Y Q G T N P DELETED
T P F s L Y Q _G__^ T N P DELETED M
T P F s L Y Q G I T N P P
T P F s L Y Q G ~T I N P P M
T P F s L Y y_ S S DELETED DELETED DELETED
T P F s L Y _, V S S DELETED DELETED DELETED M
T P F s L Y V S s DELETED DELETED P
T P F s L Y V S s DELETED DELETED P M
T P F s L Y V S s DELETED P DELETED
T P F s L Y V S s DELETED P DELETED M
T P F s L Y V S s DELETED P P
T P F s L Y V s s DELETED P P M
T P F s L Y V s s N DELETED DELETED
T P F s L Y V s s N DELETED DELETED M
T P F s L Y V s s N DELETED P
T P F s L Y V s s N DELETED P M
T P F s L Y V s s N P DELETED
T P F s L Y V s s N P DELETED M
T P F s L Y V s s N P P
T P F s L Y V s s N P P M
T P F s L Y V s T DELETED DELETED DELETED
T P F s L Y V s T DELETED DELETED DELETED M
52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S L Y V s T DELETED DELETED P l
T P F S L Y V s T DELETED DELETED P M
T P F S L Y V s T DELETED P DELETED I
T P F S L Y V s T DELETED P DELETED M
T P F s L Y V s T DELETED P P I
T P F s L Y V s T DELETED P P M
T P F s L Y V s T N DELETED DELETED I
T P F s L Y V s T N DELETED DELETED M
T P F s L Y V s T N DELETED P i
T P F s L Y V s T N DELETED P M
T P F s L Y V s T N P DELETED I
T P F s L Y V s T N P DELETED M
T P F s L Y V s T N P P I
T P F s L Y V s T N P P M
T P F s L Y V G S DELETED DELETED DELETED I
T P F s L Y V G S DELETED DELETED DELETED M
T P F s L Y ! V G s DELETED DELETED P I
T P F s L Y V G s DELETED DELETED P M
T P F s L Y V G s DELETED P DELETED I
T P F s L Y V G s DELETED P- DELETED M
T P F s L Y 1 V G s DELETED P P I
T P F s L Y V G s DELETED P P M
T P F s "" L Y V G s N DELETED DELETED I
T P F s L Y V G s N DELETED DELETED M
T P F s L Y V G s N DELETED P I
T P F s L Y 1 V G s N DELETED P M
T P F s L Y 1 V G s N P DELETED I
T P F s L Y V G s N P DELETED M
T P F s L Y V G s N P P I
T P F s L Y V G s N P P M
T P F s L Y j V G T IDELETED[ DELETED DELETED I
T P F s L Y V G T DELETED" DELETED DELETED M
T P F s L Y V G T DELETED DELETED P I
T P F s L Y V G T DELETED DELETED P M
T P F s L Y V G T DELETED P DELETED I
T P F s L Y J V G T DELETED P DELETED M
T P F s L . Y V G T DELETED P P I
T P F s L Y V G T DELETED P P M
T P F s L Y V G T N DELETED DELETED I
T P F s L Y V G T N DELETED DELETED M
T P F s L Y V G T N DELETED P I
T P F s L Y V G T N DELETED P M
T P F s L Y V G T N P DELETED I
T P F s L Y V G T N P DELETED M
T P F s L Y V G T N P P I
T P F S I L Y V G I J N p I p j M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S L H 0 S S DELETED DELETED DELETED
T P F S L H Q S S DELETED DELETED DELETED M
T P F s L H Q S S DELETED DELETED P
T P F s L H Q S S DELETED DELETED P M
T P F s L H Q S S DELETED P DELETED
T P F s L H Q S S DELETED P DELETED M
T P F s L H Q S S DELETED P P
T P F s L H Q S S DELETED P P M
T P F s L H Q S S N DELETED DELETED
T P F s L H Q S S N DELETED DELETED M
T P F s L H Q S S N DELETED P
T . P F s L H Q S S N DELETED P M
T P F s L H Q S S N P DELETED
T P F s L H Q S S N P DELETED M
T P F s L H Q s s N P P
T P F s L H Q s s N P P __M_
T P F S i L H Q s T DELETED DELETED DELETED

T P F s L H Q s T DELETED DELETEDIDELETED M
T P F s L H Q s T DELETED DELETED P
T P F s L H Q s T DELETED DELETED P M
T P F s L H Q s T DELETED P DELETED
T P F s L H Q s T DELETED P DELETED M
T P F s L H Q s T DELETED P P
T P F s L H Q s T DELETED P P M
T P F s L H Q s T N DELETED DELETED
T P F s L H Q s T N DELETED DELETED M
T P F s L H Q s T N DELETED P
T P F s L H Q s T N DELETED P M
T P F s L H Q s T N P DELETED
T P F s L H Q s T N P DELETED M
T P F s L H Q S ! T N P P
T P F s L H Q s T N P P M
T P F s L H Q G S DELETED DELETED DELETED
T P F s L H Q G S DELETED DELETED DELETED M
T P F s L H Q G s DELETED DELETED P
T P F s L H Q G s DELETED DELETED P M
T P F s L H Q G s DELETED P DELETED
T P F s L H Q G s DELETED P DELETED M
T P F s L H Q G s- DELETED P P
T P F s L H Q G s DELETED P P M
T P F s L H Q G s N DELETED DELETED
T P F s L H Q G s N DELETED DELETED M
T P F s L H Q G s N DELETED P
T P F s L H Q G s N DELETED P M
T P F s L H Q G s N P DELETED
T P F s L H Q ! G s N P DELETED M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S L H Q G s N P P I
T P F S L H Q G s N P P M
T P F s L H Q G T DELETED DELETED DELETED
T P F s L H Q G T DELETED DELETED DELETED M
T P F s L H Q G T DELETED DELETED P
T P F s L H Q G T DELETED DELETED P M
T P F s L H Q G T DELETED P DELETED
T P F s ~i L H Q G T DELETED P DELETED M
T P F s L H Q G T DELETED P P
T P F s L H Q G T DELETED P P M
T P F s L H Q G T N DELETED DELETED
T P F s L H Q G T N DELETED DELETED M
T P F s L H Q G T N DELETED P
T P F s L H Q G T N DELETED P M
T P F s I H Q G T N P DELETED
T P F s L H Q G T ! N P DELETED M
T P F s L H Q G T ; N P P
T P F s L H 0 G T N P P M
T P F s L H V S S DELETED DELETED DELETED
T P F s L H V s S DELETED DELETED DELETED M
T P F s L H V s s DELETED DELETED P
T P F s L H V s s DELETED DELETED P M
T P F s L H V s s DELETED L_ P DELETED
T P F s L H V s s DELETED P DELETED M
T P F s L H V s s DELETED P P
T P F s L H V s s DELETED P P M'
T P F s L H V s s N DELETED DELETED
T P F s L H V s s N DELETED DELETED M
T P F s L H V s s N DELETED P
T P F s' L H V s s N DELETED P M
T P F s L H V s s N P DELETED
T P F s L H V s s N P DELETED M
T P F s L H V s s N P P
T P F s L H V s s N P P M
T P F s L H V s T DELETED DELETED DELETED
T P F s L H V s T DELETED DELETED DELETED M
T P F s L H V s T DELETED DELETED P
T P F s L H V s T DELETED DELETED P M
T P F s L H V s T DELETED P DELETED
T P F s L H V s T DELETED P DELETED M
T P F s L H V s T DELETED P P
T P F s L H V s T DELETED P P M
T P F s L H V s T N DELETED DELETED
T P F s L H V s T N DELETED DELETED M
T P F s L H V s T N DELETED P
T P F s L H V s T N DELETED P M
52959 v |/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S L H V S T N P DELETED
T P F S L H V S T N P DELETED M
T P F s L H V S T N P P
T P F s L H V S T N P P M
T P F s L H V G S DELETED DELETED DELETED
T P F s L H V G S DELETED DELETED DELETED M
T P F s L H V G s DELETED DELETED P
T P F s L H V G s DELETED DELETED P M
T P F s L H V G s DELETED P DELETED
T P F s L H V G s DELETED P DELETED M
T P F s L H V G s DELETED P P
T P F s L H V G s DELETED P P M
T P F s L H V G s N DELETED DELETED
T P F s L H V G s N DELETED DELETED M
T P F s L H V G s N DELETED P
T P F s L H V G s N DELETED P M
T P F i S L H V G s N P DELETED
u_J P F s L H V G s N P DELETED M
T P F s L H V G s N P P
T P F s L H V G s N P P M
T P F s L H V G T DELETED DELETED DELETED
T P F s L H V G T DELETED DELETED DELETED M
T P F s L H V G T DELETED DELETED P
T P F s L H V G T DELETED DELETED P M
T P F s ■L H V G T DELETED P DELETED
T P F s L H V G T DELETED P DELETED M
T P F s L H V G T DELETED P P
T P F s L H V G T DELETED P P M
T P F s L - H V G T N DELETED DELETEO
T P F s L H V G T N DELETED DELETED M
T P F s L H ■ V G T N DELETED P
T P F s. L H V G T N DELETED P M
T P F s L H V G T N P DELETED
T P F s L H V G T N P DELETED M
T P F s L H V G T N P P
T P F s L H V G T N P P M
T P F s Y Q S S DELETED DELETED DELETED
T P F s Y Q S S DELETED DELETED DELETED M
T P F s Y Q s s DELETED DELETED P
T P F s Y Q s s DELETED DELETED P M-
T P F s Y Q s s DELETED P DELETED
T P F s Y Q s s DELETED P DELETED M
T P F s Y Q s s DELETED P P
T P F s Y Q s s DELETED P P M
T P F s Y Q s s N DELETED DELETED
T P F s Y Q s s N DELETED DELETED M
52959 vWDC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S Y Q S S N DELETED P I
T P F s Y Q S S N DELETED P M
T P F s Y Q s s N P DELETED I
T P F s Y Q s s N P DELETED M
T P F s Y Q s s N P P I
T P F s Y Q s s N P P M
T P F s Y Q s T DELETED DELETED DELETED I
T P F s Y Q s T DELETED DELETED DELETED M
T P F s Y Q s T DELETED DELETED P I
T P F s Y Q s T DELETED DELETED P M
T P F S i Y Q S 1 T DELETED P DELETED: r
T P F s Y Q s T DELETED P DELETED M
T P F s Y Q s T DELETED P P I
T P F s Y Q s T DELETED P P M
T P F s Y- Q s T N DELETED DELETED I
T P F s Y Q s T N DELETED DELETED M
T ; p F s Y Q s T N DELETED P I
T | P F s 1 Y Q s T N DELETED P M
T P F s Y Q S T t~ N P DELETED i
T P F s Y Q s T L N P DELETED M
T P F s Y Q s T N ■P P I
T P F s Y Q s T N P P M
T P F s Y Q G S DELETED DELETED DELETED I
T P F s Y Q G S DELETED DELETED DELETED M
T P F s Y Q G s [DELETED DELETED P I
T P F s Y Q G s DELETED DELETED P M
T P F s ■ 1 Y Q G s DELETED P DELETED I
T P F s Y Q G s DELETED P DELETED M
T P F s Y Q G s DELETED P P I
T P F s Y Q G s DELETED P P M
T P F s Y Q G s N DELETED DELETED I
T P F s Y Q G s N DELETED DELETED M
T P F s Y Q G i S N DELETED P I
T P F s Y Q G I S N DELETED P M
T P F s Y Q G s N P DELETED I
T P F s Y Q G s L N P DELETED M
T P F s Y Q G s N P P I
T P F s Y Q G s N P P M
T P F s Y Q G T DELETED DELETED DELETED I
T P F s 1 Y Q G T DELETED DELETED DELETED M
T P F s Y Q G T DELETED DELETED P I
T P F s Y Q G ■ T DELETED DELETED P M
T P F s Y 0 G T DELETED P DELETED I
T P F s Y Q G T DELETED P DELETED M
T P F s Y Q G ■ T DELETED P P | I
T P. F s Y Q G T DELETED P P | M
52959 vi/DC

ASTR013/0i WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S Y Q G T N DELETED DELETED
T P F s Y Q G T N DELETED DELETED M
T P F s Y Q G T N DELETED P
T P F s Y Q G T N DELETED P M
T P F s Y 0 G T N P DELETED
T P F s Y Q G T N P DELETED M
T P F s Y Q G T N P P
T P F s Y Q G T N P P M
T P F s Y V S S DELETED DELETED DELETED
T P F s Y V S S DELETED DELETED DELETED M
T P F s Y V S s DELETED DELETED P
T P F s Y V s s DELETED DELETED P M
T P F s Y V s s DELETED P DELETED
T P F s Y V s s DELETED P DELETED M
T P F s Y v ! s s DELETED P P
T P F s Y v ! s 3 DELETED N P P M
T P F s V V s S
DELETED DELETED
T P F S i I Y V s ! s N DELETED DELETED M
T P F s i i Y V s S N DELETED P
T P F s Y V s S N DELETED P M
T P F s Y V s S N P DELETED
T P F s Y V s S N P DELETED M
T P F s Y V s s N P P
T P F s Y V s s N P P M
T P F s Y V s T DELETED DELETED DELETED
T P F s Y V s T DELETED DELETED DELETED M
T P F s Y V s T DELETED DELETED P
T P F s Y V s T DELETED DELETED P M
T P F " s Y V s T DELETED P DELETED
T P F s Y V s T DELETED P DELETED M
T P F s Y V s T DELETED P P
T P F s Y V s T DELETED P P M
T P F s Y V s T N DELETED DELETED
T P F s Y V s T N DELETED DELETED M
T P F s Y V s T N DELETED P
T P F s Y V * s T N DELETED P M
T P F s Y V s T N P DELETED
T P F ' s Y V s T N P DELETED M
T P F s Y V s T N P P
T P F s Y V s T N P P M
T P F s Y V G S DELETED DELETED DELETED
T P F s Y V G S DELETED DELETED DELETED M
T P F s Y V G s DELETED DELETED P
T P F s Y V G s DELETED DELETED P M
T P F s Y V G s DELETED P DELETED
T P F s Y V G s DELETED P DELETED M

52959 vI/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S Y V G s DELETED P P
T P F S 1 Y V G s DELETED P P M
T P F s Y V G s N DELETED DELETED
T P F s Y V G s N DELETED DELETED M
T" P F s Y V G s N DELETED P
T P F s Y V G s N DELETED P M
T P F s Y V G s N P DELETED
T P F s Y V G s N P DELETED M
T P F s Y V G s N P P
T P F s Y V G s N P P M
T P F s Y V G T DELETED DELETED DELETED
T P F s Y V G T DELETED DELETED DELETED M
T P F s Y V G T DELETED DELETED P
T P F s Y V G T DELETED DELETED P M
T P F s Y V G T DELETED P DELETED
T P F s Y V G T DELETED P DELETED M
! T P F ' s Y V G ; T DELETED P ___
P P
T P F S I Y V G j T DELETED
P M
T P F S j ! Y V G T N DELETED DELETED
T P F s Y V G T N DELETED DELETED M
T P F s Y ' V G T N DELETED P
T P F s Y V G T N DELETED P M
T P F s Y V G T N P DELETED
T P F s Y V G T N P DELETED M
T P F s Y V G T N P P
T P F s Y V G T N P P M
T P F s H Q S S DELETED DELETED DELETED
T P F s H Q S S DELETED DELETED DELETED M
T P F s H Q S S DELETED DELETED P
T P F s H Q s S DELETED DELETED P M
T P F s H Q s S DELETED P ^ DELETED
T P F s H Q s S DELETED P DELETED M
T P F s H Q s S DELETED P P
T P F s H Q s S DELETED P P M
T P F s H Q s s N DELETED DELETED
T P F s H Q s s N DELETED DELETED M
T P F s H Q s s N DELETED P
T P F s H Q s s N DELETED P M
T P F s H Q s s N P DELETED
T P F s H Q s s N P DELETED M
T P F s H Q s s N P P I
T P F s H Q s s N P P M
T P F s t i H Q s T DELETED DELETED DELETED
T P F s 1 ! H Q s T DELETED DELETED DELETED M
T P F s i i H Q s T DELETED DELETED P
T P F s 1 1 H Q s T DELETED DELETED! P M
52939 v|/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S H Q S T DELETED P DELETED
T P F s H Q S T DELETED P DELETED M
T P F s I I H Q S T DELETED P P
T P F s I ! H Q S T DELETED P P M
T P F s I ! H Q S T N DELETED DELETED
T P F s H Q S T N DELETED DELETED M
T P F s H Q S T N DELETED P
T P F s H Q S T N DELETED P M
T P F s H Q S T N P DELETED
-T P F s H Q S T N P DELETED M
T P F s . H Q s T N P P
T P F s H Q s T N P P M
T P F s H Q G S DELETED DELETED DELETED
T P F s H Q G S DELETED DELETED DELETED M
T P F s H Q G S DELETED DELETED P
T P F s I l H Q G s DELETED DELETED P M
T P F s ! i ; H Q G s DELETED P DELETED
T P F s . H Q G s DELETED P DELETED M
T ~~' P F s H Q G s DELETED P P
T P F s H Q G s DELETED, P P M
T P F s H Q G s N DELETED DELETED
T P F s H Q G s N DELETED DELETED M
T P F s H Q G s N DELETED P
T P F s H Q G s N DELETED P M
T P F s H Q G s N P DELETED
T P F s H Q G s N P DELETED M
T P F s H Q G s N P P
T P F s H j Q G s N P P M
T P F s H Q G T DELETED DELETED DELETED
T P F s H 0 G T DELETED DELETED DELETED M
T P F s H Q G T DELETED DELETED P
T P F s H Q G T DELETED DELETED P M
T P F s H Q G T DELETED P DELETED
T P F s H Q G T DELETED P DELETED M
T P F s H Q G T DELETED P P
T P F s H Q G T DELETED P P M
T P F s H Q G T N DELETED DELETED
T P F s H Q G T N DELETED DELETED M
T P F s H Q G T N DELETED P
T P F s H Q G T N DELETED P M
T P F s j H 0 G T N P DELETED
T P F s H Q G T N P DELETED M
T P F s H Q G T N P P
T P F s H Q G T N P P M
T P F s H V S S DELETED DELETED DELETED
! T P F s H V S s DELETED DELETED DELETED M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S H V s S DELETED DELETED P
T P F S H V s S DELETED DELETED P M
T P F s H V s S DELETED P DELETED
T P F s H V ■ S S DELETED P DELETED M
T P F s H V s S DELETED P P
T P F s H V s s DELETED P P M
T P F s H V s s N DELETED DELETED
T P F s H V s s N DELETED DELETED M
T P F s H V s s N DELETED P
T . P F s H V s s N DELETED P M
T P F s H V s s N " P DELETED
T P F s H V s r s N P DELETED M
T P F s H V s s N P P
T P F s H V s s N P P M
T P F s H V s T DELETED DELETED DELETED
T P F ^JE^ H V s T DELETED DELETED DELETED M
T P F
F ^_s H V | S T DELETED DELETED P
T P
S i H V I S T DELETED DELETED P DELETED M
T P F L s H V S T DELETED P

T P F s H V s T DELETED P DELETED M
T P F s H V s T DELETED P P
T P F s H V s T DELETED P P M
T P F s H V s T N DELETED DELETED
T P F s H V s T N DELETED DELETED M
T P F s H V s T N DELETED P
T P F s H V s T N DELETED P M
T P F s H V s T N P DELETED
T P F s H V - s T N P DELETED M
T P F s H V s T N P P
T P F s H V s T N P P M
T P F s H V G S DELETED DELETED DELETED
T P F s H V G S DELETED DELETED DELETED M
T P F s H V G s DELETED DELETED P
T P F s H V G s DELETED DELETED P M
T P F s H V G s DELETED P DELETED
T P F s H V G s DELETED P DELETED M
T P F s H V G s DELETED P P
T P F s H V G s DELETED P P M
T P F s H V G s N DELETED DELETED
T P F s H V G s N DELETED DELETED M
T P F s H V G s N DELETED P
T P F s H V G s N DELETED P M
T P F s H V G s N P DELETED
T P F s H V G s N P DELETED M
T P F s H V G s N P P
T P F s H V G s N P P M

52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F S H V G T DELETED DELETED DELETED
T P F S H r v G T DELETED DELETED DELETED M
T P F s H V G T DELETED DELETED P
T P F s H V G T DELETED DELETED P M
T P F s H V G T DELETED P DELETED
T P F s H V G T DELETED P DELETED M
T P F s H V G T DELETED P P
T P F s H V G T DELETED P P M
T P F s H V G T N DELETED DELETED
T P F s H V G T N DELETED DELETED M
T P F s. H V G T N DELETED P
T P F s H V G T N DELETED P M
T P F s H V G T N P DELETED
T P F s H V G T N P DELETED M
T P F s H V G T N P P
T P F s H V G r r N P P M
T P F R L Y Q S s DELETED DELETED DELETED M—I
T P F R L Y 0 S s DELETED DELETED DELETED

T P F R L Y Q S s DELETED DELETED P

T P F R L Y Q S s DELETED DELETED P M
T P F R L Y Q s s DELETED P DELETED
T P F R L Y Q s s DELETED P DELETED M
T P F R L Y Q s s DELETED P P
T P F R L Y Q s s DELETED P P M
T P F R L Y Q s s N DELETED DELETED
T P F R L Y Q s s N DELETED DELETED M
T P F R L Y Q s s N DELETED P
T P F R L Y Q s s N DELETED P M
T P F R L Y Q s s N P DELETED
T P F R L Y Q s s N P DELETED M
T P F R L Y Q s s N P P
T P F R L Y Q s s N P P M
T P F R L Y Q s T DELETED DELETED DELETED
T P F R L Y Q s T DELETED DELETED DELETED M
T P F R L Y Q s T DELETED DELETED P
T P F R L Y Q s T DELETED DELETED P M
T P F R L Y Q s r DELETED P DELETED
T P F- R L Y Q s T DELETED P DELETED M
T P F R L Y Q s T DELETED P P
T P F R L Y Q s T DELETED P P M
T P F R L Y Q s T N DELETED DELETED
T P F R L Y Q s T N DELETED DELETED M
T P F R L Y Q s T N DELETED P
T P F R L Y Q s T N DELETED P M
T P F R L Y Q s T N P DELETED
T P F R L Y Q s T N P DELETED M

52959* I'DC

ASTRO 13/0i WO

20 25 29 31 33 49 55 56 91 94 95 i 96 107 I
T P F R L Y Q S T N P P • i
T P F R L Y Q S T N P P M
T P F R L Y Q G S DELETED DELETED DELETED
T P F R L Y Q G S [DELETED DELETED DELETED M
T P F R L Y Q G s [DELETED DELETED P
T P F R L Y Q G s DELETED DELETED P M
T P F R L Y Q G s DELETED P DELETED
T P F R L Y Q G s DELETED P DELETED M
T P F R L Y Q G s DELETED P P
T P F R L Y Q G s DELETED P P M
T P F R L Y 0. G s N DELETED DELETED
T P F R L Y Q G s N DELETED DELETED M
T P F R L Y Q G s N DELETED P
T P F R L Y Q G s N DELETED P M
T P F R L Y Q G | S N P DELETED
T P F R L ! Y Q G ! S N P DELETED M
T P F R L Y Q G s N P P I
T P F R L Y Q G s ' N P P M
T P F R L Y Q G T 'DELETED DELETED DELETED
T P F R L Y Q G T DELETED DELETED DELETED M
T P F R L Y Q G T DELETED DELETED P
T P F R L Y Q G T DELETED DELETED P M
T P F R L Y Q G T DELETED P DELETED
T P F R L Y Q G T DELETED P DELETED M
T P F R L Y Q G T [DELETED P P
T P F R L Y Q G T DELETED P P M
T P F R L Y Q G T N DELETED DELETED
T P F R L Y Q G T N DELETED DELETED M
T P F R CI Y Q G T N DELETED P
T P F R L Y Q G T N DELETED P M
T P F R L Y 0 G T r N P DELETED
T P F R L ^ Y Q G T N P DELETED M
T P F R L Y Q G T N P P
T P F R L Y Q G T N P P M
T P F R L Y V S S DELETED DELETED DELETED
T P F R L Y V S S DELETED DELETED DELETED M
T P F R L Y V S s DELETED DELETED P :
T P F R L Y V s s DELETED DELETED P M
T P F R L Y V s s DELETED P DELETED
T P F R L Y V s s DELETED P DELETED M
T P F R L Y V s s DELETED P P
T P F R L Y V s s DELETED P P M
T P F R L Y V s s N DELETED DELETED
T P F R L _, Y V s s N DELETED DELETED M
T P F R L Y V s s N DELETED P
T P F R L Y V s s N DELETED P M
5259 v!/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F R L Y V s S N P DELETED
T P F R L Y V s S N P DELETED M
T P F R L Y V s s N P P
T P F R L Y V s s N P P M
T P F R L Y V s T DELETED DELETED DELETED
T P F R L Y V s T DELETED DELETED DELETED M
T P F R I Y V s T DELETED DELETED P
T P F R L Y V s T DELETED DELETED P M
T P F R L Y V s T DELETED P DELETED
T P F R L Y V s T DELETED P DELETED M
T P F R L Y V s T DELETED P P
T P F R L Y V s T DELETED P P M
T P F R L Y V s T N DELETED DELETED
T P F R L Y V s T N DELETED DELETED M
T P F R L Y V s T N DELETED P
T P F R L Y V s T N DELETED P M
T P F R L : Y i v s T N P DELETED ■
T P F R L Y v , s T N I P DELETED M
T P F R L Y V s I N P P
T P F R L Y V s T N P P M
T P F R L Y V , G S DELETED DELETED DELETED
T P F R L Y V G S DELETED DELETED DELETED M
T P F R L Y V G s DELETED DELETED P
T P F R L Y V G ! S DELETED DELETED P M
T P F R L Y V G s DELETED P DELETED I
T P F R L Y V G s DELETED P DELETED M
T P F R L Y V G s DELETED P P
T P F R L Y V G s DELETED P P M
T P F R L Y V G s N DELETED DELETED
T P F - R L Y V G s N DELETED DELETED M
T P F R L Y V G s N DELETED P
T P F R L Y V G s N DELETED P M
T P F R L Y V G s N P DELETED
T P F R L Y V G s N P DELETED M
T P F R L Y V G s N P P
T P F R L Y V G s N P P M
T P F R L Y V G T DELETED DELETED DELETED
T P F R L Y 1 V G T DELETED DELETED DELETED M
T P F R L Y V G T DELETED DELETED . P
T P F R L Y V G T DELETED DELETED P M
T P F R L Y V G T DELETED P DELETED
T P F R L Y V G T DELETED P DELETED M
T P F R L Y V G T DELETED P P
T P F R L Y V G T DELETED P P M
T P F R L Y V G T N DELETED DELETED
T P F R L Y V i G T N DELETED DELETED M
52WV1/DC

J0/1*GS6ZS

Vi d d 0313130 s 9 D H 1 u d d 1
d d 0313130 s 9 0 H 1 a d d 1
w aai3i3a d 0313130 s 9 0 H 1 d d d 1
0313130 d 0313130 s 9 0 H 1 a d d 1
w d O313130 0313130 s 9 0 H 1 H d d 1
d 0313130] 0313130 s 0 D H 1 d d d 1
w 0313130 0313130 0313130 s 9 0 H 1 y d d 1
0313130 0313130 0313130 s 9 0 H 1 y d d 1
w d d N 1 S 0 H 1 M d d 1
d d N 1 S D H 1 y d d 1
w 0313130 d N I s 0 H 1 -a d d 1
0313130 d N 1 s 0 H 1 H d d 1
IAI d 0313130 N 1 s 0 H 1 X d d X
d 0313130 N - 1 s D H 1 y d d 1
w 0313130 031313Q N 1 s 0 H 1 * d d 1
0313130 0313130 N 1 s D H 1 y d d 1
w d d 0313130 1 s 0 H 1 y d d I
d d 0313130 1 s 0 H . 1 y d d 1
!A) 0313130 d 0313130 1 s 0 H 1 y d d 1
0313130 d 0313130 1 s 0 H 1 H d d 1
w d 0313130 0313130 1 s 0 H 1 y d d 1
d 0313130 0313130 1 s 0 H 1 y d d 1
w 0313130 0313130 0313130 1 s D H 1 y d d 1
0313130 0313130 0313130 1 s 0 H 1 y d d 1
w d d N s s 0 H 1 a d d 1
d d N s s 0 H 1 y d d I
w 0313130 d N s s 0 H 1 y d d 1
0313130 d N s s 0 H ! 1 y d d 1
L IA( d 03131301 N S s 0 H ; 1 y d d 1
d 0313130 N s s 0 H 1 y d d x
w 0313130 0313130 N s s o , H 1 y d d 1
0313130 0313130 N s s 0 H 1 y d d 1
w d d 0313130 s s 0 H 1 y d d 1
d d 0313130 s s 0 H 1 y d d 1
IN Q31313Q d 0313130 s s D H 1 y d d 1
0313130 d 0313130 s S- D H 1 y d d 1
w d 0313130 0313130 s s 0 H 1 a J d 1
d 0313130 0313130 s s 0 H 1 y d d 1
VM 0313130 0313130 0313130 s s 0 H 1 y d d 1
0313130 0313130 0313130 s s D H 1 a d d 1
W d d N 1 9 A A 1 y d d 1
d d N 1 9 A A 1 a d d 1
W 0313130 d N i 9 1 A A 1 y d d 1
0313130 d N 1 9 A A 1 a d d 1
W d 0313130 N 1 9 A A 1 a d d 1
d 0313130 N 1 9 A A 1 a d d 1
i.Ot 96 96 re 1-6 99 95 6fr es l-£ 6Z SZ 02
OMlO/UOtfJLSV

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F R L H Q G s N DELETED DELETED I
T P F R L H a G s N DELETED DELETEO M
T P F R L H Q G s N DELETED P I
T P F R L H Q G s N DELETED P M
T P F R L H Q G s N P DELETED I
T P F R L H Q G s N P DELETED M
T P F R L H Q G s N P P I
T P F R L H Q G s N P P M
T P F R L H Q G T DELETED DELETED DELETED I
T P F R L H Q G T DELETED DELETED DELETED M
T P F R L H Q G T DELETED DELETED P I
T P F R L H Q G T DELETED DELETED P M
T P F R L H Q G T DELETED P DELETED !
T P F R I H Q G T DELETED P DELETED M
T P F R L H Q G T DELETED P P I
i T P F R L H Q G T DELETED P P M
T P F R ; L H Q G : T N DELETED DELETED I
T P F R L H Q i G T N DELETED DELETED r" M
T P F R L H Q G T N ■ DELETED P i
T P F R L H Q G T N . DELETED P M
T P F R L H 0 G T N P DELETED [
T P F R L H Q G T N P DELETED M
T P F R L H Q G T ■ N P P I
T P F R L H Q G T N P P M
T P F R L H V S S DELETED DELETED DELETED I
T P F R L H V S S DELETED DELETED DELETED M
T P F R L H V s s DELETED DELETED P I
T P F R L H v ; s s DELETED DELETED P M
T P F R I H V s s DELETED P DELETED I
T P F R L H V s s DELETED P DELETED M
T P F R L H V s s DELETED P P I
T P F R L H V s s DELETED P P M
T P F R L H V s s N DELETED DELETED I
T P F R L H V s s N DELETED DELETED M
T P F R L H V s s N DELETED P I
T P F R L H V s s N DELETED P M
T P F R L H V s s N P DELETED I
T P F R L H V s s N P DELETED M
T P F R L H V s s N P P 1
T P F R L H V s s N P P M
T P F R L H V s T DELETED DELETED DELETED 1
T P F R I H V s T DELETED DELETED DELETED M
T P F R L H V s T DELETED DELETED P 1
T P F R L H V s T DELETED DELETED P M
T P F R L H V s T DELETED P DELETED 1
T P F R L H V s T DELETED P DELETED M
52959 v I /DC

ASTR 013/0] WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F R L H V s T DELETED P P
T P F R L H V s T DELETED P P M
T P F R L H V s T N DELETED DELETED
T P F R L H V s T N DELETED DELETED M
T P F R L H V s T i N DELETED P
T P F R L H V s T N DELETED P M
T P F R L I H V s T N P DELETED
T P F R L H V s T N P DELETED M !
T P F R L H 1 V s T N P P i I
T P F ■ R L H V s T N P P M
T P F R L H V G S DELETED DELETED DELETED
T P F R L H V G S DELETED DELETED DELETED M
T P j F R L H V G s DELETED DELETED P
T P F R L H V G s DELETED DELETED P M
T P F R L H V G s DELETED P DELETED
T P F R L H V r G s DELETED P DELETED M
T P F ! R L H V G s DELETED P P
T P F R L H V G s DELETED P P M
T P F R L H V G s N DELETED DELETED
T P F R L H V G s N DELETED DELETED M
T P F R L H V G s N DELETED P
T P F R L H V G s N DELETED P M
T P F R L H V G s N P DELETED
T P F R L H V G s N P DELETED M
T P F R L H V G s N P P
T P F R L H V G S i N P P M
T P F R L H V G T DELETED DELETED DELETED
T P F R L H V G T DELETED DELETED DELETED M
T P F R L H V G T DELETED DELETED P
T P F R L H v G T DELETED DELETED P M
T P F R L H V G T DELETED P DELETED
T P F R L H V G T DELETED P DELETED M
T P F R L H V G T DELETED P P
T P F R L H V G T DELETED P P M
T P F R L H V G T N DELETED DELETED
T P F R L H V G T N DELETED DELETED M
T P F R L H V G T N DELETED P
T P F R L H V G T N DELETED P - M
T P F R L H V G T N P DELETED
T P F R L H V G T N P DELETED M
T P F R L H V G T N P P
T P F R L H V G T N P P M
T P F R I Y Q S S DELETED DELETED DELETED
T P F R I Y Q S S DELETED DELETED DELETED M
T P F R ! Y Q S s DELETED DELETED P
T P F R I Y Q S s DELETED DELETED P M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F R Y Q S S DELETED P DELETED
T P F R Y Q s S DELETED P DELETED M
T P F R Y Q s S DELETED P P
T P F R Y Q s S DELETED P P M
T P F R Y Q s S N DELETED DELETED
T P F R Y Q s S N DELETED DELETED M
T P F R Y Q s S N DELETED P
T P F R Y Q s S N DELETED P M
T P F R Y Q s S N i p DELETED
T P F R Y Q s S N P DELETED M
T P F R Y Q s S N P P
T P F R Y Q s S N P P M
T P F R Y Q s T DELETED DELETED DELETED
T P ' F R Y Q s T DELETED DELETED DELETED M
T P F R Y Q s T DELETED DELETED P
T ■P F R Y Q s T DELETED DELETED P M
T P ! F R Y Q s T DELETED P DELETED
T P F ! R Y Q s T DELETED P DELETED M
T P F R Y Q s T DELETED P P
T P F R Y Q s T DELETED P P M
T P F R Y Q s T N ■ DELETED DELETED
T P F R Y Q s T N DELETED DELETED M
T P F R Y Q s T N DELETED P
T P F R Y Q s T N DELETED P M
T P F R Y Q s T N P DELETED
T P F R Y Q s T N P DELETED M
T P F R Y Q s T N P P
T P F R Y Q s T N P P M
T P F R Y Q G S DELETED DELETED DELETED
T P F R Y ! Q G s DELETED DELETED DELETED M
T P F R Y Q G s DELETED DELETED P
T P F R Y Q G s DELETED DELETED P M
T P F R Y Q G s DELETED P DELETED
T P F R Y Q G s DELETED P DELETED M
T P F R Y Q G s DELETED P P
T P F R Y Q G s DELETED P P M
T P F R Y Q G s N DELETED DELETED
T P F R Y Q G s N DELETED DELETED M
T P F R Y Q G s N DELETED P
T ■ P F R Y Q G s N DELETED P M
T P F R Y Q G s N P DELETED i
T P F R Y Q G s I N P DELETED M
T P F R Y Q G s N P P
T P F R Y Q G s N P P M
T P F R Y Q G T DELETED DELETED DELETED
T P F R Y Q G T DELETED DELETED DELETED M

S2Q59 vi/OC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 I 95 96 107
T P F R Y Q G T DELETEDIDELETED P
T P F R Y Q G T DELETED DELETED P M
T P F R Y Q G T DELETED P DELETED
T P F R Y Q G T DELETED P DELETED M
T P F R Y Q G T DELETED P P
T P F R Y Q G T DELETED P P M
T P F R Y Q G T N DELETED DELETED
T P F R Y Q G T N DELETED DELETED M
T P F R Y Q G T N DELETED P
T P F R Y Q G T N DELETED P M
T P F R Y. Q G T N P DELETED
T P F R Y Q G T N P DELETED M
T P F R Y Q G T N P P
T P F R Y Q G T N P P M
T P F R Y V S i S DELETED DELETED DELETED
! T P F R Y V S | S DELETED DELETED DELETED M
: T P F R I : Y V S ! S DELETED DELETED P
T P F R I Y V s S DELETED DELETED P M
T P F R Y V s S DELETED P DELETED
T P F R Y V s s DELETED P DELETED M
T P F R Y V s s DELETED P P
T P F R Y V s s DELETED P P M
T P F R Y V s s N DELETED' DELETED
T P F R Y V s s N DELETED DELETED M
T P F R Y V s s N DELETED P
T P F R Y V s s N DELETED P M
T P F R Y V s s N P DELETED
T P F R Y V s s N P DELETED M
T P F R Y V s s N P P
T P F R Y V s s N P P M
T P F R Y V s T DELETED DELETED DELETED
T P F R Y V s T DELETED DELETED DELETED M
T P F R Y V S I T DELETED DELETED P
T P F R Y V s T DELETED DELETED P M
T P F R ■Y V s T DELETED P DELETED
T P F R Y V s T DELETED P DELETED M
T P F R Y V s T DELETED P P
T P P F R Y V s T DELETED P P M
T P F R Y V s T N DELETED DELETED
T P F R Y V s T r^ir- DELETED DELETED M
T P F R Y V s T N DELETED P
T P F R Y V s T N DELETED P M
T P F R Y V s T N P DELETED
T P F R Y V s T N P DELETED M
T P F R Y v i s T N P P
T P F R Y v i s T N P P M
52959 vt/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F R Y V G s DELETED DELETED DELETED
T P F R Y V G s DELETED DELETED DELETED M
T P F R Y . V G s DELETED DELETED P
T P F R Y V G s DELETED DELETED P M
T P F R Y V G s DELETED P DELETED
T P F R Y V G s DELETED P DELETED M
T P F R Y V G s DELETED P P
T P F R Y v G s DELETED P P M
T P F R Y V G s N DELETED DELETED
T P F R Y V G s N DELETED DELETED M
T P F R Y V G s N DELETED P
T P F R Y V G s N DELETED P M
T P F R Y V G s N P DELETED
T P F R Y V G s N P DELETED M
T P F R Y V G s N P P
T P F R I Y V G s N P P M
T P F R Y V
_y
V G G T T DELETED DELETED DELETED1DELETED
T P F R I i Y

DELETED DELETED M
T P F R Y
G T DELETED DELETED P

T P F R Y V G T DELETED DELETED P M '
T P F R Y V G T DELETED P DELETED
T P F R Y V G T DELETED P DELETED M
T P F R Y V G T DELETED P P
T P F R Y V G T DELETED P P M
T P F R Y V G T N DELETED DELETED
T P F R Y V G T N DELETED DELETED M
T P F R Y V G T N DELETED P
T P F R Y V G T N DELETED P M
T P F R Y V G T N P DELETED
T P F R Y V G T N P DELETED M
T P F R Y V G T N P P
T P F R Y V- G T N P P M
T P F R H Q S S DELETED DELETED DELETED
T P F R H Q S s DELETED DELETED DELETED M
T P F R H Q S s DELETED DELETED P
T P F R H Q s s DELETED DELETED P M
T P F R H Q s s DELETED P DELETED
T P F R H Q s s DELETED P DELETED M
T T P F R H Q s s DELETED P . P

P F « H Q s s DELETED P P M
T P F R H Q s s N DELETED DELETED
T P F R H Q s s N DELETED DELETED M
T P F R H G s s N DELETED P
T P F R H Q s s N DELETED P M
T P F R H Q s s N P DELETED
T P F R H 0 s s N P DELETED M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T P F R H Q S S- I N P P I
T P F R H Q S S N P P M
T P F R H Q S T DELETED DELETED DELETED I
T P F R H Q S T DELETED DELETED DELETED M
T P F R H Q S T DELETED DELETED P I
T ,_ P F R H Q S T DELETED DELETED P M
T P F R H Q S T DELETED P DELETED I
T P F R H Q S T DELETED P DELETED M
T P F R H Q S T DELETED P P I
T P F R H Q S T DELETED P P M
T P F R H Q S T N DELETED DELETED I
T P F R H Q s T N DELETED DELETED M
T P F R H Q s T N DELETED P I
T P F R H Q s T N DELETED P M
T P F R H 0 s T N P DELETED I
T P F R H Q s T N P DELETED M
T P F R ' H Q s i T- N P P I
T P F R H Q S T N P P M
T P F R H Q G S DELETED DELETED DELETED I
T P F R H Q G S DELETED DELETED DELETED M
T P F R H Q ; G s DELETED DELETED P I
T P F R H Q G s DELETED DELETED P M
T P F R H Q G s DELETED P DELETED I
T P F R H Q G s DELETED P DELETED M
T P F R H Q G s DELETED P P i
T P F R H Q G s DELETED P P M
T P F R H Q G s N DELETED DELETED I
T P F R H Q G s N DELETED DELETED M
T P F R H Q G s N DELETED P I
T P F R H Q G s N DELETED P M
T P F R H Q G s N P DELETED! I
T P F R H Q G s N P DELETED! M
T P F R H Q G s N P P ! I
T P F R H Q G s »N P P M
T P F R H Q G T DELETED DELETED DELETED I
T P F R H Q G T DELETED DELETED DELETED M
T P F R H Q G T DELETED DELETED p I
T P F R H Q G T DELETED DELETED p M '
T P F R H Q G T DELETED P DELETED I
T P F R H Q G T DELETED P DELETED M
T P F R H Q G T DELETED P P I
T P F R H Q G T DELETED P P M
T P F R H Q G T N - DELETED DELETED I
T P F R H Q G T N DELETED DELETED M
T | P ! F R H Q G T N DELETED P I
T I P F R H Q G | T N DELETED P M
52959 vl/QC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 | 95 96 107
T P F R H Q G T N i P DELETED
T P F R H Q G T ' N : P DELETED M
T P F R H Q G T ~1 N P P
T P F R H Q G T N P P M
T P F R H V S S DELETED DELETED DELETED
T P F R H V S s DELETED DELETED DELETED M
T P F R H V S s DELETED DELETED P
T P F R H V S s DELETED DELETED P M
T P F R H V S s DELETED P DELETED
T P F R H V S s DELETED P DELETED M
T P F R H V S s DELETED P P
T P F R H V S s DELETED P P M
T P F R H V s s N DELETED DELETED
T P F R H V s s N DELETED DELETED M
T P F R H V s s N DELETED P
T P F R H V s s N DELETED P M
T P F R H V s s N P DELETED I i
T P F R ^ H V s s s N N P DELETED M
T P F R H V s

P P
T P F R H V s s N P P M
T P F R H V s T DELETED DELETED DELETED
T P F , R H V s T DELETED DELETED DELETED M
T P F R H V s T DELETED DELETED P
T P F R H V s T DELETED DELETED P M
T T P F R H V s T DELETED P jDELETED

P F R H V s r T DELETED P IDELETED M
T P F R H V s T DELETED P ' P

T P F R H V s T DELETED P P M
T P F R H V s T N DELETED DELETED
T P F R H V s T N DELETED DELETED M
T P F R H V s T N DELETED P
T P F R H V s T N DELETED P M
T P F R H V s T N P DELETED
T P F R H V s T N P DELETED M
T P F R H V s T N P P
T P F R H V ■ s T N P P M
T P F R H V G S DELETED DELETED DELETED
T P F ■ R H V G s DELETED DELETED DELETED M
T P F R H V G s DELETED DELETED P
T P F R H V G s DELETED DELETED P M
T P F R H V G s DELETED P DELETED
T P F R H V G s DELETED P DELETED M
T P F R H V G s DELETED P P
T P F R H V G s DELETED P P M
T P F R H V G s N DELETED DELETED
T P F R H V G s N DELETED DELETED M

5295") vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
T p F R H V G s N DELETED P
T p F R H V G s N DELETED P M
T p F R u_ H V G s N P DELETED
T p F R H r v G s N P DELETED M
T p F R H V G s N P P
T p F R H V G s N P P M
T p F R H V G T DELETED DELETED DELETED
T p F R H V G T DELETED DELETED DELETED M
T p F R H V G T DELETED DELETED P
T p F R H V G T DELETED DELETED P M
T p F R H V G T DELETED P DELETED
T p F R H V G T DELETED P DELETED M
T p F R H V G T DELETED P P
T p F R H V G T DELETED P P M
T p F R H V G T N DELETED DELETED
T p F . R H V G T N ~1 DELETED DELETED M
T p F R H V G T N DELETED P
T p F R H V G T N DELETED P ! M
T p F R H V G T N P DELETED I i
T p F R H V G T N P DELETED M
T p F R H V G T N P P
T p F R H V G T N P P M
S A S L Y Q S S DELETED DELETED DELETED
L S A S L Y 0 S S DELETED DELETED DELETED M
S A s L - Y 0 s s DELETED DELETED P
s A s L Y Q s s DELETED DELETED P M
s A s L Y Q s s DELETED P DELETED
s A s L Y Q s s DELETED P DELETED M
s A s L Y Q s s DELETED* P P
s A s L Y Q s s DELETED P P M
s A s L Y Q s s N DELETED DELETED
s A s L Y Q s s N DELETED DELETED M
s A s L Y Q s s N DELETED P
s A s L Y Q s s N DELETED P U
s A s L Y Q s s N P DELETED
s A s L Y Q s s N P DELETED M
s A s L Y Q s s N P P
s A s L Y Q s s N P P M
s A s L Y Q s T DELETED DELETED DELETED
s A s L Y Q s T DELETED DELETED DELETED M
s A s L Y Q s T DELETED DELETED P
s A s L Y Q s T DELETED DELETED P M
s A s L Y Q s T DELETED P DELETED
s A s L Y Q s T DELETED P DELETED M
s A s L Y Q s T DELETED P P
s A s I Y Q s T [DELETED p ; P ! M

S29S9vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A S L Y Q S T N DELETED DELETED
S A S L Y Q S T N DELETED DELETED M "
s A s L Y Q S T N DELETED P
s _A__i ._!__ s L Y Q S T N DELETED P M
s A s L Y Q s T N P DELETED
s A s L Y Q s T N P DELETED M
s A s L Y Q s T N P P
s A s L Y Q s T N P P M
s A s L Y Q G S DELETED DELETED DELETED
s A s L Y Q G S DELETED DELETED DELETED M
s A s L Y Q G s DELETED DELETED P
s A s L Y Q G s DELETED DELETED P M
s A s L Y Q G s DELETED P DELETED
s A s L Y Q G s DELETED P DELETED M
s A s L Y Q G s DELETED P P
s A s I Y Q G s DELETED p ! p M
s A s ; L Y Q G j S N DELETEDIDELETED
s i A s L Y Q G s N DELETED DELETED M
S i A s L Y Q G s N DELETED P i I
s A s L Y Q G s N DELETED P M
s A s L Y Q G S ! N P DELETED
s A s L Y Q G s N P DELETED M
s . A s L Y Q G s N P P
s A s L Y Q G s N P P M
s A s L Y Q G T DELETED DELETED DELETED
s A s L Y Q G T DELETED DELETED DELETED M
s A s L Y Q G T DELETED DELETED P
s A s L Y Q G T DELETED DELETED P M
s A s L Y Q G T DELETED P DELETED
s A s L Y Q G T DELETED P DELETED M
s A s L Y Q G T DELETED P P
s A s L Y Q G T DELETED P P M
s A s L Y Q G T N DELETED DELETED
s A s L Y Q G T N DELETED DELETED M
s A s L Y Q G T N DELETED P
s A s L Y Q G T N DELETED P M
s A s L Y Q G T N P DELETED
s A s L Y Q G T N P DELETED M
s A s L Y Q G T N P P
s A s L Y Q G T '" N J P P M
s A s L Y V S S JDELETED DELETED DELETED
s A s L Y V S S JDELETED DELETED DELETED M
s A s L Y V S S DELETED DELETED P
s A s L Y V S S DELETED DELETED P M
! s A s L Y V S S DELETED P DELETED
! s A s L Y V S S DELETED P DELETED M
52959 v]/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A S L Y V s S DELETED P P
s A S L Y V s s DELETED P P M
s A s L Y V s s N DELETED DELETED
s A s L Y V s s N DELETED DELETED M
s A s L Y V s S j N DELETED! P
s A s L Y V s s N DELETED P M
s A s L Y V s s N P DELETED
s A s L Y V s s N P DELETED M
s A s L Y V s s N P P
s A s L Y V s s N P P M
s A s L Y V s T DELETED DELETED DELETED I
s A s L Y V s T DELETED DELETED DELETED M
s A s L Y V s T DELETED DELETED P
s A s L Y V I S T DELETED DELETED P M
s A s L Y V s T DELETED P DELETED
s A s L Y V s T DELETED P DELETED M
s A s L Y V s T DELETED P P
s A s L Y V s T DELETED PPM
s A s J L Y V s T ; N DELETEDiDELETED
s A s L Y V s T N OELETEO DELETED M
s A s L Y V s T N DELETED P
s A s L Y V s T N DELETED P M
s A s L Y V s T N P DELETED
s A s L Y V s T N P DELETED M
s A s L Y V s T N P P
s A s L Y V s T N P P M
s A s L Y V ! G | S DELETED DELETED DELETED
s A s L Y V G S DELETED DELETED DELETED M
s A s L Y V G s DELETED DELETED P
s A s L Y V G s DELETED DELETED P M
s A s L Y V G s DELETED P DELETED
s A s I Y V G S DELETED P DELETED M
s A s L Y V G S DELETED P ; P
s A s L Y V G S DELETED P P M
s A s L Y V G s N DELETED DELETED
s A s L Y V G s N DELETED DELETED M
s A s L Y V G s N DELETED P
s A s L Y V G s N DELETED P M
s A s L Y V G s N P DELETED
s A s L Y V G s N P DELETED M
s A s L Y V G s N P P
s A s L Y V G I S N P P M
s A s L Y V | G T DELETED DELETED DELETED
s A s L Y V G T DELETED DELETED DELETED M
s A s L Y V G T DELETED DELETED P
s A s L Y V G T DELETED DELETED P M
S2959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A S L Y V G T DELETED P DELETED
s A S L Y V G T DELETED P DELETED M
s A S L Y V G T DELETED P P
s A S L Y V G T DELETED P P M
s A S L Y V G T N DELETED DELETED
s A S L Y V G T N DELETED DELETED M
s A S L Y V G T N- DELETED P
s A S L Y V G T N DELETED P M
s A s L Y V G T N P DELETED
s A s L Y V G T N P DELETED M
s A s L Y V G T N P P
s A s L Y V G T N P P M
s A s L H Q S s DELETED DELETED DELETED
s A s L H Q S s DELETED DELETED DELETED M
s A s L H Q S s DELETED DELETED P
s A ■ s L H Q S S iDELETED DELETED P M
s A s L H Q s S DELETED P DELETED
: s A s L H Q ! S S DELETED P ^DELETED M
s A s L H Q SIS DELETED P ■ P
s A s L H Q s S iDELETED P P M
s A s L H Q s S N DELETED DELETED
s A s L H Q S S N DELETED DELETED M
s A s L H Q S s N DELETED P
s A s L H Q s s N DELETED P M
s A s L H 0 s s N P DELETED
s A s L H Q s s N P DELETED M
s A s L H Q s s N • P P
s A s L H Q s s N P P M
s A s L H Q s T DELETED DELETED DELETED
s A s L H Q s T DELETED DELETED DELETED M
s A s L H Q s T DELETED DELETED P
s A s L H Q s T DELETED DELETED P M
s A s L H 0 S | T DELETED P DELETED
s A s L H Q _, s T DELETED P DELETED M
s A s L H Q s T DELETED P P
s A s L H Q s T DELETED P P M
s A s L H Q s T N DELETED DELETED
s A s L H Q s T N DELETED DELETED M
s A s L H Q s T- N DELETED P
s A s L H Q s T N DELETED P M
s A s L H Q s T N P DELETED
s A s L H Q s T i N P DELETED M
s A s L H Q s T N P P
s A s L H Q s T N P P M
s A s L H Q G S DELETED DELETED DELETED
s A s L H Q G S DELETED DELETED DELETED M
SZ'Wvl/DO

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A S L H Q G S DELETED DELETED P I |
s A S L H Q G S DELETED DELETED P M j
s A s L H Q G s DELETED P DELETED
s A s L H Q G s DELETED P DELETED M
s A s L H Q G s DELETED P P
s A s L H Q G s DELETED P P M i
s A s L H Q G s "1 N DELETED DELETED f I
s A s L H Q G s N DELETED DELETED M !
s A s L H Q G s N DELETED P
s A s L H Q G s N DELETED P M
s A s L H Q G s N P DELETED
s A s L H ' Q G s N P DELETED M
s A s L H Q G s N P P
s A s L H Q G s N P P M
s A s L H Q G T DELETED DELETED DELETED
s A ' s L H Q G T DELETED DELETED DELETED M
s A s L H Q G T DELETED DELETED P
s A s L H Q G T DELETED DELETED P M
s A s L H Q G T DELETED P DELETED
s A s L H Q G T DELETED P DELETED M
s A s L H Q G T DELETED P P
s A s L H Q G T DELETED P P .M
s A s L H Q G T N DELETED DELETED
s A s L H Q G T N DELETED DELETED M
s A s L H Q G T N DELETED P
s A s I H Q G T N DELETED P M
s A s L H Q G T "! N P DELETED
s A s L H Q G T N P DELETED M
s A s L H Q G T N P P
s A s L H Q G T N P P M
s A s L H V S S DELETED DELETED DELETED
s A s L H V S S DELETED DELETED DELETED M
s A s L H V S s DELETED DELETED P
s A s L H V S s DELETED DELETED P M
s A s L H V S s DELETED P DELETED
s A s L H V S s DELETED P DELETED M
s A s L H V S s DELETED P . P
s A s L H V S s DELETED P P M
s A s L H V S s N DELETED DELETED
s A s L H V S s N DELETED DELETED M
s A s L H V S s N DELETED P
s A s L H V S s N DELETED P M
s A s L H V S s N P DELETED
s A s L H V S s N P DELETED M
s A s L H V S s N P P
s A s L H V S s N P P M

5295'J vf/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
s A S L H V I S T DELETED DELETED DELETED I
s A S L H V j S T DELETED DELETED DELETED M
s A S L H V S T DELETED DELETED P I
s A S_L L H V S T DELETED DELETED P M
s A s L H V S T DELETED P DELETED I
s A s L H V s T DELETED P DELETED M
s A s L H V s T DELETED P P I
s A s L H V s T DELETED P P M
s A s L H V s T N DELETED DELETED I
s A s L H V s T N DELETED DELETED M
s A s L H V s T _i N DELETED P I
s A s L H V s T N DELETED P M
s A s L H V s T N P DELETED I
s A s L H V s T N P (DELETED M
s A s L H V s T N P i P I
s A s L H V s T N ! P ! P M
s A s L H V ! G S DELETEDlDELETEDjDELETED !
s A s L ■ H V G S 'DELETED DELETED DELETED M
s A sZl L ! H V G S ^DELETED DELETED P I
s A s L H V G S DELETED DELETED P M
s A s L H V G S DELETED P DELETED I
s A s I H V G s DELETED P DELETED M
s A s L H V G s DELETED P P I
s A j s L J H V G s DELETED P P M
s A s L H V G s N DELETED DELETED I
s A s L H V G s N DELETED DELETED M
s A s L H V G s N DELETED P I
s A s L H V G s N DELETED P M
s A s L H V G s N P DELETED I
s A s L H V G s N P DELETED M
s A 1 S 1 L H ■ V ! G s I N P P '
s A s L H V ! G s N P P M
s A s L H V ■ G T ^DELETED DELETED DELETED !
s A s L H V I G T DELETED DELETED DELETED M
s A s L H V I G T DELETEC DELETEC P I
s A s L H V G T DELETEC DELETEC P M
s A s L H V G T DELETEC ) P DELETEC ) I
s A s L H V G T DELETEE ) P DELETEC ) M
s A s L H V G T DELETE: ) P P I
s A s L H V G T DELETE: ) P P M
s A s L H V G T i N DELETEC )DELETEC ) I
s A s L H V G T I N DELETEC )DELETEC ) M
s A s L H V G T N DELETEC ) P I I
s A s L H V G T N DELETED! P M
s A s L ._ H V G T N ! P 'DELETEC 3 s A 1 J S ! L H V G T N P DELETEE D M

52«9 vI/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91
T 94
N 95 96 107
S A S L H V G

P P
s A S L H V G T N P P M
s A s Y Q S S DELETED DELETED DELETED
s A s Y Q S S DELETED DELETED DELETED M
s A s Y Q s s DELETED DELETED P
s A s Y Q s s DELETED DELETED P M
s A s Y Q s s ■ DELETED P DELETED
s A s Y Q s s DELETED P DELETED M
s A s Y Q s s DELETED P P
s A s Y Q s s DELETED P P M
s A s Y Q s s N DELETED DELETED
s A s Y Q s s N DELETED DELETED M
s A s Y Q s s N DELETED P
s A s Y Q s s N DELETED P M
s A s Y Q s s N P DELETED
s A s Y Q S _| s N P DELETED M
s A S i I j Y Q s
__N
DELETED P P
s A s I ' Y Q |

P P M
s A s Y Q
T
DELETED DELETED
s A s Y Q s T DELETED DELETED DELETED M
s A s Y Q s T DELETED DELETED P
s A s Y Q s T DELETED DELETED P M
s A s Y Q s T DELETED P DELETED
s A s Y Q s T DELETED P DELETED M
s A s Y Q s T DELETED P P
s A s Y Q s T DELETED P P M
s A s Y Q s T N DELETED DELETED
s A s Y Q s ■ T N DELETED DELETED M
s A s Y Q s T N DELETED P
s A s Y Q s T N DELETED P M
s A s Y Q s T N P DELETED
s A s Y Q s T N P DELETED M
s A s Y Q s T N P P
s A s Y Q s T N P P M
s A s Y Q G s DELETED DELETED DELETED
s A s Y Q G s DELETED DELETED DELETED M
s A • s Y Q G s DELETED DELETED P
s A s Y Q G s DELETED DELETED P M
s A s Y Q G i s DELETED P DELETED
s A s Y Q G ! s DELETED P DELETED M
S_j A s Y Q G s DELETED DELETED P P
s A s Y Q G I s
P P M
s A s Y Q G : s N DELETED DELETED I
s A s Y Q G s N DELETED DELETED M
s A s Y Q G s N DELETED P
s A s Y Q G s I N DELETED P M

52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91_
s 94
N 95 96 107
S A S Y Q G

P P DELETED
S A s Y Q G

DELETED M
s A s Y Q G s N P P
s A s Y Q G s DELETED P P M
s A s Y Q G T
DELETED DELETED
s A s Y Q G T DELETED DELETED DELETED M
s A s Y Q G T DELETED DELETED P
s A s Y Q G T DELETED DELETED P M
s A s Y Q G T DELETED P DELETED
s A s Y Q G T DELETED P DELETED M
s A s Y Q G T DELETED P P
s A s Y Q G T DELETED P P M
s A s Y Q G T N DELETED DELETED
s A s Y Q G T N DELETED DELETED M
s A s Y Q G T N DELETED P
s A s Y Q G T N DELETED P M
s A I S Y Q G T N_ N P DELETED
s A 1 '. S Y Q G G T
T
P DELETED M
s A i : s Y Q

N P | P
s A 1 S Y Q G T N P I P M
s A s Y V S S DELETED DELETEDiDELETED
s A s Y V S S DELETED DELETEDiDELETED M
s A s Y V S s DELETED DELETED! P
s A s Y V S^ s DELETED DELETED P M
s A s Y V s s DELETED P DELETED
s A s Y V s s DELETED! P DELETED M
s A s Y V s s DELETED! P P
s A s Y V s s DELETED P P M
s A s Y V s s N DELETED DELETED
s A s Y V s s N DELETED DELETED M
s A s Y V s s N DELETED P
s A s Y V s s N DELETED P M
s A s Y V s s N P DELETED
s A s Y V s s N ■ P DELETED M
s A s Y V s s N P P
s A s Y V s s N P P M
s A s Y V s T DELETED DELETED DELETED
s A s Y V s T DELETED DELETED DELETED M
s A s Y V s T DELETED DELETED P
s A s Y V s T DELETED DELETED P M
s A s Y V s T DELETED P DELETED
s A s Y V s T DELETED P DELETED M
s A s Y V s T DELETED P P
s A s I j Y V s T DELETED N P P M
s A s I I Y V V _.__s
s T
DELETED DELETED
s A s I i Y

T ..._.. N _ DELETED DELETED M

529S9 vl/IX"

ASTR 013/01 WO

20 25 29 31 33 49 55 55 91 94 95 96 107
S A S Y V S T N DELETED P I
s A s Y V S T N ' DELETED P M
s A s Y V S T N P DELETED
s A s Y v 1 S T T N
N N P DELETED M
s A 1 ' S Y V s

P P
s A s I Y V s T
P P M ,•
s A s Y V G S DELETED1DELETED DELETED
s A s Y V G S DELETEDIDELETED DELETED M
s A s Y V G s DELETED DELETED P
s A s Y V G s DELETED DELETED P M
s A . s Y V G s DELETED P DELETED
s A s Y V G s DELETED P DELETED M
s A s Y V G s DELETED P P
s A s Y V G s DELETED P P M
s A s Y V GH s N DELETED DELETED
s A s Y V G s N DELETED DELETED M
: S A s Y V G s ' N DELETED P
s A s I . Y V G s N jDELETED P M
s A s Y V G s N | P DELETED
s A s I i Y V G s N P DELETED M
s A s Y V G s N P P
s A s Y V G s N P P M
s A s Y V G T DELETED DELETED DELETED
s A s Y V G T DELETED DELETED DELETED M
s A s Y V G .... L DELETED DELETED P
s A s Y V G
DELETED DELETED P M
s A s Y _j V G T DELETED P DELETED
s A s Y V G T DELETED P • DELETED M
s A s Y V G T DELETED P P
s A s Y V G T DELETED P P M
s A s Y V G T N DELETED DELETED
s A s Y V G T N DELETED DELETED M
s A s Y V G T N DELETED P
s A s Y V G T N DELETED P M
s A s Y V G T N P DELETED
s A s Y V G T N P DELETED M
s A s Y V G T N P . P
s A s Y V G T N P P M
s A s H Q S S DELETED DELETED DELETED
s A s H Q S S DELETED DELETED DELETED M
s A s H Q S s DELETED DELETED P
s A s H Q S s DELETED DELETED P M
s A s H Q S s DELETED P DELETED
s A s H Q s s DELETED P DELETED M
s A s H Q s i s DELETED P P
s A s H Q s 1 s DELETED P P M

52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A S H Q S S N DELETED DELETED
S A S H Q Fs S N DELETED DELETED M
S A s H Q s S N DELETED P
S A s H Q__| s s N DELETED P M
s A s H Q s s N ; p DELETED
s A s H Q s 1 s N N P DELETED M
s A s H Q s s
P P
s A s H Q s s N P P M
s A s H Q s T DELETED DELETED DELETED
s A s H 0 s T DELETED DELETED DELETED M
s A s H 0 s T DELETED DELETED P
s A s H Q s T DELETED DELETED P M
s A s H Q s T DELETED P DELETED
s A s H Q s T DELETED P DELETED M
s A s H Q s T DELETED P P
s A s H Q s T DELETED P P M
s A s H Q s T T N N DELETED DELETED
s A S I H Q s

DELETED DELETED M
s A s H Q c
N BELETED P _l
s A s H Q s * T N ;DELETEDj P M
s A s H Q s T N P DELETED
s A s H Q s T N P DELETED M
s A s H Q s T N P P
s A s H Q s T N P P M
s A s H Q G S DELETED DELETED DELETED
s A s H Q G s DELETED DELETED DELETED M
s A s H 0 G s DELETED DELETED P
s A s H Q G s DELETED DELETED OELETED P M
s A s H Q G s
P DELETED
s A s H Q G s DELETED P DELETED M
s A s H Q G s DELETED P P
I s A s H Q G s DELETED1 P P M
s A s I H 0 G s N 'DELETED DELETED
s A s H Q G s N N N DELETED DELETED M
s A s H Q G J s
DELETED P
s A s H Q G s
DELETED P M
s A s H Q G s N P DELETED
s A s H Q G s N P DELETED M
s A s H Q G s N P P
s A s H Q G s ' N P P M
s A s H Q G T DELETED DELETED DELETED
s A s H Q G T DELETED DELETED DELETED M
s A s H Q G T DELETED DELETED P
s A s H Q G T DELETEDIDELETED P M
s A s H Q G T DELETED P DELETED
s A s H Q G T DELETED P DELETED M

52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A S H Q G T DELETED P P
s A s H Q G T DELETED P P M
s A s H Q G T N DELETED DELETED
s A s H Q G T N DELETED DELETED M
s A ■ s H Q G T N DELETED P
s A s H Q G T N DELETED P M
s A s H Q G T N P DELETED
s A s H Q G T N P DELETED M
s A S j I H ■ Q G ! T N P P
s A s H Q G T N P P M
s A s I H V S s- DELETED DELETED DELETED
s A s H V S S DELETED DELETED DELETED M
s A s H V s s DELETEDiDELETED P
s A s H V s s DELETED DELETED! P M
s A , s H V s s DELETED P DELETED
s A Ls H __y
V s s DELETED DELETED P 'DELETED M
s A SSI H
S i S
P
P P
S A s H V "s s DELETED
P M
! S A s I H V s , s s N DELETED DELETED
s A s H V
s N DELETED DELETED M
s A s H V s s N DELETED P
s A s H V s s N DELETED P M
s A s H V s s N P DELETED
s A s H V s s N P DELETED M
s A s H V s s N P P
s A s H V s s N P P M
s A s H V s T DELETED DELETED DELETED
s A s I H V s T DELETED DELETED DELETED M
s A s H V c T DELETED DELETED P
s A s H V s T DELETED DELETED P M
s A s H V s T DELETED P DELETED
s A s H V s _J T DELETED P DELETED M
s A s H V s T DELETED P P
s A s H V s T DELETED P P M
s A s H V s i T N DELETED DELETED
s A s ' H V s T N DELETED DELETED M
s A s H V s T N DELETED P
s A s H V s T N DELETED P M
s A s H V s T N P DELETED
s A s H V s T N P DELETED M
s A s H V S ! T N P P
s A s H V S I T N P P M
s A s H V G S DELETED DELETED DELETED
s A s H V u- P S DELETED DELETED DELETED M
s A s H V G s DELETED DELETED P
s A L s H V G | S DELETED DELETED P M

52959v l/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A ! i ! s H V _G__ G G s DELETED P DELETED I
s A 1 : S I H

s DELETED P DELETED M
s A 1 \ S H V
s DELETED P P I
s A S H V [ C3 l s DELETED P P M
s A S H V G s N DELETED DELETED I
s A s H V G s N DELETED DELETED M
s A s H J V G s N DELETED P I
s A s H V G s N DELETED P M
s A s H V G s N P DELETED t
s A s H L_v •G s N P DELETED M
s A s H V G s N P P I
s A s H V G s N P P- LM
s A s H V G T DELETED DELETED DELETED I
s A s H V G T DELETED DELETED DELETED M
s A s H V G T iDELETED DELETED P I
s A s H V G T DELETED DELETED P M
s All'S H V V
_.. ^.
V G
_ G
G _ G T
T DELETED DELETED P DELETED I
s A s H

P DELETED M
s A s H

T DELETED P P I
s A s H

DELETED] P P M
s A s H V G
G
___G_
G T T T N
N DELETED DELETED I
s A s H V

DELETED DELETED M
s A s H ,

N DELETED P I
s A s H V V
J__
T N DELETED P M
s A s H

N P DELETED I
s A s H V G T N P DELETED M
s A s H V L G_J T N j p P I
s A s H V G T N P P M
s A R L Y Q S S DELETED DELETED DELETED I
s A R L y I G S S j DELETED DELETED DELETED M
s A R L Y f~Q S s DELETED DELETED P I
s A R L Y Q s s DELETED DELETED P M
s A R L Y Q s s DELETED P DELETED I
s A R L Y Q s s DELETED P DELETED M
s A R L Y Q s s DELETED P P I
s A R L Y Q s s DELETED P P M
s _, A R L Y Q s s N DELETED DELETED I
s A R L Y Q . s s N DELETED DELETED M
s A R L Y Q s s . N DELETED P I
s A R L Y Q s s N DELETED P M
s A R L Y Q s
s s N P DELETED I
s A R L Y Q
s N P DELETED M
s A R L Y Q s s N P P t
s A R
R L Y Q s _s.._.
T N P ' P M
s A
L Y 0

DELETED DELETED DELETED DELETED I
s A R L Y G s T
DELETED DELETED M

52959 v!,'DC

ASTR 013/01 WO

20 25 29 31 _
R 33 49 55 Q
- JL .)
Q ; 56
s I 9_li 94 "1 TJDELETEO" 95 96 107
S A 1
L Y

DELETED P
S A 1 ' R
Y

T DELETED DELETW P M
S A R L Y

T DELETED P DELETED
S A R L Y

T DELETED! P P DELETED M
s A R L Y
s 4 T DELETED
P
s A R L Y Q s s T DELETED! P P M
s A R L Y Q
T N DELETED DELETED
s A R L Y Q s T N DELETED DELETED M
s A R L Y Q s T N DELETED P
s A R L Y Q s T N DELETED P M
s A R L Y Q s T N P DELETED
s A R L Y Q s T N P DELETED M
s A R L Y Q s T N P P
s A R L Y Q s T N P P M
s A R L Y Q G S DELETED1 DELETED DELETED
s A R L Y Q G S DELETEDjDELETED DELETED M
s A R L
L L Y Y Q Q _G_J G
G s DELETEDIDELETED P I
s A R

S _JDELETEDJDELETED P M
s A R

S DELETED P
P DELETED
s A R L Y Q
S DELETED DELETED
DELETED M
s A R L Y Q G G S
p i P
s A R L Y Q
s DELETED p
DELETED P M
s A R L Y Q ~l G
"G s N
DELETED I
s A H L__j Y Q
s__] N (DELETED N IDELETED DELETED M
s A R L Y Q
s
P
s A R L Y Q G s N DELETED P M
s A R ' L Y 0 G n s N P DELETED
s. A R L Y Q G s N P DELETED M
s A R L Y Q G s N P P
s A R L Y Q , G s N P P M
s A R L Y i Q G T DELETED DELETED DELETED
s A R L Y I 0 G T DELETED DELETED DELETED M
s A R L Y Q G T DELETED DELETED P
s A R L Y Q G T DELETED DELETED P M
s A R L Y Q G T DELETED P DELETED
s A R L Y Q G T DELETED P DELETED M
s A R L Y Q G T DELETED P P
s A R L Y Q G T DELETED P P M
s A R L Y Q G T N DELETED DELETED ]
s A R L i Y Q _ G G T M DELETED DELETED M
s A R L I Y Q
T N DELETED P
s A R L Y Q G T N [DELETED P M
s A R L Y Q G G
G T N ! P DELETED
s A R
R L L I Y I Q
! Q"
H- M p DELETED M
s I A

Y

N ■ N i—^—l- p
s I A R i L Y I o G L..I .
p ■ p M

S2951vWDC

ASTR 013/01 WO

20 25 29 31 33 49 55
v 56
1 s_
s 91
S 94 95 96 107
S A __R
R L _Y_ Y

DELETED DELETEDlDELETED I
s A

s_l DELETED DELETED DELETED M
s A R L Y v s s DELETED DELETED P
s A R L Y V s ! s DELETED DELETED P M
s A R L Y V s s DELETED P DELETED
s A . R I Y V s _, s DELETED P DELETED M
s A R L Y V s s DELETED P P
s A R L Y V s s DELETED P P M
s A R L Y V s s N DELETED DELETED
s A R L Y V s s N DELETED DELETED M
s A R L Y V s s N DELETED P
s A R L Y V s s N DELETED P M
s A R L Y V s s N P DELETED
s A R L Y V s s N P DELETED M
s A R L Y V s s N P P
s A R L Y V s
-I- s N p ! P M
s A R L Y__
Y Y Y V V
_
V
- v-
T DELETEDlDELETED DELETED
s A 1 _R
R R L L
L

T DELETED DELETEDlDELETED M
s A

T DELETED DELETED P
s A

s s T DELETED DELETED! P M
s A R L Y

T DELETED P JDELETED
s A R L Y v s 1 T DELETED p (DELETED M
s A R L Y j , V s T DELETED p P
s A 1 1 R L Y 1 v n s s T DELETED p P M
s A R L Y V
T N DELETED DELETED
s A R L Y V s T N DELETED DELETED M
s A R L Y V s T N DELETED P
s A R L Y V s T N DELETED P M
s A R L Y V s T N P DELETED
s A R L Y V s T N P DELETED M
s A R L Y V s T N P P
s A R L Y V s T N P P M
s A R L Y V G S DELETED DELETED DELETED
s A R L Y V G S DELETED DELETED DELETED M
s A R L Y V G S DELETED DELETED P
s A R L Y V G S DELETED DELETED P M
s A R L Y V G S DELETED P DELETED ■
s A R L Y V G S DELETED P DELETED M
s A R L Y V G S DELETED P P
s A R L Y V G S DELETED P P M
s A R L Y V G s N DELETED DELETED I
s A R L Y V i G _
' G
i G , G s N DELETED DELETED M
s A R L Y V
s N DELETED P ,
s A I i R L Y
Y
1 Y y_
V V
s s N DELETED P M
s A R L

N P DELETED I
s A R

N i P JDELETEDf M

5?.9S9vl/DC

ASTR 013/01 WO

20 25 29 31
R 33 49 55 56 91 94 95 96 107
S A
L Y V G
G s N i P P
S A R L Y V
s J N P P M
S A R j L Y V V G T I DELETED DELETED DELETED
S A 1 R L Y
G T DELETED DELETED DELETED M
S A R L Y V G T DELETED DELETED P
S A R L Y V G T DELETED DELETED P M
S A R L Y V G T DELETED P DELETED
s A R L Y V G T DELETED P DELETED M
s A R L Y V G T DELETED P P
s A R L Y V G T DELETED P P M
s A R L Y V G T N DELETED DELETED
s A R L Y V G T N DELETED DELETED M
s A R L Y V G T N DELETED P
s A R L Y V G T N DELETED P M
s A R L Y V G T N P DELETED
s A R L Y V G T N P DELETED M
L_S A ,_R R L_
L Y Y V
IY,
Q S T
T N P P
3 A 1

N P P M
s A R L H

S DELETED DELETED DELETED
s A
L _j H Q S s DELETED DELETED DELETED M
s A R R L H 0 s s DELETED DELETED P
s A
L H Q s s DELETED DELETED P M
s A 1 R L 1 H Q j 0 s s DELETED P DELETED
s A R L H
s s DELETED P DELETED M
s A R L H Q s s DELETED P P
s A |R L H Q s s DELETED P P M
s A R L H Q s s N DELETED DELETED
s A R L H Q s s N DELETED DELETED M
s A R L H Q s s N DELETED P
s A R L H Q s s N DELETED P M
s A R L H Q s s N P DELETED
s A R L H 0 s s N P DELETED M
s A R L H Q s ■ s N P P
s A R L H Q s s N' P P M
s A R L H Q s T DELETED DELETED DELETED
s A R L H Q s T DELETED DELETED DELETED M
s A R L H Q s T DELETED DELETED P
s A R . L H 0 s T DELETED DELETED P M
s A R L H 0 s T DELETED P DELETED
s A R L H 0 s T DELETED P DELETED M
s A
L H Q s T DELETED P P
s A R L H 0 s T DELETED P P M
s A R L H o s T N DELETED DELETED
s A ' R L H Q s T N DELETED DELETED M
s A t R L H Q s
s -7 N DELETED P
s A ■ 1 R L H 0
T N DELETEDl P M

52959v |/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 | 96 107
s A R L H Q s T H N p IDELETED
s A R L H Q s T
p DELETED M
s A R L H Q s T N p P
s A R L H a~1 s T N p P L_M
"s A R L H Q G S DELETED DELETED DELETED , s A R L H . Q G S DELETED DELETED DELETED M
s A R L H Q G s DELETED DELETED P
s A R L H Q G s DELETED DELETED P M
s A R L H Q G s DELETED P DELETED
s A R L H Q G s DELETED P DELETED M
s A R L H Q G s DELETED P P
s A R L H Q G s DELETED P ~~1 P M
s A R L H Q G s N DELETED DELETED
s A R I. H G G s N DELETED DELETED M
s A R L H Q G s N DELETED P
s A R L H Q G s N _j DELETED P M
s A L R L
L H H G Q
___Q
G G
.A... G s s N N N P DELETED
s A "■' 1 ■-R-
f _j R

P DELETED M
s A
L L H

P p
s A j ___R_ R

G s N P P M
s A
L H Q G T DELETED DELETED DELETED
s A I ! R L H Q G T DELETED DELETED DELETED M
s A I I R L H Q G T DELETED DELETED P
s A R L H Q G T DELETED DELETEDl P M
s A R L H Q G T DELETED p DELETED
s A R L H Q G T DELETED p DELETED M
s A I R_^ L H Q G T DELETED p P
s A _i. R L H Q G T DELETED p P M
s A R L H Q G T N DELETED DELETED
s A R L H Q G _\ T N DELETED DELETED M
s A R L H Q G T N DELETED P
s A I ! R L H Q G T N DELETED P M
s A 1 i R L H Q G T N P DELETED
s A R L H Q G T N P DELETED M
s A R L H Q G T N P P
s A R L. H Q G T N P P M
s A R L H V S S DELETED DELETED DELETED
s A R L H V s s DELETED DELETED DELETED M
s A R L H V s s DELETED DELETED P
s A R L H V s s DELETED DELETED P M
s A R L Hi V s s DELETED P DELETED
s A R L H~1
H V s s DELETED P DELETED M
s A R L
1 v s s DELETED P P
s A R L H V s s DELETED P P M
s A I ; R I H V 1 S s N
N DELETED DELETED
s A 1 ! R L H V s s
DELETED DELETED M

52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A R L H V V _ s
s S N DELETED P
s A R L H H

Si N DELETED; P M
s A R L
V s S N i P i DELETED
s A R L H V s s N P DELETED ■ M
s A R L H V
s N P I P
s A R L H V s s N P P M
s A R L H V s T DELETED DELETED DELETED
s A R L H V s T DELETED DELETED DELETED M
s A R L H V s T DELETED DELETED P
s A R L H V s T DELETED DELETED P M
s A R L H V s T DELETED . P DELETED
s A R L H V s T DELETED P DELETED M
s A R L H V s T DELETED P P
s A R L H V s T DELETED P P M
s A 1 R L H V V
v
V J s T N JDELETED DELETED
s A R L_
__L
L
__L
L H hi
~:^:
H H
s s
I S T
T
T N N DELETED DELETED M
s A I R

DELETED! P M
s A 1 R

N DELETED P

s A ! I R

N ' P DELETED
s A 1 1 R

V rs T N
N P DELETED M
s A l R L

Is T
P P
s A ' R L H V I s T h N P P M
s A R L H V G S DELETED DELETED DELETED
s A R L H V G S DELETED DELETED DELETED t M
s A R L H V G s DELETED DELETED P
s A R L H V G s DELETED DELETEDl P M
s A R L H V G s DELETED P '.DELETED
s A R L H V G s DELETED P DELETED M
s A R L H V G s DELETED P P
s A R L H V G s DELETED P P M
s A R L H V G s . N DELETED DELETED
s A R L ; H V G s N DELETED DELETED M
s A R L H V G s N DELETED P
s A R L H V G s N DELETED P M
s A R L H V G s N P DELETED
s A R L H V G s N P DELETED M
s A R L H V G s N P P
s A R L H V G s N P P M
s A R L H V G r~T DELETED DELETED DELETED
s A R L H H V G T DELETED DELETED DELETED M
s A R L
V V G
|_ G G T T DELETED DELETED P
s A R
i H

DELETEDIDELETED P M
s A R L

T T DELETED DELETED P DELETED
s A R L ! H y_
i V ; G I G

I P DELETED M
s A 1 j R L i H

JDELETED (DELETED P P
s A .' 1 R „ t- I H i v ' G

! P P M

52959 vl/DC

■ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A R L H H H V V G G T N DELETED DELETED
s A R R - L

T N DELETED DELETED M
s A
L
V G T N DELETED P
s A R L
V G T N DELETED P M
s A i R L H V G I T N P DELETED
s A i R L H V G T N P DELETED M
s A R L H V G T H P P
s A R L H V G T N P P M
s A R Y 0 S S DELETED DELETED DELETED
s A R Y Q S S DELETED DELETED DELETED M
s A R Y Q S S DELETED DELETED P
s A R Y Q s S DELETED DELETED P M
s A R Y Q s S DELETED P DELETED
s A R Y Q s s DELETED P DELETED M
s A R Y 0 s s DELETED P P
s A | R Y _Q _
Q s
s
'"'s ~ s DELETED P P M
s A ' R ! I ■ Y

-I— s N DELETED DELETED
s A -.— 3.1 —L_ Y

N DELETED DELETED M
s r^A R
Y
„3„_
s lid
s N DELETED P
s A R Y Q

DELETED P M
s A R Y . Q ,s
N P {DELETED
s A R Y Q s s N P DELETED M
s A R I Y Q s s N P P
s A R Y Q s s N P P M
s A R Y Q s T DELETED DELETED DELETED
s A R Y Q s T DELETED DELETED DELETED M
s A I R Y Q s T DELETED DELETED P
s A R Y Q s T DELETED DELETED P M
s A R Y Q s T DELETED P DELETED
s A R Y Q s T DELETED P DELETED M
s A R Y Q s T OELETED P P
s A R Y Q s T DELETED P P M-
s A R Y Q s T N DELETED DELETED
s A R Y Q s T N DELETED DELETED M
s A R I i Y Q s T N DELETED P
s A R Y Q s T N DELETED P M
s A R Y Q s T N P DELETED
s A R Y Q s T N P DELETED M
s A 1 !' R Y Q s T ■ N- P P
s A R Y Q s T ' N P P M
s A R Y Q G S DELETED DELETED DELETED
s A 1 j R . I Y Q __G
G s DELETED DELETED DELETED M
s A t j R 1 Y Q
s DELETED DELETED' P
s A Y Q G s DELETEDlDELETED P M
s A i '
Y Q G s DELETED p DELETED
s A 1 i R Y Q G s DELETED p DELETED M

52959 v! 'DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A R Y Q G s DELETED P P
S A R Y Q G s DELETED P P M
s A R Y Q G s N DELETED DELETED
s A ^ R Y Q G s N DELETED DELETED M
s A R Y Q G s N DELETED P
s A R Y Q_i G s N DELETED P M
s A R Y Q G s N P DELETED
s A R Y Q G s N P DELETED M
s A R Y Q G s N P P
s A R Y Q G s N P P M
s A R Y Q G T DELETED DELETED DELETED
s A R Y Q G T DELETED DELETED DELETED M
s A R Y Q G T DELETED DELETED P
s A R Y _Q.__
0 G T DELETED DELETED P M
s 1 A R Y

T DELETED P DELETED
s A K I I
Q_ Q G
G~ "~G T DELETED P P p DELETED M
_s
s A 1 R i I Y

T T DELETED DELETED
P

A 1 ! K ! 1 j Y

P M__
s A , R 1 ' Y

N OELETEDIDELETED

s A R Y Q U G
N DELETEDJDELETED M
s A R Y Q G T N DELETED! P
s A R Y Q G T N DELETED P M
s A R Y Q G T N P DELETED
s A R Y Q G T N P DELETED M
s A R Y Q G T N P P
s A R Y Q G T N P P M
s A R Y V S S DELETED] DELETED DELETED
s A R Y V s s DELETED DELETED DELETED M
s A R Y V s s DELETED DELETED P
s A R Y V s s DELETED DELETED P M
s A R Y V s s DELETED P DELETED
s A R Y V s s DELETED P DELETED M
s A R Y V s s DELETED P P
s A R Y V s s DELETED P P M
s A R Y V s s N DELETED DELETED
s A R Y Y V s s N DELETED DELETED M
s A R I
V s s N DELETED P
s A R i I Y V s s N DELETED P M
s A R i 1 Y , V s s N P DELETED
s A 1 R Y v s s N ^_ P DELETED M
s A R Y V s s N P P
s A R Y V s s N P P M
s A 1 1 R Y V s 1 T DELETED DELETED DELETED
s A 1 ! R Y V s T DELETED DELETED DELETED M
s A i : R Y V s T DELETED DELETED P
s A . 1 R Y •"V s T .DELETED .DELETED P M

52959 vl/DC

ASTR 013/01 WO

20 25 29 | 31 33 49 55 56 ] 91 94 95
P 96 107
S A I ! R Y V s T DELETED
DELETED I
s A ! | R Y V s T DELETED P DELETED M
s A ^J I R Y Y V V s T DELETED P P I
s A ^TR

S T DELETED P P M
s A I rri | Y V s T N DELETED DELETED I
s A I R Y V s T N DELETED DELETED M
s A R Y V s T N DELETED P I
s A R Y V s T N DELETED P M
s A R Y V s T N P DELETED I
s A R Y V s T N P DELETED M
s A R Y V s T N P P I
s A R Y V s T N P P M
s A R Y V V V G S DELETED DELETED DELETED I
s A R Y
1 G ' G S ^ DELETED DELETED DELETED M
s A R Y

s DELETED DELETED P I
s A R I Y v
-v-
_y_
V __G
__G _
G s DELETED DELETED1! P M
s A I R i y

s "^ """ s DELETED; P DELETED I
s A | I __J R ] \ [ Y.

DELETED P DELETED M
s A R | Y

DELETED P P I
s A R I"Y

s DELETED P P M
s A R Y V G s N DELETED DELETED I
s A R Y^ V G s N DELETED DELETER M
s A R Y V G s N DELETED P I
s A R Y V G s N DELETED P M
s A R Y V G s N P DELETED t
s A R Y V G s N P DELETED M
s A R Y V G s N P P I
s A R I | Y V G s N P 1 P M
s A R I | Y V G T DELETED DELETED DELETED I
s A R I ! Y V G T DELETED DELETED DELETED M
s A R I i Y V 1 G T DELETED DELETED P I
s A R i i Y V ! G T DELETED DELETED! P M
s A R r TTT~ V G T DELETED: P JDELETED I
s A R I | Y V 1 G T DELETED P DELETED M
s A R I ! Y V i G T DELETED P P I
s A R Y V G ' T DELETED P P M
s A R I j Y V G hh N DELETED DELETED I
s A R I Y V G
N DELETED DELETED M
s A R Y V I G ! T- N DELETED P 1
s A R I l Y V I G i T ' N DELETED P M
s A R 1 I Y v ! G ! T N P DELETED 1
s A R Y , v 1 G i T N P DELETED M
s A R Y 1 v ; G T N P P 1
s A R Y 1 v ! G j T N P P M
s A R — - H ' Q s S DELETED DELETED DELETED I
s A i i R
!_H i Q i s i s DELETED DELETED FDELETED M

S29S9v[/f>C

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A r R -——- H Q S S DELETED DELETED P
s A 1 R
H Q S S DELETED DELETED P M
s A R H i Q s S DELETED P DELETED
s A R H i Q s S DELETED P DELETED M
s A LJLH H f Q S J S DELETED P P
s A R H Q s S DELETED P P M
s A R H Q s S N DELETED DELETED
s A R H 0 s S N DELETED DELETED M
s A R H Q s S N DELETED P
s A R H Q s s N DELETED P M
s A R H Q s s N P DELETED
s A R j H Q s s N P DELETED M
s A R H Q s s N P P
s A ! 1 , R_ H Q 1 S s N P P M
s A R H Q s T DELETED DELETEDiDELETED
s A R""
__R_ R H ! 0 s T JDELETED DELETEDlDELETED M !
s A
| _J±_J.__0
H Q s T JDELETED DELETED P
s A
1
s___
s T DELETED DELETED; P M
s A
i : H Q

DELETED P DELETED! I
s A R j 1 1 H Q s T JDELETED P DELETED M
s A R 1 1 1 H Q s T iDELETED P P
s A R 1 | H Q s T DELETED P P M
s A R J | H 0 S T N DELETED DELETED
s A R H Q s T N DELETED DELETEDI M
s A R H Q s T N DELETED P
s A R H Q s T N DELETED P M
s A R H Q s T N P DELETED
s A R H Q s T N P DELETED M
s A R H Q s T N P P
s A R H Q s T N P P M
s A ! 1 R H Q G S DELETED DELETED DELETED
s Ail ! R H Q .G S DELETED DELETED DELETED M
s A R H Q ; G S DELETED DELETED P
s A R H ! G ; G ■ S DELETED DELETED P M
s A R —J H , Q j G f S DELETED P DELETED
s A ■ R
H Q G S DELETED P DELETED M
s A R H Q G s DELETED P P
s A R H " Q G s DELETED P P M
s A R H Q G s N DELETED DELETED
s A R H Q G s N DELETED DELETED M
s A R H Q G s N DELETED P
s A R H Q G s N DELETED P M
s A R - H Q G s N P DELETED
s A R 4 1 H Q G 1 S N P DELETED M
s A R i ; H Q G s s N P P
s A R 1 i ! H Q G
N P P M

52959 vl/OC

ASTR 013/01 WO

20 25 | 29 31 33 49 55 56 91 94 95 96 107
S A i i r £ —L__ H Q G T DELETED DELETED DELETED
s A R
H Q G T DELETED DELETED DELETED M
s A R H Q G T DELETED DELETED P
s A R H Q G T DELETED DELETED P M
s A R H Q G T DELETED P DELETED
s A R H Q G T DELETED P DELETED M
s A R H Q G T DELETED P P
s A ! 1 R H Q G T DELETED P P M
s A i 1 R H Q G T N DELETED DELETED
s A R H Q G T N DELETED DELETED M
s A R H Q G T N DELETED P
s A R H Q G T N DELETED P M
s A R H Q G T H P DELETED
s A R H Q G T N P DELETED M
s A R H Q G T N ! P ! p
s A _ R
R H 0 G T N _ _P_
DELETED P M I
s A
i H V_ V S s s DELETED
DELETED j ;
s A 1 i R
1 ; R : | H

DELETED'DELETED.DELETED M
s A
! M V s _
s s DELETEDIDELETED; P
s A R H

s DELETEDIDELETED! P M
s A R H V s s DELETED P DELETED
s A R H V s s DELETED P DELETED M
s A R H V s s DELETED P P
s A R H V s s DELETED P P M
. s A R H V s s N DELETED DELETED
s A R H V s s N DELETED DELETED M
s A R H V s s N DELETED P
s A R H V s s N DELETED P M
s A R H V s s N P DELETED
s A R H V s s N P DELETED M
s A R H V s s N P P
s A R H V s s N P P M
s A R H V s T DELETEDIDELETED DELETED
s A R H V s T DELETED DELETED DELETED M
s A R H V s T DELETED DELETED P
s A- R H V s T DELETED DELETED P M
s A R i ; H V s T DELETED .P ' DELETED
s A R I S H V s T DELETED P DELETED M
s A R I ! H V s T DELETED P P
s A R ! ! H^ V s T OELETED P P M
s A R I ; H V s T N DELETED DELETED
s A R I i H V s T N DELETED DELETED M
s A R I ! H V s T N DELETED P
s A R ■ I H V s T N DELETED P M
s A R ! I H V. s T N P DELETED
s A R ! I H V s T N j P DELETED M

52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A R H V S T N P P
s A R H V S T N P p M
s A R H V G S DELETED DELETED DELETED
s A R H V G s DELETED DELETED DELETED "M
s A R H V G s DELETED DELETED p
s A R H V G s DELETED DELETED p M
s A R H V G s DELETED P DELETED
s A R H V G s DELETED P DELETED M
s A R H V G s DELETED P p
s A R H V G s DELETED P p M
s A R H V G s N DELETED DELETED
s A R H V G s N DELETED DELETED M
s A R H V G s N DELETED P
s A R
V G s N DELETED P M
s A R H H H V G s N P DELETED
s A R -:■
V V G s N P DELETED M
s A _ __ i_ _R_
.._JL_. R

s N P P
s

__Y_
V G
G G s
T T N '; P P __M_
s A A

H

DELETEDIDELETED DELETED

s

R H V

DELETED OELETED DELETED M
s A R I H V G T DELETED DELETED P
s A R H V G T DELETED DELETED P M
s A R H V G T DELETED P DELETED
s A R I H V G T DELETED P DELETED M
s A R . H V G T DELETED P P
s A R H V G T DELETED P P M
s A R | H V G T N DELETED DELETED
s A R H V G T N DELETED DELETED M
s A R H V G T N DELETED P
s A R H V G T N DELETED P M
s A R H V G T N P DELETED
s A R H V G T N P DELETED M
s A R H V G T N | P P
s A R H V G T N I P P M
s A F S L L Y Y Q Q S S DELETED DELETED DELETED
s A F s

S S DELETED DELETED DELETED M
s A F s L __Y
Y Q S S DELETED DELETED P
s A F s L
Q S S DELETED DELETED P M
s A F s L Y Q S s DELETED P ' DELETED
s A F s L Y Q S s DELETED P DELETED M
s A F s L Y Q S s DELETED P I P
s A F s L Y Q s s DELETED P ! P M
s A F s s L Y Q s s N DELETEDIDELETED
s A F
L _Y_.
Y Q s s N DELETEDJDELETED M
s A F s L

s s N DELETEDI P
s A F s L Y 0 , s s N DELETEDI P M

52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A F S L Y Q S S N P DELETED
s A F S L Y Q S s N P DELETED M
s A F S L Y Q s s N P P
s A F S L Y Q s s N P P M
s A F S L Y Q s T DELETED DELETED DELETED
s A F s L Y Q s T DELETED DELETED DELETED M
s A F s L Y Q s T DELETED DELETED P
s A F s L Y Q s T DELETED DELETED P M
s A F s L Y Q s T DELETED P DELETED
s A F s L Y Q s T DELETED P DELETED M
s A F s L Y Q s T DELETED P P
s A F s L Y Q s T DELETED P P M
s A F s L Y Q s T N DELETED DELETED
s A F s L L Y Q s T N DELETED DELETED M
s A F s
Y Q s T N DELETED P
s A F s L Y Q s T N DELETED P M
s A j F F s s L L Y Q Q
s s
_ s. ,
G T
T
T N
NJ N N __ _P __ P DELETED
s A

Y 0

DELETED M
s A F s L __Y__
Y Y __L_L

P P ■ i
s A F s L

P P M
s A F s

S DELETED DELETED DELETED
s A F s L Y Q G S DELETED DELETED DELETED M
s A F s L Y Q G s DELETED DELETED P
s A F s L Y 0 G s DELETED DELETED P M
s A F s L Y Q G s DELETED P DELETED
s A F s L Y 0 G s DELETED P DELETED M
s A F s L Y Q G s DELETED P P
s A F s L Y Q G s DELETED P P M
s A F ' s L Y Q G s N DELETED DELETED
s A F s L Y Q G s N DELETED DELETED M
s A F s L Y Q G s N DELETED P
s A F s L Y Q G s N DELETED P M
s A F s L Y Q G s N P DELETED
s A F s L Y Q G s N P DELETED M
s A F s L Y Q G s N P P
s A F s L Y Q G s N P P M
s A F s L Y Q G T DELETED DELETED DELETED
s A F s L Y Q G T DELETED DELETED DELETED M
s A F s L Y Q G T DELETED DELETED P
s A F s L Y Q G T DELETED DELETED P M
s A F s L L Y Q G T DELETED P DELETED
s A F s
Y Q G T DELETED P DELETED M
s A F s L Y 0 G T T DELETED P | P
s A F s L Y 0 G
DELETED P | P M
s A F s L Y Q G t_T_
T N DELETEDlDELETED
s A F s L Y Q G
N DELETEDiDELETED M

52959 vl/iX'

ASTR 013/01 WO

20 25 29 31 33 49 55 56 ! 91 94 95 96 107
S A F i- L __
L Y Y 0 G ■ T ! N DELETED P
S A F

Q G T N DELETED P M
s A F : s L V Q G T N P DELETED
s A F s L Y Q G T N P DELETED M
s A F
L Y Q G r N P P
s A F s L Y Q G T N P P M
s A F s L Y ! V S s DELETED DELETED DELETED
s A F s L Y ! V S s DELETED DELETED DELETED M .
s A F s L Y V s s DELETED DELETED P
s A . F s L Y V s s DELETED DELETED P M
s A F s L Y V s s DELETED P DELETED
s A F s . L Y V s s DELETED P DELETED M
s A F s L Y V s s DELETED P P
s A F s L Y V s s DELETED P P M
s A F s L Y V s s N DELETED DELETED
s A F s L Y V s s N DELETED DELETED M
s A F s L Y V S ! S N DELETED P
s A F s L
L Y V s_J S N DELETED P M
s A F . S
y V s s N P DELETED
s A F s i Y V : S s _^ I— N P DELETED M
s A F s L Y V : S s N P P
s A F s L Y V S : S N P P M
s A F s _L
L Y V S '■ T DELETED DELETED DELETED
s A F s
Y V S T [DELETED DELETED DELETED M
s A F s L Y V s T DELETED DELETED P
s A F s L Y V s T DELETED DELETED P M
s A F s L Y V s T DELETED P DELETED
s A F s L Y V s T DELETED P DELETED M
s A F s L Y V s T DELETED P P
s A F s L Y V s T DELETED P P M
s A F s L Y V s T ' N DELETED DELETED
s A F s L ! Y V s T N DELETED DELETED M
s A F s L Y V s T N DELETED P
s A F s L Y V s T N DELETED P M
s A F s L Y V s T N " P DELETED
s A F s L Y V s T N P ■ DELETED M
s A F s L Y . V s T N P P
s A F s L ' Y V s . T N . - P P M
s A F s L Y V G ' S DELETED DELETED OELETED
s A F s L Y V G s DELETED DELETED DELETED M
s A F s L Y V G s DELETED DELETED P
s A F s L Y V | G s DELETED DELETED P M
s A F s L Y V ! G s |D£LETED P DELETED
s A F s ■ L Y V G s DELETED P DELETED M
s A F s s 1 -L- Y V G s .DELETED P P
s A

: L Y V ! G s DELETED P P M
S295t)v\nx

ASTK 0)3/01 WO

20 25 29 | 31 ! 33 49 55 56 ! 91 | 94 95 96 107
S A F I S L Y v ; G S N DELETED DELETED
s A F I S L Y v ! G ; s N DELETED DELETED M
s A F S L Y v ; G s N DELETED P
s A F S L Y V G s N DELETED P M
s A F s L Y V G J s N P DELETED
s A F s L Y V G s N P DELETED M
s A F s L Y V G s N P P
s A F I S L Y V G s N P P M
s A F s L Y V G T DELETED DELETED DELETED
s A F s L Y V G T DELETED DELETED DELETED M
s A F s L Y V G T DELETED DELETED P
s A F s L Y V G T DELETED DELETED P M
s A F s L Y V G T DELETED P DELETED
s A F s L Y V G T DELETED P DELETED M
s A F s L Y V G T DELETED P P
s _ __A
A LL | U. U_ s L Y V G T DELETED P P M
s

L Y V T u . I N (DELETED DELETED
s A

L Y V i G T I N IDELETED DELETED M
s A F s L Y V G T i N DELETED P
s A F J s L Y V G T N DELETED P M
s A F s L Y V G T N P DELETED
s A F s L Y V G T N P DELETED M
s A F s L Y V G G T T N P P
s A F s L Y V

N P P M
s A F s L H Q S S DELETED DELETED DELETED
s A F s L H Q S S DELETED DELETED DELETED M
s A F s L H Q s S DELETED DELETED P
s A F s L H Q s S DELETED DELETED P M
s A F s L H Q s S DELETED P DELETED
s A F s L H 0 s S DELETED P DELETED M
s A F s L H Q s S DELETED P P
s A F s L H Q s s DELETED P P M
s A F s L H Q s S N DELETED DELETED
s A F s L H Q s S N DELETED DELETED M
s A F s L H Q S I S N DELETED P
s A F s L H Q s S N DELETED P M
s A F s L H Q s s N P DELETED
s A F s L H Q s s N P . DELETED M
s A F s L H Q s s N P P
s A F s L H Q s s N P P M
s A ! F | S L H Q s T DELETED DELETED DELETED
s A . F j S L H Q s T DELETED DELETED DELETED M
s A i F s
s L H Q s T DELETED DELETED P
s A F A F
L H Q S ! T DELETED DELETED P M
s
s L H Q S j T DELETED P DELETED
s A F S*T r H Q S i T DELETED P DELETED M
52950 i
ASTR 013/01 WO

20 25 29 31 33 49 55 56 | 91 94 95 96 107
S A F S L- H Q S _L T _, DELETED P P
S A F S L
L H
H 0 S T DELETED P P fvl
S A j F S

G s T N DELETED DELETED
S A F S L H ! 0 s T N DELETED DELETED M
S A F s L H Q s T N DELETED DELETED P
S A F
L H G s T N
P M
S A F s L H G s T N P DELETED
s A F s L H Q s T N P DELETED M
s A F s L H Q s T N P P
s A F s L H Q s T N P P M
s A F s L H Q G S DELETED DELETED DELETED
s A F s L H 0 G s DELETED DELETED DELETED M
s A F s L H Q G s DELETED DELETED P
s A F s L H Q G s DELETED DELETED P M
s A F s L H Q G s DELETED P DELETED
s A F s L H Q G s DELETED P DELETED M
s A F __s
s L H o ; G 3 DELETED P P
S i A c
L L H G G s DELETED P P M
S ; A F s
H 0 G s N DELETED DELETED
S A F s L H Q ! G s N DELETED DELETED M
s A F s L H Q ! G s N DELETED P
s A F s L ; H G I G s N DELETED P M
s A F s L ' H i Q ! G s N P DELETED
s A F s L I H ! Q | G | S N ! P DELETED M
s A F s L j H 0 ! G S N P P I I
s A F s L i H G ! G s N i P ! P ! M
s A F s L ; H ' Q , G ! T DELETED!DELETED!DELETED! I
s A r~ F s L i H i Q : G ; T DELETED DELETED DELETED M
s A F s L ■ H | Q G l T DELETED DELETED P
s A F s L H Q G ] T DELETED DELETED P M
s A F s L H 0 G I T DELETED P DELETED
s A F s L H Q G T DELETED P DELETED M
s A F s L H Q G T DELETED P P
s A F s L H Q G T DELETED! P ■ P M
s A F s L H G G T N DELETED DELETED
s A F s L H Q G T N DELETED DELETED M
s A F s L H Q G T N DELETED P
s A F s L H 0 G T N DELETED P M
s A F s L H Q G T N P DELETED
s A F s L H Q G T N P DELETED M
s A F s L H G G T N P P
s A F s L H Q G T N P P M
s A F s L H V S S DELETED DELETED DELETED
s A F s L
L K V s s DELETED DELETED DELETED M
s A F s
H V s s DELETED DELETED P
s A F s L H V s s DELETED DELETED P M
S2*)59 vl/i)C

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A F S L H V s S DELETED P DELETED
S A F s L H V s S DELETED P DELETED M
S A F s L L H V s S DELETED P P
s A F s
H V S | S DELETED P P M
s A F s L H v s : s N N DELETED DELETED
s A F s L H V S i S
DELETED DELETED M
s A F s L H V s ; s N DELETED P
s A F s L H V s ! s N DELETED P M
s A F s L H V , S s N P DELETED
s A F s L H V s s N P DELETED M
s A F s L H V s s N P P
s A F s L H V s s N P P M
s A F s L H V S ■ . T DELETED DELETED DELETED
s A F s I H V s T DELETED DELETED DELETED M
s A F s L H V s T DELETED DELETED P
s A F s L H V s T DELETED DELETED P M
s A F ! S
F I S L H V s T DELETED P DELETED
j s A
L H v S I I DELETED; P DELETED M
s A F s L H j V s T DELETED P P
s A F s L H V s T DELETED P P M
s A F s L H V s T N DELETED DELETED
s A F s I H V s T N DELETED DELETED M
s A F s L H V s T N DELETED P
s A F s L H V s T N DELETED P M
s A F s I H V s T N P DELETED
s A F s L H V | S T N P DELETED M
s A F F s L H V I S T N P P
s A
s L H v ! s T N P P M
s A F s L H V G I S DELETED DELETED! DELETED
s A F s L H V G S DELETED DELETED DELETED M
s A F s L H V G : S DELETED DELETED P I
s A F s L H V G S DELETED DELETED P M
s A F s L H V G : S DELETED P DELETED
s A F s L H V G I S DELETED P DELETED M
s A F s L H V G S DELETED ■p P
s A F s L H V G S DELETED P P M
s A F s L H V G ■ s ■N . DELETED DELETED
s A F s L H V G s N DELETED DELETED M
s A F s L H V G s N DELETED P
s A F s L H V G s N DELETED P M
s A F s L H V G ! S N P DELETED
s A F s L H V G i S N P DELETED M
s A F s L H V G ! S N P P
s A F s L H V G I S N P P M
s A F s L H V G I T DELETED DELETED DELETED
s A F s L H V G T DELETED DELETED DELETED M
52959 v [/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A F S L H V V G T DELETED DELETED P
S A F S L H
G T DELETED DELETED P M
S A F _JLJ L H V G T DELETED P DELETED
s A F i s L H V G T DELETED P DELETED M
s A F s L H V G T DELETED P P
s A F s L H V G T DELETED P P M
s A F s L H V G T N DELETED DELETED
s A F s L H V " G T N DELETED DELETED M
s A F s !_ H V ' G T N DELETED P
s A F s L H V G T N DELETED P M
s A F s L H V G T N P DELETED
s A F s L H V G T N P DELETED M
s A F ■ s L H V G T N P P
s A F s L H V G T N P P M
s A F s Y Q l S S DELETED DELETED DELETED
s A F s Y Q S S DELETED DELETED DELETED M
s A A F s Y Q s s DELETED DELETED P I i
s

Y Q s s DELETED DELETED P M
s A F s Y Q s s DELETED P DELETED
s A F s Y Q s s DELETED P DELETED M
s A F s Y Q s s DELETED P P
s A F s Y Q s s DELETED P P M
s A F s r Y 0 s s N DELETED DELETED
s A F s Y Q s s N DELETED DELETED M
s A F s Y Q s s N DELETED P i | i
s A F s Y Q s s N DELETED P M
s A F s Y Q s s N P DELETED
s A F s Y Q s s N ■ - P DELETED M
s n A F s Y Q s s N P P
s A F s Y Q s s N P P M
s A F s Y Q s T DELETED DELETED DELETED
s A F n s Y Q s T DELETED DELETED DELETED M
s A F s Y Q s T DELETED DELETED P

s A F s Y Q s T DELETED DELETED P M
s A F s Y Q s T DELETED P DELETED
s A F s Y Q s T DELETED P DELETED M
s A F s Y Q s T DELETED P P
s A F s Y Q s T DELETED P P M
s A F s Y Q s T N DELETED DELETED
s A F s Y Q s T N DELETED DELETED M
s A F s Y Q s T N DELETED P
s A F s Y Q s T N - DELETED P M
s A F s j | Y Q s T N P DELETED
s A F s | | Y Q s T N P DELETED M
s A A F s i I Y Q s T N P P
! s
F s ■ i Y 0 s T N j P P M

$vm VI'DC

ASTR 013/01 WO

20 25 29 | 31 33 49 55 56 91 94 95 I 96 107
S A F ■ S Y Q G S DELETED DELETED DELETED
s A F S Y Q G s DELETED DELETED DELETED M
s A F S Y Q" G S (DELETED DELETED P
s A F s Y Q i G s IDELETED DELETED P M
s A F s I __, Y Q G s DELETED P [DELETED
s A F s Y Q G s DELETED P j'OELETED M
s A F s Y Q G s DELETED P P
s A F s Y Q G s DELETED P P M
s A F s I ! Y Q G s N DELETED DELETED
s^ A F s Y ! Q G s N DELETED DELETED M
s ! A F s Y Q G s N DELETED P
s A F s Y Q G s N DELETED! P M
s A F s Y I Q G S N P DELETED
s A ; F s Y Q G Si N P DELETED M
s A i F' "1 s Y Q G S I N P P
s _ _A_ A F s Y 0 G S N P P M
s
F s I Y ■ Q G T DELETEOlDELETECiDELETED
s A F S i Y i Q G T DELETED DELETED DELETED M
s A F s Y Q G T DELETED DELETED' P
s A F J us Y Q G T DELETED DELETED P M
s A F s Y Q G T DELETED P DELETED
S '■ A F s Y Q G T DELETED P DELETED M
s : A F __S| I ■ Y Q G I T [DELETED p i p
s A F ~~s Y Q G T DELETED P j P M
s A F ] s Y Q G T N DELETED DELETED
s A F s Y Q G T N DELETED DELETED M
s A F s Y Q G T N DELETED P
s A F s Y Q G T N DELETED P M
s A F s Y Q G T N P DELETED
s A : F s Y Q G T N P DELETED M
s A F s Y Q G T N P P
S ! A F S I Y Q ' G T N P P M
S A F s ■ Y v : s S DELETED DELETED DELETED
s A F s Y V S S DELETED DELETED DELETED M
(/> A F s Y V S S DELETED DELETED P
s A F s Y V I S s DELETED DELETED P M
s A F J_ s Y V S S DELETED P DELETED I
s A F s Y ' V S S DELETED P DELETED M
s A F s Y V s s DELETED P P
s A F s Y V s s DELETED P P M
s A F s i ; Y v s s N DELETED DELETED
s A F s Y V s s N DELETED DELETED M
S j A F s Y V s s N DELETED P
s A F s Y V s s N DELETED P M
s A F s y V s s N P DELETED j
s A F s

5205'.

■'IX

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 ! 96 107
S A F S Y V s S N P P
s A F S Y V s s N p P M
s A F S Y V s T DELETED DELETED DELETED
s A F
F s s Y V s T DELETED DELETED DELETED M
s A

Y V s T DELETED DELETED P I 1
s A F s Y V s T DELETED DELETED P M |
s A F s Y V s T DELETED P DELETED
s A F s Y V s T DELETED P DELETED M
s A F s Y V s T DELETED P P
s A F IS Y V s T DELETED P P M
s A F s Y V s T N DELETEDJDELETED
s A F s Y V s T N DELETED-DELETED M
s A F s Y V s T N DELETED! P
s A F s Y V s T N jDELETEDi P M
s A F s Y V s T N p DELETED
s A s Y V s _s_._
s T N p DELETED M
s A
s I Y V
T M p P
P
s A F s I Y V
"" T N p
M
s A F s Y V I G S DELETED DELETED!DELETED
s A F s Y V G S DELETED DELETED;DELETED M
s A F s Y V G s DELETED DELETED P
s A F s Y V G s DELETED DELETED! P M
s A F s Y V G s DELETED p DELETED
s A F s Y V G s DELETED p DELETED M
s A F s Y V G s DELETED p P
s A F s Y V G s DELETED p P ^ M
s A F s Y V G s N DELETED DELETED
s A F s Y V G s N DELETED DELETED M
s A F s Y V G s N DELETED P
s A F s Y V G s M DELETED P M
s A F s Y V G s N ; P DELETED
s A F s Y "V G s N P iDELETED M
s A F s Y V G s N P P
s A F s Y V G s N P P M
s A F s Y V G T DELETED DELETED DELETED
s A F s Y v G T DELETED DELETED DELETED M
s A F s Y V G T DELETED DELETED P
s A F s Y V G T DELETED DELETEO P M
s A F s Y V G T DELETED P DELETED
s A F s n Y V G T DELETED P DELETED] M
s A F s Y V G T DELETED P P
s A F s Y V G T DELETED P P M
s A F s Y V G T N DELETED DELETED
s A F s Y V G T N DELETED DELETED M
s A F s Y V G T N DELETED P
s A F s Y V G T N DELETED P M

52(JS9 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A F S i Y V G T N P P DELETED
s A F s Y V G T N
OELETED M
s A F s Y V G T N P P
s A F s Y V G T N P P M
s A F s H Q S S DELETED DELETED DELETED
s A F s H Q S s DELETED DELETED DELETED M
s A F s H Q s s DELETED DELETED P P
s A F s H Q s s DELETED DELETED
M
s A F s H Q s s DELETED P DELETED
s A F s H Q s s DELETED P DELETED M
s A F s H Q s s DELETED P P
s A F s i t H Q s s DELETED P P M
s A F S I H Q s s N DELETEDiDELETED
s A PF s i I H ■ 0 s s N DELETED DELETED M
s A F s I H Q s s N DELETED P
s A
A
A F • F s
s I ! H Q s
L_ s s N DELETED P M
s

H a
s N P DELETED
s

s ! ; H Q s 3 N P DELETED M i
s A r s H Q s s N P P
s A F s H Q s s N P P M
s A F s H Q s T DELETED DELETED DELETED
s A F s J H Q s T OELETED DELETED DELETED M
s A F s H Q s T DELETED DELETED P
s A F s H Q s T DELETED DELETED P M
s A F s H Q s T DELETED P DELETED]
s A F s H Q s T DELETED P DELETED M
s A F s H Q s T DELETED P P
s A F s H Q s T DELETED P P M
s A F s H Q s T N DELETED DELETED
s A F s H Q s T N DELETED DELETED M
s A F s H 0 s T N DELETED P
s A F s H Q s T N DELETED P M
s A F s H a s T N P DELETED
s A F s H Q s T N . P DELETED M
s A F s H Q s T N P P
s A F s H Q s T N P P M
s A F s H Q G S DELETED DELETED DELETED
s A F s H Q G s DELETED DELETED DELETED M
s A F s H Q G s DELETED DELETED P
s A F s H a G s DELETED DELETED P M
s
s A F s . H Q G s DELETED P DELETED

A F s H Q G s DELETED P DELETED M
s A F s H Q G s DELETED P P
s A F s H Q G s DELETED P P M
s s A F s H a G s N OELETED DELETED

A F s H Q G s N DELETED DELETED M

52')yi v|/DC

ASTK. 013/01 WO

20 25 j 29 31 33 ■ ) 49 55 56 91 94 95 | 96 107
S A | F S I ! H Q G s N DELETED! P I
s A... F S ■ H Q G S I N DELETEJJj P M
s A F s H ! Q G S I N P DELETED i
s A F s H Q G S I N P DELETED M
s A F s I i H Q G s N P P I
s A F s H 0 G s N P P M
s A F s H ! Q G T DELETED DELETED DELETED I
s A F s H Q G T DELETED DELETED DELETED M
s A F 1 S H Q G T DELETED DELETED P I
s A F 1 S i 1 H Q G T DELETED DELETED! P M
s A F s H Q G r T DELETED P DELETED I
s A F s H Q G T DELETED p DELETED M
s A F s H G G T DELETED p ■ p I
s A F s H G G—I- T DELETED p p M
S | A F s H Q G T j N DELETED:DELETED i
s A F s H ; Q G T N DELETEDjDELETED M
s A A F s H G ! G T N DELETED] P i
i_-Ji
F j S ! 1 H Q G T N DELETED': P M
r~s "1 A ! F j S \ 1 H G G T : N P iDELETED I !
s^ A F s H Q G T N P DELETED M I
s A F s H Q G T N P P I
s A F s H Q G_^ T ' N P P M
s A F s H V S S DELETED DELETED DELETED I
s A F s H V 5 s DELETED DELETED DELETED M
s A F s H V S s DELETED DELETED P i
s A F- s H V S s DELETED DELETED P M
s A F s H V s s DELETED P DELETED i
s A F S I H V s s DELETED P DELETED M
_s . A F s H V s s DELETED P P I
s A F s H V s s DELETED P P M
s A F s H V s s N DELETED DELETED t
s A F s K V s s N DELETED!DELETED M
s A IF i S H V s s N DELETED P 1
s A F s H V s s N DELETED P M
s A F s H V s s N P DELETED 1
s A F s H V s s N P DELETED M
S i A F s H ! V s s N P P 1
S 1 A F s H V s s N P P M
S i A F s H i V s T DELETED DELETED DELETED 1
s A F s H V s T DELETED DELETED DELETED M
s A F S H V s T DELETED DELETED P 1
s A F s H V s ; T DELETED DELETED P M
s A F s H V s ! T DELETED P DELETED 1
s A F s H V S T DELETED P DELETED M
s A r s I ! H V s T DELETED P P 1
1 S A ! F ' S I ! H V s T DELETED P P M
52')50 vi.'DC

ASTR 013/01 WO

20 25 | 29 31 33 49 H 55 56 91 94 95 96 107 |
S A F S
V s T N DELETED DELETED
S A F s H V s T N DELETED DELETED M
S A F s H V s T N DELETED P
S A F s H V s T N DELETED P M
S A F s H V s T N P iDELETED
S A F 3 H V s T N P [DELETED M
s A F s I j H V s T N P I P
s A F s H V s T N P I P M
s A F s H V G S DELETED DELETEDiDELETED
s A F s H V G s DELETED DELETED DELETED M
s * A F s H V G s DELETED DELETED P
s A F s H V G s DELETED DELETED P M
s A F s H V G s DELETED P 'DELETED
s A F s I ! H v I G s DELETED P
P ■
P DELETED DELETED DELETED M
s A F s H V G s DELETED
P
s
s A A F S ' I H V G s DELETED
P M

s ] H
G G
G s s N
DELETED
s

s i | H V

DELETED P M
s A F s I K V
s N DELETED

s A F s H V G s N DELETED! P M
s A F s I ! H V G s N P DELETED
s A h s H V G s N P DELETED M
s A F s H V G s N P P
s A F s H V G s N P P M
s A F s H V G T DELETED DELETED DELETED
s A F s H V G T DELETED DELETED DELETED M
s A F s H V G T DELETED DELETED P
s A F s H V G T DELETED DELETED P M
s A F s H V G T DELETED P DELETED
s A F s H V G T DELETED P DELETED M
s A F s H V G T DELETED P P
s ' A F S i I H V G T DELETED! P P M
s A F s H V G T N DELETEDIDELETED
s A F s H V G T N DELETEDiDELETED M
s A F s H V G T N DELETEDL P
s A F s I H V G T N DELETEDI P M
s A F s H V G T N p DELETED
s A F s H V G T N p DELETED M
s A F s H V G T . N p P
s ■ A F s H V G ■T N p : p M
s A F R L Y Q S S DELETED DELETED DELETED
s A F R L Y Q S s DELETED DELETED DELETED M
s A F R L Y Q I S s DELETED DELETED P
s A F ! R r L Y Q s s DELETED DELETED P M
s A F i R L Y Q s s DELETED P DELETED I
s A F I R L Y Q s s bELETEO' P DELETED M

ASTR 013/01 WO

20 25 29 31 33 __49__
Y 55 56 91 94 95 96 107
S A F R L
Q S S DELETED P P
s A F R L i Y 0 S S DELETED P P M
s A F R L i Y Q S . s N DELETED DELETED
s A F R L Y Q S s 1 N DELETED DELETED M
s A F RZJ L Y Q S s N DELETED P
s A p R L Y Q S s N [DELETED! P M
s A F R L Y Q s s N P {DELETED
s A F R L Y Q s s N P DeLETEO M
s A F R L Y Q s s N P P
s A F R L Y Q s s N P P M
s A F R L Y Q s T DELETED DELETED DELETED
s A F R L Y Q s T DELETED DELETED DELETED M
s A F R I L Y Q s T DELETED DELETED P
s A F R L Y Q s T DELETED DELETED! P M
s A F R I. L I. Y
Y Q s T DELETED P IDELETED
s A F
F — 1 R i

0 Q Q s T DELETED' P !DELETED M
; s A A
A 1

Y I
Y
S !
s I T
T ■ DELETEa P P
|s
F R L

DELETED p P M
| S
F B—J L Y Ql S ] T 1 N ~1 DELEIED] DELETED s A 1 F R L Y Q s T N DELETED DELETED M
s A F R L Y Q s T 1 N DELETED P
s A F R L Y Q s T N DELETED P M
s A F R L Y Q s T N P DELETED
s A F R L Y Q s T N P DELETED M
s A F R L Y Q s T N P P
s A F R L k Y Q s T N P P M
s A F R L Y Q G S DELETED DELETED DELETED
s A F R L Y Q G s [DELETED DELETED DELETED M
s A F R L Y Q G s DELETED DELETED P
s A F R L Y Q G s DELETED DELETED P M
s A F R L Y Q G s DELETED P _, DELETED
s s A F R L Y Q G s DELETED P DELETED M

A F R L Y Q G s DELETED P P
s A F R L Y Q G s JD6LETED P P M
s A F R L Y Q G s N DELETED DELETEC I
s A F R L Y Q G s N DELETED DELETEC M
s A F R L Y Q G s N DELETED P
s A F R L Y Q G «_ s N DELETED P M
s A F R L Y Q G s . N P DELETEC I
s A F R L Y Q G s 1 N P iDELETEC M
s A F R L Y Q G s i N P i p
s A F R i L Y Q G 4_5 J N P P M
s A F R L Y 0 G T DgLETEC DELETEC DELETE: ) I

A F R L Y Q G T DgLETEC DELETEC DELETEC ) M
s A F R L Y i Q G T DELETEC DELETEC P
s A F R L Y I Q G T DELETED DELETEC P M

52<.>5'1 vl/|)C

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 | 96 107
S A ■F R L Y Q G T DELETED P (DELETED
s A F R L Y 0 G T DELETED P .DELETED M
S A F R L V Q G T DELETED [PiP
S | A F R L Y Q G T DELETED P ! P M
S A F R L Y Q G T | N DELETED DELETED
S A F R L : Y Q G T | N DELETED DELETED M
s A F R L Y Q G T | N DELETED P
s A F R L Y Q G T i N DELETED P M
s A F R L Y Q G T N P DELETED
s A F R L Y Q G T N P DELETED M
s A F R L Y Q G T N P P
s A F- R L Y Q G T N P P M
s A F R L Y V S S DELETED DELETED DELETED
s A F R L Y V S S DELETED DELETED DELETED M
s A F R L Y V S s DELETED DELETED P
s A F R L I Y
L Y V s. s DELETED DELETEDi P M
s A F R
V s s DELETED P JDELETED

A F R L Y V s S IDELETED P DELETED M
S 1 A F R ' L Y v , s n S DELETED
P } 1 1
s__
s A F R ; L Y V s S DELETED P ! P j M

A F R i L Y V s S N DELETEDlDELETEDi I
s A F j ■ R ! L i Y V s s N DELETEDJDELETEDl M
s A F ! R L Y V s s N DELETED| P
s A F R L Y V s s N DELETEDi P M
s A F R L Y V s s N P (DELETED
S | A F R L | Y V s s N "~ P JDELETED M
S J A F R L l Y V s S N P P
s A F R L ! Y V s s N P P M
s A F R L Y V s T DELETED DELETED DELETED
s A F R L Y V s T DELETED DELETED DELETED M
s A F R L Y V s T DELETED DELETED P
s A F R L Y V s T DELETED DELETED P M
§___
s A F R L Y V s T OELETED P DELETED

A F R L Y V s T DELETED P DELETED M
s A F R L Y V s T DELETED P P
s A F R L Y V s T DELETED P P M
s A F R L Y V s T N . DELETED DELETED
s A F R L Y V s T N DELETED DELETED M
s A F R L Y V s T N DELETED P
s A F R L Y V s T N DELETED P M
s A F R L Y V | S T N P DELETED
s A _
A F R L Y V j S T N P I DELETED M
s
F R L_ L Y V S ; T N P P
s A F I R I V V S ; T ! N P p : M
s A F 1 R L Y j V G ! S DELETED DELETED DELETED; 1
s A F ! R L Y } V G I S JDELETED DELETED DELETEDi M
52959 vl/DC

ASTR 013/01 WO

20 25 29 31 33
__L
L 49 Y Y 55 56 91 94 95 96
P 107
S A F R

V G~l s DR'LETED DELETED
I
s_
s A F R

V G s DRLETED DELETED P M

A F R I L Y V G s DELETED P DELETED I
s A F R L Y V G s DFt-ETED P DELETED M
s A F R L Y V G s nFLETED P P !
s A F R L Y V ■ G s DFLETED P P M
s A F R L Y V G s N DELETED DELETED I
s A F R L Y V G s N DELETED DELETED M
s A F R L Y v G s N DELETED P I
s A F R L Y V G s N DELETED) P M
s A F R L Y V G s N P DELETED I
s A F R L Y V G s N P DELETED M
s A F R L Y V G s N P P !
s A
A F R L Y V G s N P P M
s
F R L Y v G T HFLETED DELETED DELETED I
s A F — — -i
-H R I. L Y V G T DELETED DELETEDiDELETED M
s
I *
s A
A !
R J
Y
Y""|
X V G T -1F.LETED, DFLETED DELETED] P I

R L !
V M T
DELETED'
I? P M

? 9.

T w,u=Tea
1ELETE.Q i.

A F R L Y V G T OFiLETED P DELETED M
s A A F R L Y V G T DELETED P P 1
b
F R L Y V G T DELETED P DELETED P M
s A F R L L Y V G T N
DELETED 1
s A F R
Y V G T _^- DELETED DELETED M
s A F R L Y V G T N DELETED P 1
s A F R L Y V G T N DELETED P M
s A F R L Y V G T i N P DELETED 1
s A F R L Y V G T N P DELETED M
s A F R L Y V G T N P P 1
s A F R L Y V G T N P P M
s A F R L H Q S S DIETED DELETED DELETED 1
s A F R L H Q S S DELETED DELETED DELETED M
s A F R L H Q ' S S DIETED DELETED P 1
s A -F R L H a s s Hf?LETED DELETED P M
s A F R L H Q s s DELETED P DELETED 1
s A F R L H Q s s n^LETED P DELETED M
s A F R L H Q s s nfSLETEO P P 1
s A F R L H " Q s s DELETED P . ■ P M
s A F R L H Q s s t~^ N DELETED DELETED t
s A F R L H Q s s N DELETED DELETED M
s A F ; R L H Q s s N DELETED P 1
s A F i R L i H . Q s s N DELETED P M
s A F R R L L
L H Q s s N P DELETED 1
s i A F

H H Q s s N P DELETED M
s A A p i R

Q s s T~ N P P 1
s
! F ! R "- H Q f s f S N P P | M

52451! vl/DC

ASTRO 13/0J WO

20 25 29 31 33 49 55 56 91 94 95 \ 96 107
S_
s A A F R L H Q S T DFLETED DELETEDIDELETED I

F R L H s T DENTED DELETED DELETED M
s A F R L H
s T DELETED DELETED P I
s A F R L H 0 s T DEl-ETED DELETED: P M
s A F R L H Q s T DEI-ETED P iDELETED I
s A F R L H Q s T DFI-ETED P DELETED M
s A F R L H Q s T DFJ-ETED P P I
s A F R L H Q s T DFUETED P P M
s i A F R L_| H Q s T N DELETED DELETED I
S I A F R L H Q s T N DELETED DELETED M
S | A F R L H - Q s T N DELETED P I
S 1 A F R L H Q s T N DELETED P M
S A F R L H Q s T N P DELETED I
S A F R L H Q s T N P DELETED M
S A F R L H Q s T ! N P i P I
s A F R L H Q s T N P P M !
S I A c R i L H Q ! G 3 DEl-ETED DELETED DELETED I
S 1 A F
L i H Q G S DEf-ETED DELETED DELETED M
S A F R | L H Q G s DENTED DELETED P I
S A F R L H Q G s InFLETED DELETED! P M
s A F R L H Q G s DELETED P* DELETED
s A F R L H Q G s DFLETEO P DELETED M
s A F R L H Q G s DELETED P P
s A F R L H Q G __s
s DFLETED P P M
s A F R L H Q G
N DELETED DELETED
s A i F R L H Q G s N DELETEDIDELETED M
s A F R L H Q G s N DELETED; P
s A F R L H Q G s N DELETED P M
s A F R L H Q G s N p DELETED
s A F R L H Q G s N p DELETED M
s A F R L H Q G s N p P
s A F R L H Q G s N p P M
s A F R L H Q G T DFLETED DELETED DELETED
s A F R L H Q G T OFLETED DELETED DELETED M
s A F R L H Q G T DFLETED DELETED P
s A F R L H Q G T DELETED DELETED P M
s A F R L H Q G T- DELETED P DELETED
s A F R L H Q G T DELETED P DELETED M
s A F R L H Q G T DELETED P P
s A F R L H Q G T OFLETED P P M
s A F R L H Q G T N DELETEDIDELETED I
s A F R L H Q G T N DELETED'DELETEO M
s A F R L H Q G T N iDELETED! P
s A F R t. H Q G T N JDELETEDj P M
s A F | R L ! H i Q G T N | P IDELETEC
s A F j R L ! H : 0 j_ T N P DELETEC M
52W vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 r 94 95 ! 96 107
S i A F R : R j L | H Q G T N P P
S j
s 1 A F
L H Q G T N I P P M

A F R ' L 1 H V S S DELETED DELETED DELETED
s A F F R 4 L H V s s DELETED DELETED' DELETED P M
s ' A
R L H V s s DELETED DELETED

s A F R L H V s s OEXETEOiOELETED P M
s A F R L H V s s DELETED P DELETED
s A F ' R L H V s s DELETED P DELETED M
s A F R L H V s s DELETED P P
s A F R L H V s s DELETED P P M
s A F R L H V s s N DELETED DELETED
s A F R L H V s s N DELETED DELETED M
s A F R L H V s s N DELETED P
s A F R L H V s s N DELETED P M
s A F R L H V s s N P DELETED
s s s __ A
A
A F F R L H V s s N P DELETED M

R L
L H
H V s s N P P

F R

V s s N I P P M i
s A ? | H \ V tt \ s T otv-t^o DELETE
s A F R I H V s T JDJLETED DELETED DELETED
s _A | F R L . H V s T DELETED DELETED P
s A F R I. H V s T DELETED DELETED P M
s A F R 1. H V s T DELETED P DELETED
s
s A F R L H V s T DELETED P DELETED

A F R L H V s T DELETED P P
s A F R I H V s T JDJLETED P P
s A F R I H V s T N DELETED DELETED
s i_ A F R I H V s T N DELETED DELETED M
s A F R I H V s T N DELETED P
s A F R L H V s T N DELETED P
s A F R L H V s T N P DELETED
s A F R L H V s T N P DELETED
s A F R L H V s T N ■ P P
s A F R L H V s T I N P P M
s A F R L H V G S DgLETED DELETED DELETED
s A F R L H V G S DELETED DELETED DELETED M
s A F R L H V G s DELETED DELETED P
s A F R L H V G s DELETED DELETEDl P M
s A F R L H V G s D£LETEC P DELETED j
s A F R L H V G s DELETED P DELETED M
s A F R L H V G s DELETED P P
s A F R L H V G s DELETED P P M
s A F R L i H V G s N DELETED DELETED I
s A F R L H V 1 G~~ s N DELETED DELETED M
s A F R L H V G s N DELETED P
s A F ! R L i H V G ! s N DELETED P M

S:M$
ASTRO33/01 WO

20 25 29 31 33 49 55 56 91 94 95 ( 96 107
S S A F R ' L H V G ^ s N P DELETED I

A F R L H V G s N P DELETED M
s s A F R L H V G s N P P
P
DELETED

A F R L H V GJ s N P
M
s A F R L H v G T DELETED DELETED

s A F R L H V G T DELETED DELETED DELETED M
s A F R L H V G T DELETED DELETED P
s A F R L H V G T DELETED DELETED P M
s A F R L H V G T DELETED P DELETED
s A F R L H V G T DELETED P DELETED M
s A F R L H V G T DELETED P P
s A r~F R L H V G T DELETED P P M
s A F R L H V G T N DELETED DELETED
s A F R L H V G T M DELETED DELETED M
s A F R L H V G T . N DELETED P
_s__ s
s~" s A F R L H V G T N DELETED P M

. _A__ A
A ""'"F"~ R h—L __hL.
H V V G J T N P
P DELETED I i

G T N
DELETED M

F R L H V G T N ! P P
s A F R l H V G "I T N P P M
s A U_F___ R Y Q S S DELETED DELETED DELETED
s A F R Y Q s s DELETED DELETED DELETED M
_s_„
s A F R Y Q s s DELETED DELETED P

A F R Y Q s s DELETEDlDELETED P M
s A F R Y Q s 3 DELETED P DELETED
s ~ A F R Y Q s s DELETED P DELETED M

A F R Y Q s s DELETED P P
s 1 A F l R Y Q s s DELETED P P M
s A -- -F R Y Q s s N DELETED DELETED
s A F R Y Q s s N DELETED DELETED M
s A F R Y Q s s N DELETED P
s A F R Y Q s s N DELETED P M
s A F R Y Q s s N P DELETED
s A F R Y Q s s N P DELETED M
s A F R Y Q s s N P P
s A F R Y Q s s N P P M
s A F R Y Q s T DELETED DELETED DELETED
s A F R Y Q s T DELETED DELETED DELETED M
s A F R Y Q s T DELETED DELETED P
s A F R Y Q s T DELETED DELETED P M
s A F R Y Q s T DELETED P DELETED
s A ' F R Y Q s T DELETED P DELETED M
s A , F R Y Q s T DELETED P P
s A F R Y Q s T DELETED P P M
s__
s A F R Y Q s T N DELETED DELETED

A c R Y Q s T N DELETEDlDELETED M

S2WJ vi-'DC

ASTR. 013/03 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A F R Y Q s T N (DELETED P
s A F R Y Q s T N jDELETED P M
s A F R I Y Q s T N P DELETED
s s A F R Y Q s T N P DELETED M

A F R | Y Q s T N P P
s A F R Y Q s T N P P M
s A F L R Y Q G S DELETED DELETEDIDELETED
s A F R Y Q G s DELETED DELETED DELETED M
s A F R Y Q G s DELETED DELETED P
s A F R Y Q G s DELETED DELETED P M
s A F R Y Q G s DELETED P DELETED
s A F R Y- Q G s DELETED P DELETED M
s A F R Y Q G s DELETED P P
s A F R Y Q G s DELETED P P M
s A F R Y Q G s N DELETED DELETED
s A F R Y Q G ^_s N DELETED DELETED M
__s_
s A F R I | Y Q G s N DELETED'! P

A F R i i Y Q G s N DELETED P M
s A F R I ' Y Q G s N P DELETED
s A F R J 1 1 Y Q G s N P DELETED M
s A F R 1 1 Y Q G s N P P
s A F R Y Q G s N P P M
s A F R Y Q G T DELETED DELETED DELETED
s A F R Y Q G T DELETED DELETED DELETED M
s A F R Y Q G T DELETED DELETED! P
s A F R Y Q G T DELETED DELETED P M
s A F R Y Q G T DELETED P DELETED
s A F R I Y Q G T DELETED P DELETED M
s A F R Y Q G T DELETED P P
s A F R Y Q G T DELETED P P M
s A F R Y Q G T N DELETED DELETED
s A F R Y Q G T N DELETED DELETED M
s A F R Y Q G T N DELETED P
s A F R Y Q G T N DELETED P M
s A F R Y Q G T N P DELETED
s A F R Y Q G T N P DELETED M
s A F R Y Q G T N P P
s A F R Y Q G T N P P M
s A F R Y V S S DELETED DELETED DELETED
s A F R Y V S S DELETED DELETED DELETED M
s A F R Y V S s DELETED DELETED P
s A F R Y V s s DELETED DELETED P M
s A F R Y V s s DELETED P DELETED
s A F R Y V 3 S s DELETED P DELETED M
s A F R Y V
s DELETED I P ■■ p
s A F R i Y ' V S s DELETED! P ■ P | M

1295v|.>DC

ASTR 013/01 WO

20 25 ! 29 31 33 49 55 j 56 91 94 95 96 I 107
S A F R Y ! V ) S S N DELETED DELETED |
S A F R Y VjS s N DELETED DELETED M
S A F R Y v ! s s N DELETED P
S A F R Y V S s N DELETED P M
s A F R Y V S s N P DELETED
s A F R Y V s s N P DELETED M
s A F R Y V s s N P P
s A F R Y V s s N P P M
s A F R Y V S T DELETED DELETED DELETED
s A F R Y V s T DELETED DELETED DELETED M
s A F R Y V s T DELETED DELETED P
s A F R Y V S T DELETED DELETED P M
s A F R Y V s T DELETED P DELETED
s A F R Y V S T DELETED P DELETED M
s A F R Y V S T DELETED P P
s ■ A F R Y V i S T DELETED P P M
j S j A f F R I J Y V I S ,' T N DELETED, DELETED|_ _J
DELETED] M
k" " A T F R V | S T N DELETED

A TF R ■ I i Y V j S T N DELETED P ' —I
)s_ A LJL_ R | I Y V I S | T N DELETED P ! Ml
s A F R j I Y V I S j T N P DELETED I
s A F R I I Y V S ' T N P DELETED) M
s A F R Y V s ! T N P P ' I
s A F R Y V S | T i N P P ! M
s A F R Y V G S DELETED DELETED DELETED I
s A F R Y V G s DELETED DELETED DELETED', M
s A F R Y V G S DELETED DELETED p ! s A F R Y V G s DELETED DELETED p M
s A F R Y V G s DELETED P DELETED
s A F R Y V G s DELETED P DELETED M
s A F R Y V G s DELETED P P
s A F R Y V G s DELETED! P P M
s A F R Y V G s N (DELETED DELETED
s A F R Y V G s N DELETED DELETED M
s A F R Y V G s N DELETED P
s A ■ F R Y V G s N DELETED P M
s A F R Y V G s N P DELETED
s A F R Y . V G s N P DELETED M
s A F R Y V G s N P P
s A F R Y V G s N P P M
s A F R Y V G T DELETED DELETED DELETED
s A F R Y V G T DELETED DELETED DELETED M
s A F r R Y V G T DELETED DELETED P I
_s
s A F R Y ( V G T DELETED DELETED P M

A F R Y I V G T DELETED] P DELETED
s A F j R Y I V G i T (DELETED I ? DELETED M

52159 vl.'DC

ASTR 013/03 WO

_20_
S 25 29 31 33 j 49 55 56 91 94 95 96 107

A F R ■^7 i VL-1 V G T DELETED P P
s A F R 1 Y V G T DELETED P P M_j
s A F R y V G T N DELETED DELETED
s A F u R Y V G T N DELETED DELETED M
s A F R Y V G T N DELETED P
s A F R Y V G T N DELETED P M
s A F i R Y V G T N P DELETED
s A F R ' Y V G T N P DELETED M
s A F R Y V G T N P P
s A F R Y V G T N P P M
s A F R H Q S S DELETED DELETED DELETED
s A F R H Q S S DELETED DELETED DELETED M
s A F R H Q s s DELETED DELETED P
s A F R ■ H Q s s DELETED DELETED P M
s A F R H Q s s DELETED P DELETED
J'iZ
s A F R H Q s s DELETED P DELETED M

A A A F 1 R 1 ! H 0 s s DELETED p P

__F
F R H Q s s DELETED P P J M |

R H Q s s N ^ DELETED DELETED
s A F R H Q s s N DELETED DELETED M
s A F R I H Q s s N DELETED P
3 A F R H Q s s N DELETED P M
s A F R H Q s s N P DELETED
s A F R H Q s s N P 'DELETED M
s A F L_6_J H Q s s N P P
s A F R -l H 0 s s N P P M
s A F R H Q s T DELETED DELETED DELETED
s A F R H Q s T DELETED DELETED DELETED M
s A F I R_ H Q s T DELETED DELETED P
s A F _JLJ H Q s T DELETED DELETED P M
s A u. F R H Q s T DELETED P DELETED
__s
s A F R H Q s T DELETED P DELETED M

A F R_J H Q s T DELETED P P
s A F R H Q s T DELETED P P M
s A F R H Q s T N DELETED DELETED
s A F R H Q s T N DELETED DELETED M
s A F R H Q s T N DELETED P
s A F R H Q s T N DELETED P M
s A F R H Q s T N P DELETED
s A F R H ' Q s T N P DELETED M
i__s - A F R H Q s T N P P
! s A F R H ■ Q s T N P P M
s
s A F R H G G S DELETED DELETED DELETED

A F R H 0 G s DELETED DELETED DELETED M
s A 1 F R i j H 0 G s DELETED DELETED P
..._s A F R 1 H 0 G s DELETED DELETED P M

52959 vl/IX'

ASTR 013/01 WO

20 i 25 29 J 31 4 33 49 55 56 91 94 95 j 96 107
S | A F ! R H Q G s DELETED p IDELETED I
S A F j R H Q G j s DELETED P DELETED M
S A F J R I ! H Q G s DELETED p P I
^S A F R H Q G s
s DELETED p P M
s A F R H ! Q G
N IDELETED DELETED! t
s A F R H - Q G s N DELETEDiDELETED M
s A F R H Q G s N DELETED P l
s A F R I 1 H Q G s N DELETED P M
s A F R i H Q G s N P DELETED I
s A F R H Q G s N P DELETED M
s A F R H Q G s N P P )
s A F R H Q G s N P P M
s A F R H Q G T DELETED DELETED DELETED I
s A F R H Q G T DELETED DELETED DELETED M
s A F R H Q G T DELETED DELETED P I
s A F R ! I ! H Q G T DELETED DELETED! P M
s A F R j i | H ; Q T DELETED P {DELETED

s A A F R I H 0 G T DELETED P IDELETED M
s
F R
H Q I G T DELETED P P f
! s A F j_ R H Q G T DELETED P P M
r s A F I R H Q G T N DELETED DELETED I
S ' A F R H | Q G T N DELETEDiDELETED M
S I A F R I ! H Q G T I i N DELETED P !
S I A F R I j H Q G T N DELETED P M
s A F R I i H Q "I G T N P DELETED I
s A F R I ! H Q G i_l_ N P ^DELETED M
s A j F R H O G T N P ! P i
s A F ! R H Q G T N P P M
s A F R H v i s S DELETED DELETED DELETED I
s A F R H V S S DELETED DELETED DELETED M
s A F R H V S S DELETED DELETED , P I
s A F R H V s S DELETED DELETED P M
s A F R H V s S DELETED P DELETED I
s A F R H V s s DELETED P DELETED M
s A F R H V s s DELETED P P t
s A F R H V s s DELETED P P M
s A F R H V s s N DELETED DELETED I
s A F R H V s s N DELETEDiDELETED M
s A F R H V s s N DELETED P I
s A F R H V s s N DELETED P M
s A F R H V s s N p DELETED I
s A F R H V s s i N P iDELETEDi M
s A F R 'I | H | V s s N P | P ! M
j s A : F R I H V l s i s N P ! P

j S A F i R _JL - H V S ' T DELETED DELETED iDELETED. I
i s ! A F | R I ! H V I S IT DELETED DELETED (DELETED i M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S A F R H V s T DELETED DELETED P
S A F R H V s T DELETED DELETED P ! M
S A F R i r i H V s T DELETED P DELETED!
S A F H -] H V s T DELETED P DELETED M
S A F R H V s T DELETED P ' P
S A F R H V s T DELETED P P M
S A F R H V s T N DELETED DELETED
S A P R H V s T N DELETEDJDELETED M
s A F R H V s T N DELETED P
s A F R H V s T N DELETED P M
s A F R H V s T N P DELETED
s A F R H V s T N P DELETED M
s A F R H V s T N P P
s A F R ' H V s T N P P M
s A F R H V G S DELETED DELETED DELETED
s A F R H V G S DELETED DELETED DELETED M
s s A
A p F R H V G s s s DELETED DELETED P p
DELETED M

R I ; H V G
DELETED DELETED

A F R i ; H V G
DELETED P

s A F R H V G s DELETED P DELETED M
s A F __R H V G s DELETED P P
s A F R -i H V G s DELETED P P M
s A F R H v G s N DELETED DELETED
s A F R H V G s N DELETED DELETED M
t_ s A F R H V G s N DELETED P . i
s A F . R H V G s N DELETED P M
s A F |fL H V G s N P DELETED
s A F R H V G s N P DELETED M
s A F R H V G s N P P
s A F R H V G s N P P M
s A F R H V G T DELETED DELETED DELETED
s A F R H V G T DELETED DELETED DELETED M
s A F R H V G T DELETED DELETED P
s A F R H V G T DELETED DELETED P M
s A F R H V G T DELETED P DELETED
s A r F R H V G T DELETED P DELETED M
s A F R H V G T DELETED P P
s A F R" H V G T DELETED P P M
s A F R H V G T N DELETED DELETED
s A F • R H V G T N DELETED DELETED M
s A F R H V G T N DELETED P
s A F R H V G , T N DELETED P M
s A F R H V G T N P DELETED (
s A F R H V G T N P DELETED M
s A F R i j H v G T N P P
s A F R I I H i v G T N i P P M

52()59 vl/DC

ASTR 013/01 WO

20 25 29 I 31 33 49 55 56 91 94
DELETED 'T
95 96
DELETED: 107
1
S p I i S L Y Q S S
DELETED,

s p I | S L V J Q s S DELETED! DELETEDlDELETED M
s p I I S L Y Q s s DELETED DELETED P 1
s p s L Y Q s s DELETED DELETED P M
s p s L 1 Y Q s s DELETED P DELETED: I
s 1 p s L Y Q s s DELETED P DELETED M
s p s L Y Q s s DELETED P P 1
s p s L Y Q s s DELETED P P M
s p 1 1 L V Q s s N DELETED DELETED t
s p s L Y Q s s N DELETED DELETED M
s p s L Y Q s s N DELETED P 1
s p s L Y Q s s N DELETED P M
s p s L Y Q s s N P DELETED 1
s p s L Y 0 [ s s N P DELETED M
s p s L Y Q s s N P P 1
j s p s L Y Q s s N P P M
i s P ! i s L V
Y 0 s T DELETEDlDELETED DELETED DELETEDlDELETED DELETED 1
I s p I S

Q s T
M_J
|_ S p s L Y Q s T DELETEDlDELETED P t
s p s L Y Q s T DELETED DELETED P M
s p s L Y Q s T DELETED P DELETED 1
p ' s L Y Q s T [DELETED P DELETED M
s p s L Y Q s T DELETED P P 1
s p s L Y Q s T DELETED P P M
s t p s L Y 0 s T N DELETED DELETED 1
s p s L Y Q s T N- DELETED DELETED M
s p s L Y Q s T N DELETED P i
s p i I s L Y Q s T N DELETED P M
s p s L Y Q s T N P DELETED 1
s p s L Y Q s T N P DELETED M

p s L Y Q s T N P P 1
s p s L Y Q s T N P P M
s p s L Y Q G S DELETED DELETED DELETED 1
s p s L Y Q G S DELETED DELETED DELETED M
s p s L Y Q G s DELETED DELETED P 1
s p s L Y Q G s DELETED DELETED P M
s p s L Y Q G s DELETED P DELETED 1
s p s L Y Q G s DELETED P DELETED M
s p s L Y Q G s DELETED P P I
(__§_ p s L Y Q G s DELETED P P M
s p s L Y Q G s N DELETED DELETED I
(_ s p s L ! Y Q G s N DELETED DELETED M
s p s L i Y Q G s N DELETED P s p s L Y Q G s N DELETED P j M
i s I p s L Y Q G s N P [DELETED 1 >
I s I p s L Y L_Q G s I N P [DELETED \ M

52959-'l.'DC

ASTR 013/01 WO

20 25 _ 29__ 31 33 49
Y 55 56 91 94 95 96 107
S p
s
s L
Q G s N P P
s p
L Y
G s N P P M
s p i S L Y Q G T DELETED DELETED DELETED
s p s L Y Q G T DELETED DELETED DELETED M
s p _l s L Y 0 G T DELETED DELETED P
s p s L Y Q G T DELETED DELETED P M
s p s L Y Q G T DELETED P DELETED
s p s L Y Q G T DELETED P DELETED M
s p s L Y Q G T DELETED P P
s p s L Y Q G T DELETED, P P M
s p s L Y Q G T N DELETED DELETED
s p s L Y Q G T N DELETED DELETED M
s p s L Y Q G T N DELETED P
s p s L Y Q G T N DELETED P M
s p s L Y Q G T N P DELETED
s p s L L
L Y Q G T N | P DELETED M
s p : i S
Y Y __Q_ 0 G
G J T N ' P , P
s p s

T N P P M
s p s L Y V S S DELETED DELETED DELETED M
s p i s L Y V s S DELETED DELETED DELETED

s p s^ L Y V s S DELETED DELETED P
o p s L Y V s s DELETED DELETED P M
s p s L Y V s s DELETED P DELETED
s p s L Y V s s DELETED P DELETED M
s p s L Y V s s DELETED P P
s p s L Y V s s DELETED P P M
s p s L Y V s s . N DELETED DELETED
s p s L Y V s s N DELETED DELETED M
s p s L Y V s s N DELETED P
s p s L Y V s s N DELETED P M
s p s L Y V s s N P DELETED
s p s L Y V s s N P DELETED M
s p 1 S L Y V s s N P P
s p I i S L Y V s s N P P W
s p i i s L . Y V s T DELETED DELETED DELETED
s p 1 S L Y. V s T DELETED DELETED DELETED M
s p s L Y V s T DELETED DELETED P
s p s L Y V s T DELETED DELETED P M
s p s L Y V s T DELETED P DELETED
s p s L Y V s T DELETED P DELETED M
s p s L Y V s T DELETED P P
s p s L Y V s T DELETED P P M
s p s L Y V s T N DELETED DELETED
s p s L Y V s T N DELETED DELETED M
s p 1 S L Y V s T N DELETED P
s P | ! | S L Y V s
N DELETED P M

S2l?59vl/!)C

ASTR 013/01 WO

20 25 29 31 33 49 55 56 ! 91 I 94 95 96 ; 1.07
1 S p S L Y V , S T N P DELBTEDj I
s P S L Y V S T N P DELETED! M
s P s L Y V S T N P p I
s p s I L Y V S T N P P j M
s p s L Y V G s DELETED DELETED DELETED! I
s p s L Y V G S DELETED DELETED DELETED M
s p s L Y V G s DELETED DELETED p I
s p s L Y V G s DELETED DELETED p M
s p s L Y V G s DELETED P DELETED 1
s p s L Y V G s DELETED P DELETED M
s p s L Y V G s DELETED P p 1
s p s L Y V G s DELETED P p M
s p s L Y V G s N DELETED DELETED 1
s p si L Y V G s N DELETED DELETED M
s p s L Y V G s N DELETED P 1
s p S ' L Y__
Y Y V G s f N DELETED P M ,
s
-£- — p
p —1 S _| _L__^
V V "G " s"~r _N
" N P DELETEDi I J
DELETED! M ;
s P 1 1 { S { L Y I V G s i N P P '. I
s P s L Y ! V G S | N P P M 1
s p s L Y V G T (DELETED DELETED;DELETED 1
s P . s L Y V G T DELETED DELETED|DELETED M
s p s L Y V G T DELETED DELETEDi P S ! P s L Y V G T DELETED DELETED P M
S j P s L Y V G T DELETED P DELETED 1 I
S j P s L. Y V G T DELETED P DELETED M 1
s p s L Y V G T DELETED P P i
s p s L Y V G T DELETED P P M
s p s L Y V G T N DELETED DELETED 1
s p s L Y V G T N DELETED DELETED M
s p s L Y V G T N DELETED P i
s p s L Y V G T N jDELETED P M
s p s L . Y V G T N P DELETED 1
s p s L Y V G T N P DELETED M
s p s L Y V G T N P P I
s p s L" Y V G T N P P M
s p s L H Q S S DELETED DELETED DELETED 1
s p s L H Q S S DELETED DELETED DELETED M
s p s L H Q S s DELETED DELETED P 1
s p s L H 0 S s DELETED DELETEDi P M
s p s L H Q S s DELETED p [DELETED 1
s p s L H Q S S DELETED P DELETED M
s P ! 1 s L H Q s s DELETED P P
p i
s p s L H 0 s s DELETED P
M
s p s L H Q S j S N DELETEDJDELETED ■ i
s p s L i H Q S ! S j N DELETED.'DELETED! M

52959 vl.'DC

ASTR 013/01 WO

20 25 29 ! 31 33 49 55 56 91 94 95 96 107
S p I S L H 0 S j S N DELETED| P t
s p s L H Q s s N DELETED P M
s p s L H Q s s N P DELETED I
s p s L H Q s s N P DELETED M
s p s L H Q s s N P P I
s p s L H Q s s N P P M
s p s L H L_Q s T DELETED DELETED DELETED I
s p s L H Q s T DELETED DELETED DELETED M
s p s L H Q s T DELETED DELETED P I
s p s L H Q s T DELETED DELETED P M
! cT" p s L . H Q s T DELETED P DELETED I
s p s L H Q s T DELETED P DELETED M
s p - s L H Q s T DELETED P P I
l_ s p s L H Q s T DELETED P P M
s p I S L H Q s T N DELETED DELETED I
s p s L H Q s T N DELETED DELETED M
Q p ; i s L
L H_ _
H H _Q__ Q s._ T N JDElETEp DELETED
P
P _ P
P DELETED I M
s p "T"r-S

T
T N
N

s p I s

I
I S 1 p s L
Q s
N
DELETED M
s p s L H Q s T N P P I
s p s L H Q s T N P P M
s p s L H Q G S DELETED DELETED DELETED I
s p s L r H Q G S DELETED DELETED DELETED M
s p s L H Q G s DELETED DELETED P I
s p I s L H Q G s DELETED DELETED P M
s p s L H Q G s DELETED P DELETED I
s p s ' L H Q G s DELETED P DELETED M
s p s L H Q G s DELETED P P I
s p s L H Q G s DELETED P P M
s p s L H Q G s N DELETED DELETED I
s p s L H Q G s N DELETED DELETED M
s p s L H Q G s N DELETED P I
s p s L H Q G s N DELETED P M
s p s L H Q G s N P DELETED I
s f p s L H Q G s N P DELETED M
S _j p s L H Q G s N P P I
s p s L H Q G s N P P M
s p s L H Q G T OELETED DELETED DELETED I
s p s L H Q G T DELETED DELETED DELETED M
s p s L H Q G T DELETED DELETED P s p s L H f_Q G T DELETED DELETED P M
s p- s L H Q G T DELETED P DELETED i
S_J p s L H Q G T DELETED P DELETED M
s p s L H Q G T DELETED P P I
s p s L ' H 1 Q G T DELETED P j P M

5295'*.'KIX"

ASTR 013/01 WO

20 25 29. 31 33 49 55 56 91 94 95 96 107
S p s L H Q Q G T N ^ DELETED DELETED
S p s L . H
G T N DELETED DELETED M
s
s p s L H Q G T N DELETED P

p s L H Q G T N DELETED P M
s p s L H Q G T H P DELETED
r s p s L H Q G T N ■P. DELETED M
s p 1 s L H Q G T N P P
s p 1 1 s L H Q G T N P P M
s p s L H V s S DELETED DELETED DELETED
s p s L H V S s DELETED DELETED DELETED M
s p s L H V s s DELETED DELETED P
s p s L H V s s DELETED DELETED P M
s p s L H V s s DELETED P DELETED
s p s L H V s s DELETED P DELETED M
s p s L H V s s DELETED P P
s p | i i s L H v s s DELETED P P M

P,! !_._ _s . L
L H V s s -I N DELETED DELETED

"_pj 1 s
H V s s ' N DELETED DELETED M
1 S p s L H V s s N DELETED P

p s J L H V 3 s N DELETED P M
s~l p s L H V S s N P DELETED
s p s L H V s s N P DELETED M
s p s L H V s s N P P
s p 1 s L H V s s N P P M
s p s L H V s T DELETED DELETED DELETED
s p S | L H V s T DELETED DELETED DELETED M
s p s L H V s T DELETED DELETED P
s p —£—I L H V s T DELETED DELETED P M
s p s L H V s T DELETED P DELETED
s p s L H V s T DELETED P DELETED M
s_
s p 3 L H V s T DELETED P P

p s L H V s T DELETED P P M
s p s L H V s T N DELETED DELETED
s p s L H V s T N DELETED DELETED M
s p s L H V s T N DELETED P
s p s L H V s T N DELETED P M
s p s L H V s T N P DELETED
s p s L H V s T N P DELETED M
s p s L H V s T N P P
s p s L H V s T ' N P P M
s UP— s L H V G S DELETED DELETEDjDELETED
s p s L H V G S DELETED DELETED|DELETED M
| s p s L H V G S DELETED DELETED! P
s p s L H V G S DELETED DELETED P P M
s p s L H V G s DELETED
DELETED
s i p s L I H f v G s DELETED P jDELETED M

5295') vUDC

ASTR013/01 WO

20 25 29 ~31 33 49 55 56 91
s 94 95 96 107
j__S p s L H V G
DELETED P P
s p s L h H V G s DELETED P P M
s p s L H V G s N DELETED DELETED
s p s L | H V G s N DELETED DELETED M
s p s L H V G s N DELETED P
s p s L H V G s N DELETED P M
s p s L H V G s N P DELETED
s p s L H V G s N P DELETED M
s p s L FH V ' G s N P P
s p I S L H V G s N P _, P M
s p s L H V G T DELETED DELETED DELETED
s p s L H V G T DELETED DELETED DELETED M
s p s L H V G T DELETED DELETED P
s p s L H V G T DELETED DELETED P M
s p s L H V G T DELETED P DELETED
s p i ! s I.
L H V | G T DELETED P DELETED
s p

H H G ™G " T
T
T DELETED P j P
DELETED! P \ 9

s p 1 s

M
s p s L H V G
N (DELETED DELETED
s p s -I L H V G T N DELETED DELETED M
s p s L H V G T N DELETED P
s p s L H V G T N DELETED P M
s p s L H V G T N P DELETED
s p s L H V G T N P DELETED M
s p s L H V G T N P P
s p s L H V G T N P P M
s p s Y Q S S DELETED DELETEDlDELETED
s p s Y Q S s DELETED DELETED DELETED M
s p s Y Q S s DELETED DELETED P
s p s Y Q s s DELETED DELETED P M
s p s Y Q s s DELETED P [DELETED
s p s Y Q s s DELETED P DELETED M
s p s Y Q s s DELETED P P
s p s Y Q s s DELETED P P M
s p s Y Q s s N DELETED DELETED ■
s p s Y Q s s N DELETED DELETED M
s p s Y Q s s N DELETED P I
s p - s Y Q s s N DELETED P M
s p s Y Q s s N P DELETED
s p s Y Q s s N P DELETED M
s p s Y Q s s N P P
s p s Y Q s s N p : P M
s p s Y Q s T DELETED DELETED DELETED
s p s Y Q s ' T DELETED DELETED DELETED M
s p i s ] Y Q s T DELETED DELETED P
s p s Y Q ' s T DELETED DELETED! P { M

52M9 vl/DC

ASTR 013/01 WO

20 25 29 31 ! 33 49 55 56 91 94 95
P 96 107
S p s Y 0 S T DELETED
DELETED I
S p s Y Q S T DELETED P DELETED M !
S p 1 S Y Q S T DELETED P P
s ' p s Y Q s T DELETED P P M .
s p s t i : Y Q s T N DELETED DELETED
s p S Y Q s r- T N DELETED DELETED M
s p s Y Q s T N DELETED P
s p s Y Q s T N DELETED P M
s p s Y Q s T N P jDELETED
s p s Y Q s T N P DELETED M
s p s , I Y Q s T N P P
s p s Y Q s T N P P M
s p s Y Q G S DELETED DELETED DELETED
s p s Y Q G S DELETED DELETED DELETED M
s p s Y Q G s DELETED DELETED P
s p 1 i S Y Q ^G s DELETED DELETED P M
s
_ ^ p i i s i I Y Q G s DELETED P DELETED

p 1 J S i 1 ! Y Q G s DELETED P DELETED M ;
c p i i S I Y Q G s DELETED P ! P I
s p s I Y Q G s DELETED P P M
s p s Y Q G s N DELETED DELETED
s p s Y Q G s N DELETED DELETED M
s p s Y Q G s N DELETED P
s 1 p s Y Q G s N DELETED P M
s p s Y Q G s N P DELETED
s p s Y 0 G s N P DELETED M
s p s Y Q G s N P P
s p S ! I Y Q G s N P P M
s p s j Y Q G T DELETED DELETED DELETED
s p s Y Q G T DELETED DELETED DELETED M
s p s Y Q G T DELETED DELETED P
s p s Y Q G T DELETED DELETED P M
s p s Y Q G T DELETED P iDELETED
s p s Y Q G T DELETED P DELETED M
s p s Y - Q G T DELETED P P
s p s Y Q G T DELETED P P M
s p s Y Q G T N DELETED DELETED
s p s : Y Q G T N DELETED DELETED M
s p s Y Q G T H DELETED P
s p s Y Q G T N DELETED! P M
s p s Y Q G T N P jDELETED
s p s Y Q G T N P DELETED M
s p s Y Q G T N P [ P I
s p s i i Y Q G T N P i P M
s p s Y V S S DELETED DELETED DELETED
s p 3 I ! Y V s I s DELETEDiDELETED DELETED M

52959 v],'DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S p s Y V V s S DELETED DELETED DELETED
DELETED _f
P M
s p s Y

s p s Y V s S DELETED P DELETED
s L_P s Y V s s DELETED P DELETED M
s p s Y V s S DELETED P P
s p s Y V s s DELETED P P M
s p s Y V s s N DELETED DELETED
s p s Y V s s N DELETED DELETED1 M
s p s Y V s s N DELETED P
s p s Y V s s N DELETED P M
s p s Y V s s N P DELETED
s p s Y V s s N P DELETED M
s p s Y V s s N P P
s p s i i | Y V s s N P P M
s p S i I I Y V s T DELETED DELETED DELETED
s p s ! i : Y V s T DELETEDiDELETED DELETED M
__s___
—s_. s p s I i : Y V s T DELETEDIDELETED P

p 1 s ; i ; Y V __s„ s T DELETED DELETED! P M ■

p 1 j S ! 1 i Y V
T DELETED P [DELETED
s p . S I I Y V s T DELETED P DELETED M
s p s i i Y V s T DELETED P ! P
s p s ! i Y V s T DELETED P P M
s p s ! i Y V s T N DELETED DELETED
s p s i i Y V s T N DELETED DELETED M
s p s I i Y V s T N DELETED P
s p S I Y V s T N DELETED P M
s p s Y V s T N P DELETED
s p s Y V s T N P DELETED M
~s p s Y V s T N P P
s p s Y V s T N P P M
s p s Y V G S DELETED DELETED DELETED
s p s Y V G S DELETED DELETED DELETED M
s p s Y V G s DELETED DELETED P
s p s Y V . G s DELETED DELETED P M
s^ p s Y V G s DELETED P DELETED
s p s Y V G s DELETED P DELETED M
s p s Y V G s DELETED P P
s p s Y V G s DELETED P P M
s p s Y V G s N DELETED DELETED
s p s Y V G s N DELETED DELETED M
s p s Y V G s N DELETED P
s p s Y V G s N DELETED P M
s p s Y V G s N P DELETED
s p S I I Y V G s N P DELETED M
s p S \ I Y V G s N p ! p
s p s : i Y V G s N p ! p M

5^'J59 vl/DC

ASTR 013/01 WO

20
S 3 25 j 29 31 33 49 55 56 91 94 95 96 107

P S Y V G T DELETED DELETED DELETED

P s Y V G T DELETED DELETED DELETED M
s ,. P [ . S Y V G T DELETED DELETED P
5 P 1 S Y V G T DELETED DELETED P M
S P s Y V G T DELETED P DELETED
S P s Y V G T OeLETEDi P DELETED M
I s P , s Y V G T DELETED P P
s P s Y V G T DELETED P P M
s P s Y V G . T N DELETED DELETED
S ' P s Y^ V G T N DELETED DELETED M
s P s Y V G T N DELETED P
s P s Y V G T N DELETED P M
s P s Y V G T N P DELETED
s P s Y V G T N | P DELETED M
s P 1 s Y V G T N P P
h s P s Y V i G T N P P M
s P ! S H i Q s S DELETED DELETED DELETED DELETED I |
s P ! : 3 i H Q s . s DELETED DELETED
M
s Pi 1 ■ S H Q s S DELETED DELETED P
s P IS H Q s S DELETED DELETED P M
s P s H Q s s DELETED P DELETED
s P 1 s H Q s s DELETED P DELETED M
s P s H Q s s DELETED P P
s P s H Q s s DELETED P P ! M I
s P s H Q s s N DELETED DELETED
Is P s H Q s S : N DELETED DELETED M
s P 1 S H Q s s N DELETED P
5 "! P 1 S H Q s s N DELETED P M
S ! P s H Q s s N P DELETED
S i P s H Q s s N P DELETED M
s P s H Q s s N P P
s P s H Q s s N P P M
s P s H Q s T DELETED DELETED DELETED
s P s H Q s T DELETED DELETED DELETED M
s P s H Q s T DELETED DELETED P
s P s H Q s T DELETED DELETED P M
s P s H Q s T DELETED P DELETED
s P s H Q s T DELETED P DELETED M
s P s H Q s T DELETED P P
s P s H Q s T DELETED P P M
s P s H Q s T N DELETED DELETED
s P s H Q s T N DELETED DELETED M
s P s H Q s T N DELETED P
! S I P s H Q s T N DELETED P M
s P s H Q ! S T N P DELETED

P s 1 H Q | S T N P DELETED M

5295 vMiVJ

ASTR 013/01 WO

20 25 i 29 31 33 49 j 55 56 91 94 95 96 107
S P 1 S H i Q s T N P P
s P S H Q s T N P P M
s P s H Q G S DELETED DELETEDJDELETED
s P s H Q G S DELETED DELETED DELETED M
s P s H Q G s DELETED DELETED P
s P s H 0 G j s DELETED DELETED P M
s P s H Q G s DELETED P DELETED
s P s H Q G s DELETED P DELETED M
s P s H Q G s DELETED P P
s P s H Q G s DELETED P P M
s P s H Q G s N DELETED DELETED
s P s H Q G S N DELETED DELETED M
s P s H Q G s N DELETED P
s P s H Q G s N DELETED P M
s P S I H Q s N P DELETED
s P ] s H Q G s ! N P p DELETED M
3 P | 1 s H H 0 G s N
P
s P | 1 s
Q —I G s N
P M
s P ! i s I H Q ~~l G T DELETED DELETED DELETED
s p s H Q G T DELETED DELETED DELETED M
s p s H Q G T DELETED DELETED P 1
S ! P i s H Q G T DELETED DELETED: P M
s p s H Q G T DELETED P JDELETED
s p s H Q G T DELETED P DELETED M
s p s H Q G T DELETER p P
s p s H Q G T DELETED p P M
s p s H Q G T N DELETED DELETED
s p s H Q G T N DELETED DELETED M
s p s H Q G T N DELETED P
s p s H Q G T N DELETED! P M
s p s H Q G T N P DELETED
s p s H Q G T N P DELETED M
s p s H Q G T N P P
s p s H Q G T N P P M
s p s H V S S DELETED DELETED DELETED
s p s H V S S DELETED DELETED DELETED M
s ■ p s H V S s DELETED DELETED P
% p s H V s s DELETED DELETED P M
s p s H V s s DELETED P DELETED
s . p s H V s s DELETED P DELETED M
s p 3 H V s s DELETED P P ! 1
s p s H V s s DELETED P P M
s p I ! S H V s s N DELETED OELETED
s p t s H V s s N DELETED DELETED M
s p s H V s s N DELETED1 P
S P s H V s s N DELETED| P M

ASTR013/01 WO

20 25 29 31 L 33 49 55 56 91 94 95 96 107
S p s H V s S N P DELETED
S __p 1 s H V s s N "" P DELETED M
S p s H V s s N P P
S p s H V s s N P P M
S p s H V I S T DELETED DELETED DELETED
S p s H V s T DELETED DELETED DELETED M
S p s H V s T DELETED DELETED P
3 p s H V S T DELETED DELETED P M
s p ' s I H V s T DELETED P DELETED | j
s p s H V s T DELETED P DELETED M
s p s H V s T DELETED P P
s p s H V s T DELETED P P M
s p s H V s T N DELETED DELETED
s p s H V s T N DELETED DELETED M
s p s H V s T N DELETED P
s p s H V s T N DELETED P M
s i p s I H V s T N P DELETED
s p s H V s T N P DELETED M
s ■ p s H V s T N P P
s p s H V s T . N P P M
s p s H V G S DELETED DELETED DELETED
s p s H V G s DELETED DELETED DELETED M
s p s H V G s DELETED DELETED P
s p s H V G s DELETED DELETED P M
s p s H V G s DELETED P DELETED
s p s H V G s DELETED P DELETED M
s p s H V G s DELETED P P I
s p s H V G s DELETED P P M
s p s H V G s N DELETED DELETED
s p s H V G s N DELETED DELETED M
s p s H V G . s N DELETED P
s p s H V G s N DELETED P M
s p s H V G S I N P DELETED
s p s H V G s N P DELETED M
s p s H V G s N P P
s p s H V G s N P P M
s p s H V G T DELETED DELETED DELETED
s p s - H V G T DELETED DELETED DELETED M
s p s H V G T DELETED DELETED P
s p s H V G T DELETED DELETED P M
s p s H V G T DELETED P DELETED
s p s H V G T DELETED P DELETED M s p s H V G T DELETED P P
s p 1 I S H V G T DELETED P P M
s p i!s!) H V G T N DELETED DELETED
s p 1 j S 1 H V G T j N DELETED DELETED M

S^S9 vl/IX"

ASTR 013/01 WO

20 | 25 | 29 31 ! 33 49 55 56 91 94 95 96 107
s p ! i s ! H V G T N DELETED P
s p S ! H V G T N DELETED P M
s p s 1 H V G T N P DELETED
s p s H- V G T N P DELETED M
s p s H V G T N P P
s p s 1 H V G T N P P M
S J p R L Y Q S S DELETED] DELETED DELETED
s p R L Y Q S S DELETED DELETEDj DELETED M
s p R L Y Q S s DELETED DELETED P
s p R L Y 0 s s DELETED DELETED P M
S J p R L Y Q s s DELETED P DELETED
s p R L Y Q s s DELETED P DELETED M
S _j p R L Y Q s s DELETED P P
_-JL_| p R L Y Q s s DELETED P P M
s p R L Y Q s s N DELETED DELETED
s p R L Y 0 s s N DELETED DELETED M
s p R L V Q 1 s s N DELETED P
s P ; 1 ! R L Y Q s s N IDELETED P M
s p : i R L Y G s s N | P DELETED
s P ! i R L Y Q s s N ! P DELETED M
s p R L Y Q s s N P P
s p R L Y Q s s N P P M
s p R L Y Q s T DELETED DELETED DELETED
s p R L Y Q s T DELETED DELETED DELETED M
s p R L Y Q s T DELETED DELETED P
s p R L Y Q s T DELETED DELETED P M
s p R L Y Q s T DELETED P DELETED
s p JR. L Y 0 s T DELETED P DELETED M
s p R L Y 0 s T DELETED P P
s p R L Y Q s T DELETED P P M
s p R L Y Q s T N DELETED DELETED
s p R L Y Q s T N DELETED DELETED M
s p R L Y Q s T N DELETED P
s p R L Y a s T N DELETED P M
s p R L Y a s T N P DELETED
L_s_ p R L Y Q s T N P DELETED M
s p R L Y Q s T N .P P
s p R L Y Q s T N P P M
s p R L Y Q G S DELETED DELETED DELETED
s p R L Y Q G s DELETED DELETED DELETED M
s p R L Y a G s DELETED DELETED P
s p R L Y 0 G s DELETED DELETED P M
s p R L Y Q G s DELETED P DELETED
s p R L Y Q G s DELETED P DELETED M
s p R L Y Q G s DELETED P P
s p R L Y Q G . 1 s DELETED P P M

533*3 vi/DC"

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 | 95 96 107
S p R L Y Q G s N DELETED DELETED
s p R L ! Y Q G s N DELETED DELETED M
s p R L Y Q G s I N DELETED P
s p R L Y Q G s N DELETED P M
s p R L Y Q G s N P DELETED
s p R L Y Q G s N P IDELETED M
s p R L Y Q G s N P P
s p R L Y Q G s N P P M
s p R L Y Q G T DELETED DELETED DELETED
s p '. R L Y Q G T nFlETED DELETED DELETED M
s p R L Y Q G T DELETED DELETED P
s p R L Y Q G T DELETED DELETED P M
s p R L Y Q G T DELETED P DELETED
s p R L Y Q G T DELETED P DELETED M
s s p 1 R L i V Q G T DELETED P P

p R L I Y y
y Y 0 G T DELlliP P P M
'■■ s p 1 1 R . L L I
Q G T N DELETED DELETED DELETED M
r~_s p ! J p : R R

Q Q G T N 4 DELETED DELETED

L_S_„ v s i

G ■ T I N ~f
P

T* R 1 k V Q G 7 l io ' IDEVETEd "P "M
s p R L Y Q G T N P DELETED
s p R L Y Q G T N P DELETED M
s p R L Y Q G T N P P
s p R L Y Q G T N P P M
s p R L Y V S S DELETED DELETED DELETED
s p R L Y V S S DFLETED DELETED DELETED M
s p R L Y V S s DELETED DELETED P
s p R L Y V s s DELETED DELETED P M
s p R L Y V s s DELETED P DELETED
s p R L Y V s s DELETED P DELETED M
s p R L Y V s s DELETED P P
__s
s p R L Y V s s DELETED P P M

p 1 R L Y V s s N DELETED DELETED
s p R L Y V s s N DELETED DELETED M
s p R L Y V s s N DELETED P
s p R L Y V s s N DELETED P M
s p R L Y V s s N P DELETED I
s p R L Y V s s N P DELETED M
s p R L Y V s s N P P
s p R ]_ L Y V s s N P P M
s p R L ■Y V s i T DEIFIED
DELETED DELETED DELETED I
s p R L Y V s 1 T
DELETEDJDELETED M
s p 1 R L Y V s ! T DELETED DELETED! P
s p R I. Y V s T DELETED DELETED! P M
s i P R L Y V s T DELETED P IDELETEC I
s J p R L Y V s T DELETED P (DELETED M

ASTR 013/01 WO

20 25 29 31 33_l49| 55 56 91 94 95 ! 96 107
S p R L I Y V s T DELETED P p i i
s p R L Y v s T DELETED P P M
s p R L Y V s T N DELETED DELETED
s p ■ R L Y V s T N DELETED DELETED M
s p R L Y V s T N DELETED P
s p R L Y V s T N DELETED P M
s p R L Y V s T N P DELETED
s p R L Y V S _| T N P DELETED M
s p R L Y V s T N P P
s p R L Y V s T N P P M
s p R L Y V G S DELETED DELETED DELETED
s p R L Y V G s DELETED DELETED DELETED M
s p R L Y V G s DELETED DELETED P
s P ! ! R L Y V G s IDELETED DELETED P M J
s p ! i R L Y V G s DELETED P DELETED
s p R L Y ! V G s DELETED P DELETED M
s p R L Y I V G s DELETED P p
s j P R L Y V ' G I S (DELETED1. P P M
s ; p ! i R L Y V G s N DELETEOlDELETED I I
s p i i R L Y V G s N DELETED DELETED M
s p R J L Y V G [_S N DELETED P
s p R L Y V G s N DELETED p M
S ' P R L Y V G s N P DELETED
S ? P ! R L Y V G *~ s N P DELETED M
s ! P R L Y V G s N P P
s p R L Y V G s N P P ! M
s p R L Y V G T 'DELETED DELETED DELETED
s p R L Y- V G T DELETED DELETED DELETED M
s p _5lJ L Y V G T DELETED DELETED P
s p R L Y V G- T DELETED DELETED • P M
s p R L Y V G T DELETED P DELETED
s p R L Y V G T DELETED P DELETED M
s p R L Y V G T DELETED P P I
s p R L Y V G T DELETED P P M
s p R L Y V G T N DELETED DELETED
s p R L Y V G T N DELETED DELETED M
s p R L Y V G T N DELETED P
s p R L Y V G T N DELETED P M
s p R L Y V G • T N P DELETED
s p R L Y V G T N P DELETED M
s p R L Y V G T N P P
s p R L Y V G T N P P M
s p I ! R L H Q S S DELETED DELETED DELETED
s p i 1 R _J^J H Q s i s DELETED DELETED DELETED M
s p R L H Q S f S :DELETEDiDELETED P
1 S | P ! 1 [ R L | H Q s I s IDELETEDIDELETED; P j M

52159 vl/DC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S p R L H Q S S DELETED P DELETED I
s P R L H Q s s DELETED P DELETED M
s p R L H Q s s DELETED P P P I
M
s p I R L H Q s s DELETED
P

s p i I R L H Q s s N DELETED DELETED t
s p ( 1 R L H Q s s N DELETED DELETED M
s • p 1 1 R L H Q s s N DELETED P I
s p R L H Q s s N DELETED P M
s p R L H Q s s N P DELETED I
s p R L H Q s s N P DELETED M
s p R L H Q s s N P P 1
s p R I H Q s s N P P M
s p R L H Q s T DELETED DELETED DELETED 1
s p R~~1 L H Q s T DELETED DELETED DELETED M
s p R L H Q s T DELETED DELETED P 1
s p R L H Q s T DELETED DELETED P M
1
S P_
S 1 P ~~R* _ L_ j ..H Q s T DELETED P DELETED

1 R | L !- H Q s T DELETED J>
P DELETED! M
s p 1 R i L H Q ! S T DELETED
P ! !
s p R L H Q s T DELETED P P M
s p R L H Q s T N DELETED DELETED 1
s p R L H Q s T N DELETED DELETED M
S | P R L H Q s T N .'DELETED p 1
S 1 P R L H Q s T N DELETED p M
S j P R L H Q s T N i P DELETED 1
S 1 P R L H Q s T N P DELETED M
S | P R L H Q s T N P P 1
s ! p R L H Q s T N P | P M
s p R L H Q G S DELETED DELETED DELETED t
s ■p R IS H Q G S DELETED DELETED DELETED M
s p R L , H Q G s DELETED DELETED P 1
s p R L H Q G s DELETED DELETED P M
S P R L H Q G s DELETED P DELETED 1
s p R L H Q G s DELETED P DELETED M
s p R L H Q G s DELETED P P 1
s p R L H Q G s DELETED P P • M
s p R L H Q G s N DELETED DELETED 1
s p R L H Q G s N DELETED DELETED M
s p R L H Q G s N DELETED P 1
s p R L H Q G s N DELETED P M
s p R L H Q G s N P DELETED 1
s p R L H Q G s N P DELETED M
s p R L H Q G s N P P 1
s p R L H Q G s N P P M
s p R I L H I Q G T DELETED DELETED DELETED !
L> j p R f L H Q G T DELETED DELETED DELETED M
52951 vl/DC"

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S p R L H Q G G T DELETED DELETED p
s p R J L H Q
T DELETED DELETED p M
s p R L H Q G T DELETED P DELETED
s p R_j L H 0 G T DELETED L_ P DELETED M
s p R L H Q G T DELETED P p
s p R __| L H Q
T DELETED P p M
s p R L H Q G T N DELETED DELETED
s p R L H 0 G T N DELETED DELETED M
s p - R L H Q G T N DELETED P
s p R L H Q G T N DELETED P M
s p R L H Q G T N P DELETED
s p R L H s p R L H 0 G T N P P
s p R L H 0 G T N P P M
s p i | R L H V S S DELETEDj DELETED DELETED
s p 1 i R L H v ] S S DELETED DELETED DELETED M
s s p 1 ! R L H V S s DELETEDiDELETED P P M

p 1 \ ~R~^ i H V s s DELETED DELETED

s p I i R L H V s s DELETED P DELETED
s p [ ! R L H V s s DELETED P DELETED M
s p 1 ! R L H V s s DELETED P P I
s p I ( R L H V s s DELETEO P P M
s p 1 ! R L ^ H V s s N DELETED DELETED ■
s p R L H V s s N DELETED DELETED M
s p R L H V s s N DELETED P
s p R L H V s s N DELETED! P M
s p R L H V s s N p DELETED
s p R L H V s s N p DELETED fv'i
s p R L H V s s N p ! p
s p R L H V s s N p i P M
' s p 1 1 R L H V s T DELETED DELETED!DELETED
s p t 1 R L H V s T DELETED DELETED DELETED M
s p 1 1 R I. H V s T DELETED DELETED P
s p L R L H V s T DELETED DELETED , P M
s p R L H V s T DELETED p DELETED
s p R \ L H V s T DELETED P DELETED M
s p R L H V s T DELETED ' p P
s p R L H V s T DELETED p P M
s p R L H V s T N DELETED DELETED
s p R L H V s T N DELETED DELETED M
s p |_R__ L H V s T N DELETED P I
s p R L H • V s T N DELETED P M
s p R L H V s T N p DELETED f (
s p 1 i R L H V s T N p DELETED M
s p 1 1 R L H V s T N p P
s p 1 ! R L H . v s T N p P M

52W9 vVUC

ASTR 013/01 WO

20 I 25 29 31 33 I 49 55 56 91 94 ! .95 96 107
S "1 p R L H V G S DELETE DpELETEO DELETED
s i p R L H V G s DELETED DELETED DELETED M
S ! p R L H V G s DELETEDIDELETED P
s p R I H V G s DELETED DELETED P M
s p R L H V G s DELETED P DELETED
s p R L H v G s DELETED P DELETED M
s p R L H V G s DELETED P P
s p R L H V G s DELETED P P M
s p I i R L H ^ V G s N DELETED DELETED
s p R L H V G s N DELETED DELETED M
s p ■ R L H V G s N DELETED P
s p R L H V G s N DELETED P M
s p R L H V G s N P DELETED
s p I R L H V G s N P DELETED M
s p R L H V G s N P P I
s p R L H v ■ G s N ! P P M
s p R L H V G T DELETEDiDELETED DELETED
s p 1 R L i H V G T DELETED DELETED DELETED M
s p R L H V G 1 T DELETED DELETED: P
s p R L H V G T DELETEDIDELETED; P M
s p R L H V G T DELETED! P DELETED
s p R L H V G T DELETED P DELETED
s p R L H V G T DELETED! P P
s p R L H V G T DELETED P i P M
s p R i H V G T N DELETED DELETED
s p R L H V G T N DELETED DELETED M
s p R L H J V G T N DELETED P
s p R L H V G T N DELETED P M
s p R L H V G T N P OELETED
s p R L H V G T N P DELETED
s p R L H V G , T N P" P
s p R L H V G ! T N ! P ! P M
s p R Y Q S S DELETED DELETED DELETED
s p R Y Q S s DELETED DELETED DELETED M
s p R Y Q S s DELETED DELETED P
s p R Y Q S s DELETED DELETED P M
s p R Y Q S s pELETED P DELETED
s p R - Y Q S s DELETED P DELETED M
s p R Y Q s s DELETED P P
s p R Y Q s s DELETED P P M
s p R Y Q s s I N DELETED DELETED
s p R Y Q ; s s j N DELETEDiDELETED M
s p R ■ ; Y Q 1 s s i_ N DELETED P
s p R Y Q 3 s i N DELETED P M
s PH"'~! R Y i Q i 3 s ^ s I N P DELETED I
s P 1 i I R Y ! Q i S
I N ' P 'DELETED I M

52Wv]/nc

AST& 0(3^01 Wd

20 ] 25 | 29 31 33 49 55 | 56 91 94 95 96 107
s i p R Y Q s S N -i P | P
" * "1 p R y Q s s N P I P M
s ! p R Y Q S T DELETED DELETED DELETED
1 s p i i R Y Q s T DELETED DELETED DELETED M
s , p 1 ' R y Q J s T DELETED! DELETED! P
s p 1 R Y Q s "* T DELETED DELETED P M
s p R Y Q s T DELETED! P DELETED
s p R Y Q s 4 T DELETED! P DELETED] M
s p R I Y Y 0 s T DELETED P ] P
s p R
Q s T DELETED P j P M
s p R Y Q s T N DELETED DELETED
s p R Y Q s T N DELETED DELETED M
s p 1 1 R ' Y Q s T N DELETED P
s p 1 1 R Y Q s T N DELETED P M
s p 1 1 L_R__L_L_ Y Q s T N P DELETED
s p 1 1 t~~R~l Y Y Q s T N P DELETED __M__J
s s P ! I __R i _| i Y
R ! i i Y _Q
Q 5
s .N J P -P. - i _]

p '■ 1
P 1 !

.N P P M

R I I Y Q G s DELETED DELETED DELETED
o~l
•*> n; i i r R Y Q G __JLJ DELETED DELETED DELETED M
s p i i R Y Q G s DELETED p€LETED| P
s p 1 i R Y 0 G s DELETED DELETED P M
s p 1 1 R Y Q G s DELETED P DELETED
s p i i R Y Q G s DELETED P DELETED M
s p i i R Y 0 G s DELETED P P
s p ! i R Y Q G s DELETED P P M
s p R Y Q G s N DELETED DELETED
s p R Y Q G s N DELETED DELETED M
s p R Y Q G s N DELETED P
s p R —!— Y Y 0 G s N DELETED P M
s p 1 R

Q G s N P DELETED
' s p '"R l ! Y Q G s N P DELETED M
s p R I i Y Q G s N P P
s p R Y Q L_G_ s N P P I M '
s p R Y Q G T DELETED DELETED DELETED I
s p R Y Q G T DELETED DELETED DELETED M
s p R Y 0 G T DELETED DELETED P
s p R Y Q G T DELETED DELETED P M
s p R Y Q G T DELETED P DELETED
s p R Y Q G T DELETED P DELETED M
s p R Y Q G T DELETED L p i p
s p R Y Q G T [DELETED p P I M
s p R Y Q G T I N DELETED DELETED I
s F R Y 0 G T ! N DELETED DELETED M
s p R Y Q G T I N [DELETED P I
1 s p R Y 0 G T I N JDELETED P ! M

S2959vi/iX"

ASTR 013/01 WO

20 25 1 29 31 33 49 55 56 91 94 95 96 107
s p 1 1 L_R Y Q G T N P DELETED
s p R^ 1 Y Q G T N P DELETED M
s p j I R Y Q G T N P P
s p j i R Y 0 G T N P P M
s P ! 1 1 R Y V S S DELETED DELETED DELETED
s P | 1 ! R 1 1 Y V S S DELETED DELETED DELETED M
s P ! 1 j R 1 ! Y v s s DELETED DELETED P
s , P 1 1 j R 1 I Y V s s DELETED DELETED P M
s P R " 7■" Y V s s DELETED P DELETED M
s P R Y V s s DELETED P DELETED

s P R Y V s s DELETED P P
s P R Y V s s DELETED P P M
s P R Y V s s N DELETED DELETED
s P R Y V s s N DELETED DELETED M
s P 1 R Y V s s N DELETED P
s P _ ' R _i .J - Y V s s N DELETED P M
s P R^ i ' Y v ! s v T s s N P P DELETED
s
1 i R

s N
DELETED P M I
s P ■ I ! R 1 ! Y V s s N P
! i
s P 1 R Y V s s N P P M
s P R Y V s T DELETED DELETED DELETED
s P R Y V s T DELETED DELETED DELETED M
s P R Y V s T DELETED DELETED P
s P j R Y V s T DELETED DELETED P M
s P R Y V s T DELETED P DELETED
s P i i R Y V s T DELETED P DELETED M
s P 1 1 R Y V *s T DELETED P P
s P R Y V s T DELETED P P M
s P R l_Y__ V s T N DELETED DELETED
s P R 1 Y V s T N DELETED DELETED M
s P R 1 ! Y V s T N DELETED P
s P R 1 i Y V s T N DELETED P M
s P R 1 | Y V s T I N -4 P „ DELETED
s P R i i Y V s T N I P DELETED M
s P R 1 1 Y V 3 T N P P
s P R 1 ! Y V s T N P P M
s P R t | Y V G S DELETED DELETEDiDELETED
s P R t i Y V G S DELETED DELETED DELETED M
s P R Y V G s DELETED DELETED P
s P R Y V G s DELETED DELETED* P M
s P R Y V G s DELETED p IDELETED
s P R Y V G s DELETED p DELETED M
! s P R i i Y V G s DELETED p P
1 s P R 1 | Y v G s DELETED p P M
f s P R 1 ! Y v G s N DELETED DELETED I
1 s . P_J ' R 1 '■ Y V G s N DELETED DELETED M

5259*1,'Of

ASTR 013/01 WO

20 1 25 29 31 I 33 49 55 56 91 ! 94 95 1 96 107
s .p - 1 R | i Y 1 V G 1 S N DELETED' P

p R j: r. Y 1 V G S | W DELETED P ■Vi
S j P R Y V G S I N P (DELETED
S 1 P R \ I Y_j V G S | N P DELETED M
S ! P R _| I Y V , G S j N I P P | 1
c p R j Y ! V "] G -t £ N P P i (vi 1
1 § p R Y | V G T DELETF.oioELETED DELETED 1 J
s^ p R Y V G T jDELETEDJDELETED DELETED M
G 1 p R Y V G T IDELETEDIDELETED P
s p R Y V G T DELETED DELETED P M
s p R Y V G T DELETED P DELETED
s p R Y v G T DELETED P DELETED M
s p R Y V G T DELETED P P
s p R Y V G T DELETED P P M
s p R Y V G ' T N DELETED DELETED
s p R Y V G T N DELETED DELETED M
1 S p i i R ' »"] Y" V G T N DELETED) P , l
1 s p ' 1 R i i Y V 3 r N. . DELETED P M !
1 S p j-J_' R Y V G T N P DELETED DELETED i i
i s p R Y V G T N P
M
1 s p R Y V G T N P P
1 S p R Y V G T N P P ^ rM
s p R H Q 1 S S- DELETED DELETED DELETED
s p R H Q j S S DELETED DELETED DELETED M
s p R H Q ] S S DELETED DELETED P
I S p R H Q { S S DELETED DELETED P M
1 s p R H Q S i S DELETED P DELETED
L5^ p R H Q 1 S ! S DELETED P DELETED M
i s p R H Q 1 S | S DELETED P P
s p R H Q j S j S DELETED U p M
i S p R 1 H Q 1 S ! S N DELETEDlDELETED
s p R I i H Q S S N DELETE D'DELETED M 1
s p R I ! H Q s S N DELETED! P i
s p H H Q s S N DELETED! P M
s p R H Q s s N p IDELETED
s p R H Q s s N P JDELETED M
s p R H Q s s N P P
s p R H Q s s N P P M
s p R H Q s T DELETEDIDELETED DELETED
s" p R H Q s T DELETED (DELETED DELETED M
s p R H Q s T DELETED DELETED P
s p R H 0 s T DELETED DELETED P M
s p j 1 R ' jJL Q s T DELETED! P JDELETED
s p R 1 j H Q s T DELETED! P [DELETED M
i s i p R _J±_i ° S ! T DELETED! P i P
! s i p j i R ! I ~H , Q s T DELETED ! p 1 P M

A&Tit(H3/0l WO

2G 25 [ 29 , 31 33 f 49 55 56 91 94 «^ 96 , 107 i
s p T i-1 R -I I [ H Q s T N DELETED DELETED! I
s p 1 1 R I j H Q s T N DELETED DELETED M
s p R ' L"-, Q s T N DELETED P I !
o p R i TH Q s T N DELETED P ! M
H- p R 1 ! H Q s T N P DELETED! I

p R l ! H Q s T N P DELETED! M
s p R 1 | H Q s T N P P i I
s p ■ R 1 ! H Q s T N P P ( M
s p R H Q G S DELETED DELETED DELETED) _J___|
s p R H Q G S DELETED DELETED DELETED M
s p R H Q G s DELETED DELETED P i
s p * R 1 H Q G s DELETED DELETED P M
s p R 1 ! H Q G s DELETED P. DELETED I
s p R 1 I H Q G s DELETED p !DELETED M
s p R 1 H 0 G s DELETED p I p I
s p R H Q G s DELETED p _J P
DELETED M j
1 S p _ R
I R | s
0 G _
6""1 _s_„
s
—$- N TJELETED
t i
1 S
i s p
p-
p

H Q Q

N 4DELETED|DELETED N DELETED P M !
'■ s
[ ' R 1 H r Q G s N DELETED, P 1 M !
: s p 1 R , H Q G s N P "^ DELETED I
s p 1 R H 0 G s _, N p DELETED M
s p 1 R H 0 G s N n p P I
r* s p 1 r R H 0 G s N p P M
: s p 1 R H Q G T DELETED DELETED DELETED I
! s p 1 R _H_j Q G T DELETED DELETED DELETED M
) s p \ R H Q G T DELETED DELETED P I—!—
s p' R H Q G T OELETED DELETED P M
s p R H Q G T DELETED P DELETED I
s p R H Q G T DELETED P DELETED M
s p R H Q G T DELETED P P I
s p R H 0 G T DELETED P P M
s p R H Q G T N DELETED DELETED I
s p R H Q G T N DELETED DELETED M
s p R H Q G T N DELETED P t
s p R H . Q G T N DELETED P M
i s p R H Q G T N P DELETED I
s p R H Q G T N P DELETED M
s p R H Q G T N P P I
1 s ■p R H Q G T N P P M
1 S p R H V S S DELETED DELETED DELETED L ' J
s p I™T~R~" H V S s DELETED DELETED DELATED DELETED L M
s p i i i R 1 I H V s s DELETED
P I
s p i i R _±_l H V s s IDELETED DELETED J p~ i_M s P j 1 R 1 ! H V s s DELETED P DELETED \ i
s P } 1 1 R 1 ! H V s s DELETED P DELETED M

529S*)vl/OC

ASTR 013/01 WO

20 25 29 I 31 33 49 55 56 91 94 95 96 107 (
S p i R H V s S DELETED P P I !
S p 1 .. I J_ R H V s s DELETED P P M I
s P ! 1 j R H V s s N DELETED DELETED] i !
s P ! 1 R H V S _j 3 N DELETED DELETED M i
s p I 1 R j H V s s N DELETED P I I
s P ! 1 R H V s s N DELETED) P I M
s P ! l R H V s s N P DELETED i !
s p 1 1 R I H V s s N P DELETED M i
s p i i -R I I H v-1 s s N P P I
s p 1 1 R H V s s N P P M
s p i i R i i H V s T DELETED DELETED DELETED I
s p i i R I I H v s T DELETED DELETED DELETED M
s p j 1 R I I H V s T DELETED DELETED P I
1 s p ! i I R H v s T DELETED DELETED
D P DELETED1 M [
r s P j 1 | R . 1 j H j v s T DELETED

1 s p ! i R j I I H . V s T DELETED P DELETED M
i S p
l_JL_« L-..R_Lj.„i_._li„
R ! I _, H V g T DELETEDI P P
..l.p_r_
DELETED I
i
! s

V s s T DELETED P
OELETED

( s -1

T N

i s p R r , H V s T N DELETED DELETED M
! s p R H V s T N DELETED P I
i S , p R H V s T N DELETED P M
s p R H V 1 s T N P DELETED !
s p R H' V s T N P DELETED M
! s F ,R_ H V s T N P P I
1 s P R H V s T N P P M I
I s P 1 R H V G S DELETED DELETED DELETED 1
s p ! i R H V G S DELETED DELETED DELETED M
i s "~p~i i R H V G s DELETED DELETED P 1
s p R H V G s DELETED DELETED P M
s p R H V G s DELETED P DELETED »
! s p R H V G s DELETED P DELETED M
! s p R H V G s OELETED P P 1
! S p R H V G s DELETED) P ! P M
j s p R H V G s N DELETEDJDELETED 1
1 s p R •I ! H V G s . N DELETED DELETED . M
s p R l I H V G s N DELETED P 1
s p R I j H V G s N DELETED P M
1 s p R , H V G s N P DELETED 1
1 s p R I ... H V G s N P DELETED M
1 s p __*J I ! H V G s N P P 1
1 s p R I I H V i G s N P P M
s p R t f H V G T DELETED DELETED DELETED 1
s i p i I R kiTH V i G T DELETED DELETED DELETED M
■' S rrr i' i R_ I I H i v G T DELETED DELETED p 1
1 s __p_. R I I H V G T DELETED DELETED P 1 M

S2SS5 vI/HC

ASH R 013/01 WQ

20 T 25 29 | 31 33 49 55 56 91 94 | 95 96 107
^ s p 1 1 R ] H V G T DELETED! P DELETED I
s p 1 1 R 1 ' i H V G T DELETEDj P DELETED M
s p ! i R i ! H V cT^ T DELETEDj P p ! t
s p 1 1 1 R j 1
1 H V \J T DELETED! P p i M
s p ' f R 1 ; H V G T N ! DELETED DELETED DELETED!
s ^ p [ DELETED] M
C; p i R i ! H j V G T N JDELETED . .p i
\ s p i i R i 1 H i V G T N IDELETED p 1 M
.• s p i j R I H 1
1\ V "* G T N P DELETED]
■ s p R 1
V G T N P DELETED M
' s p R [ H V G T N
N P p . 1 s p R 1 H V G T
P p M
i S "p F S L Y Q S S DELETEDj DELETED DELETED
! s p F S L Y Q S s DELETED DELETED DELETED M
I s p F S L Y Q s s DELETED DELETED p
1 s p J F S L ~^r\ Q s s DELETED DELETED p M
i Q p ' f __S_, S ' !_
L j Y 1 0 s s DELETED .__ P_ [p_ELE_TE.D
f S

Y | Q S 1 s DELETED1 P (DELETEDJ M 1
f s p 1 F 1 s L 1 _Ht Q s ( s -1- DELETEDj P ! P j
* s I p F s L V 1 Q

PHA-HIED P \ P ' . Wi
s p F s L Y"1 Q s s N n DELETED DELETED
s 1 p F s L Y 0 s s N DELETED DELETED DELETED M
r s p F s L Y Q s s N
p
3 p F s I L_Y Q s s N N DELETED p M
s L_P F s L Y Q s s
P DELETED
s P F s L , Y Q s s N P (DELETED M i
i p F s L " L-JL_ Q s s 1-N P p
i s p F s 1 L Y Q s s ] N j P.J P I M "*
s p F s ! L Y Q "S T D'ELETEDDELETEDIDELETED
!Hs p F s L Y Q s T DELETEDPELETED DELETED M
I S p i F s L Y Q s T DELETEDlDELETEO j P
s p 1 p s L ' Y Q 1 S T DELETEDIDELETEO P M
CI§__ p ! F s
, Y 0 LJL T DELETED[_ P DELETED' P DELETED] P DELETED
L_S p t F s L 1 Y 0 i s T
DELETED M
s p ! F s L Y Q s T
P
s p j F s L Y Q s T DELETED P P M
s p ! F s L L Y Q s T N DELETED DELETED
s p ) F s L Y Q s T N DELETED DELETED M
1 s p I F s L Y Q s T N DELETED P
1 s p ! F s L Y Q s T N DELETED P M
i s p L F ! F s L Y Q s T N P - DELETED
1 S p
1 s ' i Y 0 s T N P DELETED M
1 s p ! F ! s | L Y Q s i T N 1 P P '
i s p ! F ( S f L Y Q s T DELETED P ! P M
! S p i F i s ', L Y Q G S
DELETEDJDELETED 1
! s p i F 1 s i L Y Q G s DELETED DELETED|DELETED M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
s p F S L Y Q G S DELETED DELETED P i
s p F S L Y Q G s \ DELETED DELETED P—I M
s p F S L Y Q G s DELETED P DELETED I !
s p F S L Y Q G _J s DELETED P DELETED M I
s p F S i_ Y Q G I S JDELETED „_p !_p I I
s p F i S L Y Q ! G | S DELETED p i p M I
s p F I S L Y Q i G I S N DELETED DELETED i j
s p F f S 1 L Y Q I G s N DELETED DELETED M
s p F S L Y Q G s N DELETED P :- t
s p F s L Y Q G s N DELETED P I M
s p F s L Y Q G s N P DELETED 1
s p F s L Y Q G s N P DELETED M
s p F s L Y Q G j S N P P 1
s p F s L Y Q G i S N ! P P M
I S p F s L Y Q G | T DELETEDJDELETED DELETED E
■ s P F s L Y 0 G ! T DELETED|DELETED!DELETED M
3 p F F S i L Y Q i G i T DELETED DELETED P i :
: s p
S ! L Y Q I G T DELETED DELETED P P M
' S p F S L Y Q G T DELETED
DELETED! I
s p F s L Y Q G T DELETED P DELETED M
s p F ' s L Y Q G T DELETED P. P 1
s p F s L Y Q G T DELETED P P M
s p F s L Y Q G T N DELETED DELETED f
s p F s L Y Q G T N DELETED DELETED M :
s p F s L Y Q G T N DELETED P i :
s p F s L Y Q G T N DELETED P M ,
s p F s L Y Q G T N P DELETED 1
s p F s L Y Q G T N p DELETED M
s p F s L Y Q G T N P P P 1
s p F s L Y Q G T N
P i M
s p F s L Y V S S DELETED DELETED DELETED )
s p F s L Y V S S DELETED DELETED DELETED M
s p ■ F s L Y v | s s DELETED DELETED DELETED DELETED! P 1
s p F s L Y V S s
DELETED P M
s p F s L Y V S s
p DELETED 1
s p F s L Y V S s DELETED p DELETED M
s p F s L Y V S s DELETED P P 1
s p F s L Y V S s DELETED P. P M
s p F s L Y V S s N DELETED DELETED 1
s p F s L Y V S s N DELETED DELETED M
s P 1 F s L Y V S s ! N DELETED P i I
s p i F s L Y V S s M DELETEp P P M
s P ! F s L Y V S s N
DELETED 1
s p ; F s I Y V S s N P DELETED M
s P ! F J S L Y V S s N P P 1
s p F ! S L Y V s s _ _N ... P P M
;29.s
ASTR013AM WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S p F S L Y v s T DELETED DELETED DELETED
S p F S L Y V s T DELETED! DELETED DELETED M
S p F S L Y V s T DELETED DELETED P
S p F S i Y V s T DELETE!? DELETED P M
s p F s L Y V s T DELETED P DELETED
f~ s p F s L Y V s T DELETED P DELETED M
s p F s L Y V s T DELETED P P
s p F s L Y V s T DELETED P P M
s p F s i
L_ Y V s T N DELETED DELETED
s p F s L Y V s T N DELETED DELETED M
s p F s L Y V s T N DELETED P
s p F s L Y V s T N DELETED P M
s p F s L Y V s T N P DELETED
s p F s L Y V s T N P DELETED M
s p F s L Y V s T N P P
s p F s L Y V S j T N P P M
s p F s s L Y V G S DELETEDDELETED DELETED
s p F

Y V G S DELETED DELETEDDELETED M
s p F s L Y V G S DELETED DELETED P
s p F s L Y V G S DELETED DELETED P M
s p F s L Y V G s DELETED P DELETED
s p F s L Y V G s DELETED P DELETED M
s p F s L Y V G s DELETED P P
s p F s L Y V G s DELETED P P M
s p F s L Y V G s N DELETED DELETED
s p F s L Y V G s N DELETED DELETED M
s p F s L Y V G s N DELETED P
s p F s L Y V - G s N DELETED P M
s p F s L Y V" G s N P DELETED
s p F s L Y V G s N P DELETED M
s p F s L Y V G s N P P
s p F s L Y V G s N P P M
s p F s L Y V G T DELETED DELETED DELETED
s p F s L Y V G T DELETED DELETED DELETED M
s p F s L Y V G T DELETED DELETED P 1
s p F s L Y V G T DELETED DELETED P M
s p F s L Y V G T DELETED P DELETED
s p F s L Y V G T DELETED P DELETED M
s p F s L Y V G ' T DELETED P P
s p F s L Y V G T DELETED P P M
s p F s L Y V G T N DELETED DELETED
s p F s L Y V G T N DELETED DELETED M
s p F s L Y V G T N DELETED P 1
s p F s L Y V G T N DELETED P M
s p F s L Y V G T L.._N . p DELETED
s p F s L V r v G T : N P DELETED M

52'j.v.' vi/nr

ASTR 013/01 WO

20 25 29 31 33 ! 49 55 56 91 94 95 96 107
S p F S L Y V G T N P P
s p J F S L J Y V G T N P P W __j
s p F s L ! H G S S DELETED DELETED DELETED
5 p F s L ! H Q S s DELETED DELETED DELETED M
s p F s L H Q S s DELETED DELETED P
s p F s L : H Q s s DELETED DELETED P M
s p F S L i H Q s s DELETED P DELETED
s p F S L H Q s s DELETED P DELETED M
s P F S L H 0 s s DELETED P P
s p F s L H 0 s s DELETED P P M
s p F s L H Q s s N [DELETED DELETED
s p F 3 L H Q s s N (DELETED DELETED M
s p F S L H Q s s N DELETED P
s p F s L H Q s s N DELETED P M
s p F s L H Q s s -N P DELETED
s p F S L H 0 I S s N P DELETED M
S P L F S [_ H 0 s s N p P
s p F , S L H' Q s S N
P M
s P \ F s L H Q s T DELETED DELETED DELETED |
s p F s L H Q s T DELETED DELETED DELETED M
s p F s L H Q s T DELETED DELETED P
s p F s L H Q s T DELETED DELETED P M
s p F s L H Q s T 'DELETED P DELETED
s p F s L H Q s T IDELETED P DELETED! M
s p F s L H Q s T JDELETED P P
s p F s L H Q s T DELETED P P M
L_s p F s ! L H Q s T N iDELETED DELETED
s p F | S i L H Q s T N DELETED DELETED M
1 S ! P i F S L H Q s T N DELETEDF P M
S I P F s L H Q . s T
P iDELETED
s ! p F s L H 0 s T N P DELETEDI __M
s p F s L H Q s T N P
N I P P

s p F s L H Q s T
P M
s p F s L H Q G S DELETEDiDELETED DELETED
s p F s L H Q G s DELETED DELETED DELETED M
s p F s L H 0 G S DELETED DELETED P
s p F s L H Q G S DELETED DELETED P M
s p F s L ! H Q G s DELETED P DELETED
g p F s L I H Q G s DELETED P DELETED M
s p F s L I H Q G s DELETED P P I I
s p F s L i H Q G s DELETED P P M
s p F s L H Q G s N N DELETED DELETED
s P F s L H a G s
DELETED DELETED DELETED! M
s P | F s L H Q G s N
P
s P ! F s L H Q G s ■DELETED P M

AS'rii on/OS wo

20 25 29 31 33 49 55 56 91 94 95 96 107
S p F S L H 0 G s N P DELETED I
S p F S L H 0 G s N p ~~! DELETED M
s p F s I H J 0 G s N p P I
s p F s ! H 0 G s N P P M
s p F s L H Q G T DELETED DELETED DELETED I
s p F s L H Q G T DELETED DELETED DELETED M
s p F s I H Q G T DELETED DELETED P I
s p F s L - H 0 G T DELETED DELETED P P M
s , p F s 1_ H Q G T DELETED
DELETED 1
s p F s L H Q G T DELETED P DELETED M
s p F s L H Q G T DELETED p P 1 1
s p F s L H Q G T DELETED P P M
s p F s L H Q G T N DELETED DELETED 1
s p F s L H Q G T N DELETED DELETED DELETED M
s p F s L H Q G T N
P 1
; s p F F F s L
_ _.L
L H 0 G j T N DELETED P M
rl- p
p
s
_JL_„ s
_ H
H H 0 G i N ! P N ! P DELETED
DELETED
P 1

G

M
1
1 ^-
F

^"Q G ' N P

1 s p F s L H Q G T N P P M
1 s p F s L H V S S DELETED DELETED DELETED 1
s p l F s L H V S S DF.LETEDIDELFTED DELETED M
s p F s L H V s S ' DELETED (DELETED P 1
s p F s L H V s s [DELETED DELETED P M
s p F s L H V s s DELETED DELETED P DELETED 1
s p F s L H V s s
P DELETED M
s p F s L H V s s DELETED P P {
s p F s L H V 3 s DELETED P P M
s p F s L H V S s N DELETED DELETED 1
s p F s L _, H V s s N DELETED DELETED M
| S p F s L H V s s _..M N DELETED P 1
! s p r s L H V s s
DELETED P M
1 s p F s i H V s 3 N I P
N I P ' DELETED 1
s p F s L H V . s s
DELETED M
s p F I S L H V s s N P P 1
s p F s L H V s s N P P M
s p F s L H V s T DELETED DELETED DELETED i
s p F s L H V s T DELETED DELETED DELETED DELETED M
s p F s L H V s T
DELETED P 1
s p F s L H V s T DELETED DELETED ' P M
s p F s L H V s T DELETED DELETED P DELETED 1
s p F s L H V s T
P DELETED M
s p F s L , H V s T DELETED P P 1
s p F s l_ H V s T DELETED p P M
s p F s L H V s T N DELETED DELETED 1
s p F s L H V s T U DELETED DELETED M

53959'-■].'!)(•

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 | 95 96 107
S p F S L H V S T N iDELETED P
s p F s L H V S T N DELETED P M
s p F s L H V S T N P DELETED
s p F s L H V S T N P DELETED M
s p F s L H V s J T N P P
s p F s L H V s T N P P M I
s p F S ■ L H V G S DELETED DELETED DELETED
s~1 p F s L H V G S DELETED DELETED DELETED M
s p F s L H V G S DELETED DELETED P
s p F s L H V G s DELETED DELETED P M
s p F s L H V G s DELETED P DELETED I
s p F s L H V G s DELETED P DELETED M
s p F s L H V G s DELETED P P
s p F s L H V G s DELETED P P M
s p F s L H V G s N DELETED DELETED
s p F 3 L H V G s u— N DELETED DELETED M |
s p F
F ____§ !_ L H V G s N DELETED P M
s p

__JH
H V G s N DELETED P

s p F s L
V G s N ! P DELETED
s p^ F s i
L- H V G s N P DELETED M
s p F s L H V G s H P P
s p F s L H V G s N P P M
i s p F s L H V G T DELETEDJDELETEDIDELETED i
; S p F s L H V G T DELETEDlDELETED DELETED M
s p . F s L H V G T DELETED;DELETED P
i S p F s L H V ' G T DELETED DELETED P M
s p F s L H V G T DELETED P DELETED
s p F s L H V G T„ DELETED P DELETED ■M :
s p p s L ^H V G T DELETED P j P ■
s p F s L H V G T DELETED P P M
s p F s L H V G T N DELETED DELETED
5 p F s L H v G T N DELETED DELETED M
s p F s L H V G T N DELETED P
s p F s L H V. G T N DELETED P M
s p F s L H v. G T N N P DELETED
s p F s L H V G T
P DELETED M
s p F s L H V G T N P P
s p F s L H V G T N P P M
s p F s Y 0 S S DELETED DELETED DELETED
s p F s Y 0 s ■ S ^DELETED DELETED DELETED M
s p F s Y Q S s DELETED DELETED P
s p F s Y Q S s DELETED DELETED P M
s p F s Y Q S s DELATED P DELETED
s p F s Y Q S s DELETED P DELETED M
5 p F s Y O S s DELETED; P P
i s p F s Y Q s s DELETED P_.._ P M

stwjvuiic

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S p F S Y 0 S S j N iDELETED DELETED I
s p F _JL_J Y Q S S N JDELETED DELETED M
' s p F s Y Q S S N N DELETED P I !
s p F s i i Y 0 S s
DELETED __P, M
s p F S h ' Y Q S s N N P DELETED I
s p F s Y Q S s
P DELETED M
s p F s Y Q S s M P P ]
s p F LJL Y Q s s I N P P j
M
s p F s Y Q s T (DELETED DELETED DELETED I
s P ! F s V -I Q s T DELETED DELETED DELETED M
s p F s Y ~1 Q s T DELETED DELETED P I
s p F ■ s Y Q s T DELETED DELETED P M
s p F s Y Q s T DELETED P DELETED I
s p F s Y Q s T DELETED P DELETED M
s p F s Y Q s T DELETED P P I
s p F s Y 0 S i T DELETED P P M
s p_ F j S i 1 Y 0 S i N DELETED DELETED I
1 s p F s Y Q s T M _
N
N DELETEDlDELETED M
s P ■ F s Y Q s T
DELETED[_ P I
s P F s I Y Q s T
DELETRDi P M
s __PI F s Y Q s T
P DELETED I
s P F s Y Q s T N P DELETED M
s P F s Y Q s T N P P I
s P F s Y Q s T N P P M
s P F s Y Q G S DELETED DELETED DELETED I
s P F s Y Q G S DELETF.n DELETED DELETED M »
s P F s Y Q G s DELETED DELETED P I
s P i F s Y Q G s DELETED DELETED P M
s p F i S Y Q G s DELETED P DELETED I
s p F s Y Q G s DELETED P DELETED! M
s p F s I Y Q G s DELETED, DELETED P P I
, s p F S ! I i Y Q G s
P P M
s p F ! s Y Q G s N DELETED DELETED I
s p F s Y Q G s N DELETED DELETED M
s p F s Y Q G s N DELETED P i
s p F s Y Q G s N DELETED P M
s p F - s Y Q G s N P DELETED I
s p F s Y Q G s N P DELETED M
s p F s Y Q G s P P I
s p F s Y 0 G s
P P M
s ■ p F s Y Q G T DELETED DELETED DELETED I
i s p F s Y Q G ! T DELETED DELETED DELETED M
s p—i F s Y a G I T OGLU.TEO OELETEO P f
s p F S J i Y G G T DELETED DELETED P M
s P , F s Y Q G T DELETED! P DELETED ]
s P j F s Y Q G T DELETED P DELETEDi M
■^

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 | 95 ! 96 107
s p F S Y Q G T DELETED! P l p I
s p F s Y Q G T DELETED P P M
s p F s Y Q G T N DELETED DELETED
s p F s I ! Y 0 G T N ' DELETED DELETED M
S J p F s I Y Q G T N DELETED P [ !
s p F s Y Q G T N DELETED P M 1
s p F s I | Y Q G T N P DELETED
s p F s i : Y Q G i T N P DELETED M
s p F s~i Y Q G T N P P
s p F s Y Q G T N P P M
s p F s Y V S S DELETED DELETED DELETED
s p F s Y V s S DELETED DELETED DELETED M
s p F s Y V s s DELETED DELETED P
s p F s Y V s s DELETED DELETED P M
s p F s I i Y V s s DELETED DELETED P DELETED
s p F s I ' Y V s s
P DELETED M
; s p c s Y Y V V s
s s s DELETED' P P
P

s p
s

DELI/TED P
M
s p p s V V s s N DELETEDIDELETED
s p F s Y V s s N
N DELETED DELETED M
s p F s Y V s s
DELETED P
s p F s Y V s s tt iOELETED P M
s p F s Y V s s K
N P DELETED
s p F s Y V s s
P DELETED M
s p F s Y V s s W P P
s p F is Y V s s N P P M
s p F s L Y V s T DELETED DELETED DELETED DELETED I i
p F S i I Y V s T
DELETED DELETED M
s p F s Y V s T DELETEDJDELETED P
s p F s Y V s T DELETED DELETED P M
s p F s I Y V s T DELETED P DELETED
s p F s I Y V s T DELETED; P DELETED M ""
s p F s I ; Y V s T DELETED' P P
s p F s Y V s T DFI..FTED P P M
s p F s Y V s T N DELETED DELETED
s p F s Y V s T N DELETED DELETED M
s p F s Y V s T N DELETED P
s p F s Y V s T N DELETED P P M
s p F s Y V s T N
DELETED
I s p F s I Y V s T N P DELETED M
s p F s Y V s T N ! P N | P P
s p F s Y V s T
P M
s p F s Y v G S DELETEDIDELETED DELETED
s p F s Y V G s DELETED DF.LETED DELETED DELETED M
S : p F S I ! Y V G s
{DELETED P
s p F s i i Y V G s DELETEDIDELETED P M

5?59v|:r)C

ASTRO 13/0J WO

20
S 25 29 31 33 ! 49 55 56 91 94 95 j 96 107

p F s ~n Y " V G s DELETED P DELETED i
s p F
I ! Y V G ' s DELETED P DELETED M
s p F s I Y V G s DELETED P P I
„_s._._ s p F s Y V G s DELETED P I P M

p F s Y V G s . N DELETEDjDELETED i
£ p F s Y V G s N DELETED DELETED M
s p__j F s Y V G s N DELETED P I
s p F s I \ Y V G s N DELETED P M !
s P F s I Y V G s N P P DELETED I
s p F s Y V G s N
DELETED M
s p F s Y V G s N P P 'I
s p F s Y V G s N P P M
s p F s Y V G T DELETED DELETED DELETED [
s p F s Y v G T DELETED DELETED DELETED M
s p F s Y V G T DELETED DELETED DELETED P I
s p F s Y V G T DELETED
P M
s p F s V V G T DELETED P P DELETED I I
s p F
F s ._ i Y V G T DELATED
DELETED M
s p
s Y V G T DELETED
P I
s p F s Y V G T DELETED P P M
s p F s I ! Y V G T N DELETED DELETED I
s p F s i : Y V G J T N N DELETED DELETED M J
s p F s Y V G T
DELETED P P I
s p F s Y V G T _ _N
N DELETED
M
s p F s Y V G T
P DELETED I
s p F s Y V G T _N P DELETED M 1
s p 1 'p s ' _r . V G T
P P {
s p F s Y V ■ G T N P P M
s p- F s H Q S S DELETED DELETED DELETED I
s p F s i H Q S s DELETED DELETED DELETED ■M
s p F s H Q s s DELETED DELETED DELETED P I
s p c s H Q s s DELETED
P M
s p F s H Q s s DELETED! P DELETED I
s p __F| s H Q s " s DELETED P DELETED M
s p F s H Q s s DELETED P P I
s - p F s H Q s s DELETED P P M
s p F s H Q s s N DELETEDIDELETED I
s p F s H Q s s N DELETED DELETED M
s p F - s H Q s s N IDELETED P I
s p F s H Q s s N DELETED P M
s p F s H Q s s - N P DELETED i
s p F s H Q s s N P DELETED M
s p F s H Q s s _.__N
N P P I
s p F s H 0 s 3
P DELETED P V,
s p p F s H Q s T DELETED
DELETED !
s
F s i | H Q s T DELETED; DELETED DELETED M
S295l> v|/i)C

ASTR 013/01 WO

20 25 29 31 I 33 49 55 56 91 S4 | 95 96 107~'
S p F S j J j W 0 S T DELETED)DELETED P ■ > 1
S p F S | I ! H Q s T DELETED DELETED DELETED P M |
s s s p F , S_ ! I H Q s T
P DELETED] ! 1

P ! F S „L_U^ 0 s T DELETED P DELETED M |

p F s \ ! H 0 s T DELETED DELETED
, P_ -I
■ i i i
s p F 5 \ ' H Q s T
...P P M
s p F S i ! H Q s T N DELETED DELETED
s p F S I I H 0 s T N DELETED DELETED h-M
s p F s" ] i ■ H Q s T . " DELETED! P
s p F s H Q s T N
H DELETED P L w ,
s p r s H Q s T
P DELETED
s p F s H Q s T N P DELETED M
s p F s i H Q s T N i p P
s p F S i I H Q s T N P P M
s p F s ! i H 0 G S DELETED DELETED DELETED
s p F s ; i H Q G s DELETED DELETEDiDELETED M
s p F F s H Q G s DELETED DELETED! P M
s p
__s„_
" s I I H Q G s s DELETED ■DELETED P

1 s p F
] i H 0 G
DELETED. p
DELETED! P DELETED
s p F s H 0 G s
DELETED M
s p F s H Q G s DELETED p P
S , p F s H Q s DELETED! P P M
L s„i p F s I j H 0 G s N ^DELETED DELETED i j
f s_n p F s I I H Q G_J s r-,i DELETED DELETED M
s p F s I i H Q G s N DELETED P
s p F s I ! H Q J G s N DELETED P M
s p F s i i H 0 G s N D DELETED
s p F S j I H Q G s -M P DELETED M
s p F S ! H Q G s N P P
s p F S I I H Q G s
P P M
s p F S I Ft 0 G T DELETEDiDELETED DELETED
s p F S ! ! i H Q G T DELETED DELETED DELETED M ■
s p F s ! H 0 G T DELETED DELETED DELETED P
s ,p_ F s H Q G T
DELETED P M
s p F s H Q G T DELETED . P DELETED
s p F s H Q G T DELETED! p DELETED M
s p F s H 0 G T DELETED P P
s p F s H Q G T DELETED P P M
s p F s H Q G T r"j DELETEDiDELETED
s p F s H Q G T N DELETEDiDELETED M
s p F s > . H Q G T N DELETED DELETED P
s p F S i I j H Q G T N
P M
s —£L_i F S I | H 0 G T N p N P DELETED .
s p F s H Q G y
DELETED M
s p F s H Q G T N P P
si p F s H Q G T N P L_ P M

5295!J vl/f>r

ASTfc 013/01 WO

20 25 29 31 33 ! 49 55 56 91 94 95 96 107 1
p F S I H V s S DELETEDiDELETED DELETED

p 1 F s H V s s DELETEDiDELETED DELETED M
SI p F s H V s s DELETED DELETED DELETED P
s p F s H V j s s DELETED
P M
s p F s I H V s s DELETED! P DELETED]
s p r s t ! H V s s DELETED P DELETED M
S _j p F s_ ! ! H V s s DELETED DELETED P P
S_J p F s i ! H V s s
P c M
s p F s—\ H V s s N
N
N DELETED DELETED
s p F s H V 3 s
DELETED DELETED M
s p F s I H V s s
DELETED P
s p F s I i H V s s N N DELETED P M
s p F s ! i i H V s s
P DELETED
s p F s I ! H V s s
__._P
P DELETED M
s p F s t | H V s s N
P
s p F s I ! H V s s N; p P M
s p F
I i H v__
V s s T T CI-i.ETED DF.-LETED DELETEDiDELETED
s p F s

DELETED DELETED DELETED DELETED M !
s p F s i : H V s T DELETED
P I
s p F s I j H V s T DELETED
P M |
s p F s ! H V s T TJELETED P DELETED |
s p F s H V s T DELETED DELETED P DELETED M
s p F s H V s T
P P
s p F s H V s T DELETED P DELETED DELETED P M
s p F s H V s T i'i
DELETED
s p F s H V. s T N
DELETED M ;
s ^ p F ^p I H V s n T N jDELETED P f
s p F
I H V s T N DELETED P P M
_S | p F S ! H V s T N / J
DELETED , :
s p F s I H V s T
P DELETED M
s p F s H V s i

P
s p F s H V s -r
P P M
s p F s H V G s DELETED DELETED DELETED
s p r s I H V VJ s DELETED DELETED DELETED DELETED M
s p F s '• ' I ! H V G s DEL ETED
P
s p F s I ! H V G s DELETED DELETED P M
s p F s I i H V G s DELETED P. DELETED
s p F s I i H V G s DELETED P DELETED M
s p F s H V G s DELETED! P | P
s p F s H V G s DEIETED! P i P M
1 S p F s H V G s \t .DELETED DELETED .
s p F s H V G s N DELETED DELETED M
s p F •s H V G s N
\ • i DELETED P
s p c s I H V G s
DELETED P M
s p F s I 3 DELETED
s p F s H V G s I ,. P DELETED M

s^yj-.-i/ijc

ASTR 013/01 WO

i 20 25 29 . 31 33 49 55 56 91 94 ...__95_
P
P 96 107 !
S p F S H V G s__
s "N
P ,
s p F s H V G
N ■
P M !
s p F s H V G T DELETEDjOELETED DELETED i i
s p F s I H V G T DELETEDiDELETED DELETED M~l
i S p F s H V G T DELETED'DELETED P I I
s p F s H V G T DELETEDiDELETED P M
s p F s H V G T DELETED DELETED P
P
P
P DELETED
s p F s , H V G T

DELETED M
s p F s H v G T DELETED
P
s p F s H V L G T DELETED
P M "1
s p F s H V ' G T N DELETED DELETED
s p F s H V G T N DELETED DELETED M
s p F s H v G T N N DELETED! P
s p F s H v G T
DELETED p P M
s p F s H v G T N
DELETED
s p F s H V G T N P DELETED
v M
s'" p F s I L H V ___G__ T i'.: P

p F s
H V
T DELETEDiDELETED D __M__
s p F R
Y Q S S
DELETED

s p F R L Y Q s s DELETED DELETEDIDELETED M
s p F R __| Y Q 1 s s DELETED DELETED! P
s p F R L L Y Q s s DELETED:DELETE:M P M
s p F R
Y Q s s DELETED P IDELETED
s p F R L Y Q s s DELETED P IDELETED M
' s p F R L Y Q s s DELETED P P
s p F R L Y Q s s DELETED P P M
s p F R L Y 0 s s N DELETE?-DELETE0 DELETED
s 1 p F R L Y Q s s M
DELETED M
s p F R L Y Q s s N [DELETED P
s p F R L Y Q s s N DELETED p P M
5 p F R L Y 0 s s \-
DELETED 1
s p F R L Y 0 s s :■-: '. P DELETED M
s p F R L Y Q s s
P
s p F R L Y 0 s s W F I P M
s p F R L Y Q s T DELETED DELETEL DELETED
s p F R L Y Q s T DELETED DELETED DELETED DELETED M
s p F R L Y Q s T
DELETEC DELETED P
s p F R L Y 0 s T DELETED
! P M
s p F R L Y Q s T DELETED P IDELETED
s p F R L Y Q s T DELETED --~.P__ P DELETED M
s p F | R L Y Q 3 T DELATED DELETED
! P
s p F R L Y Q s T

: P M
s p F R L Y Q s T
DELETE!":[OELETED
s p F R L Y Q s T M (DELETE!" _DELET=:: DELETE:' 'DELETED ( M
s p F R L Y Q s T W
P 1
s p F R L Y Q s T N
P i M

52^' vl/MC

ASTR 013/01 WO

20 25 29 31 33 49 55 56 S 91 94 95
P 96 107
S p F R L L Y Y 0
T N
DELETED
s p F R

Q S T N
DELETED P P P DELETED M
s p F R L Y Q S T

P
s p F R L Y 1 Q e T

P M
3 p F R L Y r~Q G S
DELETED DELETED DELETED
S p F R L
L " Y Q G S DELET£DiQEL£TED
M
S p F R
Y 0 G s DELETEDIDELETEO P
s p F R L Y Q "" G s DELETEDIDELETED P M
s p F R L Y Q G s DELETED! P DELETED
s p F R L Y Q G s DELETED P DELETED M
s p F R L Y Q G s DELETED; P P
s p F R L Y Q G s DELETEDi P P M
s p F R L Y Q G s N DELETED.DELETED
s p F R L Y Q G s N DELETED-DELETED M
s p F R L Y Q G s N DELETED: P
s p F R L Y Q G s __N„ DELETED
■;■ P
M P
N P P M
s p F
F R
R L L Y 0 G s
DELETED
s p

Y Q G s
DELETED M
s p F R L Y Q G s
P
s p F R L Y Q G s K P ! P M
s p F R L Y Q G T DELETED DELETED DELETED DELETED
s p F R L Y Q G T DELETED
DELETED M
s p F R L Y Q G T DELETED DELETED P
s p F R L Y Q G T DELETED'DELETED P M
s p F R L Y Q G T DELETED: P
DELETED1 _P.._. DELETED: ' P DELETED
s p F R L Y Q G T
DELETED M
s p ~" F R L Y Q G T
P
s p F R L Y Q G T DELETED p P M
s p F R L Y Q G T ■_ rj jOELETED
N (DELETED DELETED
s p F R L Y Q G T
DELETED M
s p F R L Y Q G T t-l (DELETED P
5 p F R L Y Q G T s p F R L Y Q G T .'. P DELETED
s p F R L Y Q G T ;-; : p DELETED M
s p F R L Y Q G T N ; P P
s p F R L Y Q G T N P P M
s p F R L Y V S S DELETED DELETED DELETED DELETED DELETED
s p F R L Y V S S DELETED DELETED DELETED
DELETED M
s p F R L Y V S s

P
s. p F R L Y V S s
DELETED P M
s p F
F R L Y V S s DELETED- P DELETED
s p
R I L~ Y V S s DELETED P DELETED M
s p F R L Y V S s DELETED P
P P
s p F R L Y V s s DELETED
P M
s p F R L Y V s s N ;DELETE-: „_M .DELETED DELETED
s p
R L Y V 5 s
DELETED M

I

ASTRO! 3/01 WO

20 25 29 31 33 49 55 56 91 94 DELETED 96 107 I
S 4 p F R L Y V s S
P ! I i
S p F R L Y V V s S
PELETED
_P__
P p _^ M
s p F R L Y
s S N
DELETED
s p _l F R L Y V s S N
DELETE? M !
s p F R
Y V s S N P
P__ DELETED P
p 4
s p F R L Y V s s N

S/i
s p F L—R— L Y V s T DELETED DELETED
DELETED
s p F R L Y V I s T
DELETEDJDELETED M
s p F R L Y V s T DELETED:DELETED DELETED'DELETED P

s p F R L Y V s T
P M
s p F R L Y V s T DELETED P
P P DELETED
s p F R L Y V s T DELETED
DELETED M
s p F R L Y V s T DELETED
P
s p F R L Y V s T DELETED P
DELETED DELETED P M
s p F R L Y V s T N
DELETED
s p c r R L_
L _
"~L Y_
Y
V V s T N
DELETED M
' 5 p r R

V s_ f N .DELETED P I I
1 s -1 p P

M DELETE:"' P M
s p F R
Y V s T N ■ P .-■LLETED
s p F R L Y V s T N P P DELETED M
s p F R L Y V s T N
P
s p F R L Y V s T M P P M
s p F R L Y V G S DELFT EDjCELETED DELETL'p'UELETEn DELETEDJDELETED DELETED
s p F R L Y V G S
DELETED M
s p F R L Y V G s
P
s p F R i_ Y V G s DELETED DELETED P_
P
P
DELETED DELETED DELETED
OELETEL: P M
s p F R L Y V G s DELETED
DELETED,
s s p F • R L Y V G s DELETED
DELETED M

p F R L Y V G s DELETED
P
s p F R L Y V G ■ s DELETED
N
P M
s p F R L Y V G s

DELETED
s p F R L Y V G s N
DELETED M
s p F R L Y V G s N
P I
s p F R L Y V G s M
P M
s p F R L Y V G s N p DELETED
s p F R L Y V G s N P P DELETED M
s p F R L Y V G s N
P
s p F R L Y V G s N p ! p M
s p F R L Y V G T DELETED DELETEDDELETED
s p F R L Y V G T DELETEDlDELETED D^LETEO"DEL_ETE_D DELETED;DELETEr ;DELETED M
s p F R L Y V G T
P
s p F R L Y V G T
p M
s p F R L Y V G T DELETED p
P _ P DELETED |
s p F R L Y V d T jDELETED
DELETED ! M
p
p" f F R R _L_ L Y . Y y
V f T IDEL^TE;:
P

t T !OELETF.O; P P ! M

5291*; vl.'DC"

ASTRO!VOS WO

1- 20 25 29 31 33
L 49 — , ...
55 56 91 94 95 ! 96 l 107 ]
s p F P.
V V G i N JDELETEDbGLETED I
s s
s p r R R
V" L__
L,
L . Y V G T__
T
T
T T N iOELETEDjOELETED
_____N iDELETEpj P.. _
_,J!_ JlLELEJiP; P __j
N j P :DELETED M
t

p F

Y V G

p _J F 1

_Y
Y — _J?_. -G

M !

p__
p F R R

i j

Y V G
N
N N P 'DELETED M j
s—i p F R L L Y V G T
P j P I
s __P_J F R
Y V G ■*•
P . P M
s p _l F R j L H Q S S DELETEDJDELETEDJDCLETED I
s p F R L H Q S s DELATED
DELETED: DELETED'DELETED M
s p F R L H . Q S s
DELETED: P I
s p F R L H Q S s DELETED'DELETED P M
s p F R L H Q S s DELETED] P DELETED I
s p F R L H Q s s DELETED P DELETED M
s p F R L H Q s s DELETEDj P P I
s p F R R _ J.
L
L H
H H Q s
5 s s DELETED P P DELETED HLETED _M__ I
s p F

s

Q s s
DELETED DELETED M
fi p F R
H Q s s
DELETED, P I
s p P _R
R " L H 0 5 j s
DELETED; P M
s p F
L H Q s 1 s r-:_ J p pPLETiP I
s p F R L
L j H H Q s 1 s P Ob'LETEO M ~*
s p F ~~F R R

0 0 s s s
! V
p p -J.....J
s__
s p__
p

1-1

N ' P P
DELETED "ELETED M

F R L H Q s ! T DELF.TED DELETED DELETED
'
s p F R »_ H Q s [ T
DELETEU'DELETED M
s p F R L H Q s s j *>" 1 T
DELETED P I
s p .- F R L H Q

DELETED DELETE!." P M
s p F R L H Q s i T DELETED P DELETED i
s p c R \ H Q s ! T DELETED
DELETED P DELETED M
s s p F R L H Q s ! T
P P I

p F R L H Q s i T DELfTED i N P P M
s p F ■ R L r
H Q s i I
DELETED DELETED !
s p F R L H Q s ! T
DELETED. "ELETED U
s p F R i H Q s I T
DELETED P 1
s p„_ F R L H Q s ! T ! N
!_ N
[ M DELETED P M
s p F R L H Q s I T
P DELETED 1
s p F R L H Q s ! T
P DELETED M
s L_JL_ F R L H Q s 1 T !"' M P P t
s . p ! F R L H Q 8 1 T T" N p ; p M
s p J F R L H Q G s iDEI.ETED ■DELE TEC iOELrTL=D :OELi"TEC .DEU1TEL DELIMHC DELETE:/DELETED !
s p F 1 R L ! H Q G ! s
iDELETEr.OELETEC 1 M
! S p I F j _R
i I\ L
L
i ! H
1 n 0 G 1 S
1 S ■ 3
JDELETED P \ !
i C p i F

Q G_._
G .... ^ _.
i \_3

'DELETED P 4 M
: S I p ! F
; F \ R 1 R

n ^lE'rEL ! P " . ^ELETEC i
i s p

L ! H

M

52i/5
ASTRO 13/01 WO

1 20 25 29 31 33 49 55 56 91 94_
DELETED 95 96 107
S p F R L L H „ H __Q__
Q

Q _J3
G S
P
P PJLETEp DELETED P i
rs p F R R

s DELETED
P M I
s p F
_ L_ i H
G s N
DELETED

s p P R
H Q
s >'i
DELETE"?
P
s p F
H
G s N DELETED

s p h | R L H 0 G s N DELETED P P i
s p F R L H Q G s N
DELETED

s p F R t_ H Q G s N p DELETED M
s p F R L H Q G s N P p I
s p c R L H Q G s N p p M
s p F R L H Q G T DELETED DELETED.DELETED I
s p F R L L H Q G T DELETED DELETEDDELETED M
s p F R L H Q G T DELETED DELETED P I
s p F R L H Q G T DELGTEDIOELETEP P M
s p F R L H Q G T DELETED! P {DELETED I
s p F R L L H Q G T DELATED P _ DELETED M
! S p p R
H ..a
Q G T DEL-TED DELilTED
P P i
s p IT R R L
L H
r
. .P .
M
__s
s p F

H G G T N JDELETEC -ELETED I

p F R L H Q G T N !DELETED:!:ELETED M
s p F R L H Q G T ^_ N OELETED DELETED
__P
P P I
s p F R L H Q G T N M
P M
s p F R L H Q G T

DELETED I
s p F R L__ H 0 T fc - DELETED P M
s p F_, R
H 0 G T ._....P_„_
P
D~ELETEC:
I
s p F
L
L H Q V __G
3 T

F M
s p F R
H

S DELL TED
DELETED I
s p F R L H V S s DELETED DELATED DELETEDiDELETED M
s p F R- L H V S s
DELETEDl P I
s p F R L H V s 's DELETED DELETED P P.. M
s p F R L H V s s DELETED
DELETED I
s p F R L H V s s DELETED P DELETED M
s p F R L H V s s DELETED
P I
s p F R L H V s s DEU.HTCiD
P M
s p F R L H V s s *'-! DELETED DELETED I
s p ■ F R L H V s s N DELETED DELETED
DELETE/-' P DELETED M
s p F R L H V s s N
P i
s p F R L H V s s N
P M
s J p F R L H V s s N
DELETED I
s p F R L H V 5 s N P DELETED P M
i s , p F R L H V s s -j P
J
S_J p F R i- H V s s DELETED DELETED P M
s p F R L H V 3 T
DELETED I
s p c R
H V s T DE!. =TEC DELETED DELETED DELETE" CELETEJJ P M
I s p F R L H H V s T DEl.FTF.r;

I
s p F R t_
V s T DELETED
P M

S2';S
ASTRO\3A)i WO

20 25 29 31 33 49 55 56 91 94 | 95 96 107
S p F R L _H
H V s T DELETED P DELETED I
s p F R

S j T DELETED p DELETED I
s~1 p F R _k__ L H H V V s s T. DELETED! P ' p

s p F R

T DELETED P
DELETED DELETED P

s P F R L H V s T N
DELETED I
s p F R L H V
T N
DELETED M
s p F R L H V s T N DELETED P I
s p F R L H V s T N DELETED P P M
s p F R L H V s T N
DELETED I
s p F R L H v s T N p DELETED M
s p F R L H V s T N P | P I
s p F R L H V s T N P P M
s p F R L H V G S DELETED DELETED DELETED I
s p F R L H V G S DELETED DELETED DELETED M
s p F R L H V G s DELETED DELETED P i
S ! p F R L H V G s DELETED DELETE!"' P P M
s p F F R R ._J- _ L H V G s DELETED
DELETED DELETED i
s p_
p

s DELETED P_ _
DELETED; P
M
s
F R L H V G s
P I
s p F R L H V G s DELETED P \ P M
s p F R L H V G s N
N DELETED DELETED "ELETED i
1 *
L s p F R L H V G s

DELETED M__j
s __p _
p F R L H V G s N DELETED P i
s
F R L H V G s N DELETE!' P P M
r s p F R L H V G s N
DELETED I
s p F R L H V G s \i P P DELETED M
L s p F R L H V G s N
P I
I s p F R L H V G s N P P M
s p F R L H V G T DELETED DELETED DELETED DELETED DELETED I
s p F R L H V G T DELETED
DELETED M
s p F R L H V G T DELETED
P I
s p F R L H V G T DELETF:D:DELl:THD P M
s p F R L H v G T DELETED ill DELETED I
s p F R L H V G T DELETED P DELETED M
s p F R L H V G T DELETED -■> p I
s p F R L H V G T DELETED P ' p M
s p F R L H V G T N DELETE^.DELETED i t
s p F R L H .*v G T N DELETEDiDELETED M I
s p F R L H V G T N DELETED DELETEr P I
s p F R L H V G T M
P M
s p F R L H V G T N P .DELETED I
s ! P i F R L H V G T N i P__
! P__
p
DELETEr
DELETE: DELETED M
! S ! P i F R L ' H V G T N N
P I
' S p F R L H V G T

P M
1 s p : F R I Y Q S S DELETED
DELETED I
1 £ p
R I Y Q s s DELETED
DELETED M

52'5'i viroC

ASTR 013/111 WO

20 25 29 31 33 I 49 55 56 91 94 DELETED 95 96 107
S p F R I I Y Q S S
DELETF.P- P "M"
s p F R |_J-J. v Q s s DELETED DELETEM P

s p F R Y Q s s DELETED P iDELETED
C-, p F o
Q s s s DELETED P DELETED M
s p F R I [ Y Q
3 DELETED P 1 P
s p F R ._L_ Y Q s . S DELETED P P M
s p F R
Y Q s s ~l N DELETEDJDELETED
s p F R I Y Q s s N DELETED DELETED M
s p F R Y Q s s N DELETED! P |
s p F R I Y. Q s s N DELETED! P M
s p F R Y Q s s ."J P DELETED
s p F R Y Q s s M P iDELETED M
s s p F R Y Q s s N ' P j p

p F R I j Y Q s s
1
T N DELETED P : P M
s p F R I I Y Q s

DELETE:;-;DELETED
s p p R I Y G Q s T DELETED OCldjllD DELETED DELETED DELETED DELETED M
s s" p p - R Y Y
s
s "1 T
DELETt." P M

■ R R —-

T
" T
DELETE -> P

s p F

Y Q s

P DELETED
s p F R I i Y Q s T DELETED1 P DELETED M
s p F R I ! Y Q s T DELETED! P ! P
s p F R I Y Q s T DELETED
N N P j P M
s p F' R Y Q s T
DELETEDJDELETED
s p F R ! I Y Q s T
DELETER-DELETED M
s p F R \ I Y Q s T ■± DELETED. P
s p F " R l'l Y Q s T
DELETE:: P M
s p F R i I __Y_ Y Q s T r,! | P DELETED
s p F R ; I
Q s T M P ,DELETED M
s p F R ! I Y Q , s T N P i P
s p F R ! I Y__
Y Q s T N S P P M
s p p R i i
Q S DELETED'DELETEC'.DELETED
s p F R R I t Y Q G S DELE_TF_D DELETED DELETE;;-DELETED M
s p F
I [ Y Q G s
DELETEL; P
s p F H J Y Q 1 G s DELETED DELETED DELETfH P M
s p F R Y Q G s
P iDELETED
s p F R Y Q G s DELETEDl P . JDELETED M
s p F R Y Q G s DELETED! P ! P
s p p R Y Q G s DELETED! P i P M
' S p F R V Q G s N iDELETE-'[DELETED
s p F R I j Y Q G s N IDELFTEDIDELETED M
s p F R I i Y Q G s N DELETED! P
s p F R Y Q G s N DELETE;;1 P M
s p F R Y Q G s N P DELETED
s p F R ! Y Q G 1 s s ^ i P ^DELETED M
s s p = R I Y Q G ^

p P

p r R I y Q G s \\ p ■ p M
S295
ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 95 95 107
S p F R Y 0 G T DELETED DELETE:) DELETED I

p F R 1 1 i Y Q G T DELETED DELETED DELETED M
s p F R _j 1 ' Y 0 G T DELETED DELETED P I
s p F R Y Q G T DELETED DELETED P M
s p F R
Y Q
Q G T DELETED P !D£LETED I
s p F ■ R J J_J Y
G T DELETED P JDELETED M
s p F R 1 ' . Y Q G T DELETED P P I
s p F R 1 I Y Q G u T DELETED P
N jDELETED P M
s p F R .1 Y Q G T
DELETED I
s p F R 1 Y 0 G T N DELETED DELETED M
s p F R Y Q .6 T N DELETED P I
s p F R Y Q G T N DELETED! P M
s p F R Y Q G T N P 1DELETED I
s p F _R_i Y | 0 _, G T iv ; P DELETED M
s p F R~^ Y Q _ G T K P P I
s p F R V Q G T V P ! P M
s
s p F R Y V S s DEi.rTED DELETED DEL Em DELETED DELETED I

p F R —- Y v s

DELETED M
s p F R
Y V s 3 DELETEDiOEL-'fTEi: P I
s p F R i i Y V s s DELETED'DELETED P M
s p F R Y V s s DELETED 7J DELETED i
s p F R Y V s s DELETED ro OELETED M
s p F R Y V s s DEL ETED P P I
s p F R 1 Y V s s DELETED P P M
s p F R Y V s s M DELETED DELETED I
s p F " R . Y V s s s DELETED DELETED M
s p F R 1 Y V s
N DELL-TED P I
s p F R 1 ; Y V s s ■■: ^DELETE.:' P M
s p F R Y V u S s
s f.' f,1 P DELETED '—I
s p F R Y V s

p DELETED M
s p F R | ! Y V s 1 s s
'!' P I
s p F R j I Y V
s U DELETED P DELETED M I
s p F R 1 1 ! Y V s T DELETED DELETED

s p F R \ ; Y V s T
DELETO DELETED M
s p F R Y V s T DELATED DELETED DELETED P I
s p F _Ji_^ ) • Y V s T DELETED
P M
s p F R . Y V s T DELETED P DELETED I
s p F R Y V s T DELETED P DELETED M
s p F R Y V s T DELEXI2 DELETED p P i
s p F R Y V s T

P M
s p F R Y V s
s T tJ DELrOi'J DELETED I
s p F R j I Y V
T N DELETED DELETED M
s p F , R| I Y V s T
DELETED DELETED
.... ll P I
s p F R j 1 Y V s T

P M
s p F R j 1 Y V s T ' J
DELETED I
s p F R i Y V s T \'
DELETED M

ASTRO HA) I WO

20 25 29 31 33 49 55 56 91 94 95 96 107
S p F R Y V 5 T N P P
s p F R Y V s T N P P M
c p F R I I Y V G c DELETED DELETED DELETED
s p F R
R _Y__ Y V G c DELETED DELETED DELETED DELETED M j
s p F

V G s n DELETED
P
s p F R
Y V G s DELETED DELETED P M
s p p F R Y Y V G j s DELETED P DELETED

F R I
V G s DELETED P DELETED M
s p F R Y V G c DELETED P
p
DELETED P
s p F R
Y V G s s DELETED N
P M
s
s p F R i I Y V G

DELETED

p F R Y V G s N DELETED DELETED M
s p F R I I Y V G s N DELETED P
s p F R ! I V V G s N DELETED P M
s p F R t I ! Y V G s N P DELETED i i
s p F R l I
R , I V V V3 3 *.' p DELETED M !
s s p
p p F F
__ Y
Y V V 'J

P i P

R R I

O 8
P P M i

I Y V G T DELETED DELETED DELETED DELETED DELETED
s p F R Y V G T
DELETED DELETED DELETED M
s p F R Y V G T

P
s p F R Y V G T DELISTED DELETED "-—- P M
s p F R Y V G T DELETED
DELETED
s p F R i i Y V G T DELETED P
P
P DELETED M
s p F R I Y V G T DEI.F TED
P
s__
s ' p F R I I I Y V G T DELETED
P M I

p F R ,_I ! Y I V G T M DELETED DELETED DELETED

p F-- R I I Y V G T N
DELETED M
s p F R I j Y V G T i'i DELETED
DELETED P
s p F R ' t ! v V G T f.;
P M
s p p R j I i Y V G T
_ P DELETED i i
s p F R i I i Y V G T M
DELETED M i
s p F R ! i ; Y V G T ■j P P i ' i
s p F R I Y V G T i-i
P M "I
s p F R H Q S s DELETED.DELETEDlDELETED
s p F R H Q S s OELETED!OELETEO;OELETEO ■ M
s p F R H Q S s DELETED DELETED 'DELETEDi P
s p F R H Q s s
IDELETED1. P M
s p F R H Q s s DELETED P iDELETED
s p F R H Q s s DELETED P ^DELETED M
s p F R H Q s s DELETED P P
s p F R H Q s s DELETED N P i P M
s p F R H Q s s
:DELETED!DELETED
1 — p F R ._ I ._ H Q s > s M :DE LETEDiOELETED M
s p
p F R i I l H Q s s ■ i DELETED P
! Q
L „_Y.
F R I I I H Q s s N iDELETED P M

S2'>>')vi/nc.-

ASTRO J 3/01 WO

20 25 29 31 33 49 55 56 91 94 j 95 i 96 107
S p 1= R H Q S S N i P DELETED !
s p F R H 0 S S_ N j P IDELETED M .
s p F rL_j H Q S s N ... P
P_ P I
s p p F R H i. ° ^ s s N
P M

F R , I H i_0_ s T DELETED DELETEDlDELETED I !
s p F R H Q s T DELETED DELETED DELETED M
s p c R H 0 s T DELETED DELETED P 1
s p f- R H 0 s T DELETED! DELETED P M
3 p F R i J H Q Q s T DELETED. P JQELETED 1
s p F R i ; H
s T DELETED P iDELETED M
s p F R H 0 s T DELETED P i P i
s p F R ■ H Q s _, T DELETED P 1 P M
s p F R H Q s T N DELETED DELETED DELETED DELETED i
s , p F R 1 i H 0 5 T N N
M
DELETED M
s p F R " I 1 H Q s
s T

P I
s p F
f
f R ! I H Q
T
DELETED P M
1 s _._p_.
JJ
F
R_ _
R H Q s s
s T ...ii i_--p
i
!-j ! P DELETED 1
s

1 hi Q
T
DELETED P IVl
s
F R H Q
T "■•-, ' P
1
s p F R H Q s T N P P M
s p F R H Q G S DELETETJI DELETED DELETED t
s p F R I I H Q G j S DELETED DELETED;DELETED M
s p F R ! I H Q G 1 _ s DELETED DELETED DELETED DELETED P 1
_JL s* p F R s H Q G s

P M

p F R H Q G s DELETED P DELETED s p F R H Q G s DELETED DLL-lTfiO DELETED P DELETED M
i s p F F R & — ■ H Q G s
._ _ DELETED p i
s p

H Q G s

P M
s p F R i ! H Q s M
DELETED
s p F R \ I H 0 G s
DHLETEDlDELETED M

p r- R I 1 H Q G s N DELETED! P I

p F R 1 ! H Q « s 'nULETrD P M
s p
R ! i H Q G s '■ P P DELETED i
s p 1= R 1 H Q G s .... ^
DELETED M
s p F R i H Q G s
p P 1
i s p F R i i H Q G s
P
DELETED P M
■ s p F R H Q G T DELETED
OELETED I
s p F R H Q G T DELETED DELETED DELETED M
s p F R H Q G T DEj.EJEip DELETED DELETED P 1
s p F R H Q G T
pELETED P M
s p F R H Q G T DELETED
DELETED 1
s p F R H Q G T DELETED DELETED p OELETED M
s p F R H Q G T
;-■ P 1
3 ? F R hi Q G T DEI r.TED| P P M
s p F R ; 1 H Q G T N DELETED DELETED DELETED 1
! s p > R i I H Q G T i.i
DELETED M

ASTR 013/01 WO

20 25 29 31 33 49 55 56 91 94 i 95 i 96 107
S
s p F R H Q G T N N DELETED! P

p F R i i H Q L_ G T
DELETED! P M
s p F R H Q G G
^G T M P
P DELETED I
s p F R H Q
T N
DELETED M
s
F R H I Q
T

P
s p F R H Q
T N p P M
s p F R i ! H V s S DELETED DELETEDiDELETED
s p F R I I H V s S DELETED DELETEDiDELETED M
s p F R i ; H V s s DELETEDiDELETED: P I i
S | p F R —J— H V s s DELETEDIDELETED1 P M _,
s p F R
H V s s DELATED; p DELETED
s p F R
H V s s DELETED! P DELETED M
s p F R I H V s s DELETED DELETED p P
s p F R H V s s
p P M
s p F R H V s s f.l DELETED DELETED
s p F R H V V s s s L_ :"' DELETED DELETED M
s
s " -i- F
F R H
H

s '.' DELETED P

R
V l__s s P M
s p F R j ) H V s s
DELETED

s p F R i I H V s s ■:i l"J P DELETED M
s p F R ! I H V s s M
P
s p F R i i H V s s I! ; P P M
s p F R I I | H V s T DEl.HTEDjDELETEDjDELETED
s p F R i I H V s T DELATED DELETED DELETED DELETED M
s p F R H V s T
DELETED P
s p F R H V s T DELETEDiDELETED
DELETED! P
DELIlTEDi P P M
s p F R H V s T
DELETED DELETED
s p F R H V s T

M
s p F R H V s T DELETED DELETED I-' P
s p F R H V s T
P DELETED P M
s p F R H V s T : J
DELETED I
s„
s p
p F
F R -— H V s T
DELETED DELETED DELETED M

R
__H
H V V 3 T

P
s p F R

T
DELF1E- P M
s p F R H V s T H P DELETED
s p F R H V s T N j P DELETED M
s p F R H V s T P P
s p F . R H V s T
P P M
s- p F R H V G S D-tFT^D DELETED DELETED
s p F R H V G S L"i:LET^'D:DELETKD DELETED M
s p F R H V G S DEL ET-D DELETED P-arTEDTELETED i)F.l.i:.'IED: !"■ P
s p F R H V G s
P M
s p F R H V G s
DELETED
c-
s p P R H V G s
3 DEL!-TED. E DELETED M

p r R —I—
V G
PE! r-~rDi P P
s p P R
H V G s
P . M 1

521^ vi/iX"

ASTR 013/01 WO

20 25 29 31 : 33 49 55
V 56 G G 91 S-1 95
;;::LE;;E!)
DELETED 96 107
S P F R I H

S M i'J
DELETED t
S P F R I I H H V
s

DELETED M
s P F R ; i
V G s " ! [DELETED P I
s P F R I I H V G s .'J DELETED ? P M
s P F
F R L— H V G s

DELETED I
s P
R
H V G s '■.' P DELETED M
s P F R H V G J s M P P I
s P F R I i H V G s N P P M
s 1 P | F R I I H V G T DELETED'TJELEJED1 DELETEDIDELETED DELETED !
s P F R I I H V l_G T
DELETED M
s P F R H V G T DELETED DELETED P I
s P F R H V G T DELETED DELETED DELETED P P M
s P F R H V G T

DELETED I
s P F R ! I H V G T DELETED DELETED r p DELETED M
s P F R ! I I H V G T

P !
s P F R ■ H V G T
T DELETED p
DF.LFTEr-7)FA : r.PD P M
! S P F R
H V G

DELETED i
s _ p F R H V G T

DELETED M

P F R H
G T '.' JDELETED
\> :rsr ELITE*
•: P " >~1 I
s P F R
H V G T
P M
c P F R I! V G T
DELETED I
s P t— R —L— H v G T
DELETED M
s P F «
H v G T -. ■. -
V r P I
s P F R
H v G T
;; P M
Table 10. Exemplary Mutations of mAb 2.998.2 Heavy Cluin (SGQ ID NO: 1^1) to Germline
at the Indicated Residue Nuwln-r.

27 32 33 52 ss H)M DI ■LI-1 ED AMjLE'i'hp DELETED 103 112
G S s s s DEIJ-Ti-.M
DELETED L
G S s s s DEU-T:H
DELETED Q
G s s s s DELETi-:-)
V L
G s s s s DELlITf!), DELETED V Q
G s s s s DELETED 11 DELETED L
G s s s s DELE'ITD !I DELETED Q
G -. s s s s DELETED V L
G s s s s DELETED
V 0
G s s c s II DEI.ETi-:!) DI:LE'iED '.)\ '.E'i'EEj DEE;.: !'! DELETED L
G s s s s !;
DELETED 0
G s s s s (!
V L
G s
s s s s s
V Q
G
s s
1 i
DELETED L
G s s s s ]]
DELETED 0
SSWvi/'X-"
**^jj1^ l$l

ASTR 013/0! WO

27 32 | 33 52 85 100 101
1: 103 | U2
G S s s S i!
V L
G S s s s H
V 0
G s s s R DELETE!) DELETED'DELETED L
G s s s R DELETED DELETED DELETED DELETED Q
G s s s R DELETED
V V L
G s s s R DELETED DELETED
Q
G s s s R DELETED H DELETED L
G s s s R DELETED Tl DELETED Q
G s s s R DELETED
V L
G s s s R DELETED 11 | V Q
G s s s R H DELETED (DELETED L
G s s s R 'i! DELETED DELETED 0
G s s ~^ s R !i DELETED DELE'IED v L
G s s s R
V ! Q
^ G s s s k )i D DELETED: L
S i S s R | \\ DELETED, Q
G s s s ^ J '] -.
V L
G s s s R I-l
V Q
G s s ' T s DELETED DELETED DELETED L
G s ! s T s DELETED DELETED DELETED Q
G s ! s T s DELETED DELETED V L
G s s T s DELETED DELETED u V Q
G s ! s T s DELETED
DELETED L
G s s T s ^DELETED i i DELETED Q
G s s T s DELETED
V L
G s s T s DELETED ;! V 0
G s s T s H DELETED DELETED L
G s s T s i-j DELETED
DELETED EEI.ETED
i 1 DELETED 0
G s s T s i!
V L
G s s T s !!
V Q
G s s T s li
DELETED L
G s s T s !l if DELETED 0
G s s T _ s 11 li I V L
G s S | T s 11 !■ j V 0
G s s T R jDELETr.D DELETED" DELETED L
G S i S T R DELETED
DELETED Q
G s | s T R DELETE!) Oll\ ETED
DE;.E'IE:D
! ; i ; V L
G s | s T R DELETED
v Q
G S ! S T R DELETED
DELETED L
G S j S T R DELETED
DELETED Q
G r^s | s T R DELETED
V L
G sis x R DELETED
V Q
5205'; vi,'!X"

ASTR 013/01 WO

ASTR 033/01 WO

u- 21 i 32 1 33 ; 52 85 10*> iPJDELETEDj V i Pi DELETED! v ! 112
L
0
G s i T s DELE'P

G s i i T s DEI.E'ti

G ! s ! T s DELE'1"' -P" I! .DELETED!
-:P, ii 'DELETED! L
0
G s T s DELE'i!

G
G s
s DELE'l" ■:P; II I v j L

s T s DELEl'i ■:P FT j v 1 Q i
G s T s 11 1 DELETED iDELETED! L i
G s T_J s H .J.lMiil^ii^LETED;
iDELETED! V ! 0 J L
G s T s 11

G s T s II !DELETED| V 0
G s T s H H .'DELETED, L
G s T s II i K 'DELETED! 0
G s T s il 1-1 1 V L
G s T s H : H v ■ DELETEpJPELnTEPj L 0
1 G 4 s s s s T
T
T R_
K R DEI.E'i'
DVAM'-DELE""

r~ r.

jDELETED-DELETED

[ G
,

■P PEi.ETEP' V i
■:D-DELETED V L "1 0
G
r T R DELiP"

G s T R DELE •- :D! [-1 {DELETED L
G s . T R DELI-; ' ■:P: H DELETED Q
G s i ! T R DELE"" -"!"■« ■ IE V L
G s ' T R DI-.1 E1 ■;■'. :•! v Q
G s ' i T R li jDELETED DELETED L
G s T R j J DGLETEP.iDELETED Q
G s i T R 1-1 ;DELETED' V T V
G s T 7 R \\ iDELETEDj V Q
' G s T R il II : DELETED , L_
G G s T R i-i ! H ..DELETED Q

s T R -1 II ! V , L
G s T R
11 V
.-P DELETED:DKLETED 0 J L
G r 5 S S DELE"

G r S S 1 S DEEiP .-.,"'iDl-ll ETEP DELETED 0
G F s s S DELFT ED1DELETED: V L
G F 1 s 1 S s DELE'l EP1DELETED! V Q
G F s 1 s 1 s iDELL- FP. I-l DELETED L
G F s s 1 s s jj)E_LE_!
IDE!/:;
jDELl7-' LP; H j DELETED Q
G F
1 s s
LP. !! V L
G F ! S s s
'■P! H V Q
G
G F 1 s 1 s s I ;' iOE! ETEP'DELETED L

r ! S '■ S ■ s
: S : s 1 ■■ IDE! ETEP-DELETED Q
G F

r s
DELETED V i L
! „
52->5

ASTR 013/01 WO

27 32 33 : 52 f 85 U>« (01 M H 103 112
C F S S '• s ii
DELETED L
G F ' S j s s H
DELETED Q
G F S i s s i! ! M V T 1^
G F S s s !! ; H V Q
G F S s R DELFT;.;) DELETED DELETED DELETED L
G F s s R DELETED
DELETED Q
G F s s R DELE*: ;■!> DELETED V L
0 F- s s R DELE'iED DELETED V Q
G F s s R DELE'! ED DELE': ED !J ]] M DELETED L
G F s s R

DELETED Q
G F s s R DELETED
V L
G F s s R DEI.!-"'! ID 1-1 V Q
G F s s R ;| DELETED1DELETED L
G F s s R i: DELETED r;YiLET>':P DELETEDl 0
G p s s R _
R. •■ i
v L
G C F F
r —"—■ *~"—
F s s
>'• 1 DELETED V Q

s
s s - R ii DELETED L
G

s R ! '
DELETED Q "1
G F s s R ! i ! :-i V L
G F .-
^ s R ": ! 11 V Q
G F s T S DELETED DELETED DELETED DELETED 'DELETED L
G F s T s DE; .:■.■:-. :)
DELETED Q
G F s T s DELETED
v L
G F s T s DELETED DELETED V Q
G F s T s
DELETED L
G F s T s DELETED II
!■[ DELETED Q
G F s T s DEEE'i ED
V L
G F s T s DEI ET.-Di H V Q
G F s T s ii I DEI ETEP DELETED L
G F s T ^1 DELETED
DELETED
jDELETED DELETED Q
G F s T s i;
V L
G F s . T s :
V Q
G F s T s !; ! i-I
1 V~~"
i ~"H .DELETED L
G F s T s li
tDELETED Q
G F s T s !i
i V L
G F s T s DE; ■:':;■:•
DEI "IED
V Q
G F s T R
!PH ETED
j ot-:i ETED | PJ;E ETE D |DE: ETED
: I DELETED L
G F .. s T R

iDELETED Q
G F s T R DE! ETEP
V L
G F s T R IDF! : ■' !■.;?
V Q
G i F ■ s T R IDE! ■-'■.D
■ DELETED L
Ci ! F L s-. T R JDEI P :i DELETED Q

52Wv;'Or

A.STR 013/01 WO

27 32 33 52 85 | i MO ifn :-;n":,rT|"" ~;f" " 103 112
G '■' 3 T R DP.:
V L
G F s T R DEi ! M V _5ZT
G F S
s T R
pi"l -Ti-p DELETED L
G F
T R il (DELETED DELETED Q
G l: s T R j ! V L
G F s T R i! DELETED U ! il A j I! v n Q "•
G F s T R
■DELETED L
G F s T R
DELETED Q
G F s 1 T R ETED H . ; V L
G F s T K
V Q
~G~~] F I S S DO!
DELETED DELETED L
1 G F I s S DEi E'i ED [DELETED DELETED _fi—
G F I [ s S DE: :TLP|nL!_Ej;[:!' ETEDJDELETED
■ViiiD'" u V L
G F I s S DEI
V Q
G F F -1 s S DE!
DELETED L
G
1 s G F 1 s s DE!
H V L
G F r s s DE: '{TED! II
is DEi ETED V Q
G F i s s
DELETED L
' G F i S | s ( DEI ETED'DELETED Q
G L r 1 s "~i s

I1!-:: ETED V L
G F 1 s s :i -DELETED V Q
G rr L 1 s s 'i !i DELETED h—L—1
G F 1 s s ■; ii DELETED 0
G F I s s ! i
Li; n j i V Q
G F 1 _s , R DF'
DELETED DELETED L
Ci 1 p- J s R DE-1 ETED.DE! ETED ■TED' i .;Li:.l i-.Il DELETED Q
G F 1 s R DF!
V [__k_
G F 1 S 1 R DF:
V "~Q~
G • J* 1. s R Or1 -:"!-■•"'") | i ; DELETED 1_ L
G F 1 s R Dr.:
DELETED Q
Ci F 1 s R DE; ETED I 1! V L
G F I s R DE! ETED i-i v Q
G F 1 s R
DELETED'DELETED L
G F 1 I s R
DELETED DELETED Q
G F I \~ s R •i 1 DEi ETED V L
G F I s R
i i -E:- ETED V Q
G F I s R
DELETED L
G F F I s R i i ; .DELETED Q
\G
i 1" S R
J V ' L
G F I s R

V ! o
52'>59 v-i/DC
r^T^

ASTRO! 3/0 i WO

1
27 32 33 ; 52 85 {fi't iHi / ; 103 f7n ~
G p i T s DEPPPHD DELETED
DELETED
DELETED ; DELETED , L
G F 1 T s DELETED
1 DELETED Q
G F 1 / T s DELETED
V L 1-
G F 7 s D£J.:.n':> ■)-.:\ i: "i.*n
p V Q
G F 7 s DFJP-PEP
DELETED L
, G F T s DEi PTEPJ ii DELETED Q
G F T S !DEI :;TEL"> n V L
G p T S IDE!, PTPP )! DELETED V Q
G F T S !f
DELETED L
G F T S i : DFEU'HD DELETED
P..E':TED DELETED . Q
G F T S 1 ;
V , L
G F T s .. p
V Q
G F f T j;
DELETED L
G F 1 T . .
DELETED £
G p i T s
1 ' V L
G i; 1 T .,■
V -Q
P,
0
G G F l "J K Pi. PP.! PEE.. PEP-DELETED

F —__ T R DF:I .;:-.!■ DELETED PI-!! ETED DELETED DELETED

G F
7 ii (DEL.-.TED
V L
G F '1 K DHL ■'!■.':
V Q .
G F ' '1' R DPI.: TED : i DELETED t L
G F T R DEE. TFP
DELETED .. Q
G F T R DEEP PEP
V L
G F 7 R uDP.i .' i'!-P
V Q 1
G F 7 R :; PELD1TD 1) EL:/TED DELETED L
G F ■ - T R

DELETED Q
G F T R DELi.EED DELETED V L
G F T R ! :
V Q
G F i 1 T R !
DELETED L
G F i
1 T R ■.'.
DELETED Q
G~ F f r f V L

IT T R .; :;i::..pi;BD^
DELETED DELETED V Q
D .s s s S DPI.., ;■;:;>
DELETED L
D s s s s DPI :.::'P
DELETED Q
0 s s s s DEL! TED
V L
D s s s s !DP: Ti p DEI TED
1 t V Q
D s s s s DP. TP::
DELETED , L
0 s s s s DEI r;-!'
DELETED Q
D s s s s OF.!. TED ' --.-A !'ED
' '■: PEP V L
D s
s" <: s dpp r- p> V LQ
b
s s s

! )ELETED L
D s ~ s s s
' JELETED Q
SjtiS'i vi/or ^-s^-J ^2—

ASTR 013/01 WO

27 32 33 52 85 Ml Wi | 103 m
D S s s s ■-! DELID'ED! V
"\- DELETED L
D s s s s
1—-—1
0
! o s s s s ■r "" ' ■ • j
L !
D s s s s : i D -DELETED Q i
D s s s s ii ! !i ; V L !
1 S 1 s ' s s ! ! ! ;; j v o !
D s s s R DELETED! DELETEDiDELETEDj L j
D s s s L R DELETED! Di:LETEDjDELETED 0 !
D s s s R DELETED! DELETED! v L
D s s s K DELATED! DELETED! V 0
D s s s R DELETED;
DEI ETED, II ! DELETED L
D s s s R
! 'DELETED Q
D s s s K DEI.LTPD- D V L
D s s s s s R DELETED' - i V Q
D s
s R l-l
1 [ ""-.LETED'DELETED L
D
" D* s
s R
D-..L LTD DELETED EEL1 -:.'" V 0

S s s R

L
r D s s s R '■ i D"LI- :'ED D s s s R I i ! DELETED L
D s s s R
L 'DELETED Q
D s s s H "I D V L
D | S s s R ' i i' V 0
D s s T S DELETE!'1 DELETED DELETED L
D s s T S JJEUHT; :
DELETED' DELETEDIDELETED ' 'ELE'ELD1 V __S i
D s s T S

L '
D s s T s DELETED. D LETED' V Q
D s s T s DELETED !! 'DELETED !i DELETED L
D s s T s DELETED
Q
D D s s ■[■ s DELETED
DELETED
H V L

s s ■I" s
;. v 0
D s s T 5
DELETED-DELETED L
D s s T s ■I DEL! !*ED [DELETED Q
D s s T s
DELL LED! V L
D s s T s
DELETED; V 0
D s s T s i ! D :DELETED L
D s s T s il
M
DED.-TED DELETED Q
D s s T s
V L
D s s T s
: v Q
D s s T R
DE!. ;":-D:DELETED L
D s s T ■R ]):■! ■■"i'i.'n
DELETED 0
D ' S s T R
. :u .'E;D v L
D s s T R DE! ■"'!■; D '.-LTD,: V 0
529s u vi/nr T=^

A STR 013/01 WO

A.-TR 013/01 WO

A;STR 013/01 WO

27 32 33 52 85 !"' 101 103
' DELETED "' DELETED 112 i
I) F S s S i- !DELETE
L !
D I7 S s S M ;DL JVi'l-1 !' 'M:.l l-'l"!
o i
D F s s s
V L ;
D F s s s i! jDELHTt-
!; » r f L ... V ' 'ELETED '•■ELETED Q i
D F s s s

L D F s s s H ; n
0 '
D F s s s li ! H V L !
D F s s s 15iTrrfi:!)!bn"nTfE DELETED!DELETE V
A .'DELETED El DELETED Q i
1) F s s K

1 i
D F 1 s R

o !
D F s s R DEL: TEDjOELE'l |; V DELETED DELETED L i
D f s s R ED_EL: TED D!;: !•;;'-
o !
D F s s R DELVED ;■
L
D 0 F s
s "
s
s s s
s R K"
R
R DEI'. ri:'D_ ^ (!
ni-!.■■':■■ '• DEL ii-.:'
:: ,Dr;,.ET ■■
0. J
L
0 F

' ELETED
'■ DELETED
— ■ ■
V
V
'DELETED
ELETED
v 1 Q i
D F

L :
D F s s R ■i 'ii!-:: ETE
Q !
D F s s R

L 1
D F s s R

Q "
0 P s s. R ! 1
L 1
D F s s R i II
Q :
D F s s R

L D F s s R
V Q i
D F s T s DELr;E! D;DELETE DEUTi-.D'DELETE :■ '-ELETED L- ,
D F s T s
A DELETED V o !
D F s T S DELETED! DE1 FT1-'
L
D F s T s DELETED.'E i.E"! !■ DELETED !! DEL. 'ED' ii V 0
D F s T s
DELETED L
D F s T s
.AT.ETED
V V 0 !
D I7 s T s DEL: ■'■I'-:). !■! DEL1 i'l-D' li
L !
D F s T s

0 i
U F s T s i. ,DEI 1"!' . ■ DELETED L !
D F s T s E .DELETE D DELETED Q j
D F s T s ;. !DELET! V V t~T~!
D F s T s

0 i
D t—F s T s i! DEL'"":;.."'; >EEE'"E
a%6 ELETED DELETED V" L !
D F s T s

o ;
D F s T s

L 1
o F s L_J s
■ : ELETED ': LETED Q :
D i. s T R

L i
J) F s T R

0 !
529S9V1/]JC • -^yr-0

I'R 013/01 WO

'-•R Q13/01 WO

.__._ 1- ' "\ 1 T s
D J: i T' 1 s
D F i T s .
D l: 1 T s
D L F I T u DEI.
1) F I T R DEL
*~D F 1 T R DEI
D 1- ! T U DEI.
*~D F J T R DEI.
D F_ I T R DLL
0 F I
1 T R OLE
D 1;
F
T R DEL
i !■>

T K
A
D
T

1 ELETED L i
ELETED o 1
V L i
V 1 o '■
DELETED I
DELETED o 1
V_J L
V Q
'ELETED I n
DELETED Q
V L
\r $ 1
^LETEDi i- i
DELETED 0 !
V Q :
"■ "LE'reo i _
:'ELETED o i
V L !
V Q
ELETED L
'"■ELETED 0
V L
V Q
DELETED E !
DELETED o 1
v L
V 0 |
' E;i.Ei'ED L '
ELETED Q ,
Y ! L
V Q
>ELETED L
DELETED 0
v i L
V Q

r>2«'}-.-i/Dr

TR0!3/0f WQ

Table ! 1. Exemplary Mutations of mAb 2.99S.2 Light f' ,ii:
at The Indicated Residue N---^.

to Germiinc

57^9 vl.'DC"

■■■SYR 0(3/01 WO

.9y'i vi,TK

AST#GiM«i WO

" 1 "" 7 SO 92 «?3 I ':i)f j
D I S
V 1 T l I i I j
D S s V T
D s V A S

D ■S V A S s , . v i
D 1 S V A S ! I ! i 1
0 s V A s 1 I V
D s v A T s D D S V A T s ! v !

S ! V A T i ! j 1 1
i'.) i s V A T i 1 v
D s V V S j S j 1 1
0 s
s V V s S ! V
D _1
v _J v s s „ I - — 1
D | S V V

p s V V
V r Is : i . 1. .L.J ^ -L 1
0
u v

D i" ^ V v T ! i ' v :
n
s A s : s i i 1
n , F r~s A s i s ■ ^ i
D !■• ! s A s i J j_ i
n :: 1 S A 1 S ! 1 ' "'" ;
D D I 1 S A '[' 1 .s ■ i ■

V j S A T S :
o ' i; ! s A T I._ ' : _ i-'
D V ' S A T : 1
!') [) 1)
' b I- s r v r s" v; i
s

F i S V
V 1 S -

F ! S ; S
f S

F
v j s ;,_. ; '
o r s V ! T s '■■ ___ i__ I ■
] i i' v
u i !■■ ! s v ; r

n | F i s V i T „

_ ( ....__ 1 s V 1 r"„

V rh. L i„

! V A ! s
s

D .. i; ! V ' A

■ i) ! F_ , V . A s

1 0 F ' V A ! T

i_ »L !.__ F I v' A ~ T ' ■
i- v A T | ; _.

I- V A j T _ J _ ■ . ' __
52^59 vl.'Dr ^00=- 20

;9i-i/ic

30^

ASTRO 13/01 WO

ASTR^W'WO
TAL1LE 12 A.K'll-rDGFR-Al.PHA ANTIBODY HEAVY CHAIN SEQUENCES

o3

■JO rO
Z
ID
3 a
V
23
I

£
i>";

2:
c-
a
H ^
w

a^V

ASTROiM)! WO
EXAMPLE g
Al-TINITY DETERMINATION UV Bl/- : '■' ■" '■- VSIS
|00241 [ Biaeore experiments were performed . i: '— TioO instrument at
22 °C. Stand:]!-;! aldehyde coupling of the biosensor suri ' ■ ;!' ' -:'libony was utilized.
Specifically, 50 fig of each mAb was reacted wiih -1 ml. ""«" : NaOAc, pH 5.5. and then the oxidation reaction was si..fi: *■'.*■■::■ nng die sample on a
Sephadex G-25 Nucleic Acid Purification-5 column (N/ ' • ' : '■i-'-~iences) with 10 mM
NaOAC, pH 4.0. The mAbs were then flowed over a C: '-" "~i reacted with EDC/NHS, carbohydrazide, and ethano! . "" '"'"" ,5lc desired surface
capacity had been reached, the hydrazone bonds heiv., ' :;u! '-"nc surface were
reduced by flawing 0.1 M NaBH3CN in 0.1 M NaOAc, r" " -' ,;'!'-' immobilized mAbs
u.'i S.KJ '.,',! {0(1241\ Mate 2.993.2 (SEQ IO Nos:!4 and K ' '■' ':-' *& ^os: 5 anJ 4).
2.375.3 variant A (SEQ ID NO: 2 with 3Q, 80Y (SEQ 11) ':-,;0 *D NO: 4 with 46L,
77S (SEQ ID NO: 135)). 2.449.1 (SEQ ID NO: 10 and r' - !-'° I variant A (SEQ ID
NO: 10; SBO !D NO: 12 with 49Y, 1071 (SEQ ID NO- ' ' " ■'obili/.ed on a CMS
biosensor ehi-. RcconVomnnt human sPDGFR-alpha ■' ' -" 322-PR/CF; ioi«
QY056081) was injected for 90 seconds at a concent r;" ■ ' J ^-6 - 0.806 nM (2x
serial dilution) followed by a 3 minute dissociation. -' ■'■" ''-' ■' -sociation phase was
obviously extremely slow for all the interactions studied. ■"■' ": injections, three at
25.S nM and three blank buffer injections, were perform ",iwi injection with a
dissociation phase of 14.^00 seconds (4 hrs.) after ■': completed. The samples were prepared in Hepes-buiTen-: "' '■'■'■ ""' ' '• polysorbate 20. phi
7.4 (HBS-P) with 100 ug/ml of BSA added. All samples ■ - - " ■ •' ejected in triplicate
with over ten buffer injections interspersed for double re' ' ■vnsorgram data were
processed will: Scrubber 2.0 and globally fit to a l:i inte' - ■ deluding a tenri for
mass transpon using CLAMP. The resulting binding cc- " ' f ' '■ in the table below.
MAbs are liste:! in order from highest to lowest affinity.

ASTR 013/01 WO
Tabic 14. AFFINITY OF SELECT!:

-->:iiliiii C
ka(MV)
2.175.3 variant A\ 3.55 X !05

2.53

pVl! t

I 2.449.1 variant A I 4.40 X 10'

3. SO

2.175.3

5.16 X 10'

2.59

so

2.449.1

4.40 X \Q*

6A6>

140

2.998.2

2.98 X 30'

4.S9 ;■■

164

iOft'243; The results in Table 14 show that tl-2.449.1 showed increased affinity for soluble PDGFR; compared in 'he respective non-gcmiiincd antibodies reduced di-.>
-'-•v-s of 2.175.3 and y Biacore analysis
'■! antibodies show "'•e!: contributes to
■isU-Sny in TshJo )4
e 2 and an MG-63 '.ivies are lisied in

Antibody H753-
Table ;5. ACTIVITY OF SELECTED ANTnv ELISA AND KECEPTOR PHOSPHORYLATION ASS.
sPDGFRa Elisa IC50 (n-
38
2.175.3 Wiv.-. A
46
2.449.1,3
44
2.449.!.3 Vn.-i::;!l A
45

DGFRa BINDING

';-■ 1C50 (ng/ml)

EXAMilLTL'" EVALUATION1 OF ANTITUMOR EFFF XENOGRAFI"MODF

b'MOR

A.STK0(3/0i WO

J0OZ---SJ Tiic anliiuaior efficacy of two of the ;P xenograft model of non small celi king carcinoma. Calu-6. a cross bcU'.i H BlackO':^ mice that had tiic murk;,: . human iMXi!;Ra by homologous recombination and S* expressed ru-. human i'OGFRa receptor and no-, knookin/knaek^ui truce 19 weeks of aye (KVgroup) were : OJ ml of mairigci into the right Hank. When the tumors : size, the an'Todics in a phosphate buffered saline ve! ;. adminislered ^trapcritoncally at 10 mg of antibody per '•■" duration of;!- ^tusly. Figure 2a shows the average timir- ~ while Fi^i.rc "'; shows the average body weight over tin reduce;! ':IL- = ■ ;-J:" r_;r-.)v.:h ,ac significantly; treatment v ■ growth ip-'Q. '■' i while i:v.;:me:i! with 2.449.1.3 prodir' ; 0.001). The; ■ was no ^g!:i:lcan[ difference between •.:>:• change durin-.' :ho, studv {F'g.ure 2b).
f0024': The ?.niii'.i:iior effiency of 2.449.1.3 :■ evaluated m ,:u- U; !S glioma xenograft model. SOD n.u:-. injected w\'\\ "XI06 ceils in 0,1 ml of matrige! into the :'■-tumors reached an average of 2SQ mm3 in size, the described abr-*c i'ov the Caiu-6 model. The results an' ■ 2.449.!.3 re.-: vd growth of the U11S tumors by 9--'"-2.449.1.3 red- ed t>rn\vth by 101%. Therefore both 2,"-highly aeto.e : ■ reducing growih of this glioma xenogra:: , not reduce in \ .vo activiiv in tins model.

■ vo evaluated in a
= ■ -vere derived from
replaced with the
.ie requiting mice
receptor. These
.' age of 170 mnij in
:;i:nc vehicle were
r s per week for the
"•: {.-.roup over time,
'h both antibodies
vd ;■ 55% reduced
. growth rate (y:
- ci in body weight
i A was further
e -:' 10/group) were
:: rials. When the
■• .'dininistercd as
;. The antibody
■•'.). Variant A of
.1.'}. Variant A are
:s .*f Variant A do

INCORPORATION BY REF:"-. ^ \fH)24i ' All re fere: tecs cited herein, including ;■>:■■ text books, a:- tlit: 'ike. ami the references cited llie: ',. aircadv. ;v.\- f ■ .-he mc:iroor;:;ed herein by reference in f-

'-v:c;itions, p;ipcrs, '■laf they are not

ASTKOlVOi WO

EQUIVALENTS ;(i:}2--r'| The tbjv.jiiiin.u wr-IUen ypceirjwiilo-i ;:■ ;■■'.-Ofit sklik-d !i. '.tie voi. to practice die invention. '! he :- i>e ;• invention should be construed in accordance with 'die ap ■ -thereof.

.-i:"":kioiii te Diablo '.» :: iiiid Exatr.piys '- die besf mode .;,;er h<:nvr detailed :-iv ways and the :.ii any equivalents>

52-J50 ■-■■,">;"■

SEQUENCE LISTING
AstraZeneca AB
Targeted Binding Agents Directed to PDGFR-Alpha and Uses Thereof
ASTR-013/01WO
US 60/835,647 2006-08-03
136
Patentln version 3.4
1
360
DNA
Homo sapiens
1
cacgtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
ccctgtgcag cctctgcatt cacctrcagt gactactaca tccactggat ccgccagcct 120
ccagggaagg gcctggagtg ggtttcatac attagtagaa gtggcagtct catatactac ISO
gtagactctg tgaagggccg attcaccatc tccagggaca aegecaagaa ctcactgaat 240
ctgcaaatga acagectgag agecgaggae acggccgtgt actactgtgc gagaggggcg 300
ccgtatagtg ggagcccctt tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
2
120
PRT
Homo sapiens
2
Gin Val His Leu Val Glu Ser Gly Gly Giy Leu Val Lys Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
'yr Met His Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 15
Ser Tyr lie Ser Arc Ser Gly Ser Leu lie Tyr Tyr Val Asp Ser Val
50 55 60
Lys GLy Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu ASP
65 70 " 75 B0

JHUGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
^ B5 90 95
Ala Arg Gly Gly Pro Tyr Ser Gly Ser Pro Phe Asp Tyr Trp Gly Gin
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
3
324
DNA
Homo sapiens
3
gacatccaga tgacccagcc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc ggccaagtca gagaattagc aggtatttaa attggtatca gcagaaacca 120
gggaaagccc ctaagttcct gatctatgct ccatccagtt tgccaagtgg ggtcccatca 180
aggttcagtg gcagcggacc tgggacagat ttcaccctca ccatcagcac .ttacaacct 240
gaagattttg caactnacta ctgtcaacag agttacagta cccctccgtg gacgttcggc 300
caagggacca aggtggaaat caaa 324
4
108
PRT
Homo sapiens
4
Asp lie Gin Met Thr Gin Ser Pro Ser Ser-Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arg Pro Ser Gin Arg He Ser Arg Tyr
20 25 30
Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Phe Leu lie
35 40 45
Tyr Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Thr Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pro
95 90 95

T?P'Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
5
360
DNA
Homo sapiens
5
cagatgcagc tggtggagtc tcggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gactactaca tgaactggat ccgccaggct 120
ccagggaagg ggctggagtg ggtttcattc atragtagta gtggtagcac catatactac ISO
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtgt atnactgtgc gagagatggt 3GC
caratagcag ctcgtqgcat ggacgtctgg ggccaaggga ccacggtcac cgtctcctce 360
6
120
?RT
Komo sapiens
6
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Tyr Met Asn Trp lie Arc Gin Ala Pre Gly Lys Gly Leu Glu Trp Vai
35 " " 40 45
Ser Phe lie Ser Ser Ser Gly Ser Thr He Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 7 0 7 5 30
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly His He Ala Ala Arg Gly Met Asp Val Trp Gly Gin
100 105 lib
Gly Thr Thr Val Thr Val Ser Ser
115 120

7
336
DMA
Homo sapiens
7
gtcatccaca Cgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcgagtca ggtcattacc aattatttag cctggtatca gcagaaacca 120
gggaaagttc ctaagctcct gatctttgct ^icatccactt tgcaatcagg ggtcccatct 180
cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 24C
gaagatgttg cgacttatta ctgtcagaag tataacagtg cccctccaag gactcgatcg 300
atcaccttcg gccaagggac acgactggag attaaa 336
8
112
PRT
Homo sapiens
8
Val lie Gin Met Thr Gin Ser Pro Set Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Val lie Thr Asn Tyr
20 25 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pro Lys Leu Leu lie
35 40 45
Phe Ala Ser Ser Thr Leu Gin Ser Gly Val Pro-Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
65 70 7 5 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gin Lys Tyr Asn Ser Ala Pre Pro
35 '90 95
Arg Thr Arg Ser lie Thr Phe Gly Gin Gly Thr Arc Lsu Glu lie Lys
100 105 110
9
360
DNA
Homo sapiens

caggtgcagc cggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgaggctc 60
tcctgtgcag cctctggatt caccttcagt gactactaca tgaactggat ccgccagcct 120
ccagggaagg ggctggagtg ggtttcatac attagtagta gtggtagtat catatactac 180
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gacagaaggg 300
cgtatagcag ctcgtggtat ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360
10
120
PRT
Homo sapiens
10
Gin Val Gin Leu Val Glu Ser Gly Glv Gly Leu Val Lys Pro Gly Gly
1 5 1C 15
Ser Leu Arg Leu Ser Cys Ala Ma Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Tyr Met Asn Trp He Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr He Ser Ser Ser Gly Ser He He Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Arg He Ala Ala Arg Gly Met Asp Val Trp Gly Gin
100 105 110
Gly Thr Thr Val Thr Val Ser Ser
115 120
11
324
DNA
Homo sapiens
11
gacatccaga tgacccagtc tccatcctcc ctctccgcat ctctaqgaaa cagagtctcc 6C

aAiscttgcc ggccaagtca gagctttagc aggtatataa attggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatccatgCt gcatccagtt rggtaggtgg ggtcccatca 180
aggttcagtg gcagtggatc cgggacagat ttcactctca ccatcagcac tctgcaacct 240
gaagattttg caacttacta ctctcaacag acttacagta accccccgat caccttcggc 300
caagggacac gactggagat gaaa 324
12
109
PRT
Homo sapiens
«J00> 12
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Acq Val Ser He Thr Cys Arc Pro Ser Gin Ser Phe Ser Arc Tyr
20 2 5 30
He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He
35 40 45
His Ala Ala Ser Ser Leu Val Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 90
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Asn Pro Pro
85 90 95
:ie Thr Phe Gly Gin Gly Thr Arg Leu Glu Met Lys
100 105
13
351
DNA
Homo sapiens
13
cagctgcagc tgcaggagcc gggcccagca ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtga ctccaccagc agttttattt actactgggg ccgcatccgc 120
cagcccccag ggaaggggct cgagtqcaut gggactattc a~tatagtgg gagcacctac j.3C
tacaacccgr ccctcaagag tccagtcacc atatccgtag acacgtccas gaaccagttc 24C
tccctgaagc cgaggtctgt caccgccgca gacacggctg cgtattactg tgcgagacat 30C

:actg
cacTgggttt ttgactactg gggccaggga acccaggtca ccgtctcccc a 351
14
111
PRT
Homo sapiens
14
Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Lea Val Lys Pro Ser Glu
15 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser lie Ser Ser Phe
20 25 30
lie Tyr Tyr Trp Gly Trp He Arg Gin Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp He Gly Thr lie Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe
65 70 75 80
Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg His His Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Gin
100 105 110
Val Thr Val Ser Ser
115
15
321
DNA
Homo sapiens
15
gacattgtgc tgactcagtt tccagacttt cagtctgtga ctccaaagga gaaagtcacc 60
atcacttqcc gggccagtca ggtcattgqt agtagcttac actggtacca gcagaaacca 120
gatcagtctc cgaagctcct catcaagtat gcttcccagt ccttctcagg ggtcccctcc 180
aggttcagtg gcagtggatc taggacagat ttcaccctca ccatcaataq cctggaagtt 2^0
gaagatgctg caacgtatta ctgtcatcag actactattt taccgtggac gttcqgccaa 300
gqgaccaagg tggaagtcaa a 32;

16
10"?
PRT
Homo sapiens
16
Asp He Val Leu Thr Gin Phe Pro Asp Phe Gin Ser Val Thr Pro Lys
15 10 15
llu Lys Val Thr He Thr Cys Arg Ala Ser Gin Vai lie Gly Ser Ser
20 25 30
Leu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pre Lys Leu Leu He
35 40 45
Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Sec Gly Ser Gly Thr Asp Phe Thr Leu Thr He Asn Ser Leu Glu Val
65 70 7 5 80
Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Thr lie Leu Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu Val Lys
100 105
17
35',
DNA
Homo sapiens
17
cagctgcagc tgcaggagtc gggcccagga ctggcgaagc etteggagae cctgcccctc 6C
acccgcactg cccctggtgg ctccatcagc agtagtagtt actactgggc ctggatccgc 120
cagcccccag ggaagggact ggagtggatt gggaccatcc actatagtgg gaccacctac 180
tacaattcgt ccctgaagag tcgagtcacc atatccgtag acacgtccca gaaccagttc 240
rccctgaagc zgaqczctgz gaccgccgca gataeggctg tgtattactg tgegagacat 3C0
cactgggtt- ttgac^acxg gggccaggga accctggtca ccgtctcctc a 351
18
117
PRT
Homo sapiens
1.8

;JS
!,eu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Phe lie Ser Ser Se;
20 25 30
Ser Tyr Tyr Trp Gly Trp lie Arg Gin Pro Pro Gly Lys Gly Leu Glu
35 * 40 45
Trp lie Gly Thr He Tyr Tyr Ser Gly Thr Thr Tyr Tyr Asn Ser Ser
50 55 60
Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Gin Asn Gin Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg His His Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Leu
100 105 110
Val Thr Val Ser Ser 115
19
321
DNA
Hoino sapiens
19
gaagttgtgc tgactcagtc tccagacttt cagtctgtga ctccaaagga gaaaatcacc 60
atcacctgcc gggccagtca catcatrggt actagcttac actggtatca gaagaaacca 120
gatcagtctc caaagctcct catcaactac gcttcccagt ccttctcagg ggtcccctcg 190
aggttcagtg gcagtggatc tgggacagaa ttcaccctca ccatcaatag cctggaagct 24 0
gaagatactg caacgtatta ctgtcatcag agtactaatt taccgtggac gttcgaccaa 300
gggaccaagg tggaaatcaa a 321
2C
107
PR?
Homo sapiens
20
Glu Val Val Leu Thr Gin Ser Pro Asp Phe Gin Ser Val Thr Pro Lys
15 10 15

Glu Lys lie Thr He Thr Cys Arg Ala Ser Gin lie lie Gly Thr Ser
20 ' 25 30
Leu His Trp Tyr Gin Lys Lys Pro Asp Gin Ser Pro Lys Leu Leu lie
35 40 45
Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Ar9 Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Asn Ser Leu Glu Ala
65 70 75 80
Glu Asp Thr Ala Thr Tyr Tyr Cys His Gin Ser Thr Asn Leu Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
21
324
DNA
H omo sapiens
21
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgcc gggcaagrca cagcattacc aggtatazaa attggtatca gcagaaacca
gggaaagccc ctaacctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccttca
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tccgcaacct
gaagattttc caacttacta ctgtcaacag agctacagtc cccctc^gat caccttccgc
caagggacac gactggagat taaa
22
108
PRT
Homo sapiens
22
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser His Ser lie Thr Arg :yr
20 25 30
lie Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Asn Leu Leu He

35

40

45

Tyr Ala Ala Ser S^r Leu Gin Ser Gly Vai Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Pro Gin Pro
65 7G 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Ser Pro Pro
85 90 95
lie Thr Phe Gly Gin Gly Thr Arg Leu Glu lie Lys
100 105
23
372
DMA
Homo sapiens
«S00> 23
gaggtgcagc tagtgg-agtc tgggggaggc ctggtccagc ctggggcgtc cctcagactc 60
tcctgtgcag cctctggatt cacctttagt agctactgca zgagctgggt ccgccaggct 12C
ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaagtga gaagtactat 180
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 24C
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagatggggg 300
gtttttggtt cggggagtta ttatatccct tttgactact ggggccaggg aaccctggtc 36G
accgtctcct ca 372
24
124
PRT
B.ora.Q sapie-fia
24
Glu Val Gin Leu val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly
15 10 15
Ser Leu Arg Leu ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Trp Met Ser Trp val Arc Gin Ala Pro Gly Lys Gly Lei: Glu Trp Val
35 40 45
Ala Asn lie Lys Gin Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Vai Tyr Tyr Cys
85 9C 95
Ala Arg Trp Gly Val Phe Gly Ser Gly Ser Tyr Tyr lie Pro Phe Asp
100 105 110
Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser
115 120
25
321
DNA
Homo sapiens
25
gp.catccaga tcacccagcc tccatcctca ctgtctccat ctgtgcgaga cagagtcace 6C
atcacttgtc gggegagtea gggcattagg aattatttag cctggtttca gcagaaacca 12C
gggaaagece ctaagtccct gatctatgct gcatccagtt tgcaaagtgg cgtcccatca 180
acgttcsgcg gcagtggatc tgggacacat tccactctca ccatcagtag tttgeagect 200
gaagattttg caagttatnc ctgccaacag tatgagattt atcctctcac tttcggcgga 300
gggaccaagg tggagaicaa a 321
26
107
PRT
Homo sapiens
26
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Arg Asn Tyr
20 25 30
Leu Ala Trp Phe Gin Gin Lys Pro Gly Lys Ala Pro Lys Ser Leu lie
35 AG 15
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Thr Phe Ser Gly
50 55 6C
Ser Gly Ser Gly Thr His Phe Thr Leu Thr lie Ser Ser Leu Gin Pro

70

75

80

Glu Asp Phe Ala Ser Tyr Phe Cys Gin Gin Tyr Glu He Tyr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu He Lys
100 105
27
354
DNA
Homo sapiens
27
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaacg ggctggagtg ggtggcagtt atatggtatg atagaagtaa taaatactat 180
gcagactccg tgaagggccg gutcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatgg acagcctgag agccgaggac acggcrgtgt attactgtgc ggggggacgs 300
tcccggggag cctttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354
28
118
PRT
Homo sapiens
28
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
15 10 15
Ser Leu Arc Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gin Mer Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cy-
35 90* 95

Airily Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thr
~^* i_00 105 110
Leu Val Thr Val Ser Ser 115
29
321
DNA
Homo sapiens
29
gacatccaga tgacccagtc tccatcttcc ctgtctgcat ctgtagtf^ga cagagtcacc 60
atcacttgtc gggcgagtca gggtattagc agctggttag cctggtsitca gcagaaaccc 120
gggaaagccc ctaagctcct gatctatgct gcatccagct tgcaaacjtgg gqtcccatca 180
agattcagcg gcagtggccc tgggacagat ttcactctca ccatcadcag cctgcagcct 240
gaagattttg caacttacta ttgccaacgg actaacagcc tccctcdgac gtccggcnaa 300
gggaccaagg cggaaatcaa a 321
30
107
PRT
Homo sapiens
30
Asp He Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ai 15 10 15
Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Ly5 Leu Leu He
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg" Phe Ser Gly
50 55 6G
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Sei^ ^=u Gin Pro
65 70 75 20
Glu ASD Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Set ?-ie Pro Arc
85 SO 95
Thr Phe Gly Gin Gly Thr Lys Val Glu lie Lys
100 105

31
351
DNA
Homo sapiens
31
cagctgcagt tgcagg^gtc gggcccagga ctggtgaacc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc agtagtaatt actactgggg ctggatccgc 12G
cagcccccac ggaagg^gct ggagtggatt gggactatat attatactgg gagtacctac 18C
tacaacccgt ccctca^gag tcgagtcacc atatccgtag acacgtccaa gaaccagttc 240
tccctgaagt tgagct^tgt gaccgccgca gacacggctg tg-attactg tgcgagacat 300
cactgggttt ttgact^ctg gggccaggga accctggtca ccgtctcctc a 351
32
117
?HT
Honio sapiens
32
Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pre Ser Glu
15 10 15
Thr Leu Ser Leu Tar Cys Thr Val Ser Gly Gly Ser lie Ser Ser Ser
20 25 30
Asn Tyr Tyr Trp Gly Trp He Arq Gin Pro Pro Gly Lys Gly Leu Glu
35 4 0 4 5
Trp He Gly Thr lie Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Vqi Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe
65 TO 75 80
Ser Leu Lys Leu St>r Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
8$ 90 95
:ys Ala Arg His H.i_s Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Leu
100 105 110
'ai Thr Vai Ser S^r 115
33 321

:2l5V
33
gaaattgtgc tgactcagtc tccagacttt ctgtctgtga ctccaaagga gaaacticacc 60
atcacctgcc gggccagtca gatcattggt agtagcttac actggtacca acagaaacca 120
gatcagtctc caaaactcct catcaagtat gcttcccagt ccttctcagg ggtcccctca LEO
aggttcagtg gcagtggatc tgggacagat ttcaccctca ccctcaatag cctggaagct 240
gaagatgctg caacgtatta ctgtcatcag agtactattt tiaccgtggac gtucggccaa 300
gggaccaagg tggaaatcaa a 321
34
107
PRT
Homo sapiens
34
Giu lie Val Lea Thr Gin Ser Pro Asp Phe Leu Ser Val Thr Pro Lys
15 10 15
Glu Lys Val Thr He Thr Cys Arg Ala Ser Gin He He Gly Ser Ser
20 25 3C
Leu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Lys Leu Leu He
35 40 45
Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Leu Asn Ser Leu Glu Ala
65 70 75 80
Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Thr He Leu Pre Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
35
351
DNA
Homo sapiens
35
cagengcage tgcaggagtc gggcccagqa ctggugaagc cctcggagac cc^gtccctc 60
acctgcactg tctctggtgc ctccaccagc agtagtacci: actacteggg ctggatccgc 120

cagcccccag ggaaggggct ggagtggatt gggactatat attatagtgg gagcacctac ISO
tacaacccgt ccctcaaaag tcgagtcacc atarccgtag acacgtccaa gaaccagttc 240
tccctgaagc tgaactctgt gaccgccgca gacacggctg tgtattactg tgcgagacat 300
cactgggttt ttgactactg gggccaggga accctggtca ccgtctccrc a 351
36
117
PRT
Homo sapiens
36
Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GIu
15 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser He Ser Ser Ser
20 25 30
Thr Tyr Tyr Trp Gly Trp lie Arg Gin Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp He Gly Thr He Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe
65 70 75 80
Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
65 90 95
:ys Ala Arg His His Trp Val Phe Asp Tyr Trp Gly Gin Gly Thr Leu
100 105 110
Val Thr Val Ser Ser 115
37
321
DNA
Homo sapiens
37
gaaattgtgc tgactcagtc ~ccagacttt ctgtctgtga ctccaaagga gaaagtcacc 60
atcacctgcc gggccagtca caccattiggt agtagtttac acteg-acca acagaaacca 120
gatcagtctc caaacctcct caccaagtat gctcctcagt ccgtc-cagg ggtcccctcg Ifid

L
^■fcttcagtg gcagtgggtc tgggacagat ttcaccctca ccctc^atag cctggaagct 240
gaagatgctg caacgtatta ctgtcatcag agtactattt taccgCggac gctcggccaa 300
gggaccaagg tggaaatcaa a 321
38
107
FRT
Homo sapiens
30
Glu He Val Leu Thr Gin Ser Pro Asp Phe Leu Ser V#l Thr Pre Lys
15 10 15
Glu Lys Val Thr He Thr Cys Arg Ala Ser Gin He He Gly Ser Ser
20 25 30
.eu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Asn Leu Leu He
35 4 0 4 5
jys Tyr Ala Ser Gin Ser Val Ser Gly Val Pro Ser Al~g Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Leu Asn Ser Leu Glu Ala
65 70 75 80
Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Thr He Leu Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu lie Lys
100 105
35
360
DNA
Homo sapiens
39
caggtgcagc tggtggagtc tgggggaggc tcggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagg gactattaca tgagctggat ccgccaggct 120
ccagggaagg ggctggagtg ggttgcattc attagtagta gtggtagtat tatatactac 130
gcagactctg tgaagggccg atucaccatc tccagggaca aegec^agaa ctcactgttt 240
ccgcaaatga acagectgag agecgaggae acggccgtgt attaccgtgc gagagatgeg 300
catatagcag ctcgtggcac ggacgtctgg cgccaacgga ccacggtcac cqzctcc.tza 36C

^,0> 4 0
'9m> i2o
PRT
Homo sapiens
40
Gin Vai Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asp Tyr
20 25 30
Tyr Met Ser Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Phe lie Ser Ser Ser Gly Ser tie lie Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg phe Thr lie Ser -Arg Asp Asn Ala Lys Asn Ser Leu Phi
65 7 0 7 5 30
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly His He Ala Ala Arg Gly Met Asp Val Trp Gly Gin
100 105 11C
Gly Thr Thr Val Thr Val Ser Ser
115 120
41
324
DNA
Homo sapiens
41
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 63
atcacttgcc gggcaagtca gagcattaac aagtatataa attggtatca gcagaaacca 120
gggaaagece ctaagctcct gatttatgct gcatccagtt tgcaaagtgq ggtcccatca 180
aggttcaatg gcagtggatc tggcacagat ttcactttca ccatcaacac cctgcaacct 240
gaagattttg caacttacta ctgtcagcag acttacagta cccccccgat caccttcggc 300
caagggacac gactggagat: taaa 32 4
42 108 PRT

^%

*
Homo sapiens
42
Asp He Gin Met Thr Glr. Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15

Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Ser lie Asn Lys Tyr
20 25 30
He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He
35 40 4S
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Asn Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr He Asn Thr Leu Glr. Pre
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Thr Fro Pro
85 90 95
He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys
100 105
43
360
DNA
Homo sapiens
43
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt cacctccagt gactactaca tgaactggat ccgccaggct 120
ccagggaagg cgctggagtg ggtttcattc attagtagta gtggtagtac catatactac 180
gcagactctg tgaagggccg attcaccatc tccagggaca aegecaagaa ctcactgtat 240
ctgcaaatga acagcctgag aaccgaggac acggccgtgt attactgtgc gagagatggg 300
catatagcag ctcgtggtat ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360
14
120
PRT
Homo sapiens
44
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Giy Gly
1 5 10 15

Se^Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Tyr Met Asn Trp lie Arg Glr. Ala Pre Gly Lys Gly Leu GIu Trp Val
35 40 45
Ser Phe lie Ser Ser Ser Gly Ser Thr lie tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 "JO 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly His lie Ala Ala Arg Gly Met Asp Val Trp Gly Gin
100 1C5 110
;iy Thr Thr Val Thr Val Ser Ser
115 120
45
324
DNA
Homo sapiens
45
gacarccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc ' 6G
atcacttgcc gggcaagtca gagttttagc aggtatataa attggtatca gcagaaacca 120
gggaaagccc ctaaactcct gatctatgct gcatccagtt tgcaaggtgg ggtcccatca 180
aggttcagtg gcagtggatc tgggacagat ttcactctcg ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtcaacag acttacagta cccctccgat caccttcggc 300
caagggscac gactggagat taaa 324
46
108
PRT
Homo sapiens
46
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Ser Phe Ser Arg Tyr
20 25 30

lie 7isn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie
35 10 45
Tyr Ala Ala Ser Ser Leu Gin Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Ala lie Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Thr Pro Pro
85 90 95
lie Thr Phe Giy Gin Gly Thr Arg Leu Glu lie Lys
100 105
47
360
DNA
Homo sapiens
47
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctg~gcag cctctggatt caccttcagt gactactaca Cgaactggat ccgccaggct 120
ccagggaagg ggctggagtg ggtttcatat attagtagta gtggtagtat tatatactac 180
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcacngtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gagagatggg 300
cgtatagtag ctcgtggtat gcacgtctgg ggccaaggga ccacggtcac cgtctcctca 360
48
120
PRT
Homo sapiens
48
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 * 25 30
Tyr Met Asn Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp VaZ
35 A0 45
Ser Tyr lie Ser Ser Ser Gly Ser He He Tyr Tyr Ala Asp Sar Val

t

55

60

Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 ' 70 " 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Arg He Val Ala Arg Gly Met Asp Val Trp Gly Gin
100 105 110
Gly Thr Thr Val Thr Val Ser Ser
115 120
49
324
<:2i2> DNA
Hnrao sapiens
4 9
gacacccaga tgacccagtc tccatcctcc ctgtgtgcat ctgtaggaga cagagtcacc 6C
atcacttgcc gggcaagtcg gagcattacc aggtatttaa attggtatca gcagaaacca 12G
gggaaagccc ctaagctcct gatccatggt gcatccagtt tgcaaagtgg ggtcccatcc 180
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtcaacag agttacagta cccctccgat caccttcggc 300
caagggacac gactggagat taaa 324*
50
108
PRT
Homo sapiens
50
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Cys Ala Ser Val Gly
15 1C 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Arg Ser lie Thr Arg Tyr
20 25 30
Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie
35 40 45
Tyr Gly Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arc Phe Ser Gly
50 55 60

SfiAtGly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
6^ 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser T'hr Pro Pro
95 90 95
He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys
100 105
51
363
DNA
Homo sapiens
51
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggcc cctgagactc 60
tcctgrgcag cgtctggatt ctccttcagt atctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atttggtttg atggtagtaa taaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
cLC gcgtcttact atggttcggg gatggactac tggggccagg gaacccCggt caccgtctcc 360
tea 3 63
52
121
PRT
Homo sapiens
52
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro GTy Arg
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser He Tyr
20 25 30
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu QJ_U Trp Val
35 40 45
Ala Val He Trp Phe Asp Gly Ser Asn Lys Tyr Tyr Aia }\Sp ser val
50 55 60
Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ser Lys Asn -r^r LSU Ty3
65 70 75 go
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys

85

90

95

Ala Arg Asp Lys Ala Ser Tyr Tyr Gly Ser Gly Met Asp Tyr Trp Gly
100 105 110
Gin Gly Thr Leu Vai Thr Vai Ser Ser
115 120
53
327
DNA
Homo sapiens
53
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttacc agcacctact taccctggta ccagcacaga 120
cctggccagg ctcccaggct cctcatctct ggtgcatcca ggagggccac tggcatccca 180
gacacg'tca gzggcagtgg gtctgggaca gacttcacr.c ccaccatcaq cagaccgcag 24C
cctgaagatt ttgcagtgta ttactgtcag cactatgcta gctcattcac gtggacgttc 300
ggccagggga ccaaggtgga aatcaaa 327
54
109
?RT
Homo sapiens
54
Glu He Vai Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
15 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Vai Ser Ser Thr
20 25 30
Tyr Leu Ala Trp Tyr Gin His Arg Pro Gly Gin Ala Pro Arg Leu Leu
35 40 45
lie Ser Gly Ala Ser Arg Arg Ala Thr Gly lie Pro Asp Arg Phe Ser
50 55 6C
Giy Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Arg Leu Glu
65 70 73 30
Pro Glu Asp Phe Ala Vai Tyr Tyr Cys Gin His Tyr Gly Ser Ser Phe
35 90 95

TtJkrrp Thr Pbe Gly Gin Gly Thr Lys Val Glu He iys
^ 100 105
55
351
DNA
Homo sapiens
«900> 55
gaggtgcagt tggtggagag tgggggaggc ttggtccagc ctggggggtc cctgagactc 6C
tcctgtgcag cctctggatt cacctttagt aacttttgga tgagctgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtggccaac ataaagcacg gtggaagtga gaaatactat 180
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acacactgag agccgaggac acggctgtgt attactgtgc gagagatcct 300
atgtactact ttgactactg gggccaggga accctggtca ccgtctcctc a 351
56
117
PRT
Homo sapiens
56
Giu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe
20 25 30
Trp Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 15
Ala Asn He Lys His Gly Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gin Met Asn Arg Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Pro Met Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu
100 105 110
Val Thr Val Ser Ser 115

57
321
DNA
Homo sapiens
57
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca ggacattaga aatgatttag actggtatca gcagaaacca 120
gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtctacag cataatggtt accctcccag ttttggccag 300
gggaccaagc tggagatcaa a 321
53
107
FRT
Hcrr.c sapiens
58
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Glv
15 10 15
Asp Arg Val Thr lie Thr Cys Arg Ala Sec Gin Asp lie Arg Asn Asp
20 25 * 30
Leu Asp Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pre Lys Arg Leu He
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gin His Asn Gly Tyr Pro Arg
85 90 95
Ser Phe Gly Gin Gly Thr Lys Leu Glu He Lys
100 105
59
354
DNA
Komo sapiens
59

CM^tgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctgqagtg ggtgqcagtt atatggtatg atagaagtaa caaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgrat 240
ctgcaaatga acagcctgag agccgaggac acggctgrgt attactgtgc ggggggacga 300
tcccggggag cctttgacta ctggcgccag ggaaccctgg tcaccgtctc ctca 354
60
ne
PRT
Hono sapiens
60
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ty:
20 25 30
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp val
35 4 0 4 5
Ala Val He Trp Tyr Asp Arg Ser Asri Lys Tyr Tyr Ala Asp Ser Val
50 " 55 60
Lys Gly-Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 " 75 80
Leu Gin Mei Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thi
100 105 110
Leu Val Thr Val Ser Ser 115
61
321
DNA
Homo sapiens
61
gacarccaca r.gacccagrc tccatcntcc g-gtctgcat ctgtaggaga cagaqtcacc 60
at;cacttgLC qcqcgagtca gggtattagc agttggttag cctggtatca qcagaaacca 12C

gggl^agccc ctaagctcct gatctttgct ccatccagtt tgcaaagtgg ggtcccatca 160
agattcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttacta ttgtcaacgg actaacagtt tccctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
62
107
FRT
Homo sapiens
62
Asp lie Gin Met Thr Gin Ser Fro Ser Ser Val Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr lie Thr Cys Arc Ala Ser Gin Gly He Ser Ser Trp
20 2 5 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Tie
35 40 45
Phe Ala Ala Ser Ser Leu Gin Ser Giy Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 90
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Ser Phe Pro Arg
85 ' 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
63
363
DNA
Homo sapiens
63
gaggtgcagc tggtggagtc fcgggggaggc tcggtacagc ctagggggtc cctgagaccc 50
tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct 120
ccagggaagg ggctggagtg ggrttcattc attagtggta gtagtactac car.gr.acnac ISO
gcagactctg tgaagggccg attcaccatc tccagagaca angccaagaa ctcaccg~ae 240
ctgcaaatga acagcctgag agacgaggac acggctgtgt atractgtgc gagattacga 300

tjjkttgact ggtcatatgc ttttgatatc tggggccaag ggacaatggt caccgtctct 360
tea 363
64
121
PR?
Homo sapiens
64
Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Giu Trp Val
35 40 45
Ser Phe lie Ser Gly Ser Ser Ser Thr Men Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr j.Ie Ser Arg Asp Asn Ala Lys Asp. Ser Leu Tyr
65 10 75 80
Leu Gin Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
ALa Arg Leu Arg Tyr Phe Asp Trp Ser Tyr Ala Phe Asp lie Trp Gly
100 " 105 110
Gin Gly Thr Met Val Thr Val Ser Ser
115 120
65
321
DNA
Homo sapiens
65
gacatccaga tgacccagtc tccaccttcc gtgtctacat ctgtaggaga cagagtcacc 60
atcacttgtc gggcgagtca gggtattege agctggttag cctggtatca gcagagacca 120
gggaaagece ctaagctcct gatctatget gcatccagtt tacaa^atgc ggtcccatca 130
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatc^gcag cctgcagcct 240
gaagattttg caacttactt ttgtcaacag gctaccagtt tcccatccac ttccggccct 300
gggaccaaag tggatatcaa c 321

66
10"?
PRT
Homo sapiens
66
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Tbr Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arc Ala Ser Gin Gly lie Arg Ser Trj
20 25 30
Leu Ala Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Lys Leu Leu lie
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Asn Gly Val Pro Ser Acg Phe Ser Gly
50 55 ■ 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin lJro
65 "7 0 75 80
Glu Asp Phe Ala Thr Tyr Phe Cys Gin Gin Ala Thr Ser Phe Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp He Asn
100 105
6"?
354
DNA
Homo sapiens
67
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atagaagtaa taaatactat 160
gtagactccg tgaagcgccg attcaccatc tccagagaca attccaagaa cacgttgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgrgc gqggggscga 300
tcccggggag cctttgacta czggggccag ggaaccctgc tcaccgcctc ctca 35 4
68
118
PRT
Homo sapien;

•4
68
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
15 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 "70 7$ 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thr
100 105 110
Leu Val Thr Val Ser Ser 115
69
321
DNA
Homo sapiens
69
gacacccaga tgacccagtc tccatcttcc gtgtctccac ctgtaggaga cagagtcacc 60
ancacttgtc gggcgagtca ggatattagc agctggttac cctggtatca gcacaaacca 120
gggaaagccc ctaagctcct gatctttgct gcatccagct -gcaaagtgg ggtcccacca 180
agattcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttacta ttgtcaacgg actagcagtt tccctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
70
107
PRT
Homo sapiens
70
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly

5

10

15

Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp He Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He
35 40 45
Phe Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Ser Ser Phe Pro Arg
85 90 95
Thr ?he Gly Gin Gly Thr Lys Val Glu He Lys
100 105
71
" 354
DNA
Homo sapiens
71
caggtgcagc Cggtggagtc rgggggaggc gtggtccagc ctgggaggtc cctcagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactcggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtcgcagtt atatggtatg atagaagtaa taaatactat 180
gcagactccg -gaagggccg attcaccatc tccagagaca attccaagaa cacgctgta'c 240
ctgcaaatga acagcctgag agccgaggac acggctgtat attactgtgc gggggcacga 300
tcccggggag cctttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354
72
118
PRT
Homo sapiens
72
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
2C 2 5 30

4

Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Tyr Trp Gly Gin Gly Thr
100 105 110
Leu Val Thr Val Ser Ser 115
73
321
DN'A
Homo sapiens
73
gacatccaga tgacccagtc tccatcttcc gtg^ctgcat ctgttggaga cagagtcacc 60
atcacttgtc gggcgagtca gggtattagc aqctggttag cctggtatca gcagaaaccc 120
gggaaagccc ctaacctcct gatttatgct gcatccagtt tgcaaagtgg ggtcccatca 180
agattcagcg gcagtggatc tgggacagat ttcactctce ccatcagcag cctgcagcct 240
gaagattttg caacttacca ttgtcaacgg actaacaatt tccctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
74
107
PRT
Homo sapiens
74
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala .Ser Val. Gly
I 5 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Gly He Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Asn Leu Leu He
35 40 45

Ty^Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
'5C 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Asn Phe Pro Arg
85 " 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
75
363
DNA
Homo sapiens
7 5
gaggtgcagc tgccggagte tegqgqaggc ttggcacagc ctggggggtc cctgaqactc GO
tcctgtgcag cctctggat" caccttcact agctatagca tgaactgggr ccgccaggct 120
ccagggaagg ggctqgagtg ggtttcatac attagtggta gtagtactac catgtactac 180
gcagactctg tgaagggccg attcaccatc tccagagaca atgccaagaa ctcactytat 210
ctgcaaatga acagcctgag agacgaggac acggctgtgt attactgtgc gaqattacga 300
cattttgact ggtcatatgc ttttgatatc tggcgccaag ggacaatgct caccgtctct 360
tea 363
76
121
PRT
Homo sapiens
76
Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly phe Thr Phe Ser Ser Tyr
20 25 3C
Ssr Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly LQ.J Glu Trp Vei
35 10 45
Ser Tyr lie Ser Gly Ser Ser Thr Thr Met Tyr Tyr Ala ASD Ser Val
50 55 60

4
Lj^^Sly Arg Phe Thr He Ser Arg Asp Asr. Ala Lys Asn Ser Leu Tyr
70 75 80

Leu Gin Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Vai Tyr Tyr Cys
85 90 95
Ala Arg Leu Arg His Phe Asp Trp Ser Tyr Ala Phe Asp He Trp Gly
100 105 110
Gin Gly Thr Met Val Thr Vai Ser Ser
115 120
77
321
DNA
Homo sapiens
77
gacatccaqa tgacccagtc tccatcttcc gtctctacat ctgtaggaga cacagtcacc 60
atcacttgrc gggccagtca gggtattagc agccggtzaq cctggcatca gcagagacca 120
gggaaagccc ctaagctcct gatcratgct gcatccagtt rgcaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttactt ttgtcaacag gctaccagtt tcccattcac tttcggccct 300
gggaccaaag tgggtatcaa a 321
79
107
PRT
Homo sapiens
78
Asp He Gin Met Thr Gin Ser Pro Ser Ser Val Ser Thr Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Gly He Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gin Gin Arg Pro Gly Lys Ala Pro Lys Leu Leu lie
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 7C 75 80

iflRs
GHTOsp Phe Ala Thr Tyr Phe Cys Gin Gin Ala Thr Ser Phe Pro Phe
85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Gly lie Lys
100 105
79
366
DNA
Homo sapiens
79
caggtgcagc tggtgcagtc tggggctgag gtgaagaaac ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggata caccttcacc ggctaccata tgcactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcaacccta acagtggtgg cacaaactat 130
gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctac 240
atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagagatagg 300
gctttttgga gtggttatca cggttcggac gtctggggcc aagggaccac ggtcaccgtc 360
tcctca 366
80
122
PRT
Homo sapiens
80
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
15 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
His Met His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met
35 40 45
Gly Trp lie Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gin Lys Phe
50 55 60
C-ln Gly Arg Val Thr Mat Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr
65 70 75 8C
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Al.a Val Tyr Tyr Cys
85 90 95

Arg Asp Arg Ala Phe Trp Ser Gly Tyr His Gly L§u Asp Val Trp
100 105 110
Gly Gin Gly Thr Thr Val Thr Val Ser Ser
115 120
81
321
DNA
Homo sapiens
81
gacatccaga tgacccagcc tccatcctcc ctgtctgcat ctgtacjgaga cagagtcacc 60
atcacttgcc gggcgagtca ggtcattgcc aattatttag cctggtatca gcagaaacca 129
ggaaaagttc ctaaactcct gatctatgct gcatccactt tgcaat;Cagg ggtcccatct 180
cggttcagtg gcagtggatc cgggacagat ttcactctca ccatc^gcag cctgcagcct 240
gaagatgttc caacttatta ctgtcacacg tataagagtg ccccgt^ggac gttcggccaa 3C0
gggaccaagg tggaaatcas a 321
82
107
PRT
Homo sapiens
82
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Val IIe Ala Asn Tyr
20 25 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pre Lys Leu Leu He
35 40 4$
Tyr Ala Ala Ser Thr Leu Gin Ser Gly Val Pro Ser Atg phe Ser Gly
50 55 ' 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser S&r Leu Gin Pro
65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys His Thr Tyr Lys S^r Ala Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu tie Lys
100 105

> 83 .
357
DNA
Homo sapiens
83
caggtgcagc tggtgcagtc tggggctgag gtcaagaagc ctggggcctc agtgaaggtt 60
tcctgcaagg cttctggata caccttcacc aqttatgata tcaactgggt gcgacagccc 120
actggacaac ggcttgagtg gatgggatgg atgaacccta acagtggtaa cacaggctat 160
gcacagcagt tccagggcag agtcaccatg accaggaaca cctccataac tacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagaaaag 300
tatagcagtt cgctctttga ctcctggggc cagggaaccc tggtcaccgt ctcctca 357
34
119
PRT
Horr.c sapiens
34
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
15 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Asp lie Asn Trp Val Arg Gin Ala Thr Gly Gin Gly Leu Glu Trp Met
35 4 0 .. .-_ 4 5
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gin Gin Phe
50 55 60
Gin Gly Arg Val Thr Met Thr Arg Asn Thr Ser lie Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Glu Tyr Ser Ser Ser Leu Phe Asp Ser Trp Gly Gin Gly
1C0 105 110
Thr Leu Val Thr Val Ser Ser 115
85 321

4
DNA
I3> Homo sapiens

85
gacatccaga tgacccagcc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcactrgcc gggcaagtca gggcattaga aataatttag gctggtttca gcagaagcca 120
gggaaagccc ctaagcgcct aatctatgct gcatccagtt tgcaaagtgg ggtcccatca 18C
aggttcagcg gcagtggatc tggcacaaaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caacttattt ctgtctacag cataataggt accctctcac tttcggcgga 300
gggaccaagg tggagatcaa a 321
86
107
PRT
Homo sapiens
86
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Aia Ser Val Gly
1 5 10 15
Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Arg Asn Asn
20 25 30
Leu Gly Trp Phe Gin Gin L-ys pro Gly Lys Ala Pro Lys Arg Leu lie
35 40 45
Tyr Ala Aia Ser Ser Leu Gin Ser Gly Vai Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Lys Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 10 IS 80
Glu Asp Phe Ala Thr Tyr Phe Cys Leu Gin His Asn Arg Tyr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys val Glu He Lys
100 105
87
372
ON'A
Home sapiens
87
cagctccagc tgg'ggagtc zgggggaggc gtcgtccagc ctgggaggtc cctgacaccc 60
tcctgtgcag cctctggatt caccttcagt agctaccgca tgcactggct cecccaggct 120

^Rggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtac 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt tttactgtgc gagagataga 300
tattgtagta gtaccagctg ctataggggg ctaggctact ggggccaggg aaccctggtg 360
acggtttcat ca 372
88
124
PRT
Homo sapiens
88
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Scr Gly Phe Thr Phe Ser Ser Tyr
20 ' 25 30
Gly Met His Trp Val Arg Gin Ala Fro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val lie Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 " 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Phe Tyr Cys
85 90 95
Ala Arg Asp Arg Tyr Cys Ser Ser Thr Ser Cys Tyr Arg Gly Leu Gly
100 ~ 105 110
Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Se^
115 120
89
321
DNA
Home sapiens
89
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgcaggaaa cagag'ccagc 60
atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatcu gcagaaacca 120

A*
goMLaagccc ctacgcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
aggttcagtg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caagttatta ctgtctacag cataatagtt tcccgtggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
90
107
PRr
Homo sapiens
90
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Ser lie Thr Cys Arg Ala Ser Gin Gly He Arg Asn Asp
20 25 30
Leu Gly Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Thr Arg Leu Hi
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 8G
Glu Asp Phe Ala Ser Tyr Tyr Cys Leu Gin His Asn Ser Phe Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
91
360
DNA
Homo sapiens
91
caggtgcagc tggtggagtc tggggaaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccrtcagt gactactaca rgaactggat ccgccacgct 120
ccagggaagg ggctggagtg gqtttcatac attegtagta gtggcag-iat tatatactac ISC
gcagactctg tgaagggccc attcaccatc tccagggaca accccaagaa ctcactgr.at 2^.0
ctgcaaarga acagcctgag agccgaggac acggccgtgt atcactgLgc gagagar.ggg 30C
cacatagcag ctcgtggtat ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360

92
120
PRT
Homo sapiens
92
Gin Vai Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Giy
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ty:
20 25 30
Tyr Met Asn Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 4S
Ser Tyr lie Ser Ser Ser Gly Ser lie lie Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arc Asp Asn Ala Lys Asn Ser Leu Tyr
65 " 70 75 80
Leu Gin Met Asn Ser Leu Arg Ala Giu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly His lie Ala Ala Arg Gly Met Asp Val Trp Gly Gin
100 105 110
Gly Thr Thr Val Thr Val Ser Ser
115 120
93
324
DNA
Homo sapiens
93
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgcc gggcaagtca gagctttagc aggtatataa attggtatca gcagaaacca
gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaggtgg ggtcccatca
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct
gaagattccg caacctacta ctgccaacag actcacagta accctccgat cacctccggc
caagggacac gactggagat taaa
9d

OjL> PRT
Homo sapiens
91
Asp lie Gin Met Tbr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Ser Phe Ser Arg Tyr
20 25 30
He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly ?hr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
65 70 75 30
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Asn Pro Pro
85 90 95
He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys
100 105
95
360
DNA
Homo sapiens
95
caggcgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagaccc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggcg 120
ccaggcaagg ggctggagCg ggtggcagtt atatggtatg atagaagtaa taaatactat 180
gcagactccg tgaagggCCg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcttgag agccgaggac acggctgtgt attactgtgc ggggggacga 300
tcccggggag cctttgac*:t ctggggccag ggaaccctgg tcaccgtctc ctcagccccc 360
96
118
PRT
Homo sapiens
96
Gin Val Gin Leu vai G-__u Ser Gly Gly Gly Val Val Gin Pro Gly Arg

b

10

15

Ser Leu Arg Leu Ser Cys Ma Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val lie Trp Tyr Asp Arg Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Gly Arg Ser Arq Gly Ala Phe Asp Phe Trp Gly Gin Gly Thr
100 " 105 110
Leu Val Thr Val Ser Ser 115
97
321
DNA
Homo sapiens
97
gacatccaga tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60
atcacttgtc gggcgaatca agacattagc agctggctag cctggtatca gcagaaaqca 120
gggaaagccc ctaaactcct catctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
agattcagcg gcagcggatc tgggacagat ttcactctca ccatcagcag cctgcagccr 240
gaagattttc caacttacta ttgtcaacgg actaacagtt ttcctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
9B
107
PRT
<:213> Homo sapiens
98
Asp lie Gin Met Thr Gin Ser Pre Ser Ser Val Ser Ala Ser Vsl Gly
1 5 10 15

4
A^^Arg Val Thr lie Thr Cys Arg Ala Ser Gin Asp Ile Ser Ser Trp
20 25 30

Leu Ala Trp Tyr Gin Gin Lys Ala Gly Lys Ala Pro Lys Leu Leu lie
35" 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
65 70 75 60
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Ser Phe Pro Arg
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys
100 105
99
351
DNA
Homo sapiens
99
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60
tcctgcaagg catctggata caccttcacc agctactata tgtactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggaata atcaacccta gtcgtggCag cacaacctac 180
gcacagaagt tccagggcag agtcaccatg accagggaca cgtccaCgag cacagtctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt antactgtgc gagagqcagc 300
tcgccgttct ctgactactg gggccaggga accctggtca ccgtctCctc a 351
100
117
PRT
Homo sapiens
100
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys pro Gly Ala
15 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr ?he Thr Ser Tyr
20 25 30
Tyr Met Tyr Trp Val Arc Gin Ala Pro Gly Gin Gly Leu Glu Trs Met
35 40 45

Giy""*rie He Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gin Lys Phe
50 55 60
Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyj
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Ser Ser Pro Phe Phe Asp Tyr Trp Gly Gin Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
101
321
DNA
Homo sapiens
101
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcactitgcc gggcaagtca gatcattagc cactttttaa attggtatca gcagaaacca 12C
gggaaagccc ctaagctcct ggtctatgtt gcatccagtt tgcaaagtgq ggtcccatca 180
agattcagng gcagtggatc tgggactgat ttcactctca ccatcagcag -ictgcaacct 240
gaacattttg caacttacta ttgtcaacag agtttcagta taccgctcac tttcggcgga 300
gggaccaagg tggagatcaa a 321
102
107
PRT
Homo sapiens
102
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin He He Ser His Phe
20 25 30
Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Va'.
35 40 45
Tyr Val Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser S£r ^eu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Phe S«?r Ile Pro ^eu
85 90 35
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
103
361
DNA
Homo sapiens
103
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctggga^gtc cctgagagtc 60
tcctgtgcag cgtctggatt tatgttcaga agctatggca tqcact-9QQz ccgccaggcr 120
ccaggcaagg ggctggagtg ggtggcagtt atatcgcatg atggaa^taa taaaaatca:: 1SD
ggagactccg tgaagggccg attcaccatc tccagagaca attcc#a9aa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgrgt attact9t9c gagagggaga 300
ctggcagggg ggggccccta ttactattac tactacggta tggaccjtct(3 gggccaacgg 360
accacggtca ccgtctcctc a 331
104
127
PRT
Homo sapiens
104
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro G1y Ar 15 10 15
Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Met PJ»e Arg Ser Tyr
20 25 3°
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly L 35 Ala Val He Trp His Asp Gly Ser Asn Lys Asn His GJ-Y AsP Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys A^ ?h- Leu Ty;
65 70 75 RO

.■sw^bxn Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Va1 TVr TYr CYS
85 90 95
Ala Arg Gly Arg Leu Ala Gly Gly Gly Pro Tyr Tyr Tyf Tvr Tyr TYr
100 105 1X0
Gly Met Asp Val rrp Gly Gin Gly Thr Thr Val Thr Va1 Ser Ser
115 120 125

105
333
DNA
Homo sapiens
105
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctg^a?a gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtaatg gataca?cta tttggattgg 120
tacctgcaga agccagggca gtcrccacag ctcctgatct atttgg zccggggtcc ctgacaggtt cagtggcact ggatcaggca cagattt-tac actgaaaatc 240
300
accttcggcc aagggacacg actggagatt aaa 333
agcagagtgg aggctgagga tgttgggctt tattactgca tgcaatctct acaaactatc
106
111
PRT
Homo sapiens
106
Asp Ile Val Met Thr Gin Ser Pro Leu Ser Leu Pro Va* Thr pro GIY
; 5 10 15

Glu Pro Ala Ser lie Ser Cys Arg Ser Ser Gin Ser Le
20 25

Li Leu His Ser 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gin Lys Pr° GiY Gin Ser
35 40 45
Fro Gin Leu Leu He Tyr Leu Gly Ser His Arg Ala Se*" G1y Val pco
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Th* Leu L^'s Ile
55 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met Gin Ser
85 90 95

Leu Gin Thr lie Thr Phe Gly Gin Gly Thr Arg Leu Glu lie Lys
100 105 110
107
360
DNA
Homo sapiens
107
caggtgcagc tggcggagtc tgggggaggc ttggtcaagc ctggagggcc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gactactaca tgaactggat ccgccaggct 120
ccagggaagg ggctggagtg ggtttcatac attagT:agta ctggtagtat catatactac 180
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactcxat 2 ctacaaatga acagcctgag agccgaggac acggccgtgt actactgtgc gagaga-ggg 300
cgtatagtag ctcgtggtat cgacgtctgg ggccaaggca ccacggtcac cgtczcctca 360
108
120
PRT
Homo sapiens
108
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Tyr Met Asn Trp He Arc Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 ' 40 45
Ser Tyr lie Ser Ser Ser Gly Ser He He Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 7C 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Arg He Val Ala Arg Gly Met Asp Val Trp Gly Gin
100 105 110
Gly Thr Thr Val Thr Val Ser Ser

115

120

109
324
DMA
Homo sapiens
109
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
ctcacttgcc gggcaagtca cagcattaac aggtatataa attggtatca gcagaaacca 120
gggaaagccc ctaaactcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatct 180
aggttcagtg gcaatggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 2*30
gaagattttg caacttacta ctgtcaacag agttacagta cccctccgat caccttcggc 300
caagggacac gactggagat tact 323
110
108
PRT
Homo sapiens
110
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr Leu Thr Cys Arg Ala Ser His Ser He Asn Arg Tyr
20 25 30
He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser -Gly
50 55 60
Asn Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pro
85 90 95
He Thr Phe Gly Gin Gly Thr Arg Leu Glu He Thr
100 105
111
360
DNA
Homo sapiens

111
caggtgcagc tggtggagtc tgggggaggc gcggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt aga~atggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atatggtacg atggaagaaa taaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attartgtgt gggagtgggt 300
ataacagtga ctggtgcctt tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
112
120
PRT
Homo sapiens
112
Gin Val Gin Leu Val Glu Ser Gly Gly Giy Val Val Gin Pro Gly Arc
5 ■ 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr
20 25 30
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val lie Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Val Asp Ser Val
50 55 " 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 l "75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Gly Val Gly He Thr Val Thr Gly Ala Phe Asp Tyr Trp Gly Gin
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
113
321
DNA
Homo sapiens
113
gaaatagtga tgacgcagtc tccacccacc ctgcctgtgt ctccagggga aagagccacc 60

cTt^Kcctgca gggcca9tca gagtgttcgc agcaacttag cctggtacca acagaaacct 120
aqccaqgctc ccagqctcct- catctatggt gcatccacca gggccactga catcccaacc 180
aqgttcaqtq gcagtq'99tc tgggacagag ttcactccct ccatcagcag cccgcagtct 24C
caagattttg cagtttatta ttgtcagcag tataataact ggcctcggac gtttggccaa 300
gggaccaagg tggaa#tcaa a 321
114
107
PRT
Homo sapi 114
Glu He Val Met l'hr Gin Ser Pro Ala Thr Leu Ser Val Ser Pro G1y
1 5 ' 10 15
Jlu Arg Ala ?h>- l>eu $ez Cys Arg Ala Ser Gin Ser Val Arg Ser Asn
20~ 25 30
Leu Ala Trp Tyr (5ln dn Lys pro G^V G^n A^a Pro Ar9 Leu Leu H-e
35 40 45
Tyr Gly Ala Ser fnr Ar9 Vai Tnr AsP Ile Pro Thr Ar9 p^e Ser G1V
50 55 60
Ser Gly Ser Gly t"r G^-u phe ^r Leu Ser *le Ser Ser Leu G*-n Ser
65 TO 75 80
ilu Asp Phe Ala Vai Tyr Tyr CYS Gin Gin Tyr Asn Asn Trp Pro Arg
g5 90 35
T*\i V\\t Q,Y$ ^\T, €>Vi "^ V}* ^"^ ^» Wfc \*}-&
100 105
115
354
DNA
Homo sapi^ns
115
caggtgcagc tggr.g3a9tc c99g99aggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtct#9at- caccttcagc agctatggca rgcactgggt ccgccaggct 120
ccaggcaagc ggccgga9t9 ggtggcagtc atatggtatg atacaagtaa taaaCactat 180
qcagactccg tgaagg9cc9 attcaccatc tccagagaca attccaagaa cacgctgtat 2-50

cicaaatga acagcctgag agccgaggac acggctgtgt attactgtgc ggggggacga tcciggggag cctttgactt ctggggccag ggaaccctgg tcaccgtctc ctca
116
118
PRT
Homo sapiens
116
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
15 10 15
Ser Leu Arg Leu Ser- Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val lie Trp Tyr Asp Arg Ser Asn l.ys Tyr Tyr Ala Asp Ser Val
50 " 55' 60
Lys Gly Arg Phe Thr lie Ser Arc Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 V5 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Gly Arg Ser Arg Gly Ala Phe Asp Phe Trp Gly Gin Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
117
306
DNA
Homo sapiens
117
cagtctccat cttccgtgtc tgcatctgta ggacacagag tcaccatcac ttgtcgggcg
agtcagggta ttagcagctg gttagcctgg tatcagcaga aagcagggaa agcccctaaa
ctcctgatct attctgcatc cagr.ttgcaa agtggggtcc catcaagatt cagcggcagt
ggatctggga cagatttcac tctcaccatc agcagcctgc agcctgaaga ttttgcaact
cactatt-gcc aacggactaa cagttttcct cggacgttcg cccaagggac caaggtggaa
atcaaa

A
118
107
PRT
Homo sapiens
118
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Gly lie Ser Ser Trp
20 25 30
Lea Ala Trp Tyr Gin Gin Lys Ala Gly Lys Ala Pro Lys Leu Leu He
35 40 45
Tyr Ser Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 30
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Arg Thr Asn Ser Phe Pro Arg
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
119
351
DNA
Homo sapiens
119
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg cttcatcagc agtagtagtt actactgggg ctggatccgc 120
cagcccccag ggaagggact ggagtggatt gggaccatct attatagtgg gaccacctac 180
tacaattcgt ccctgaagag tcgagtcacc atatccgtag acacgtccca gaaccaqttc 24C
tccctgaagc tgagctctgt gaccgccgca gatacggctg tgtattactg tgcgagacat 30C
cactgggttt ttgactactg gggccaggga accctggtca ccgtctcctc a 351
120
117
PRT
Homo saniens

A
M$> 120

Glrv Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val L/s pro Ser Giu
15 10 ^5
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Phe lj-e Ser Ser Se^
20 25 30
Ser Tyr Tyr Trp Gly Trp lie Arg Gin Pro Pro Gly L^s G1V Leu Glu
35 40 4?
Trp lie Gly Thr He Tyr Tyr Ser Gly Thr Thr Tyr T/r Asn Ser Ser
50 55 60
Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser G±n Asn Gln Phe
65 70 75 so
Ser Leu Lys Leu Ser Ser val Thr Ala Ala Ass Thr A>a Val TV"r Tyr
8 5 90 95
Cys Ala Arg ttis nis Trp Val Phe Asp Tyr Trp Gly G>n "^V "1'nr '^eu
100 105 u0
Val Thr Val Ser Ser 115
121
321
DMA
Homo sapiens
121
gaagttgtgc tgactcagtc tccagacttt cagtctgtga ctcca^a99a gaaaatcacc 6C
atcacctgcc gggccagtca gatcattggt actagcttac actgg^atca gaagaaacca 120
gatcagtctc caaagctcct catcaactat gcttcccagt ccttctcai39 ggtcccctcg 180
aggttcagtg gcagtggatc tgggacagaa ttcaccctca ccatc^ata9 cctggaagct 240
gaagatactg caacgtatta ctgtcatcag agtactaatt taccgOS30 gttcggccaa 300
gggaccaagg tggaaatcaa a 321
122
107
PRT
Homo sapiens
122
Glu Val Val Leu Thr Gin Ser Pro Asc Phe Gin Ser V^1 Thr Pre Lys

5

10

15

Glu Lys He Thr He Thr Cys Arg Ala Ser Gin He He Gly Thr Ser
20 25 3G
Leu His Trp Tyr Gin Lys Lys Pro Asp Gin Ser Pro Lys Leu Leu He
35 40 45
Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr He Asn Ser Leu Glu Ala
65 70 75 80
Glu Asp Thr Ala Thr Tyr Tyr Cys His Gin Ser Thr Asn Leu Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
IOC 105
123
381
DNA
Homo sapiens
123
caggtgcagc tggcgcagcc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggata caccttcatc ggctactatc ttcactgggt gcgacaggcc 120
cctggacaag ggcttgaatg gatgggatcg atcaacccta acagtggtgg cacaaactat 180
gcacagaagt ttcagggcag ggtcaccatg atcagggaca cgtccatcaa cacagcctac 240
atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagacataaa 300
cgtatcacta tggttcgggg agtccactat ctctactacg gttgggacgt ctggggccaa 360
gggaccacgg tcaccgtctc ctca 384
124
128
PRT
Homo sapiens
124
Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe He Gly Tyr
20 25 30

Tyr Leu His Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met
35 40 45
Gly Ser lie Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gin Lys Phe
50 55 60
Gin Gly Arg Val Thr Met lie Arg Asp Thr Ser He Asn Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 . 90 95
Ala Arg Asp Lys Arg He Thr Met Val Arg Gly Val His Tyr Leu Tyr
100 105 HO
Tyr Gly Trp Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser
115 120 125
125
321
DNA
Homo sapiens
125
gacatccaga tgacccagtc tccatccccc ctgtctgcat ctgtaggaga cagagtcacc 6C
atcacttgcc gggcgagtca ggtcattagc aattatttag cctggtiatca gcagaaacca 12C
gggaaagttc ctcagctccc gatctatgct gcatccactt tgcaa'cagg ggtcccatcc 180
cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagatgtug caacttatta ctgtcaaaac tataaaagtg ccccgtggac gtccggccaa 300
gggaccaagg tggaaatcaa a 321
126
107
PRT
Homo sapiens
126
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
ASD Arg Val Thr He Thr Cys Arg Ala Ser Gin Val lie Ser Asn Tyr
20 25 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pro Gin Leu Leu He

35 40 45
Tyr Ala Ala Ser Thr Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gin Asn Tyr Lys Ser Ala Pro Trp
8S 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu lie Lys
100 105
127
116
PRT
Homo sapiens
127
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Tyr Met Ser Trp lie Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 43
Ser Tyr He Ser Ser Ser Gly Ser Thr He Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 " 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Tyr Ser Gly Ser Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val
100 105 HO
Thr Val Ser Ser
115
128 118 PRT

*
i\3> Homo sapiens 128

Gin Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Tyr Met Ser Trp He Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr lie Ser Ser Ser Gly Ser Thr He Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr lie Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 * 75 60
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
35 90 95
Ala Arg Ser He Ala Ala Arg Gly Met Asp Val Trp Gly Gin Gly Thr
100 105 110
Thr Val Thr Val Ser Ser 115
129
114
PRT
Homo sapiens
129
Gin Leu Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
15 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser He Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp He Arg Gin Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp He Gly Ser He Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser Lys Asn Gin Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
130
108
PRT
Homo sapiens
130
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Ser lie Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pre
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pro
85 90 95
Trp Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
131
107
PRT
Homo sapiens
131
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Gly He Ser Asn Tyr

20 25 30
Lea Ala Trp Tyr Gin Gin Lys Pro Gly Lys Val Pro Lys Leu Leu He
35 40 Tyr Ala Ala Ser Thr Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gin Lys Tyr Asn Ser Ala Pro He
85 90 95
Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys
100 105
132
107
PRT
Homo sapiens
«300> 132
Glu He Val Leu Thr Gin Ser Pro Asp Phe Gin Ser Val Thr Pro Lys
1 5 10 15
Glu Lys Val Thr He Thr Cys Arg Ala Ser Gin Ser He Gly Ser Ser
20 25 30
Leu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Lys Leu Leu He
35 40 45
Lys Tyr Ala Ser Gin Ser Fhe Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Asn Ser Leu Glu Ala
65 70 75 80
Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Ser Ser Leu Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
133 105 PRT

Homo sapiens
133
Aso lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 * 5 10 IS
Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Ser He Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 "?5 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser He Thr Phe
55 90 95
Gly Gin Gly Thr Arg Leu Glu He Lys
100 105
134
120
PRT
Homo sapiens
134
Gin Vai Gin Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
15 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Tyr Met His Trp He Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35 " 40 45
Ser Tyr He Ser Arg Ser Gly Ser Leu He Tyr Tyr Val Asp Ser Val
50 55 60
Lys Giy Arg Phe Thr He Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
,eu Gin Ket Asn Ser Leu Arq Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Air. Arg Gly Gly Pro Tyr Ser Gly Ser Pro Phe Asp Tyr Trp Gly Gin
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
135
108
PRT
Homo sapiens
135
Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Thr He Thr Cys Arg Pro Ser Gin Arg He Ser Arg Tyr
20 25 30
Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He
35 ' 40 15
Tyr Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 €0
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pre
85 90 95
Trp Thr Phe Gly Gin Gly Thr Lys Val Glu He Lys
100 105
136
108
PRT
Homo sapiens
136
Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
15 10 15
Asp Arg Val Ser He Thr Cvs Arg Pro Ser Gin Ser Phe Ser Arg Tyr
20 25 30
He Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He

35 40 45
Tyr Ala Ala Ser Ser Leu Val Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Thr Tyr Ser Asn Pro Pro
65 90 95
lie Thr Phe Gly Gin Gly Thr Arg Leu Glu He Lys
100 105
-6^3**

1. / A targeted binding agent that specifically binds to PDGFR-alpha and
^ inhibits the growth of cells that express PDGFR-alpha, wherein the targeted binding agent binds PDGFR-alpha with a KD less than about 40pM.
2. The targeted binding agent of claim 1, wherein said targeted binding agent binds
to PDGFR-alpha and at a concentration of 2 g/ml inhibits greater than or equal to 90%
of tyrosine phosphorylation of PDGFR-alpha on MG-63 cells incubated with 25ng/ml PDGF-AA.
3. The targeted binding agent according to any one of the preceding claims, wherein said targeted binding agent inhibits the proliferation of MG-63 cells incubated with 3.45nM PDGF-AA with an IC50 of less than 3.2nM.
4. The targeted binding agent according to any one of the preceding claims, wherein said targeted binding agent binds to PDGFR-alpha and
inhibits binding of PDGF-AA, PDGF-AB, PDGF-BB, and/or PDGF-CC iigands
to PDGFR-alpha;
inhibits downstream cell signaling implicated in cell growth;
does not cross-react with PDGFR-beta receptor; and/or
does not cross react with other Class III receptor tyrosine kinase family members.
5. The targeted binding agent according to any one of the preceding claims wherein said targeted binding agent inhibits tumor growth and metastasis in a mammal.
6. The targeted binding agent according to any one of the preceding claims, wherein said targeted binding agent comprises a polypeptide comprising the sequence of
i. SEQIDNO. :2;
ii. SEQ ID NO.: 2, wherein the sequence comprises any one of the unique
combinations of germline and non-germline residues indicated by each
row of Table 6; iii. SEQIDNO. : 10; iv. SEQ ID NO. : 10, wherein the sequence comprises any one of the unique
combinations of germline and non-germline residues indicated by each
row of Table 8; v. SEQIDNO.: 14;

vi. SEQ ID NO. : 14, wherein the sequence comprises any one of the unique
combinations of germline and non-germline residues indicated by each
row of Table 10; vii.SEQIDNO. : 4;
viii. SEQ ID NO. : 4, wherein the sequence comprises any one of the
unique combinations of germline and non-germline residues indicated by each row of Table 7; ix. SEQ ID NO. : 12; x. SEQ ID NO. : 12, wherein the sequence comprises any one of the unique
combinations of germline and non-germline residues indicated by each
row of Table 9; xi. SEQ ID NO. : 16; or xii. SEQ ID NO. : 16, wherein the sequence comprises any one of the unique
combinations of germline and non-germline residues indicated by each
row of Table 11.
7. A targeted binding agent according to any one of the preceding claims comprising an
amino acid sequence comprising
a CDR3 sequence as shown in Table 12 or Table 13;
a CDR3 sequence as shown in Table 12 and a CDR3 sequence as shown in
Table 13; a CDRI, CDR2 and CDR3 sequence as shown in Table 12; a CDRI, CDR2 and CDR3 sequence as shown in Table 13; or a CDRI, CDR2 and CDR3 sequence as shown in Table 12 and a CDRI. CDR2 and CDR3 sequence as shown in Table 13.
8. A targeted binding agent according to any one of the preceding claims wherein said
targeted binding agent is
an antibody;
a monoclonal antibody;
a fully human monoclonal antibody;
a binding fragment of a fully human monoclonal antibody; or
a binding fragment of a fully human monoclonal antibody selected

from the group consisting of Fab, Fab', F(ab') 2, Fv and dAb. A targeted binding agent according to any one of the preceding claims wherein said targeted binding agent is
i. any one of the monoclonal antibodies as shown in Tabic 1; ii. monoclonal antibody 2 .175 .3; iii. monoclonal antibody 2 .175 .3 variant A; iv. monoclonal antibody 2 .449.1 .3; v. monoclonal antibody 2.449 .1 .3 variant A;
vi. monoclonal antibody 2 .449.1 .3 wherein the antibody comprises a light chain polypeptide comprising the sequence of SEQ ID NO.: 12, wherein the sequence comprises the unique combination of germline and non-germline residues indicated by row 3968 of Table 9; or monoclonal antibody 2.998 .2.
10. A targeted binding agent wherein said targeted binding agent comprises an antibody
which comprises variants or derivatives of the monoclonal antibodies of any
one of claims 6 to 9: and/or has at least 80% amino acid sequence identity with the monoclonal antibody
of any one of claims 6 to 9.
11. A targeted binding agent which
competes for binding to PDGFR-alpha with any one of the targeted binding
agents of claims 1-10; and/or binds to the same epitope on PDGFR-alpha as any one of the targeted binding
agents of claims 1-10.
12. A nucleic acid molecule encoding the targeted binding agent of any one of the preceding claims.
13. A vector comprising the nucleic acid molecule of claim 12.
14. A host cell comprising the vector of claim 13.
15. A method of producing an antibody by culturing the host cell of claim 14 under conditions wherein a nucleic acid molecule is expressed to produce the antibody, followed by recovering the antibody.
16. A method of treating a neoplastic disease in an mammal, comprising :

selecting an animal in need of treatment for a neoplastic disease ; and ^ ^ administering to said animal a therapeutically effective dose of the targeted binding agent of any one of claims 1 to 11.
17. The method of claim 16, wherein said neoplastic disease is selected from the group consisting of. melanoma, small cell lung cancer, non-small cell lung cancer, glioma, hepatocellular (liver) carcinoma, thyroid tumor, gastric (stomach) cancer, prostate cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, esophageal carcinoma, head and neck cancers, mesothelioma, sarcomas, biliary (cholangiocarcinoma), small bowel adenocarcinoma, pediatric malignancies, epidermoid carcinoma and gastrointestinal stromal tumor (GIST).
18. A method of treating a non-neoplastic disease, comprising :
selecting an animal in need of treatment for a non-neoplastic disease; and administering to said animal a therapeutically effective dose of the targeted binding agent of any one of claims 1 to 11.
19. The method of claim 18, wherein the non-neoplastic disease is selected from
fibrotic or immune system diseases.
■ Dated this 05th day of January, 2009
(&MRISH TTWARI) T)F K & S PARTNERS AGENT FOR THE APPLICANTS)

TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA

Documents:

Inventors:

PCT Conventions: